<SEC-DOCUMENT>0001628280-22-012662.txt : 20220506
<SEC-HEADER>0001628280-22-012662.hdr.sgml : 20220506
<ACCEPTANCE-DATETIME>20220505161710
ACCESSION NUMBER:		0001628280-22-012662
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		56
CONFORMED PERIOD OF REPORT:	20220331
FILED AS OF DATE:		20220505
DATE AS OF CHANGE:		20220505

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CORCEPT THERAPEUTICS INC
		CENTRAL INDEX KEY:			0001088856
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				770487658
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-50679
		FILM NUMBER:		22896521

	BUSINESS ADDRESS:	
		STREET 1:		149 COMMONWEALTH DRIVE
		CITY:			MENLO PARK
		STATE:			CA
		ZIP:			94025
		BUSINESS PHONE:		650.688.8803

	MAIL ADDRESS:	
		STREET 1:		149 COMMONWEALTH DRIVE
		CITY:			MENLO PARK
		STATE:			CA
		ZIP:			94025
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>cort-20220331.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:e53d3b2d-fdb0-4be1-948b-2f6fb33fb115,g:87e34f93-b135-45b2-b829-febf6d6a95d5,d:0a44765832c1416181e5729d6aaf7059--><html xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns="http://www.w3.org/1999/xhtml" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:cort="http://www.corcept.com/20220331" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>cort-20220331</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV80L2ZyYWc6MzFmYzVlMTM1N2E1NDgzM2FiZDY0ZGZiNDI0ODExM2EvdGFibGU6Y2ZlZjRlMGM3N2UzNDJmZWFiNTdkZjZkNjM3MjA0NzYvdGFibGVyYW5nZTpjZmVmNGUwYzc3ZTM0MmZlYWI1N2RmNmQ2MzcyMDQ3Nl8zLTEtMS0xLTI4MjIx_b50b3db0-0d3b-49a2-b084-fd7e4c2070ab">false</ix:nonNumeric><ix:nonNumeric contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV80L2ZyYWc6MzFmYzVlMTM1N2E1NDgzM2FiZDY0ZGZiNDI0ODExM2EvdGFibGU6Y2ZlZjRlMGM3N2UzNDJmZWFiNTdkZjZkNjM3MjA0NzYvdGFibGVyYW5nZTpjZmVmNGUwYzc3ZTM0MmZlYWI1N2RmNmQ2MzcyMDQ3Nl80LTEtMS0xLTI4MjIx_c1a7716f-4877-4b36-9a29-515d6bc36577">2022</ix:nonNumeric><ix:nonNumeric contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV80L2ZyYWc6MzFmYzVlMTM1N2E1NDgzM2FiZDY0ZGZiNDI0ODExM2EvdGFibGU6Y2ZlZjRlMGM3N2UzNDJmZWFiNTdkZjZkNjM3MjA0NzYvdGFibGVyYW5nZTpjZmVmNGUwYzc3ZTM0MmZlYWI1N2RmNmQ2MzcyMDQ3Nl81LTEtMS0xLTI4MjIx_de507060-1c7b-45ba-9640-8b230a5401d2">Q1</ix:nonNumeric><ix:nonNumeric contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV80L2ZyYWc6MzFmYzVlMTM1N2E1NDgzM2FiZDY0ZGZiNDI0ODExM2EvdGFibGU6Y2ZlZjRlMGM3N2UzNDJmZWFiNTdkZjZkNjM3MjA0NzYvdGFibGVyYW5nZTpjZmVmNGUwYzc3ZTM0MmZlYWI1N2RmNmQ2MzcyMDQ3Nl84LTEtMS0xLTI4MjIx_b16bb318-7f1f-4fe3-bb2c-3ef9d8d16ca7">0001088856</ix:nonNumeric><ix:nonNumeric contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331" name="dei:CurrentFiscalYearEndDate" format="ixt:date-month-day" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV80L2ZyYWc6MzFmYzVlMTM1N2E1NDgzM2FiZDY0ZGZiNDI0ODExM2EvdGFibGU6Y2ZlZjRlMGM3N2UzNDJmZWFiNTdkZjZkNjM3MjA0NzYvdGFibGVyYW5nZTpjZmVmNGUwYzc3ZTM0MmZlYWI1N2RmNmQ2MzcyMDQ3Nl85LTEtMS0xLTI4MjIx_2f43ce6c-896b-4bf2-90fd-456f2d4f8cc0">12/31</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="cort-20220331.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001088856</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib88f9c07449d45b0b9e7fb78200517da_I20220428"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001088856</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i93f424f685944c1aab994f99b0146441_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001088856</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="iac7c0f0822b942fa8f45ea15693a76af_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001088856</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0ebb8d8bac3445859e468a3d048cfaf5_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001088856</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="idf01ece55408406c8103d0d47b49800a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001088856</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i82ca1385b4a848fd8ea581edd7dcbfdb_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001088856</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5ff8ab6f19e4485da8179e610307bf6f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001088856</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia2e3456ee78d4b7e862e98401e421964_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001088856</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iead727f3eb2b4b8fadf3c853db5498a8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001088856</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3c4a2585fb954bd1a1458a2999b7852e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001088856</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iefe5359585e240dbbfd8196f176fb8d6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001088856</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibb5595d6b13d41d2bcc8ba20feea26f6_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001088856</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4e7dfdbf5bce4f52bb81937e0ca5ac46_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001088856</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3e50c96f60264b66aa29d189127a2f73_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001088856</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i785869b1921844f2925c8f4fcaf4ba3c_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001088856</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i56ca5c5bdd7045309e1ff91b29ed0b86_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001088856</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9a1952ba686644179308d0cef13927e8_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001088856</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i20c028d8e2514f38962d2bb482734e70_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001088856</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4202ad56ab444c9cb8f35568184c2c74_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001088856</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i73577ab94ef744cb885730e8ac822b29_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001088856</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib16bf7702efd44cdbe57df570c7d75fb_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001088856</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icfafed6603474886b192b0632a2c6200_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001088856</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i01f702e8e03c41358b69877f0f51d991_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001088856</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6c9d9c7004234ed49109777c938ab2ce_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001088856</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8b5fa79d20ab4ee28c43d8f3802fba08_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001088856</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia7ed3ef4514f42b8bd6ae955926a1ea8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001088856</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0f04c1d847904902a0065f4c9a444cf1_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001088856</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1687f4482d3249aa9d6829a5eabaa2b3_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001088856</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6208146b7098480389c1e89596396c07_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001088856</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i46f01246740a46a892ddb27be4dd69aa_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001088856</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i583bb074d98646df863c37e27250f660_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001088856</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i06b129367f5c4d9ab7b570f6972b2ed1_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001088856</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i47740de74c10439fbf11f8788c4cba45_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001088856</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5f57f8164f0a46daacc1c2551a60659f_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001088856</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic45e1a7a754a469fa7d8a3ad69b13727_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001088856</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i75024e565e314398a3b2b50b649c5486_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001088856</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="series"><xbrli:measure>cort:series</xbrli:measure></xbrli:unit><xbrli:context id="i6b6f130b2b314f4cb240b19c11d8ccfc_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001088856</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cort:LongLivedTangibleAssetAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i320d5eb76f6e462191442b9efd3d1df7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001088856</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cort:LongLivedTangibleAssetAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i300a48854f3e4841a4231047bf2b6d83_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001088856</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cort:LongLivedTangibleAssetAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if054d789bd774097bce632cad662d551_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001088856</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cort:LongLivedTangibleAssetAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9a00554864174d1583c51eb587009a9e_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001088856</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cort:LongLivedTangibleAssetAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9a314602e38747e383f53643af483ebe_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001088856</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cort:LongLivedTangibleAssetAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3b8ab391633246798d3dcce8ecce1732_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001088856</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8199115c34a347bfa2af4840cc8fab44_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001088856</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if03d19cb5acb4fc88cca882cb4bdfcc0_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001088856</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">cort:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idecfc47be18a4b0abf858e6bac29beee_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001088856</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">cort:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9ae15632947d447792ec41cd858483f8_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001088856</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">cort:LongTermMarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib244710dd5db4d8095a0f665560759d1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001088856</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">cort:LongTermMarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id653930fdecf4c64ad438a3b2c5adabb_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001088856</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9384505b63ff4625835d945a86192942_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001088856</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i189a43eed86a4d37b00b3efd25b569ec_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001088856</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie44aabc8e0234ddab3cc8531b3c28b30_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001088856</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibb4f2da4afdc4173bbcc618511bfd330_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001088856</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib430d4f8526c49d2965e6d0cbfc5179d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001088856</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iddcc04669caf4c4f8e77d0b0ead4adba_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001088856</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i80d4096c7b334e54b411518bb6b5d22b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001088856</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic608ebc41f164c878a62e74c33164b0a_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001088856</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifa8d40f1022a4fdbad599ef4cc0332c2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001088856</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5f690dc4c12e4400835f0643973b82b2_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001088856</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibd5d76c213a042ae897b90f0a8ec4a60_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001088856</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i99f1fc2c348e48a0bb5c6c67e90ffd73_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001088856</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieaf64132df2543a583e4e8f6aa3d5517_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001088856</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id8d3c6d4eed84ccdb36200d115427751_I20190131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001088856</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="stockoptionplan"><xbrli:measure>cort:stockOptionPlan</xbrli:measure></xbrli:unit><xbrli:context id="iea23a3d3fb214422896877163db10055_D20211201-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001088856</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cort:StockOptionsFiscalTwentyTwelvePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i52a9c7a889214b11ad5675cc29794ba8_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001088856</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i84ac47ee98bd42c490c47ffe50f5648d_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001088856</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6b5e7570f4ee4e91920827cf4275116e_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001088856</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i715a1de9af124f9bbf4fc1f32f12f6c8_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001088856</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i056b689380d140aca93fdcee21bcdca1_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001088856</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6cbc329d8aed49d7b08ed92b59aa995b_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001088856</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia5de86b46aad4df397dd31ed521a5161_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001088856</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia962305aacde4486929d4801fcf01b30_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001088856</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibdfffff05fb64ff191febd1261049d75_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001088856</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i79418e09cbdb47588dfeae9d2b02dc38_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001088856</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i461a8de5644c45629b64932556c34fff_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001088856</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i0a44765832c1416181e5729d6aaf7059_1"></div><div style="min-height:31.5pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:120%">  </span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.468%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_______________________________________________________</span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xL2ZyYWc6ZjUyZWNlMDExOWFmNDY0NzllZmY1ODA1ZmI3NmY5YWUvdGV4dHJlZ2lvbjpmNTJlY2UwMTE5YWY0NjQ3OWVmZjU4MDVmYjc2ZjlhZV8yMzk4_8f37ee92-b6f4-44cf-ba57-36874f46e6bf">10-Q</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_______________________________________________________</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:2.766%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.934%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331" name="dei:DocumentQuarterlyReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xL2ZyYWc6ZjUyZWNlMDExOWFmNDY0NzllZmY1ODA1ZmI3NmY5YWUvdGFibGU6YjFlY2VmZDk3YTUyNDI3NmFjMWI3YjFlODYwYzlhZTcvdGFibGVyYW5nZTpiMWVjZWZkOTdhNTI0Mjc2YWMxYjdiMWU4NjBjOWFlN18wLTAtMS0xLTI4MjIx_d8054509-5bd1-41d1-aae8-d5f5aeface38">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xL2ZyYWc6ZjUyZWNlMDExOWFmNDY0NzllZmY1ODA1ZmI3NmY5YWUvdGV4dHJlZ2lvbjpmNTJlY2UwMTE5YWY0NjQ3OWVmZjU4MDVmYjc2ZjlhZV8yMzg_b8180fa0-2280-4f15-be93-fef211c61ad1">March 31, 2022</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">or</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:2.766%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.934%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xL2ZyYWc6ZjUyZWNlMDExOWFmNDY0NzllZmY1ODA1ZmI3NmY5YWUvdGFibGU6NWUzZWZmNzY5ZDAwNDI2ZDgyMTkxMmY0OTgzNDE4YTAvdGFibGVyYW5nZTo1ZTNlZmY3NjlkMDA0MjZkODIxOTEyZjQ5ODM0MThhMF8wLTAtMS0xLTI4MjIx_2eca9613-90ed-4a5b-943d-bddec40b08ff">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the transition period from&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; to &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission File Number:</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xL2ZyYWc6ZjUyZWNlMDExOWFmNDY0NzllZmY1ODA1ZmI3NmY5YWUvdGV4dHJlZ2lvbjpmNTJlY2UwMTE5YWY0NjQ3OWVmZjU4MDVmYjc2ZjlhZV8yMzkz_f510c461-c557-43dd-9def-7935555458c1">000-50679</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_______________________________________________________</span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:24pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xL2ZyYWc6ZjUyZWNlMDExOWFmNDY0NzllZmY1ODA1ZmI3NmY5YWUvdGV4dHJlZ2lvbjpmNTJlY2UwMTE5YWY0NjQ3OWVmZjU4MDVmYjc2ZjlhZV8yMzk0_041bb6e7-0ef9-49b1-a71c-d70c94f7cd6a">CORCEPT THERAPEUTICS INC</ix:nonNumeric>ORPORATED</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Exact Name of Corporation as Specified in Its Charter)</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_______________________________________________________</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xL2ZyYWc6ZjUyZWNlMDExOWFmNDY0NzllZmY1ODA1ZmI3NmY5YWUvdGFibGU6NWZiYWI3Y2RiYmZjNDc3ZDg3MDIxYWIyYWMxNWNmZmYvdGFibGVyYW5nZTo1ZmJhYjdjZGJiZmM0NzdkODcwMjFhYjJhYzE1Y2ZmZl8wLTAtMS0xLTI4MjIx_5c9b1a01-1ff5-4016-82ea-acab00403744">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xL2ZyYWc6ZjUyZWNlMDExOWFmNDY0NzllZmY1ODA1ZmI3NmY5YWUvdGFibGU6NWZiYWI3Y2RiYmZjNDc3ZDg3MDIxYWIyYWMxNWNmZmYvdGFibGVyYW5nZTo1ZmJhYjdjZGJiZmM0NzdkODcwMjFhYjJhYzE1Y2ZmZl8wLTEtMS0xLTI4MjIx_a4b9cc96-d2d4-4264-b18a-fbce5772bbaf">77-0487658</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(I.R.S. Employer<br/>Identification No.)</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xL2ZyYWc6ZjUyZWNlMDExOWFmNDY0NzllZmY1ODA1ZmI3NmY5YWUvdGV4dHJlZ2lvbjpmNTJlY2UwMTE5YWY0NjQ3OWVmZjU4MDVmYjc2ZjlhZV8yMzk1_55aa67ef-b290-42f3-b330-92add0a6affd">149 Commonwealth Drive</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xL2ZyYWc6ZjUyZWNlMDExOWFmNDY0NzllZmY1ODA1ZmI3NmY5YWUvdGV4dHJlZ2lvbjpmNTJlY2UwMTE5YWY0NjQ3OWVmZjU4MDVmYjc2ZjlhZV8yMzk2_cb808003-4b82-4fd7-b72b-54e19c1b748a">Menlo Park</ix:nonNumeric>, <ix:nonNumeric contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xL2ZyYWc6ZjUyZWNlMDExOWFmNDY0NzllZmY1ODA1ZmI3NmY5YWUvdGV4dHJlZ2lvbjpmNTJlY2UwMTE5YWY0NjQ3OWVmZjU4MDVmYjc2ZjlhZV8yMzk5_2db4719b-f70d-4bcb-bb6a-e550eee398a4">CA</ix:nonNumeric> <ix:nonNumeric contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xL2ZyYWc6ZjUyZWNlMDExOWFmNDY0NzllZmY1ODA1ZmI3NmY5YWUvdGV4dHJlZ2lvbjpmNTJlY2UwMTE5YWY0NjQ3OWVmZjU4MDVmYjc2ZjlhZV8yNDAw_c93a3331-50ef-49f5-95a0-002b390f2aea">94025</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Address of principal executive offices, including zip code)</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_______________________________________________________</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xL2ZyYWc6ZjUyZWNlMDExOWFmNDY0NzllZmY1ODA1ZmI3NmY5YWUvdGV4dHJlZ2lvbjpmNTJlY2UwMTE5YWY0NjQ3OWVmZjU4MDVmYjc2ZjlhZV8yMzkw_de7d2328-e903-41fc-a3dd-273d21affda7">650</ix:nonNumeric>) <ix:nonNumeric contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xL2ZyYWc6ZjUyZWNlMDExOWFmNDY0NzllZmY1ODA1ZmI3NmY5YWUvdGV4dHJlZ2lvbjpmNTJlY2UwMTE5YWY0NjQ3OWVmZjU4MDVmYjc2ZjlhZV8yNDAx_c4d4499a-6c19-4dd3-8342-7802dabf29e0">327-3270</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_______________________________________________________</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act: </span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:62.711%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xL2ZyYWc6ZjUyZWNlMDExOWFmNDY0NzllZmY1ODA1ZmI3NmY5YWUvdGFibGU6NGQxOTYxNGJhYWUyNDgyMTk1ZThlMmNlOGZhYTU3ZjUvdGFibGVyYW5nZTo0ZDE5NjE0YmFhZTI0ODIxOTVlOGUyY2U4ZmFhNTdmNV8xLTAtMS0xLTI4MjIx_f451d4b9-388d-4984-906b-ae3f57655382">Common Stock, $0.001 par value</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xL2ZyYWc6ZjUyZWNlMDExOWFmNDY0NzllZmY1ODA1ZmI3NmY5YWUvdGFibGU6NGQxOTYxNGJhYWUyNDgyMTk1ZThlMmNlOGZhYTU3ZjUvdGFibGVyYW5nZTo0ZDE5NjE0YmFhZTI0ODIxOTVlOGUyY2U4ZmFhNTdmNV8xLTEtMS0xLTI4MjIx_f7783942-a77b-4249-8565-ca5bd46494bd">CORT</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xL2ZyYWc6ZjUyZWNlMDExOWFmNDY0NzllZmY1ODA1ZmI3NmY5YWUvdGFibGU6NGQxOTYxNGJhYWUyNDgyMTk1ZThlMmNlOGZhYTU3ZjUvdGFibGVyYW5nZTo0ZDE5NjE0YmFhZTI0ODIxOTVlOGUyY2U4ZmFhNTdmNV8xLTItMS0xLTI4MjIx_892b3a45-0eda-4ce6-8ac2-ddd1b728e211">The Nasdaq Stock Market</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant: (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xL2ZyYWc6ZjUyZWNlMDExOWFmNDY0NzllZmY1ODA1ZmI3NmY5YWUvdGV4dHJlZ2lvbjpmNTJlY2UwMTE5YWY0NjQ3OWVmZjU4MDVmYjc2ZjlhZV8yMzkx_262122e0-f660-493f-87bd-a2f1ca97ebdd">Yes</ix:nonNumeric>&#160;&#160;&#9746;&#160;&#160;&#160;&#160;No&#160;&#160;&#9744;</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T&#160;during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xL2ZyYWc6ZjUyZWNlMDExOWFmNDY0NzllZmY1ODA1ZmI3NmY5YWUvdGV4dHJlZ2lvbjpmNTJlY2UwMTE5YWY0NjQ3OWVmZjU4MDVmYjc2ZjlhZV8yMzky_20f14249-3490-4d45-8b7f-3f9f4ced44cd">Yes</ix:nonNumeric>&#160;&#160;&#9746;&#160;&#160;&#160;&#160;No&#160;&#160;&#9744;</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:21.498%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.419%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.662%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.498%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.423%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xL2ZyYWc6ZjUyZWNlMDExOWFmNDY0NzllZmY1ODA1ZmI3NmY5YWUvdGFibGU6M2I2NWNjZGNlNzI0NDlhMzhiZTg1MWNjMzk3MGE1MGUvdGFibGVyYW5nZTozYjY1Y2NkY2U3MjQ0OWEzOGJlODUxY2MzOTcwYTUwZV8wLTAtMS0xLTI4MjIx_553e34ca-ff34-44de-a408-60ced8fc1b7b">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accelerated&#160;filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;&#160;&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Smaller&#160;reporting&#160;company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xL2ZyYWc6ZjUyZWNlMDExOWFmNDY0NzllZmY1ODA1ZmI3NmY5YWUvdGFibGU6M2I2NWNjZGNlNzI0NDlhMzhiZTg1MWNjMzk3MGE1MGUvdGFibGVyYW5nZTozYjY1Y2NkY2U3MjQ0OWEzOGJlODUxY2MzOTcwYTUwZV8xLTQtMS0xLTI4MjIx_6fe6c5d4-dffa-4c79-9a8c-60058b708b75">&#9744;</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging&#160;growth&#160;company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xL2ZyYWc6ZjUyZWNlMDExOWFmNDY0NzllZmY1ODA1ZmI3NmY5YWUvdGFibGU6M2I2NWNjZGNlNzI0NDlhMzhiZTg1MWNjMzk3MGE1MGUvdGFibGVyYW5nZTozYjY1Y2NkY2U3MjQ0OWEzOGJlODUxY2MzOTcwYTUwZV8yLTQtMS0xLTI4MjIx_0ca48bb9-ee14-441d-b577-e3b684b899d8">&#9744;</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;&#9744;</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&#160;&#160;&#160;&#160;Yes&#160;&#160;&#9744;&#160;&#160;&#160;&#160;No&#160;&#160;<ix:nonNumeric contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331" name="dei:EntityShellCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xL2ZyYWc6ZjUyZWNlMDExOWFmNDY0NzllZmY1ODA1ZmI3NmY5YWUvdGV4dHJlZ2lvbjpmNTJlY2UwMTE5YWY0NjQ3OWVmZjU4MDVmYjc2ZjlhZV84MjQ2MzM3MjEwNzQ2_fc4b6788-e540-4a90-a4ae-8b38fd3360b1">&#9746;</ix:nonNumeric></span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April&#160;28, 2022, there were <ix:nonFraction unitRef="shares" contextRef="ib88f9c07449d45b0b9e7fb78200517da_I20220428" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xL2ZyYWc6ZjUyZWNlMDExOWFmNDY0NzllZmY1ODA1ZmI3NmY5YWUvdGV4dHJlZ2lvbjpmNTJlY2UwMTE5YWY0NjQ3OWVmZjU4MDVmYjc2ZjlhZV8yMzE1_f498eefd-86e1-4f22-a581-caac8c7e124c">106,250,716</ix:nonFraction> shares of common stock outstanding at a par value of $0.001 per share.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.468%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:9pt;text-indent:27pt"><span><br/></span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i0a44765832c1416181e5729d6aaf7059_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:94.221%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.579%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0a44765832c1416181e5729d6aaf7059_10">PART I. FINANCIAL INFORMATION</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i0a44765832c1416181e5729d6aaf7059_10">3</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:24.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0a44765832c1416181e5729d6aaf7059_13">ITEM&#160;1. FINANCIAL STATEMENTS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i0a44765832c1416181e5729d6aaf7059_13">3</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:47.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0a44765832c1416181e5729d6aaf7059_16">CONDENSED CONSOLIDATED BALANCE SHEETS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i0a44765832c1416181e5729d6aaf7059_16">3</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:47.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0a44765832c1416181e5729d6aaf7059_19">CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i0a44765832c1416181e5729d6aaf7059_19">4</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:47.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0a44765832c1416181e5729d6aaf7059_22">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i0a44765832c1416181e5729d6aaf7059_22">5</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:47.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0a44765832c1416181e5729d6aaf7059_25">CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i0a44765832c1416181e5729d6aaf7059_25">6</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:47.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0a44765832c1416181e5729d6aaf7059_31">NOTES TO CONDENSED FINANCIAL STATEMENTS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i0a44765832c1416181e5729d6aaf7059_31">7</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:24.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0a44765832c1416181e5729d6aaf7059_52">ITEM&#160;2. MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i0a44765832c1416181e5729d6aaf7059_52">13</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:24.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0a44765832c1416181e5729d6aaf7059_55">ITEM&#160;3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i0a44765832c1416181e5729d6aaf7059_55">18</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:24.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0a44765832c1416181e5729d6aaf7059_58">ITEM&#160;4. CONTROLS AND PROCEDURES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i0a44765832c1416181e5729d6aaf7059_58">18</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0a44765832c1416181e5729d6aaf7059_61">PART II. OTHER INFORMATION</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i0a44765832c1416181e5729d6aaf7059_61">19</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:24.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0a44765832c1416181e5729d6aaf7059_64">ITEM&#160;1. LEGAL PROCEEDINGS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i0a44765832c1416181e5729d6aaf7059_64">19</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:24.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0a44765832c1416181e5729d6aaf7059_67">ITEM&#160;1A. RISK FACTORS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i0a44765832c1416181e5729d6aaf7059_67">21</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:24.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0a44765832c1416181e5729d6aaf7059_70">ITEM&#160;2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i0a44765832c1416181e5729d6aaf7059_70">36</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:24.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0a44765832c1416181e5729d6aaf7059_73">ITEM&#160;3. DEFAULTS UPON SENIOR SECURITIES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i0a44765832c1416181e5729d6aaf7059_73">36</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:24.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0a44765832c1416181e5729d6aaf7059_76">ITEM&#160;4. MINE SAFETY DISCLOSURES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i0a44765832c1416181e5729d6aaf7059_76">36</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:24.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0a44765832c1416181e5729d6aaf7059_79">ITEM&#160;5. OTHER INFORMATION</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i0a44765832c1416181e5729d6aaf7059_79">36</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:24.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0a44765832c1416181e5729d6aaf7059_82">ITEM&#160;6. EXHIBITS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i0a44765832c1416181e5729d6aaf7059_82">37</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0a44765832c1416181e5729d6aaf7059_85">SIGNATURES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i0a44765832c1416181e5729d6aaf7059_85">38</a></span></div></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="i0a44765832c1416181e5729d6aaf7059_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I. FINANCIAL INFORMATION</span></div><div id="i0a44765832c1416181e5729d6aaf7059_13"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1.&#160;&#160;FINANCIAL STATEMENTS</span></div><div id="i0a44765832c1416181e5729d6aaf7059_16"></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CORCEPT THERAPEUTICS INCORPORATED</span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED BALANCE SHEETS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(In thousands)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.882%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.545%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(See Note 1)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93f424f685944c1aab994f99b0146441_I20220331" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xNi9mcmFnOmU4MjIyODA5YjE3NDQ2N2ZiMmJmZTk1NDliZjYyYmVkL3RhYmxlOmQwYzI0YzI3ZmRmZjQ3MTE5OTFmZTEyNWUzNjkwZmQzL3RhYmxlcmFuZ2U6ZDBjMjRjMjdmZGZmNDcxMTk5MWZlMTI1ZTM2OTBmZDNfNC0xLTEtMS0yODIyMQ_4d76b186-2cae-44bb-86a6-be42090b05a9">61,862</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac7c0f0822b942fa8f45ea15693a76af_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xNi9mcmFnOmU4MjIyODA5YjE3NDQ2N2ZiMmJmZTk1NDliZjYyYmVkL3RhYmxlOmQwYzI0YzI3ZmRmZjQ3MTE5OTFmZTEyNWUzNjkwZmQzL3RhYmxlcmFuZ2U6ZDBjMjRjMjdmZGZmNDcxMTk5MWZlMTI1ZTM2OTBmZDNfNC0zLTEtMS0yODIyMQ_14ce683b-3481-4676-b64f-4fa50fe621dc">77,617</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93f424f685944c1aab994f99b0146441_I20220331" decimals="-3" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xNi9mcmFnOmU4MjIyODA5YjE3NDQ2N2ZiMmJmZTk1NDliZjYyYmVkL3RhYmxlOmQwYzI0YzI3ZmRmZjQ3MTE5OTFmZTEyNWUzNjkwZmQzL3RhYmxlcmFuZ2U6ZDBjMjRjMjdmZGZmNDcxMTk5MWZlMTI1ZTM2OTBmZDNfNS0xLTEtMS0yODIyMQ_4dd29eb8-096f-4535-af6d-c27db04f622a">283,665</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac7c0f0822b942fa8f45ea15693a76af_I20211231" decimals="-3" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xNi9mcmFnOmU4MjIyODA5YjE3NDQ2N2ZiMmJmZTk1NDliZjYyYmVkL3RhYmxlOmQwYzI0YzI3ZmRmZjQ3MTE5OTFmZTEyNWUzNjkwZmQzL3RhYmxlcmFuZ2U6ZDBjMjRjMjdmZGZmNDcxMTk5MWZlMTI1ZTM2OTBmZDNfNS0zLTEtMS0yODIyMQ_775e5e26-27fb-493c-93ea-2b80a096b338">145,918</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade receivables, net of allowances</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93f424f685944c1aab994f99b0146441_I20220331" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xNi9mcmFnOmU4MjIyODA5YjE3NDQ2N2ZiMmJmZTk1NDliZjYyYmVkL3RhYmxlOmQwYzI0YzI3ZmRmZjQ3MTE5OTFmZTEyNWUzNjkwZmQzL3RhYmxlcmFuZ2U6ZDBjMjRjMjdmZGZmNDcxMTk5MWZlMTI1ZTM2OTBmZDNfNi0xLTEtMS0yODIyMQ_117cc670-31d3-4e20-bc90-74f14f1b8f44">27,178</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac7c0f0822b942fa8f45ea15693a76af_I20211231" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xNi9mcmFnOmU4MjIyODA5YjE3NDQ2N2ZiMmJmZTk1NDliZjYyYmVkL3RhYmxlOmQwYzI0YzI3ZmRmZjQ3MTE5OTFmZTEyNWUzNjkwZmQzL3RhYmxlcmFuZ2U6ZDBjMjRjMjdmZGZmNDcxMTk5MWZlMTI1ZTM2OTBmZDNfNi0zLTEtMS0yODIyMQ_09de070c-794f-4063-8cf5-33da4b1ec226">27,625</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93f424f685944c1aab994f99b0146441_I20220331" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xNi9mcmFnOmU4MjIyODA5YjE3NDQ2N2ZiMmJmZTk1NDliZjYyYmVkL3RhYmxlOmQwYzI0YzI3ZmRmZjQ3MTE5OTFmZTEyNWUzNjkwZmQzL3RhYmxlcmFuZ2U6ZDBjMjRjMjdmZGZmNDcxMTk5MWZlMTI1ZTM2OTBmZDNfNy0xLTEtMS0yODIyMQ_32d334d1-c862-4b20-b80f-e106cad05a4a">5,079</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac7c0f0822b942fa8f45ea15693a76af_I20211231" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xNi9mcmFnOmU4MjIyODA5YjE3NDQ2N2ZiMmJmZTk1NDliZjYyYmVkL3RhYmxlOmQwYzI0YzI3ZmRmZjQ3MTE5OTFmZTEyNWUzNjkwZmQzL3RhYmxlcmFuZ2U6ZDBjMjRjMjdmZGZmNDcxMTk5MWZlMTI1ZTM2OTBmZDNfNy0zLTEtMS0yODIyMQ_a163f515-08ac-4a5a-82f1-3ea2e7073438">4,988</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93f424f685944c1aab994f99b0146441_I20220331" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xNi9mcmFnOmU4MjIyODA5YjE3NDQ2N2ZiMmJmZTk1NDliZjYyYmVkL3RhYmxlOmQwYzI0YzI3ZmRmZjQ3MTE5OTFmZTEyNWUzNjkwZmQzL3RhYmxlcmFuZ2U6ZDBjMjRjMjdmZGZmNDcxMTk5MWZlMTI1ZTM2OTBmZDNfOC0xLTEtMS0yODIyMQ_fe6a2f68-9c3a-4ce5-9220-142d70b74be4">10,436</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac7c0f0822b942fa8f45ea15693a76af_I20211231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xNi9mcmFnOmU4MjIyODA5YjE3NDQ2N2ZiMmJmZTk1NDliZjYyYmVkL3RhYmxlOmQwYzI0YzI3ZmRmZjQ3MTE5OTFmZTEyNWUzNjkwZmQzL3RhYmxlcmFuZ2U6ZDBjMjRjMjdmZGZmNDcxMTk5MWZlMTI1ZTM2OTBmZDNfOC0zLTEtMS0yODIyMQ_bfddf265-0fbc-4062-8786-af56baafffb2">10,315</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93f424f685944c1aab994f99b0146441_I20220331" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xNi9mcmFnOmU4MjIyODA5YjE3NDQ2N2ZiMmJmZTk1NDliZjYyYmVkL3RhYmxlOmQwYzI0YzI3ZmRmZjQ3MTE5OTFmZTEyNWUzNjkwZmQzL3RhYmxlcmFuZ2U6ZDBjMjRjMjdmZGZmNDcxMTk5MWZlMTI1ZTM2OTBmZDNfOS0xLTEtMS0yODIyMQ_d644c8e0-0c05-451e-b33a-8c0dd301cbc6">388,220</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac7c0f0822b942fa8f45ea15693a76af_I20211231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xNi9mcmFnOmU4MjIyODA5YjE3NDQ2N2ZiMmJmZTk1NDliZjYyYmVkL3RhYmxlOmQwYzI0YzI3ZmRmZjQ3MTE5OTFmZTEyNWUzNjkwZmQzL3RhYmxlcmFuZ2U6ZDBjMjRjMjdmZGZmNDcxMTk5MWZlMTI1ZTM2OTBmZDNfOS0zLTEtMS0yODIyMQ_b29b7463-8850-49a9-beeb-2af4ff12d7f6">266,463</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Strategic inventory</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93f424f685944c1aab994f99b0146441_I20220331" decimals="-3" name="us-gaap:InventoryNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xNi9mcmFnOmU4MjIyODA5YjE3NDQ2N2ZiMmJmZTk1NDliZjYyYmVkL3RhYmxlOmQwYzI0YzI3ZmRmZjQ3MTE5OTFmZTEyNWUzNjkwZmQzL3RhYmxlcmFuZ2U6ZDBjMjRjMjdmZGZmNDcxMTk5MWZlMTI1ZTM2OTBmZDNfMTAtMS0xLTEtMjgyMjE_3a8e2754-3a8d-4c07-bef9-0d21400e74a3">13,098</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac7c0f0822b942fa8f45ea15693a76af_I20211231" decimals="-3" name="us-gaap:InventoryNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xNi9mcmFnOmU4MjIyODA5YjE3NDQ2N2ZiMmJmZTk1NDliZjYyYmVkL3RhYmxlOmQwYzI0YzI3ZmRmZjQ3MTE5OTFmZTEyNWUzNjkwZmQzL3RhYmxlcmFuZ2U6ZDBjMjRjMjdmZGZmNDcxMTk5MWZlMTI1ZTM2OTBmZDNfMTAtMy0xLTEtMjgyMjE_15250e1e-55a1-45bf-8a72-e956998c15e3">12,962</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use asset</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93f424f685944c1aab994f99b0146441_I20220331" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xNi9mcmFnOmU4MjIyODA5YjE3NDQ2N2ZiMmJmZTk1NDliZjYyYmVkL3RhYmxlOmQwYzI0YzI3ZmRmZjQ3MTE5OTFmZTEyNWUzNjkwZmQzL3RhYmxlcmFuZ2U6ZDBjMjRjMjdmZGZmNDcxMTk5MWZlMTI1ZTM2OTBmZDNfMTEtMS0xLTEtMjgyMjE_aa0e3c79-052b-4841-a1c2-3bc00ca43722">2,816</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac7c0f0822b942fa8f45ea15693a76af_I20211231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xNi9mcmFnOmU4MjIyODA5YjE3NDQ2N2ZiMmJmZTk1NDliZjYyYmVkL3RhYmxlOmQwYzI0YzI3ZmRmZjQ3MTE5OTFmZTEyNWUzNjkwZmQzL3RhYmxlcmFuZ2U6ZDBjMjRjMjdmZGZmNDcxMTk5MWZlMTI1ZTM2OTBmZDNfMTEtMy0xLTEtMjgyMjE_9d2abb1c-7613-4afa-9be1-461f041c3833">514</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net of accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93f424f685944c1aab994f99b0146441_I20220331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xNi9mcmFnOmU4MjIyODA5YjE3NDQ2N2ZiMmJmZTk1NDliZjYyYmVkL3RhYmxlOmQwYzI0YzI3ZmRmZjQ3MTE5OTFmZTEyNWUzNjkwZmQzL3RhYmxlcmFuZ2U6ZDBjMjRjMjdmZGZmNDcxMTk5MWZlMTI1ZTM2OTBmZDNfMTItMS0xLTEtMjgyMjE_4566c21a-0f6a-4968-856d-f40f53b4ac65">726</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac7c0f0822b942fa8f45ea15693a76af_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xNi9mcmFnOmU4MjIyODA5YjE3NDQ2N2ZiMmJmZTk1NDliZjYyYmVkL3RhYmxlOmQwYzI0YzI3ZmRmZjQ3MTE5OTFmZTEyNWUzNjkwZmQzL3RhYmxlcmFuZ2U6ZDBjMjRjMjdmZGZmNDcxMTk5MWZlMTI1ZTM2OTBmZDNfMTItMy0xLTEtMjgyMjE_828db3e2-8d42-4834-823e-5dbcbad29e87">1,002</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93f424f685944c1aab994f99b0146441_I20220331" decimals="-3" name="us-gaap:MarketableSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xNi9mcmFnOmU4MjIyODA5YjE3NDQ2N2ZiMmJmZTk1NDliZjYyYmVkL3RhYmxlOmQwYzI0YzI3ZmRmZjQ3MTE5OTFmZTEyNWUzNjkwZmQzL3RhYmxlcmFuZ2U6ZDBjMjRjMjdmZGZmNDcxMTk5MWZlMTI1ZTM2OTBmZDNfMTMtMS0xLTEtMjgyMjE_aaf76697-d8ff-45f8-b90a-5d391523d72d">22,566</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac7c0f0822b942fa8f45ea15693a76af_I20211231" decimals="-3" name="us-gaap:MarketableSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xNi9mcmFnOmU4MjIyODA5YjE3NDQ2N2ZiMmJmZTk1NDliZjYyYmVkL3RhYmxlOmQwYzI0YzI3ZmRmZjQ3MTE5OTFmZTEyNWUzNjkwZmQzL3RhYmxlcmFuZ2U6ZDBjMjRjMjdmZGZmNDcxMTk5MWZlMTI1ZTM2OTBmZDNfMTMtMy0xLTEtMjgyMjE_31d0eadb-c8f3-43f3-9660-61aff797f530">112,277</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93f424f685944c1aab994f99b0146441_I20220331" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xNi9mcmFnOmU4MjIyODA5YjE3NDQ2N2ZiMmJmZTk1NDliZjYyYmVkL3RhYmxlOmQwYzI0YzI3ZmRmZjQ3MTE5OTFmZTEyNWUzNjkwZmQzL3RhYmxlcmFuZ2U6ZDBjMjRjMjdmZGZmNDcxMTk5MWZlMTI1ZTM2OTBmZDNfMTQtMS0xLTEtMjgyMjE_c0ccd199-c3e7-4cec-872d-7d1c5820e66c">2,984</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac7c0f0822b942fa8f45ea15693a76af_I20211231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xNi9mcmFnOmU4MjIyODA5YjE3NDQ2N2ZiMmJmZTk1NDliZjYyYmVkL3RhYmxlOmQwYzI0YzI3ZmRmZjQ3MTE5OTFmZTEyNWUzNjkwZmQzL3RhYmxlcmFuZ2U6ZDBjMjRjMjdmZGZmNDcxMTk5MWZlMTI1ZTM2OTBmZDNfMTQtMy0xLTEtMjgyMjE_495c7ebd-29e3-4621-8295-111ed526892e">3,083</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93f424f685944c1aab994f99b0146441_I20220331" decimals="-3" name="us-gaap:DeferredIncomeTaxAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xNi9mcmFnOmU4MjIyODA5YjE3NDQ2N2ZiMmJmZTk1NDliZjYyYmVkL3RhYmxlOmQwYzI0YzI3ZmRmZjQ3MTE5OTFmZTEyNWUzNjkwZmQzL3RhYmxlcmFuZ2U6ZDBjMjRjMjdmZGZmNDcxMTk5MWZlMTI1ZTM2OTBmZDNfMTUtMS0xLTEtMjgyMjE_62d9d0bb-4df2-45d3-a299-4d304172d265">37,713</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac7c0f0822b942fa8f45ea15693a76af_I20211231" decimals="-3" name="us-gaap:DeferredIncomeTaxAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xNi9mcmFnOmU4MjIyODA5YjE3NDQ2N2ZiMmJmZTk1NDliZjYyYmVkL3RhYmxlOmQwYzI0YzI3ZmRmZjQ3MTE5OTFmZTEyNWUzNjkwZmQzL3RhYmxlcmFuZ2U6ZDBjMjRjMjdmZGZmNDcxMTk5MWZlMTI1ZTM2OTBmZDNfMTUtMy0xLTEtMjgyMjE_b063efa8-138f-4076-a534-7809c4fcb95d">27,455</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93f424f685944c1aab994f99b0146441_I20220331" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xNi9mcmFnOmU4MjIyODA5YjE3NDQ2N2ZiMmJmZTk1NDliZjYyYmVkL3RhYmxlOmQwYzI0YzI3ZmRmZjQ3MTE5OTFmZTEyNWUzNjkwZmQzL3RhYmxlcmFuZ2U6ZDBjMjRjMjdmZGZmNDcxMTk5MWZlMTI1ZTM2OTBmZDNfMTYtMS0xLTEtMjgyMjE_b97623a0-f980-4527-abf3-2d50963566ff">468,123</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac7c0f0822b942fa8f45ea15693a76af_I20211231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xNi9mcmFnOmU4MjIyODA5YjE3NDQ2N2ZiMmJmZTk1NDliZjYyYmVkL3RhYmxlOmQwYzI0YzI3ZmRmZjQ3MTE5OTFmZTEyNWUzNjkwZmQzL3RhYmxlcmFuZ2U6ZDBjMjRjMjdmZGZmNDcxMTk5MWZlMTI1ZTM2OTBmZDNfMTYtMy0xLTEtMjgyMjE_108abb93-8a2e-4658-a4cc-80d985dabc71">423,756</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93f424f685944c1aab994f99b0146441_I20220331" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xNi9mcmFnOmU4MjIyODA5YjE3NDQ2N2ZiMmJmZTk1NDliZjYyYmVkL3RhYmxlOmQwYzI0YzI3ZmRmZjQ3MTE5OTFmZTEyNWUzNjkwZmQzL3RhYmxlcmFuZ2U6ZDBjMjRjMjdmZGZmNDcxMTk5MWZlMTI1ZTM2OTBmZDNfMTktMS0xLTEtMjgyMjE_ad35240d-af80-4bdb-9a8f-4e5f5abd1f17">9,269</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac7c0f0822b942fa8f45ea15693a76af_I20211231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xNi9mcmFnOmU4MjIyODA5YjE3NDQ2N2ZiMmJmZTk1NDliZjYyYmVkL3RhYmxlOmQwYzI0YzI3ZmRmZjQ3MTE5OTFmZTEyNWUzNjkwZmQzL3RhYmxlcmFuZ2U6ZDBjMjRjMjdmZGZmNDcxMTk5MWZlMTI1ZTM2OTBmZDNfMTktMy0xLTEtMjgyMjE_72887183-d734-470f-b8c7-7fc288ef3de0">6,908</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued research and development expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93f424f685944c1aab994f99b0146441_I20220331" decimals="-3" name="cort:AccruedClinicalExpensesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xNi9mcmFnOmU4MjIyODA5YjE3NDQ2N2ZiMmJmZTk1NDliZjYyYmVkL3RhYmxlOmQwYzI0YzI3ZmRmZjQ3MTE5OTFmZTEyNWUzNjkwZmQzL3RhYmxlcmFuZ2U6ZDBjMjRjMjdmZGZmNDcxMTk5MWZlMTI1ZTM2OTBmZDNfMjAtMS0xLTEtMjgyMjE_f833e04b-33b7-4c0b-a67c-e4a609428d86">13,051</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac7c0f0822b942fa8f45ea15693a76af_I20211231" decimals="-3" name="cort:AccruedClinicalExpensesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xNi9mcmFnOmU4MjIyODA5YjE3NDQ2N2ZiMmJmZTk1NDliZjYyYmVkL3RhYmxlOmQwYzI0YzI3ZmRmZjQ3MTE5OTFmZTEyNWUzNjkwZmQzL3RhYmxlcmFuZ2U6ZDBjMjRjMjdmZGZmNDcxMTk5MWZlMTI1ZTM2OTBmZDNfMjAtMy0xLTEtMjgyMjE_603f3a54-0a1f-4f93-a620-fed9c34aed3b">12,442</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued and other liabilities </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93f424f685944c1aab994f99b0146441_I20220331" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xNi9mcmFnOmU4MjIyODA5YjE3NDQ2N2ZiMmJmZTk1NDliZjYyYmVkL3RhYmxlOmQwYzI0YzI3ZmRmZjQ3MTE5OTFmZTEyNWUzNjkwZmQzL3RhYmxlcmFuZ2U6ZDBjMjRjMjdmZGZmNDcxMTk5MWZlMTI1ZTM2OTBmZDNfMjEtMS0xLTEtMjgyMjE_8564740d-ab01-4d87-87a7-2a7ee3ef2f8e">32,660</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac7c0f0822b942fa8f45ea15693a76af_I20211231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xNi9mcmFnOmU4MjIyODA5YjE3NDQ2N2ZiMmJmZTk1NDliZjYyYmVkL3RhYmxlOmQwYzI0YzI3ZmRmZjQ3MTE5OTFmZTEyNWUzNjkwZmQzL3RhYmxlcmFuZ2U6ZDBjMjRjMjdmZGZmNDcxMTk5MWZlMTI1ZTM2OTBmZDNfMjEtMy0xLTEtMjgyMjE_115cc370-97fe-44be-ba5c-0593744e6f90">27,665</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term operating lease liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93f424f685944c1aab994f99b0146441_I20220331" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xNi9mcmFnOmU4MjIyODA5YjE3NDQ2N2ZiMmJmZTk1NDliZjYyYmVkL3RhYmxlOmQwYzI0YzI3ZmRmZjQ3MTE5OTFmZTEyNWUzNjkwZmQzL3RhYmxlcmFuZ2U6ZDBjMjRjMjdmZGZmNDcxMTk5MWZlMTI1ZTM2OTBmZDNfMjItMS0xLTEtMjgyMjE_e3febf93-47d2-40e5-bb43-f7c33cfbbc6c">2,264</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac7c0f0822b942fa8f45ea15693a76af_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xNi9mcmFnOmU4MjIyODA5YjE3NDQ2N2ZiMmJmZTk1NDliZjYyYmVkL3RhYmxlOmQwYzI0YzI3ZmRmZjQ3MTE5OTFmZTEyNWUzNjkwZmQzL3RhYmxlcmFuZ2U6ZDBjMjRjMjdmZGZmNDcxMTk5MWZlMTI1ZTM2OTBmZDNfMjItMy0xLTEtMjgyMjE_5efb28da-0b43-4572-a39d-77c615b3b2d1">526</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93f424f685944c1aab994f99b0146441_I20220331" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xNi9mcmFnOmU4MjIyODA5YjE3NDQ2N2ZiMmJmZTk1NDliZjYyYmVkL3RhYmxlOmQwYzI0YzI3ZmRmZjQ3MTE5OTFmZTEyNWUzNjkwZmQzL3RhYmxlcmFuZ2U6ZDBjMjRjMjdmZGZmNDcxMTk5MWZlMTI1ZTM2OTBmZDNfMjMtMS0xLTEtMjgyMjE_2acdc02d-dded-483c-8932-8c2f5cecaaf7">57,244</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac7c0f0822b942fa8f45ea15693a76af_I20211231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xNi9mcmFnOmU4MjIyODA5YjE3NDQ2N2ZiMmJmZTk1NDliZjYyYmVkL3RhYmxlOmQwYzI0YzI3ZmRmZjQ3MTE5OTFmZTEyNWUzNjkwZmQzL3RhYmxlcmFuZ2U6ZDBjMjRjMjdmZGZmNDcxMTk5MWZlMTI1ZTM2OTBmZDNfMjMtMy0xLTEtMjgyMjE_31e7dcaf-807a-460e-81e8-4c63831cee98">47,541</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term operating lease liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93f424f685944c1aab994f99b0146441_I20220331" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xNi9mcmFnOmU4MjIyODA5YjE3NDQ2N2ZiMmJmZTk1NDliZjYyYmVkL3RhYmxlOmQwYzI0YzI3ZmRmZjQ3MTE5OTFmZTEyNWUzNjkwZmQzL3RhYmxlcmFuZ2U6ZDBjMjRjMjdmZGZmNDcxMTk5MWZlMTI1ZTM2OTBmZDNfMjQtMS0xLTEtMjgyMjE_8fbd720a-b0ff-4f50-a775-77b9d108ed70">552</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac7c0f0822b942fa8f45ea15693a76af_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xNi9mcmFnOmU4MjIyODA5YjE3NDQ2N2ZiMmJmZTk1NDliZjYyYmVkL3RhYmxlOmQwYzI0YzI3ZmRmZjQ3MTE5OTFmZTEyNWUzNjkwZmQzL3RhYmxlcmFuZ2U6ZDBjMjRjMjdmZGZmNDcxMTk5MWZlMTI1ZTM2OTBmZDNfMjQtMy0xLTEtMjgyMjE_7ccbc64d-0d73-4aa4-8afd-358822db490f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term accrued income taxes payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93f424f685944c1aab994f99b0146441_I20220331" decimals="-3" name="us-gaap:AccruedIncomeTaxesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xNi9mcmFnOmU4MjIyODA5YjE3NDQ2N2ZiMmJmZTk1NDliZjYyYmVkL3RhYmxlOmQwYzI0YzI3ZmRmZjQ3MTE5OTFmZTEyNWUzNjkwZmQzL3RhYmxlcmFuZ2U6ZDBjMjRjMjdmZGZmNDcxMTk5MWZlMTI1ZTM2OTBmZDNfMjUtMS0xLTEtMjgyMjE_e3ac91cb-379e-4f50-930a-17b1331cc601">2,516</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac7c0f0822b942fa8f45ea15693a76af_I20211231" decimals="-3" name="us-gaap:AccruedIncomeTaxesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xNi9mcmFnOmU4MjIyODA5YjE3NDQ2N2ZiMmJmZTk1NDliZjYyYmVkL3RhYmxlOmQwYzI0YzI3ZmRmZjQ3MTE5OTFmZTEyNWUzNjkwZmQzL3RhYmxlcmFuZ2U6ZDBjMjRjMjdmZGZmNDcxMTk5MWZlMTI1ZTM2OTBmZDNfMjUtMy0xLTEtMjgyMjE_8d1025b4-aace-472c-ba15-f1f8d4bd1f72">409</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93f424f685944c1aab994f99b0146441_I20220331" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xNi9mcmFnOmU4MjIyODA5YjE3NDQ2N2ZiMmJmZTk1NDliZjYyYmVkL3RhYmxlOmQwYzI0YzI3ZmRmZjQ3MTE5OTFmZTEyNWUzNjkwZmQzL3RhYmxlcmFuZ2U6ZDBjMjRjMjdmZGZmNDcxMTk5MWZlMTI1ZTM2OTBmZDNfMjYtMS0xLTEtMjgyMjE_776270f0-d467-48b9-b7a5-f1132a06ed1e">60,312</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac7c0f0822b942fa8f45ea15693a76af_I20211231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xNi9mcmFnOmU4MjIyODA5YjE3NDQ2N2ZiMmJmZTk1NDliZjYyYmVkL3RhYmxlOmQwYzI0YzI3ZmRmZjQ3MTE5OTFmZTEyNWUzNjkwZmQzL3RhYmxlcmFuZ2U6ZDBjMjRjMjdmZGZmNDcxMTk5MWZlMTI1ZTM2OTBmZDNfMjYtMy0xLTEtMjgyMjE_e22f9fe5-1a01-4d79-8601-80bc4c43aeb5">47,950</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and contingencies (Note 4)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders&#8217; equity:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93f424f685944c1aab994f99b0146441_I20220331" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xNi9mcmFnOmU4MjIyODA5YjE3NDQ2N2ZiMmJmZTk1NDliZjYyYmVkL3RhYmxlOmQwYzI0YzI3ZmRmZjQ3MTE5OTFmZTEyNWUzNjkwZmQzL3RhYmxlcmFuZ2U6ZDBjMjRjMjdmZGZmNDcxMTk5MWZlMTI1ZTM2OTBmZDNfMjktMS0xLTEtMjgyMjE_db9256c7-32e9-490d-98e6-a99bb95be8b8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac7c0f0822b942fa8f45ea15693a76af_I20211231" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xNi9mcmFnOmU4MjIyODA5YjE3NDQ2N2ZiMmJmZTk1NDliZjYyYmVkL3RhYmxlOmQwYzI0YzI3ZmRmZjQ3MTE5OTFmZTEyNWUzNjkwZmQzL3RhYmxlcmFuZ2U6ZDBjMjRjMjdmZGZmNDcxMTk5MWZlMTI1ZTM2OTBmZDNfMjktMy0xLTEtMjgyMjE_185786e0-8212-4fd5-a98d-283883c0d46d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93f424f685944c1aab994f99b0146441_I20220331" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xNi9mcmFnOmU4MjIyODA5YjE3NDQ2N2ZiMmJmZTk1NDliZjYyYmVkL3RhYmxlOmQwYzI0YzI3ZmRmZjQ3MTE5OTFmZTEyNWUzNjkwZmQzL3RhYmxlcmFuZ2U6ZDBjMjRjMjdmZGZmNDcxMTk5MWZlMTI1ZTM2OTBmZDNfMzAtMS0xLTEtMjgyMjE_58c1b73e-4383-4e48-a383-d0b95bf4d6fa">128</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac7c0f0822b942fa8f45ea15693a76af_I20211231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xNi9mcmFnOmU4MjIyODA5YjE3NDQ2N2ZiMmJmZTk1NDliZjYyYmVkL3RhYmxlOmQwYzI0YzI3ZmRmZjQ3MTE5OTFmZTEyNWUzNjkwZmQzL3RhYmxlcmFuZ2U6ZDBjMjRjMjdmZGZmNDcxMTk5MWZlMTI1ZTM2OTBmZDNfMzAtMy0xLTEtMjgyMjE_769c2d71-c428-4a19-9880-3edfdc2268c8">127</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treasury stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i93f424f685944c1aab994f99b0146441_I20220331" decimals="-3" name="us-gaap:TreasuryStockCommonValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xNi9mcmFnOmU4MjIyODA5YjE3NDQ2N2ZiMmJmZTk1NDliZjYyYmVkL3RhYmxlOmQwYzI0YzI3ZmRmZjQ3MTE5OTFmZTEyNWUzNjkwZmQzL3RhYmxlcmFuZ2U6ZDBjMjRjMjdmZGZmNDcxMTk5MWZlMTI1ZTM2OTBmZDNfMzEtMS0xLTEtMzExNjE_9be36633-8941-4ba5-9397-033fb0e35900">417,448</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iac7c0f0822b942fa8f45ea15693a76af_I20211231" decimals="-3" name="us-gaap:TreasuryStockCommonValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xNi9mcmFnOmU4MjIyODA5YjE3NDQ2N2ZiMmJmZTk1NDliZjYyYmVkL3RhYmxlOmQwYzI0YzI3ZmRmZjQ3MTE5OTFmZTEyNWUzNjkwZmQzL3RhYmxlcmFuZ2U6ZDBjMjRjMjdmZGZmNDcxMTk5MWZlMTI1ZTM2OTBmZDNfMzEtMy0xLTEtMzExNjE_dd49ee52-a1e0-4609-bbfa-30581568ec62">410,411</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93f424f685944c1aab994f99b0146441_I20220331" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xNi9mcmFnOmU4MjIyODA5YjE3NDQ2N2ZiMmJmZTk1NDliZjYyYmVkL3RhYmxlOmQwYzI0YzI3ZmRmZjQ3MTE5OTFmZTEyNWUzNjkwZmQzL3RhYmxlcmFuZ2U6ZDBjMjRjMjdmZGZmNDcxMTk5MWZlMTI1ZTM2OTBmZDNfMzEtMS0xLTEtMjgyMjE_f9f2fcdb-6fa6-4438-8c70-e7583b927d29">608,717</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac7c0f0822b942fa8f45ea15693a76af_I20211231" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xNi9mcmFnOmU4MjIyODA5YjE3NDQ2N2ZiMmJmZTk1NDliZjYyYmVkL3RhYmxlOmQwYzI0YzI3ZmRmZjQ3MTE5OTFmZTEyNWUzNjkwZmQzL3RhYmxlcmFuZ2U6ZDBjMjRjMjdmZGZmNDcxMTk5MWZlMTI1ZTM2OTBmZDNfMzEtMy0xLTEtMjgyMjE_306b8011-4fbc-4778-9ee2-248c80aba479">591,349</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i93f424f685944c1aab994f99b0146441_I20220331" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xNi9mcmFnOmU4MjIyODA5YjE3NDQ2N2ZiMmJmZTk1NDliZjYyYmVkL3RhYmxlOmQwYzI0YzI3ZmRmZjQ3MTE5OTFmZTEyNWUzNjkwZmQzL3RhYmxlcmFuZ2U6ZDBjMjRjMjdmZGZmNDcxMTk5MWZlMTI1ZTM2OTBmZDNfMzMtMS0xLTEtMjgyMjE_b4a3c592-a011-41e2-9798-af1e4247b21a">1,351</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iac7c0f0822b942fa8f45ea15693a76af_I20211231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xNi9mcmFnOmU4MjIyODA5YjE3NDQ2N2ZiMmJmZTk1NDliZjYyYmVkL3RhYmxlOmQwYzI0YzI3ZmRmZjQ3MTE5OTFmZTEyNWUzNjkwZmQzL3RhYmxlcmFuZ2U6ZDBjMjRjMjdmZGZmNDcxMTk5MWZlMTI1ZTM2OTBmZDNfMzMtMy0xLTEtMjgyMjE_05bcf237-412a-4cf2-98d6-223df3ee2b01">227</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retained earnings</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93f424f685944c1aab994f99b0146441_I20220331" decimals="-3" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xNi9mcmFnOmU4MjIyODA5YjE3NDQ2N2ZiMmJmZTk1NDliZjYyYmVkL3RhYmxlOmQwYzI0YzI3ZmRmZjQ3MTE5OTFmZTEyNWUzNjkwZmQzL3RhYmxlcmFuZ2U6ZDBjMjRjMjdmZGZmNDcxMTk5MWZlMTI1ZTM2OTBmZDNfMzQtMS0xLTEtMjgyMjE_2b2264e5-d4b2-4f9f-a287-7ff9ec2e3c10">217,765</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac7c0f0822b942fa8f45ea15693a76af_I20211231" decimals="-3" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xNi9mcmFnOmU4MjIyODA5YjE3NDQ2N2ZiMmJmZTk1NDliZjYyYmVkL3RhYmxlOmQwYzI0YzI3ZmRmZjQ3MTE5OTFmZTEyNWUzNjkwZmQzL3RhYmxlcmFuZ2U6ZDBjMjRjMjdmZGZmNDcxMTk5MWZlMTI1ZTM2OTBmZDNfMzQtMy0xLTEtMjgyMjE_923cfb76-0825-422e-a1dc-3c868295d680">194,968</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93f424f685944c1aab994f99b0146441_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xNi9mcmFnOmU4MjIyODA5YjE3NDQ2N2ZiMmJmZTk1NDliZjYyYmVkL3RhYmxlOmQwYzI0YzI3ZmRmZjQ3MTE5OTFmZTEyNWUzNjkwZmQzL3RhYmxlcmFuZ2U6ZDBjMjRjMjdmZGZmNDcxMTk5MWZlMTI1ZTM2OTBmZDNfMzUtMS0xLTEtMjgyMjE_086ca7f5-8d31-4401-b05d-5ccaa930fede">407,811</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac7c0f0822b942fa8f45ea15693a76af_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xNi9mcmFnOmU4MjIyODA5YjE3NDQ2N2ZiMmJmZTk1NDliZjYyYmVkL3RhYmxlOmQwYzI0YzI3ZmRmZjQ3MTE5OTFmZTEyNWUzNjkwZmQzL3RhYmxlcmFuZ2U6ZDBjMjRjMjdmZGZmNDcxMTk5MWZlMTI1ZTM2OTBmZDNfMzUtMy0xLTEtMjgyMjE_ff7002ba-b400-43fa-bee4-4275b68cf28f">375,806</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; equity</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93f424f685944c1aab994f99b0146441_I20220331" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xNi9mcmFnOmU4MjIyODA5YjE3NDQ2N2ZiMmJmZTk1NDliZjYyYmVkL3RhYmxlOmQwYzI0YzI3ZmRmZjQ3MTE5OTFmZTEyNWUzNjkwZmQzL3RhYmxlcmFuZ2U6ZDBjMjRjMjdmZGZmNDcxMTk5MWZlMTI1ZTM2OTBmZDNfMzYtMS0xLTEtMjgyMjE_17802af9-c581-4ef6-8585-0b23e5704cb7">468,123</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac7c0f0822b942fa8f45ea15693a76af_I20211231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xNi9mcmFnOmU4MjIyODA5YjE3NDQ2N2ZiMmJmZTk1NDliZjYyYmVkL3RhYmxlOmQwYzI0YzI3ZmRmZjQ3MTE5OTFmZTEyNWUzNjkwZmQzL3RhYmxlcmFuZ2U6ZDBjMjRjMjdmZGZmNDcxMTk5MWZlMTI1ZTM2OTBmZDNfMzYtMy0xLTEtMjgyMjE_089f9127-aa44-411f-8de9-1d7103e76ca5">423,756</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="i0a44765832c1416181e5729d6aaf7059_19"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CORCEPT THERAPEUTICS INCORPORATED</span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(In thousands, except per share data)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.882%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.545%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product revenue, net</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xOS9mcmFnOjY0MjE1YWY5MjUwYzQwYzU5ZThiMWE4ODQwNmExYzNiL3RhYmxlOmMxZGEzOWUyYWE0MzQxNWQ4MzYzOGE4MmEwMmFhZjFiL3RhYmxlcmFuZ2U6YzFkYTM5ZTJhYTQzNDE1ZDgzNjM4YTgyYTAyYWFmMWJfMi0xLTEtMS0yODIyMQ_3b4944c0-9dc3-482e-894b-ab0bcb771666">93,688</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ebb8d8bac3445859e468a3d048cfaf5_D20210101-20210331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xOS9mcmFnOjY0MjE1YWY5MjUwYzQwYzU5ZThiMWE4ODQwNmExYzNiL3RhYmxlOmMxZGEzOWUyYWE0MzQxNWQ4MzYzOGE4MmEwMmFhZjFiL3RhYmxlcmFuZ2U6YzFkYTM5ZTJhYTQzNDE1ZDgzNjM4YTgyYTAyYWFmMWJfMi0zLTEtMS0yODIyMQ_48194608-6f89-4f16-a791-8fd581a8f4d6">79,437</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xOS9mcmFnOjY0MjE1YWY5MjUwYzQwYzU5ZThiMWE4ODQwNmExYzNiL3RhYmxlOmMxZGEzOWUyYWE0MzQxNWQ4MzYzOGE4MmEwMmFhZjFiL3RhYmxlcmFuZ2U6YzFkYTM5ZTJhYTQzNDE1ZDgzNjM4YTgyYTAyYWFmMWJfNC0xLTEtMS0yODIyMQ_8478a20c-ebb4-4660-af01-bc98f5c7c983">1,250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ebb8d8bac3445859e468a3d048cfaf5_D20210101-20210331" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xOS9mcmFnOjY0MjE1YWY5MjUwYzQwYzU5ZThiMWE4ODQwNmExYzNiL3RhYmxlOmMxZGEzOWUyYWE0MzQxNWQ4MzYzOGE4MmEwMmFhZjFiL3RhYmxlcmFuZ2U6YzFkYTM5ZTJhYTQzNDE1ZDgzNjM4YTgyYTAyYWFmMWJfNC0zLTEtMS0yODIyMQ_887beeda-9bb4-417b-8fda-2907f63139b1">1,268</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xOS9mcmFnOjY0MjE1YWY5MjUwYzQwYzU5ZThiMWE4ODQwNmExYzNiL3RhYmxlOmMxZGEzOWUyYWE0MzQxNWQ4MzYzOGE4MmEwMmFhZjFiL3RhYmxlcmFuZ2U6YzFkYTM5ZTJhYTQzNDE1ZDgzNjM4YTgyYTAyYWFmMWJfNS0xLTEtMS0yODIyMQ_5fd11f9e-e341-4843-b666-75b66cb050bf">28,120</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ebb8d8bac3445859e468a3d048cfaf5_D20210101-20210331" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xOS9mcmFnOjY0MjE1YWY5MjUwYzQwYzU5ZThiMWE4ODQwNmExYzNiL3RhYmxlOmMxZGEzOWUyYWE0MzQxNWQ4MzYzOGE4MmEwMmFhZjFiL3RhYmxlcmFuZ2U6YzFkYTM5ZTJhYTQzNDE1ZDgzNjM4YTgyYTAyYWFmMWJfNS0zLTEtMS0yODIyMQ_9f593a49-cf97-4e87-a6e2-18380ca13a98">29,022</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xOS9mcmFnOjY0MjE1YWY5MjUwYzQwYzU5ZThiMWE4ODQwNmExYzNiL3RhYmxlOmMxZGEzOWUyYWE0MzQxNWQ4MzYzOGE4MmEwMmFhZjFiL3RhYmxlcmFuZ2U6YzFkYTM5ZTJhYTQzNDE1ZDgzNjM4YTgyYTAyYWFmMWJfNi0xLTEtMS0yODIyMQ_b977c004-01c8-4775-b49b-001112987edc">37,549</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ebb8d8bac3445859e468a3d048cfaf5_D20210101-20210331" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xOS9mcmFnOjY0MjE1YWY5MjUwYzQwYzU5ZThiMWE4ODQwNmExYzNiL3RhYmxlOmMxZGEzOWUyYWE0MzQxNWQ4MzYzOGE4MmEwMmFhZjFiL3RhYmxlcmFuZ2U6YzFkYTM5ZTJhYTQzNDE1ZDgzNjM4YTgyYTAyYWFmMWJfNi0zLTEtMS0yODIyMQ_4ed86c97-00ac-4073-85b2-6352300b8865">29,509</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xOS9mcmFnOjY0MjE1YWY5MjUwYzQwYzU5ZThiMWE4ODQwNmExYzNiL3RhYmxlOmMxZGEzOWUyYWE0MzQxNWQ4MzYzOGE4MmEwMmFhZjFiL3RhYmxlcmFuZ2U6YzFkYTM5ZTJhYTQzNDE1ZDgzNjM4YTgyYTAyYWFmMWJfNy0xLTEtMS0yODIyMQ_829fd094-17d2-412c-9e00-64743b1b89cf">66,919</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ebb8d8bac3445859e468a3d048cfaf5_D20210101-20210331" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xOS9mcmFnOjY0MjE1YWY5MjUwYzQwYzU5ZThiMWE4ODQwNmExYzNiL3RhYmxlOmMxZGEzOWUyYWE0MzQxNWQ4MzYzOGE4MmEwMmFhZjFiL3RhYmxlcmFuZ2U6YzFkYTM5ZTJhYTQzNDE1ZDgzNjM4YTgyYTAyYWFmMWJfNy0zLTEtMS0yODIyMQ_c9b3a573-e138-4d96-a782-f9baea4fa6bc">59,799</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xOS9mcmFnOjY0MjE1YWY5MjUwYzQwYzU5ZThiMWE4ODQwNmExYzNiL3RhYmxlOmMxZGEzOWUyYWE0MzQxNWQ4MzYzOGE4MmEwMmFhZjFiL3RhYmxlcmFuZ2U6YzFkYTM5ZTJhYTQzNDE1ZDgzNjM4YTgyYTAyYWFmMWJfOC0xLTEtMS0yODIyMQ_d4a92377-a4bc-48e4-a08c-9df102227f71">26,769</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ebb8d8bac3445859e468a3d048cfaf5_D20210101-20210331" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xOS9mcmFnOjY0MjE1YWY5MjUwYzQwYzU5ZThiMWE4ODQwNmExYzNiL3RhYmxlOmMxZGEzOWUyYWE0MzQxNWQ4MzYzOGE4MmEwMmFhZjFiL3RhYmxlcmFuZ2U6YzFkYTM5ZTJhYTQzNDE1ZDgzNjM4YTgyYTAyYWFmMWJfOC0zLTEtMS0yODIyMQ_4d33b9c4-1e4b-4dfc-af19-9af386765013">19,638</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest and other income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xOS9mcmFnOjY0MjE1YWY5MjUwYzQwYzU5ZThiMWE4ODQwNmExYzNiL3RhYmxlOmMxZGEzOWUyYWE0MzQxNWQ4MzYzOGE4MmEwMmFhZjFiL3RhYmxlcmFuZ2U6YzFkYTM5ZTJhYTQzNDE1ZDgzNjM4YTgyYTAyYWFmMWJfOS0xLTEtMS0yODIyMQ_b55fa211-e21a-4f9b-9904-87fabd408589">80</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ebb8d8bac3445859e468a3d048cfaf5_D20210101-20210331" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xOS9mcmFnOjY0MjE1YWY5MjUwYzQwYzU5ZThiMWE4ODQwNmExYzNiL3RhYmxlOmMxZGEzOWUyYWE0MzQxNWQ4MzYzOGE4MmEwMmFhZjFiL3RhYmxlcmFuZ2U6YzFkYTM5ZTJhYTQzNDE1ZDgzNjM4YTgyYTAyYWFmMWJfOS0zLTEtMS0yODIyMQ_0c9e46a3-0022-4810-acaf-49cba8eb52ee">275</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income before income taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xOS9mcmFnOjY0MjE1YWY5MjUwYzQwYzU5ZThiMWE4ODQwNmExYzNiL3RhYmxlOmMxZGEzOWUyYWE0MzQxNWQ4MzYzOGE4MmEwMmFhZjFiL3RhYmxlcmFuZ2U6YzFkYTM5ZTJhYTQzNDE1ZDgzNjM4YTgyYTAyYWFmMWJfMTAtMS0xLTEtMjgyMjE_ebe00406-4d3e-403d-8261-711fb82d2b84">26,849</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ebb8d8bac3445859e468a3d048cfaf5_D20210101-20210331" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xOS9mcmFnOjY0MjE1YWY5MjUwYzQwYzU5ZThiMWE4ODQwNmExYzNiL3RhYmxlOmMxZGEzOWUyYWE0MzQxNWQ4MzYzOGE4MmEwMmFhZjFiL3RhYmxlcmFuZ2U6YzFkYTM5ZTJhYTQzNDE1ZDgzNjM4YTgyYTAyYWFmMWJfMTAtMy0xLTEtMjgyMjE_247bbadd-93af-4e03-a5b1-5f85926b689c">19,913</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax (expense) benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xOS9mcmFnOjY0MjE1YWY5MjUwYzQwYzU5ZThiMWE4ODQwNmExYzNiL3RhYmxlOmMxZGEzOWUyYWE0MzQxNWQ4MzYzOGE4MmEwMmFhZjFiL3RhYmxlcmFuZ2U6YzFkYTM5ZTJhYTQzNDE1ZDgzNjM4YTgyYTAyYWFmMWJfMTEtMS0xLTEtMjgyMjE_d23a5868-7f5e-40fa-a328-9d7f841d68c2">4,052</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ebb8d8bac3445859e468a3d048cfaf5_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xOS9mcmFnOjY0MjE1YWY5MjUwYzQwYzU5ZThiMWE4ODQwNmExYzNiL3RhYmxlOmMxZGEzOWUyYWE0MzQxNWQ4MzYzOGE4MmEwMmFhZjFiL3RhYmxlcmFuZ2U6YzFkYTM5ZTJhYTQzNDE1ZDgzNjM4YTgyYTAyYWFmMWJfMTEtMy0xLTEtMjgyMjE_4d2131be-bf1e-4ad0-b5b0-f302d4d454e5">3,552</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xOS9mcmFnOjY0MjE1YWY5MjUwYzQwYzU5ZThiMWE4ODQwNmExYzNiL3RhYmxlOmMxZGEzOWUyYWE0MzQxNWQ4MzYzOGE4MmEwMmFhZjFiL3RhYmxlcmFuZ2U6YzFkYTM5ZTJhYTQzNDE1ZDgzNjM4YTgyYTAyYWFmMWJfMTItMS0xLTEtMjgyMjE_4f021180-7b89-454d-8786-2379ec4d4fb2">22,797</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ebb8d8bac3445859e468a3d048cfaf5_D20210101-20210331" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xOS9mcmFnOjY0MjE1YWY5MjUwYzQwYzU5ZThiMWE4ODQwNmExYzNiL3RhYmxlOmMxZGEzOWUyYWE0MzQxNWQ4MzYzOGE4MmEwMmFhZjFiL3RhYmxlcmFuZ2U6YzFkYTM5ZTJhYTQzNDE1ZDgzNjM4YTgyYTAyYWFmMWJfMTItMy0xLTEtMjgyMjE_2cd59acc-beea-4e6a-8b23-eec790e51cf3">23,465</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized loss on available-for-sale investments, net of tax effect of $<ix:nonFraction unitRef="usd" contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xOS9mcmFnOjY0MjE1YWY5MjUwYzQwYzU5ZThiMWE4ODQwNmExYzNiL3RhYmxlOmMxZGEzOWUyYWE0MzQxNWQ4MzYzOGE4MmEwMmFhZjFiL3RhYmxlcmFuZ2U6YzFkYTM5ZTJhYTQzNDE1ZDgzNjM4YTgyYTAyYWFmMWJfMTQtMC0xLTEtMjgyMjEvdGV4dHJlZ2lvbjowMWE0N2M3NWFjZTA0YjcwODg4OGY5ZTMzYWI2M2FiZF84OA_7546fec8-f564-444d-a256-a9cc465ca6a6">323</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i0ebb8d8bac3445859e468a3d048cfaf5_D20210101-20210331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xOS9mcmFnOjY0MjE1YWY5MjUwYzQwYzU5ZThiMWE4ODQwNmExYzNiL3RhYmxlOmMxZGEzOWUyYWE0MzQxNWQ4MzYzOGE4MmEwMmFhZjFiL3RhYmxlcmFuZ2U6YzFkYTM5ZTJhYTQzNDE1ZDgzNjM4YTgyYTAyYWFmMWJfMTQtMC0xLTEtMjgyMjEvdGV4dHJlZ2lvbjowMWE0N2M3NWFjZTA0YjcwODg4OGY5ZTMzYWI2M2FiZF85Ng_3953ca27-f4a9-45e6-8386-6e5b0ee5b7b1">61</ix:nonFraction>, respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xOS9mcmFnOjY0MjE1YWY5MjUwYzQwYzU5ZThiMWE4ODQwNmExYzNiL3RhYmxlOmMxZGEzOWUyYWE0MzQxNWQ4MzYzOGE4MmEwMmFhZjFiL3RhYmxlcmFuZ2U6YzFkYTM5ZTJhYTQzNDE1ZDgzNjM4YTgyYTAyYWFmMWJfMTQtMS0xLTEtMjgyMjE_0ec31587-b278-445c-a6f2-e761751c0c1c">1,019</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0ebb8d8bac3445859e468a3d048cfaf5_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xOS9mcmFnOjY0MjE1YWY5MjUwYzQwYzU5ZThiMWE4ODQwNmExYzNiL3RhYmxlOmMxZGEzOWUyYWE0MzQxNWQ4MzYzOGE4MmEwMmFhZjFiL3RhYmxlcmFuZ2U6YzFkYTM5ZTJhYTQzNDE1ZDgzNjM4YTgyYTAyYWFmMWJfMTQtMy0xLTEtMjgyMjE_cf479975-e49e-40dc-a4ae-26f8a5e5c316">192</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation (loss) gain, net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xOS9mcmFnOjY0MjE1YWY5MjUwYzQwYzU5ZThiMWE4ODQwNmExYzNiL3RhYmxlOmMxZGEzOWUyYWE0MzQxNWQ4MzYzOGE4MmEwMmFhZjFiL3RhYmxlcmFuZ2U6YzFkYTM5ZTJhYTQzNDE1ZDgzNjM4YTgyYTAyYWFmMWJfMTUtMS0xLTEtMjgyMjE_428bbbb3-ee36-428d-836c-175622dbc65b">105</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ebb8d8bac3445859e468a3d048cfaf5_D20210101-20210331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xOS9mcmFnOjY0MjE1YWY5MjUwYzQwYzU5ZThiMWE4ODQwNmExYzNiL3RhYmxlOmMxZGEzOWUyYWE0MzQxNWQ4MzYzOGE4MmEwMmFhZjFiL3RhYmxlcmFuZ2U6YzFkYTM5ZTJhYTQzNDE1ZDgzNjM4YTgyYTAyYWFmMWJfMTUtMy0xLTEtMjgyMjE_61816b24-67d1-4cb1-a7c0-984a372a8e5d">26</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total comprehensive income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331" decimals="-3" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xOS9mcmFnOjY0MjE1YWY5MjUwYzQwYzU5ZThiMWE4ODQwNmExYzNiL3RhYmxlOmMxZGEzOWUyYWE0MzQxNWQ4MzYzOGE4MmEwMmFhZjFiL3RhYmxlcmFuZ2U6YzFkYTM5ZTJhYTQzNDE1ZDgzNjM4YTgyYTAyYWFmMWJfMTYtMS0xLTEtMjgyMjE_16fb0b25-400e-45dc-8f16-3b6784764280">21,673</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ebb8d8bac3445859e468a3d048cfaf5_D20210101-20210331" decimals="-3" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xOS9mcmFnOjY0MjE1YWY5MjUwYzQwYzU5ZThiMWE4ODQwNmExYzNiL3RhYmxlOmMxZGEzOWUyYWE0MzQxNWQ4MzYzOGE4MmEwMmFhZjFiL3RhYmxlcmFuZ2U6YzFkYTM5ZTJhYTQzNDE1ZDgzNjM4YTgyYTAyYWFmMWJfMTYtMy0xLTEtMjgyMjE_742e30bf-9430-4a68-8487-a6230e9c0b44">23,299</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Basic net income per share</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xOS9mcmFnOjY0MjE1YWY5MjUwYzQwYzU5ZThiMWE4ODQwNmExYzNiL3RhYmxlOmMxZGEzOWUyYWE0MzQxNWQ4MzYzOGE4MmEwMmFhZjFiL3RhYmxlcmFuZ2U6YzFkYTM5ZTJhYTQzNDE1ZDgzNjM4YTgyYTAyYWFmMWJfMTgtMS0xLTEtMjgyMjE_1e3c4b72-25f0-4e72-9c6c-d0f16ff09afc">0.22</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0ebb8d8bac3445859e468a3d048cfaf5_D20210101-20210331" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xOS9mcmFnOjY0MjE1YWY5MjUwYzQwYzU5ZThiMWE4ODQwNmExYzNiL3RhYmxlOmMxZGEzOWUyYWE0MzQxNWQ4MzYzOGE4MmEwMmFhZjFiL3RhYmxlcmFuZ2U6YzFkYTM5ZTJhYTQzNDE1ZDgzNjM4YTgyYTAyYWFmMWJfMTgtMy0xLTEtMjgyMjE_a52bc082-8023-4ad1-9071-e7019e1b3a41">0.20</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Diluted net income per share</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xOS9mcmFnOjY0MjE1YWY5MjUwYzQwYzU5ZThiMWE4ODQwNmExYzNiL3RhYmxlOmMxZGEzOWUyYWE0MzQxNWQ4MzYzOGE4MmEwMmFhZjFiL3RhYmxlcmFuZ2U6YzFkYTM5ZTJhYTQzNDE1ZDgzNjM4YTgyYTAyYWFmMWJfMjAtMS0xLTEtMjgyMjE_ca02b6ea-ccc2-4715-85c6-7b61bfce762a">0.20</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0ebb8d8bac3445859e468a3d048cfaf5_D20210101-20210331" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xOS9mcmFnOjY0MjE1YWY5MjUwYzQwYzU5ZThiMWE4ODQwNmExYzNiL3RhYmxlOmMxZGEzOWUyYWE0MzQxNWQ4MzYzOGE4MmEwMmFhZjFiL3RhYmxlcmFuZ2U6YzFkYTM5ZTJhYTQzNDE1ZDgzNjM4YTgyYTAyYWFmMWJfMjAtMy0xLTEtMjgyMjE_4b4e3778-5b04-4f07-9b1a-e3ac6121dd0e">0.18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-average shares outstanding used in computing net income per share</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xOS9mcmFnOjY0MjE1YWY5MjUwYzQwYzU5ZThiMWE4ODQwNmExYzNiL3RhYmxlOmMxZGEzOWUyYWE0MzQxNWQ4MzYzOGE4MmEwMmFhZjFiL3RhYmxlcmFuZ2U6YzFkYTM5ZTJhYTQzNDE1ZDgzNjM4YTgyYTAyYWFmMWJfMjMtMS0xLTEtMjgyMjE_2415efe6-dbc3-4f65-b0d5-d791380e3dec">106,012</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0ebb8d8bac3445859e468a3d048cfaf5_D20210101-20210331" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xOS9mcmFnOjY0MjE1YWY5MjUwYzQwYzU5ZThiMWE4ODQwNmExYzNiL3RhYmxlOmMxZGEzOWUyYWE0MzQxNWQ4MzYzOGE4MmEwMmFhZjFiL3RhYmxlcmFuZ2U6YzFkYTM5ZTJhYTQzNDE1ZDgzNjM4YTgyYTAyYWFmMWJfMjMtMy0xLTEtMjgyMjE_9aecb556-e242-44f8-a242-05aa4f1c8a13">116,818</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xOS9mcmFnOjY0MjE1YWY5MjUwYzQwYzU5ZThiMWE4ODQwNmExYzNiL3RhYmxlOmMxZGEzOWUyYWE0MzQxNWQ4MzYzOGE4MmEwMmFhZjFiL3RhYmxlcmFuZ2U6YzFkYTM5ZTJhYTQzNDE1ZDgzNjM4YTgyYTAyYWFmMWJfMjQtMS0xLTEtMjgyMjE_9aa0aace-2e86-4f26-97ac-c977acf479a0">115,037</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0ebb8d8bac3445859e468a3d048cfaf5_D20210101-20210331" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xOS9mcmFnOjY0MjE1YWY5MjUwYzQwYzU5ZThiMWE4ODQwNmExYzNiL3RhYmxlOmMxZGEzOWUyYWE0MzQxNWQ4MzYzOGE4MmEwMmFhZjFiL3RhYmxlcmFuZ2U6YzFkYTM5ZTJhYTQzNDE1ZDgzNjM4YTgyYTAyYWFmMWJfMjQtMy0xLTEtMjgyMjE_f3a7cbb2-3de8-4038-ae6d-cc495eb422e1">129,668</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="i0a44765832c1416181e5729d6aaf7059_22"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CORCEPT THERAPEUTICS INCORPORATED</span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(In thousands)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.882%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.545%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from operating activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yMi9mcmFnOjE0YmZlMmE4ZmYxMDRkZTk5MmJlYWMwYWM0MmY1NjA2L3RhYmxlOmZiY2M3NTk2ZDZhZjQ1NjRhYzg2NThhZTA2MjMyMGVjL3RhYmxlcmFuZ2U6ZmJjYzc1OTZkNmFmNDU2NGFjODY1OGFlMDYyMzIwZWNfMy0xLTEtMS0yODIyMQ_a66c9fa4-6065-48ee-8689-0996d5b67946">22,797</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ebb8d8bac3445859e468a3d048cfaf5_D20210101-20210331" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yMi9mcmFnOjE0YmZlMmE4ZmYxMDRkZTk5MmJlYWMwYWM0MmY1NjA2L3RhYmxlOmZiY2M3NTk2ZDZhZjQ1NjRhYzg2NThhZTA2MjMyMGVjL3RhYmxlcmFuZ2U6ZmJjYzc1OTZkNmFmNDU2NGFjODY1OGFlMDYyMzIwZWNfMy0zLTEtMS0yODIyMQ_b9f9f788-e827-4576-a45d-1f014c2186b7">23,465</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net income to net cash provided by operations:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yMi9mcmFnOjE0YmZlMmE4ZmYxMDRkZTk5MmJlYWMwYWM0MmY1NjA2L3RhYmxlOmZiY2M3NTk2ZDZhZjQ1NjRhYzg2NThhZTA2MjMyMGVjL3RhYmxlcmFuZ2U6ZmJjYzc1OTZkNmFmNDU2NGFjODY1OGFlMDYyMzIwZWNfNS0xLTEtMS0yODIyMQ_42d31c6b-c1bb-4c60-b152-b17532d52439">10,761</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ebb8d8bac3445859e468a3d048cfaf5_D20210101-20210331" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yMi9mcmFnOjE0YmZlMmE4ZmYxMDRkZTk5MmJlYWMwYWM0MmY1NjA2L3RhYmxlOmZiY2M3NTk2ZDZhZjQ1NjRhYzg2NThhZTA2MjMyMGVjL3RhYmxlcmFuZ2U6ZmJjYzc1OTZkNmFmNDU2NGFjODY1OGFlMDYyMzIwZWNfNS0zLTEtMS0yODIyMQ_700d679f-9c99-4a7b-afa6-971e3ce86c95">10,101</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331" decimals="-3" name="cort:AccretionExpenseIncome" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yMi9mcmFnOjE0YmZlMmE4ZmYxMDRkZTk5MmJlYWMwYWM0MmY1NjA2L3RhYmxlOmZiY2M3NTk2ZDZhZjQ1NjRhYzg2NThhZTA2MjMyMGVjL3RhYmxlcmFuZ2U6ZmJjYzc1OTZkNmFmNDU2NGFjODY1OGFlMDYyMzIwZWNfNy0xLTEtMS0yODIyMQ_13c27b17-8663-4aad-802c-1d37161d3044">1,106</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ebb8d8bac3445859e468a3d048cfaf5_D20210101-20210331" decimals="-3" name="cort:AccretionExpenseIncome" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yMi9mcmFnOjE0YmZlMmE4ZmYxMDRkZTk5MmJlYWMwYWM0MmY1NjA2L3RhYmxlOmZiY2M3NTk2ZDZhZjQ1NjRhYzg2NThhZTA2MjMyMGVjL3RhYmxlcmFuZ2U6ZmJjYzc1OTZkNmFmNDU2NGFjODY1OGFlMDYyMzIwZWNfNy0zLTEtMS0yODIyMQ_b30618d5-65c9-4fde-b8c9-cfcddbbab43c">1,194</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization of property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yMi9mcmFnOjE0YmZlMmE4ZmYxMDRkZTk5MmJlYWMwYWM0MmY1NjA2L3RhYmxlOmZiY2M3NTk2ZDZhZjQ1NjRhYzg2NThhZTA2MjMyMGVjL3RhYmxlcmFuZ2U6ZmJjYzc1OTZkNmFmNDU2NGFjODY1OGFlMDYyMzIwZWNfOC0xLTEtMS0yODIyMQ_3866098e-7ecd-4447-b83c-eee873d364fc">288</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ebb8d8bac3445859e468a3d048cfaf5_D20210101-20210331" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yMi9mcmFnOjE0YmZlMmE4ZmYxMDRkZTk5MmJlYWMwYWM0MmY1NjA2L3RhYmxlOmZiY2M3NTk2ZDZhZjQ1NjRhYzg2NThhZTA2MjMyMGVjL3RhYmxlcmFuZ2U6ZmJjYzc1OTZkNmFmNDU2NGFjODY1OGFlMDYyMzIwZWNfOC0zLTEtMS0yODIyMQ_2cededa8-fd5d-4f82-abcb-a0cc385b3466">254</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yMi9mcmFnOjE0YmZlMmE4ZmYxMDRkZTk5MmJlYWMwYWM0MmY1NjA2L3RhYmxlOmZiY2M3NTk2ZDZhZjQ1NjRhYzg2NThhZTA2MjMyMGVjL3RhYmxlcmFuZ2U6ZmJjYzc1OTZkNmFmNDU2NGFjODY1OGFlMDYyMzIwZWNfOS0xLTEtMS0zMTI1NA_131f6bb4-d58f-492b-ae48-355acb58ac89">9,935</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0ebb8d8bac3445859e468a3d048cfaf5_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yMi9mcmFnOjE0YmZlMmE4ZmYxMDRkZTk5MmJlYWMwYWM0MmY1NjA2L3RhYmxlOmZiY2M3NTk2ZDZhZjQ1NjRhYzg2NThhZTA2MjMyMGVjL3RhYmxlcmFuZ2U6ZmJjYzc1OTZkNmFmNDU2NGFjODY1OGFlMDYyMzIwZWNfOS0zLTEtMS0zMTI1NA_ed451d89-a2a4-41f9-aecd-3edf82745d84">5,360</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash amortization of right-of-use asset</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yMi9mcmFnOjE0YmZlMmE4ZmYxMDRkZTk5MmJlYWMwYWM0MmY1NjA2L3RhYmxlOmZiY2M3NTk2ZDZhZjQ1NjRhYzg2NThhZTA2MjMyMGVjL3RhYmxlcmFuZ2U6ZmJjYzc1OTZkNmFmNDU2NGFjODY1OGFlMDYyMzIwZWNfOS0xLTEtMS0yODIyMQ_2b8b0d3e-b154-4e04-8b6d-6f3af0b3d43e">514</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ebb8d8bac3445859e468a3d048cfaf5_D20210101-20210331" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yMi9mcmFnOjE0YmZlMmE4ZmYxMDRkZTk5MmJlYWMwYWM0MmY1NjA2L3RhYmxlOmZiY2M3NTk2ZDZhZjQ1NjRhYzg2NThhZTA2MjMyMGVjL3RhYmxlcmFuZ2U6ZmJjYzc1OTZkNmFmNDU2NGFjODY1OGFlMDYyMzIwZWNfOS0zLTEtMS0yODIyMQ_52ece2d1-c9d8-4406-8904-a0abfaaf4f50">489</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yMi9mcmFnOjE0YmZlMmE4ZmYxMDRkZTk5MmJlYWMwYWM0MmY1NjA2L3RhYmxlOmZiY2M3NTk2ZDZhZjQ1NjRhYzg2NThhZTA2MjMyMGVjL3RhYmxlcmFuZ2U6ZmJjYzc1OTZkNmFmNDU2NGFjODY1OGFlMDYyMzIwZWNfMTEtMS0xLTEtMjgyMjE_6ed23314-4b5c-41be-9316-14cfe08a6cb1">447</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ebb8d8bac3445859e468a3d048cfaf5_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yMi9mcmFnOjE0YmZlMmE4ZmYxMDRkZTk5MmJlYWMwYWM0MmY1NjA2L3RhYmxlOmZiY2M3NTk2ZDZhZjQ1NjRhYzg2NThhZTA2MjMyMGVjL3RhYmxlcmFuZ2U6ZmJjYzc1OTZkNmFmNDU2NGFjODY1OGFlMDYyMzIwZWNfMTEtMy0xLTEtMjgyMjE_fa166ed4-0ec0-4fde-81a5-e551326db01c">3,998</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yMi9mcmFnOjE0YmZlMmE4ZmYxMDRkZTk5MmJlYWMwYWM0MmY1NjA2L3RhYmxlOmZiY2M3NTk2ZDZhZjQ1NjRhYzg2NThhZTA2MjMyMGVjL3RhYmxlcmFuZ2U6ZmJjYzc1OTZkNmFmNDU2NGFjODY1OGFlMDYyMzIwZWNfMTItMS0xLTEtMjgyMjE_3b3f6c40-47c9-419d-8bf5-95bad65c4790">163</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ebb8d8bac3445859e468a3d048cfaf5_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yMi9mcmFnOjE0YmZlMmE4ZmYxMDRkZTk5MmJlYWMwYWM0MmY1NjA2L3RhYmxlOmZiY2M3NTk2ZDZhZjQ1NjRhYzg2NThhZTA2MjMyMGVjL3RhYmxlcmFuZ2U6ZmJjYzc1OTZkNmFmNDU2NGFjODY1OGFlMDYyMzIwZWNfMTItMy0xLTEtMjgyMjE_38744232-bca5-4cd8-b596-880484d2310c">866</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yMi9mcmFnOjE0YmZlMmE4ZmYxMDRkZTk5MmJlYWMwYWM0MmY1NjA2L3RhYmxlOmZiY2M3NTk2ZDZhZjQ1NjRhYzg2NThhZTA2MjMyMGVjL3RhYmxlcmFuZ2U6ZmJjYzc1OTZkNmFmNDU2NGFjODY1OGFlMDYyMzIwZWNfMTMtMS0xLTEtMjgyMjE_f055e798-1e87-4fb3-a639-457dc04b6852">9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0ebb8d8bac3445859e468a3d048cfaf5_D20210101-20210331" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yMi9mcmFnOjE0YmZlMmE4ZmYxMDRkZTk5MmJlYWMwYWM0MmY1NjA2L3RhYmxlOmZiY2M3NTk2ZDZhZjQ1NjRhYzg2NThhZTA2MjMyMGVjL3RhYmxlcmFuZ2U6ZmJjYzc1OTZkNmFmNDU2NGFjODY1OGFlMDYyMzIwZWNfMTMtMy0xLTEtMjgyMjE_ab6837b5-84ca-431b-bae6-1e4df1241eb0">2,850</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yMi9mcmFnOjE0YmZlMmE4ZmYxMDRkZTk5MmJlYWMwYWM0MmY1NjA2L3RhYmxlOmZiY2M3NTk2ZDZhZjQ1NjRhYzg2NThhZTA2MjMyMGVjL3RhYmxlcmFuZ2U6ZmJjYzc1OTZkNmFmNDU2NGFjODY1OGFlMDYyMzIwZWNfMTQtMS0xLTEtMjgyMjE_252fb358-b986-4410-ba2c-a118f57333e2">2,256</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0ebb8d8bac3445859e468a3d048cfaf5_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yMi9mcmFnOjE0YmZlMmE4ZmYxMDRkZTk5MmJlYWMwYWM0MmY1NjA2L3RhYmxlOmZiY2M3NTk2ZDZhZjQ1NjRhYzg2NThhZTA2MjMyMGVjL3RhYmxlcmFuZ2U6ZmJjYzc1OTZkNmFmNDU2NGFjODY1OGFlMDYyMzIwZWNfMTQtMy0xLTEtMjgyMjE_418fedad-fbdd-417d-9048-9b904b41a912">3,493</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued research and development expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331" decimals="-3" name="cort:IncreaseDecreaseInAccruedClinicalExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yMi9mcmFnOjE0YmZlMmE4ZmYxMDRkZTk5MmJlYWMwYWM0MmY1NjA2L3RhYmxlOmZiY2M3NTk2ZDZhZjQ1NjRhYzg2NThhZTA2MjMyMGVjL3RhYmxlcmFuZ2U6ZmJjYzc1OTZkNmFmNDU2NGFjODY1OGFlMDYyMzIwZWNfMTUtMS0xLTEtMjgyMjE_34d9d904-7d10-471d-a6fb-817c3c29d23e">609</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0ebb8d8bac3445859e468a3d048cfaf5_D20210101-20210331" decimals="-3" sign="-" name="cort:IncreaseDecreaseInAccruedClinicalExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yMi9mcmFnOjE0YmZlMmE4ZmYxMDRkZTk5MmJlYWMwYWM0MmY1NjA2L3RhYmxlOmZiY2M3NTk2ZDZhZjQ1NjRhYzg2NThhZTA2MjMyMGVjL3RhYmxlcmFuZ2U6ZmJjYzc1OTZkNmFmNDU2NGFjODY1OGFlMDYyMzIwZWNfMTUtMy0xLTEtMjgyMjE_cfb1dd1b-540e-497f-962a-d1120c0608df">138</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued and other liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yMi9mcmFnOjE0YmZlMmE4ZmYxMDRkZTk5MmJlYWMwYWM0MmY1NjA2L3RhYmxlOmZiY2M3NTk2ZDZhZjQ1NjRhYzg2NThhZTA2MjMyMGVjL3RhYmxlcmFuZ2U6ZmJjYzc1OTZkNmFmNDU2NGFjODY1OGFlMDYyMzIwZWNfMTYtMS0xLTEtMjgyMjE_dbd3f8b5-f7a6-42f0-8d4d-4b6e4698c997">4,995</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0ebb8d8bac3445859e468a3d048cfaf5_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yMi9mcmFnOjE0YmZlMmE4ZmYxMDRkZTk5MmJlYWMwYWM0MmY1NjA2L3RhYmxlOmZiY2M3NTk2ZDZhZjQ1NjRhYzg2NThhZTA2MjMyMGVjL3RhYmxlcmFuZ2U6ZmJjYzc1OTZkNmFmNDU2NGFjODY1OGFlMDYyMzIwZWNfMTYtMy0xLTEtMjgyMjE_7fa82dfb-9531-4124-adc2-58a1a1a7b490">3,217</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term accrued income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedTaxesPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yMi9mcmFnOjE0YmZlMmE4ZmYxMDRkZTk5MmJlYWMwYWM0MmY1NjA2L3RhYmxlOmZiY2M3NTk2ZDZhZjQ1NjRhYzg2NThhZTA2MjMyMGVjL3RhYmxlcmFuZ2U6ZmJjYzc1OTZkNmFmNDU2NGFjODY1OGFlMDYyMzIwZWNfMTctMS0xLTEtMjgyMjE_05c00244-2448-41ae-b963-22fecf4d1353">2,107</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ebb8d8bac3445859e468a3d048cfaf5_D20210101-20210331" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedTaxesPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yMi9mcmFnOjE0YmZlMmE4ZmYxMDRkZTk5MmJlYWMwYWM0MmY1NjA2L3RhYmxlOmZiY2M3NTk2ZDZhZjQ1NjRhYzg2NThhZTA2MjMyMGVjL3RhYmxlcmFuZ2U6ZmJjYzc1OTZkNmFmNDU2NGFjODY1OGFlMDYyMzIwZWNfMTctMy0xLTEtMjgyMjE_68948a46-5a51-4f65-855b-776a91e42f95">597</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yMi9mcmFnOjE0YmZlMmE4ZmYxMDRkZTk5MmJlYWMwYWM0MmY1NjA2L3RhYmxlOmZiY2M3NTk2ZDZhZjQ1NjRhYzg2NThhZTA2MjMyMGVjL3RhYmxlcmFuZ2U6ZmJjYzc1OTZkNmFmNDU2NGFjODY1OGFlMDYyMzIwZWNfMTgtMS0xLTEtMjgyMjE_31c54d88-bc18-469c-8e38-e6e94255350d">526</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0ebb8d8bac3445859e468a3d048cfaf5_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yMi9mcmFnOjE0YmZlMmE4ZmYxMDRkZTk5MmJlYWMwYWM0MmY1NjA2L3RhYmxlOmZiY2M3NTk2ZDZhZjQ1NjRhYzg2NThhZTA2MjMyMGVjL3RhYmxlcmFuZ2U6ZmJjYzc1OTZkNmFmNDU2NGFjODY1OGFlMDYyMzIwZWNfMTgtMy0xLTEtMjgyMjE_85e5f1c5-0779-4f3b-ac54-3d3cf14113cf">484</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331" decimals="-3" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yMi9mcmFnOjE0YmZlMmE4ZmYxMDRkZTk5MmJlYWMwYWM0MmY1NjA2L3RhYmxlOmZiY2M3NTk2ZDZhZjQ1NjRhYzg2NThhZTA2MjMyMGVjL3RhYmxlcmFuZ2U6ZmJjYzc1OTZkNmFmNDU2NGFjODY1OGFlMDYyMzIwZWNfMTktMS0xLTEtMjgyMjE_0c2bdfb7-1a4c-4d5b-b21c-602d83e090b3">35,247</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ebb8d8bac3445859e468a3d048cfaf5_D20210101-20210331" decimals="-3" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yMi9mcmFnOjE0YmZlMmE4ZmYxMDRkZTk5MmJlYWMwYWM0MmY1NjA2L3RhYmxlOmZiY2M3NTk2ZDZhZjQ1NjRhYzg2NThhZTA2MjMyMGVjL3RhYmxlcmFuZ2U6ZmJjYzc1OTZkNmFmNDU2NGFjODY1OGFlMDYyMzIwZWNfMTktMy0xLTEtMjgyMjE_50057706-7681-413d-b0cc-309bff541145">25,422</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yMi9mcmFnOjE0YmZlMmE4ZmYxMDRkZTk5MmJlYWMwYWM0MmY1NjA2L3RhYmxlOmZiY2M3NTk2ZDZhZjQ1NjRhYzg2NThhZTA2MjMyMGVjL3RhYmxlcmFuZ2U6ZmJjYzc1OTZkNmFmNDU2NGFjODY1OGFlMDYyMzIwZWNfMjEtMS0xLTEtMjgyMjE_1554b063-989c-44a0-8a16-ca7fc5feaa3c">12</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0ebb8d8bac3445859e468a3d048cfaf5_D20210101-20210331" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yMi9mcmFnOjE0YmZlMmE4ZmYxMDRkZTk5MmJlYWMwYWM0MmY1NjA2L3RhYmxlOmZiY2M3NTk2ZDZhZjQ1NjRhYzg2NThhZTA2MjMyMGVjL3RhYmxlcmFuZ2U6ZmJjYzc1OTZkNmFmNDU2NGFjODY1OGFlMDYyMzIwZWNfMjEtMy0xLTEtMjgyMjE_58f8219e-431a-4dab-8017-e7fb3942f844">126</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from maturities of marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yMi9mcmFnOjE0YmZlMmE4ZmYxMDRkZTk5MmJlYWMwYWM0MmY1NjA2L3RhYmxlOmZiY2M3NTk2ZDZhZjQ1NjRhYzg2NThhZTA2MjMyMGVjL3RhYmxlcmFuZ2U6ZmJjYzc1OTZkNmFmNDU2NGFjODY1OGFlMDYyMzIwZWNfMjItMS0xLTEtMjgyMjE_e08c9b37-9d48-4e6c-8781-5ee1ce065549">42,127</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ebb8d8bac3445859e468a3d048cfaf5_D20210101-20210331" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yMi9mcmFnOjE0YmZlMmE4ZmYxMDRkZTk5MmJlYWMwYWM0MmY1NjA2L3RhYmxlOmZiY2M3NTk2ZDZhZjQ1NjRhYzg2NThhZTA2MjMyMGVjL3RhYmxlcmFuZ2U6ZmJjYzc1OTZkNmFmNDU2NGFjODY1OGFlMDYyMzIwZWNfMjItMy0xLTEtMjgyMjE_65c8006d-ebfc-4ba7-bdbb-e0a889b07f70">124,230</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331" decimals="-3" name="us-gaap:PaymentsToAcquireMarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yMi9mcmFnOjE0YmZlMmE4ZmYxMDRkZTk5MmJlYWMwYWM0MmY1NjA2L3RhYmxlOmZiY2M3NTk2ZDZhZjQ1NjRhYzg2NThhZTA2MjMyMGVjL3RhYmxlcmFuZ2U6ZmJjYzc1OTZkNmFmNDU2NGFjODY1OGFlMDYyMzIwZWNfMjMtMS0xLTEtMjgyMjE_74fd2bf0-70b3-4872-a8a6-4e343f9f6a53">92,611</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0ebb8d8bac3445859e468a3d048cfaf5_D20210101-20210331" decimals="-3" name="us-gaap:PaymentsToAcquireMarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yMi9mcmFnOjE0YmZlMmE4ZmYxMDRkZTk5MmJlYWMwYWM0MmY1NjA2L3RhYmxlOmZiY2M3NTk2ZDZhZjQ1NjRhYzg2NThhZTA2MjMyMGVjL3RhYmxlcmFuZ2U6ZmJjYzc1OTZkNmFmNDU2NGFjODY1OGFlMDYyMzIwZWNfMjMtMy0xLTEtMjgyMjE_7fc5042a-9d8d-4dec-a18a-58e6b4e81017">127,388</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yMi9mcmFnOjE0YmZlMmE4ZmYxMDRkZTk5MmJlYWMwYWM0MmY1NjA2L3RhYmxlOmZiY2M3NTk2ZDZhZjQ1NjRhYzg2NThhZTA2MjMyMGVjL3RhYmxlcmFuZ2U6ZmJjYzc1OTZkNmFmNDU2NGFjODY1OGFlMDYyMzIwZWNfMjQtMS0xLTEtMjgyMjE_13faaac0-ccbf-4ea5-b03d-daa5754dba2a">50,496</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0ebb8d8bac3445859e468a3d048cfaf5_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yMi9mcmFnOjE0YmZlMmE4ZmYxMDRkZTk5MmJlYWMwYWM0MmY1NjA2L3RhYmxlOmZiY2M3NTk2ZDZhZjQ1NjRhYzg2NThhZTA2MjMyMGVjL3RhYmxlcmFuZ2U6ZmJjYzc1OTZkNmFmNDU2NGFjODY1OGFlMDYyMzIwZWNfMjQtMy0xLTEtMjgyMjE_a0af3fd9-f914-4ffc-8c61-35adfb6630ed">3,284</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from exercise of stock options, net of issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331" decimals="-3" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yMi9mcmFnOjE0YmZlMmE4ZmYxMDRkZTk5MmJlYWMwYWM0MmY1NjA2L3RhYmxlOmZiY2M3NTk2ZDZhZjQ1NjRhYzg2NThhZTA2MjMyMGVjL3RhYmxlcmFuZ2U6ZmJjYzc1OTZkNmFmNDU2NGFjODY1OGFlMDYyMzIwZWNfMjYtMS0xLTEtMjgyMjE_d1f23e61-0f57-4472-89e9-a0b09f398528">1,382</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ebb8d8bac3445859e468a3d048cfaf5_D20210101-20210331" decimals="-3" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yMi9mcmFnOjE0YmZlMmE4ZmYxMDRkZTk5MmJlYWMwYWM0MmY1NjA2L3RhYmxlOmZiY2M3NTk2ZDZhZjQ1NjRhYzg2NThhZTA2MjMyMGVjL3RhYmxlcmFuZ2U6ZmJjYzc1OTZkNmFmNDU2NGFjODY1OGFlMDYyMzIwZWNfMjYtMy0xLTEtMjgyMjE_e3152dea-d3d5-413c-9100-96dc33e03256">4,038</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repurchase of common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331" decimals="-3" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yMi9mcmFnOjE0YmZlMmE4ZmYxMDRkZTk5MmJlYWMwYWM0MmY1NjA2L3RhYmxlOmZiY2M3NTk2ZDZhZjQ1NjRhYzg2NThhZTA2MjMyMGVjL3RhYmxlcmFuZ2U6ZmJjYzc1OTZkNmFmNDU2NGFjODY1OGFlMDYyMzIwZWNfMjctMS0xLTEtMjgyMjE_fba2d0db-f182-4b4d-b9af-b2051ca4a076">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0ebb8d8bac3445859e468a3d048cfaf5_D20210101-20210331" decimals="-3" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yMi9mcmFnOjE0YmZlMmE4ZmYxMDRkZTk5MmJlYWMwYWM0MmY1NjA2L3RhYmxlOmZiY2M3NTk2ZDZhZjQ1NjRhYzg2NThhZTA2MjMyMGVjL3RhYmxlcmFuZ2U6ZmJjYzc1OTZkNmFmNDU2NGFjODY1OGFlMDYyMzIwZWNfMjctMy0xLTEtMjgyMjE_a23f9720-f9cd-4cc0-ba54-f5695e605ef8">33,541</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid to satisfy statutory withholding requirement for net settlement of cashless option exercises</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yMi9mcmFnOjE0YmZlMmE4ZmYxMDRkZTk5MmJlYWMwYWM0MmY1NjA2L3RhYmxlOmZiY2M3NTk2ZDZhZjQ1NjRhYzg2NThhZTA2MjMyMGVjL3RhYmxlcmFuZ2U6ZmJjYzc1OTZkNmFmNDU2NGFjODY1OGFlMDYyMzIwZWNfMjgtMS0xLTEtMjgyMjE_dc706619-103e-4181-a128-ae1edc12bc3d">1,888</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0ebb8d8bac3445859e468a3d048cfaf5_D20210101-20210331" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yMi9mcmFnOjE0YmZlMmE4ZmYxMDRkZTk5MmJlYWMwYWM0MmY1NjA2L3RhYmxlOmZiY2M3NTk2ZDZhZjQ1NjRhYzg2NThhZTA2MjMyMGVjL3RhYmxlcmFuZ2U6ZmJjYzc1OTZkNmFmNDU2NGFjODY1OGFlMDYyMzIwZWNfMjgtMy0xLTEtMjgyMjE_ddf58ccf-0235-435a-8ba3-3b696e2f3013">16,444</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yMi9mcmFnOjE0YmZlMmE4ZmYxMDRkZTk5MmJlYWMwYWM0MmY1NjA2L3RhYmxlOmZiY2M3NTk2ZDZhZjQ1NjRhYzg2NThhZTA2MjMyMGVjL3RhYmxlcmFuZ2U6ZmJjYzc1OTZkNmFmNDU2NGFjODY1OGFlMDYyMzIwZWNfMjktMS0xLTEtMjgyMjE_14fd0ea9-3fb9-4db5-86eb-5979221961fb">506</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0ebb8d8bac3445859e468a3d048cfaf5_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yMi9mcmFnOjE0YmZlMmE4ZmYxMDRkZTk5MmJlYWMwYWM0MmY1NjA2L3RhYmxlOmZiY2M3NTk2ZDZhZjQ1NjRhYzg2NThhZTA2MjMyMGVjL3RhYmxlcmFuZ2U6ZmJjYzc1OTZkNmFmNDU2NGFjODY1OGFlMDYyMzIwZWNfMjktMy0xLTEtMjgyMjE_45676314-a111-47b3-8ba3-b64e367fc8e4">45,947</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net decrease in cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yMi9mcmFnOjE0YmZlMmE4ZmYxMDRkZTk5MmJlYWMwYWM0MmY1NjA2L3RhYmxlOmZiY2M3NTk2ZDZhZjQ1NjRhYzg2NThhZTA2MjMyMGVjL3RhYmxlcmFuZ2U6ZmJjYzc1OTZkNmFmNDU2NGFjODY1OGFlMDYyMzIwZWNfMzAtMS0xLTEtMjgyMjE_43598ba1-d6c7-4fbc-becf-38cb34df8141">15,755</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0ebb8d8bac3445859e468a3d048cfaf5_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yMi9mcmFnOjE0YmZlMmE4ZmYxMDRkZTk5MmJlYWMwYWM0MmY1NjA2L3RhYmxlOmZiY2M3NTk2ZDZhZjQ1NjRhYzg2NThhZTA2MjMyMGVjL3RhYmxlcmFuZ2U6ZmJjYzc1OTZkNmFmNDU2NGFjODY1OGFlMDYyMzIwZWNfMzAtMy0xLTEtMjgyMjE_035b80f3-99c7-43e8-a540-d8eb64aa9a36">23,809</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents, at beginning of period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac7c0f0822b942fa8f45ea15693a76af_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yMi9mcmFnOjE0YmZlMmE4ZmYxMDRkZTk5MmJlYWMwYWM0MmY1NjA2L3RhYmxlOmZiY2M3NTk2ZDZhZjQ1NjRhYzg2NThhZTA2MjMyMGVjL3RhYmxlcmFuZ2U6ZmJjYzc1OTZkNmFmNDU2NGFjODY1OGFlMDYyMzIwZWNfMzEtMS0xLTEtMjgyMjE_99ffa09c-55ca-4608-b993-a0351284168a">77,617</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf01ece55408406c8103d0d47b49800a_I20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yMi9mcmFnOjE0YmZlMmE4ZmYxMDRkZTk5MmJlYWMwYWM0MmY1NjA2L3RhYmxlOmZiY2M3NTk2ZDZhZjQ1NjRhYzg2NThhZTA2MjMyMGVjL3RhYmxlcmFuZ2U6ZmJjYzc1OTZkNmFmNDU2NGFjODY1OGFlMDYyMzIwZWNfMzEtMy0xLTEtMjgyMjE_51407fdf-bfed-415c-9e00-66332930b03f">76,190</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents, at end of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93f424f685944c1aab994f99b0146441_I20220331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yMi9mcmFnOjE0YmZlMmE4ZmYxMDRkZTk5MmJlYWMwYWM0MmY1NjA2L3RhYmxlOmZiY2M3NTk2ZDZhZjQ1NjRhYzg2NThhZTA2MjMyMGVjL3RhYmxlcmFuZ2U6ZmJjYzc1OTZkNmFmNDU2NGFjODY1OGFlMDYyMzIwZWNfMzItMS0xLTEtMjgyMjE_c0aa1c3f-40c3-4473-9c83-628034f63fde">61,862</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82ca1385b4a848fd8ea581edd7dcbfdb_I20210331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yMi9mcmFnOjE0YmZlMmE4ZmYxMDRkZTk5MmJlYWMwYWM0MmY1NjA2L3RhYmxlOmZiY2M3NTk2ZDZhZjQ1NjRhYzg2NThhZTA2MjMyMGVjL3RhYmxlcmFuZ2U6ZmJjYzc1OTZkNmFmNDU2NGFjODY1OGFlMDYyMzIwZWNfMzItMy0xLTEtMjgyMjE_03d57dbd-ae54-4a4f-b5d7-473ad8fb2979">52,381</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental disclosure: </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of shares repurchased for net settlement of cashless option exercises</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331" decimals="-3" name="cort:SharesRepurchasedInNetSettlementOfCashlessOptionExercise" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yMi9mcmFnOjE0YmZlMmE4ZmYxMDRkZTk5MmJlYWMwYWM0MmY1NjA2L3RhYmxlOmZiY2M3NTk2ZDZhZjQ1NjRhYzg2NThhZTA2MjMyMGVjL3RhYmxlcmFuZ2U6ZmJjYzc1OTZkNmFmNDU2NGFjODY1OGFlMDYyMzIwZWNfMzUtMS0xLTEtMjgyMjE_06dba241-46e3-4e56-aabc-bf499b68d558">5,149</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ebb8d8bac3445859e468a3d048cfaf5_D20210101-20210331" decimals="-3" name="cort:SharesRepurchasedInNetSettlementOfCashlessOptionExercise" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yMi9mcmFnOjE0YmZlMmE4ZmYxMDRkZTk5MmJlYWMwYWM0MmY1NjA2L3RhYmxlOmZiY2M3NTk2ZDZhZjQ1NjRhYzg2NThhZTA2MjMyMGVjL3RhYmxlcmFuZ2U6ZmJjYzc1OTZkNmFmNDU2NGFjODY1OGFlMDYyMzIwZWNfMzUtMy0xLTEtMjgyMjE_cede10d8-1f10-4e16-9fe2-d852af38f6c3">6,045</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognition of right-of-use asset and lease liability</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331" decimals="-3" name="cort:NonCashTransactionRecognitionOfRightOfUseAssetAndLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yMi9mcmFnOjE0YmZlMmE4ZmYxMDRkZTk5MmJlYWMwYWM0MmY1NjA2L3RhYmxlOmZiY2M3NTk2ZDZhZjQ1NjRhYzg2NThhZTA2MjMyMGVjL3RhYmxlcmFuZ2U6ZmJjYzc1OTZkNmFmNDU2NGFjODY1OGFlMDYyMzIwZWNfMzYtMS0xLTEtMzU5NTk_cc3ff20c-3d5c-4c3c-9ae5-4d2f0d270752">2,816</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ebb8d8bac3445859e468a3d048cfaf5_D20210101-20210331" decimals="-3" name="cort:NonCashTransactionRecognitionOfRightOfUseAssetAndLeaseLiability" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yMi9mcmFnOjE0YmZlMmE4ZmYxMDRkZTk5MmJlYWMwYWM0MmY1NjA2L3RhYmxlOmZiY2M3NTk2ZDZhZjQ1NjRhYzg2NThhZTA2MjMyMGVjL3RhYmxlcmFuZ2U6ZmJjYzc1OTZkNmFmNDU2NGFjODY1OGFlMDYyMzIwZWNfMzYtMy0xLTEtMzU5NTk_e3e8b142-0e3a-4157-bc19-41a696bf9c7a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="i0a44765832c1416181e5729d6aaf7059_25"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CORCEPT THERAPEUTICS INCORPORATED</span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(In thousands)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.087%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.478%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.478%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.087%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.502%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.874%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common&#160;Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Treasury Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Income (Loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Retained Earnings</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Stockholders&#8217;<br/>Equity</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5ff8ab6f19e4485da8179e610307bf6f_I20201231" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yNS9mcmFnOmM1YmM1ZTZhMTI5NjQyZGJiZjExYjI1MWYxMjkyOTc4L3RhYmxlOjFiYTMwMzQ5NmYzMzRkOGI4ZTFjN2ZjYjYyMWZkNmIxL3RhYmxlcmFuZ2U6MWJhMzAzNDk2ZjMzNGQ4YjhlMWM3ZmNiNjIxZmQ2YjFfMi0xLTEtMS0yODIyMQ_7c6e9d97-9c5d-4d18-bd97-24a9470b8d9f">116,735</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ff8ab6f19e4485da8179e610307bf6f_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yNS9mcmFnOmM1YmM1ZTZhMTI5NjQyZGJiZjExYjI1MWYxMjkyOTc4L3RhYmxlOjFiYTMwMzQ5NmYzMzRkOGI4ZTFjN2ZjYjYyMWZkNmIxL3RhYmxlcmFuZ2U6MWJhMzAzNDk2ZjMzNGQ4YjhlMWM3ZmNiNjIxZmQ2YjFfMi0zLTEtMS0yODIyMQ_9a8401bb-9085-4244-8f8a-a38ca36ab0c9">122</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2e3456ee78d4b7e862e98401e421964_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yNS9mcmFnOmM1YmM1ZTZhMTI5NjQyZGJiZjExYjI1MWYxMjkyOTc4L3RhYmxlOjFiYTMwMzQ5NmYzMzRkOGI4ZTFjN2ZjYjYyMWZkNmIxL3RhYmxlcmFuZ2U6MWJhMzAzNDk2ZjMzNGQ4YjhlMWM3ZmNiNjIxZmQ2YjFfMi01LTEtMS0yODIyMQ_514aba18-e079-427a-b50c-70c29902a157">516,140</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iead727f3eb2b4b8fadf3c853db5498a8_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yNS9mcmFnOmM1YmM1ZTZhMTI5NjQyZGJiZjExYjI1MWYxMjkyOTc4L3RhYmxlOjFiYTMwMzQ5NmYzMzRkOGI4ZTFjN2ZjYjYyMWZkNmIxL3RhYmxlcmFuZ2U6MWJhMzAzNDk2ZjMzNGQ4YjhlMWM3ZmNiNjIxZmQ2YjFfMi03LTEtMS0yODIyMQ_1520ae43-9a5c-4eef-9362-1e7a33482e88">75,795</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c4a2585fb954bd1a1458a2999b7852e_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yNS9mcmFnOmM1YmM1ZTZhMTI5NjQyZGJiZjExYjI1MWYxMjkyOTc4L3RhYmxlOjFiYTMwMzQ5NmYzMzRkOGI4ZTFjN2ZjYjYyMWZkNmIxL3RhYmxlcmFuZ2U6MWJhMzAzNDk2ZjMzNGQ4YjhlMWM3ZmNiNjIxZmQ2YjFfMi05LTEtMS0yODIyMQ_748f93b8-64a8-4cfe-b46a-25b13f51572b">415</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iefe5359585e240dbbfd8196f176fb8d6_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yNS9mcmFnOmM1YmM1ZTZhMTI5NjQyZGJiZjExYjI1MWYxMjkyOTc4L3RhYmxlOjFiYTMwMzQ5NmYzMzRkOGI4ZTFjN2ZjYjYyMWZkNmIxL3RhYmxlcmFuZ2U6MWJhMzAzNDk2ZjMzNGQ4YjhlMWM3ZmNiNjIxZmQ2YjFfMi0xMS0xLTEtMjgyMjE_64e9236b-cf02-486e-851d-de3a80f06add">82,456</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf01ece55408406c8103d0d47b49800a_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yNS9mcmFnOmM1YmM1ZTZhMTI5NjQyZGJiZjExYjI1MWYxMjkyOTc4L3RhYmxlOjFiYTMwMzQ5NmYzMzRkOGI4ZTFjN2ZjYjYyMWZkNmIxL3RhYmxlcmFuZ2U6MWJhMzAzNDk2ZjMzNGQ4YjhlMWM3ZmNiNjIxZmQ2YjFfMi0xMy0xLTEtMjgyMjE_af79423e-93ba-4a33-bc15-fc05d15fdc17">523,338</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock upon exercise of options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibb5595d6b13d41d2bcc8ba20feea26f6_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yNS9mcmFnOmM1YmM1ZTZhMTI5NjQyZGJiZjExYjI1MWYxMjkyOTc4L3RhYmxlOjFiYTMwMzQ5NmYzMzRkOGI4ZTFjN2ZjYjYyMWZkNmIxL3RhYmxlcmFuZ2U6MWJhMzAzNDk2ZjMzNGQ4YjhlMWM3ZmNiNjIxZmQ2YjFfMy0xLTEtMS0yODIyMQ_4e6dc776-d632-4126-b0a6-3c12a68ccc29">1,832</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb5595d6b13d41d2bcc8ba20feea26f6_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yNS9mcmFnOmM1YmM1ZTZhMTI5NjQyZGJiZjExYjI1MWYxMjkyOTc4L3RhYmxlOjFiYTMwMzQ5NmYzMzRkOGI4ZTFjN2ZjYjYyMWZkNmIxL3RhYmxlcmFuZ2U6MWJhMzAzNDk2ZjMzNGQ4YjhlMWM3ZmNiNjIxZmQ2YjFfMy0zLTEtMS0yODIyMQ_3fc580c0-dfa5-498a-9eb1-d1625ffa713c">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e7dfdbf5bce4f52bb81937e0ca5ac46_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yNS9mcmFnOmM1YmM1ZTZhMTI5NjQyZGJiZjExYjI1MWYxMjkyOTc4L3RhYmxlOjFiYTMwMzQ5NmYzMzRkOGI4ZTFjN2ZjYjYyMWZkNmIxL3RhYmxlcmFuZ2U6MWJhMzAzNDk2ZjMzNGQ4YjhlMWM3ZmNiNjIxZmQ2YjFfMy01LTEtMS0yODIyMQ_a2ee2489-c72a-42a6-9083-3edf42312e79">10,081</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ebb8d8bac3445859e468a3d048cfaf5_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yNS9mcmFnOmM1YmM1ZTZhMTI5NjQyZGJiZjExYjI1MWYxMjkyOTc4L3RhYmxlOjFiYTMwMzQ5NmYzMzRkOGI4ZTFjN2ZjYjYyMWZkNmIxL3RhYmxlcmFuZ2U6MWJhMzAzNDk2ZjMzNGQ4YjhlMWM3ZmNiNjIxZmQ2YjFfMy0xMy0xLTEtMjgyMjE_6a121a95-1242-4be1-b6a6-6aec82154fb9">10,083</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchases of treasury stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ibb5595d6b13d41d2bcc8ba20feea26f6_D20210101-20210331" decimals="-3" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yNS9mcmFnOmM1YmM1ZTZhMTI5NjQyZGJiZjExYjI1MWYxMjkyOTc4L3RhYmxlOjFiYTMwMzQ5NmYzMzRkOGI4ZTFjN2ZjYjYyMWZkNmIxL3RhYmxlcmFuZ2U6MWJhMzAzNDk2ZjMzNGQ4YjhlMWM3ZmNiNjIxZmQ2YjFfNC0xLTEtMS0yODIyMQ_6525ac13-e7b1-495c-bbb6-817d82d6f812">1,282</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e50c96f60264b66aa29d189127a2f73_D20210101-20210331" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yNS9mcmFnOmM1YmM1ZTZhMTI5NjQyZGJiZjExYjI1MWYxMjkyOTc4L3RhYmxlOjFiYTMwMzQ5NmYzMzRkOGI4ZTFjN2ZjYjYyMWZkNmIxL3RhYmxlcmFuZ2U6MWJhMzAzNDk2ZjMzNGQ4YjhlMWM3ZmNiNjIxZmQ2YjFfNC03LTEtMS0yODIyMQ_f951f951-5700-44dc-a93f-54e227c55216">33,540</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0ebb8d8bac3445859e468a3d048cfaf5_D20210101-20210331" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yNS9mcmFnOmM1YmM1ZTZhMTI5NjQyZGJiZjExYjI1MWYxMjkyOTc4L3RhYmxlOjFiYTMwMzQ5NmYzMzRkOGI4ZTFjN2ZjYjYyMWZkNmIxL3RhYmxlcmFuZ2U6MWJhMzAzNDk2ZjMzNGQ4YjhlMWM3ZmNiNjIxZmQ2YjFfNC0xMy0xLTEtMjgyMjE_c0e76f14-c870-4155-88cb-cad263b10a9f">33,540</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares purchased to satisfy cost and statutory withholding requirements for net settlement of cashless option exercises</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ibb5595d6b13d41d2bcc8ba20feea26f6_D20210101-20210331" decimals="-3" name="us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yNS9mcmFnOmM1YmM1ZTZhMTI5NjQyZGJiZjExYjI1MWYxMjkyOTc4L3RhYmxlOjFiYTMwMzQ5NmYzMzRkOGI4ZTFjN2ZjYjYyMWZkNmIxL3RhYmxlcmFuZ2U6MWJhMzAzNDk2ZjMzNGQ4YjhlMWM3ZmNiNjIxZmQ2YjFfNS0xLTEtMS0zMTI3OA_029aafec-4e78-461b-a114-5e681c32ad1d">808</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e50c96f60264b66aa29d189127a2f73_D20210101-20210331" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yNS9mcmFnOmM1YmM1ZTZhMTI5NjQyZGJiZjExYjI1MWYxMjkyOTc4L3RhYmxlOjFiYTMwMzQ5NmYzMzRkOGI4ZTFjN2ZjYjYyMWZkNmIxL3RhYmxlcmFuZ2U6MWJhMzAzNDk2ZjMzNGQ4YjhlMWM3ZmNiNjIxZmQ2YjFfNS03LTEtMS0zMTI3OA_8975ca5c-9ca1-4a02-a08c-392ff3f34db9">22,520</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0ebb8d8bac3445859e468a3d048cfaf5_D20210101-20210331" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yNS9mcmFnOmM1YmM1ZTZhMTI5NjQyZGJiZjExYjI1MWYxMjkyOTc4L3RhYmxlOjFiYTMwMzQ5NmYzMzRkOGI4ZTFjN2ZjYjYyMWZkNmIxL3RhYmxlcmFuZ2U6MWJhMzAzNDk2ZjMzNGQ4YjhlMWM3ZmNiNjIxZmQ2YjFfNS0xMy0xLTEtMzEyNzg_6687cd5d-a01d-4cd3-ae89-975076fd7a68">22,520</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e7dfdbf5bce4f52bb81937e0ca5ac46_D20210101-20210331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yNS9mcmFnOmM1YmM1ZTZhMTI5NjQyZGJiZjExYjI1MWYxMjkyOTc4L3RhYmxlOjFiYTMwMzQ5NmYzMzRkOGI4ZTFjN2ZjYjYyMWZkNmIxL3RhYmxlcmFuZ2U6MWJhMzAzNDk2ZjMzNGQ4YjhlMWM3ZmNiNjIxZmQ2YjFfNS01LTEtMS0yODIyMQ_62596c26-d409-4281-b806-527e3dc7d881">10,142</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ebb8d8bac3445859e468a3d048cfaf5_D20210101-20210331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yNS9mcmFnOmM1YmM1ZTZhMTI5NjQyZGJiZjExYjI1MWYxMjkyOTc4L3RhYmxlOjFiYTMwMzQ5NmYzMzRkOGI4ZTFjN2ZjYjYyMWZkNmIxL3RhYmxlcmFuZ2U6MWJhMzAzNDk2ZjMzNGQ4YjhlMWM3ZmNiNjIxZmQ2YjFfNS0xMy0xLTEtMjgyMjE_040e54ee-65d9-4f76-9815-98d8e7de9132">10,142</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive loss, net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i785869b1921844f2925c8f4fcaf4ba3c_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yNS9mcmFnOmM1YmM1ZTZhMTI5NjQyZGJiZjExYjI1MWYxMjkyOTc4L3RhYmxlOjFiYTMwMzQ5NmYzMzRkOGI4ZTFjN2ZjYjYyMWZkNmIxL3RhYmxlcmFuZ2U6MWJhMzAzNDk2ZjMzNGQ4YjhlMWM3ZmNiNjIxZmQ2YjFfNi05LTEtMS0yODIyMQ_341049fb-08ff-42c5-a40c-016c7048bc98">166</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0ebb8d8bac3445859e468a3d048cfaf5_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yNS9mcmFnOmM1YmM1ZTZhMTI5NjQyZGJiZjExYjI1MWYxMjkyOTc4L3RhYmxlOjFiYTMwMzQ5NmYzMzRkOGI4ZTFjN2ZjYjYyMWZkNmIxL3RhYmxlcmFuZ2U6MWJhMzAzNDk2ZjMzNGQ4YjhlMWM3ZmNiNjIxZmQ2YjFfNi0xMy0xLTEtMjgyMjE_edd5022b-eafa-48e9-b55f-7152c88c2735">166</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56ca5c5bdd7045309e1ff91b29ed0b86_D20210101-20210331" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yNS9mcmFnOmM1YmM1ZTZhMTI5NjQyZGJiZjExYjI1MWYxMjkyOTc4L3RhYmxlOjFiYTMwMzQ5NmYzMzRkOGI4ZTFjN2ZjYjYyMWZkNmIxL3RhYmxlcmFuZ2U6MWJhMzAzNDk2ZjMzNGQ4YjhlMWM3ZmNiNjIxZmQ2YjFfNy0xMS0xLTEtMjgyMjE_8c9517fb-d18b-41d9-a5cf-11dfcb499de4">23,465</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ebb8d8bac3445859e468a3d048cfaf5_D20210101-20210331" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yNS9mcmFnOmM1YmM1ZTZhMTI5NjQyZGJiZjExYjI1MWYxMjkyOTc4L3RhYmxlOjFiYTMwMzQ5NmYzMzRkOGI4ZTFjN2ZjYjYyMWZkNmIxL3RhYmxlcmFuZ2U6MWJhMzAzNDk2ZjMzNGQ4YjhlMWM3ZmNiNjIxZmQ2YjFfNy0xMy0xLTEtMjgyMjE_56743350-7e56-4c65-bcd2-f32c5239092a">23,465</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at March 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9a1952ba686644179308d0cef13927e8_I20210331" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yNS9mcmFnOmM1YmM1ZTZhMTI5NjQyZGJiZjExYjI1MWYxMjkyOTc4L3RhYmxlOjFiYTMwMzQ5NmYzMzRkOGI4ZTFjN2ZjYjYyMWZkNmIxL3RhYmxlcmFuZ2U6MWJhMzAzNDk2ZjMzNGQ4YjhlMWM3ZmNiNjIxZmQ2YjFfOC0xLTEtMS0yODIyMQ_6dabf6ef-aa83-474c-8ebd-e6f1bde6f94b">116,477</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a1952ba686644179308d0cef13927e8_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yNS9mcmFnOmM1YmM1ZTZhMTI5NjQyZGJiZjExYjI1MWYxMjkyOTc4L3RhYmxlOjFiYTMwMzQ5NmYzMzRkOGI4ZTFjN2ZjYjYyMWZkNmIxL3RhYmxlcmFuZ2U6MWJhMzAzNDk2ZjMzNGQ4YjhlMWM3ZmNiNjIxZmQ2YjFfOC0zLTEtMS0yODIyMQ_ac0d6f54-08b5-4742-a0b7-2e2921f85b3e">124</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20c028d8e2514f38962d2bb482734e70_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yNS9mcmFnOmM1YmM1ZTZhMTI5NjQyZGJiZjExYjI1MWYxMjkyOTc4L3RhYmxlOjFiYTMwMzQ5NmYzMzRkOGI4ZTFjN2ZjYjYyMWZkNmIxL3RhYmxlcmFuZ2U6MWJhMzAzNDk2ZjMzNGQ4YjhlMWM3ZmNiNjIxZmQ2YjFfOC01LTEtMS0yODIyMQ_bf14ddbd-ad35-4bcf-8c8c-72307f78fe20">536,363</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4202ad56ab444c9cb8f35568184c2c74_I20210331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yNS9mcmFnOmM1YmM1ZTZhMTI5NjQyZGJiZjExYjI1MWYxMjkyOTc4L3RhYmxlOjFiYTMwMzQ5NmYzMzRkOGI4ZTFjN2ZjYjYyMWZkNmIxL3RhYmxlcmFuZ2U6MWJhMzAzNDk2ZjMzNGQ4YjhlMWM3ZmNiNjIxZmQ2YjFfOC03LTEtMS0yODIyMQ_5622a65d-c240-4608-a1c2-058871f70417">131,855</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73577ab94ef744cb885730e8ac822b29_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yNS9mcmFnOmM1YmM1ZTZhMTI5NjQyZGJiZjExYjI1MWYxMjkyOTc4L3RhYmxlOjFiYTMwMzQ5NmYzMzRkOGI4ZTFjN2ZjYjYyMWZkNmIxL3RhYmxlcmFuZ2U6MWJhMzAzNDk2ZjMzNGQ4YjhlMWM3ZmNiNjIxZmQ2YjFfOC05LTEtMS0yODIyMQ_3c8f2cd3-76ca-4f4f-aa23-21d1ca645cb5">249</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib16bf7702efd44cdbe57df570c7d75fb_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yNS9mcmFnOmM1YmM1ZTZhMTI5NjQyZGJiZjExYjI1MWYxMjkyOTc4L3RhYmxlOjFiYTMwMzQ5NmYzMzRkOGI4ZTFjN2ZjYjYyMWZkNmIxL3RhYmxlcmFuZ2U6MWJhMzAzNDk2ZjMzNGQ4YjhlMWM3ZmNiNjIxZmQ2YjFfOC0xMS0xLTEtMjgyMjE_d2109268-1a97-4476-964a-056188d2eb3c">105,921</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82ca1385b4a848fd8ea581edd7dcbfdb_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yNS9mcmFnOmM1YmM1ZTZhMTI5NjQyZGJiZjExYjI1MWYxMjkyOTc4L3RhYmxlOjFiYTMwMzQ5NmYzMzRkOGI4ZTFjN2ZjYjYyMWZkNmIxL3RhYmxlcmFuZ2U6MWJhMzAzNDk2ZjMzNGQ4YjhlMWM3ZmNiNjIxZmQ2YjFfOC0xMy0xLTEtMjgyMjE_c45f4cea-6601-4f4a-803a-b7011a5d9846">510,802</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icfafed6603474886b192b0632a2c6200_I20211231" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yNS9mcmFnOmM1YmM1ZTZhMTI5NjQyZGJiZjExYjI1MWYxMjkyOTc4L3RhYmxlOjFiYTMwMzQ5NmYzMzRkOGI4ZTFjN2ZjYjYyMWZkNmIxL3RhYmxlcmFuZ2U6MWJhMzAzNDk2ZjMzNGQ4YjhlMWM3ZmNiNjIxZmQ2YjFfMTAtMS0xLTEtMjgyMjE_b1c17722-a354-429e-95b1-4c44efa0461c">105,940</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfafed6603474886b192b0632a2c6200_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yNS9mcmFnOmM1YmM1ZTZhMTI5NjQyZGJiZjExYjI1MWYxMjkyOTc4L3RhYmxlOjFiYTMwMzQ5NmYzMzRkOGI4ZTFjN2ZjYjYyMWZkNmIxL3RhYmxlcmFuZ2U6MWJhMzAzNDk2ZjMzNGQ4YjhlMWM3ZmNiNjIxZmQ2YjFfMTAtMy0xLTEtMjgyMjE_6a80e682-e1d0-44e8-a759-c9ab9ce1edb9">127</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01f702e8e03c41358b69877f0f51d991_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yNS9mcmFnOmM1YmM1ZTZhMTI5NjQyZGJiZjExYjI1MWYxMjkyOTc4L3RhYmxlOjFiYTMwMzQ5NmYzMzRkOGI4ZTFjN2ZjYjYyMWZkNmIxL3RhYmxlcmFuZ2U6MWJhMzAzNDk2ZjMzNGQ4YjhlMWM3ZmNiNjIxZmQ2YjFfMTAtNS0xLTEtMjgyMjE_0a392857-546f-4757-917b-5c51687bfde5">591,349</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6c9d9c7004234ed49109777c938ab2ce_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yNS9mcmFnOmM1YmM1ZTZhMTI5NjQyZGJiZjExYjI1MWYxMjkyOTc4L3RhYmxlOjFiYTMwMzQ5NmYzMzRkOGI4ZTFjN2ZjYjYyMWZkNmIxL3RhYmxlcmFuZ2U6MWJhMzAzNDk2ZjMzNGQ4YjhlMWM3ZmNiNjIxZmQ2YjFfMTAtNy0xLTEtMjgyMjE_18dac129-859e-4cd4-85e4-117e9823c31a">410,411</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8b5fa79d20ab4ee28c43d8f3802fba08_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yNS9mcmFnOmM1YmM1ZTZhMTI5NjQyZGJiZjExYjI1MWYxMjkyOTc4L3RhYmxlOjFiYTMwMzQ5NmYzMzRkOGI4ZTFjN2ZjYjYyMWZkNmIxL3RhYmxlcmFuZ2U6MWJhMzAzNDk2ZjMzNGQ4YjhlMWM3ZmNiNjIxZmQ2YjFfMTAtOS0xLTEtMjgyMjE_83ff1c27-de4e-497e-bb0f-71a15ae03efd">227</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7ed3ef4514f42b8bd6ae955926a1ea8_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yNS9mcmFnOmM1YmM1ZTZhMTI5NjQyZGJiZjExYjI1MWYxMjkyOTc4L3RhYmxlOjFiYTMwMzQ5NmYzMzRkOGI4ZTFjN2ZjYjYyMWZkNmIxL3RhYmxlcmFuZ2U6MWJhMzAzNDk2ZjMzNGQ4YjhlMWM3ZmNiNjIxZmQ2YjFfMTAtMTEtMS0xLTI4MjIx_c2f3565f-d827-4891-83b6-b472de103c64">194,968</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac7c0f0822b942fa8f45ea15693a76af_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yNS9mcmFnOmM1YmM1ZTZhMTI5NjQyZGJiZjExYjI1MWYxMjkyOTc4L3RhYmxlOjFiYTMwMzQ5NmYzMzRkOGI4ZTFjN2ZjYjYyMWZkNmIxL3RhYmxlcmFuZ2U6MWJhMzAzNDk2ZjMzNGQ4YjhlMWM3ZmNiNjIxZmQ2YjFfMTAtMTMtMS0xLTI4MjIx_3a90785a-e782-46b4-8968-f5242c821296">375,806</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock upon exercise of options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0f04c1d847904902a0065f4c9a444cf1_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yNS9mcmFnOmM1YmM1ZTZhMTI5NjQyZGJiZjExYjI1MWYxMjkyOTc4L3RhYmxlOjFiYTMwMzQ5NmYzMzRkOGI4ZTFjN2ZjYjYyMWZkNmIxL3RhYmxlcmFuZ2U6MWJhMzAzNDk2ZjMzNGQ4YjhlMWM3ZmNiNjIxZmQ2YjFfMTEtMS0xLTEtMjgyMjE_97c384f9-8fd0-4f03-9000-8358991bf0a2">586</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f04c1d847904902a0065f4c9a444cf1_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yNS9mcmFnOmM1YmM1ZTZhMTI5NjQyZGJiZjExYjI1MWYxMjkyOTc4L3RhYmxlOjFiYTMwMzQ5NmYzMzRkOGI4ZTFjN2ZjYjYyMWZkNmIxL3RhYmxlcmFuZ2U6MWJhMzAzNDk2ZjMzNGQ4YjhlMWM3ZmNiNjIxZmQ2YjFfMTEtMy0xLTEtMjgyMjE_83a03cca-8c48-4ec7-948a-9c012e0cc73b">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1687f4482d3249aa9d6829a5eabaa2b3_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yNS9mcmFnOmM1YmM1ZTZhMTI5NjQyZGJiZjExYjI1MWYxMjkyOTc4L3RhYmxlOjFiYTMwMzQ5NmYzMzRkOGI4ZTFjN2ZjYjYyMWZkNmIxL3RhYmxlcmFuZ2U6MWJhMzAzNDk2ZjMzNGQ4YjhlMWM3ZmNiNjIxZmQ2YjFfMTEtNS0xLTEtMjgyMjE_8f2f8f4c-f6ba-4397-affb-fb47851a0769">6,543</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yNS9mcmFnOmM1YmM1ZTZhMTI5NjQyZGJiZjExYjI1MWYxMjkyOTc4L3RhYmxlOjFiYTMwMzQ5NmYzMzRkOGI4ZTFjN2ZjYjYyMWZkNmIxL3RhYmxlcmFuZ2U6MWJhMzAzNDk2ZjMzNGQ4YjhlMWM3ZmNiNjIxZmQ2YjFfMTEtMTMtMS0xLTI4MjIx_f8e6f14a-3db7-4092-86ae-377d938d6856">6,544</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares purchased to satisfy cost and statutory withholding requirements for net settlement of cashless option exercises</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i0f04c1d847904902a0065f4c9a444cf1_D20220101-20220331" decimals="-3" name="us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yNS9mcmFnOmM1YmM1ZTZhMTI5NjQyZGJiZjExYjI1MWYxMjkyOTc4L3RhYmxlOjFiYTMwMzQ5NmYzMzRkOGI4ZTFjN2ZjYjYyMWZkNmIxL3RhYmxlcmFuZ2U6MWJhMzAzNDk2ZjMzNGQ4YjhlMWM3ZmNiNjIxZmQ2YjFfMTMtMS0xLTEtMjgyMjE_4a4a293a-0d26-4b18-a8f4-1d4bf0679e86">305</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6208146b7098480389c1e89596396c07_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yNS9mcmFnOmM1YmM1ZTZhMTI5NjQyZGJiZjExYjI1MWYxMjkyOTc4L3RhYmxlOjFiYTMwMzQ5NmYzMzRkOGI4ZTFjN2ZjYjYyMWZkNmIxL3RhYmxlcmFuZ2U6MWJhMzAzNDk2ZjMzNGQ4YjhlMWM3ZmNiNjIxZmQ2YjFfMTMtNy0xLTEtMjgyMjE_4d122151-cf4c-42e1-8eee-714ee4946329">7,037</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yNS9mcmFnOmM1YmM1ZTZhMTI5NjQyZGJiZjExYjI1MWYxMjkyOTc4L3RhYmxlOjFiYTMwMzQ5NmYzMzRkOGI4ZTFjN2ZjYjYyMWZkNmIxL3RhYmxlcmFuZ2U6MWJhMzAzNDk2ZjMzNGQ4YjhlMWM3ZmNiNjIxZmQ2YjFfMTMtMTMtMS0xLTI4MjIx_b5037f49-dd06-442d-b19b-8701fefc0297">7,037</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1687f4482d3249aa9d6829a5eabaa2b3_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yNS9mcmFnOmM1YmM1ZTZhMTI5NjQyZGJiZjExYjI1MWYxMjkyOTc4L3RhYmxlOjFiYTMwMzQ5NmYzMzRkOGI4ZTFjN2ZjYjYyMWZkNmIxL3RhYmxlcmFuZ2U6MWJhMzAzNDk2ZjMzNGQ4YjhlMWM3ZmNiNjIxZmQ2YjFfMTQtNS0xLTEtMjgyMjE_e59e0939-c2a3-450a-ae43-89c13ea44b65">10,825</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yNS9mcmFnOmM1YmM1ZTZhMTI5NjQyZGJiZjExYjI1MWYxMjkyOTc4L3RhYmxlOjFiYTMwMzQ5NmYzMzRkOGI4ZTFjN2ZjYjYyMWZkNmIxL3RhYmxlcmFuZ2U6MWJhMzAzNDk2ZjMzNGQ4YjhlMWM3ZmNiNjIxZmQ2YjFfMTQtMTMtMS0xLTI4MjIx_ee5b9259-0cc8-4a26-bf67-cc6eb7af6a4d">10,825</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive loss, net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i46f01246740a46a892ddb27be4dd69aa_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yNS9mcmFnOmM1YmM1ZTZhMTI5NjQyZGJiZjExYjI1MWYxMjkyOTc4L3RhYmxlOjFiYTMwMzQ5NmYzMzRkOGI4ZTFjN2ZjYjYyMWZkNmIxL3RhYmxlcmFuZ2U6MWJhMzAzNDk2ZjMzNGQ4YjhlMWM3ZmNiNjIxZmQ2YjFfMTUtOS0xLTEtMjgyMjE_89987c4b-137b-4227-83f6-74625025c14e">1,124</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yNS9mcmFnOmM1YmM1ZTZhMTI5NjQyZGJiZjExYjI1MWYxMjkyOTc4L3RhYmxlOjFiYTMwMzQ5NmYzMzRkOGI4ZTFjN2ZjYjYyMWZkNmIxL3RhYmxlcmFuZ2U6MWJhMzAzNDk2ZjMzNGQ4YjhlMWM3ZmNiNjIxZmQ2YjFfMTUtMTMtMS0xLTI4MjIx_14cb3900-a058-461a-8de9-50ced5ab8366">1,124</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i583bb074d98646df863c37e27250f660_D20220101-20220331" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yNS9mcmFnOmM1YmM1ZTZhMTI5NjQyZGJiZjExYjI1MWYxMjkyOTc4L3RhYmxlOjFiYTMwMzQ5NmYzMzRkOGI4ZTFjN2ZjYjYyMWZkNmIxL3RhYmxlcmFuZ2U6MWJhMzAzNDk2ZjMzNGQ4YjhlMWM3ZmNiNjIxZmQ2YjFfMTYtMTEtMS0xLTI4MjIx_53f4a467-4af8-40f5-9155-f043a3a8d86a">22,797</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yNS9mcmFnOmM1YmM1ZTZhMTI5NjQyZGJiZjExYjI1MWYxMjkyOTc4L3RhYmxlOjFiYTMwMzQ5NmYzMzRkOGI4ZTFjN2ZjYjYyMWZkNmIxL3RhYmxlcmFuZ2U6MWJhMzAzNDk2ZjMzNGQ4YjhlMWM3ZmNiNjIxZmQ2YjFfMTYtMTMtMS0xLTI4MjIx_959e18e3-68b8-46a8-a22e-ce4839a408ff">22,797</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at March 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i06b129367f5c4d9ab7b570f6972b2ed1_I20220331" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yNS9mcmFnOmM1YmM1ZTZhMTI5NjQyZGJiZjExYjI1MWYxMjkyOTc4L3RhYmxlOjFiYTMwMzQ5NmYzMzRkOGI4ZTFjN2ZjYjYyMWZkNmIxL3RhYmxlcmFuZ2U6MWJhMzAzNDk2ZjMzNGQ4YjhlMWM3ZmNiNjIxZmQ2YjFfMTctMS0xLTEtMjgyMjE_62aff1ca-6618-4e6d-9daa-e39689a14233">106,221</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06b129367f5c4d9ab7b570f6972b2ed1_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yNS9mcmFnOmM1YmM1ZTZhMTI5NjQyZGJiZjExYjI1MWYxMjkyOTc4L3RhYmxlOjFiYTMwMzQ5NmYzMzRkOGI4ZTFjN2ZjYjYyMWZkNmIxL3RhYmxlcmFuZ2U6MWJhMzAzNDk2ZjMzNGQ4YjhlMWM3ZmNiNjIxZmQ2YjFfMTctMy0xLTEtMjgyMjE_b9142781-ff0c-42a3-ab6c-e9be33328c3c">128</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47740de74c10439fbf11f8788c4cba45_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yNS9mcmFnOmM1YmM1ZTZhMTI5NjQyZGJiZjExYjI1MWYxMjkyOTc4L3RhYmxlOjFiYTMwMzQ5NmYzMzRkOGI4ZTFjN2ZjYjYyMWZkNmIxL3RhYmxlcmFuZ2U6MWJhMzAzNDk2ZjMzNGQ4YjhlMWM3ZmNiNjIxZmQ2YjFfMTctNS0xLTEtMjgyMjE_9122f2a8-6ef3-4d43-bc3a-034db49bfeac">608,717</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5f57f8164f0a46daacc1c2551a60659f_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yNS9mcmFnOmM1YmM1ZTZhMTI5NjQyZGJiZjExYjI1MWYxMjkyOTc4L3RhYmxlOjFiYTMwMzQ5NmYzMzRkOGI4ZTFjN2ZjYjYyMWZkNmIxL3RhYmxlcmFuZ2U6MWJhMzAzNDk2ZjMzNGQ4YjhlMWM3ZmNiNjIxZmQ2YjFfMTctNy0xLTEtMjgyMjE_d5d83358-864f-4283-bd80-046a0e2cafbd">417,448</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic45e1a7a754a469fa7d8a3ad69b13727_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yNS9mcmFnOmM1YmM1ZTZhMTI5NjQyZGJiZjExYjI1MWYxMjkyOTc4L3RhYmxlOjFiYTMwMzQ5NmYzMzRkOGI4ZTFjN2ZjYjYyMWZkNmIxL3RhYmxlcmFuZ2U6MWJhMzAzNDk2ZjMzNGQ4YjhlMWM3ZmNiNjIxZmQ2YjFfMTctOS0xLTEtMjgyMjE_2637180c-305b-4f54-8960-86feb629ae17">1,351</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75024e565e314398a3b2b50b649c5486_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yNS9mcmFnOmM1YmM1ZTZhMTI5NjQyZGJiZjExYjI1MWYxMjkyOTc4L3RhYmxlOjFiYTMwMzQ5NmYzMzRkOGI4ZTFjN2ZjYjYyMWZkNmIxL3RhYmxlcmFuZ2U6MWJhMzAzNDk2ZjMzNGQ4YjhlMWM3ZmNiNjIxZmQ2YjFfMTctMTEtMS0xLTI4MjIx_a53f27bf-cfa1-40a0-b145-c909a6323b44">217,765</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93f424f685944c1aab994f99b0146441_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yNS9mcmFnOmM1YmM1ZTZhMTI5NjQyZGJiZjExYjI1MWYxMjkyOTc4L3RhYmxlOjFiYTMwMzQ5NmYzMzRkOGI4ZTFjN2ZjYjYyMWZkNmIxL3RhYmxlcmFuZ2U6MWJhMzAzNDk2ZjMzNGQ4YjhlMWM3ZmNiNjIxZmQ2YjFfMTctMTMtMS0xLTI4MjIx_c8949280-0c87-4027-a557-598e8e911a16">407,811</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed consolidated financial statements</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><div id="i0a44765832c1416181e5729d6aaf7059_28"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CORCEPT THERAPEUTICS INCORPORATED</span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div id="i0a44765832c1416181e5729d6aaf7059_31"></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1. <ix:nonNumeric contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zMS9mcmFnOjE4Y2EyYjU1ODFkZjQzZmNhZWY1M2QyMWU1YzkyOGMzL3RleHRyZWdpb246MThjYTJiNTU4MWRmNDNmY2FlZjUzZDIxZTVjOTI4YzNfMjg2NA_28e216a4-3f65-421a-a105-341d13e75478" continuedAt="ic2ec61eda1514c61b499c28b70b6938c" escape="true">Basis of Presentation and Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="ic2ec61eda1514c61b499c28b70b6938c"><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Description of Business and Basis of Presentation</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corcept Therapeutics Incorporated is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe endocrine, metabolic, oncologic, and neurological disorders by modulating the effects of the hormone cortisol.&#160;In 2012, the United States Food and Drug Administration (&#8220;FDA&#8221;) approved Korlym&#160;(&#8220;mifepristone&#8221;) 300&#160;mg tablets, as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing&#8217;s syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. We have discovered&#160;and patented <ix:nonFraction unitRef="series" contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331" decimals="INF" name="cort:NumberOfSeriesOfSelectiveCortisolModulators" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zMS9mcmFnOjE4Y2EyYjU1ODFkZjQzZmNhZWY1M2QyMWU1YzkyOGMzL3RleHRyZWdpb246MThjYTJiNTU4MWRmNDNmY2FlZjUzZDIxZTVjOTI4YzNfNzY2_acdf09b1-2fd9-4fa4-b4d7-0aa9f6f4ea36">four</ix:nonFraction>&#160;structurally distinct series of selective cortisol modulators, consisting of more than&#160;1,000&#160;compounds. We are developing compounds from these series as potential treatments for a broad range of serious disorders.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We were incorporated in the State of&#160;Delaware&#160;in&#160;May 1998. Our headquarters are located in Menlo Park, California.</span></div><ix:nonNumeric contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zMS9mcmFnOjE4Y2EyYjU1ODFkZjQzZmNhZWY1M2QyMWU1YzkyOGMzL3RleHRyZWdpb246MThjYTJiNTU4MWRmNDNmY2FlZjUzZDIxZTVjOTI4YzNfMjg0OA_210f8c6c-ad72-4d6a-b382-3d0ffe376b54" escape="true"><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have prepared the following in accordance with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X: (i) condensed consolidated balance sheet as of March&#160;31, 2022 and (ii) condensed consolidated statements of comprehensive income, cash flows and stockholders&#8217; equity for the three-month periods ended March&#160;31, 2022 and 2021. These do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments considered necessary for a fair presentation (which in the applicable periods consist only of normal, recurring adjustments) have been included. Operating results for the three months ended March 31, 2022 are not necessarily indicative of the results for the remainder of 2022 or any other period. These financial statements and notes should be read in conjunction with the financial statements for the year ended December&#160;31, 2021 included in our Annual Report on Form 10-K. The December&#160;31, 2021 balance sheet was derived from audited financial statements at that date.</span></div></ix:nonNumeric><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material changes to the significant accounting policies described in our Annual Report on Form&#160;10-K for the year ended&#160;December&#160;31, 2021.</span></div></ix:continuation><div id="i0a44765832c1416181e5729d6aaf7059_34"></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2. <ix:nonNumeric contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331" name="us-gaap:SupplementalBalanceSheetDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNC9mcmFnOjJjMDM1ZTVhYzJjNDQwN2U4NzM5NmY1YjU2ZDg1NWVkL3RleHRyZWdpb246MmMwMzVlNWFjMmM0NDA3ZTg3Mzk2ZjViNTZkODU1ZWRfNTEz_f7ff9c4b-9689-484a-8969-a79bf1e1626d" continuedAt="i50fa1f860f854bd28a17247c350259c5" escape="true">Composition of Certain Balance Sheet Items</ix:nonNumeric></span></div><ix:continuation id="i50fa1f860f854bd28a17247c350259c5" continuedAt="i56f21095f3a34d3f9585941cd546ba09"><ix:nonNumeric contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNC9mcmFnOjJjMDM1ZTVhYzJjNDQwN2U4NzM5NmY1YjU2ZDg1NWVkL3RleHRyZWdpb246MmMwMzVlNWFjMmM0NDA3ZTg3Mzk2ZjViNTZkODU1ZWRfNTAz_5597066b-f438-4408-a651-1a175c0006d1" escape="true"><ix:nonNumeric contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331" name="us-gaap:ScheduleOfInventoryNoncurrentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNC9mcmFnOjJjMDM1ZTVhYzJjNDQwN2U4NzM5NmY1YjU2ZDg1NWVkL3RleHRyZWdpb246MmMwMzVlNWFjMmM0NDA3ZTg3Mzk2ZjViNTZkODU1ZWRfNTAz_9327322b-f5d6-4dee-a3d9-0857ca0840a6" escape="true"><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Inventory</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.028%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.545%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in progress</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93f424f685944c1aab994f99b0146441_I20220331" decimals="-3" name="cort:InventoryWorkInProcessCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNC9mcmFnOjJjMDM1ZTVhYzJjNDQwN2U4NzM5NmY1YjU2ZDg1NWVkL3RhYmxlOjNmYjFhM2JiMjc2MTQ3NGY4NTNmNDRiZjY0ZDc2YTg3L3RhYmxlcmFuZ2U6M2ZiMWEzYmIyNzYxNDc0Zjg1M2Y0NGJmNjRkNzZhODdfNC0xLTEtMS0yODIyMQ_9a688ad4-d31d-46a4-a24a-7978c625c3d5">12,637</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac7c0f0822b942fa8f45ea15693a76af_I20211231" decimals="-3" name="cort:InventoryWorkInProcessCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNC9mcmFnOjJjMDM1ZTVhYzJjNDQwN2U4NzM5NmY1YjU2ZDg1NWVkL3RhYmxlOjNmYjFhM2JiMjc2MTQ3NGY4NTNmNDRiZjY0ZDc2YTg3L3RhYmxlcmFuZ2U6M2ZiMWEzYmIyNzYxNDc0Zjg1M2Y0NGJmNjRkNzZhODdfNC0zLTEtMS0yODIyMQ_c3d4a1fc-8c75-48b4-a070-245396d625e2">11,450</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93f424f685944c1aab994f99b0146441_I20220331" decimals="-3" name="cort:InventoryFinishedGoodsCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNC9mcmFnOjJjMDM1ZTVhYzJjNDQwN2U4NzM5NmY1YjU2ZDg1NWVkL3RhYmxlOjNmYjFhM2JiMjc2MTQ3NGY4NTNmNDRiZjY0ZDc2YTg3L3RhYmxlcmFuZ2U6M2ZiMWEzYmIyNzYxNDc0Zjg1M2Y0NGJmNjRkNzZhODdfNS0xLTEtMS0yODIyMQ_8d2edc40-51bb-444e-865d-26f31b53c30d">5,540</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac7c0f0822b942fa8f45ea15693a76af_I20211231" decimals="-3" name="cort:InventoryFinishedGoodsCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNC9mcmFnOjJjMDM1ZTVhYzJjNDQwN2U4NzM5NmY1YjU2ZDg1NWVkL3RhYmxlOjNmYjFhM2JiMjc2MTQ3NGY4NTNmNDRiZjY0ZDc2YTg3L3RhYmxlcmFuZ2U6M2ZiMWEzYmIyNzYxNDc0Zjg1M2Y0NGJmNjRkNzZhODdfNS0zLTEtMS0yODIyMQ_7a50245a-1ac3-40dc-8c73-f1e992628f9e">6,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventory</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93f424f685944c1aab994f99b0146441_I20220331" decimals="-3" name="cort:InventoryCurrentNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNC9mcmFnOjJjMDM1ZTVhYzJjNDQwN2U4NzM5NmY1YjU2ZDg1NWVkL3RhYmxlOjNmYjFhM2JiMjc2MTQ3NGY4NTNmNDRiZjY0ZDc2YTg3L3RhYmxlcmFuZ2U6M2ZiMWEzYmIyNzYxNDc0Zjg1M2Y0NGJmNjRkNzZhODdfNi0xLTEtMS0yODIyMQ_72030d5e-ede4-4700-8cab-6758fefcd581">18,177</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac7c0f0822b942fa8f45ea15693a76af_I20211231" decimals="-3" name="cort:InventoryCurrentNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNC9mcmFnOjJjMDM1ZTVhYzJjNDQwN2U4NzM5NmY1YjU2ZDg1NWVkL3RhYmxlOjNmYjFhM2JiMjc2MTQ3NGY4NTNmNDRiZjY0ZDc2YTg3L3RhYmxlcmFuZ2U6M2ZiMWEzYmIyNzYxNDc0Zjg1M2Y0NGJmNjRkNzZhODdfNi0zLTEtMS0yODIyMQ_26ac613d-879b-42d0-b440-a5fe48f81faf">17,950</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less strategic inventory classified as non-current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i93f424f685944c1aab994f99b0146441_I20220331" decimals="-3" name="us-gaap:InventoryNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNC9mcmFnOjJjMDM1ZTVhYzJjNDQwN2U4NzM5NmY1YjU2ZDg1NWVkL3RhYmxlOjNmYjFhM2JiMjc2MTQ3NGY4NTNmNDRiZjY0ZDc2YTg3L3RhYmxlcmFuZ2U6M2ZiMWEzYmIyNzYxNDc0Zjg1M2Y0NGJmNjRkNzZhODdfNy0xLTEtMS0yODIyMQ_95d2dd36-358e-493a-800c-dca773ae5629">13,098</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iac7c0f0822b942fa8f45ea15693a76af_I20211231" decimals="-3" name="us-gaap:InventoryNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNC9mcmFnOjJjMDM1ZTVhYzJjNDQwN2U4NzM5NmY1YjU2ZDg1NWVkL3RhYmxlOjNmYjFhM2JiMjc2MTQ3NGY4NTNmNDRiZjY0ZDc2YTg3L3RhYmxlcmFuZ2U6M2ZiMWEzYmIyNzYxNDc0Zjg1M2Y0NGJmNjRkNzZhODdfNy0zLTEtMS0yODIyMQ_6aa07b2b-51c2-473f-af70-6bc62c10e9d3">12,962</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventory classified as current</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93f424f685944c1aab994f99b0146441_I20220331" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNC9mcmFnOjJjMDM1ZTVhYzJjNDQwN2U4NzM5NmY1YjU2ZDg1NWVkL3RhYmxlOjNmYjFhM2JiMjc2MTQ3NGY4NTNmNDRiZjY0ZDc2YTg3L3RhYmxlcmFuZ2U6M2ZiMWEzYmIyNzYxNDc0Zjg1M2Y0NGJmNjRkNzZhODdfOC0xLTEtMS0yODIyMQ_e2162cc8-7097-4894-b050-b15b39566e98">5,079</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac7c0f0822b942fa8f45ea15693a76af_I20211231" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNC9mcmFnOjJjMDM1ZTVhYzJjNDQwN2U4NzM5NmY1YjU2ZDg1NWVkL3RhYmxlOjNmYjFhM2JiMjc2MTQ3NGY4NTNmNDRiZjY0ZDc2YTg3L3RhYmxlcmFuZ2U6M2ZiMWEzYmIyNzYxNDc0Zjg1M2Y0NGJmNjRkNzZhODdfOC0zLTEtMS0yODIyMQ_d8e2570e-1519-4d1b-a3d2-54aaa77cdd5f">4,988</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:nonNumeric><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because we rely on a single manufacturer to produce Korlym&#8217;s active pharmaceutical ingredient (&#8220;API&#8221;), we have purchased and hold significant quantities of API, included in work in progress inventory. We classify inventory we do not expect to sell within 12 months of the balance sheet date as &#8220;Strategic Inventory,&#8221; a long-term asset.&#160;</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><ix:continuation id="i56f21095f3a34d3f9585941cd546ba09"><ix:nonNumeric contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNC9mcmFnOjJjMDM1ZTVhYzJjNDQwN2U4NzM5NmY1YjU2ZDg1NWVkL3RleHRyZWdpb246MmMwMzVlNWFjMmM0NDA3ZTg3Mzk2ZjViNTZkODU1ZWRfNTE3_1a3e7a28-02f0-4792-a330-ec085918744c" escape="true"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Property and equipment</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.882%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.545%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and equipment</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b6f130b2b314f4cb240b19c11d8ccfc_I20220331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNC9mcmFnOjJjMDM1ZTVhYzJjNDQwN2U4NzM5NmY1YjU2ZDg1NWVkL3RhYmxlOmNkZWMwZDBiMDdkMzRjOTliNGNhNTg1YzFkN2U5OTBjL3RhYmxlcmFuZ2U6Y2RlYzBkMGIwN2QzNGM5OWI0Y2E1ODVjMWQ3ZTk5MGNfMy0xLTEtMS0yODIyMQ_0d75a32b-7766-4d6a-a32f-879b99501dcf">1,169</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i320d5eb76f6e462191442b9efd3d1df7_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNC9mcmFnOjJjMDM1ZTVhYzJjNDQwN2U4NzM5NmY1YjU2ZDg1NWVkL3RhYmxlOmNkZWMwZDBiMDdkMzRjOTliNGNhNTg1YzFkN2U5OTBjL3RhYmxlcmFuZ2U6Y2RlYzBkMGIwN2QzNGM5OWI0Y2E1ODVjMWQ3ZTk5MGNfMy0zLTEtMS0yODIyMQ_4a74b681-61e6-411a-b4f9-d18bdaea7927">1,157</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i300a48854f3e4841a4231047bf2b6d83_I20220331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNC9mcmFnOjJjMDM1ZTVhYzJjNDQwN2U4NzM5NmY1YjU2ZDg1NWVkL3RhYmxlOmNkZWMwZDBiMDdkMzRjOTliNGNhNTg1YzFkN2U5OTBjL3RhYmxlcmFuZ2U6Y2RlYzBkMGIwN2QzNGM5OWI0Y2E1ODVjMWQ3ZTk5MGNfNC0xLTEtMS0yODIyMQ_dc263b09-8875-4ce5-96a7-e30f86784a33">1,508</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if054d789bd774097bce632cad662d551_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNC9mcmFnOjJjMDM1ZTVhYzJjNDQwN2U4NzM5NmY1YjU2ZDg1NWVkL3RhYmxlOmNkZWMwZDBiMDdkMzRjOTliNGNhNTg1YzFkN2U5OTBjL3RhYmxlcmFuZ2U6Y2RlYzBkMGIwN2QzNGM5OWI0Y2E1ODVjMWQ3ZTk5MGNfNC0zLTEtMS0yODIyMQ_1d35799e-2fa4-49cc-8484-78ad697dcb25">1,508</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a00554864174d1583c51eb587009a9e_I20220331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNC9mcmFnOjJjMDM1ZTVhYzJjNDQwN2U4NzM5NmY1YjU2ZDg1NWVkL3RhYmxlOmNkZWMwZDBiMDdkMzRjOTliNGNhNTg1YzFkN2U5OTBjL3RhYmxlcmFuZ2U6Y2RlYzBkMGIwN2QzNGM5OWI0Y2E1ODVjMWQ3ZTk5MGNfNS0xLTEtMS0yODIyMQ_7f792909-8e10-4c7b-8c0d-31c8f4d6b50a">1,262</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a314602e38747e383f53643af483ebe_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNC9mcmFnOjJjMDM1ZTVhYzJjNDQwN2U4NzM5NmY1YjU2ZDg1NWVkL3RhYmxlOmNkZWMwZDBiMDdkMzRjOTliNGNhNTg1YzFkN2U5OTBjL3RhYmxlcmFuZ2U6Y2RlYzBkMGIwN2QzNGM5OWI0Y2E1ODVjMWQ3ZTk5MGNfNS0zLTEtMS0yODIyMQ_353487e1-5ae9-4bb6-9f4b-2c2332e380b1">1,262</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93f424f685944c1aab994f99b0146441_I20220331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNC9mcmFnOjJjMDM1ZTVhYzJjNDQwN2U4NzM5NmY1YjU2ZDg1NWVkL3RhYmxlOmNkZWMwZDBiMDdkMzRjOTliNGNhNTg1YzFkN2U5OTBjL3RhYmxlcmFuZ2U6Y2RlYzBkMGIwN2QzNGM5OWI0Y2E1ODVjMWQ3ZTk5MGNfNi0xLTEtMS0yODIyMQ_f55ed158-30d5-466a-8a8a-3d2ff92f284d">3,939</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac7c0f0822b942fa8f45ea15693a76af_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNC9mcmFnOjJjMDM1ZTVhYzJjNDQwN2U4NzM5NmY1YjU2ZDg1NWVkL3RhYmxlOmNkZWMwZDBiMDdkMzRjOTliNGNhNTg1YzFkN2U5OTBjL3RhYmxlcmFuZ2U6Y2RlYzBkMGIwN2QzNGM5OWI0Y2E1ODVjMWQ3ZTk5MGNfNi0zLTEtMS0yODIyMQ_2fad7fa2-32f1-4eac-899a-5f3fad9d106c">3,927</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i93f424f685944c1aab994f99b0146441_I20220331" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNC9mcmFnOjJjMDM1ZTVhYzJjNDQwN2U4NzM5NmY1YjU2ZDg1NWVkL3RhYmxlOmNkZWMwZDBiMDdkMzRjOTliNGNhNTg1YzFkN2U5OTBjL3RhYmxlcmFuZ2U6Y2RlYzBkMGIwN2QzNGM5OWI0Y2E1ODVjMWQ3ZTk5MGNfNy0xLTEtMS0yODIyMQ_e2023ccc-af56-4fc0-ab66-2468b65c941a">3,213</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iac7c0f0822b942fa8f45ea15693a76af_I20211231" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNC9mcmFnOjJjMDM1ZTVhYzJjNDQwN2U4NzM5NmY1YjU2ZDg1NWVkL3RhYmxlOmNkZWMwZDBiMDdkMzRjOTliNGNhNTg1YzFkN2U5OTBjL3RhYmxlcmFuZ2U6Y2RlYzBkMGIwN2QzNGM5OWI0Y2E1ODVjMWQ3ZTk5MGNfNy0zLTEtMS0yODIyMQ_72f51641-7d60-4fd4-ac50-2609b5df8ba5">2,925</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net of accumulated depreciation and amortization</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93f424f685944c1aab994f99b0146441_I20220331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNC9mcmFnOjJjMDM1ZTVhYzJjNDQwN2U4NzM5NmY1YjU2ZDg1NWVkL3RhYmxlOmNkZWMwZDBiMDdkMzRjOTliNGNhNTg1YzFkN2U5OTBjL3RhYmxlcmFuZ2U6Y2RlYzBkMGIwN2QzNGM5OWI0Y2E1ODVjMWQ3ZTk5MGNfOC0xLTEtMS0yODIyMQ_fb29fd6a-ec49-4de4-981d-dd236330ca96">726</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac7c0f0822b942fa8f45ea15693a76af_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNC9mcmFnOjJjMDM1ZTVhYzJjNDQwN2U4NzM5NmY1YjU2ZDg1NWVkL3RhYmxlOmNkZWMwZDBiMDdkMzRjOTliNGNhNTg1YzFkN2U5OTBjL3RhYmxlcmFuZ2U6Y2RlYzBkMGIwN2QzNGM5OWI0Y2E1ODVjMWQ3ZTk5MGNfOC0zLTEtMS0yODIyMQ_a9d3200c-ef1d-44be-8218-af6f12a6d265">1,002</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNC9mcmFnOjJjMDM1ZTVhYzJjNDQwN2U4NzM5NmY1YjU2ZDg1NWVkL3RleHRyZWdpb246MmMwMzVlNWFjMmM0NDA3ZTg3Mzk2ZjViNTZkODU1ZWRfNTEx_049ad0df-c76a-4328-940e-1d30bb719698" escape="true"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accrued and other liabilities</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.882%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.545%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government rebates</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93f424f685944c1aab994f99b0146441_I20220331" decimals="-3" name="cort:AccruedGovernmentRebateCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNC9mcmFnOjJjMDM1ZTVhYzJjNDQwN2U4NzM5NmY1YjU2ZDg1NWVkL3RhYmxlOjAzZTIyMGI5ZWZlMDQ2YmM5MTExZjc2MjZkMzhkNmM0L3RhYmxlcmFuZ2U6MDNlMjIwYjllZmUwNDZiYzkxMTFmNzYyNmQzOGQ2YzRfMy0xLTEtMS0yODIyMQ_e998d12e-12b5-4910-8326-074c77c74baa">12,377</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac7c0f0822b942fa8f45ea15693a76af_I20211231" decimals="-3" name="cort:AccruedGovernmentRebateCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNC9mcmFnOjJjMDM1ZTVhYzJjNDQwN2U4NzM5NmY1YjU2ZDg1NWVkL3RhYmxlOjAzZTIyMGI5ZWZlMDQ2YmM5MTExZjc2MjZkMzhkNmM0L3RhYmxlcmFuZ2U6MDNlMjIwYjllZmUwNDZiYzkxMTFmNzYyNmQzOGQ2YzRfMy0zLTEtMS0yODIyMQ_4bacaea1-6932-48c9-b13d-adb287d17ef6">11,174</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued income taxes payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93f424f685944c1aab994f99b0146441_I20220331" decimals="-3" name="us-gaap:AccruedIncomeTaxesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNC9mcmFnOjJjMDM1ZTVhYzJjNDQwN2U4NzM5NmY1YjU2ZDg1NWVkL3RhYmxlOjAzZTIyMGI5ZWZlMDQ2YmM5MTExZjc2MjZkMzhkNmM0L3RhYmxlcmFuZ2U6MDNlMjIwYjllZmUwNDZiYzkxMTFmNzYyNmQzOGQ2YzRfMy0xLTEtMS0zNzA5Nw_2ea23080-399a-4d1c-a925-8bf8a38e4c80">11,523</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac7c0f0822b942fa8f45ea15693a76af_I20211231" decimals="-3" name="us-gaap:AccruedIncomeTaxesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNC9mcmFnOjJjMDM1ZTVhYzJjNDQwN2U4NzM5NmY1YjU2ZDg1NWVkL3RhYmxlOjAzZTIyMGI5ZWZlMDQ2YmM5MTExZjc2MjZkMzhkNmM0L3RhYmxlcmFuZ2U6MDNlMjIwYjllZmUwNDZiYzkxMTFmNzYyNmQzOGQ2YzRfMy0zLTEtMS0zNzA5Nw_f8be67f3-df57-4ec8-98dc-0411155d9adc">513</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93f424f685944c1aab994f99b0146441_I20220331" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNC9mcmFnOjJjMDM1ZTVhYzJjNDQwN2U4NzM5NmY1YjU2ZDg1NWVkL3RhYmxlOjAzZTIyMGI5ZWZlMDQ2YmM5MTExZjc2MjZkMzhkNmM0L3RhYmxlcmFuZ2U6MDNlMjIwYjllZmUwNDZiYzkxMTFmNzYyNmQzOGQ2YzRfNC0xLTEtMS0yODIyMQ_deafcefc-1743-40b9-852d-11a727bef6f3">4,968</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac7c0f0822b942fa8f45ea15693a76af_I20211231" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNC9mcmFnOjJjMDM1ZTVhYzJjNDQwN2U4NzM5NmY1YjU2ZDg1NWVkL3RhYmxlOjAzZTIyMGI5ZWZlMDQ2YmM5MTExZjc2MjZkMzhkNmM0L3RhYmxlcmFuZ2U6MDNlMjIwYjllZmUwNDZiYzkxMTFmNzYyNmQzOGQ2YzRfNC0zLTEtMS0yODIyMQ_d5546046-9158-4ac4-9691-a237a3f53d12">13,339</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legal fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93f424f685944c1aab994f99b0146441_I20220331" decimals="-3" name="cort:AccruedLegalFeesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNC9mcmFnOjJjMDM1ZTVhYzJjNDQwN2U4NzM5NmY1YjU2ZDg1NWVkL3RhYmxlOjAzZTIyMGI5ZWZlMDQ2YmM5MTExZjc2MjZkMzhkNmM0L3RhYmxlcmFuZ2U6MDNlMjIwYjllZmUwNDZiYzkxMTFmNzYyNmQzOGQ2YzRfNS0xLTEtMS0yODIyMQ_0a512fb1-0551-4fca-bfea-c79a6b791af7">1,802</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac7c0f0822b942fa8f45ea15693a76af_I20211231" decimals="-3" name="cort:AccruedLegalFeesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNC9mcmFnOjJjMDM1ZTVhYzJjNDQwN2U4NzM5NmY1YjU2ZDg1NWVkL3RhYmxlOjAzZTIyMGI5ZWZlMDQ2YmM5MTExZjc2MjZkMzhkNmM0L3RhYmxlcmFuZ2U6MDNlMjIwYjllZmUwNDZiYzkxMTFmNzYyNmQzOGQ2YzRfNS0zLTEtMS0yODIyMQ_d326fbfd-1f96-4f33-980a-a13a94722cb9">842</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued selling and marketing costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93f424f685944c1aab994f99b0146441_I20220331" decimals="-3" name="us-gaap:AccruedMarketingCostsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNC9mcmFnOjJjMDM1ZTVhYzJjNDQwN2U4NzM5NmY1YjU2ZDg1NWVkL3RhYmxlOjAzZTIyMGI5ZWZlMDQ2YmM5MTExZjc2MjZkMzhkNmM0L3RhYmxlcmFuZ2U6MDNlMjIwYjllZmUwNDZiYzkxMTFmNzYyNmQzOGQ2YzRfNi0xLTEtMS0yODIyMQ_beaf3af4-86dc-4463-9df1-3c168569e8b6">861</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac7c0f0822b942fa8f45ea15693a76af_I20211231" decimals="-3" name="us-gaap:AccruedMarketingCostsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNC9mcmFnOjJjMDM1ZTVhYzJjNDQwN2U4NzM5NmY1YjU2ZDg1NWVkL3RhYmxlOjAzZTIyMGI5ZWZlMDQ2YmM5MTExZjc2MjZkMzhkNmM0L3RhYmxlcmFuZ2U6MDNlMjIwYjllZmUwNDZiYzkxMTFmNzYyNmQzOGQ2YzRfNi0zLTEtMS0yODIyMQ_b7bd4d65-c686-4aec-9e23-d4af976e0490">1,351</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93f424f685944c1aab994f99b0146441_I20220331" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNC9mcmFnOjJjMDM1ZTVhYzJjNDQwN2U4NzM5NmY1YjU2ZDg1NWVkL3RhYmxlOjAzZTIyMGI5ZWZlMDQ2YmM5MTExZjc2MjZkMzhkNmM0L3RhYmxlcmFuZ2U6MDNlMjIwYjllZmUwNDZiYzkxMTFmNzYyNmQzOGQ2YzRfNi0xLTEtMS0zNjQ0MQ_35097420-ce78-4dd6-9721-06624da4c703">652</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac7c0f0822b942fa8f45ea15693a76af_I20211231" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNC9mcmFnOjJjMDM1ZTVhYzJjNDQwN2U4NzM5NmY1YjU2ZDg1NWVkL3RhYmxlOjAzZTIyMGI5ZWZlMDQ2YmM5MTExZjc2MjZkMzhkNmM0L3RhYmxlcmFuZ2U6MDNlMjIwYjllZmUwNDZiYzkxMTFmNzYyNmQzOGQ2YzRfNi0zLTEtMS0zNjQ0MQ_2884f18f-4d0d-4e33-95a9-817d504bb96c">150</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93f424f685944c1aab994f99b0146441_I20220331" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNC9mcmFnOjJjMDM1ZTVhYzJjNDQwN2U4NzM5NmY1YjU2ZDg1NWVkL3RhYmxlOjAzZTIyMGI5ZWZlMDQ2YmM5MTExZjc2MjZkMzhkNmM0L3RhYmxlcmFuZ2U6MDNlMjIwYjllZmUwNDZiYzkxMTFmNzYyNmQzOGQ2YzRfOC0xLTEtMS0yODIyMQ_2d3ed213-bbbe-45f9-bf38-d5f7e949790a">477</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac7c0f0822b942fa8f45ea15693a76af_I20211231" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNC9mcmFnOjJjMDM1ZTVhYzJjNDQwN2U4NzM5NmY1YjU2ZDg1NWVkL3RhYmxlOjAzZTIyMGI5ZWZlMDQ2YmM5MTExZjc2MjZkMzhkNmM0L3RhYmxlcmFuZ2U6MDNlMjIwYjllZmUwNDZiYzkxMTFmNzYyNmQzOGQ2YzRfOC0zLTEtMS0yODIyMQ_dcbe0f45-814c-4486-8cc0-3aaec0904a96">296</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued and other liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93f424f685944c1aab994f99b0146441_I20220331" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNC9mcmFnOjJjMDM1ZTVhYzJjNDQwN2U4NzM5NmY1YjU2ZDg1NWVkL3RhYmxlOjAzZTIyMGI5ZWZlMDQ2YmM5MTExZjc2MjZkMzhkNmM0L3RhYmxlcmFuZ2U6MDNlMjIwYjllZmUwNDZiYzkxMTFmNzYyNmQzOGQ2YzRfOS0xLTEtMS0yODIyMQ_6d3a0d6c-36f3-4b6a-bb75-0bbee0f8d0d9">32,660</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac7c0f0822b942fa8f45ea15693a76af_I20211231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNC9mcmFnOjJjMDM1ZTVhYzJjNDQwN2U4NzM5NmY1YjU2ZDg1NWVkL3RhYmxlOjAzZTIyMGI5ZWZlMDQ2YmM5MTExZjc2MjZkMzhkNmM0L3RhYmxlcmFuZ2U6MDNlMjIwYjllZmUwNDZiYzkxMTFmNzYyNmQzOGQ2YzRfOS0zLTEtMS0yODIyMQ_9e3bb8ea-84ca-4d4e-b915-08578d1a9fd9">27,665</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other assets</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2022 and December&#160;31, 2021, other assets included $<ix:nonFraction unitRef="usd" contextRef="i93f424f685944c1aab994f99b0146441_I20220331" decimals="-5" name="cort:DepositsForClinicalTrials" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNC9mcmFnOjJjMDM1ZTVhYzJjNDQwN2U4NzM5NmY1YjU2ZDg1NWVkL3RleHRyZWdpb246MmMwMzVlNWFjMmM0NDA3ZTg3Mzk2ZjViNTZkODU1ZWRfMjE5OTAyMzI1NjU2Ng_2f385757-2dca-45e5-adb0-c9cbd1aa5575">2.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="iac7c0f0822b942fa8f45ea15693a76af_I20211231" decimals="-5" name="cort:DepositsForClinicalTrials" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNC9mcmFnOjJjMDM1ZTVhYzJjNDQwN2U4NzM5NmY1YjU2ZDg1NWVkL3RleHRyZWdpb246MmMwMzVlNWFjMmM0NDA3ZTg3Mzk2ZjViNTZkODU1ZWRfMjE5OTAyMzI1NjU1OA_a4bf4a01-aaac-496b-a0a1-7b6e2509286d">2.9</ix:nonFraction> million of deposits for clinical trials, respectively.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><div id="i0a44765832c1416181e5729d6aaf7059_37"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3. <ix:nonNumeric contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331" name="cort:AvailableForSaleSecuritiesAndFairValueMeasurementsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNy9mcmFnOmZlMTQxZDk2ZjU2MTRmM2ZhMmZhYjQ3OTgwODk1YzkxL3RleHRyZWdpb246ZmUxNDFkOTZmNTYxNGYzZmEyZmFiNDc5ODA4OTVjOTFfMjEyNw_b02d48a9-7097-4edf-a5a4-68b4616d680f" continuedAt="idde6ebcd62ae4b9e9d20fd1972335f12" escape="true">Available-for-Sale Securities and Fair Value Measurements</ix:nonNumeric></span></div><ix:continuation id="idde6ebcd62ae4b9e9d20fd1972335f12" continuedAt="i4f205b083fec4a579a5fdec1a876944d"><ix:nonNumeric contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNy9mcmFnOmZlMTQxZDk2ZjU2MTRmM2ZhMmZhYjQ3OTgwODk1YzkxL3RleHRyZWdpb246ZmUxNDFkOTZmNTYxNGYzZmEyZmFiNDc5ODA4OTVjOTFfMjEzMQ_f2ba99c1-dfc1-443f-bb38-00d25ead5fa5" escape="true"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The available-for-sale securities in our Condensed Consolidated Balance Sheets are as follows:</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.028%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.545%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b8ab391633246798d3dcce8ecce1732_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNy9mcmFnOmZlMTQxZDk2ZjU2MTRmM2ZhMmZhYjQ3OTgwODk1YzkxL3RhYmxlOmYwZjE1ZWE5MTRiNDQwZGRhODg4MjA3ZDc1YjMwZmNlL3RhYmxlcmFuZ2U6ZjBmMTVlYTkxNGI0NDBkZGE4ODgyMDdkNzViMzBmY2VfMy0xLTEtMS0yODIyMQ_4aa8f065-2e17-4814-8bda-cd2444b8ba87">24,266</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8199115c34a347bfa2af4840cc8fab44_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNy9mcmFnOmZlMTQxZDk2ZjU2MTRmM2ZhMmZhYjQ3OTgwODk1YzkxL3RhYmxlOmYwZjE1ZWE5MTRiNDQwZGRhODg4MjA3ZDc1YjMwZmNlL3RhYmxlcmFuZ2U6ZjBmMTVlYTkxNGI0NDBkZGE4ODgyMDdkNzViMzBmY2VfMy0zLTEtMS0yODIyMQ_402f19ac-9c99-4379-9e93-0ed1ab6bc5fb">45,088</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if03d19cb5acb4fc88cca882cb4bdfcc0_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNy9mcmFnOmZlMTQxZDk2ZjU2MTRmM2ZhMmZhYjQ3OTgwODk1YzkxL3RhYmxlOmYwZjE1ZWE5MTRiNDQwZGRhODg4MjA3ZDc1YjMwZmNlL3RhYmxlcmFuZ2U6ZjBmMTVlYTkxNGI0NDBkZGE4ODgyMDdkNzViMzBmY2VfNC0xLTEtMS0yODIyMQ_9cbadf81-d189-48b9-8ea1-fcaaaecc6c9e">283,665</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idecfc47be18a4b0abf858e6bac29beee_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNy9mcmFnOmZlMTQxZDk2ZjU2MTRmM2ZhMmZhYjQ3OTgwODk1YzkxL3RhYmxlOmYwZjE1ZWE5MTRiNDQwZGRhODg4MjA3ZDc1YjMwZmNlL3RhYmxlcmFuZ2U6ZjBmMTVlYTkxNGI0NDBkZGE4ODgyMDdkNzViMzBmY2VfNC0zLTEtMS0yODIyMQ_d4f7d032-80c0-4446-b193-1f580de00304">145,918</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ae15632947d447792ec41cd858483f8_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNy9mcmFnOmZlMTQxZDk2ZjU2MTRmM2ZhMmZhYjQ3OTgwODk1YzkxL3RhYmxlOmYwZjE1ZWE5MTRiNDQwZGRhODg4MjA3ZDc1YjMwZmNlL3RhYmxlcmFuZ2U6ZjBmMTVlYTkxNGI0NDBkZGE4ODgyMDdkNzViMzBmY2VfNS0xLTEtMS0yODIyMQ_9479f81d-7fc6-47ae-a3b0-0df6d4026a99">22,566</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib244710dd5db4d8095a0f665560759d1_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNy9mcmFnOmZlMTQxZDk2ZjU2MTRmM2ZhMmZhYjQ3OTgwODk1YzkxL3RhYmxlOmYwZjE1ZWE5MTRiNDQwZGRhODg4MjA3ZDc1YjMwZmNlL3RhYmxlcmFuZ2U6ZjBmMTVlYTkxNGI0NDBkZGE4ODgyMDdkNzViMzBmY2VfNS0zLTEtMS0yODIyMQ_2668859c-74e7-4783-91b4-1a8abe79a7c1">112,277</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total marketable securities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93f424f685944c1aab994f99b0146441_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNy9mcmFnOmZlMTQxZDk2ZjU2MTRmM2ZhMmZhYjQ3OTgwODk1YzkxL3RhYmxlOmYwZjE1ZWE5MTRiNDQwZGRhODg4MjA3ZDc1YjMwZmNlL3RhYmxlcmFuZ2U6ZjBmMTVlYTkxNGI0NDBkZGE4ODgyMDdkNzViMzBmY2VfNi0xLTEtMS0yODIyMQ_20f674c7-7899-4cfa-b513-eedc0ab40434">330,497</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac7c0f0822b942fa8f45ea15693a76af_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNy9mcmFnOmZlMTQxZDk2ZjU2MTRmM2ZhMmZhYjQ3OTgwODk1YzkxL3RhYmxlOmYwZjE1ZWE5MTRiNDQwZGRhODg4MjA3ZDc1YjMwZmNlL3RhYmxlcmFuZ2U6ZjBmMTVlYTkxNGI0NDBkZGE4ODgyMDdkNzViMzBmY2VfNi0zLTEtMS0yODIyMQ_7c970acc-f3c6-49dc-abd7-c099c74c3812">303,283</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331" name="us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNy9mcmFnOmZlMTQxZDk2ZjU2MTRmM2ZhMmZhYjQ3OTgwODk1YzkxL3RleHRyZWdpb246ZmUxNDFkOTZmNTYxNGYzZmEyZmFiNDc5ODA4OTVjOTFfMjEyNA_1efa97d4-de5a-4c5b-89aa-cd45d34567a7" escape="true"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents our available-for-sale securities grouped by asset type:</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:16.590%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.538%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value<br/>Hierarchy<br/>Level</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr style="height:29pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="45" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id653930fdecf4c64ad438a3b2c5adabb_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNy9mcmFnOmZlMTQxZDk2ZjU2MTRmM2ZhMmZhYjQ3OTgwODk1YzkxL3RhYmxlOjA5MDBhY2M4MTE5MjQ5N2RiYWI3YTU2NjVkMjg0ZGNhL3RhYmxlcmFuZ2U6MDkwMGFjYzgxMTkyNDk3ZGJhYjdhNTY2NWQyODRkY2FfNC0zLTEtMS0yODIyMQ_bf344695-97b4-443a-8eaf-4408af14f8d0">147,177</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id653930fdecf4c64ad438a3b2c5adabb_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNy9mcmFnOmZlMTQxZDk2ZjU2MTRmM2ZhMmZhYjQ3OTgwODk1YzkxL3RhYmxlOjA5MDBhY2M4MTE5MjQ5N2RiYWI3YTU2NjVkMjg0ZGNhL3RhYmxlcmFuZ2U6MDkwMGFjYzgxMTkyNDk3ZGJhYjdhNTY2NWQyODRkY2FfNC01LTEtMS0yODIyMQ_7d0ed209-ff91-4e8a-8279-bd4622506e25">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id653930fdecf4c64ad438a3b2c5adabb_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNy9mcmFnOmZlMTQxZDk2ZjU2MTRmM2ZhMmZhYjQ3OTgwODk1YzkxL3RhYmxlOjA5MDBhY2M4MTE5MjQ5N2RiYWI3YTU2NjVkMjg0ZGNhL3RhYmxlcmFuZ2U6MDkwMGFjYzgxMTkyNDk3ZGJhYjdhNTY2NWQyODRkY2FfNC03LTEtMS0yODIyMQ_9b518262-525c-464f-ba56-f6f99186c3f9">1,023</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id653930fdecf4c64ad438a3b2c5adabb_I20220331" decimals="-3" name="cort:AvailableForSaleSecuritiesIncludingCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNy9mcmFnOmZlMTQxZDk2ZjU2MTRmM2ZhMmZhYjQ3OTgwODk1YzkxL3RhYmxlOjA5MDBhY2M4MTE5MjQ5N2RiYWI3YTU2NjVkMjg0ZGNhL3RhYmxlcmFuZ2U6MDkwMGFjYzgxMTkyNDk3ZGJhYjdhNTY2NWQyODRkY2FfNC05LTEtMS0yODIyMQ_2a804abf-c9df-4557-bfe2-68376689807e">146,158</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9384505b63ff4625835d945a86192942_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNy9mcmFnOmZlMTQxZDk2ZjU2MTRmM2ZhMmZhYjQ3OTgwODk1YzkxL3RhYmxlOjA5MDBhY2M4MTE5MjQ5N2RiYWI3YTU2NjVkMjg0ZGNhL3RhYmxlcmFuZ2U6MDkwMGFjYzgxMTkyNDk3ZGJhYjdhNTY2NWQyODRkY2FfNC0xMS0xLTEtMjgyMjE_179e68b0-dd22-4516-9aa4-f49a653d5956">125,370</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9384505b63ff4625835d945a86192942_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNy9mcmFnOmZlMTQxZDk2ZjU2MTRmM2ZhMmZhYjQ3OTgwODk1YzkxL3RhYmxlOjA5MDBhY2M4MTE5MjQ5N2RiYWI3YTU2NjVkMjg0ZGNhL3RhYmxlcmFuZ2U6MDkwMGFjYzgxMTkyNDk3ZGJhYjdhNTY2NWQyODRkY2FfNC0xMy0xLTEtMjgyMjE_8c9ac8c2-36b0-4375-95f3-0056969a994b">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9384505b63ff4625835d945a86192942_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNy9mcmFnOmZlMTQxZDk2ZjU2MTRmM2ZhMmZhYjQ3OTgwODk1YzkxL3RhYmxlOjA5MDBhY2M4MTE5MjQ5N2RiYWI3YTU2NjVkMjg0ZGNhL3RhYmxlcmFuZ2U6MDkwMGFjYzgxMTkyNDk3ZGJhYjdhNTY2NWQyODRkY2FfNC0xNS0xLTEtMjgyMjE_4f980794-4442-48bc-97bc-9b431d8d36ec">276</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9384505b63ff4625835d945a86192942_I20211231" decimals="-3" name="cort:AvailableForSaleSecuritiesIncludingCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNy9mcmFnOmZlMTQxZDk2ZjU2MTRmM2ZhMmZhYjQ3OTgwODk1YzkxL3RhYmxlOjA5MDBhY2M4MTE5MjQ5N2RiYWI3YTU2NjVkMjg0ZGNhL3RhYmxlcmFuZ2U6MDkwMGFjYzgxMTkyNDk3ZGJhYjdhNTY2NWQyODRkY2FfNC0xNy0xLTEtMjgyMjE_76e6027f-c35d-4b90-a7b4-f2d3cde0d729">125,097</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i189a43eed86a4d37b00b3efd25b569ec_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNy9mcmFnOmZlMTQxZDk2ZjU2MTRmM2ZhMmZhYjQ3OTgwODk1YzkxL3RhYmxlOjA5MDBhY2M4MTE5MjQ5N2RiYWI3YTU2NjVkMjg0ZGNhL3RhYmxlcmFuZ2U6MDkwMGFjYzgxMTkyNDk3ZGJhYjdhNTY2NWQyODRkY2FfNS0zLTEtMS0yODIyMQ_18addb9a-86d4-4608-b6c4-7e427ac10d6d">56,751</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i189a43eed86a4d37b00b3efd25b569ec_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNy9mcmFnOmZlMTQxZDk2ZjU2MTRmM2ZhMmZhYjQ3OTgwODk1YzkxL3RhYmxlOjA5MDBhY2M4MTE5MjQ5N2RiYWI3YTU2NjVkMjg0ZGNhL3RhYmxlcmFuZ2U6MDkwMGFjYzgxMTkyNDk3ZGJhYjdhNTY2NWQyODRkY2FfNS01LTEtMS0yODIyMQ_e2126747-828a-45bf-950f-e92f1f2f1d56">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i189a43eed86a4d37b00b3efd25b569ec_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNy9mcmFnOmZlMTQxZDk2ZjU2MTRmM2ZhMmZhYjQ3OTgwODk1YzkxL3RhYmxlOjA5MDBhY2M4MTE5MjQ5N2RiYWI3YTU2NjVkMjg0ZGNhL3RhYmxlcmFuZ2U6MDkwMGFjYzgxMTkyNDk3ZGJhYjdhNTY2NWQyODRkY2FfNS03LTEtMS0yODIyMQ_29767199-56e2-4957-8acf-3b3544ccfed9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i189a43eed86a4d37b00b3efd25b569ec_I20220331" decimals="-3" name="cort:AvailableForSaleSecuritiesIncludingCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNy9mcmFnOmZlMTQxZDk2ZjU2MTRmM2ZhMmZhYjQ3OTgwODk1YzkxL3RhYmxlOjA5MDBhY2M4MTE5MjQ5N2RiYWI3YTU2NjVkMjg0ZGNhL3RhYmxlcmFuZ2U6MDkwMGFjYzgxMTkyNDk3ZGJhYjdhNTY2NWQyODRkY2FfNS05LTEtMS0yODIyMQ_99d33098-9b54-4ae6-8e57-a9f1a645087d">56,751</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie44aabc8e0234ddab3cc8531b3c28b30_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNy9mcmFnOmZlMTQxZDk2ZjU2MTRmM2ZhMmZhYjQ3OTgwODk1YzkxL3RhYmxlOjA5MDBhY2M4MTE5MjQ5N2RiYWI3YTU2NjVkMjg0ZGNhL3RhYmxlcmFuZ2U6MDkwMGFjYzgxMTkyNDk3ZGJhYjdhNTY2NWQyODRkY2FfNS0xMS0xLTEtMjgyMjE_8b5bc008-4fbf-4993-8516-d44264c868d8">30,963</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie44aabc8e0234ddab3cc8531b3c28b30_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNy9mcmFnOmZlMTQxZDk2ZjU2MTRmM2ZhMmZhYjQ3OTgwODk1YzkxL3RhYmxlOjA5MDBhY2M4MTE5MjQ5N2RiYWI3YTU2NjVkMjg0ZGNhL3RhYmxlcmFuZ2U6MDkwMGFjYzgxMTkyNDk3ZGJhYjdhNTY2NWQyODRkY2FfNS0xMy0xLTEtMjgyMjE_07f2dac3-dacc-435b-b0c0-4c59afb93565">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie44aabc8e0234ddab3cc8531b3c28b30_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNy9mcmFnOmZlMTQxZDk2ZjU2MTRmM2ZhMmZhYjQ3OTgwODk1YzkxL3RhYmxlOjA5MDBhY2M4MTE5MjQ5N2RiYWI3YTU2NjVkMjg0ZGNhL3RhYmxlcmFuZ2U6MDkwMGFjYzgxMTkyNDk3ZGJhYjdhNTY2NWQyODRkY2FfNS0xNS0xLTEtMjgyMjE_e686f60e-9bb7-4aaf-b524-c7019dc81d24">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie44aabc8e0234ddab3cc8531b3c28b30_I20211231" decimals="-3" name="cort:AvailableForSaleSecuritiesIncludingCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNy9mcmFnOmZlMTQxZDk2ZjU2MTRmM2ZhMmZhYjQ3OTgwODk1YzkxL3RhYmxlOjA5MDBhY2M4MTE5MjQ5N2RiYWI3YTU2NjVkMjg0ZGNhL3RhYmxlcmFuZ2U6MDkwMGFjYzgxMTkyNDk3ZGJhYjdhNTY2NWQyODRkY2FfNS0xNy0xLTEtMjgyMjE_370458d2-35fc-4a60-aa82-b7bff38381ef">30,963</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb4f2da4afdc4173bbcc618511bfd330_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNy9mcmFnOmZlMTQxZDk2ZjU2MTRmM2ZhMmZhYjQ3OTgwODk1YzkxL3RhYmxlOjA5MDBhY2M4MTE5MjQ5N2RiYWI3YTU2NjVkMjg0ZGNhL3RhYmxlcmFuZ2U6MDkwMGFjYzgxMTkyNDk3ZGJhYjdhNTY2NWQyODRkY2FfNi0zLTEtMS0yODIyMQ_2eca22a7-8047-4643-97f5-481430ce8cef">29,372</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb4f2da4afdc4173bbcc618511bfd330_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNy9mcmFnOmZlMTQxZDk2ZjU2MTRmM2ZhMmZhYjQ3OTgwODk1YzkxL3RhYmxlOjA5MDBhY2M4MTE5MjQ5N2RiYWI3YTU2NjVkMjg0ZGNhL3RhYmxlcmFuZ2U6MDkwMGFjYzgxMTkyNDk3ZGJhYjdhNTY2NWQyODRkY2FfNi01LTEtMS0yODIyMQ_7764fe70-2f1c-4fb3-8803-af939d91a9b3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibb4f2da4afdc4173bbcc618511bfd330_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNy9mcmFnOmZlMTQxZDk2ZjU2MTRmM2ZhMmZhYjQ3OTgwODk1YzkxL3RhYmxlOjA5MDBhY2M4MTE5MjQ5N2RiYWI3YTU2NjVkMjg0ZGNhL3RhYmxlcmFuZ2U6MDkwMGFjYzgxMTkyNDk3ZGJhYjdhNTY2NWQyODRkY2FfNi03LTEtMS0yODIyMQ_2dbb7977-c147-468d-a251-2bc6209b771a">110</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb4f2da4afdc4173bbcc618511bfd330_I20220331" decimals="-3" name="cort:AvailableForSaleSecuritiesIncludingCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNy9mcmFnOmZlMTQxZDk2ZjU2MTRmM2ZhMmZhYjQ3OTgwODk1YzkxL3RhYmxlOjA5MDBhY2M4MTE5MjQ5N2RiYWI3YTU2NjVkMjg0ZGNhL3RhYmxlcmFuZ2U6MDkwMGFjYzgxMTkyNDk3ZGJhYjdhNTY2NWQyODRkY2FfNi05LTEtMS0yODIyMQ_7aba70bd-aa47-4a43-a686-8abe1cf9cd38">29,262</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib430d4f8526c49d2965e6d0cbfc5179d_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNy9mcmFnOmZlMTQxZDk2ZjU2MTRmM2ZhMmZhYjQ3OTgwODk1YzkxL3RhYmxlOjA5MDBhY2M4MTE5MjQ5N2RiYWI3YTU2NjVkMjg0ZGNhL3RhYmxlcmFuZ2U6MDkwMGFjYzgxMTkyNDk3ZGJhYjdhNTY2NWQyODRkY2FfNi0xMS0xLTEtMjgyMjE_9d5cb352-3d85-46c2-96ed-8d08bfbf6e20">57,801</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib430d4f8526c49d2965e6d0cbfc5179d_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNy9mcmFnOmZlMTQxZDk2ZjU2MTRmM2ZhMmZhYjQ3OTgwODk1YzkxL3RhYmxlOjA5MDBhY2M4MTE5MjQ5N2RiYWI3YTU2NjVkMjg0ZGNhL3RhYmxlcmFuZ2U6MDkwMGFjYzgxMTkyNDk3ZGJhYjdhNTY2NWQyODRkY2FfNi0xMy0xLTEtMjgyMjE_8781cc20-98f8-472d-837e-eb7eea1acded">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib430d4f8526c49d2965e6d0cbfc5179d_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNy9mcmFnOmZlMTQxZDk2ZjU2MTRmM2ZhMmZhYjQ3OTgwODk1YzkxL3RhYmxlOjA5MDBhY2M4MTE5MjQ5N2RiYWI3YTU2NjVkMjg0ZGNhL3RhYmxlcmFuZ2U6MDkwMGFjYzgxMTkyNDk3ZGJhYjdhNTY2NWQyODRkY2FfNi0xNS0xLTEtMjgyMjE_5ec24f0e-daa1-49f4-9164-0e165a6207b0">67</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib430d4f8526c49d2965e6d0cbfc5179d_I20211231" decimals="-3" name="cort:AvailableForSaleSecuritiesIncludingCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNy9mcmFnOmZlMTQxZDk2ZjU2MTRmM2ZhMmZhYjQ3OTgwODk1YzkxL3RhYmxlOjA5MDBhY2M4MTE5MjQ5N2RiYWI3YTU2NjVkMjg0ZGNhL3RhYmxlcmFuZ2U6MDkwMGFjYzgxMTkyNDk3ZGJhYjdhNTY2NWQyODRkY2FfNi0xNy0xLTEtMjgyMjE_cc9a66f4-e4b8-4491-9f29-6e00973bdc8c">57,734</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iddcc04669caf4c4f8e77d0b0ead4adba_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNy9mcmFnOmZlMTQxZDk2ZjU2MTRmM2ZhMmZhYjQ3OTgwODk1YzkxL3RhYmxlOjA5MDBhY2M4MTE5MjQ5N2RiYWI3YTU2NjVkMjg0ZGNhL3RhYmxlcmFuZ2U6MDkwMGFjYzgxMTkyNDk3ZGJhYjdhNTY2NWQyODRkY2FfNy0zLTEtMS0yODIyMQ_e44f62ef-fa57-4450-95f7-2f306f51734a">74,363</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iddcc04669caf4c4f8e77d0b0ead4adba_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNy9mcmFnOmZlMTQxZDk2ZjU2MTRmM2ZhMmZhYjQ3OTgwODk1YzkxL3RhYmxlOjA5MDBhY2M4MTE5MjQ5N2RiYWI3YTU2NjVkMjg0ZGNhL3RhYmxlcmFuZ2U6MDkwMGFjYzgxMTkyNDk3ZGJhYjdhNTY2NWQyODRkY2FfNy01LTEtMS0yODIyMQ_b7b88696-f3cb-4d8a-aaec-64e6ab3e5eff">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iddcc04669caf4c4f8e77d0b0ead4adba_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNy9mcmFnOmZlMTQxZDk2ZjU2MTRmM2ZhMmZhYjQ3OTgwODk1YzkxL3RhYmxlOjA5MDBhY2M4MTE5MjQ5N2RiYWI3YTU2NjVkMjg0ZGNhL3RhYmxlcmFuZ2U6MDkwMGFjYzgxMTkyNDk3ZGJhYjdhNTY2NWQyODRkY2FfNy03LTEtMS0yODIyMQ_e9011551-4bc7-4e57-8a15-3e01cd629f5a">303</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iddcc04669caf4c4f8e77d0b0ead4adba_I20220331" decimals="-3" name="cort:AvailableForSaleSecuritiesIncludingCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNy9mcmFnOmZlMTQxZDk2ZjU2MTRmM2ZhMmZhYjQ3OTgwODk1YzkxL3RhYmxlOjA5MDBhY2M4MTE5MjQ5N2RiYWI3YTU2NjVkMjg0ZGNhL3RhYmxlcmFuZ2U6MDkwMGFjYzgxMTkyNDk3ZGJhYjdhNTY2NWQyODRkY2FfNy05LTEtMS0yODIyMQ_4a806cbe-d23d-45cd-a706-e6e21fc680f3">74,060</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80d4096c7b334e54b411518bb6b5d22b_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNy9mcmFnOmZlMTQxZDk2ZjU2MTRmM2ZhMmZhYjQ3OTgwODk1YzkxL3RhYmxlOjA5MDBhY2M4MTE5MjQ5N2RiYWI3YTU2NjVkMjg0ZGNhL3RhYmxlcmFuZ2U6MDkwMGFjYzgxMTkyNDk3ZGJhYjdhNTY2NWQyODRkY2FfNy0xMS0xLTEtMjgyMjE_0fe98ca6-945c-4e3d-ab66-91ee05a378b1">44,473</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80d4096c7b334e54b411518bb6b5d22b_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNy9mcmFnOmZlMTQxZDk2ZjU2MTRmM2ZhMmZhYjQ3OTgwODk1YzkxL3RhYmxlOjA5MDBhY2M4MTE5MjQ5N2RiYWI3YTU2NjVkMjg0ZGNhL3RhYmxlcmFuZ2U6MDkwMGFjYzgxMTkyNDk3ZGJhYjdhNTY2NWQyODRkY2FfNy0xMy0xLTEtMjgyMjE_f62ae142-9439-4904-bc41-4117a2445e43">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i80d4096c7b334e54b411518bb6b5d22b_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNy9mcmFnOmZlMTQxZDk2ZjU2MTRmM2ZhMmZhYjQ3OTgwODk1YzkxL3RhYmxlOjA5MDBhY2M4MTE5MjQ5N2RiYWI3YTU2NjVkMjg0ZGNhL3RhYmxlcmFuZ2U6MDkwMGFjYzgxMTkyNDk3ZGJhYjdhNTY2NWQyODRkY2FfNy0xNS0xLTEtMjgyMjE_49104567-a8cb-435e-91f2-a2ae5831aae4">72</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80d4096c7b334e54b411518bb6b5d22b_I20211231" decimals="-3" name="cort:AvailableForSaleSecuritiesIncludingCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNy9mcmFnOmZlMTQxZDk2ZjU2MTRmM2ZhMmZhYjQ3OTgwODk1YzkxL3RhYmxlOjA5MDBhY2M4MTE5MjQ5N2RiYWI3YTU2NjVkMjg0ZGNhL3RhYmxlcmFuZ2U6MDkwMGFjYzgxMTkyNDk3ZGJhYjdhNTY2NWQyODRkY2FfNy0xNy0xLTEtMjgyMjE_d22f0d09-4dd2-428b-a1c1-7619e67af6e3">44,401</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic608ebc41f164c878a62e74c33164b0a_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNy9mcmFnOmZlMTQxZDk2ZjU2MTRmM2ZhMmZhYjQ3OTgwODk1YzkxL3RhYmxlOjA5MDBhY2M4MTE5MjQ5N2RiYWI3YTU2NjVkMjg0ZGNhL3RhYmxlcmFuZ2U6MDkwMGFjYzgxMTkyNDk3ZGJhYjdhNTY2NWQyODRkY2FfOC0zLTEtMS0yODIyMQ_3ccc7b70-b8b7-49f9-92b1-186737fbb502">24,266</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic608ebc41f164c878a62e74c33164b0a_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNy9mcmFnOmZlMTQxZDk2ZjU2MTRmM2ZhMmZhYjQ3OTgwODk1YzkxL3RhYmxlOjA5MDBhY2M4MTE5MjQ5N2RiYWI3YTU2NjVkMjg0ZGNhL3RhYmxlcmFuZ2U6MDkwMGFjYzgxMTkyNDk3ZGJhYjdhNTY2NWQyODRkY2FfOC01LTEtMS0yODIyMQ_b405316b-9766-4eee-9813-ed2d22245d38">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic608ebc41f164c878a62e74c33164b0a_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNy9mcmFnOmZlMTQxZDk2ZjU2MTRmM2ZhMmZhYjQ3OTgwODk1YzkxL3RhYmxlOjA5MDBhY2M4MTE5MjQ5N2RiYWI3YTU2NjVkMjg0ZGNhL3RhYmxlcmFuZ2U6MDkwMGFjYzgxMTkyNDk3ZGJhYjdhNTY2NWQyODRkY2FfOC03LTEtMS0yODIyMQ_141d0456-c8d8-46a3-9a42-10a6c3003332">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic608ebc41f164c878a62e74c33164b0a_I20220331" decimals="-3" name="cort:AvailableForSaleSecuritiesIncludingCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNy9mcmFnOmZlMTQxZDk2ZjU2MTRmM2ZhMmZhYjQ3OTgwODk1YzkxL3RhYmxlOjA5MDBhY2M4MTE5MjQ5N2RiYWI3YTU2NjVkMjg0ZGNhL3RhYmxlcmFuZ2U6MDkwMGFjYzgxMTkyNDk3ZGJhYjdhNTY2NWQyODRkY2FfOC05LTEtMS0yODIyMQ_fcefd6dd-60b6-4c56-9c3e-7107b7690e66">24,266</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa8d40f1022a4fdbad599ef4cc0332c2_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNy9mcmFnOmZlMTQxZDk2ZjU2MTRmM2ZhMmZhYjQ3OTgwODk1YzkxL3RhYmxlOjA5MDBhY2M4MTE5MjQ5N2RiYWI3YTU2NjVkMjg0ZGNhL3RhYmxlcmFuZ2U6MDkwMGFjYzgxMTkyNDk3ZGJhYjdhNTY2NWQyODRkY2FfOC0xMS0xLTEtMjgyMjE_df9b6f55-b0c9-4f43-9c07-edfca2cdea4b">45,088</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa8d40f1022a4fdbad599ef4cc0332c2_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNy9mcmFnOmZlMTQxZDk2ZjU2MTRmM2ZhMmZhYjQ3OTgwODk1YzkxL3RhYmxlOjA5MDBhY2M4MTE5MjQ5N2RiYWI3YTU2NjVkMjg0ZGNhL3RhYmxlcmFuZ2U6MDkwMGFjYzgxMTkyNDk3ZGJhYjdhNTY2NWQyODRkY2FfOC0xMy0xLTEtMjgyMjE_b09a80c5-f05a-42bc-8d06-dd93ec203f76">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa8d40f1022a4fdbad599ef4cc0332c2_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNy9mcmFnOmZlMTQxZDk2ZjU2MTRmM2ZhMmZhYjQ3OTgwODk1YzkxL3RhYmxlOjA5MDBhY2M4MTE5MjQ5N2RiYWI3YTU2NjVkMjg0ZGNhL3RhYmxlcmFuZ2U6MDkwMGFjYzgxMTkyNDk3ZGJhYjdhNTY2NWQyODRkY2FfOC0xNS0xLTEtMjgyMjE_417596d6-e143-4a56-8e90-ff764ebbb312">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa8d40f1022a4fdbad599ef4cc0332c2_I20211231" decimals="-3" name="cort:AvailableForSaleSecuritiesIncludingCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNy9mcmFnOmZlMTQxZDk2ZjU2MTRmM2ZhMmZhYjQ3OTgwODk1YzkxL3RhYmxlOjA5MDBhY2M4MTE5MjQ5N2RiYWI3YTU2NjVkMjg0ZGNhL3RhYmxlcmFuZ2U6MDkwMGFjYzgxMTkyNDk3ZGJhYjdhNTY2NWQyODRkY2FfOC0xNy0xLTEtMjgyMjE_f5d5e099-acb8-4912-ae6b-f1f67d14584e">45,088</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f690dc4c12e4400835f0643973b82b2_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNy9mcmFnOmZlMTQxZDk2ZjU2MTRmM2ZhMmZhYjQ3OTgwODk1YzkxL3RhYmxlOjA5MDBhY2M4MTE5MjQ5N2RiYWI3YTU2NjVkMjg0ZGNhL3RhYmxlcmFuZ2U6MDkwMGFjYzgxMTkyNDk3ZGJhYjdhNTY2NWQyODRkY2FfOS0zLTEtMS0yODIyMQ_f565dfc0-7115-47d8-bf4f-ded5adf4865c">331,929</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f690dc4c12e4400835f0643973b82b2_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNy9mcmFnOmZlMTQxZDk2ZjU2MTRmM2ZhMmZhYjQ3OTgwODk1YzkxL3RhYmxlOjA5MDBhY2M4MTE5MjQ5N2RiYWI3YTU2NjVkMjg0ZGNhL3RhYmxlcmFuZ2U6MDkwMGFjYzgxMTkyNDk3ZGJhYjdhNTY2NWQyODRkY2FfOS01LTEtMS0yODIyMQ_8e89e883-2ddc-43ec-b8ef-9af464f84241">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5f690dc4c12e4400835f0643973b82b2_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNy9mcmFnOmZlMTQxZDk2ZjU2MTRmM2ZhMmZhYjQ3OTgwODk1YzkxL3RhYmxlOjA5MDBhY2M4MTE5MjQ5N2RiYWI3YTU2NjVkMjg0ZGNhL3RhYmxlcmFuZ2U6MDkwMGFjYzgxMTkyNDk3ZGJhYjdhNTY2NWQyODRkY2FfOS03LTEtMS0yODIyMQ_8e7e0433-23c7-4f8d-a10e-8fadef1a0f32">1,436</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f690dc4c12e4400835f0643973b82b2_I20220331" decimals="-3" name="cort:AvailableForSaleSecuritiesIncludingCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNy9mcmFnOmZlMTQxZDk2ZjU2MTRmM2ZhMmZhYjQ3OTgwODk1YzkxL3RhYmxlOjA5MDBhY2M4MTE5MjQ5N2RiYWI3YTU2NjVkMjg0ZGNhL3RhYmxlcmFuZ2U6MDkwMGFjYzgxMTkyNDk3ZGJhYjdhNTY2NWQyODRkY2FfOS05LTEtMS0yODIyMQ_233d9323-57ad-47fc-ad58-05b553e93b9d">330,497</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd5d76c213a042ae897b90f0a8ec4a60_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNy9mcmFnOmZlMTQxZDk2ZjU2MTRmM2ZhMmZhYjQ3OTgwODk1YzkxL3RhYmxlOjA5MDBhY2M4MTE5MjQ5N2RiYWI3YTU2NjVkMjg0ZGNhL3RhYmxlcmFuZ2U6MDkwMGFjYzgxMTkyNDk3ZGJhYjdhNTY2NWQyODRkY2FfOS0xMS0xLTEtMjgyMjE_ceda885c-3ab3-46a5-933c-56bddca9c382">303,695</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd5d76c213a042ae897b90f0a8ec4a60_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNy9mcmFnOmZlMTQxZDk2ZjU2MTRmM2ZhMmZhYjQ3OTgwODk1YzkxL3RhYmxlOjA5MDBhY2M4MTE5MjQ5N2RiYWI3YTU2NjVkMjg0ZGNhL3RhYmxlcmFuZ2U6MDkwMGFjYzgxMTkyNDk3ZGJhYjdhNTY2NWQyODRkY2FfOS0xMy0xLTEtMjgyMjE_08e572ae-618c-4e31-81cd-75c8ef930e8a">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibd5d76c213a042ae897b90f0a8ec4a60_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNy9mcmFnOmZlMTQxZDk2ZjU2MTRmM2ZhMmZhYjQ3OTgwODk1YzkxL3RhYmxlOjA5MDBhY2M4MTE5MjQ5N2RiYWI3YTU2NjVkMjg0ZGNhL3RhYmxlcmFuZ2U6MDkwMGFjYzgxMTkyNDk3ZGJhYjdhNTY2NWQyODRkY2FfOS0xNS0xLTEtMjgyMjE_3273c78f-9588-4189-818f-7fc34db21755">415</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd5d76c213a042ae897b90f0a8ec4a60_I20211231" decimals="-3" name="cort:AvailableForSaleSecuritiesIncludingCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNy9mcmFnOmZlMTQxZDk2ZjU2MTRmM2ZhMmZhYjQ3OTgwODk1YzkxL3RhYmxlOjA5MDBhY2M4MTE5MjQ5N2RiYWI3YTU2NjVkMjg0ZGNhL3RhYmxlcmFuZ2U6MDkwMGFjYzgxMTkyNDk3ZGJhYjdhNTY2NWQyODRkY2FfOS0xNy0xLTEtMjgyMjE_ac10152e-135f-4610-a25d-d0c3e9086b05">303,283</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate the fair value of marketable securities classified as Level 1 using quoted market prices for these or identical investments obtained from a commercial pricing service. We estimate the fair value of marketable securities classified as Level 2 using inputs that may include benchmark yields, reported trades, broker/dealer quotes and issuer spreads.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We periodically review our debt securities to determine if any of our investments is impaired due to credit-related or other issues. If the fair value of our investment in any debt security is less than our amortized cost basis, we determine whether an allowance for credit losses is appropriate by assessing quantitative and subjective factors including, but not limited to, the nature of security, changes in credit ratings, analyst reports concerning the security&#8217;s issuer and industry, interest rate fluctuations and general market conditions.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2022 and December&#160;31, 2021, unrealized losses on our available-for-sale debt securities were $<ix:nonFraction unitRef="usd" contextRef="i93f424f685944c1aab994f99b0146441_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNy9mcmFnOmZlMTQxZDk2ZjU2MTRmM2ZhMmZhYjQ3OTgwODk1YzkxL3RleHRyZWdpb246ZmUxNDFkOTZmNTYxNGYzZmEyZmFiNDc5ODA4OTVjOTFfMjE5OTAyMzI2MjA2NA_0ed7a987-0770-420f-af2a-f1765ee49320">1.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="iac7c0f0822b942fa8f45ea15693a76af_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNy9mcmFnOmZlMTQxZDk2ZjU2MTRmM2ZhMmZhYjQ3OTgwODk1YzkxL3RleHRyZWdpb246ZmUxNDFkOTZmNTYxNGYzZmEyZmFiNDc5ODA4OTVjOTFfMjE5OTAyMzI2MjA3Mg_96984209-fd79-4436-a759-17ba65290000">0.4</ix:nonFraction> million, respectively.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of our investments, including those with unrealized losses, are not impaired. Unrealized losses on our investments are due to interest rate fluctuations. We do not intend to sell investments that currently have unrealized losses and it is highly unlikely that we will sell any investment before recovery of its amortized cost basis, which may be at maturity. Accordingly, we have not recorded an allowance for credit losses associated with these investments.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We classified accrued interest on our marketable securities of $<ix:nonFraction unitRef="usd" contextRef="i93f424f685944c1aab994f99b0146441_I20220331" decimals="-5" name="us-gaap:InterestReceivableCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNy9mcmFnOmZlMTQxZDk2ZjU2MTRmM2ZhMmZhYjQ3OTgwODk1YzkxL3RleHRyZWdpb246ZmUxNDFkOTZmNTYxNGYzZmEyZmFiNDc5ODA4OTVjOTFfMTY3MQ_9eaf397b-0d88-43c5-a094-153c0ca01ee2">1.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="iac7c0f0822b942fa8f45ea15693a76af_I20211231" decimals="-5" name="us-gaap:InterestReceivableCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNy9mcmFnOmZlMTQxZDk2ZjU2MTRmM2ZhMmZhYjQ3OTgwODk1YzkxL3RleHRyZWdpb246ZmUxNDFkOTZmNTYxNGYzZmEyZmFiNDc5ODA4OTVjOTFfMTY3OA_d98ec88f-bff6-44da-a034-4dfcb380b319">1.4</ix:nonFraction> million as of March&#160;31, 2022 and December&#160;31, 2021, respectively, as prepaid and other current assets on our condensed consolidated balance sheets.</span></div></ix:continuation><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i4f205b083fec4a579a5fdec1a876944d">As of March&#160;31, 2022, all our marketable securities had original maturities of less than <ix:nonNumeric contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331" name="cort:MarketableSecuritiesMaximumMaturityPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNy9mcmFnOmZlMTQxZDk2ZjU2MTRmM2ZhMmZhYjQ3OTgwODk1YzkxL3RleHRyZWdpb246ZmUxNDFkOTZmNTYxNGYzZmEyZmFiNDc5ODA4OTVjOTFfMTg3MQ_c2bf08fc-1716-4f8c-a6df-6e45fe88edd8">two years</ix:nonNumeric>. The weighted-average maturity of our holdings was <ix:nonNumeric contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331" name="cort:MarketableSecuritiesWeightedAverageMaturityPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNy9mcmFnOmZlMTQxZDk2ZjU2MTRmM2ZhMmZhYjQ3OTgwODk1YzkxL3RleHRyZWdpb246ZmUxNDFkOTZmNTYxNGYzZmEyZmFiNDc5ODA4OTVjOTFfMTkyNQ_65301e8d-3f92-4cba-a66e-1703ef6a9ba7">seven months</ix:nonNumeric>. As of March&#160;31, 2022, our long-term marketable securities had remaining maturities ranging from <ix:nonNumeric contextRef="i99f1fc2c348e48a0bb5c6c67e90ffd73_D20220101-20220331" name="cort:LongTermMarketableSecuritiesRemainingMaturity" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNy9mcmFnOmZlMTQxZDk2ZjU2MTRmM2ZhMmZhYjQ3OTgwODk1YzkxL3RleHRyZWdpb246ZmUxNDFkOTZmNTYxNGYzZmEyZmFiNDc5ODA4OTVjOTFfMjAxMw_7382c091-b9fe-468d-8891-1e7567d7127e">12</ix:nonNumeric> to <ix:nonNumeric contextRef="ieaf64132df2543a583e4e8f6aa3d5517_D20220101-20220331" name="cort:LongTermMarketableSecuritiesRemainingMaturity" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNy9mcmFnOmZlMTQxZDk2ZjU2MTRmM2ZhMmZhYjQ3OTgwODk1YzkxL3RleHRyZWdpb246ZmUxNDFkOTZmNTYxNGYzZmEyZmFiNDc5ODA4OTVjOTFfMjAxOQ_ebaef7cd-388f-4ace-9108-e2e94dc0ac54">24</ix:nonNumeric> months. None of our marketable securities changed from one fair value hierarchy to another during the three months ended March 31, 2022</ix:continuation>.</span></div><div id="i0a44765832c1416181e5729d6aaf7059_40"></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4. <ix:nonNumeric contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV80MC9mcmFnOmYyOWJhODdjNmQ0YzRlNDZiN2JkMjY0MGZlY2Y3NzMxL3RleHRyZWdpb246ZjI5YmE4N2M2ZDRjNGU0NmI3YmQyNjQwZmVjZjc3MzFfNzIy_b1f98d76-9e53-4253-8c3e-b2586f8e3c33" continuedAt="ibc9fbd9355664bc1ab9e6b55b820d488" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><ix:continuation id="ibc9fbd9355664bc1ab9e6b55b820d488" continuedAt="i0480595157464829b6664b22e5abd8bb"><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> There have been no material changes in our obligations under contractual agreements described in our Annual Report on Form&#160;10-K for the year ended&#160;December&#160;31, 2021. </span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of business, we may be subject to legal claims and regulatory actions that could have a material adverse effect on our business or financial position. We assess our potential liability in such situations by analyzing potential </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><ix:continuation id="i0480595157464829b6664b22e5abd8bb"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">outcomes under various litigation, regulatory and settlement strategies.&#160;If we determine a loss is probable and its amount can be reasonably estimated, we accrue an amount equal to the estimated loss.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i93f424f685944c1aab994f99b0146441_I20220331" decimals="INF" name="us-gaap:LossContingencyAccrualAtCarryingValue" format="ixt-sec:numwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV80MC9mcmFnOmYyOWJhODdjNmQ0YzRlNDZiN2JkMjY0MGZlY2Y3NzMxL3RleHRyZWdpb246ZjI5YmE4N2M2ZDRjNGU0NmI3YmQyNjQwZmVjZjc3MzFfNzE4_23884279-9cc2-42bf-afe2-3eafdf03e081">No</ix:nonFraction> losses and&#160;<ix:nonFraction unitRef="usd" contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331" decimals="INF" name="us-gaap:LossContingencyAccrualProvision" format="ixt-sec:numwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV80MC9mcmFnOmYyOWJhODdjNmQ0YzRlNDZiN2JkMjY0MGZlY2Y3NzMxL3RleHRyZWdpb246ZjI5YmE4N2M2ZDRjNGU0NmI3YmQyNjQwZmVjZjc3MzFfNzE5_8ef169be-1790-40fd-8f63-09927bb8f447">no</ix:nonFraction> provision for a loss contingency have been recorded to date.</span></div></ix:continuation><div id="i0a44765832c1416181e5729d6aaf7059_838"></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5. <ix:nonNumeric contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV84MzgvZnJhZzpkNjM0YjRiZTYxZGI0MDVjYTk4MGRhOWJlMDhlMjcwYS90ZXh0cmVnaW9uOmQ2MzRiNGJlNjFkYjQwNWNhOTgwZGE5YmUwOGUyNzBhXzYwNDczMTM5NTQ1NzM_8de2abef-4b29-41c6-ae47-75d035e85bf8" continuedAt="id5b6da086fcd41258b0365fea5b0f1d0" escape="true">Leases</ix:nonNumeric></span></div><ix:continuation id="id5b6da086fcd41258b0365fea5b0f1d0"><div style="margin-top:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We lease our office facilities in Menlo Park, California. In March 2022, we amended our lease to extend its term from March 31, 2022 to June 30, 2023. As a result of this amendment, we recognized an additional right-of-use asset and corresponding lease liability of $<ix:nonFraction unitRef="usd" contextRef="id8d3c6d4eed84ccdb36200d115427751_I20190131" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV84MzgvZnJhZzpkNjM0YjRiZTYxZGI0MDVjYTk4MGRhOWJlMDhlMjcwYS90ZXh0cmVnaW9uOmQ2MzRiNGJlNjFkYjQwNWNhOTgwZGE5YmUwOGUyNzBhXzIxOTkwMjMyNTczMzU_ad5ec2c1-72d0-4450-910f-f2e0fc211566"><ix:nonFraction unitRef="usd" contextRef="id8d3c6d4eed84ccdb36200d115427751_I20190131" decimals="-5" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV84MzgvZnJhZzpkNjM0YjRiZTYxZGI0MDVjYTk4MGRhOWJlMDhlMjcwYS90ZXh0cmVnaW9uOmQ2MzRiNGJlNjFkYjQwNWNhOTgwZGE5YmUwOGUyNzBhXzIxOTkwMjMyNTczMzU_b8e7a75f-fe9a-43fa-9eda-9996a8fa8137">2.8</ix:nonFraction></ix:nonFraction> million. The right-of-use asset and lease liability recognized equals the present value of the remaining payments due under our amended lease.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the operating lease for our facilities does not include an expressly stated interest rate, we calculated the present value of remaining lease payments using a discount rate equal to the interest rate we would pay on a collateralized loan with monthly payments and a term equal to the monthly payments and remaining term of our lease. We recognize operating lease payments as expenses using the straight-line method over the term of the lease.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease expense for each of the three months ended March&#160;31, 2022 and 2021 was approximately $<ix:nonFraction unitRef="usd" contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331" decimals="-5" name="us-gaap:OperatingLeaseExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV84MzgvZnJhZzpkNjM0YjRiZTYxZGI0MDVjYTk4MGRhOWJlMDhlMjcwYS90ZXh0cmVnaW9uOmQ2MzRiNGJlNjFkYjQwNWNhOTgwZGE5YmUwOGUyNzBhXzIxOTkwMjMyNTczODk_a185d092-92cd-49b1-a9ab-51cd10e6e951"><ix:nonFraction unitRef="usd" contextRef="i0ebb8d8bac3445859e468a3d048cfaf5_D20210101-20210331" decimals="-5" name="us-gaap:OperatingLeaseExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV84MzgvZnJhZzpkNjM0YjRiZTYxZGI0MDVjYTk4MGRhOWJlMDhlMjcwYS90ZXh0cmVnaW9uOmQ2MzRiNGJlNjFkYjQwNWNhOTgwZGE5YmUwOGUyNzBhXzIxOTkwMjMyNTczODk_b17d8422-31c8-4fe8-a18c-f1507ef9d831">0.5</ix:nonFraction></ix:nonFraction>&#160;million.</span></div><ix:nonNumeric contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331" name="us-gaap:LeaseCostTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV84MzgvZnJhZzpkNjM0YjRiZTYxZGI0MDVjYTk4MGRhOWJlMDhlMjcwYS90ZXh0cmVnaW9uOmQ2MzRiNGJlNjFkYjQwNWNhOTgwZGE5YmUwOGUyNzBhXzYwNDczMTM5NTQ1NzQ_d97326bc-a21e-4250-ad42-506b51f2289e" escape="true"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our right-of-use assets and related lease liabilities were as follows </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(in thousands, except weighted average amounts)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.213%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.452%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.454%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for operating lease liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331" decimals="-3" name="us-gaap:OperatingLeasePayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV84MzgvZnJhZzpkNjM0YjRiZTYxZGI0MDVjYTk4MGRhOWJlMDhlMjcwYS90YWJsZTowZjE0ZWVkYTAwMjE0MjUwYjc3ZGQ2NzE1NTJhNjQ5OC90YWJsZXJhbmdlOjBmMTRlZWRhMDAyMTQyNTBiNzdkZDY3MTU1MmE2NDk4XzItMS0xLTEtMzUyNjI_ff2a01fc-eb44-4145-aa91-69cda159ae10">530</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ebb8d8bac3445859e468a3d048cfaf5_D20210101-20210331" decimals="-3" name="us-gaap:OperatingLeasePayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV84MzgvZnJhZzpkNjM0YjRiZTYxZGI0MDVjYTk4MGRhOWJlMDhlMjcwYS90YWJsZTowZjE0ZWVkYTAwMjE0MjUwYjc3ZGQ2NzE1NTJhNjQ5OC90YWJsZXJhbmdlOjBmMTRlZWRhMDAyMTQyNTBiNzdkZDY3MTU1MmE2NDk4XzItMy0xLTEtMzUyNjI_4aece9d7-2401-4536-b19a-9fcc85896330">514</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for new operating lease obligations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV84MzgvZnJhZzpkNjM0YjRiZTYxZGI0MDVjYTk4MGRhOWJlMDhlMjcwYS90YWJsZTowZjE0ZWVkYTAwMjE0MjUwYjc3ZGQ2NzE1NTJhNjQ5OC90YWJsZXJhbmdlOjBmMTRlZWRhMDAyMTQyNTBiNzdkZDY3MTU1MmE2NDk4XzMtMS0xLTEtMzUyNjI_deb247f9-d16d-4124-9947-a91939df75be">2,816</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ebb8d8bac3445859e468a3d048cfaf5_D20210101-20210331" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV84MzgvZnJhZzpkNjM0YjRiZTYxZGI0MDVjYTk4MGRhOWJlMDhlMjcwYS90YWJsZTowZjE0ZWVkYTAwMjE0MjUwYjc3ZGQ2NzE1NTJhNjQ5OC90YWJsZXJhbmdlOjBmMTRlZWRhMDAyMTQyNTBiNzdkZDY3MTU1MmE2NDk4XzMtMy0xLTEtMzUyNjI_a2312419-cfd3-4b7e-a653-42d73d2c3f12">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i93f424f685944c1aab994f99b0146441_I20220331" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV84MzgvZnJhZzpkNjM0YjRiZTYxZGI0MDVjYTk4MGRhOWJlMDhlMjcwYS90YWJsZTowZjE0ZWVkYTAwMjE0MjUwYjc3ZGQ2NzE1NTJhNjQ5OC90YWJsZXJhbmdlOjBmMTRlZWRhMDAyMTQyNTBiNzdkZDY3MTU1MmE2NDk4XzQtMS0xLTEtMzUyNjI_77026c60-b75d-4a54-8817-f7648d0b4550">15</ix:nonNumeric> months</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i82ca1385b4a848fd8ea581edd7dcbfdb_I20210331" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV84MzgvZnJhZzpkNjM0YjRiZTYxZGI0MDVjYTk4MGRhOWJlMDhlMjcwYS90YWJsZTowZjE0ZWVkYTAwMjE0MjUwYjc3ZGQ2NzE1NTJhNjQ5OC90YWJsZXJhbmdlOjBmMTRlZWRhMDAyMTQyNTBiNzdkZDY3MTU1MmE2NDk4XzQtMy0xLTEtMzUyNjI_67bc8173-c26f-4f46-8927-2ecda76063a4">12</ix:nonNumeric> months</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i93f424f685944c1aab994f99b0146441_I20220331" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV84MzgvZnJhZzpkNjM0YjRiZTYxZGI0MDVjYTk4MGRhOWJlMDhlMjcwYS90YWJsZTowZjE0ZWVkYTAwMjE0MjUwYjc3ZGQ2NzE1NTJhNjQ5OC90YWJsZXJhbmdlOjBmMTRlZWRhMDAyMTQyNTBiNzdkZDY3MTU1MmE2NDk4XzUtMS0xLTEtMzUyNjI_cf0becc4-03b4-4385-8e29-97d0f3a17563">4.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i82ca1385b4a848fd8ea581edd7dcbfdb_I20210331" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV84MzgvZnJhZzpkNjM0YjRiZTYxZGI0MDVjYTk4MGRhOWJlMDhlMjcwYS90YWJsZTowZjE0ZWVkYTAwMjE0MjUwYjc3ZGQ2NzE1NTJhNjQ5OC90YWJsZXJhbmdlOjBmMTRlZWRhMDAyMTQyNTBiNzdkZDY3MTU1MmE2NDk4XzUtMy0xLTEtMzUyNjI_032cf413-dffd-4ba6-9500-1edbe9667841">4.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV84MzgvZnJhZzpkNjM0YjRiZTYxZGI0MDVjYTk4MGRhOWJlMDhlMjcwYS90ZXh0cmVnaW9uOmQ2MzRiNGJlNjFkYjQwNWNhOTgwZGE5YmUwOGUyNzBhXzYwNDczMTM5NTQ1NzU_9ae1b7bf-0033-4e64-a5c1-7a801b94407a" escape="true"><div style="margin-top:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2022, future minimum lease payments under non-cancelable operating leases were as follows </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(in thousands)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:83.256%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.544%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022 (remainder)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93f424f685944c1aab994f99b0146441_I20220331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV84MzgvZnJhZzpkNjM0YjRiZTYxZGI0MDVjYTk4MGRhOWJlMDhlMjcwYS90YWJsZTphMjk2MTBhYjc5MjU0YmE4YTFlZGE1YzNkOTNjNjA0YS90YWJsZXJhbmdlOmEyOTYxMGFiNzkyNTRiYThhMWVkYTVjM2Q5M2M2MDRhXzAtMS0xLTEtMzUyNzA_56914309-4f76-40b2-bc49-b27f6a339e29">1,735</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93f424f685944c1aab994f99b0146441_I20220331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV84MzgvZnJhZzpkNjM0YjRiZTYxZGI0MDVjYTk4MGRhOWJlMDhlMjcwYS90YWJsZTphMjk2MTBhYjc5MjU0YmE4YTFlZGE1YzNkOTNjNjA0YS90YWJsZXJhbmdlOmEyOTYxMGFiNzkyNTRiYThhMWVkYTVjM2Q5M2M2MDRhXzEtMS0xLTEtMzUyNzA_d9a27276-17ea-4200-8bc2-9edac20b4036">1,157</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93f424f685944c1aab994f99b0146441_I20220331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV84MzgvZnJhZzpkNjM0YjRiZTYxZGI0MDVjYTk4MGRhOWJlMDhlMjcwYS90YWJsZTphMjk2MTBhYjc5MjU0YmE4YTFlZGE1YzNkOTNjNjA0YS90YWJsZXJhbmdlOmEyOTYxMGFiNzkyNTRiYThhMWVkYTVjM2Q5M2M2MDRhXzItMS0xLTEtMzUyNzA_fa0a4014-1a6d-4759-9fb1-1481ac4b0d14">2,892</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i93f424f685944c1aab994f99b0146441_I20220331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV84MzgvZnJhZzpkNjM0YjRiZTYxZGI0MDVjYTk4MGRhOWJlMDhlMjcwYS90YWJsZTphMjk2MTBhYjc5MjU0YmE4YTFlZGE1YzNkOTNjNjA0YS90YWJsZXJhbmdlOmEyOTYxMGFiNzkyNTRiYThhMWVkYTVjM2Q5M2M2MDRhXzMtMS0xLTEtMzUyNzA_a219a2f8-097b-44c9-81b2-105af36d76be">76</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of operating lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93f424f685944c1aab994f99b0146441_I20220331" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV84MzgvZnJhZzpkNjM0YjRiZTYxZGI0MDVjYTk4MGRhOWJlMDhlMjcwYS90YWJsZTphMjk2MTBhYjc5MjU0YmE4YTFlZGE1YzNkOTNjNjA0YS90YWJsZXJhbmdlOmEyOTYxMGFiNzkyNTRiYThhMWVkYTVjM2Q5M2M2MDRhXzQtMS0xLTEtMzUyNzA_759e26cb-5067-4d08-a05f-74f0440d8e30">2,816</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i0a44765832c1416181e5729d6aaf7059_43"></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6. <ix:nonNumeric contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV80My9mcmFnOjZlMTRkN2FhMWVjYTQ2NDQ4MTNkOTU3ZjhlNTNkMzc0L3RleHRyZWdpb246NmUxNGQ3YWExZWNhNDY0NDgxM2Q5NTdmOGU1M2QzNzRfMjQxNQ_e2cd587f-dfd9-4175-857b-47c731481806" continuedAt="i56cba4c0396a468bbd15f7d67e33bcbc" escape="true">Stockholders&#8217; Equity</ix:nonNumeric></span></div><ix:continuation id="i56cba4c0396a468bbd15f7d67e33bcbc" continuedAt="id93ddd2bfb9b4660896858553bccae9f"><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Incentive Award Plan</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have <ix:nonFraction unitRef="stockoptionplan" contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331" decimals="INF" name="cort:NumberOfStockOptionPlans" format="ixt-sec:numwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV80My9mcmFnOjZlMTRkN2FhMWVjYTQ2NDQ4MTNkOTU3ZjhlNTNkMzc0L3RleHRyZWdpb246NmUxNGQ3YWExZWNhNDY0NDgxM2Q5NTdmOGU1M2QzNzRfNjA0NzMxMzk4Njk2Mw_6f2bf276-f2b0-41df-b41b-2e13014028bb">one</ix:nonFraction> stock option plan &#8211; the 2012 Incentive Award Plan (the &#8220;2012 Plan&#8221;).&#160;In December 2021, our Board of Directors authorized a <ix:nonFraction unitRef="shares" contextRef="iea23a3d3fb214422896877163db10055_D20211201-20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV80My9mcmFnOjZlMTRkN2FhMWVjYTQ2NDQ4MTNkOTU3ZjhlNTNkMzc0L3RleHRyZWdpb246NmUxNGQ3YWExZWNhNDY0NDgxM2Q5NTdmOGU1M2QzNzRfMjE5OTAyMzI1ODA1MA_5da00738-749d-438e-9830-ac81eca02b8b">4.2</ix:nonFraction>&#160;million increase in the shares available for grant under the 2012 Plan.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2022, we issued <ix:nonFraction unitRef="shares" contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV80My9mcmFnOjZlMTRkN2FhMWVjYTQ2NDQ4MTNkOTU3ZjhlNTNkMzc0L3RleHRyZWdpb246NmUxNGQ3YWExZWNhNDY0NDgxM2Q5NTdmOGU1M2QzNzRfMzI5_5b589f29-9489-48ba-8ae2-b5a214ce2ed5">0.6</ix:nonFraction>&#160;million shares of our common stock upon the exercise of stock options. Certain option holders exercised their options on a &#8220;net exercise&#8221; basis, pursuant to which they surrendered to us, and we purchased from them at the current market price, enough shares to cover the exercise price and tax withholding obligations arising from the exercise. During the three months ended March 31, 2022, we purchased <ix:nonFraction unitRef="shares" contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331" decimals="-5" name="us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV80My9mcmFnOjZlMTRkN2FhMWVjYTQ2NDQ4MTNkOTU3ZjhlNTNkMzc0L3RleHRyZWdpb246NmUxNGQ3YWExZWNhNDY0NDgxM2Q5NTdmOGU1M2QzNzRfNjgy_5dc2025d-e5c7-42ef-a7b5-6d3b251b55ee">0.3</ix:nonFraction>&#160;million shares in connection with such option net exercises. In connection with the shares purchased, during the three months ended March 31, 2022, we paid $<ix:nonFraction unitRef="usd" contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331" decimals="-5" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV80My9mcmFnOjZlMTRkN2FhMWVjYTQ2NDQ4MTNkOTU3ZjhlNTNkMzc0L3RleHRyZWdpb246NmUxNGQ3YWExZWNhNDY0NDgxM2Q5NTdmOGU1M2QzNzRfMjE5OTAyMzI1ODU5OQ_d3fc2204-2875-4a83-94c5-48e5e070597e">1.9</ix:nonFraction>&#160;million to satisfy associated tax withholding obligations.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2021, we issued <ix:nonFraction unitRef="shares" contextRef="i0ebb8d8bac3445859e468a3d048cfaf5_D20210101-20210331" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV80My9mcmFnOjZlMTRkN2FhMWVjYTQ2NDQ4MTNkOTU3ZjhlNTNkMzc0L3RleHRyZWdpb246NmUxNGQ3YWExZWNhNDY0NDgxM2Q5NTdmOGU1M2QzNzRfODg0_07838585-d7fc-4ab4-8acb-47fa42cabd5a">1.8</ix:nonFraction>&#160;million shares of our common stock upon the exercise of stock options. We purchased <ix:nonFraction unitRef="shares" contextRef="i0ebb8d8bac3445859e468a3d048cfaf5_D20210101-20210331" decimals="-5" name="us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV80My9mcmFnOjZlMTRkN2FhMWVjYTQ2NDQ4MTNkOTU3ZjhlNTNkMzc0L3RleHRyZWdpb246NmUxNGQ3YWExZWNhNDY0NDgxM2Q5NTdmOGU1M2QzNzRfMjE5OTAyMzI5MDEzMA_db5f17f0-0f7d-4639-af99-82eb37b27433">0.8</ix:nonFraction>&#160;million shares in connection with option net exercises, at a total cost of $<ix:nonFraction unitRef="usd" contextRef="i0ebb8d8bac3445859e468a3d048cfaf5_D20210101-20210331" decimals="-5" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV80My9mcmFnOjZlMTRkN2FhMWVjYTQ2NDQ4MTNkOTU3ZjhlNTNkMzc0L3RleHRyZWdpb246NmUxNGQ3YWExZWNhNDY0NDgxM2Q5NTdmOGU1M2QzNzRfMjE5OTAyMzI5MDEwNw_3fc61cc3-07c9-4b77-ab76-83bc7d486aca">16.4</ix:nonFraction>&#160;million, to satisfy associated tax withholding obligations.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recorded purchased shares as treasury stock on our condensed consolidated balance sheets at cost. As of March&#160;31, 2022 and December&#160;31, 2021, we had <ix:nonFraction unitRef="shares" contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV80My9mcmFnOjZlMTRkN2FhMWVjYTQ2NDQ4MTNkOTU3ZjhlNTNkMzc0L3RleHRyZWdpb246NmUxNGQ3YWExZWNhNDY0NDgxM2Q5NTdmOGU1M2QzNzRfMjI1OQ_37256e3b-9938-4fbe-8b89-a51cf479a883">21.6</ix:nonFraction>&#160;million and <ix:nonFraction unitRef="shares" contextRef="i0ebb8d8bac3445859e468a3d048cfaf5_D20210101-20210331" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV80My9mcmFnOjZlMTRkN2FhMWVjYTQ2NDQ4MTNkOTU3ZjhlNTNkMzc0L3RleHRyZWdpb246NmUxNGQ3YWExZWNhNDY0NDgxM2Q5NTdmOGU1M2QzNzRfMjI2Ng_b5f303cc-c950-4a70-bd82-b65f0a1403c7">21.3</ix:nonFraction>&#160;million treasury shares outstanding, respectively.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><ix:continuation id="id93ddd2bfb9b4660896858553bccae9f"><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units (&#8220;RSUs&#8221;)</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2022, we granted employees <ix:nonFraction unitRef="shares" contextRef="i52a9c7a889214b11ad5675cc29794ba8_D20220101-20220331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV80My9mcmFnOjZlMTRkN2FhMWVjYTQ2NDQ4MTNkOTU3ZjhlNTNkMzc0L3RleHRyZWdpb246NmUxNGQ3YWExZWNhNDY0NDgxM2Q5NTdmOGU1M2QzNzRfMjE5OTAyMzI4OTcxNw_b4f23974-762a-45c6-9c53-94f1c4969a56">0.2</ix:nonFraction> million RSUs with a weighted-average grant date fair value of $<ix:nonFraction unitRef="usdPerShare" contextRef="i52a9c7a889214b11ad5675cc29794ba8_D20220101-20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV80My9mcmFnOjZlMTRkN2FhMWVjYTQ2NDQ4MTNkOTU3ZjhlNTNkMzc0L3RleHRyZWdpb246NmUxNGQ3YWExZWNhNDY0NDgxM2Q5NTdmOGU1M2QzNzRfMjE5OTAyMzI4OTcyOQ_3a89ecb9-e8b9-4e78-8e58-6e96a553701f">19.34</ix:nonFraction> per share. No RSUs vested during the period.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Stock Purchase Plan (&#8220;ESPP&#8221;)</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2022 we adopted an ESPP that allows employees to set aside, by means of payroll deductions, up to ten percent of their annual compensation for the purchase of our commons stock. Shares are issued to participating employees from the 2012 Plan on March 1st and September 1st of each year (or, if those dates fall on holidays, on the first business day thereafter) at the then-current fair market value of our stock, as determined at the close of trading on those days. Payroll deductions for participating employees began April 1, 2022, and the first purchase under the plan will take place on September 1, 2022.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For each purchased share held for one year, the purchasing employee will receive one matching share, also issued from the 2012 Plan, net of any applicable tax withholding. There is no vesting requirement with respect to shares issued pursuant to the ESPP. Shares purchased pursuant to the ESPP as well as any matching shares issued upon satisfaction of the one-year holding requirement may be held, sold or otherwise transferred at the employee&#8217;s sole discretion.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-based Compensation</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense associated with stock options and awards of restricted stock is measured at the grant date based on the fair value of the award, and is recognized, net of forfeitures, as expense over the remaining requisite service period on a straight-line basis.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company values restricted stock at the closing market price of the Company&#8217;s common stock on the date of grant.</span></div><ix:nonNumeric contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV80My9mcmFnOjZlMTRkN2FhMWVjYTQ2NDQ4MTNkOTU3ZjhlNTNkMzc0L3RleHRyZWdpb246NmUxNGQ3YWExZWNhNDY0NDgxM2Q5NTdmOGU1M2QzNzRfMjQxNA_dd947806-b0a1-4f55-8b47-2d353cb0643b" escape="true"><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our stock-based compensation by account:</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.882%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.545%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation capitalized in inventory</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331" decimals="-3" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV80My9mcmFnOjZlMTRkN2FhMWVjYTQ2NDQ4MTNkOTU3ZjhlNTNkMzc0L3RhYmxlOmE0YTQwZmI1MjdhYTQ5MzY5M2Q0YTNmODRkMjQzMmU2L3RhYmxlcmFuZ2U6YTRhNDBmYjUyN2FhNDkzNjkzZDRhM2Y4NGQyNDMyZTZfNC0xLTEtMS0yODIyMQ_5e4f5378-db56-4b70-ad9f-46a64f00a2c7">64</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ebb8d8bac3445859e468a3d048cfaf5_D20210101-20210331" decimals="-3" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV80My9mcmFnOjZlMTRkN2FhMWVjYTQ2NDQ4MTNkOTU3ZjhlNTNkMzc0L3RhYmxlOmE0YTQwZmI1MjdhYTQ5MzY5M2Q0YTNmODRkMjQzMmU2L3RhYmxlcmFuZ2U6YTRhNDBmYjUyN2FhNDkzNjkzZDRhM2Y4NGQyNDMyZTZfNC0zLTEtMS0yODIyMQ_6afda0b6-484a-4454-9941-727789e6752a">41</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84ac47ee98bd42c490c47ffe50f5648d_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV80My9mcmFnOjZlMTRkN2FhMWVjYTQ2NDQ4MTNkOTU3ZjhlNTNkMzc0L3RhYmxlOmE0YTQwZmI1MjdhYTQ5MzY5M2Q0YTNmODRkMjQzMmU2L3RhYmxlcmFuZ2U6YTRhNDBmYjUyN2FhNDkzNjkzZDRhM2Y4NGQyNDMyZTZfNS0xLTEtMS0yODIyMQ_c1bddd90-c282-4234-9f69-2f95a7aef1e9">16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b5e7570f4ee4e91920827cf4275116e_D20210101-20210331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV80My9mcmFnOjZlMTRkN2FhMWVjYTQ2NDQ4MTNkOTU3ZjhlNTNkMzc0L3RhYmxlOmE0YTQwZmI1MjdhYTQ5MzY5M2Q0YTNmODRkMjQzMmU2L3RhYmxlcmFuZ2U6YTRhNDBmYjUyN2FhNDkzNjkzZDRhM2Y4NGQyNDMyZTZfNS0zLTEtMS0yODIyMQ_95971c0f-5692-41f7-aaea-564a7b034356">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i715a1de9af124f9bbf4fc1f32f12f6c8_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV80My9mcmFnOjZlMTRkN2FhMWVjYTQ2NDQ4MTNkOTU3ZjhlNTNkMzc0L3RhYmxlOmE0YTQwZmI1MjdhYTQ5MzY5M2Q0YTNmODRkMjQzMmU2L3RhYmxlcmFuZ2U6YTRhNDBmYjUyN2FhNDkzNjkzZDRhM2Y4NGQyNDMyZTZfNi0xLTEtMS0yODIyMQ_b46b91fd-0e8b-4a34-93a1-d366ae3b4aee">3,371</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i056b689380d140aca93fdcee21bcdca1_D20210101-20210331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV80My9mcmFnOjZlMTRkN2FhMWVjYTQ2NDQ4MTNkOTU3ZjhlNTNkMzc0L3RhYmxlOmE0YTQwZmI1MjdhYTQ5MzY5M2Q0YTNmODRkMjQzMmU2L3RhYmxlcmFuZ2U6YTRhNDBmYjUyN2FhNDkzNjkzZDRhM2Y4NGQyNDMyZTZfNi0zLTEtMS0yODIyMQ_d667fcb8-8c1b-43ea-b8fe-1d2c7c6fa685">3,505</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cbc329d8aed49d7b08ed92b59aa995b_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV80My9mcmFnOjZlMTRkN2FhMWVjYTQ2NDQ4MTNkOTU3ZjhlNTNkMzc0L3RhYmxlOmE0YTQwZmI1MjdhYTQ5MzY5M2Q0YTNmODRkMjQzMmU2L3RhYmxlcmFuZ2U6YTRhNDBmYjUyN2FhNDkzNjkzZDRhM2Y4NGQyNDMyZTZfNy0xLTEtMS0yODIyMQ_e660a3ad-8bcc-46d5-a961-58395073ee7b">7,374</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5de86b46aad4df397dd31ed521a5161_D20210101-20210331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV80My9mcmFnOjZlMTRkN2FhMWVjYTQ2NDQ4MTNkOTU3ZjhlNTNkMzc0L3RhYmxlOmE0YTQwZmI1MjdhYTQ5MzY5M2Q0YTNmODRkMjQzMmU2L3RhYmxlcmFuZ2U6YTRhNDBmYjUyN2FhNDkzNjkzZDRhM2Y4NGQyNDMyZTZfNy0zLTEtMS0yODIyMQ_bcb25147-f12e-48c2-8dea-c326530c9c47">6,586</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV80My9mcmFnOjZlMTRkN2FhMWVjYTQ2NDQ4MTNkOTU3ZjhlNTNkMzc0L3RhYmxlOmE0YTQwZmI1MjdhYTQ5MzY5M2Q0YTNmODRkMjQzMmU2L3RhYmxlcmFuZ2U6YTRhNDBmYjUyN2FhNDkzNjkzZDRhM2Y4NGQyNDMyZTZfOC0xLTEtMS0yODIyMQ_5dfa9abd-f0a1-4779-bc97-6b1dfd591d0a">10,825</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ebb8d8bac3445859e468a3d048cfaf5_D20210101-20210331" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV80My9mcmFnOjZlMTRkN2FhMWVjYTQ2NDQ4MTNkOTU3ZjhlNTNkMzc0L3RhYmxlOmE0YTQwZmI1MjdhYTQ5MzY5M2Q0YTNmODRkMjQzMmU2L3RhYmxlcmFuZ2U6YTRhNDBmYjUyN2FhNDkzNjkzZDRhM2Y4NGQyNDMyZTZfOC0zLTEtMS0yODIyMQ_09006278-82eb-4ac2-bfd6-dc89a180d5eb">10,142</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i0a44765832c1416181e5729d6aaf7059_46"></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7. <ix:nonNumeric contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV80Ni9mcmFnOjU5Mjk1M2U0NTk3NjQwNThiYWQ2MjQ2ZDJhOTVlM2FjL3RleHRyZWdpb246NTkyOTUzZTQ1OTc2NDA1OGJhZDYyNDZkMmE5NWUzYWNfNzUz_d9a53f9d-14ee-418c-8356-c9e3462c9509" continuedAt="i421ee057c77c4a75b3298fefd62cc610" escape="true">Net Income Per Share</ix:nonNumeric></span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i421ee057c77c4a75b3298fefd62cc610" continuedAt="if77fca4215fc4403a65168978c64e680">We compute basic and diluted net income per share by dividing our net income by the weighted-average number of common shares outstanding during the period, including potentially dilutive stock options and RSUs. We use the treasury stock method to determine the number of dilutive shares of common stock resulting from stock options and restricted stock.</ix:continuation></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><ix:continuation id="if77fca4215fc4403a65168978c64e680" continuedAt="i121cf77b44ad4eef9220523bd93a856a"><ix:nonNumeric contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV80Ni9mcmFnOjU5Mjk1M2U0NTk3NjQwNThiYWQ2MjQ2ZDJhOTVlM2FjL3RleHRyZWdpb246NTkyOTUzZTQ1OTc2NDA1OGJhZDYyNDZkMmE5NWUzYWNfNzU1_4ec5eee6-3e96-4f5a-b936-088c45171d62" escape="true"><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the computation of net income per share for each period:</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.882%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.545%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV80Ni9mcmFnOjU5Mjk1M2U0NTk3NjQwNThiYWQ2MjQ2ZDJhOTVlM2FjL3RhYmxlOjAyMmVjYWUwNjQwNTQxOTE5Nzc1YmY5NzA0NWJmZTQxL3RhYmxlcmFuZ2U6MDIyZWNhZTA2NDA1NDE5MTk3NzViZjk3MDQ1YmZlNDFfNS0xLTEtMS0yODIyMQ_4991e9d3-9f2a-41e4-8176-409761da4afd">22,797</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ebb8d8bac3445859e468a3d048cfaf5_D20210101-20210331" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV80Ni9mcmFnOjU5Mjk1M2U0NTk3NjQwNThiYWQ2MjQ2ZDJhOTVlM2FjL3RhYmxlOjAyMmVjYWUwNjQwNTQxOTE5Nzc1YmY5NzA0NWJmZTQxL3RhYmxlcmFuZ2U6MDIyZWNhZTA2NDA1NDE5MTk3NzViZjk3MDQ1YmZlNDFfNS0zLTEtMS0yODIyMQ_6e16372d-992a-44c8-a9b6-1b107fc33d10">23,465</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares used to compute basic net income per share</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV80Ni9mcmFnOjU5Mjk1M2U0NTk3NjQwNThiYWQ2MjQ2ZDJhOTVlM2FjL3RhYmxlOjAyMmVjYWUwNjQwNTQxOTE5Nzc1YmY5NzA0NWJmZTQxL3RhYmxlcmFuZ2U6MDIyZWNhZTA2NDA1NDE5MTk3NzViZjk3MDQ1YmZlNDFfNy0xLTEtMS0yODIyMQ_2d60ac57-1bce-4492-9fba-4fc2a8101060">106,012</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0ebb8d8bac3445859e468a3d048cfaf5_D20210101-20210331" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV80Ni9mcmFnOjU5Mjk1M2U0NTk3NjQwNThiYWQ2MjQ2ZDJhOTVlM2FjL3RhYmxlOjAyMmVjYWUwNjQwNTQxOTE5Nzc1YmY5NzA0NWJmZTQxL3RhYmxlcmFuZ2U6MDIyZWNhZTA2NDA1NDE5MTk3NzViZjk3MDQ1YmZlNDFfNy0zLTEtMS0yODIyMQ_0ce276dd-0b91-4cf2-a020-35f0df619114">116,818</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive effect of employee stock options and restricted stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV80Ni9mcmFnOjU5Mjk1M2U0NTk3NjQwNThiYWQ2MjQ2ZDJhOTVlM2FjL3RhYmxlOjAyMmVjYWUwNjQwNTQxOTE5Nzc1YmY5NzA0NWJmZTQxL3RhYmxlcmFuZ2U6MDIyZWNhZTA2NDA1NDE5MTk3NzViZjk3MDQ1YmZlNDFfOC0xLTEtMS0yODIyMQ_dedda398-a94e-4012-a367-05794b6d2bbf">9,025</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0ebb8d8bac3445859e468a3d048cfaf5_D20210101-20210331" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV80Ni9mcmFnOjU5Mjk1M2U0NTk3NjQwNThiYWQ2MjQ2ZDJhOTVlM2FjL3RhYmxlOjAyMmVjYWUwNjQwNTQxOTE5Nzc1YmY5NzA0NWJmZTQxL3RhYmxlcmFuZ2U6MDIyZWNhZTA2NDA1NDE5MTk3NzViZjk3MDQ1YmZlNDFfOC0zLTEtMS0yODIyMQ_e99cca95-e6a7-4e00-8b6a-42aa28c72ea5">12,850</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares used to compute diluted net income per share</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV80Ni9mcmFnOjU5Mjk1M2U0NTk3NjQwNThiYWQ2MjQ2ZDJhOTVlM2FjL3RhYmxlOjAyMmVjYWUwNjQwNTQxOTE5Nzc1YmY5NzA0NWJmZTQxL3RhYmxlcmFuZ2U6MDIyZWNhZTA2NDA1NDE5MTk3NzViZjk3MDQ1YmZlNDFfOS0xLTEtMS0yODIyMQ_d4bdce85-ddbd-405e-8785-2961338993e6">115,037</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0ebb8d8bac3445859e468a3d048cfaf5_D20210101-20210331" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV80Ni9mcmFnOjU5Mjk1M2U0NTk3NjQwNThiYWQ2MjQ2ZDJhOTVlM2FjL3RhYmxlOjAyMmVjYWUwNjQwNTQxOTE5Nzc1YmY5NzA0NWJmZTQxL3RhYmxlcmFuZ2U6MDIyZWNhZTA2NDA1NDE5MTk3NzViZjk3MDQ1YmZlNDFfOS0zLTEtMS0yODIyMQ_89a1ecce-7222-46f5-a122-f0b36fefe727">129,668</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV80Ni9mcmFnOjU5Mjk1M2U0NTk3NjQwNThiYWQ2MjQ2ZDJhOTVlM2FjL3RhYmxlOjAyMmVjYWUwNjQwNTQxOTE5Nzc1YmY5NzA0NWJmZTQxL3RhYmxlcmFuZ2U6MDIyZWNhZTA2NDA1NDE5MTk3NzViZjk3MDQ1YmZlNDFfMTEtMS0xLTEtMjgyMjE_3e0b089a-3922-4553-9f0a-c817499e04c5">0.22</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0ebb8d8bac3445859e468a3d048cfaf5_D20210101-20210331" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV80Ni9mcmFnOjU5Mjk1M2U0NTk3NjQwNThiYWQ2MjQ2ZDJhOTVlM2FjL3RhYmxlOjAyMmVjYWUwNjQwNTQxOTE5Nzc1YmY5NzA0NWJmZTQxL3RhYmxlcmFuZ2U6MDIyZWNhZTA2NDA1NDE5MTk3NzViZjk3MDQ1YmZlNDFfMTEtMy0xLTEtMjgyMjE_a72365a1-9f1b-4deb-ac0d-c22092a40dd7">0.20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV80Ni9mcmFnOjU5Mjk1M2U0NTk3NjQwNThiYWQ2MjQ2ZDJhOTVlM2FjL3RhYmxlOjAyMmVjYWUwNjQwNTQxOTE5Nzc1YmY5NzA0NWJmZTQxL3RhYmxlcmFuZ2U6MDIyZWNhZTA2NDA1NDE5MTk3NzViZjk3MDQ1YmZlNDFfMTItMS0xLTEtMjgyMjE_ca90c21d-c4a2-4a2d-bf77-ea454c0674a6">0.20</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0ebb8d8bac3445859e468a3d048cfaf5_D20210101-20210331" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV80Ni9mcmFnOjU5Mjk1M2U0NTk3NjQwNThiYWQ2MjQ2ZDJhOTVlM2FjL3RhYmxlOjAyMmVjYWUwNjQwNTQxOTE5Nzc1YmY5NzA0NWJmZTQxL3RhYmxlcmFuZ2U6MDIyZWNhZTA2NDA1NDE5MTk3NzViZjk3MDQ1YmZlNDFfMTItMy0xLTEtMjgyMjE_be356707-d84a-4607-9e09-08e1408ba6e8">0.18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2022, we had <ix:nonFraction unitRef="shares" contextRef="ia962305aacde4486929d4801fcf01b30_I20220331" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV80Ni9mcmFnOjU5Mjk1M2U0NTk3NjQwNThiYWQ2MjQ2ZDJhOTVlM2FjL3RleHRyZWdpb246NTkyOTUzZTQ1OTc2NDA1OGJhZDYyNDZkMmE5NWUzYWNfNDgy_21fdb546-689c-4e93-9e77-ac05eb606c4e">26.0</ix:nonFraction> million stock options and <ix:nonFraction unitRef="shares" contextRef="ibdfffff05fb64ff191febd1261049d75_I20220331" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV80Ni9mcmFnOjU5Mjk1M2U0NTk3NjQwNThiYWQ2MjQ2ZDJhOTVlM2FjL3RleHRyZWdpb246NTkyOTUzZTQ1OTc2NDA1OGJhZDYyNDZkMmE5NWUzYWNfMjE5OTAyMzI1ODUyMg_f597d969-9fb0-48ce-a5ec-d7b545b62aba">0.2</ix:nonFraction> million RSUs outstanding. As of March&#160;31, 2021, we had <ix:nonFraction unitRef="shares" contextRef="i82ca1385b4a848fd8ea581edd7dcbfdb_I20210331" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV80Ni9mcmFnOjU5Mjk1M2U0NTk3NjQwNThiYWQ2MjQ2ZDJhOTVlM2FjL3RleHRyZWdpb246NTkyOTUzZTQ1OTc2NDA1OGJhZDYyNDZkMmE5NWUzYWNfMjE5OTAyMzI1ODUzMA_f9147a13-c3c5-43dc-a59d-c04bd9556e8c">26.8</ix:nonFraction> million stock options outstanding.</span></div></ix:continuation><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i121cf77b44ad4eef9220523bd93a856a">We excluded from the computation of diluted net income per share, on a weighted-average basis,&#160;<ix:nonFraction unitRef="shares" contextRef="i79418e09cbdb47588dfeae9d2b02dc38_D20220101-20220331" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV80Ni9mcmFnOjU5Mjk1M2U0NTk3NjQwNThiYWQ2MjQ2ZDJhOTVlM2FjL3RleHRyZWdpb246NTkyOTUzZTQ1OTc2NDA1OGJhZDYyNDZkMmE5NWUzYWNfNjgw_e3cdd73c-6f78-4ff2-b07a-a3eea651d180">6.9</ix:nonFraction> million stock options and RSUs outstanding during the three months ended March 31, 2022 and <ix:nonFraction unitRef="shares" contextRef="i461a8de5644c45629b64932556c34fff_D20210101-20210331" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV80Ni9mcmFnOjU5Mjk1M2U0NTk3NjQwNThiYWQ2MjQ2ZDJhOTVlM2FjL3RleHRyZWdpb246NTkyOTUzZTQ1OTc2NDA1OGJhZDYyNDZkMmE5NWUzYWNfNjg3_99fa9596-b7c6-4f7f-9cc6-9688a6f4681b">2.4</ix:nonFraction> million stock options outstanding during the three months ended March 31, 2021, because including them would have reduced dilution</ix:continuation>.</span></div><div id="i0a44765832c1416181e5729d6aaf7059_49"></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8. <ix:nonNumeric contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV80OS9mcmFnOjNjYWViMjFiYWNkZDQwZGFiY2JiYjUzN2Q5Nzk0ZTc0L3RleHRyZWdpb246M2NhZWIyMWJhY2RkNDBkYWJjYmJiNTM3ZDk3OTRlNzRfMTkwOQ_1324d364-1936-4048-9d2b-47ad60e82615" continuedAt="iac4712f92a7b4165a34497e82dc78cc7" escape="true">Income Taxes</ix:nonNumeric></span></div><ix:continuation id="iac4712f92a7b4165a34497e82dc78cc7"><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recorded income tax expense of $<ix:nonFraction unitRef="usd" contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV80OS9mcmFnOjNjYWViMjFiYWNkZDQwZGFiY2JiYjUzN2Q5Nzk0ZTc0L3RleHRyZWdpb246M2NhZWIyMWJhY2RkNDBkYWJjYmJiNTM3ZDk3OTRlNzRfNTg_7fc0acdd-f9b5-44cd-8b2e-cbc4f07eecec">4.1</ix:nonFraction> million for the three months ended March 31, 2022, and an income tax benefit of $<ix:nonFraction unitRef="usd" contextRef="i0ebb8d8bac3445859e468a3d048cfaf5_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV80OS9mcmFnOjNjYWViMjFiYWNkZDQwZGFiY2JiYjUzN2Q5Nzk0ZTc0L3RleHRyZWdpb246M2NhZWIyMWJhY2RkNDBkYWJjYmJiNTM3ZDk3OTRlNzRfMTAy_eeb12625-af1c-4595-9f94-e6ffdbe26f5c">3.6</ix:nonFraction> million for the three months ended March 31, 2021. The increase in income tax expense during the three months ended March 31, 2022 was primarily due to increased income before income taxes and decreased excess tax deductions from stock-based compensation as compared to the corresponding period in 2021.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our effective tax rate differs from the federal statutory rate due to state income taxes and the non-deductible portion of our stock-based compensation, which increased our tax expense, offset by tax benefits for research and development tax credits and the excess tax deduction arising from the exercise of employee stock options, which reduced our taxable income.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2022, unrecognized tax benefits increased by $<ix:nonFraction unitRef="usd" contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsPeriodIncreaseDecrease" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV80OS9mcmFnOjNjYWViMjFiYWNkZDQwZGFiY2JiYjUzN2Q5Nzk0ZTc0L3RleHRyZWdpb246M2NhZWIyMWJhY2RkNDBkYWJjYmJiNTM3ZDk3OTRlNzRfNjg5_171b279f-5e3e-4f27-a144-3dbe28891e34">0.4</ix:nonFraction> million. As of March&#160;31, 2022, the Company had unrecognized tax benefits of $<ix:nonFraction unitRef="usd" contextRef="i93f424f685944c1aab994f99b0146441_I20220331" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV80OS9mcmFnOjNjYWViMjFiYWNkZDQwZGFiY2JiYjUzN2Q5Nzk0ZTc0L3RleHRyZWdpb246M2NhZWIyMWJhY2RkNDBkYWJjYmJiNTM3ZDk3OTRlNzRfNzQ4_af61395d-f9df-48d8-b615-f226c061fee2">7.7</ix:nonFraction> million that, if recognized, would affect the Company&#8217;s effective tax rate and approximately $<ix:nonFraction unitRef="usd" contextRef="i93f424f685944c1aab994f99b0146441_I20220331" decimals="-5" name="cort:UnrecognizedTaxBenefitsThatWouldBeOffsetByAChangeInValuationAllowance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV80OS9mcmFnOjNjYWViMjFiYWNkZDQwZGFiY2JiYjUzN2Q5Nzk0ZTc0L3RleHRyZWdpb246M2NhZWIyMWJhY2RkNDBkYWJjYmJiNTM3ZDk3OTRlNzRfODY2_d5030926-eec6-40c4-b562-5fc814e4c522">1.9</ix:nonFraction> million of unrecognized tax benefits that would not impact the effective tax rate as they would be offset by a corresponding change in valuation allowance.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each quarter, we assess the likelihood that we will generate sufficient taxable income to make use of our federal and state deferred tax assets. If we believe that recovery of these deferred tax assets is not more likely than not, we establish a valuation allowance offsetting such assets on our balance sheet. Significant judgment is required in assessing the need for a valuation allowance. We consider all available evidence, including our recent operating results and our forecasts of future taxable income. Other than valuation allowances against our California net deferred tax assets, we have determined that it is more likely than not we will realize the benefit related to all other deferred tax assets. To the extent we increase a valuation allowance, we will include an expense in the Condensed Consolidated Statement of Comprehensive Income in the period in which such determination is made.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in 2022, the Tax Cuts and Jobs Act of 2017 (&#8220;TCJA&#8221;) eliminates the right to deduct research and development expenditures for tax purposes in the period the expenses were incurred and instead requires all U.S. and foreign research and development expenditures to be amortized over five and fifteen tax years, respectively. Although Congress is considering legislation that would defer the amortization requirement to later years, it is not certain that the provision will be repealed or otherwise modified. As of March&#160;31, 2022, the requirement has not been modified. We have capitalized our research and development expenses, which caused our taxes payable to increase to $<ix:nonFraction unitRef="usd" contextRef="i93f424f685944c1aab994f99b0146441_I20220331" decimals="-5" name="us-gaap:TaxesPayableCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV80OS9mcmFnOjNjYWViMjFiYWNkZDQwZGFiY2JiYjUzN2Q5Nzk0ZTc0L3RleHRyZWdpb246M2NhZWIyMWJhY2RkNDBkYWJjYmJiNTM3ZDk3OTRlNzRfMjE5OTAyMzI2OTExNw_7ec241a6-e560-425a-b73b-053b00cc55ba">11.5</ix:nonFraction> million as of March&#160;31, 2022, compared to $<ix:nonFraction unitRef="usd" contextRef="iac7c0f0822b942fa8f45ea15693a76af_I20211231" decimals="-5" name="us-gaap:TaxesPayableCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV80OS9mcmFnOjNjYWViMjFiYWNkZDQwZGFiY2JiYjUzN2Q5Nzk0ZTc0L3RleHRyZWdpb246M2NhZWIyMWJhY2RkNDBkYWJjYmJiNTM3ZDk3OTRlNzRfMjE5OTAyMzI2OTEyOA_7459a859-ccc6-48ee-b8c8-616d23b17e76">0.5</ix:nonFraction> million as of December&#160;31, 2021.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><div id="i0a44765832c1416181e5729d6aaf7059_52"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 2.&#160;&#160;MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The following Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations (&#8220;MD&amp;A&#8221;) is intended to help the reader understand our results of operations and financial condition and is provided as a supplement to, and should be read in conjunction with our condensed consolidated financial statements and the accompanying notes to financial statements, risk factors and other disclosures included in this Form 10-Q. Our condensed consolidated financial statements have been prepared in accordance with U.S. Generally Accepted Accounting Principles (&#8220;U.S. GAAP&#8221;).</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We make statements in this section that are forward-looking statements within the meaning of the federal securities laws. For a complete discussion of such forward-looking statements and the potential risks and uncertainties that may affect their accuracy, see the &#8220;Risk Factors&#8221; section of this Form 10-Q and the &#8220;Overview&#8221; and &#8220;Liquidity and Capital Resources&#8221; sections of this MD&amp;A.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a commercial-stage company engaged in the discovery and development of drugs that treat severe endocrine, metabolic, oncologic, and neurological disorders by modulating the effects of the hormone cortisol. Since 2012, we have marketed Korlym (mifepristone) for the treatment of patients suffering from Cushing&#8217;s syndrome. Our portfolio of proprietary selective cortisol modulators consists of four structurally distinct series totaling more than 1,000 compounds.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cushing&#8217;s Syndrome</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Korlym</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We sell Korlym in the United States, using experienced clinical sales representatives to call on physicians caring for patients with endogenous Cushing&#8217;s syndrome (hypercortisolism). Because many people who suffer from Cushing&#8217;s syndrome are undiagnosed or inadequately treated, we have developed and continue to refine and expand programs to educate physicians and patients about screening for hypercortisolism and the role Korlym can play in treating patients with the disorder. We also have a field-based force of medical science liaisons.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use one specialty pharmacy and one specialty distributor to distribute Korlym and provide logistical support to physicians and patients. Our policy is that no patient with Cushing&#8217;s syndrome will be denied access to Korlym for financial reasons. To help us achieve that goal, we fund our own patient support programs and donate money to independent charitable foundations that help patients pay for all aspects of their Cushing&#8217;s syndrome care, whether or not that care includes taking Korlym.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Relacorilant</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#160;We are conducting two Phase 3 trials (named GRACE and GRADIENT) of our proprietary, selective cortisol modulator, relacorilant, as a treatment for patients with Cushing&#8217;s syndrome. Relacorilant was well-tolerated in its Phase 1 and Phase 2 trials. Patients in the Phase 2 trial exhibited meaningful improvements in glucose control, hypertension, weight, liver function, coagulopathy, cognition, mood, insulin resistance and quality of life measures. Relacorilant shares Korlym&#8217;s affinity for the glucocorticoid receptor (&#8220;GR&#8221;), but, unlike Korlym, has no affinity for the progesterone receptor (&#8220;PR&#8221;), and so is not the &#8220;abortion pill&#8221; and does not cause the effects associated with the PR affinity, including endometrial thickening and vaginal bleeding. Relacorilant also does not appear to cause hypokalemia (low potassium), a potentially serious adverse event that is a leading cause of patients stopping treatment with Korlym. Forty-four percent of patients in Korlym&#8217;s pivotal trial experienced hypokalemia.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the GRACE trial, each patient receives relacorilant for 22 weeks. Patients who exhibit pre-specified improvements in hypertension and/or glucose metabolism enter a 12-week, double-blind, &#8220;randomized withdrawal&#8221; phase, in which half of the patients continue receiving relacorilant and half receive placebo. The trial&#8217;s primary endpoint is the rate and degree of relapse in patients receiving placebo measured against the rate and degree of relapse in those continuing relacorilant. GRACE has a planned enrollment of 130 patients with Cushing&#8217;s syndrome at sites in the United States, Canada, Europe and Israel. If successful, we expect GRACE to provide the basis for a new drug application (&#8220;NDA&#8221;) for relacorilant as a treatment for patients with any etiology of endogenous Cushing&#8217;s syndrome.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our second Phase 3 trial of relacorilant, GRADIENT, is studying patients whose Cushing&#8217;s syndrome is caused by a benign adrenal tumor. These patients often exhibit less severe symptoms or have a more gradual course of disease than patients with other etiologies of Cushing&#8217;s syndrome, although their health outcomes are ultimately poor. Half of the patients in GRADIENT will receive relacorilant for 26 weeks and half will receive placebo. The trial&#8217;s primary endpoints are improvements in glucose metabolism and hypertension. The planned enrollment for this study is 130 patients. Many of the clinical sites in GRACE are participating in GRADIENT.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The United States Food and Drug Administration (&#8220;FDA&#8221;) and the European Commission (&#8220;EC&#8221;) have designated relacorilant as an orphan drug for the treatment of Cushing&#8217;s syndrome. In the United States, relacorilant&#8217;s orphan designation confers tax credits, reduced regulatory fees and, provided we obtain approval for the treatment of patients with Cushing&#8217;s syndrome, seven years of exclusive marketing rights. Benefits of orphan drug designation by the EC are similar, but also include protocol assistance from the European Medicines Agency (&#8220;EMA&#8221;), access to the centralized marketing authorization procedure in the European Union (&#8220;EU&#8221;) and, if we obtain approval, ten years of exclusive marketing rights in the EU for the treatment of patients with Cushing&#8217;s syndrome.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Oncology</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is substantial in vitro, in vivo and clinical evidence that cortisol&#8217;s activity allows certain solid tumors to resist treatment. In some cancers, cortisol retards cellular apoptosis &#8211; the tumor-killing effect many treatments are meant to stimulate. In other cancers, cortisol activity promotes tumor growth. Cortisol also suppresses the body&#8217;s immune response; activating &#8211; not suppressing &#8211; the immune system is beneficial in fighting certain cancers. Modulating cortisol&#8217;s activity may help existing anti-cancer treatments achieve their intended effect. Many types of solid tumors express the GR, and are potential targets for cortisol modulation therapy, among them ovarian, adrenal and prostate cancer.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Relacorilant in Patients with Advanced Ovarian Cancer</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#160;In May 2021, we announced preliminary results from our 178-patient, controlled, multi-center, Phase 2 trial of relacorilant combined with nab-paclitaxel in patients with platinum-resistant ovarian cancer. Study participants were randomized to one of three treatment arms: 60 women received 150 mg of relacorilant intermittently (the day before, the day of and the day after their weekly nab-paclitaxel infusion) and 58 women received a daily relacorilant dose of 100 mg per day in addition to nab-paclitaxel. Sixty women received nab-paclitaxel alone. The trial&#8217;s primary endpoint was progression-free survival (&#8220;PFS&#8221;).</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patients in both of the relacorilant plus nab-paclitaxel treatment arms experienced longer PFS than did the patients who received nab-paclitaxel alone. Patients who received a higher dose of relacorilant intermittently exhibited a statistically significant improvement in median PFS (5.6 months versus 3.8 months, hazard ratio: 0.66; p-value: &lt;0.038). Patients who received a lower dose of relacorilant daily exhibited a median PFS that was 1.5 months longer than did the patients who received nab-paclitaxel alone (5.3 months versus 3.8 months, hazard ratio: 0.83; p-value: not significant). Patients who received relacorilant intermittently also had a longer median duration of response (&#8220;DoR&#8221;) (5.6 months versus 3.7 months, hazard ratio: 0.36; p-value: 0.006) compared to those who received nab-paclitaxel alone. </span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2022, we announced overall survival (&#8220;OS&#8221;) data from this trial. OS was assessed after a pre-determined number of patient deaths had occurred. At the time of database cutoff, 128 of the 178 patients who enrolled in the study had died. Patients who received relacorilant intermittently lived longer (median OS: 13.9 months versus 12.2 months, hazard ratio: 0.67; p-value: 0.066) compared to those who received nab-paclitaxel alone.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As is typical of late-stage clinical trials, Corcept&#8217;s upcoming Phase 3 trial will exclude patients with either primary platinum-refractory disease or who have already received four or more prior lines of therapy, both indicators of a very poor prognosis. Excluding such patients, women in the intermittent arm experienced significantly improved PFS (median PFS: 5.6 months versus 3.8 months, hazard ratio: 0.58; p-value: 0.016) and OS relative to patients in the comparator arm (median OS: 13.9 months versus 12.2 months, hazard ratio: 0.52; p-value: 0.010). The patients in the intermittent arm also experienced a significant improvement in DoR relative to those in the comparator arm (median DoR: 5.6 months versus 3.6 months, hazard ratio: 0.26; p-value: 0.001).</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Safety and tolerability of relacorilant plus nab-paclitaxel were comparable to nab-paclitaxel monotherapy. Based on these positive results, we plan to initiate a pivotal Phase 3 trial in the second quarter of 2022.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Relacorilant in Patients with Adrenal Cancer with Cortisol Excess.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We are conducting an open-label, Phase 1b trial of relacorilant plus the PD-1 checkpoint inhibitor pembrolizumab in 20 patients with metastatic or unresectable adrenal cancer whose tumors produce cortisol. The trial is examining whether adding relacorilant to pembrolizumab therapy reduces cortisol-activated immune suppression sufficiently to help pembrolizumab achieve its intended tumor-killing effect. Relacorilant is also expected to treat the patients&#8217; Cushing's syndrome generated by their tumors&#8217; excess production of cortisol.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Exicorilant and Relacorilant in Patients with Castration-Resistant Prostate Cancer (&#8220;CRPC&#8221;)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Androgen deprivation is the standard treatment for metastatic prostate cancer because androgens stimulate prostate tumor growth. Tumors often escape androgen deprivation therapy when cortisol&#8217;s activity at the GR supplants androgen&#8217;s in stimulating tumor growth. Combining a cortisol modulator with an androgen modulator may block this escape route. We are conducting a dose-finding trial of our proprietary, selective cortisol modulator exicorilant in combination with enzalutamide in patients with metastatic CRPC. Investigators at the University of Chicago are conducting a dose-finding trial of relacorilant combined with enzalutamide in the same patient population.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Metabolic Diseases</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Antipsychotic-Induced Weight Gain (&#8220;AIWG&#8221;). </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, six million people take antipsychotic medications such as olanzapine and risperidone to treat illnesses such as schizophrenia, bipolar disorder and depression. While these drugs are very effective, they often cause rapid and sustained weight gain, other metabolic disturbances and, ultimately, cardiovascular disease. Patients taking these medications experience a 10 to 25-year reduction in life expectancy, due in large part to increased cardiovascular events, such as heart attacks and strokes. We are studying our selective cortisol modulator miricorilant as a potential treatment for AIWG.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, we completed a double-blind, placebo-controlled Phase 1b trial, in which 96 healthy subjects received daily doses of the antipsychotic medication olanzapine (10 mg) and either miricorilant (600 mg or 900 mg) or placebo for 14 days. Study participants who received miricorilant gained less weight than subjects receiving placebo. In addition, markers of liver damage that rise temporarily at the start of olanzapine therapy increased less sharply in subjects receiving miricorilant. The results of this study were published in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Journal of Clinical Psychopharmacology</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Hunt et al., 2021) and are consistent with the findings of similar studies we conducted in healthy volunteers using mifepristone (published in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Advances in Therapy and Obesity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in 2009 and 2010).</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Based on these positive results in healthy subjects and compelling pre-clinical data, we are conducting two double-blind, placebo-controlled, Phase 2 trials of miricorilant &#8211; GRATITUDE and GRATITUDE II.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">GRATITUDE is evaluating whether a daily dose of miricorilant (600 mg) can reverse recent AIWG. Study participants receive their established antipsychotic medication plus either miricorilant or placebo for 12 weeks. GRATITUDE has enrolled patients with schizophrenia or bipolar disorder and is being conducted at 30 sites in the United States.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">GRATITUDE II is evaluating whether miricorilant can reverse long-standing AIWG. Study participants receive their established antipsychotic medication plus either miricorilant (600 mg or 900 mg daily) or placebo for 26 weeks. GRATITUDE II has enrolled patients with schizophrenia and is being conducted at 35 centers in the United States.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The primary endpoint in both the GRATITUDE and GRATITUDE II trials is the change in body weight from baseline, relative to placebo. Other important metabolic endpoints are also being measured. Both trials have completed enrollment.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Liver Disease. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are studying miricorilant as a potential treatment for nonalcoholic steatohepatitis (&#8220;NASH&#8221;). In April 2021, we suspended our Phase 2a trial after observing elevated liver enzymes in four of the five patients who received miricorilant, which resolved after miricorilant was withdrawn. The patients with elevated liver enzymes also exhibited large, rapid reductions in liver fat. We are conducting a Phase 1b dose-finding trial in patients with presumed NASH to see if an alternative miricorilant dosing regimen can capture this benefit without causing excessive liver irritation.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Amyotrophic Lateral Sclerosis (&#8220;ALS&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">)</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have completed our Phase 1 trial of our selective cortisol modulator dazucorilant, which has shown promise in animal models of ALS. We plan to advance it to Phase 2 as a potential treatment for ALS.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">COVID-19 Pandemic</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Much of the world is subject to varying degrees of pandemic-related public health restrictions, including California, where we are headquartered, and in the jurisdictions where our vendors are located and where we sell Korlym and conduct clinical trials.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These restrictions, as well as measures voluntarily undertaken by patients, physicians, hospitals and medical clinics, have reduced our revenue and make it difficult to grow our Korlym business.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The pandemic&#8217;s impact on the pace of our clinical development programs has been variable. Our trials of indications not considered immediately life-threatening, such as Cushing&#8217;s syndrome, CRPC and AIWG have experienced slower enrollment. In addition, some clinical sites have stopped enrolling new patients or have reduced the frequency with which physicians see study participants. Some sites have suspended or halted the initiation of new clinical trials. Our trials in patients with immediately life-threatening diseases, such as advanced pancreatic and ovarian cancer, did not encounter delays.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that pandemic-related impediments to our business will continue so long as there are COVID-19 public health restrictions and/or risk-reducing behavior by physicians and patients.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Please see the risk factor under Item 1A of this Quarterly Report, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8220;The COVID-19 pandemic has adversely affected and is continuing to adversely affect our business. Other public health emergencies, natural disasters, terrorism or other </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">catastrophes could disrupt our activities and render our own or our vendors&#8217; facilities and equipment inoperable or inaccessible and require us to curtail or cease operations.&#8221;</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Product Revenue </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net product revenue is gross product revenue from sales to our customers less deductions for estimated government rebates and chargebacks.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net product revenue was $93.7 million for the three months ended March 31, 2022, compared to $79.4 million for the comparable period in 2021. For the three months ended March 31, 2022, higher sales volumes accounted for 53.6 percent of the increases. Increases in the average price of Korlym accounted for the remaining growth due to price increases effective January 1, 2022 and March 1, 2021.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of sales includes the cost of API, tableting, packaging, personnel, overhead, stability testing and distribution.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of sales was $1.3 million for each of the three months ended March 31, 2022 and 2021. Cost of sales as a percentage of revenue was 1.3 percent and 1.6 percent for the three months ended March 31, 2022 and 2021, respectively. The decrease in cost of sales as a percentage of revenue was due to reduced manufacturing costs.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#8211; Research and development expense includes the cost of (1) recruiting and compensating development personnel, (2) third-party costs for clinical trials, (3) drug product and preclinical studies in support of clinical trials and regulatory submissions, (4) discovery research and (5) the development of drug formulations and manufacturing processes. </span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expense was $28.1 million for the three months ended March 31, 2022, compared to $29.0 million for the comparable period in 2021. The decrease was primarily due to reduced spending on our Phase 2 trial in ovarian cancer and our Phase 3 trial in pancreatic cancer, as patients completed their time on study, partially offset by increased spending on employee recruiting and compensation expenses and the advancement of our other development programs.</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.882%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.545%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Development programs:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oncology</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,823&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,959&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cushing&#8217;s syndrome</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,107&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,634&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Metabolic diseases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,377&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,951&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical and early-stage selective cortisol modulators</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,306&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,096&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unallocated activities, including manufacturing and regulatory activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,136&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,877&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,371&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,505&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total research and development expense</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,120&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,022&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is difficult to predict the timing and cost of development activities, which are subject to many uncertainties and risks, including inconclusive or negative results, slow patient enrollment, adverse side effects and difficulties in the formulation or manufacture of study drugs and lack of drug-candidate efficacy. In addition, clinical development is subject to government oversight and regulations that may change without notice. We expect our research and development expense to be higher in 2022 than in 2021 as our clinical programs advance. Research and development spending in future years will depend on the outcome of our pre-clinical and clinical trials and our development plans.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling, general and administrative expense </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expense includes (1) compensation of employees, consultants and contractors engaged in commercial and administrative activities, (2) the cost of vendors supporting commercial activities and (3) legal and accounting fees.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expense was $37.5 million for the three months ended March 31, 2022, compared to $29.5 million for the comparable period in 2021. The increase was due to increased employee compensation expenses, legal fees, and sales and marketing expenses.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect our selling, general and administrative expense to be higher in 2022 than in 2021 due to increased commercial and administrative activities, including litigation and administrative support for increased research and development and marketing efforts.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest and other income </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest and other income was $0.1 million for the three months ended March 31, 2022, compared to $0.3 million for the comparable period in 2021. The decrease in interest and other income was due to a lower cash and investments balance.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income tax (expense) benefit </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax expense was $4.1 million for the three months ended March 31, 2022, compared to an income tax benefit of $3.6 million for the comparable period in 2021. The change was primarily due to an increase in income before income taxes and a decrease in excess tax deductions from stock-based compensation as compared to the corresponding period in 2021.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since 2015, we have relied on revenues from the sale of Korlym to fund our operations.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on our current plans and expectations, we expect to fund our operations and planned research and development activities over the next 12 months and beyond without needing to raise additional funds, although we may choose to raise additional funds for other reasons. If we were to raise funds, equity financing would be dilutive, debt financing could involve restrictive covenants and funds raised through collaborations with other companies may require us to relinquish certain rights in our product candidates.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2022, we had cash, cash equivalents and marketable securities of $368.1 million, consisting of cash and cash equivalents of $61.9 million and marketable securities of $306.2 million, compared to cash, cash equivalents and marketable securities of $335.8 million, consisting of cash and cash equivalents of $77.6 million and marketable securities of $258.2 million as of December&#160;31, 2021. </span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cash in our bank accounts and our marketable securities could be affected if the financial institutions holding them were to fail or severely adverse conditions were to arise in the markets for public or private debt securities. We have never experienced a lack of access to cash or material realized losses. </span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by operating activities was $35.2 million for the three months ended March 31, 2022, compared to $25.4 million for the comparable period in 2021. This increase was primarily due to higher revenue.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in investing activities was $50.5 million for the three months ended March 31, 2022, compared to $3.3 million for the comparable period in 2021. The increase was primarily due to allocation of cash generated from our operating activities towards marketable securities instead of share repurchases.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in financing activities was $0.5 million for the three months ended March 31, 2022, compared to $45.9 million for the comparable period in 2021. In the three months ended March 31, 2022, we spent $1.9 million acquiring shares of our common stock in connection with the net exercise of employee and executive stock options, offset by $1.4 million received from the exercise of stock options. In the comparable period in 2021, we spent $50.0 million acquiring shares of our common stock ($33.5 million pursuant to our Stock Purchase Program that expired on September 30, 2021 and $16.4 million in connection with the net exercise of employee and director stock options), offset by $4.0 million received from the exercise of stock options.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2022, we had retained earnings of $217.8 million.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contractual Obligations and Commitments</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our contractual payment obligations and purchase commitments are disclosed in our Annual Report on Form 10-K for the year ended December&#160;31, 2021. Our payment obligations and purchase commitments did not change materially during the three months ended March 31, 2022. See Note 4 to our Unaudited Condensed Consolidated Financial Statements for more information regarding our purchase commitments.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Off-Balance Sheet Arrangements</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Estimates</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our condensed consolidated financial statements have been prepared in accordance with U.S. GAAP, which requires us to make estimates and judgments that affect the amount of assets, liabilities and expenses we report. We base our estimates on historical experience and on other assumptions we believe to be reasonable. Actual results may differ from our estimates. Our significant accounting policies are discussed in our Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2021. There were no changes that occurred during the fiscal quarter covered by this report that materially affected, or are reasonably likely to materially affect, our critical accounting policies and estimates. </span></div><div id="i0a44765832c1416181e5729d6aaf7059_55"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 3.&#160;&#160;QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our market risks as of March&#160;31, 2022 are disclosed in our Annual Report on Form 10-K for the year ended December&#160;31, 2021.&#160;The market risks associated with our cash, cash equivalents and marketable securities, which consist entirely of debt instruments with original maturities of less than 24 months, did not change materially during the three months ended March 31, 2022.</span></div><div id="i0a44765832c1416181e5729d6aaf7059_58"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 4.&#160;&#160;CONTROLS AND PROCEDURES</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Evaluation of disclosure controls and procedures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. As of March&#160;31, 2022, our management conducted an evaluation, under the supervision and with the participation of our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934 (the &#8220;Exchange Act&#8221;). Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that, as of March&#160;31, 2022, our disclosure controls and procedures were effective to provide reasonable assurance that the information required to be disclosed by the Company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms and that such information is accumulated and communicated to the officers who certify our financial reports and to the members of the Company&#8217;s senior management and board of directors as appropriate to allow timely decisions regarding required disclosure at the reasonable assurance level.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in internal control over financial reporting</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#160;Our Chief Financial Officer and other members of management evaluated the changes in our internal control over financial reporting during the quarter ended March&#160;31, 2022 and concluded that there was no change during the quarter that materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><div id="i0a44765832c1416181e5729d6aaf7059_61"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II. OTHER INFORMATION</span></div><div id="i0a44765832c1416181e5729d6aaf7059_64"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1.&#160;&#160;LEGAL PROCEEDINGS</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Teva Litigation</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2018, we received a Paragraph IV Notice Letter advising that Teva had submitted an Abbreviated New Drug Application (&#8220;ANDA&#8221;) to the United States Food and Drug Administration (&#8220;FDA&#8221;) seeking authorization to manufacture and sell a generic version of Korlym prior to the expiration of patents related to Korlym that are listed in the FDA&#8217;s Approved Drug Products with Therapeutic Equivalence Evaluations (the &#8220;Orange Book&#8221;). Teva&#8217;s February 5, 2018 Notice Letter alleged that our patents would not be infringed by Teva&#8217;s proposed product, were invalid and/or were unenforceable. On March 15, 2018, we filed a lawsuit in the United States District Court for the District of New Jersey against Teva for infringement of our patents. On October 12, 2018, Teva received tentative approval from the FDA for its ANDA. In accordance with the Hatch-Waxman Act, however, FDA final approval of Teva&#8217;s ANDA was stayed until August 1, 2020.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 6, 2018, we filed an amended complaint and on February 8, 2019, we filed a separate lawsuit against Teva, asserting infringement of several patents, including U.S. Patent No. 10,195,214 (the &#8220;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#700;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">214 patent&#8221;). On December 13, 2019, we filed a third lawsuit against Teva, asserting infringement of U.S. Patent Nos. 10,500,216 (the &#8220;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#700;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">216 patent&#8221;). The District Court consolidated our lawsuits against Teva into a single action and set a trial date of February 2, 2021. On September 24, 2020, the Court vacated the February 2, 2021 trial date. A new trial date has not been set.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 7, 2019, Teva submitted to the Patent Trial and Appeal Board (&#8220;PTAB&#8221;) a petition for post-grant review (&#8220;PGR&#8221;) of the &#8217;214 patent. On November 20, 2019, the PTAB agreed to initiate the PGR, and on November 19, 2020 issued a decision upholding the validity of the &#8217;214 patent in its entirety. Teva appealed its loss to the Federal Circuit Court of Appeals, which on December 7, 2021, ruled in Corcept&#8217;s favor.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The time for Teva to appeal or seek reconsideration of these adverse decisions has passed. This matter is closed.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our current lawsuit against Teva asserts the &#8216;214 patent and the &#8216;216 patent. The parties have completed briefing cross-motions for summary judgment regarding infringement of the &#8217;214 patent.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is no timetable as to when the Court will rule on these motions and there are currently no further calendared dates for the litigation.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will vigorously enforce our intellectual property rights relating to Korlym but cannot predict the outcome of this matter.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sun ANDA Litigation and Settlement</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 10, 2019, we received a Paragraph IV Notice Letter advising that Sun had submitted an ANDA to the FDA seeking authorization to manufacture, use or sell a generic version of Korlym in the United States prior to the expiration of certain of our patents related to Korlym listed in the Orange Book.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 22, 2019, we filed a lawsuit in the United States District Court for the District of New Jersey against Sun for infringement of our patents.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 23, 2020, we filed an amended complaint against Sun asserting infringement of two additional patents.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 9, 2021, we entered into an agreement with Sun resolving this litigation. Pursuant to the agreement, we have granted Sun the right to sell a generic version of Korlym in the United States beginning October 1, 2034 or earlier under circumstances customary for settlement agreements of this type. As required by law, we and Sun have submitted the settlement agreement to the United States Federal Trade Commission and the United States Department of Justice for review.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Hikma ANDA Litigation</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 1, 2021, we received a Paragraph IV Notice Letter advising that Hikma Pharmaceuticals USA Inc. (&#8220;Hikma&#8221;) had submitted an ANDA to the FDA seeking authorization to manufacture, use or sell a generic version of Korlym in the United States.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Notice Letter contains Paragraph IV certifications against certain of our patents related to Korlym, alleging that these patents will not be infringed by Hikma&#8217;s proposed product, are invalid and/or are unenforceable.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 12, 2021, we filed a lawsuit in the United States District Court for the District of New Jersey against Hikma for infringement of the &#8217;214 patent, the &#700;216 patent, U.S. Patent Nos. 10,842,800, and U.S. Patent Nos. 10,842,801. The 30-month stay of FDA approval of Hikma&#8217;s ANDA expires on August 1, 2023. Hikma responded to our complaint on May 17, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021, denying our claims. On July 13, 2021, the Court entered a schedule for the case setting a fact discovery deadline of July 1, 2022.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to vigorously enforce our intellectual property rights relating to Korlym but cannot predict the outcome of this matter.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Matters</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 14, 2019, a purported securities class action complaint was filed in the United States District Court for the Northern District of California by Nicholas Melucci (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Melucci v. Corcept Therapeutics Incorporated, et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Case No. 5:19-cv-01372-LHK) (the &#8220;Melucci litigation&#8221;). The complaint named us and certain of our executive officers as defendants asserting violations of Sections 10(b) and 20(a) of the Exchange Act and Rule 10b-5 promulgated thereunder and alleges that the defendants made false and materially misleading statements and failed to disclose adverse facts about our business, operations, and prospects. The complaint asserts a putative class period extending from August 2, 2017 to February 5, 2019 and seeks unspecified monetary relief, interest and attorneys&#8217; fees. On October 7, 2019, the Court appointed a lead plaintiff and lead counsel. The lead plaintiff&#8217;s consolidated complaint was filed on December 6, 2019. </span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We moved to dismiss the consolidated complaint on January 27, 2020. Rather than oppose our motion to dismiss, on March 20, 2020, the lead plaintiff withdrew its consolidated complaint and filed a second amended complaint. On May 11, 2020, we moved to dismiss the second amended complaint. On November 20, 2020, the Court granted our motion to dismiss, while granting plaintiff leave to file a third amended complaint, which plaintiff did on December 21, 2020. On February 19, 2021, we moved to dismiss this third amended complaint. Plaintiff filed its opposition to our motion on April 20, 2021 and we filed our reply on June 4, 2021.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 24, 2021, the Court granted our motion in part, but also denied it in part. Certain of plaintiff&#8217;s claims have proceeded to discovery. Discovery is currently scheduled to close in April 2023.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will respond vigorously to plaintiff&#8217;s claims but cannot predict the outcome of this matter.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 30, 2019, a purported shareholder derivative complaint was filed in the United States District Court for the District of Delaware by Lauren Williams, captioned </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lauren Williams v. G. Leonard Baker, et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Civil Action No. 1:19-cv-01830. The complaint named our board of directors, Chief Executive Officer and current Chief Business Officer as defendants, and us as nominal defendant. The complaint alleges breach of fiduciary duty, violation of Section 14(a) of the Exchange Act, insider selling, misappropriation of insider information and waste of corporate assets and seeks damages in an amount to be proved at trial. On October 23, 2019, this action was stayed pending a resolution of our motions to dismiss the Melucci litigation. On December 20, 2020, the case was further stayed pending a resolution of our motion to dismiss the third amended complaint in the Melucci litigation. On September 30, 2021, the case was further stayed pending a resolution of the Melucci litigation.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will respond to this complaint vigorously but cannot predict the outcome of this matter.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 19, 2019, a second purported shareholder derivative complaint was filed in the United States District Court for the District of Delaware by Jeweltex Pension Plan, captioned </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Jeweltex Pension Plan v. James N. Wilson, et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Civil Action No. 1:19-cv-02308. The complaint named our board of directors, Chief Executive Officer and current Chief Business Officer as defendants, and us as nominal defendant. The complaint alleges causes of action for breach of fiduciary duty, violation of section 14(a) of the Exchange Act, waste of corporate assets, contribution and indemnification, aiding and abetting, and gross mismanagement. The complaint seeks damages in an amount to be proved at trial. On April 6, 2020, this action was stayed pending a resolution of our motions to dismiss the Melucci litigation. On December 20, 2020, the case was further stayed pending a resolution of our motion to dismiss the third amended complaint in the Melucci litigation. On September 30, 2021, the case was further stayed pending a resolution of the Melucci litigation.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will respond to this complaint vigorously but cannot predict the outcome of this matter.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 31, 2022, a purported shareholder derivative complaint was filed in the Delaware Court of Chancery by Joel B. Ritchie, captioned Joel B. Ritchie v. G. Leonard Baker, et al., Case No. 2022-0102-SG. The complaint named our board of directors, Chief Executive Officer, current Chief Business Officer, and President of Corcept Endocrinology as defendants, and us as nominal defendant. The complaint alleges a single cause of action for breach of fiduciary duty. The complaint seeks damages in an amount to be proved at trial. On April 20, 2022, the case was further stayed pending a resolution of the Melucci litigation.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will respond to this complaint vigorously but cannot predict the outcome of this matter.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2021, we received a records subpoena from the United States Attorney&#8217;s Office for the District of New Jersey (the &#8220;NJ USAO&#8221;) pursuant to Section 248 of the Health Insurance Portability and Accountability Act of 1996 (HIPAA) seeking information relating to the sale and promotion of Korlym, our relationships with and payments to health care professionals who can prescribe or recommend Korlym and prior authorizations and reimbursement for Korlym. The NJ USAO has informed us that it is investigating whether any criminal or civil violations by us occurred in connection with the matters referenced in the subpoena. It has also informed us that it does not currently consider us a defendant but rather an entity whose conduct is within the scope of the government&#8217;s investigation.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the above-described matters, we are involved from time-to-time in other legal proceedings arising in the ordinary course of our business. Although the outcome of any such matters and the amount, if any, of our liability with respect to them cannot be predicted with certainty, we do not believe that they will have a material adverse effect on our business, results of operations or financial position.</span></div><div id="i0a44765832c1416181e5729d6aaf7059_67"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1A.&#160;&#160;RISK FACTORS</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investing in our common stock involves significant risks. Before investing, carefully consider the risks described below and the other information in this quarterly report, including our condensed consolidated financial statements and related notes. The risks and uncertainties described below are the ones we believe may materially affect us. Many of them have been or may become exacerbated by the COVID-19 pandemic. There may be others of which we are unaware that could materially harm our business or financial condition and cause the price of our stock to decline, in which case you could lose all or part of your investment.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summary of Principal Risks</span></div><div style="margin-top:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following bullet points summarize the principal risks we face, each of which could adversely affect our business, operations, and financial results. For clarity of presentation, we have arranged these risks by the part of our business they most directly affect &#8211; (i) commercial operations, (ii) research and development, (iii) capital need and financial results, (iv) intellectual property and (v) our stock price. A sixth group of &#8220;general risks&#8221; lists risks that affect our business as a whole.</span></div><div style="margin-top:9pt;text-align:center;text-indent:27.35pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to our Commercial Activities</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Failure to generate sufficient revenue from the sale of Korlym would harm our financial results and would likely cause our stock price to decline.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The COVID-19 pandemic has adversely affected and is continuing to adversely affect our business. Other public health emergencies, natural disasters, terrorism or other catastrophes could further disrupt our activities and render our own or our vendors&#8217; facilities and equipment inoperable or inaccessible and require us to curtail or cease operations.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">New laws, government regulations, or changes to existing laws and regulations could make it difficult or impossible for us to obtain acceptable prices or adequate insurance coverage and reimbursement for Korlym, which would adversely affect our results of operations and financial position.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If generic versions of Korlym are approved and successfully commercialized, our business, results of operations and financial position would be adversely affected.</span></div><div style="margin-top:9pt;text-align:center;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to our Research and Development Activities</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our efforts to discover, develop and commercialize our product candidates may not succeed. Clinical drug development is lengthy, expensive and often unsuccessful. Results of early studies and trials are often not predictive of later trial results. Failure can occur at any time.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The COVID-19 pandemic has lengthened the time it takes to initiate and advance some of our clinical trials.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Vendors perform many of the activities necessary to carry out our clinical trials, including drug product distribution, trial management and oversight and data collection and analysis. Failure of these vendors to perform their duties or meet expected timelines may prevent or delay approval of our product candidates.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may be unable to obtain or maintain regulatory approvals for our product or product candidates, which would prevent us from commercializing our product candidates.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our products and product candidates may cause undesirable side effects that halt their clinical development, prevent their regulatory approval, limit their commercial potential or cause us significant liability.</span></div><div style="margin-top:9pt;text-align:center;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Relating to our Intellectual Property</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">To succeed, we must secure, maintain and effectively assert adequate patent protection for the composition and methods of use of our proprietary, selective cortisol modulators and for the use of Korlym to treat Cushing&#8217;s syndrome.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div style="margin-top:9pt;text-align:center;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to our Stock</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The price of our common stock fluctuates widely and is likely to continue to do so. Opportunities for investors to sell shares may be limited.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our stock price may decline if our financial performance does not meet the guidance we have provided to the public, estimates published by research analysts or other investor expectations.</span></div><div style="margin-top:9pt;text-align:center;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General Risks</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We rely on information technology systems to conduct our business. A breakdown or breach of these systems or our failure to protect confidential information concerning our business, patients or employees could interrupt the operation of our business and subject us to liability.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risk Factors - Discussion</span></div><div style="margin-top:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The following section discusses the principal risks listed above, as well as other risks we believe to be material.</span></div><div style="margin-top:9pt;text-align:center;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to our Commercial Activities</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Failure to generate sufficient revenue from the sale of Korlym would harm our financial results and would likely cause our stock price to decline.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to generate revenue and to fund our commercial operations and development programs is dependent on the sale of Korlym to treat patients with Cushing&#8217;s syndrome. Physicians will prescribe Korlym only if they determine that it is preferable to other treatments, even if those treatments are not approved for Cushing&#8217;s syndrome. Because Cushing&#8217;s syndrome is rare, most physicians are inexperienced diagnosing or caring for patients with the illness and it can be hard to persuade them to identify appropriate patients and treat them with Korlym.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many factors could limit our Korlym revenue, including:</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the preference of some physicians for competing treatments for Cushing&#8217;s syndrome, including off-label treatments and generic versions of Korlym, should any such generic versions be introduced; </span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">natural disasters or other catastrophes, such as the COVID-19 pandemic, that reduce the ability or willingness of physicians to see patients or of patients to bear the risk of leaving their homes to seek medical care; and</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">lack of availability of government or private insurance, the shift of a significant number of patients to Medicaid, which reimburses Korlym at a significantly lower price, or the introduction of government price controls or other price-reducing regulations.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Failure to generate sufficient Korlym revenue could prevent us from fully funding our planned commercial and clinical activities and would likely cause our stock price to decline.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The COVID-19 pandemic has adversely affected and is continuing to adversely affect our business. Other public health emergencies, natural disasters, terrorism or other catastrophes could further disrupt our activities and render our own or our vendors&#8217; facilities and equipment inoperable or inaccessible and require us to curtail or cease operations.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">COVID-19, a serious and sometimes fatal illness, has spread to every country in the world and throughout the United States. Many countries, including most states of the United States, reacted by instituting quarantines, &#8220;lockdowns&#8221; and other public health restrictions on leisure activities, work and travel. In California, where our headquarters are located, and in the states where our clinical specialists and medical science liaisons live and work, residents have been subject to significant public health restrictions. We have been managing our business with limited in-person activities, supplemented primarily by video conference, teleconference and email. Although pandemic-related restrictions have been eased or removed in some places, including California, our business remains subject to pandemic-related controls, which may become more restrictive at any time. We rely on third-party manufacturers, distributors (including the specialty pharmacy that dispenses Korlym), information technology and software service providers, law and accounting firms, clinical research organizations and consultants who are subject to, or may become subject to, pandemic-related controls. If these third parties cannot perform the services we require in a timely way and we cannot successfully implement replacements or workarounds, our business, results of operations and financial condition could be harmed.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">COVID-19 has made it difficult to grow our commercial business. Many physicians have reduced the frequency of patient office visits and barred office visits by third parties, including our clinical specialists and medical science liaisons. In addition, many patients have postponed visits to their physicians or testing at clinical laboratories or imaging centers. These </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">precautions have made it harder for physicians to identify patients who may benefit from Korlym, begin their treatment, arrive at an optimum dose and maintain their patients&#8217; regimens.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot predict the duration of these impacts on our business or how severe future impacts may be. If physicians do not prescribe Korlym to new patients or have difficulty increasing a patient&#8217;s Korlym dose to its optimal level, or if patients already receiving Korlym discontinue treatment, our revenue will be unlikely to grow and may decline.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other disasters could harm our business, operating results and financial condition. Our headquarters are in the San Francisco Bay Area, which experiences earthquakes. Our specialty pharmacy, tablet manufacturers and warehouses are in areas subject to hurricanes and tornadoes. Political considerations relating to mifepristone put us and our manufacturers at increased risk of protests and disruptive events. If a disaster were to occur, we might not be able to operate our business. Our insurance, if available at all, would likely be insufficient to cover losses resulting from disasters or other business interruptions.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">If generic versions of Korlym are approved and successfully commercialized, our business, results of operations and financial position would be adversely affected.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The marketing exclusivity provided by Korlym&#8217;s orphan drug designation expired in February 2019, which means other companies may now seek to introduce generic equivalents of Korlym for Korlym&#8217;s approved indication, provided such parties receive FDA approval and can show that they would not infringe our applicable patents or that those patents are invalid or unenforceable. If our patents are successfully challenged and a generic version of Korlym becomes available, our sales of Korlym tablets and their price could decline rapidly and significantly, which would reduce our revenue and materially harm our results of operations and financial position. Competition from a generic version of Korlym may also cause our revenue to be materially less than the public guidance we have provided, which would likely cause the price of our common stock to decline.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Legal action to enforce or defend intellectual property rights is complex, costly and involves significant commitments of management time. There can be no assurance of a successful outcome. We have sued Teva and Hikma in Federal District Court with respect to their proposed generic versions of Korlym. In November 2020, the PTAB ruled against Teva in a challenge Teva had brought to one of our patents, a ruling which the Federal Circuit Court of Appeals has affirmed. We had also sued Sun with respect to its proposed generic version of Korlym, although we settled that lawsuit in June 2021. The terms of our settlement with Sun are subject to customary review by the Federal Trade Commission and Department of Justice. Please see &#8220;Part II, Item 1, Legal Proceedings.&#8221; Because Teva has received FDA approval, Teva may choose to begin marketing its generic product at any time, notwithstanding our ongoing litigation. We would seek a court order stopping such a course of action, but even if we were to prevail (i.e., Teva were to withdraw its product and pay us damages), the temporary availability of a generic version of Korlym might materially harm our results of operations and financial condition.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is likely that other companies will seek FDA approval to market a generic version of Korlym. While we will vigorously protect our intellectual property, there can be no assurance our efforts will be successful.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other companies offer or are attempting to develop different medications to treat patients with Cushing&#8217;s syndrome. The availability of competing treatments could limit our revenue from Korlym.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since 2012, a medication owned by the Italian pharmaceutical company Recordati-S.p.A., the somatostatin analogue Signifor</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (pasireotide) Injection, has been marketed in both the United States and the European Union (&#8220;EU&#8221;) for adult patients with Cushing&#8217;s disease (a subset of Cushing&#8217;s syndrome). On March 6, 2020, the FDA granted Recordati approval to market another cortisol synthesis inhibitor, Isturisa&#174; (osilodrostat) tablets, to treat patients with Cushing&#8217;s disease. Osilodrostat is approved in the EU for the treatment of patients with Cushing&#8217;s syndrome.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 31, 2021, Xeris Biopharma Holdings, Inc. (&#8220;Xeris&#8221;) received FDA approval to market the cortisol synthesis inhibitor Recorlev</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (levoketoconazole) to treat patients with Cushing&#8217;s syndrome in the United States. Levoketoconazole is an enantiomer of the generic anti-fungal medication, ketoconazole, that is prescribed off-label to treat patients with Cushing&#8217;s syndrome.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Osilodrostat and levoketoconazole have been designated orphan drugs in both the EU and the United States.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">New laws, government regulations, or changes to existing laws and regulations could make it difficult or impossible for us to obtain acceptable prices or adequate insurance coverage and reimbursement for Korlym, which would adversely affect our results of operations and financial position.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The commercial success of Korlym depends on the availability of acceptable pricing and adequate insurance coverage and reimbursement. Government payers, including Medicare, Medicaid and the Veterans Administration, as well as private insurers and health maintenance organizations, are increasingly attempting to contain healthcare costs by limiting reimbursement for medicines. If government or private payers cease to provide adequate and timely coverage, pricing and </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">reimbursement for Korlym, physicians may not prescribe the medication and patients may not purchase it, even if it is prescribed, or the price we receive may be reduced, which would reduce our revenue.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In many foreign markets, drug prices and the profitability of prescription medications are subject to government control. In the United States, we expect that there will continue to be federal and state proposals for similar controls. Also, the trends toward managed health care in the United States and recent laws and legislation intended to increase the public visibility of drug prices and reduce the cost of government and private insurance programs could significantly influence the purchase of health care services and products and may result in lower prices for Korlym.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, there have been and continue to be legislative initiatives to contain healthcare costs. The Patient Protection and Affordable Care Act (&#8220;ACA&#8221;) which was passed in 2010, substantially changed the way health care is financed by both governmental and private insurers. The ACA, among other things, expanded Medicaid program eligibility and access to commercial health insurance coverage, increased the minimum Medicaid rebates owed by manufacturers under the Medicaid Drug Rebate Program and extended the rebate program to individuals enrolled in Medicaid managed care organizations, established annual fees and taxes on manufacturers of certain branded prescription drugs, and promoted a new Medicare Part D coverage gap discount program. The ACA also appropriated funding to comparative clinical effectiveness research, although it remains unclear how the research will affect Medicare coverage and reimbursement or how new information will influence other third-party payer policies.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other legislative and regulatory changes have been adopted in the United States since the ACA was enacted. These changes included an aggregate reduction in Medicare payments to providers of 2 percent per fiscal year, which went into effect on April 1, 2013 and will remain in effect through 2030, with the exception of a temporary suspension from May 1, 2020 through March 31, 2022, and a 1 percent reduction from May 1, 2022 through June 30, 2022, unless additional Congressional action is taken. In addition, the American Taxpayer Relief Act of 2012, further reduced Medicare payments to several providers, including hospitals, imaging centers and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. In March 2021, the American Rescue Plan Act of 2021 was also signed into law, which, among other things, eliminated the statutory cap on drug manufacturers&#8217; Medicaid Drug Rebate Program rebate liability, effective January 1, 2024. Under current law enacted as part of the ACA, drug manufacturers&#8217; Medicaid Drug Rebate Program rebate liability is capped at 100% of the average manufacturer price for a covered outpatient drug. Moreover, the federal government and the individual states in the United States have become increasingly active in developing proposals, passing legislation and implementing regulations designed to control drug pricing, including price or patient reimbursement constraints, discounts, formulary flexibility, marketing cost disclosure and transparency measures.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There also continue to be federal and state initiatives to contain healthcare costs, in part informed by the current atmosphere of mounting criticism of prescription drug costs in the United States. We expect governmental oversight and scrutiny of pharmaceutical companies will continue to increase and there will continue to be proposals to change the healthcare system in ways that could harm our ability to sell Korlym profitably. We anticipate that the United States Congress, state legislatures, and regulators may implement healthcare policies intended to curb healthcare costs, such as federal and state controls on reimbursement for drugs (including under Medicare and commercial health plans), new or increased requirements to pay prescription drug rebates and penalties to government health care programs and policies that require drug companies to disclose and justify the prices they charge. For example, measures have been introduced in Congress that would impose caps on prescription drug prices and would require manufacturers to negotiate drug pricing with the government.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recently enacted laws and the regulations and policies implementing them, as well as other healthcare-related measures that may be adopted in the future, could materially reduce our Korlym revenues and our ability to develop and commercialize our product candidates.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We depend on vendors to manufacture Korlym&#8217;s active ingredient, form it into tablets, package it and dispense it to patients. We also depend on vendors to manufacture the API and capsules or tablets for our product candidates. If our suppliers become unable or unwilling to perform these functions and we cannot transfer these activities to replacement vendors in a timely manner, our business will be harmed.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A single third-party manufacturer, Produits Chimiques Auxiliaires et de Synthese SA (&#8220;PCAS&#8221;), supplies the API in Korlym. Two other third-party manufacturers produce and bottle Korlym tablets. Our agreement with PCAS automatically renews for two one-year terms, unless either party provides 12-months&#8217; written notice of its intent not to renew. A single specialty pharmacy, Optime Care, Inc. (&#8220;Optime&#8221;) dispenses Korlym directly to patients and collects payments from insurers representing approximately 99 percent of our revenue. If Optime does not adhere to its agreements with payers, it may not be able to collect some or all of the payments due to us. Our agreement with Optime has a five-year term and renews upon the written consent of both parties, subject to customary termination provisions, including the right of Optime to terminate in the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">event of a material breach by us that we do not cure in a reasonable period of time after receiving written notice. In addition, we may terminate the agreement for convenience. In the event any of these vendors fails to perform its contractual obligations to us or is materially impaired in its performance by the COVID-19 pandemic or for any other reason, we may experience disruptions and delays in our supply chain and our ability to deliver Korlym to patients, which would adversely affect our business, results of operations and financial position.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The facilities used by our vendors to manufacture and package the API and drug product for Korlym and our product candidates must be approved by the FDA and, in some cases, the European Medicines Agency (&#8220;EMA&#8221;) or the Medicines and Healthcare products Regulatory Agency (&#8220;MHRA&#8221;). We do not control the activities of these vendors, including whether they maintain adequate quality control and hire qualified personnel. We are dependent on them for compliance with the regulatory requirements known as current good manufacturing practices (&#8220;cGMPs&#8221;). If our vendors cannot manufacture material that conforms to our specifications and the strict requirements of the FDA or others, they will not be able to maintain regulatory authorizations for their facilities and we could be prohibited from using the API or drug product they have provided. If the FDA, EMA, MHRA or other regulatory authorities withdraw regulatory authorizations of these facilities, we may need to find alternative vendors or facilities, which would be time-consuming, complex and expensive and could significantly hamper our ability to develop, obtain regulatory approval for and market our products. Sanctions could be imposed on us, including fines, injunctions, civil penalties, refusal of regulators to approve our product candidates, delays, suspensions or withdrawals of approvals, seizures or recalls of products, operating restrictions and criminal prosecutions, any of which could harm our business.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The unfavorable public perception of mifepristone may limit our ability to sell Korlym.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The active ingredient in Korlym, mifepristone, is approved by the FDA in another drug for the termination of early pregnancy. As a result, mifepristone is the subject of considerable debate in the United States and elsewhere. Public perception of mifepristone may limit the acceptance of Korlym by patients and physicians. Even though we have taken measures to minimize the chance that Korlym will accidentally be prescribed to a pregnant woman, physicians may choose not to prescribe Korlym to a woman simply to avoid the risk of terminating a pregnancy.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We may not have adequate insurance to cover our exposure to product liability claims.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may be subject to product liability or other claims based on allegations that Korlym or one of our product candidates has harmed a patient. Such a claim may damage our reputation by raising questions about Korlym or our product candidates&#8217; safety and could prevent or interfere with product development or commercialization. Less common adverse effects of a pharmaceutical product are sometimes not known until long after the product is approved for marketing. Because the active ingredient in Korlym is used to terminate pregnancy, clinicians using Korlym in clinical trials and physicians prescribing the medicine to women must take strict precautions to ensure that it is not administered to pregnant women. Failure to observe these precautions could result in significant product liability claims.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our insurance may not fully cover our potential product liabilities. Inability to obtain adequate insurance coverage could inhibit development of our product candidates or result in significant uninsured liability. Defending a lawsuit could be costly and divert management from productive activities.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">If we are unable to maintain regulatory approval of Korlym or if we fail to comply with other requirements, we will be unable to generate revenue and may be subject to penalties.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to oversight by the FDA and other regulatory authorities in the United States and elsewhere with respect to our research, testing, manufacturing, labeling, distribution, adverse event reporting, storage, advertising, promotion, recordkeeping and sales and marketing activities. These requirements include submissions of safety information, annual updates on manufacturing activities and continued compliance with FDA regulations, including cGMPs, good laboratory practices and good clinical practices (&#8220;GCP&#8221;). The FDA enforces these regulations through inspections of us and the laboratories, manufacturers and clinical sites we use. Foreign regulatory authorities have comparable requirements and enforcement mechanisms. Discovery of previously unknown problems with a product or product candidate, such as adverse events of unanticipated severity or frequency or deficiencies in manufacturing processes or management, as well as failure to comply with FDA or other U.S. or foreign regulatory requirements, may subject us to substantial civil and criminal penalties, injunctions, holds on clinical trials, product seizure, refusal to permit the import or export of products, restrictions on product marketing, withdrawal of the product from the market, product recalls, total or partial suspension of production, refusal to approve pending new drug applications (&#8220;NDAs&#8221;) or supplemental NDAs, and suspension or revocation of product approvals.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We may be subject to civil or criminal penalties if our marketing of Korlym violates FDA regulations or health care fraud and abuse laws.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to FDA regulations governing the promotion and sale of medications. Although physicians are permitted to prescribe drugs for any indication they choose, manufacturers may only promote products for their FDA-approved use. All other uses are referred to as &#8220;off-label.&#8221; In the United States, we market Korlym to treat hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing&#8217;s syndrome who have type 2 diabetes mellitus or glucose intolerance and for whom surgery has failed or is not an option. We provide promotional materials and training programs to physicians covering the use of Korlym for this indication. The FDA may change its policies or enact new regulations at any time that restrict our ability to promote our products.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the FDA were to determine that we engaged in off-label promotion, the FDA could require us to change our practices and subject us to regulatory enforcement actions, including issuance of a public &#8220;warning letter,&#8221; untitled letter, injunction, seizure, civil fine or criminal penalties. Other federal or state enforcement authorities might act if they believe that the alleged improper promotion led to the submission and payment of claims for an unapproved use, which could result in significant fines or penalties under other statutory authorities, such as laws prohibiting false claims for reimbursement. Even if it is determined that we are not in violation of these laws, we may receive negative publicity, incur significant expenses and be forced to devote management time to defending our position. </span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to laws prohibiting off-label promotion, we are also subject to federal and state healthcare fraud and abuse laws and regulations designed to prevent fraud, kickbacks, self-dealing, and other abusive practices. The United States healthcare laws and regulations that may affect our ability to operate include, but are not limited to:</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal Anti-Kickback Statute, which prohibits, among other things, knowingly and willfully soliciting, receiving, offering or paying remuneration, directly or indirectly, in exchange for or to induce either the referral of an individual for, or the purchase, order or recommendation of, any good or service for which payment may be made under federal health care programs such as Medicare and Medicaid. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">federal false claims laws, including, without limitation, the False Claims Act, which prohibit any person from knowingly presenting, or causing to be presented, a false claim for payment to the federal government, or knowingly making, or causing to be made, a false statement to get a false claim paid. In addition, the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act. Pharmaceutical companies have been prosecuted under these laws for a variety of promotional and marketing activities, such as allegedly providing free product to or entering into &#8220;sham&#8221; consulting arrangements with customers to induce such customers to purchase, order or recommend the company&#8217;s products in violation of the Anti-Kickback Statute and federal false claims laws and regulations; reporting to pricing services inflated average wholesale prices that were then used by certain governmental programs to set reimbursement rates; engaging in the promotion of &#8220;off-label&#8221; uses that caused customers to submit claims to and obtain reimbursement from governmental payers for non-covered &#8220;off-label&#8221; uses; and submitting inflated best price information to the Medicaid Drug Rebate Program; the government may assert that a claim including items and services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal Civil Monetary Penalties law, which prohibits, among other things, offering or transferring remuneration to a federal healthcare beneficiary that a person knows or should know is likely to influence the beneficiary&#8217;s decision to order or receive items or services reimbursable by the government from a particular provider or supplier;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal Health Insurance Portability and Accountability Act of 1996 (&#8220;HIPAA&#8221;), which created federal criminal laws that prohibit executing a scheme to defraud any health care benefit program or making false statements relating to health care matters; similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">federal &#8220;sunshine&#8221; laws, including the federal Physician Payment Sunshine Act, that require transparency regarding financial arrangements with health care providers, such as the reporting and disclosure requirements imposed by the ACA on drug manufacturers regarding any &#8220;transfer of value&#8221; made or distributed to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), certain non-physician practitioners (physician assistants, nurse practitioners, clinical nurse specialists, anesthesiologist assistants, certified registered nurse anesthetists, anesthesiology assistants and certified nurse midwives), teaching hospitals, and ownership or investment interests held by physicians and their immediate family members. Manufacturers are required to submit reports detailing these financial arrangements by the 90th day of each calendar year;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers; and</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">state law equivalents of each of the above federal laws, such as anti-kickback and false claims laws which may apply to items or services reimbursed by any third-party payer, including commercial insurers; state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government or otherwise restrict payments that may be made to healthcare providers; and state laws that require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures and pricing information.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The risk of being found in violation of these laws and regulations is increased by the fact that many of them have not been definitively interpreted by regulatory authorities or the courts and their provisions are open to a variety of interpretations. Because of the breadth of these laws and the narrowness of the statutory exceptions and safe harbors available under them, it is possible that some of our business activities, including our relationships with physicians and other healthcare providers (some of whom recommend, purchase and/or prescribe our products) and the manner in which we promote our products, could be subject to challenge. We are also exposed to the risk that our employees, independent contractors, principal investigators, consultants, vendors, distributors, and contract research organizations (&#8220;CROs&#8221;) may engage in fraudulent or other illegal activity. Although we have policies and procedures prohibiting such activity, it is not always possible to identify and deter misconduct and the precautions we take may not be effective in controlling unknown risks or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with applicable laws and regulations. </span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2021, we received a records subpoena from the NJ USAO seeking information relating to the sale and promotion of Korlym, our relationships with and payments to health care professionals who can prescribe or recommend Korlym and prior authorizations and reimbursement for Korlym. The NJ USAO has informed us that it is investigating whether any criminal or civil violations by us occurred in connection with the matters referenced in the subpoena. It has also informed us that it does not currently consider us a defendant but rather an entity whose conduct is within the scope of the government&#8217;s investigation.  We are cooperating with the investigation. Please see &#8220;Part II, Item 1, Legal Proceedings.&#8221;</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are found in violation of any of the laws described above or any other government regulations, we may be subject to civil and criminal penalties, damages, fines, exclusion from governmental health care programs, a corporate integrity agreement or other agreement to resolve allegations of non-compliance, individual imprisonment, and the curtailment or restructuring of our operations, any of which could adversely affect our financial results and ability to operate.</span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to our Research and Development Activities</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our efforts to discover, develop and commercialize our product candidates may not succeed. Clinical drug development is lengthy, expensive and often unsuccessful. Results of early studies and trials are often not predictive of later trial results. Failure can occur at any time.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical development is costly, time-consuming and unpredictable. Positive data from clinical trials are susceptible to varying interpretations, which could delay, limit or prevent regulatory approval. The results from early clinical trials are often not predictive of results in later clinical trials. Product candidates may fail to show the desired safety and efficacy traits despite having produced positive results in preclinical studies and initial clinical trials. Many companies have suffered significant setbacks in late-stage clinical trials due to lack of efficacy or unanticipated or unexpectedly severe adverse events.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our current clinical trials may prove inadequate to support marketing approvals. Even trials that generate positive results may have to be confirmed in much larger, more expensive and lengthier trials before we could seek regulatory approval.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trials may take longer to complete, cost more than expected and fail for many reasons, including:</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure to show efficacy or acceptable safety;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">slow patient enrollment or delayed activation of clinical trial sites due to the COVID-19 pandemic or other factors;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays obtaining regulatory permission to start a trial, changes to the size or design of a trial or changes in regulatory requirements for a trial already underway;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">inability to secure acceptable terms with vendors and an appropriate number of clinical trial sites;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays or inability to obtain institutional review board (&#8220;IRB&#8221;) approval at prospective trial sites;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure of patients or investigators to comply with the clinical trial protocol;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">unforeseen safety issues; and</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">negative findings of inspections of clinical sites or manufacturing operations by us, the FDA or other authorities.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A trial may also be suspended or terminated by us, the trial&#8217;s data safety monitoring board, the IRBs governing the sites where the trial is being conducted or the FDA for many reasons, including failure to comply with regulatory requirements or clinical protocols, negative findings in an inspection of our clinical trial operations or trial sites by the FDA or other authorities, unforeseen safety issues, failure to demonstrate a benefit or changes in government regulations. Disruptions caused by the COVID-19 pandemic increase the likelihood of delays in initiating or completing our planned and ongoing clinical trials, thereby increasing their costs. Please see the risk factor, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8220;The COVID-19 pandemic has lengthened the time it takes to initiate and advance some of our clinical trials.&#8221;</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the development of a product candidate, we may decide, or the FDA or other regulatory authorities may require us, to conduct more pre-clinical or clinical studies or to change the size or design of a trial already underway, thereby delaying or preventing the completion of development and increase its cost. Even if we conduct the clinical trials and supportive studies that we consider appropriate and the results are positive, we may not receive regulatory approval. Following regulatory approval, there are significant risks to its commercial success, such as development of competing products by other companies or the reluctance of physicians to prescribe it.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The COVID-19 pandemic has lengthened the time it takes to initiate and advance some of our clinical trials.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conduct clinical trials at sites in the United States, Canada, Europe and Israel. In the United States, Canada and Europe, authorities have imposed significant public health restrictions of varying degrees of severity which are likely to persist as long as COVID-19 public health concerns remain. In addition, physicians, patients and medical institutions have changed their behavior in an attempt to reduce the risk of infection, which makes clinical trials more expensive, time-consuming and risky to initiate and conduct.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of the sites where we are conducting clinical trials have from time-to-time stopped enrolling new patients or reduced the frequency with which enrolled patients see their physicians. Some clinical sites have temporarily stopped initiating new trials. Many patients are reluctant to participate in procedures required by our clinical trial protocols because they fear infection. In general, COVID-19 has slowed the pace of our clinical trials, including our studies in Cushing&#8217;s syndrome and Antipsychotic-Induced Weight Gain (&#8220;AIWG&#8221;). Studies of diseases perceived to be acutely life-threatening, such as advanced solid tumors, have not experienced delay or disruption.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may continue to experience disruptions from the COVID-19 pandemic, which could have a material adverse impact on our clinical trial plans and timelines, including: </span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays in enrolling patients or the loss of enrolled patients due to COVID-19 related restrictions;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays in clinical site initiation, including difficulties in recruiting clinical investigators and staff;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays in receiving authorizations from local regulatory authorities and internal review boards to initiate clinical trials or amend existing protocols;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays in clinical sites receiving necessary supplies and materials due to interruptions in local and global shipping;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in local regulations that require us to change the ways in which our clinical trials are conducted, which may result in unexpected costs or cause us to suspend or discontinue a trial in the affected jurisdiction; </span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">diversion of healthcare resources, including facilities, supplies and staff, away from the conduct of clinical trials;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">interruption of key clinical trial activities, such as clinical trial site monitoring, patient visits and follow-up, study procedures and data collection, that could affect the integrity of clinical trial data, due to limitations on travel;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the infection of patients enrolled in our clinical trials with COVID-19, which could affect the results of the clinical trial, including by increasing the number of observed adverse events or by causing patients to drop out of the study;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">patient discontinuations due to fear of infection with COVID-19 or public health restrictions implemented by clinical trial sites which make trial participation more time consuming or difficult;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">interruptions or delays in preclinical studies due to restricted or limited operations at laboratory facilities; </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays in necessary interactions with local regulators, ethics committees and other third parties and contractors due to limitations in employee resources or the furlough of government employees; and</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">limitations caused by the sickness of our employees or their families or the desire of employees to avoid contact with large groups of people.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The extent to which the COVID-19 pandemic affects our business, preclinical studies and clinical trials will depend on future developments, which are highly uncertain and cannot be predicted with confidence.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Vendors perform many of the activities necessary to carry out our clinical trials, including drug product distribution, trial management and oversight and data collection and analysis. Failure of these vendors to perform their duties or meet expected timelines may prevent or delay approval of our product candidates.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Third-party clinical investigators and clinical sites enroll patients and CROs manage many of our trials and perform data collection and analysis. Although we control only certain aspects of these third parties&#8217; activities, we are responsible for ensuring that every study adheres to its protocol and meets regulatory and scientific standards. If any of our vendors does not perform its duties or meet expected deadlines or fails to adhere to applicable GCPs, or if the quality or accuracy of the data it produces is compromised, affected clinical trials may be extended, delayed or terminated and we may be unable to obtain approval for our product candidates. Failure of our manufacturing vendors to perform their duties or comply with cGMPs may require us to recall drug product or repeat clinical trials, which would delay regulatory approval. If our agreements with any of these vendors terminate, we may not be able to enter into alternative arrangements in a timely manner or on reasonable terms.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to physically inspect our vendors and clinical sites has been limited by the COVID-19 pandemic and associated public health restrictions, which increases the risk that failures to meet applicable requirements will go undetected.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We may be unable to obtain or maintain regulatory approvals for our product candidates, which would prevent us from commercializing our product candidates.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot sell a product without the approval of the FDA or comparable foreign regulatory authority. Obtaining such approval is difficult, uncertain, lengthy and expensive. Failure can occur at any stage. In order to receive FDA approval for a new drug, we must demonstrate to the FDA&#8217;s satisfaction that the new drug is safe and effective for its intended use and that our manufacturing processes comply with cGMPs. Our inability or the inability of our vendors to comply with applicable FDA and other regulatory requirements can result in delays in or denials of new product approvals, warning letters, untitled letters, fines, consent decrees restricting or suspending manufacturing operations, injunctions, civil penalties, recall or seizure of products, total or partial suspension of product sales and criminal prosecution. We may seek to commercialize our products in international markets, which would require us to receive a marketing authorization and, in many cases, pricing approval, from the appropriate regulatory authorities. Approval procedures vary between countries and can require additional pre-clinical or clinical studies. Obtaining approval may take longer than it does in the United States. Although approval by the FDA does not ensure approval by regulatory authorities in other countries, and approval by one foreign regulatory authority does not ensure approval by others, failure or delay in obtaining regulatory approval in one country may have a negative effect on the regulatory process in others. Any of these or other regulatory actions could materially harm our business and financial condition.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we receive regulatory approval for a product candidate, we will be subject to ongoing requirements and oversight by the FDA and other regulatory authorities, such as continued safety and other reporting requirements, as well as post-approval marketing restrictions and additional costly clinical trials. If we are not able to maintain regulatory compliance, we may be required to stop development of a product candidate or to stop selling a product that has already been approved. We may also be subject to product recalls or seizures. Future governmental action or changes in regulatory authority policy or personnel may also result in delays or rejection of pending or anticipated product approvals.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our products and product candidates may cause undesirable side effects that halt their clinical development, prevent their regulatory approval, limit their commercial potential or cause us significant liability.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patients in clinical trials report changes in their health, including new illnesses, injuries, and discomforts, to their study doctor. Often, it is not possible to determine whether or not these conditions were caused by the drug candidate being studied or something else. As we test our product candidates in larger, longer and more extensive clinical trials, or as use of them becomes more widespread if we receive regulatory approval, patients may report serious adverse events that did not occur or went undetected in previous trials. Many times, serious side effects are only detected in large-scale, Phase 3 clinical trials or following commercial approval.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adverse events reported in clinical trials can slow or stop patient recruitment, prevent enrolled patients from completing a trial and could give rise to liability claims. Regulatory authorities could respond to reported adverse events by interrupting or </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">halting our clinical trials or limiting the scope of, delaying or denying marketing approval. If we elect, or are required by authorities, to delay, suspend or terminate any clinical trial or commercialization efforts, the commercial prospects of such product candidates or products may be harmed, and our ability to generate product revenues from them may be delayed or eliminated.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If one of our product candidates receives marketing approval, and we or others later identify undesirable side effects or adverse events, potentially significant negative consequences could result, including but not limited to:</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory authorities may suspend, limit or withdraw approvals of such product;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory authorities may require additional warnings on the label, including &#8220;boxed&#8221; warnings, or issue safety alerts and other safety information about the product;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be required to change the way the product is administered or conduct additional studies or clinical trials;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be required to create a Risk Evaluation and Mitigation Strategy, which could include a medication guide outlining the risks of such side effects for distribution to patients, a communication plan for healthcare providers and/or other elements to assure safe use;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the product may become less competitive; </span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be subject to fines, injunctions or the imposition of criminal penalties; and</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we could be sued and held liable for harm caused to patients;</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of these events could seriously harm our business.</span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to our Capital Needs and Financial Results</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We may need additional capital to fund our operations or for strategic reasons. Such capital may not be available on acceptable terms or at all.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are dependent on revenue from the sale of Korlym and our cash reserves to fund our commercial operations and development programs. If Korlym revenue declines significantly, we may need to curtail our operations or raise funds to support our plans. We may also choose to raise funds for strategic reasons. We cannot be certain funding will be available on acceptable terms or at all. Equity financing would cause dilution, debt financing may involve restrictive covenants. Neither type of financing may be available to us on attractive terms or at all. If we obtain funds through collaborations with other companies, we may have to relinquish rights to one or more of our product candidates. If our revenue declines and our cash reserves are depleted, and if adequate funds are not available from other sources, we may have to delay, reduce the scope of, or eliminate one or more of our development programs.</span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Relating to our Intellectual Property</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">To succeed, we must secure, maintain and effectively assert adequate patent protection for the composition and methods of use of our proprietary, selective cortisol modulators and for the use of Korlym to treat Cushing&#8217;s syndrome.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patents are uncertain, involve complex legal and factual questions and are frequently the subject of litigation. The patents issued or licensed to us may be challenged at any time. Competitors may take actions we believe infringe our intellectual property, causing us to take legal action to defend our rights. Intellectual property litigation is lengthy, expensive and requires significant management attention. Outcomes are uncertain. If we do not protect our intellectual property, competitors may erode our competitive advantage. Please see &#8220;Part II, Item 1, Legal Proceedings.&#8221;</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our patent applications may not result in issued patents and patents issued to us may be challenged, invalidated, held unenforceable or circumvented. Our patents may not prevent third parties from producing competing products. The foreign countries where we may someday operate may not protect our intellectual property to the extent the laws of the United States do. If we fail to obtain adequate patent protection in other countries, others may produce products in those countries based on our technology.</span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to our Stock</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The price of our common stock fluctuates widely and is likely to continue to do so. Opportunities for investors to sell shares may be limited.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot assure investors that a liquid trading market for our common stock will exist at any particular time. As a result, holders of our common stock may not be able to sell shares quickly or at the current market price. During the 52-week period ended April&#160;28, 2022, our average daily trading volume was approximately 937,877 shares and the intra-day sales prices per share of our common stock on The Nasdaq Stock Market ranged from $15.82 to $25.68. As of April&#160;28, 2022, our officers, directors and principal stockholders beneficially owned approximately 19 percent of our common stock.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our stock price can experience extreme price and volume fluctuations that are unrelated or disproportionate to our operating performance or prospects. Securities class action lawsuits are often instituted against companies following periods of stock market volatility. Such litigation is costly and diverts management&#8217;s attention from productive efforts.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Factors that may cause the price of our common stock to fluctuate rapidly and widely include:</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">actual or anticipated variations in our operating results or changes to any public guidance we have provided;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">actual or anticipated timing and results of our clinical trials;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in the expected or actual timing of our competitors&#8217; development programs;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">general market and economic conditions, including the effects of the COVID-19 pandemic;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disputes or other developments relating to our intellectual property, including developments in ANDA litigation and proceedings before the PTAB;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">short-selling of our common stock, the publication of speculative opinions about our business or other market manipulation activities that are intended to lower our stock price or increase its volatility;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in estimates or recommendations by securities analysts or the failure of our performance to meet the published expectations of those analysts or public guidance we have provided;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">actual or anticipated regulatory approvals of our product candidates or competing products;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">purchases or sales of our common stock by our officers, directors or stockholders;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in laws or regulations applicable to Korlym, our product candidates or our competitors&#8217; products;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">technological innovations by us, our collaborators or our competitors;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">conditions in the pharmaceutical industry, including the market valuations of companies similar to ours;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">additions or departures of key personnel;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcements by us or our competitors of significant acquisitions, strategic partnerships, joint ventures, collaborations or capital commitments; and</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">additional financing activities.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our stock price may decline if our financial performance does not meet the guidance we have provided to the public, estimates published by research analysts or other investor expectations.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The guidance we provide as to our expected 2022 revenue is only an estimate of what we believe is realizable at the time we give such guidance. It is difficult to predict our revenue and our actual results may vary materially from our guidance. The effect on our business of the COVID-19 pandemic is difficult to forecast. In addition, the rate of physician adoption of Korlym and the actions of government and private payers is uncertain. We may experience competition from generic versions of Korlym, which our public revenue guidance does not anticipate. We may not meet our financial guidance or other investor expectations for other reasons, including those arising from the risks and uncertainties described in this report and in our other public filings and public statements. Research analysts publish estimates of our future revenue and earnings based on their own analysis. The revenue guidance we provide may be one factor they consider when determining their estimates.</span></div><div style="margin-top:9pt;text-align:center;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General Risk Factors</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We need to increase the size of our organization and may experience difficulties in managing growth.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial and research and development efforts are constrained by our limited administrative, operational and management resources. To date, we have relied on a small management team. Growth will impose significant added </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">responsibilities on members of management, including the need to recruit and retain additional employees. Our financial performance and ability to compete will depend on our ability to manage growth effectively. To that end, we must:</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">manage our sales and marketing efforts, clinical trials, research and manufacturing activities effectively;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">hire more management, clinical development, administrative and sales and marketing personnel; and</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">continue to develop our administrative systems and controls.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Failure to accomplish any of these tasks, which are more difficult during the COVID-19 pandemic, could harm our business.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">If we lose key personnel or are unable to attract more skilled personnel, we may be unable to pursue our product development and commercialization goals.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to operate successfully and manage growth depends upon hiring and retaining skilled managerial, scientific, sales, marketing and financial personnel. The job market for qualified personnel is intensely competitive and turnover rates have reached record highs within our industry and the geographical areas from which we recruit. We depend on the principal members of our management and scientific staff. Any officer or employee may terminate his or her relationship with us at any time and work for a competitor. We do not have employment insurance covering any of our personnel. The loss of key individuals could delay our research, development and commercialization efforts.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We are subject to government regulation and other legal obligations relating to privacy and data protection. Compliance with these requirements is complex and costly. Failure to comply could materially harm our business.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and our partners are subject to federal, state and foreign laws and regulations concerning data privacy and security, including HIPAA and the EU General Data Protection Regulation, or the GDPR. These and other regulatory frameworks are evolving rapidly as new rules are enacted and existing ones updated and made more stringent. </span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, numerous federal and state laws and regulations, including state data breach notification laws, state health information privacy, laws, and federal and state consumer protection laws and regulations (e.g., Section 5 of the FTC Act), that govern the collection, use, disclosure, and protection of health-related and other personal information could apply to our operations or the operations of our partners. In addition, we may obtain health information from third parties (including research institutions from which we obtain clinical trial data) that are subject to privacy and security requirements under HIPAA. Depending on the facts and circumstances, we could be subject to criminal penalties if we knowingly obtain, use, or disclose individually identifiable health information maintained by a HIPAA-covered entity in a manner that is not authorized or permitted by HIPAA. </span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even when HIPAA does not apply, according to the Federal Trade Commission or the FTC, violating consumers&#8217; privacy or failing to take appropriate steps to keep consumers&#8217; personal information secure may constitute unfair acts or practices in or affecting commerce in violation of Section 5(a) of the Federal Trade Commission Act. The FTC expects a company&#8217;s data security measures to be reasonable and appropriate in light of the sensitivity and volume of consumer information it holds, the size and complexity of its business, and the cost of available tools to improve security and reduce vulnerabilities. Individually identifiable health information is considered sensitive data that merits stronger safeguards.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, certain state laws govern the privacy and security of health information in certain circumstances, some of which are more stringent than HIPAA and many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts. Failure to comply with these laws, where applicable, can result in the imposition of significant civil and/or criminal penalties and private litigation. For example, the California Confidentiality of Medical Information Act imposes restrictive requirements regulating the use and disclosure of health information and other personally identifiable information. Further, on June 28, 2018, California enacted the California Consumer Privacy Act, or the CCPA, which took effect on January 1, 2020. The CCPA creates individual privacy rights for California consumers and increases the privacy and security obligations of entities handling certain personal information. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches that is expected to increase data breach litigation. The CCPA may increase our compliance costs and potential liability. Further, the California Privacy Rights Act, or CPRA, recently passed in California. The CPRA will impose additional data protection obligations on covered businesses, including additional consumer rights processes, limitations on data uses, new audit requirements for higher risk data, and opt outs for certain uses of sensitive data. It will also create a new California data protection agency authorized to issue substantive regulations and could result in increased privacy and information security enforcement. The majority of the provisions will go into effect on January 1, 2023, and additional compliance investment and potential business process changes may be required. In the event that we are subject to or affected by HIPAA, the CCPA, the CPRA or other domestic privacy and data protection laws, any liability from </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">failure to comply with the requirements of these laws could adversely affect our financial condition. Similar laws have been passed in Virginia, Colorado and Utah, and have been proposed at the federal level and in other states, reflecting a trend toward more stringent privacy legislation in the United States.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The GDPR went into effect in 2018 and imposes stringent requirements for controllers and processors of personal data of individuals within the European Economic Area (&#8220;EEA&#8221;), particularly with respect to clinical trials. The GDPR provides that EEA member states may make their own further laws and regulations limiting the processing of health data, which could limit our ability to use and share personal data or could cause our costs to increase and harm our business and financial condition. In addition, the GDPR increases the scrutiny that clinical trial sites located in the EEA should apply to transfers of personal data from such sites to countries that are considered to lack an adequate level of data protection, such as the United States. Recent legal developments have also created complexity and compliance uncertainty regarding certain transfers of information from the EEA to the United States. For example, on June 16, 2020, the Court of Justice of the European Union, or the CJEU, limited how organizations could lawfully transfer personal data from the EEA to the United States by invalidating the EU-US Privacy Shield Framework for purposes of international transfers and imposing further restrictions on use of the standard contractual clauses, or SCCs. These restrictions include a requirement for companies to carry out a transfer impact assessment which, among other things, assesses the laws governing access to personal data in the recipient country and considers whether supplementary measures that provide privacy protections additional to those provided under SCCs will need to be implemented to ensure an essentially equivalent level of data protection to that afforded in the EEA. The European Commission (&#8220;EC&#8221;) issued revised SCCs on June 4, 2021 to account for the decision of the CJEU and recommendations made by the European Data Protection Board. The revised SCCs must be used for relevant new data transfers from September 27, 2021; existing standard contractual clauses arrangements must be migrated to the revised clauses by December 27, 2022. There is some uncertainty around whether the revised clauses can be used for all types of data transfers, particularly whether they can be relied on for data transfers to non-EEA entities subject to the GDPR. As supervisory authorities issue further guidance on personal data export mechanisms, including circumstances where the SCCs cannot be used, and/or start taking enforcement action, we could suffer additional costs, complaints and/or regulatory investigations or fines, and/or if we are otherwise unable to transfer personal data between and among countries and regions in which we operate, it could affect the manner in which we provide our services, the geographical location or segregation of our relevant systems and operations, and could adversely affect our financial results. The GDPR imposes substantial fines for breaches of data protection requirements, which can be up to four percent of global revenue for the preceding financial year or &#8364;20 million, whichever is greater, and it also confers a private right of action on data subjects for breaches of data protection requirements. Compliance with European data protection laws is a rigorous and time intensive process that may increase our cost of doing business, and despite those efforts, there is a risk that we may be subject to fines and penalties, litigation and reputational harm in connection with our European activities. From January 1, 2021, we have had to comply with the GDPR and separately the United Kingdom GDPR, which, together with the amended United Kingdom Data Protection Act 2018, retains the GDPR in United Kingdom national law, each regime having the ability to fine up to the greater of &#8364;20 million/ &#163;17.5 million or 4% of global turnover. It is unclear how United Kingdom data protection laws and regulations will develop in the medium to longer term and these changes may lead to additional costs and increase our overall risk exposure. On June 28, 2021, the EC adopted an adequacy decision in favor of the United Kingdom, enabling data transfers from EU member states to the United Kingdom without additional safeguards. However, the United Kingdom adequacy decision will automatically expire in June 2025 unless the EC renews or extends that decision and remains under review by the Commission during this period.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Complying with U.S. and foreign privacy and security laws and regulations is complex and costly. Failure to comply by us or our vendors could subject us to litigation, government enforcement actions and substantial penalties and fines, which could harm our business.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We rely on information technology systems to conduct our business. A breakdown or breach of these systems or our failure to protect confidential information concerning our business, patients or employees could interrupt the operation of our business and subject us to liability.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We store valuable confidential information relating to our business, patients and employees on our computer networks and on the networks of our vendors. In addition, we rely heavily on internet technology, including video conference, teleconference and file-sharing services, to conduct business. Despite our security measures, our networks and the networks of our vendors are at risk of break-ins, installation of malware or ransomware, denial-of-service attacks, data theft and other forms of malfeasance by persons seeking to commit fraud or theft, which could result in unauthorized access to, and misuse of, our clinical data or other confidential information, including confidential information relating to our patients or employees. COVID-19 may increase our cybersecurity risks, due to our reliance on internet technology and the number of our employees that are working remotely, which may create additional opportunities for cybercriminals to exploit vulnerabilities.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and our vendors have experienced data breaches, theft, &#8220;phishing&#8221; attacks and other unauthorized access to confidential data and information. Russia&#8217;s invasion of Ukraine or another war of international dispute may cause a general </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">increase in the number and severity of such malicious incidents. There can be no assurance that our cybersecurity systems and processes will prevent unauthorized access in the future that causes serious harm to us, our patients or employees. We may also experience security breaches that remain undetected for an extended period.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disruptions or security breaches that result in the disclosure of confidential or proprietary information could cause us to incur liability and delay or otherwise harm our research, development and commercialization efforts. We may be liable for losses suffered by patients or employees or other individuals whose confidential information is stolen as a result of a breach of the security of the systems that we or third parties and our vendors store this information on, and any such liability could be material. Even if we are not liable for such losses, any breach of these systems could expose us to material costs in notifying affected individuals, as well as regulatory fines or penalties. In addition, any breach of these systems could disrupt our normal business operations and expose us to reputational damage and harm our business, operating results and financial condition. Any insurance we maintain against the risk of this type of loss may not be sufficient to cover actual losses, or may not apply to the circumstances relating to any particular loss.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We are dependent on the continued functioning of the FDA and other federal instrumentalities. Their partial or complete closure, whether due to public health concerns or a budgetary dispute, or their diversion of significant resources to advance pandemic-related issues could materially harm our business.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The government&#8217;s ability to carry out its mandated functions is affected by a variety of factors, including diversion of resources and limited operating capacity caused by the COVID-19 pandemic, as well as other events that may reduce the government&#8217;s ability to perform routine functions, such as inadequate funding, the inability to hire and retain key personnel, and statutory, regulatory and policy changes. If a prolonged government shutdown occurs, or if global health concerns continue to prevent the FDA or other regulatory authorities from conducting their regular inspections, reviews, or other regulatory activities, it could significantly impact the ability of the FDA or other regulatory authorities to timely review and process our regulatory submissions, which could have a material adverse effect on our business. Similarly, disruptions at the Securities and Exchange Commission (&#8220;SEC&#8221;) could temporarily stop its ability to review and approve proposed financing transactions.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Separately, in response to the COVID-19 pandemic, in March 2020, the FDA announced its intention to postpone most inspections of foreign manufacturing facilities and on March 18, 2020, the FDA temporarily postponed routine surveillance inspections of domestic manufacturing facilities. Subsequently, in July 2020, the FDA resumed certain on-site inspections of domestic manufacturing facilities subject to a risk-based prioritization system. The FDA utilized this risk-based assessment system to assist in determining when and where it was safest to conduct prioritized domestic inspections. Additionally, on April 15, 2021, the FDA began conducting voluntary remote interactive evaluations of certain drug manufacturing facilities and clinical research sites, among other facilities, in circumstances where the FDA determines that such remote evaluation would be appropriate based on mission needs and travel limitations. In July 2021, the FDA resumed standard inspections of domestic facilities, since that time, the FDA has continued to monitor and implement changes to its inspections to ensure the safety of its employees and those of the firms it regulates as it adapts to the evolving COVID-19 pandemic. Regulatory authorities outside the United States may adopt similar changes.If a prolonged government shutdown occurs, or if global health concerns continue to hinder or prevent the FDA or other regulatory authorities from conducting their regular inspections, reviews, or other regulatory activities, it could significantly impact the ability of the FDA or other regulatory authorities to timely review and process our regulatory submissions, which could have a material adverse effect on our business.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in federal, state and local tax laws may reduce our net earnings.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our earnings are subject to federal, state and local taxes. We offset a portion of our earnings using net operating losses and our taxes using research and development tax credits, which reduces the amount of tax we pay. Some jurisdictions require that we pay taxes or fees calculated as a percentage of sales, payroll expense, or other indicia of our activities. Please see &#8220;Part I, Item 1, Notes to Unaudited Condensed Consolidated Financial Statements - Income Taxes.&#8221; Changes to existing tax laws could materially increase the amounts we pay, which would reduce our after tax net income.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We may face competition from companies with greater financial, technical and marketing resources than our own.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The pharmaceutical industry is competitive and subject to rapid technological change. Our potential competitors include large pharmaceutical companies and innovative biotechnology companies, many of which have greater clinical, marketing and sales resources than our own and may develop and commercialize medications that are superior to and less expensive than ours, which could negatively affect our financial results and the prospects of our product candidates.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research analysts may not continue to provide or initiate coverage of our common stock or may issue negative reports.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The market for our common stock may be affected by the reports financial analysts publish about us. If any of the analysts covering us downgrades or discontinues coverage of our stock, the price of our common stock could decline rapidly and significantly. Paucity of research coverage may also adversely affect our stock price.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Sale of a substantial number of shares of our common stock may cause its price to decline.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of a substantial number of shares of our stock in the public market could reduce its price. As additional shares of our stock become available for public resale, whether by the exercise of stock options by employees or directors or because of an equity financing by us, the supply of our stock will increase, which could cause its price to fall. Substantially all of the shares of our stock are eligible for sale, subject to applicable volume and other resale restrictions.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in laws and regulations may significantly increase our costs or reduce our revenue, which could harm our financial results.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">New laws and regulations, as well as changes to existing laws and regulations, including statutes and regulations concerning taxes and the development, approval, marketing and pricing of medications, the provisions of the ACA requiring the reporting of aggregate spending related to health care professionals, the provisions of the Sarbanes-Oxley Act of 2002 and rules adopted by the SEC and by The Nasdaq Stock Market have and will likely continue to increase our cost of doing business and divert management&#8217;s attention from revenue-generating activities.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">If we acquire products or product candidates, we will incur significant costs and may not realize the benefits we anticipate.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may acquire a product or product candidate that complements our strategic plan. Such an acquisition may give rise to unforeseen difficulties and costs and may absorb significant management attention. We may not realize the anticipated benefits of any acquisition, which could dilute our stockholders&#8217; ownership interest or cause us to incur significant expenses and debt.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We may fail to comply with our public company obligations, including securities laws and regulations. Such compliance is costly and requires significant management attention.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The federal securities laws and regulations, including the corporate governance and other requirements of the Sarbanes-Oxley Act of 2002, impose complex and continually changing regulatory requirements on our operations and reporting. These developing requirements will continue to increase our compliance costs. Section 404 of the Sarbanes-Oxley Act of 2002 requires that we evaluate the effectiveness of, and provide a management report with respect to, our internal controls over financial reporting. It also requires that the independent registered public accounting firm auditing our consolidated financial statements must attest to and report on the effectiveness of our internal controls over financial reporting. If we are unable to complete the required assessment and report or if our independent registered public accounting firm is unable to issue an unqualified opinion as to the effectiveness of our internal control over financial reporting, investors could lose confidence in our financial reporting and our stock price would likely decline.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Anti-takeover provisions in our charter and bylaws and under Delaware law may make an acquisition of us or a change in our management more expensive or difficult, even if an acquisition or a management change would be beneficial to our stockholders.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provisions in our charter and bylaws may delay or prevent an acquisition of us or a change in our management. Some of these provisions allow us to issue preferred stock without any vote or further action by the stockholders, require advance notification of stockholder proposals and nominations of candidates for election as directors and prohibit stockholders from acting by written consent. In addition, a supermajority vote of stockholders is required to amend our bylaws. Our bylaws provide that special meetings of the stockholders may be called only by our Chairman, President or the Board of Directors and that the authorized number of directors may be changed only by resolution of the Board of Directors. These provisions may prevent or delay a change in our Board of Directors or our management, which our Board of Directors appoints. In addition, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporation Law. Section 203 may prohibit large stockholders, in particular those owning 15 percent or more of our outstanding voting stock, from merging or combining with us. These provisions in our charter and bylaws and under Delaware law could reduce the price that investors would be willing to pay for shares of our common stock.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our officers, directors and principal stockholders, acting as a group, could significantly influence corporate actions.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of April&#160;28, 2022, our officers and directors beneficially owned approximately 19 percent of our common stock. Acting together, these stockholders could significantly influence any matter requiring approval by our stockholders, including the election of directors and the approval of mergers or other business combinations. The interests of this group may not always coincide with our interests or the interests of other stockholders and may prevent or delay a change in control. This significant </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">concentration of share ownership may adversely affect the trading price of our common stock because many investors perceive disadvantages to owning stock in companies with controlling stockholders.</span></div><div id="i0a44765832c1416181e5729d6aaf7059_70"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 2.&#160;&#160;UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no unregistered sales of equity securities during the period covered by this report.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Issuer Purchases of Equity Securities</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table contains information relating to the purchases of our common stock in the three months ended March 31, 2022 as part of the cashless net exercises of stock options (in thousands, except average price per share):</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.848%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.009%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.009%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.012%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fiscal Period</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Number of Shares Purchased</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Average Price Per Share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Purchase Price of Shares</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 1, 2022 to January 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.16&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">435&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 1, 2022 to February 28, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.51&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,126&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 1, 2022 to March 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,476&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.05&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,037&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1) In January 2022, we issued 40,000 shares of common stock as part of a net-share settlement of a cashless option exercise, of which 25,350 shares were surrendered to us in satisfaction of related exercise cost and tax obligations. In February 2022, we issued 144,154 shares of common stock as part of net-share settlement of cashless option exercises, of which 94,461 shares were surrendered to us. In March 2022, we issued 256,809 shares of common stock as part of net-share settlement of cashless option exercises, of which 185,457 shares were surrendered to us.</span></div></td></tr><tr><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2) We paid $1.9 million to satisfy the tax withholding obligations associated with the net-share settlement of these cashless option exercises.</span></div></td></tr></table></div><div id="i0a44765832c1416181e5729d6aaf7059_73"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 3.&#160;&#160;DEFAULTS UPON SENIOR SECURITIES</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i0a44765832c1416181e5729d6aaf7059_76"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 4.&#160;&#160;MINE SAFETY DISCLOSURES</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i0a44765832c1416181e5729d6aaf7059_79"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 5.&#160;&#160;OTHER INFORMATION</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><div id="i0a44765832c1416181e5729d6aaf7059_82"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div style="-sec-extract:summary;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 6.&#160;&#160;EXHIBITS</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:8.284%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.783%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit<br/>Number</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Description of Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1088856/000119312512347804/d357533dex31.htm">Amended and Restated Certificate of Incorporation, as amended (incorporated by reference to Exhibit 3.1 to the registrant&#8217;s Quarterly Report on Form 10-Q filed on August&#160;9, 2012).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1088856/000119312507208805/dex31.htm">Amended and Restated Bylaws (incorporated by reference to Exhibit 3.1 to the registrant&#8217;s Current Report on Form 8-K filed on February 13, 2017).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="cort33122ex101seventhamend.htm">Seventh Amendment to Office Lease Agreement by and between Exponent Realty, LLC and Corcept Therapeutics Incorporated, made and entered into as of March 18, 2022.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="cort33122ex311.htm">Rule 13a-14(a)/15d-14(a) Certifications of Joseph K. Belanoff, M.D., Chief Executive Officer of the registrant.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="cort33122ex312.htm">Rule 13a-14(a)/15d-14(a) Certifications of Atabak Mokari, Chief Financial Officer of the registrant.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="cort33122ex321.htm">18 U.S.C. Section 1350 Certifications of Joseph K. Belanoff, M.D., Chief Executive Officer of the registrant.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="cort33122ex322.htm">18 U.S.C. Section 1350 Certifications of Atabak Mokari, Chief Financial Officer of the registrant.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following materials from the registrant&#8217;s Quarterly Report on Form 10-Q for the quarter ended March&#160;31, 2022, formatted in Extensible Business Reporting Language (XBRL): (i) Unaudited Condensed Consolidated Balance Sheets at March&#160;31, 2022 and December&#160;31, 2021, (ii) Unaudited Condensed Consolidated Statements of Comprehensive Income for the three month periods ended March&#160;31, 2022 and 2021, (iii) Unaudited Condensed Consolidated Statements of Cash Flows for the three month periods ended March&#160;31, 2022 and 2021, (iv) Unaudited Condensed Consolidated Statement of Stockholders&#8217; Equity and (v) Notes to Unaudited Condensed Consolidated Financial Statements.</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document.</span></td></tr></table></div><div style="margin-top:9pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><div id="i0a44765832c1416181e5729d6aaf7059_85"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.186%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.584%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.930%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CORCEPT THERAPEUTICS INCORPORATED</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 5, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Joseph K. Belanoff</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Joseph K. Belanoff, M.D.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Chief Executive Officer</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: <br/></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 5, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Atabak Mokari</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Atabak Mokari</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Chief Financial Officer</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 5, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Joseph D. Lyon</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Joseph D. Lyon</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Chief Accounting Officer</span></td></tr></table></div><div style="margin-top:9pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>cort33122ex101seventhamend.htm
<DESCRIPTION>EX-10.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ib9090c976f5c450bb0be8bb545e066cb_1"></div><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:0.06pt;margin-top:0.06pt"><font><br></font></div></div><div style="margin-top:9pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exhibit 10.1</font></div><div style="margin-bottom:0.06pt;margin-top:0.06pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SEVENTH AMENDMENT TO LEASE</font></div><div style="margin-top:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">THIS SEVENTH AMENDMENT TO LEASE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (the &#34;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Seventh Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#34;) is made and entered into as of March 18, 2022 by and between </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exponent Realty, LLC, a Delaware limited liability company </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(&#34;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Landlord</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#34;), and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Corcept Therapeutics Incorporated, a Delaware corporation </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Tenant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RECITALS</font></div><div style="margin-top:9pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A.&#160;&#160;&#160;&#160;Landlord and Tenant are parties to that certain lease dated April 1, 2016 (the &#34;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Lease</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#34;), the first amendment (the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8220;First Amendment&#8221;)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> dated June 1, 2017, the second amendment (the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8220;Second Amendment&#8221;)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> dated March 12, 2018, the third amendment (the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8220;Third Amendment&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) dated November 8, 2018, the Fourth Amendment dated October 23, 2019 (the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8220;Fourth Amendment&#8221;) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the Fifth Amendment dated June 17, 2020 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fifth Amendment&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) and the Sixth Amendment dated July 22, 2020 (the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8220;Sixth Amendment&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). Pursuant to the Lease, the First Amendment, the Second Amendment, the Third Amendment, the Fourth Amendment, the Fifth Amendment, and the Sixth Amendment, Landlord has leased to Tenant space currently containing approximately 36,062 rentable square feet (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Premises</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) on the first and second floor of the building, located at 149 Commonwealth Dr., Menlo Park, CA 94025 (the &#34;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Building</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#34;).</font></div><div style="margin-top:9pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">B.&#160;&#160;&#160;&#160;Tenant and Landlord now desire to amend Lease on the following terms and conditions&#58;</font></div><div style="margin-top:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOW, THEREFORE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in consideration of the above recitals which by this reference are incorporated herein, the mutual covenants and conditions contained herein and other valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Landlord and Tenant agree as follows&#58;</font></div><div style="margin-top:9pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Modification of Premises.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Effective as of April 1, 2022 (the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8220;Modification of Premises Date&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), the Premises shall be modified to expand into suites 1004 and 1014, shown on Exhibit A, such that the new Premises covered by the Lease shall thereafter be a total rentable square footage of 47,022 rentable square feet.</font></div><div style="margin-top:9pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Tenant Improvements.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Landlord shall not provide any allowance for Tenant Improvements in the Premises. Upon the execution of this Lease, Tenant may immediately have access to the new portion of the Premises to construct Tenant&#8217;s improvements.</font></div><div style="margin-top:9pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Lease Term.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Term of the Lease shall be extended through June 30, 2023.</font></div><div style="margin-top:9pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Base Rent.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Base Rent for the Premises shall be as shown in the schedule below. Tenant shall continue to pay its proportionate share of the Operating Expenses and Real Estate Taxes on the Premises. As of April 1, 2022, the schedule of Base Rent payable with respect to the Premises is the following&#58;</font></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:22.876%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.104%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.104%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.104%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.104%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.108%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">DATE</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">PERIOD</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">RENTABLE<br>SQ. FT.</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;text-indent:-14.7pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">BASE RENT PER RSF* PER YEAR</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">MONTHLY<br>AMOUNT</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">PERIODIC<br>AMOUNT</font></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">04&#47;01&#47;2022 to 06&#47;30&#47;2023</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">15 months</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">47,022</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$49.20</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$192,790.20</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$2,891,853.00</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*RSF is defined as Rentable Square Foot&#47;Feet</font></div><div style="margin-top:9pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Tenant's Building Percentage.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Effective on the Modification of Premises Date, the Tenant's Building Percentage set forth in section C.5 of the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BASIC LEASE PROVISIONS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is hereby changed to read&#58;</font></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">C.5. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Tenant's Building Percentage&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Thirty and Six Tenths (30.6%)</font></div><div style="margin-top:9pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Option to Extend Lease.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Tenant shall have one option to extend the Term of the Lease by 12 months. In order to extend the Term, Tenant must notify Landlord in writing, by December 31, 2022 of Tenant&#8217;s exercise of this option. In the event that Tenant exercises this option, Tenant shall continue to pay its proportionate share of the Operating Expenses and Real Estate Taxes on the Premises through the extended Term and the schedule of Base Rent payable with respect to the Premises shall be the following&#58;</font></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:22.876%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.104%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.104%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.104%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.104%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.108%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">DATE</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">PERIOD</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">RENTABLE<br>SQ. FT.</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">BASE RENT PER RSF* PER YEAR</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">MONTHLY<br>AMOUNT</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">PERIODIC<br>AMOUNT</font></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">07&#47;01&#47;2023 to 06&#47;30&#47;2024</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">12 months</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">47,022</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$51.00</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$199,843.50</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$2,398,122.00</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.06pt;margin-top:0.06pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:0.06pt;margin-top:0.06pt"><font><br></font></div></div><div style="margin-top:9pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Signage</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Landlord and Tenant shall work cooperatively to increase signage for Tenant on the marquee sign near the visitor parking.</font></div><div style="margin-top:9pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Miscellaneous.</font></div><div style="margin-top:9pt;padding-left:27pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.1  This Seventh Amendment, which is hereby incorporated into and made a part of the Lease, sets forth the entire agreement between the parties with respect to the matters herein. There have been no additional oral or written representations or agreements. Under no circumstances shall Tenant be entitled to any Rent abatement, improvement allowance, leasehold improvements, or other work to the Premises, or any similar economic incentives that may have been provided Tenant in connection with entering into the Lease, unless specifically set forth in this Seventh Amendment or previously agreed to provisions of the Lease or any amendment thereto. Tenant agrees that neither Tenant nor its agents or any other parties acting on behalf of Tenant shall disclose any matters set forth in this Seventh Amendment or disseminate or distribute any information concerning the terms, details or conditions hereof to any person, firm, entity, broker or other tenants in the Building without obtaining the express written consent of Landlord.</font></div><div style="margin-top:9pt;padding-left:27pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.2  Except as herein modified or amended, the provisions, conditions and terms of the Lease shall remain unchanged and in full force and effect.</font></div><div style="margin-top:9pt;padding-left:27pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.3  In the case of any inconsistency between the provisions of the Lease and the Seventh Amendment, the provisions of this Seventh Amendment shall govern and control.</font></div><div style="margin-top:9pt;padding-left:27pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.4  Submission of this Seventh Amendment by Landlord is not an offer to enter into this Seventh Amendment but rather is a solicitation for such an offer by Tenant. Landlord shall not be bound by this Seventh Amendment until Tenant and Landlord have executed and Landlord delivered the same to Tenant.</font></div><div style="margin-top:9pt;padding-left:27pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.5  Tenant hereby represents to Landlord that Tenant has dealt with no real estate brokers or agents in connection with this Seventh Amendment. Tenant agrees to indemnify and hold Landlord, its members, principals, beneficiaries, partners, officers, directors, employees, mortgagee(s) and agents, and the respective principals and members of any such real estate brokers or agents (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Landlord Related Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) harmless from all claims of any real estate brokers or agents claiming to have represented Tenant in connection with this Seventh Amendment. Landlord hereby represents to Tenant that Landlord has dealt with no real estate brokers or agents in connection with this Seventh Amendment. Landlord agrees to indemnify and hold Tenant, its members, principals, beneficiaries, partners, officers, directors, employees, and agents, and the respective principals and members of any such real estate brokers or agents (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Tenant Related Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) harmless from all claims of any real estate brokers or agents claiming to have represented Landlord in connection with this Seventh Amendment.</font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CONTINUED ON NEXT PAGE </font></div><div style="margin-top:9pt;padding-left:27pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Each signatory of this Seventh Amendment represents hereby that he or she has the authority to execute and deliver the same on behalf of the party hereto for which such signatory is acting.</font></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">IN WITNESS WHEREOF</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Landlord and Tenant have duly executed this Seventh Amendment as of the day and year first above written.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.06pt;margin-top:0.06pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:0.06pt;margin-top:0.06pt"><font><br></font></div></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LANDLORD&#58;</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXPONENT REALTY, L.L.C.,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">a Delaware limited liability company</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; 3&#47;18&#47;22</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By&#58; &#47;s&#47; Richard L. Schlenker</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Name&#58; Richard L. Schlenker</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Title&#58; Executive Vice President &#38; CFO</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TENANT&#58;</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Corcept Therapeutics Incorporated,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">a Delaware corporation</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; 3&#47;18&#47;22</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By&#58; &#47;s&#47; Charlie Robb</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Name&#58; Charlie Robb</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Title&#58; Chief Business Officer</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.06pt;margin-top:0.06pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:0.06pt;margin-top:0.06pt"><font><br></font></div></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT A</font></div><div style="margin-top:9pt;text-align:center"><img alt="image.jpg" src="image.jpg" style="height:898px;margin-bottom:5pt;vertical-align:text-bottom;width:570px"></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.06pt;margin-top:0.06pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>cort33122ex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ie38f77b25f8f48b2837d9bd4d41928f8_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:9pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exhibit 31.1</font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">CERTIFICATION</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Joseph K. Belanoff, M.D., certify that&#58;</font></div><div style="margin-top:9pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this Quarterly Report on Form 10-Q for the period ended March&#160;31, 2022 of Corcept Therapeutics Incorporated&#59;</font></div><div style="margin-top:9pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:9pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:9pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:9pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:39.035%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Joseph K. Belanoff</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Joseph K. Belanoff, M.D.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer and President</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 5, 2022</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>cort33122ex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i80df68a7515b412bbdd09cab9b28a313_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:9pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exhibit 31.2</font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">CERTIFICATION</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Atabak Mokari, certify that&#58;</font></div><div style="margin-top:9pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this Quarterly Report on Form 10-Q for the period ended March&#160;31, 2022 of Corcept Therapeutics Incorporated&#59;</font></div><div style="margin-top:9pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:9pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:9pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:9pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:39.035%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Atabak Mokari</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Atabak Mokari</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 5, 2022</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>5
<FILENAME>cort33122ex321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i3174a4b0b64b4085af6bb4171e8448fe_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:9pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exhibit 32.1</font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Corcept Therapeutics Incorporated</font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18 U.S.C. SECTION 1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Quarterly&#160;Report of Corcept Therapeutics Incorporated (the &#8220;Company&#8221;) on Form 10-Q&#160;for the period ended March&#160;31, 2022, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Joseph K. Belanoff, M.D., Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that&#58;</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:39.035%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Joseph K. Belanoff</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Joseph K. Belanoff, M.D.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer&#160;and President</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 5, 2022</font></td></tr></table></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This certification is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of Corcept Therapeutics Incorporated under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, irrespective of any general incorporation language contained in such filing.</font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>6
<FILENAME>cort33122ex322.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i68f55066e577495b84747c1d86052c85_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:9pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exhibit 32.2</font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Corcept Therapeutics Incorporated</font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18 U.S.C. SECTION 1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Quarterly&#160;Report of Corcept Therapeutics Incorporated (the &#8220;Company&#8221;) on Form 10-Q&#160;for the period ended March&#160;31, 2022, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Atabak Mokari, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that&#58;</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:39.035%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Atabak Mokari</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Atabak Mokari</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 5, 2022</font></td></tr></table></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This certification is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of Corcept Therapeutics Incorporated under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, irrespective of any general incorporation language contained in such filing.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>cort-20220331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:e53d3b2d-fdb0-4be1-948b-2f6fb33fb115,g:87e34f93-b135-45b2-b829-febf6d6a95d5-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:cort="http://www.corcept.com/20220331" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.corcept.com/20220331">
  <xs:import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2021q4" schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cort-20220331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cort-20220331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cort-20220331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cort-20220331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.corcept.com/role/CoverPage">
        <link:definition>0001001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDBALANCESHEETS" roleURI="http://www.corcept.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS">
        <link:definition>1001002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" roleURI="http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME">
        <link:definition>1002003 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEParenthetical" roleURI="http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEParenthetical">
        <link:definition>1003004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" roleURI="http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS">
        <link:definition>1004005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" roleURI="http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY">
        <link:definition>1005006 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPolicies" roleURI="http://www.corcept.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies">
        <link:definition>2101101 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.corcept.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>2202201 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails" roleURI="http://www.corcept.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails">
        <link:definition>2403401 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CompositionofCertainBalanceSheetItems" roleURI="http://www.corcept.com/role/CompositionofCertainBalanceSheetItems">
        <link:definition>2104102 - Disclosure - Composition of Certain Balance Sheet Items</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CompositionofCertainBalanceSheetItemsTables" roleURI="http://www.corcept.com/role/CompositionofCertainBalanceSheetItemsTables">
        <link:definition>2305301 - Disclosure - Composition of Certain Balance Sheet Items (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CompositionofCertainBalanceSheetItemsScheduleofCompositionofInventoryDetails" roleURI="http://www.corcept.com/role/CompositionofCertainBalanceSheetItemsScheduleofCompositionofInventoryDetails">
        <link:definition>2406402 - Disclosure - Composition of Certain Balance Sheet Items - Schedule of Composition of Inventory (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CompositionofCertainBalanceSheetItemsScheduleofCompositionofInventoryDetails_1" roleURI="http://www.corcept.com/role/CompositionofCertainBalanceSheetItemsScheduleofCompositionofInventoryDetails_1">
        <link:definition>2406402 - Disclosure - Composition of Certain Balance Sheet Items - Schedule of Composition of Inventory (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CompositionofCertainBalanceSheetItemsScheduleofPropertyandEquipmentDetails" roleURI="http://www.corcept.com/role/CompositionofCertainBalanceSheetItemsScheduleofPropertyandEquipmentDetails">
        <link:definition>2407403 - Disclosure - Composition of Certain Balance Sheet Items - Schedule of Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CompositionofCertainBalanceSheetItemsScheduleofOtherAccruedLiabilitiesDetails" roleURI="http://www.corcept.com/role/CompositionofCertainBalanceSheetItemsScheduleofOtherAccruedLiabilitiesDetails">
        <link:definition>2408404 - Disclosure - Composition of Certain Balance Sheet Items - Schedule of Other Accrued Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CompositionofCertainBalanceSheetItemsNarrativeDetails" roleURI="http://www.corcept.com/role/CompositionofCertainBalanceSheetItemsNarrativeDetails">
        <link:definition>2409405 - Disclosure - Composition of Certain Balance Sheet Items - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AvailableforSaleSecuritiesandFairValueMeasurements" roleURI="http://www.corcept.com/role/AvailableforSaleSecuritiesandFairValueMeasurements">
        <link:definition>2110103 - Disclosure - Available-for-Sale Securities and Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AvailableforSaleSecuritiesandFairValueMeasurementsTables" roleURI="http://www.corcept.com/role/AvailableforSaleSecuritiesandFairValueMeasurementsTables">
        <link:definition>2311302 - Disclosure - Available-for-Sale Securities and Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AvailableforSaleSecuritiesandFairValueMeasurementsSummaryoftheClassificationofAvailableforSaleSecuritiesinCondensedConsolidatedBalanceSheetsDetails" roleURI="http://www.corcept.com/role/AvailableforSaleSecuritiesandFairValueMeasurementsSummaryoftheClassificationofAvailableforSaleSecuritiesinCondensedConsolidatedBalanceSheetsDetails">
        <link:definition>2412406 - Disclosure - Available-for-Sale Securities and Fair Value Measurements - Summary of the Classification of Available-for-Sale Securities in Condensed Consolidated Balance Sheets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AvailableforSaleSecuritiesandFairValueMeasurementsScheduleofAvailableforSaleSecuritiesDetails" roleURI="http://www.corcept.com/role/AvailableforSaleSecuritiesandFairValueMeasurementsScheduleofAvailableforSaleSecuritiesDetails">
        <link:definition>2413407 - Disclosure - Available-for-Sale Securities and Fair Value Measurements - Schedule of Available-for-Sale Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AvailableforSaleSecuritiesandFairValueMeasurementsNarrativeDetails" roleURI="http://www.corcept.com/role/AvailableforSaleSecuritiesandFairValueMeasurementsNarrativeDetails">
        <link:definition>2414408 - Disclosure - Available-for-Sale Securities and Fair Value Measurements - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.corcept.com/role/CommitmentsandContingencies">
        <link:definition>2115104 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesDetails" roleURI="http://www.corcept.com/role/CommitmentsandContingenciesDetails">
        <link:definition>2416409 - Disclosure - Commitments and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://www.corcept.com/role/Leases">
        <link:definition>2117105 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://www.corcept.com/role/LeasesTables">
        <link:definition>2318303 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesNarrativeDetails" roleURI="http://www.corcept.com/role/LeasesNarrativeDetails">
        <link:definition>2419410 - Disclosure - Leases - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesRightofuseAssetsandRelatedLiabilitiesDetails" roleURI="http://www.corcept.com/role/LeasesRightofuseAssetsandRelatedLiabilitiesDetails">
        <link:definition>2420411 - Disclosure - Leases - Right-of-use Assets and Related Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesFutureMinimumLeasePaymentsDetails" roleURI="http://www.corcept.com/role/LeasesFutureMinimumLeasePaymentsDetails">
        <link:definition>2421412 - Disclosure - Leases - Future Minimum Lease Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesFutureMinimumLeasePaymentsDetails_1" roleURI="http://www.corcept.com/role/LeasesFutureMinimumLeasePaymentsDetails_1">
        <link:definition>2421412 - Disclosure - Leases - Future Minimum Lease Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquity" roleURI="http://www.corcept.com/role/StockholdersEquity">
        <link:definition>2122106 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityTables" roleURI="http://www.corcept.com/role/StockholdersEquityTables">
        <link:definition>2323304 - Disclosure - Stockholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityNarrativeDetails" roleURI="http://www.corcept.com/role/StockholdersEquityNarrativeDetails">
        <link:definition>2424413 - Disclosure - Stockholders' Equity - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquitySummaryofStockBasedCompensationDetails" roleURI="http://www.corcept.com/role/StockholdersEquitySummaryofStockBasedCompensationDetails">
        <link:definition>2425414 - Disclosure - Stockholders' Equity - Summary of Stock-Based Compensation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetIncomePerShare" roleURI="http://www.corcept.com/role/NetIncomePerShare">
        <link:definition>2126107 - Disclosure - Net Income Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetIncomePerShareTables" roleURI="http://www.corcept.com/role/NetIncomePerShareTables">
        <link:definition>2327305 - Disclosure - Net Income Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetIncomePerShareScheduleofComputationofNetIncomePerShareDetails" roleURI="http://www.corcept.com/role/NetIncomePerShareScheduleofComputationofNetIncomePerShareDetails">
        <link:definition>2428415 - Disclosure - Net Income Per Share - Schedule of Computation of Net Income Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetIncomePerShareNarrativeDetails" roleURI="http://www.corcept.com/role/NetIncomePerShareNarrativeDetails">
        <link:definition>2429416 - Disclosure - Net Income Per Share - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.corcept.com/role/IncomeTaxes">
        <link:definition>2130108 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncometaxesDetails" roleURI="http://www.corcept.com/role/IncometaxesDetails">
        <link:definition>2431417 - Disclosure - Income taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="cort_AccruedLegalFeesCurrent" abstract="false" name="AccruedLegalFeesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cort_LongLivedTangibleAssetDomain" abstract="true" name="LongLivedTangibleAssetDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cort_InventoryCurrentNoncurrent" abstract="false" name="InventoryCurrentNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cort_AccretionExpenseIncome" abstract="false" name="AccretionExpenseIncome" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cort_AvailableForSaleSecuritiesAndFairValueMeasurementsDisclosureTextBlock" abstract="false" name="AvailableForSaleSecuritiesAndFairValueMeasurementsDisclosureTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="cort_InventoryFinishedGoodsCurrentAndNoncurrent" abstract="false" name="InventoryFinishedGoodsCurrentAndNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cort_ShortTermMarketableSecuritiesMember" abstract="true" name="ShortTermMarketableSecuritiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cort_UnrecognizedTaxBenefitsThatWouldBeOffsetByAChangeInValuationAllowance" abstract="false" name="UnrecognizedTaxBenefitsThatWouldBeOffsetByAChangeInValuationAllowance" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cort_AvailableForSaleSecuritiesAndFairValueMeasurementsAbstract" abstract="true" name="AvailableForSaleSecuritiesAndFairValueMeasurementsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cort_InventoryWorkInProcessCurrentAndNoncurrent" abstract="false" name="InventoryWorkInProcessCurrentAndNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cort_LongTermMarketableSecuritiesMember" abstract="true" name="LongTermMarketableSecuritiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cort_DepositsForClinicalTrials" abstract="false" name="DepositsForClinicalTrials" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cort_SharesRepurchasedInNetSettlementOfCashlessOptionExercise" abstract="false" name="SharesRepurchasedInNetSettlementOfCashlessOptionExercise" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cort_IncreaseDecreaseInAccruedClinicalExpenses" abstract="false" name="IncreaseDecreaseInAccruedClinicalExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cort_LongLivedTangibleAssetAxis" abstract="true" name="LongLivedTangibleAssetAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="cort_NumberOfStockOptionPlans" abstract="false" name="NumberOfStockOptionPlans" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="cort_NumberOfSeriesOfSelectiveCortisolModulators" abstract="false" name="NumberOfSeriesOfSelectiveCortisolModulators" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="cort_LongTermMarketableSecuritiesRemainingMaturity" abstract="false" name="LongTermMarketableSecuritiesRemainingMaturity" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="cort_NonCashTransactionRecognitionOfRightOfUseAssetAndLeaseLiability" abstract="false" name="NonCashTransactionRecognitionOfRightOfUseAssetAndLeaseLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cort_MarketableSecuritiesMaximumMaturityPeriod" abstract="false" name="MarketableSecuritiesMaximumMaturityPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="cort_StockOptionsFiscalTwentyTwelvePlanMember" abstract="true" name="StockOptionsFiscalTwentyTwelvePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cort_AccruedGovernmentRebateCurrent" abstract="false" name="AccruedGovernmentRebateCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cort_AvailableForSaleSecuritiesIncludingCashEquivalents" abstract="false" name="AvailableForSaleSecuritiesIncludingCashEquivalents" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cort_MarketableSecuritiesWeightedAverageMaturityPeriod" abstract="false" name="MarketableSecuritiesWeightedAverageMaturityPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="cort_AccruedClinicalExpensesCurrent" abstract="false" name="AccruedClinicalExpensesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>cort-20220331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:e53d3b2d-fdb0-4be1-948b-2f6fb33fb115,g:87e34f93-b135-45b2-b829-febf6d6a95d5-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.corcept.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="cort-20220331.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETS"/>
  <link:calculationLink xlink:role="http://www.corcept.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_457f7617-6e33-4ce6-8a78-e34429627c01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_71f7f157-5655-44ad-9934-347878dd7427" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_457f7617-6e33-4ce6-8a78-e34429627c01" xlink:to="loc_us-gaap_LiabilitiesCurrent_71f7f157-5655-44ad-9934-347878dd7427" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_eed416d4-a3cc-4e69-93d0-644a8b9909f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_457f7617-6e33-4ce6-8a78-e34429627c01" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_eed416d4-a3cc-4e69-93d0-644a8b9909f0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesNoncurrent_f05d3e3f-95fb-4f42-a986-37309a60568c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedIncomeTaxesNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_457f7617-6e33-4ce6-8a78-e34429627c01" xlink:to="loc_us-gaap_AccruedIncomeTaxesNoncurrent_f05d3e3f-95fb-4f42-a986-37309a60568c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_2732079b-3918-48c7-a80b-7f139fb05942" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_ddb6eb75-3985-45c1-950c-fcb1c8bde5d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_2732079b-3918-48c7-a80b-7f139fb05942" xlink:to="loc_us-gaap_AssetsCurrent_ddb6eb75-3985-45c1-950c-fcb1c8bde5d4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent_a4d0b75a-8fd2-4def-9efd-1344d5452a18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_2732079b-3918-48c7-a80b-7f139fb05942" xlink:to="loc_us-gaap_InventoryNoncurrent_a4d0b75a-8fd2-4def-9efd-1344d5452a18" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_9095f4dd-406e-44e1-a4e2-e04f04667329" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_2732079b-3918-48c7-a80b-7f139fb05942" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_9095f4dd-406e-44e1-a4e2-e04f04667329" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_0e04c436-15eb-4d83-b289-7e89617fcc81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_2732079b-3918-48c7-a80b-7f139fb05942" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_0e04c436-15eb-4d83-b289-7e89617fcc81" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent_5eec9e0a-e282-4b28-9e49-1f91206d7cec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_2732079b-3918-48c7-a80b-7f139fb05942" xlink:to="loc_us-gaap_MarketableSecuritiesNoncurrent_5eec9e0a-e282-4b28-9e49-1f91206d7cec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_d9d0c144-36b9-41a4-821e-4874e7ec3128" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_2732079b-3918-48c7-a80b-7f139fb05942" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_d9d0c144-36b9-41a4-821e-4874e7ec3128" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_f2ae9ca4-ace5-4885-ba5a-0033e8619f82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_2732079b-3918-48c7-a80b-7f139fb05942" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_f2ae9ca4-ace5-4885-ba5a-0033e8619f82" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_ddf3cd54-6211-4135-961f-a1a25f87b5d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_0af68647-54f2-41dd-8e96-559469e964e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_ddf3cd54-6211-4135-961f-a1a25f87b5d7" xlink:to="loc_us-gaap_StockholdersEquity_0af68647-54f2-41dd-8e96-559469e964e2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_af272e7d-e755-4073-9c36-cd4ebe4d5547" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_ddf3cd54-6211-4135-961f-a1a25f87b5d7" xlink:to="loc_us-gaap_Liabilities_af272e7d-e755-4073-9c36-cd4ebe4d5547" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_d55640f2-92b6-4dd8-8d9a-6ce9ede0cf86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_222c13f2-f1e5-47d1-8230-a7b929388bbc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d55640f2-92b6-4dd8-8d9a-6ce9ede0cf86" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_222c13f2-f1e5-47d1-8230-a7b929388bbc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_1e677d0f-fc29-47c1-9f8f-f0b26f773050" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d55640f2-92b6-4dd8-8d9a-6ce9ede0cf86" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_1e677d0f-fc29-47c1-9f8f-f0b26f773050" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_37db7aad-7a8e-4778-8343-401898d45905" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d55640f2-92b6-4dd8-8d9a-6ce9ede0cf86" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_37db7aad-7a8e-4778-8343-401898d45905" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_4ab6b5fd-2258-4d3d-9d27-8c26b6886a88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d55640f2-92b6-4dd8-8d9a-6ce9ede0cf86" xlink:to="loc_us-gaap_InventoryNet_4ab6b5fd-2258-4d3d-9d27-8c26b6886a88" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_87bee06e-2bfa-4c26-9e1a-40b67b3c1659" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d55640f2-92b6-4dd8-8d9a-6ce9ede0cf86" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_87bee06e-2bfa-4c26-9e1a-40b67b3c1659" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_838535b2-3d94-43c0-a73a-1661b804d4f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_a9764c44-5b02-4b07-92f7-9583eaa4909b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_838535b2-3d94-43c0-a73a-1661b804d4f3" xlink:to="loc_us-gaap_AccountsPayableCurrent_a9764c44-5b02-4b07-92f7-9583eaa4909b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cort_AccruedClinicalExpensesCurrent_797bbab4-79e0-4e3c-bb5f-88caf48ed905" xlink:href="cort-20220331.xsd#cort_AccruedClinicalExpensesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_838535b2-3d94-43c0-a73a-1661b804d4f3" xlink:to="loc_cort_AccruedClinicalExpensesCurrent_797bbab4-79e0-4e3c-bb5f-88caf48ed905" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_1cc68605-fdef-4c99-b5da-3f73d65a145f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_838535b2-3d94-43c0-a73a-1661b804d4f3" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_1cc68605-fdef-4c99-b5da-3f73d65a145f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_214162a7-ad9b-4a98-920c-5720b04dbd31" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_838535b2-3d94-43c0-a73a-1661b804d4f3" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_214162a7-ad9b-4a98-920c-5720b04dbd31" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_8618d113-33d2-462c-8e19-0aa50ca1f1b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_f48e2ee6-9cb0-49f7-bc08-31d5da831f8c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_8618d113-33d2-462c-8e19-0aa50ca1f1b0" xlink:to="loc_us-gaap_PreferredStockValue_f48e2ee6-9cb0-49f7-bc08-31d5da831f8c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_61576db6-98ed-4ca5-9edd-25a2b01813d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_8618d113-33d2-462c-8e19-0aa50ca1f1b0" xlink:to="loc_us-gaap_CommonStockValue_61576db6-98ed-4ca5-9edd-25a2b01813d7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_dd18f376-c38a-48aa-8fdb-3792f30b8404" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_8618d113-33d2-462c-8e19-0aa50ca1f1b0" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_dd18f376-c38a-48aa-8fdb-3792f30b8404" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonValue_78a7ba95-fc32-47f5-8aa1-a10ec84b5dec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockCommonValue"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_8618d113-33d2-462c-8e19-0aa50ca1f1b0" xlink:to="loc_us-gaap_TreasuryStockCommonValue_78a7ba95-fc32-47f5-8aa1-a10ec84b5dec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_02f24a7f-15c5-42f0-9d6e-efefc21d6c80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_8618d113-33d2-462c-8e19-0aa50ca1f1b0" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_02f24a7f-15c5-42f0-9d6e-efefc21d6c80" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_7470fbff-431e-4f8e-89ed-eb061c462211" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_8618d113-33d2-462c-8e19-0aa50ca1f1b0" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_7470fbff-431e-4f8e-89ed-eb061c462211" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" xlink:type="simple" xlink:href="cort-20220331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"/>
  <link:calculationLink xlink:role="http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_99a19de7-1832-4bb0-a02b-d76515f3c7f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_8a7ae0f8-d053-4aed-b890-56d8feeb375a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_99a19de7-1832-4bb0-a02b-d76515f3c7f7" xlink:to="loc_us-gaap_NetIncomeLoss_8a7ae0f8-d053-4aed-b890-56d8feeb375a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_6236a19d-b48b-433c-bf9f-e3d152d90995" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_99a19de7-1832-4bb0-a02b-d76515f3c7f7" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_6236a19d-b48b-433c-bf9f-e3d152d90995" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_9be21c03-4c8c-4eb9-a239-49827598380b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_99a19de7-1832-4bb0-a02b-d76515f3c7f7" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_9be21c03-4c8c-4eb9-a239-49827598380b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_0d039074-2142-4273-a380-145a500b461c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_904a242b-913b-4dba-a7a9-dc5b49bfd5d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_0d039074-2142-4273-a380-145a500b461c" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_904a242b-913b-4dba-a7a9-dc5b49bfd5d1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_10ceee5b-e34d-4266-8354-7781bf30e404" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_0d039074-2142-4273-a380-145a500b461c" xlink:to="loc_us-gaap_CostsAndExpenses_10ceee5b-e34d-4266-8354-7781bf30e404" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_81658482-b3d1-4bef-95ce-c4fe5e7e870d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_db1d4877-6f16-4821-9c88-3b1475ea0992" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_81658482-b3d1-4bef-95ce-c4fe5e7e870d" xlink:to="loc_us-gaap_OperatingIncomeLoss_db1d4877-6f16-4821-9c88-3b1475ea0992" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_bfbc5d6e-366a-425f-a1f4-35f7f89aea55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_81658482-b3d1-4bef-95ce-c4fe5e7e870d" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_bfbc5d6e-366a-425f-a1f4-35f7f89aea55" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_a0e12af6-db99-42b3-bc2e-0df815e099a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_d06a6ec1-92bb-4605-879a-50a96824ad67" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_a0e12af6-db99-42b3-bc2e-0df815e099a7" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_d06a6ec1-92bb-4605-879a-50a96824ad67" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_663d2846-d556-41ee-8eff-1edeb29f5e67" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_a0e12af6-db99-42b3-bc2e-0df815e099a7" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_663d2846-d556-41ee-8eff-1edeb29f5e67" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_89a07eeb-4146-41d0-950e-52a861cf19bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_8d452838-328a-4e0e-aa56-899aed42b128" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_89a07eeb-4146-41d0-950e-52a861cf19bd" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_8d452838-328a-4e0e-aa56-899aed42b128" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_3c48a588-fbd1-4df3-946c-06dc3f6b9ff2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_89a07eeb-4146-41d0-950e-52a861cf19bd" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_3c48a588-fbd1-4df3-946c-06dc3f6b9ff2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_7d3ba31d-f95c-4e59-b023-dfce6c6e7f47" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_89a07eeb-4146-41d0-950e-52a861cf19bd" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_7d3ba31d-f95c-4e59-b023-dfce6c6e7f47" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="cort-20220331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7329f6dd-a65c-47b8-afc2-81d6b96d344e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_b050152f-0aa1-487b-9d7b-b53d6011e072" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7329f6dd-a65c-47b8-afc2-81d6b96d344e" xlink:to="loc_us-gaap_ProfitLoss_b050152f-0aa1-487b-9d7b-b53d6011e072" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_12a2b570-d9ea-4f94-ad60-2a03fb9bbb48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7329f6dd-a65c-47b8-afc2-81d6b96d344e" xlink:to="loc_us-gaap_ShareBasedCompensation_12a2b570-d9ea-4f94-ad60-2a03fb9bbb48" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_bef2d5b4-f4f2-4e45-bd7f-d1ee34b3b96f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7329f6dd-a65c-47b8-afc2-81d6b96d344e" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_bef2d5b4-f4f2-4e45-bd7f-d1ee34b3b96f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_11a1208a-6e36-433b-b897-62dce9048b68" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7329f6dd-a65c-47b8-afc2-81d6b96d344e" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_11a1208a-6e36-433b-b897-62dce9048b68" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_a5601510-16f2-466d-87c9-d8df2dc3cd16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccruedLiabilities"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7329f6dd-a65c-47b8-afc2-81d6b96d344e" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_a5601510-16f2-466d-87c9-d8df2dc3cd16" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_d75861c4-f528-4e5c-af41-01d6d8324fd2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7329f6dd-a65c-47b8-afc2-81d6b96d344e" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_d75861c4-f528-4e5c-af41-01d6d8324fd2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_4da67b89-c1f1-4801-bb34-18223a779e75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7329f6dd-a65c-47b8-afc2-81d6b96d344e" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_4da67b89-c1f1-4801-bb34-18223a779e75" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_a7c6533d-6b79-4883-99a4-5d62d3e0c664" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7329f6dd-a65c-47b8-afc2-81d6b96d344e" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_a7c6533d-6b79-4883-99a4-5d62d3e0c664" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_d12fc2f6-475a-40ce-ae5c-4ea2299744a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7329f6dd-a65c-47b8-afc2-81d6b96d344e" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_d12fc2f6-475a-40ce-ae5c-4ea2299744a0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_2656d71b-503f-4c3b-81df-dd300cb9d2a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7329f6dd-a65c-47b8-afc2-81d6b96d344e" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_2656d71b-503f-4c3b-81df-dd300cb9d2a0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cort_IncreaseDecreaseInAccruedClinicalExpenses_904fff33-fffc-4fb5-a0bc-492d2f053bef" xlink:href="cort-20220331.xsd#cort_IncreaseDecreaseInAccruedClinicalExpenses"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7329f6dd-a65c-47b8-afc2-81d6b96d344e" xlink:to="loc_cort_IncreaseDecreaseInAccruedClinicalExpenses_904fff33-fffc-4fb5-a0bc-492d2f053bef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_5f125182-77e1-4211-a8e8-f66f2e587698" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7329f6dd-a65c-47b8-afc2-81d6b96d344e" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_5f125182-77e1-4211-a8e8-f66f2e587698" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cort_AccretionExpenseIncome_ce4b4772-345b-4b0b-bf8e-822151191a97" xlink:href="cort-20220331.xsd#cort_AccretionExpenseIncome"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7329f6dd-a65c-47b8-afc2-81d6b96d344e" xlink:to="loc_cort_AccretionExpenseIncome_ce4b4772-345b-4b0b-bf8e-822151191a97" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedTaxesPayable_292a257c-5c88-42bf-8316-7d45ca2f7857" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedTaxesPayable"/>
    <link:calculationArc order="14" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7329f6dd-a65c-47b8-afc2-81d6b96d344e" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedTaxesPayable_292a257c-5c88-42bf-8316-7d45ca2f7857" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_423e1f7a-f835-4234-b389-5518f5260e7f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ef61e44e-6605-4954-aeec-791b37b7baa6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_423e1f7a-f835-4234-b389-5518f5260e7f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ef61e44e-6605-4954-aeec-791b37b7baa6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_36252e64-030e-4efe-bc40-a4af5f914185" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_423e1f7a-f835-4234-b389-5518f5260e7f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_36252e64-030e-4efe-bc40-a4af5f914185" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f16435f4-22f6-4358-8553-ffd9da0da404" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_423e1f7a-f835-4234-b389-5518f5260e7f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f16435f4-22f6-4358-8553-ffd9da0da404" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b0899361-5ad0-4d2a-9de2-77ad00c4fde7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_910c7733-383d-4b73-8513-2ce1cd13edf6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b0899361-5ad0-4d2a-9de2-77ad00c4fde7" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_910c7733-383d-4b73-8513-2ce1cd13edf6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_42ee8073-0622-456d-9a80-bdc8c7da3594" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b0899361-5ad0-4d2a-9de2-77ad00c4fde7" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_42ee8073-0622-456d-9a80-bdc8c7da3594" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_798bbc3f-02b6-4edc-b057-1deae62c749f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b0899361-5ad0-4d2a-9de2-77ad00c4fde7" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_798bbc3f-02b6-4edc-b057-1deae62c749f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_5116b1ea-ad5e-4ad5-b58f-574b2f5f7a22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_fac887e0-8b14-4f28-a911-c6d82f85abeb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_5116b1ea-ad5e-4ad5-b58f-574b2f5f7a22" xlink:to="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_fac887e0-8b14-4f28-a911-c6d82f85abeb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_b05100ea-022b-4331-bcb1-3fcf06f3e3ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_5116b1ea-ad5e-4ad5-b58f-574b2f5f7a22" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_b05100ea-022b-4331-bcb1-3fcf06f3e3ac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_465f9cdc-2de1-4ee5-af62-8894db6dcf31" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_5116b1ea-ad5e-4ad5-b58f-574b2f5f7a22" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_465f9cdc-2de1-4ee5-af62-8894db6dcf31" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.corcept.com/role/CompositionofCertainBalanceSheetItemsScheduleofCompositionofInventoryDetails" xlink:type="simple" xlink:href="cort-20220331.xsd#CompositionofCertainBalanceSheetItemsScheduleofCompositionofInventoryDetails"/>
  <link:calculationLink xlink:role="http://www.corcept.com/role/CompositionofCertainBalanceSheetItemsScheduleofCompositionofInventoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_cort_InventoryCurrentNoncurrent_62491bce-59b4-4415-9f22-f41ae63bf322" xlink:href="cort-20220331.xsd#cort_InventoryCurrentNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_cort_InventoryWorkInProcessCurrentAndNoncurrent_b3ecde4d-012c-402e-8404-2498abf581bc" xlink:href="cort-20220331.xsd#cort_InventoryWorkInProcessCurrentAndNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_cort_InventoryCurrentNoncurrent_62491bce-59b4-4415-9f22-f41ae63bf322" xlink:to="loc_cort_InventoryWorkInProcessCurrentAndNoncurrent_b3ecde4d-012c-402e-8404-2498abf581bc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cort_InventoryFinishedGoodsCurrentAndNoncurrent_d73e53ce-fe2e-4ff6-acac-c556c1363a4f" xlink:href="cort-20220331.xsd#cort_InventoryFinishedGoodsCurrentAndNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_cort_InventoryCurrentNoncurrent_62491bce-59b4-4415-9f22-f41ae63bf322" xlink:to="loc_cort_InventoryFinishedGoodsCurrentAndNoncurrent_d73e53ce-fe2e-4ff6-acac-c556c1363a4f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.corcept.com/role/CompositionofCertainBalanceSheetItemsScheduleofCompositionofInventoryDetails_1" xlink:type="simple" xlink:href="cort-20220331.xsd#CompositionofCertainBalanceSheetItemsScheduleofCompositionofInventoryDetails_1"/>
  <link:calculationLink xlink:role="http://www.corcept.com/role/CompositionofCertainBalanceSheetItemsScheduleofCompositionofInventoryDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_cort_InventoryCurrentNoncurrent_5d6052bc-29c0-4aed-8b6b-76916ed82dd3" xlink:href="cort-20220331.xsd#cort_InventoryCurrentNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent_6f689b67-4b76-4a07-9cf4-4ba49d60052a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_cort_InventoryCurrentNoncurrent_5d6052bc-29c0-4aed-8b6b-76916ed82dd3" xlink:to="loc_us-gaap_InventoryNoncurrent_6f689b67-4b76-4a07-9cf4-4ba49d60052a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_d0ee67af-0763-47c1-afe8-633f85ad3ad5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_cort_InventoryCurrentNoncurrent_5d6052bc-29c0-4aed-8b6b-76916ed82dd3" xlink:to="loc_us-gaap_InventoryNet_d0ee67af-0763-47c1-afe8-633f85ad3ad5" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.corcept.com/role/CompositionofCertainBalanceSheetItemsScheduleofPropertyandEquipmentDetails" xlink:type="simple" xlink:href="cort-20220331.xsd#CompositionofCertainBalanceSheetItemsScheduleofPropertyandEquipmentDetails"/>
  <link:calculationLink xlink:role="http://www.corcept.com/role/CompositionofCertainBalanceSheetItemsScheduleofPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_2c3597cd-ced2-4eb9-9cae-e851861f33dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_7c0ce899-342f-471a-a996-4a40958bc629" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_2c3597cd-ced2-4eb9-9cae-e851861f33dc" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_7c0ce899-342f-471a-a996-4a40958bc629" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_8294e924-609a-48f2-ada1-457bba830760" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_2c3597cd-ced2-4eb9-9cae-e851861f33dc" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_8294e924-609a-48f2-ada1-457bba830760" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.corcept.com/role/CompositionofCertainBalanceSheetItemsScheduleofOtherAccruedLiabilitiesDetails" xlink:type="simple" xlink:href="cort-20220331.xsd#CompositionofCertainBalanceSheetItemsScheduleofOtherAccruedLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.corcept.com/role/CompositionofCertainBalanceSheetItemsScheduleofOtherAccruedLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_a41c61bd-10df-43ef-a314-bc8bc1a359f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_cort_AccruedGovernmentRebateCurrent_d99753ba-b829-4ad0-bb1d-33cabb84c4a4" xlink:href="cort-20220331.xsd#cort_AccruedGovernmentRebateCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_a41c61bd-10df-43ef-a314-bc8bc1a359f5" xlink:to="loc_cort_AccruedGovernmentRebateCurrent_d99753ba-b829-4ad0-bb1d-33cabb84c4a4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_068ef0ea-0d77-4703-818e-ee7ec5e4e75c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_a41c61bd-10df-43ef-a314-bc8bc1a359f5" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent_068ef0ea-0d77-4703-818e-ee7ec5e4e75c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_a69b4cbe-f3e4-4d02-bc8a-420179c1ebbb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_a41c61bd-10df-43ef-a314-bc8bc1a359f5" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_a69b4cbe-f3e4-4d02-bc8a-420179c1ebbb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cort_AccruedLegalFeesCurrent_96a9bd9a-b11f-4eb6-88f6-526f9b1c9b3a" xlink:href="cort-20220331.xsd#cort_AccruedLegalFeesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_a41c61bd-10df-43ef-a314-bc8bc1a359f5" xlink:to="loc_cort_AccruedLegalFeesCurrent_96a9bd9a-b11f-4eb6-88f6-526f9b1c9b3a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedMarketingCostsCurrent_42ae98a9-7582-45be-9707-6c9db61b85cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedMarketingCostsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_a41c61bd-10df-43ef-a314-bc8bc1a359f5" xlink:to="loc_us-gaap_AccruedMarketingCostsCurrent_42ae98a9-7582-45be-9707-6c9db61b85cd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_2c795c70-71dd-4f22-b661-db33d3c315d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_a41c61bd-10df-43ef-a314-bc8bc1a359f5" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_2c795c70-71dd-4f22-b661-db33d3c315d7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_89f8533c-5b6d-43f6-b4cb-8a657b572fbc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_a41c61bd-10df-43ef-a314-bc8bc1a359f5" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_89f8533c-5b6d-43f6-b4cb-8a657b572fbc" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.corcept.com/role/AvailableforSaleSecuritiesandFairValueMeasurementsScheduleofAvailableforSaleSecuritiesDetails" xlink:type="simple" xlink:href="cort-20220331.xsd#AvailableforSaleSecuritiesandFairValueMeasurementsScheduleofAvailableforSaleSecuritiesDetails"/>
  <link:calculationLink xlink:role="http://www.corcept.com/role/AvailableforSaleSecuritiesandFairValueMeasurementsScheduleofAvailableforSaleSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_68750825-09c2-4b6c-bd5a-7e70978fedd6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_d4663ec4-696e-45cb-a5fc-97b7dc18529f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_68750825-09c2-4b6c-bd5a-7e70978fedd6" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_d4663ec4-696e-45cb-a5fc-97b7dc18529f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_f949c6b5-1c89-43cc-b186-492f5b2f9426" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_68750825-09c2-4b6c-bd5a-7e70978fedd6" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_f949c6b5-1c89-43cc-b186-492f5b2f9426" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cort_AvailableForSaleSecuritiesIncludingCashEquivalents_0fcc6c20-9ee2-4817-82be-4c0af0201ac5" xlink:href="cort-20220331.xsd#cort_AvailableForSaleSecuritiesIncludingCashEquivalents"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_68750825-09c2-4b6c-bd5a-7e70978fedd6" xlink:to="loc_cort_AvailableForSaleSecuritiesIncludingCashEquivalents_0fcc6c20-9ee2-4817-82be-4c0af0201ac5" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.corcept.com/role/LeasesFutureMinimumLeasePaymentsDetails" xlink:type="simple" xlink:href="cort-20220331.xsd#LeasesFutureMinimumLeasePaymentsDetails"/>
  <link:calculationLink xlink:role="http://www.corcept.com/role/LeasesFutureMinimumLeasePaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0e5fa468-4d04-41d4-bc5d-823c004a88d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_717baa27-dcc8-407f-a154-7d4cc79c77be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0e5fa468-4d04-41d4-bc5d-823c004a88d2" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_717baa27-dcc8-407f-a154-7d4cc79c77be" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_6e444b39-89d6-4711-96cb-8f7520e8f441" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0e5fa468-4d04-41d4-bc5d-823c004a88d2" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_6e444b39-89d6-4711-96cb-8f7520e8f441" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.corcept.com/role/LeasesFutureMinimumLeasePaymentsDetails_1" xlink:type="simple" xlink:href="cort-20220331.xsd#LeasesFutureMinimumLeasePaymentsDetails_1"/>
  <link:calculationLink xlink:role="http://www.corcept.com/role/LeasesFutureMinimumLeasePaymentsDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2dfbc037-e489-4ab1-a0e0-32d6cef6daa7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_499d1daf-e2a5-4794-bb1f-700e1bd0bf62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2dfbc037-e489-4ab1-a0e0-32d6cef6daa7" xlink:to="loc_us-gaap_OperatingLeaseLiability_499d1daf-e2a5-4794-bb1f-700e1bd0bf62" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_dbe42267-6cad-4794-9319-9428f65519cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2dfbc037-e489-4ab1-a0e0-32d6cef6daa7" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_dbe42267-6cad-4794-9319-9428f65519cc" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.corcept.com/role/StockholdersEquitySummaryofStockBasedCompensationDetails" xlink:type="simple" xlink:href="cort-20220331.xsd#StockholdersEquitySummaryofStockBasedCompensationDetails"/>
  <link:calculationLink xlink:role="http://www.corcept.com/role/StockholdersEquitySummaryofStockBasedCompensationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1_b335fac2-c935-4690-b2f6-983a18e2b7ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_bdeaf54e-129d-4699-a891-c84ed7d23f55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1_b335fac2-c935-4690-b2f6-983a18e2b7ba" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_bdeaf54e-129d-4699-a891-c84ed7d23f55" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_ffac3c41-216c-4228-b02e-92df7845cf8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1_b335fac2-c935-4690-b2f6-983a18e2b7ba" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_ffac3c41-216c-4228-b02e-92df7845cf8e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.corcept.com/role/NetIncomePerShareScheduleofComputationofNetIncomePerShareDetails" xlink:type="simple" xlink:href="cort-20220331.xsd#NetIncomePerShareScheduleofComputationofNetIncomePerShareDetails"/>
  <link:calculationLink xlink:role="http://www.corcept.com/role/NetIncomePerShareScheduleofComputationofNetIncomePerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_0037575c-29d7-4686-91eb-596c4f57fe9b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_754cca8b-7397-4b0b-b6a1-6d062f13bf76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_0037575c-29d7-4686-91eb-596c4f57fe9b" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_754cca8b-7397-4b0b-b6a1-6d062f13bf76" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_5cf1707b-192b-4202-80b4-f497c0f5b7c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_0037575c-29d7-4686-91eb-596c4f57fe9b" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_5cf1707b-192b-4202-80b4-f497c0f5b7c2" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>cort-20220331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:e53d3b2d-fdb0-4be1-948b-2f6fb33fb115,g:87e34f93-b135-45b2-b829-febf6d6a95d5-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="cort-20220331.xsd#CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"/>
  <link:definitionLink xlink:role="http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="extended" id="i3838a36a006a40d6b4d96c1b962ab676_CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_2d210720-6e88-4ded-8724-f878834a1ace" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_77761aef-c366-4f37-9edd-e62278c1a2ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2d210720-6e88-4ded-8724-f878834a1ace" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_77761aef-c366-4f37-9edd-e62278c1a2ab" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_e01a19be-ce19-4905-80b5-9c876d0fc033" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_77761aef-c366-4f37-9edd-e62278c1a2ab" xlink:to="loc_us-gaap_SharesOutstanding_e01a19be-ce19-4905-80b5-9c876d0fc033" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_1d1f423c-d1d1-4c6e-bb89-ab493bf24b79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_77761aef-c366-4f37-9edd-e62278c1a2ab" xlink:to="loc_us-gaap_StockholdersEquity_1d1f423c-d1d1-4c6e-bb89-ab493bf24b79" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_597569b7-6e60-4b22-a9d2-b50a8d2146ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_77761aef-c366-4f37-9edd-e62278c1a2ab" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_597569b7-6e60-4b22-a9d2-b50a8d2146ae" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_9e4d263b-4d7b-449a-a307-20d6dbb90afb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_77761aef-c366-4f37-9edd-e62278c1a2ab" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_9e4d263b-4d7b-449a-a307-20d6dbb90afb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_40680155-9c56-47f2-8f2f-ea013c111df6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_77761aef-c366-4f37-9edd-e62278c1a2ab" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_40680155-9c56-47f2-8f2f-ea013c111df6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_ee7da8c1-f591-45b7-b2fd-4af0946272ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_77761aef-c366-4f37-9edd-e62278c1a2ab" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_ee7da8c1-f591-45b7-b2fd-4af0946272ff" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_5cc998b1-46b5-4ad3-a2d6-6eb153c87329" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_77761aef-c366-4f37-9edd-e62278c1a2ab" xlink:to="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_5cc998b1-46b5-4ad3-a2d6-6eb153c87329" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_0657f7e1-f031-4b3f-9743-38ac821924ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_77761aef-c366-4f37-9edd-e62278c1a2ab" xlink:to="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_0657f7e1-f031-4b3f-9743-38ac821924ee" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_51e19c31-3e7e-417c-977b-4f52b345c0fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_77761aef-c366-4f37-9edd-e62278c1a2ab" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_51e19c31-3e7e-417c-977b-4f52b345c0fc" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss_fbb3a327-229d-4257-a821-24e704bf5902" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_77761aef-c366-4f37-9edd-e62278c1a2ab" xlink:to="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss_fbb3a327-229d-4257-a821-24e704bf5902" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_cf8b0396-e0c7-4a41-a755-6a7604cb669d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_77761aef-c366-4f37-9edd-e62278c1a2ab" xlink:to="loc_us-gaap_NetIncomeLoss_cf8b0396-e0c7-4a41-a755-6a7604cb669d" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_905b6b56-c69f-493d-b66e-00b596ffbce0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_14c65718-b123-44fe-944e-2b771c2ad9e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_caa328a4-3027-44c0-9d2b-48af2b133d6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_2d210720-6e88-4ded-8724-f878834a1ace" xlink:to="loc_us-gaap_StatementTable_caa328a4-3027-44c0-9d2b-48af2b133d6b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_c5790f51-c098-4a2e-8872-3b4ff94055ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_caa328a4-3027-44c0-9d2b-48af2b133d6b" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_c5790f51-c098-4a2e-8872-3b4ff94055ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_c5790f51-c098-4a2e-8872-3b4ff94055ba_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_c5790f51-c098-4a2e-8872-3b4ff94055ba" xlink:to="loc_us-gaap_EquityComponentDomain_c5790f51-c098-4a2e-8872-3b4ff94055ba_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_4d961eb4-47d7-4575-80fa-12bec1624228" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_c5790f51-c098-4a2e-8872-3b4ff94055ba" xlink:to="loc_us-gaap_EquityComponentDomain_4d961eb4-47d7-4575-80fa-12bec1624228" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_49df7d06-a6c2-4a62-82f4-d4d9369f316b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_4d961eb4-47d7-4575-80fa-12bec1624228" xlink:to="loc_us-gaap_CommonStockMember_49df7d06-a6c2-4a62-82f4-d4d9369f316b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_e24b727d-3ac0-45ac-9af2-cfee2dc93e88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_4d961eb4-47d7-4575-80fa-12bec1624228" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_e24b727d-3ac0-45ac-9af2-cfee2dc93e88" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_7638f29f-772a-4595-b91a-8f4570cf0249" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_4d961eb4-47d7-4575-80fa-12bec1624228" xlink:to="loc_us-gaap_TreasuryStockMember_7638f29f-772a-4595-b91a-8f4570cf0249" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_f337778f-f339-4426-9b0a-e0f3731def86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_4d961eb4-47d7-4575-80fa-12bec1624228" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_f337778f-f339-4426-9b0a-e0f3731def86" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_2d80e94c-1535-40cc-ae1f-4eb27892c21d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_4d961eb4-47d7-4575-80fa-12bec1624228" xlink:to="loc_us-gaap_RetainedEarningsMember_2d80e94c-1535-40cc-ae1f-4eb27892c21d" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.corcept.com/role/CompositionofCertainBalanceSheetItemsScheduleofPropertyandEquipmentDetails" xlink:type="simple" xlink:href="cort-20220331.xsd#CompositionofCertainBalanceSheetItemsScheduleofPropertyandEquipmentDetails"/>
  <link:definitionLink xlink:role="http://www.corcept.com/role/CompositionofCertainBalanceSheetItemsScheduleofPropertyandEquipmentDetails" xlink:type="extended" id="ic2237452801244cbb41ef5d6b39d51db_CompositionofCertainBalanceSheetItemsScheduleofPropertyandEquipmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2b4aaae9-77c5-47f4-8d11-22c23f457358" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_0dc76f2c-8477-41bb-b74d-e0617d60aed5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2b4aaae9-77c5-47f4-8d11-22c23f457358" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_0dc76f2c-8477-41bb-b74d-e0617d60aed5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_948a1ea9-dc38-4f74-a030-cfbf96f9cb03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2b4aaae9-77c5-47f4-8d11-22c23f457358" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_948a1ea9-dc38-4f74-a030-cfbf96f9cb03" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_4c9da5fc-15a2-431b-8b7b-6ad62601a1af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2b4aaae9-77c5-47f4-8d11-22c23f457358" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_4c9da5fc-15a2-431b-8b7b-6ad62601a1af" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2070a378-5042-47f3-ac06-f8417bb71b44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2b4aaae9-77c5-47f4-8d11-22c23f457358" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2070a378-5042-47f3-ac06-f8417bb71b44" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_cort_LongLivedTangibleAssetAxis_0e11dc2e-ba00-4efd-bcf6-a4893d5c81f6" xlink:href="cort-20220331.xsd#cort_LongLivedTangibleAssetAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2070a378-5042-47f3-ac06-f8417bb71b44" xlink:to="loc_cort_LongLivedTangibleAssetAxis_0e11dc2e-ba00-4efd-bcf6-a4893d5c81f6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cort_LongLivedTangibleAssetDomain_0e11dc2e-ba00-4efd-bcf6-a4893d5c81f6_default" xlink:href="cort-20220331.xsd#cort_LongLivedTangibleAssetDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_cort_LongLivedTangibleAssetAxis_0e11dc2e-ba00-4efd-bcf6-a4893d5c81f6" xlink:to="loc_cort_LongLivedTangibleAssetDomain_0e11dc2e-ba00-4efd-bcf6-a4893d5c81f6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cort_LongLivedTangibleAssetDomain_00b47edf-8d31-4804-9389-e0074eb8bd10" xlink:href="cort-20220331.xsd#cort_LongLivedTangibleAssetDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cort_LongLivedTangibleAssetAxis_0e11dc2e-ba00-4efd-bcf6-a4893d5c81f6" xlink:to="loc_cort_LongLivedTangibleAssetDomain_00b47edf-8d31-4804-9389-e0074eb8bd10" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_13b21440-793f-42a9-ae7f-a5a8da9ed2e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cort_LongLivedTangibleAssetDomain_00b47edf-8d31-4804-9389-e0074eb8bd10" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_13b21440-793f-42a9-ae7f-a5a8da9ed2e2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_1643bffe-17ac-4df6-9853-a6582de4811b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cort_LongLivedTangibleAssetDomain_00b47edf-8d31-4804-9389-e0074eb8bd10" xlink:to="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_1643bffe-17ac-4df6-9853-a6582de4811b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_556be540-7539-48d8-8f69-505d4f4f0f7e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cort_LongLivedTangibleAssetDomain_00b47edf-8d31-4804-9389-e0074eb8bd10" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_556be540-7539-48d8-8f69-505d4f4f0f7e" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.corcept.com/role/AvailableforSaleSecuritiesandFairValueMeasurementsSummaryoftheClassificationofAvailableforSaleSecuritiesinCondensedConsolidatedBalanceSheetsDetails" xlink:type="simple" xlink:href="cort-20220331.xsd#AvailableforSaleSecuritiesandFairValueMeasurementsSummaryoftheClassificationofAvailableforSaleSecuritiesinCondensedConsolidatedBalanceSheetsDetails"/>
  <link:definitionLink xlink:role="http://www.corcept.com/role/AvailableforSaleSecuritiesandFairValueMeasurementsSummaryoftheClassificationofAvailableforSaleSecuritiesinCondensedConsolidatedBalanceSheetsDetails" xlink:type="extended" id="i7b6023b19dd74be4bf7f395920abe9a0_AvailableforSaleSecuritiesandFairValueMeasurementsSummaryoftheClassificationofAvailableforSaleSecuritiesinCondensedConsolidatedBalanceSheetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_bece9060-cdc4-4df6-96e8-cfcfb48951f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_3f5cd1f1-bdec-48d3-ab6a-22f07d5f62ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_bece9060-cdc4-4df6-96e8-cfcfb48951f3" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_3f5cd1f1-bdec-48d3-ab6a-22f07d5f62ad" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_c1a57f78-d14a-4855-bfcc-82a303bdf121" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_bece9060-cdc4-4df6-96e8-cfcfb48951f3" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_c1a57f78-d14a-4855-bfcc-82a303bdf121" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_55eeb95c-2945-4d0b-aef4-cc81256274b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_c1a57f78-d14a-4855-bfcc-82a303bdf121" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_55eeb95c-2945-4d0b-aef4-cc81256274b1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_55eeb95c-2945-4d0b-aef4-cc81256274b1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_55eeb95c-2945-4d0b-aef4-cc81256274b1" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_55eeb95c-2945-4d0b-aef4-cc81256274b1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_3e2e015d-38b0-4834-a74f-277e3e26374c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_55eeb95c-2945-4d0b-aef4-cc81256274b1" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_3e2e015d-38b0-4834-a74f-277e3e26374c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsMember_aa6f535c-3557-4dcd-89bd-9fa6d2ef9c3b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_3e2e015d-38b0-4834-a74f-277e3e26374c" xlink:to="loc_us-gaap_CashEquivalentsMember_aa6f535c-3557-4dcd-89bd-9fa6d2ef9c3b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cort_ShortTermMarketableSecuritiesMember_82f77950-1391-4bbb-8f1f-ba4a37da83ae" xlink:href="cort-20220331.xsd#cort_ShortTermMarketableSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_3e2e015d-38b0-4834-a74f-277e3e26374c" xlink:to="loc_cort_ShortTermMarketableSecuritiesMember_82f77950-1391-4bbb-8f1f-ba4a37da83ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cort_LongTermMarketableSecuritiesMember_467dde18-a36d-45ea-a7e1-e5a243c83c32" xlink:href="cort-20220331.xsd#cort_LongTermMarketableSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_3e2e015d-38b0-4834-a74f-277e3e26374c" xlink:to="loc_cort_LongTermMarketableSecuritiesMember_467dde18-a36d-45ea-a7e1-e5a243c83c32" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.corcept.com/role/AvailableforSaleSecuritiesandFairValueMeasurementsScheduleofAvailableforSaleSecuritiesDetails" xlink:type="simple" xlink:href="cort-20220331.xsd#AvailableforSaleSecuritiesandFairValueMeasurementsScheduleofAvailableforSaleSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://www.corcept.com/role/AvailableforSaleSecuritiesandFairValueMeasurementsScheduleofAvailableforSaleSecuritiesDetails" xlink:type="extended" id="id5027f1e650b4664aee9034cc3c46ff9_AvailableforSaleSecuritiesandFairValueMeasurementsScheduleofAvailableforSaleSecuritiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e6d7e907-9d15-4462-beef-bac95a02719f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_b4965326-7708-45b8-9ab6-5fb591047bc5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e6d7e907-9d15-4462-beef-bac95a02719f" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_b4965326-7708-45b8-9ab6-5fb591047bc5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_b5b027e2-10d7-4a33-893a-7e68bc393a25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e6d7e907-9d15-4462-beef-bac95a02719f" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_b5b027e2-10d7-4a33-893a-7e68bc393a25" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_11c0101e-9917-4edd-979a-67a4b31947b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e6d7e907-9d15-4462-beef-bac95a02719f" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_11c0101e-9917-4edd-979a-67a4b31947b3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cort_AvailableForSaleSecuritiesIncludingCashEquivalents_48a195b3-36a0-4846-90dc-37c0eda44f68" xlink:href="cort-20220331.xsd#cort_AvailableForSaleSecuritiesIncludingCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e6d7e907-9d15-4462-beef-bac95a02719f" xlink:to="loc_cort_AvailableForSaleSecuritiesIncludingCashEquivalents_48a195b3-36a0-4846-90dc-37c0eda44f68" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_a94aac8d-5f2d-407a-87e8-50d6298f22a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e6d7e907-9d15-4462-beef-bac95a02719f" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_a94aac8d-5f2d-407a-87e8-50d6298f22a5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_e8f329b2-7c67-4615-9ee8-919bccd69c8c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_a94aac8d-5f2d-407a-87e8-50d6298f22a5" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_e8f329b2-7c67-4615-9ee8-919bccd69c8c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_e8f329b2-7c67-4615-9ee8-919bccd69c8c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_e8f329b2-7c67-4615-9ee8-919bccd69c8c" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_e8f329b2-7c67-4615-9ee8-919bccd69c8c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_d79e2dec-f5ee-45b2-b132-e32321f5a115" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_e8f329b2-7c67-4615-9ee8-919bccd69c8c" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_d79e2dec-f5ee-45b2-b132-e32321f5a115" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_d864de19-0cb6-4694-a563-57dab69913a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_d79e2dec-f5ee-45b2-b132-e32321f5a115" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_d864de19-0cb6-4694-a563-57dab69913a8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_8904f777-bf06-4471-84b4-0f5897f224cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_d864de19-0cb6-4694-a563-57dab69913a8" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_8904f777-bf06-4471-84b4-0f5897f224cd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_b32b228e-e5a3-4241-a7c0-5bee18a8fb29" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_a94aac8d-5f2d-407a-87e8-50d6298f22a5" xlink:to="loc_us-gaap_FinancialInstrumentAxis_b32b228e-e5a3-4241-a7c0-5bee18a8fb29" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b32b228e-e5a3-4241-a7c0-5bee18a8fb29_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_b32b228e-e5a3-4241-a7c0-5bee18a8fb29" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b32b228e-e5a3-4241-a7c0-5bee18a8fb29_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d5c7fa15-f5f5-4c06-b4f2-d0b2af41b74a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_b32b228e-e5a3-4241-a7c0-5bee18a8fb29" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d5c7fa15-f5f5-4c06-b4f2-d0b2af41b74a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_61dda9b9-71d2-42a8-940a-9a8528ce8aba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d5c7fa15-f5f5-4c06-b4f2-d0b2af41b74a" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_61dda9b9-71d2-42a8-940a-9a8528ce8aba" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_80615319-5fe5-471c-9749-d62beb13e97c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d5c7fa15-f5f5-4c06-b4f2-d0b2af41b74a" xlink:to="loc_us-gaap_CommercialPaperMember_80615319-5fe5-471c-9749-d62beb13e97c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_96b2b216-c875-443d-be43-15caa9f9d91f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d5c7fa15-f5f5-4c06-b4f2-d0b2af41b74a" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_96b2b216-c875-443d-be43-15caa9f9d91f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_03c92325-d5d9-4399-87b0-edd5746b6ae1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d5c7fa15-f5f5-4c06-b4f2-d0b2af41b74a" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_03c92325-d5d9-4399-87b0-edd5746b6ae1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_20b04007-309f-4634-985d-dfde81af586d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d5c7fa15-f5f5-4c06-b4f2-d0b2af41b74a" xlink:to="loc_us-gaap_MoneyMarketFundsMember_20b04007-309f-4634-985d-dfde81af586d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2a8565ba-c68d-49db-8d4a-93b0840e8d47" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_a94aac8d-5f2d-407a-87e8-50d6298f22a5" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2a8565ba-c68d-49db-8d4a-93b0840e8d47" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2a8565ba-c68d-49db-8d4a-93b0840e8d47_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2a8565ba-c68d-49db-8d4a-93b0840e8d47" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2a8565ba-c68d-49db-8d4a-93b0840e8d47_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b5162aa7-fc22-4c2f-994c-afe40ba686f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2a8565ba-c68d-49db-8d4a-93b0840e8d47" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b5162aa7-fc22-4c2f-994c-afe40ba686f1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_180e7acd-5a0f-409e-998b-e55ab1a20110" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b5162aa7-fc22-4c2f-994c-afe40ba686f1" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_180e7acd-5a0f-409e-998b-e55ab1a20110" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_aef20dbd-1014-4b2e-8d3c-e84166c8f7e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b5162aa7-fc22-4c2f-994c-afe40ba686f1" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_aef20dbd-1014-4b2e-8d3c-e84166c8f7e5" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.corcept.com/role/AvailableforSaleSecuritiesandFairValueMeasurementsNarrativeDetails" xlink:type="simple" xlink:href="cort-20220331.xsd#AvailableforSaleSecuritiesandFairValueMeasurementsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.corcept.com/role/AvailableforSaleSecuritiesandFairValueMeasurementsNarrativeDetails" xlink:type="extended" id="i2eea32200f714b718ae6021434877c23_AvailableforSaleSecuritiesandFairValueMeasurementsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_e0207cad-844e-4a32-9f26-681ebc1108cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_a8ff5493-b5a3-4c8e-9630-9695c5a6dcf5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_e0207cad-844e-4a32-9f26-681ebc1108cb" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_a8ff5493-b5a3-4c8e-9630-9695c5a6dcf5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestReceivableCurrent_d499fd37-115d-49b1-adf1-94b12f476884" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestReceivableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_e0207cad-844e-4a32-9f26-681ebc1108cb" xlink:to="loc_us-gaap_InterestReceivableCurrent_d499fd37-115d-49b1-adf1-94b12f476884" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cort_MarketableSecuritiesMaximumMaturityPeriod_f8581714-bc75-4659-8c49-c90a5cf53c2d" xlink:href="cort-20220331.xsd#cort_MarketableSecuritiesMaximumMaturityPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_e0207cad-844e-4a32-9f26-681ebc1108cb" xlink:to="loc_cort_MarketableSecuritiesMaximumMaturityPeriod_f8581714-bc75-4659-8c49-c90a5cf53c2d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cort_MarketableSecuritiesWeightedAverageMaturityPeriod_289fa606-031e-4389-a6d3-9f0d53903d23" xlink:href="cort-20220331.xsd#cort_MarketableSecuritiesWeightedAverageMaturityPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_e0207cad-844e-4a32-9f26-681ebc1108cb" xlink:to="loc_cort_MarketableSecuritiesWeightedAverageMaturityPeriod_289fa606-031e-4389-a6d3-9f0d53903d23" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cort_LongTermMarketableSecuritiesRemainingMaturity_302660cd-c86e-45f3-8700-2053f8988e8a" xlink:href="cort-20220331.xsd#cort_LongTermMarketableSecuritiesRemainingMaturity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_e0207cad-844e-4a32-9f26-681ebc1108cb" xlink:to="loc_cort_LongTermMarketableSecuritiesRemainingMaturity_302660cd-c86e-45f3-8700-2053f8988e8a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_a0a89187-2d64-4adb-acde-d8956f2e1af0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_e0207cad-844e-4a32-9f26-681ebc1108cb" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_a0a89187-2d64-4adb-acde-d8956f2e1af0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_e467a841-f47f-4862-b518-d1dd83f50faf" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_a0a89187-2d64-4adb-acde-d8956f2e1af0" xlink:to="loc_srt_RangeAxis_e467a841-f47f-4862-b518-d1dd83f50faf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e467a841-f47f-4862-b518-d1dd83f50faf_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_e467a841-f47f-4862-b518-d1dd83f50faf" xlink:to="loc_srt_RangeMember_e467a841-f47f-4862-b518-d1dd83f50faf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_cc1352f7-e187-4a51-a5dc-15e24d39d2b9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_e467a841-f47f-4862-b518-d1dd83f50faf" xlink:to="loc_srt_RangeMember_cc1352f7-e187-4a51-a5dc-15e24d39d2b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_a77faac1-f7d1-432c-a13d-0a92e6da415e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_cc1352f7-e187-4a51-a5dc-15e24d39d2b9" xlink:to="loc_srt_MinimumMember_a77faac1-f7d1-432c-a13d-0a92e6da415e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_fea5b4ef-b879-4072-87cc-82b04aace081" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_cc1352f7-e187-4a51-a5dc-15e24d39d2b9" xlink:to="loc_srt_MaximumMember_fea5b4ef-b879-4072-87cc-82b04aace081" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.corcept.com/role/StockholdersEquityNarrativeDetails" xlink:type="simple" xlink:href="cort-20220331.xsd#StockholdersEquityNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.corcept.com/role/StockholdersEquityNarrativeDetails" xlink:type="extended" id="i54cb84df2ce7497d93295dedc5d31ece_StockholdersEquityNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_009ea75b-ed09-4097-bb5a-70debc64f60e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_cort_NumberOfStockOptionPlans_d11f1d63-def3-4044-9adc-8f57fdea2ae2" xlink:href="cort-20220331.xsd#cort_NumberOfStockOptionPlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_009ea75b-ed09-4097-bb5a-70debc64f60e" xlink:to="loc_cort_NumberOfStockOptionPlans_d11f1d63-def3-4044-9adc-8f57fdea2ae2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_db229ca3-ac20-46cc-80d3-bf5376a430d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_009ea75b-ed09-4097-bb5a-70debc64f60e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_db229ca3-ac20-46cc-80d3-bf5376a430d6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_c5ad446e-8a0c-4e60-b0e3-def4c0688ba6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_009ea75b-ed09-4097-bb5a-70debc64f60e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_c5ad446e-8a0c-4e60-b0e3-def4c0688ba6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_2f738fb5-a3ba-43ca-8c89-6b791cc5ce18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_009ea75b-ed09-4097-bb5a-70debc64f60e" xlink:to="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_2f738fb5-a3ba-43ca-8c89-6b791cc5ce18" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_2f53dc99-4e02-4963-a0d8-2e93445b9209" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_009ea75b-ed09-4097-bb5a-70debc64f60e" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_2f53dc99-4e02-4963-a0d8-2e93445b9209" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_2acc51cd-fd54-41af-9297-bf76b3f1fd34" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_009ea75b-ed09-4097-bb5a-70debc64f60e" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_2acc51cd-fd54-41af-9297-bf76b3f1fd34" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_620014fe-37f0-47ae-9f2f-6af8acff7d29" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_009ea75b-ed09-4097-bb5a-70debc64f60e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_620014fe-37f0-47ae-9f2f-6af8acff7d29" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_98b7a29b-27b4-4472-af8b-7fae9d7a242b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_009ea75b-ed09-4097-bb5a-70debc64f60e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_98b7a29b-27b4-4472-af8b-7fae9d7a242b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_d5292aa2-e281-4c97-b77f-d441208df9f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_009ea75b-ed09-4097-bb5a-70debc64f60e" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_d5292aa2-e281-4c97-b77f-d441208df9f5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_0056decd-64a3-428d-a7af-93e2203e4a1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_d5292aa2-e281-4c97-b77f-d441208df9f5" xlink:to="loc_us-gaap_PlanNameAxis_0056decd-64a3-428d-a7af-93e2203e4a1f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_0056decd-64a3-428d-a7af-93e2203e4a1f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_0056decd-64a3-428d-a7af-93e2203e4a1f" xlink:to="loc_us-gaap_PlanNameDomain_0056decd-64a3-428d-a7af-93e2203e4a1f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_d39f0151-dbf7-4f28-a910-eea3957aeccc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_0056decd-64a3-428d-a7af-93e2203e4a1f" xlink:to="loc_us-gaap_PlanNameDomain_d39f0151-dbf7-4f28-a910-eea3957aeccc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cort_StockOptionsFiscalTwentyTwelvePlanMember_351a9b14-29ab-46a4-a013-dc8fdd4ece2f" xlink:href="cort-20220331.xsd#cort_StockOptionsFiscalTwentyTwelvePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_d39f0151-dbf7-4f28-a910-eea3957aeccc" xlink:to="loc_cort_StockOptionsFiscalTwentyTwelvePlanMember_351a9b14-29ab-46a4-a013-dc8fdd4ece2f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_c0442146-394c-4c01-8f95-2c221ce05cd7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_d5292aa2-e281-4c97-b77f-d441208df9f5" xlink:to="loc_us-gaap_AwardTypeAxis_c0442146-394c-4c01-8f95-2c221ce05cd7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c0442146-394c-4c01-8f95-2c221ce05cd7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_c0442146-394c-4c01-8f95-2c221ce05cd7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c0442146-394c-4c01-8f95-2c221ce05cd7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_16d665df-c07c-4bad-8d1f-524ee72b758e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_c0442146-394c-4c01-8f95-2c221ce05cd7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_16d665df-c07c-4bad-8d1f-524ee72b758e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_089ace95-43ee-4615-a39d-e597b8205915" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_16d665df-c07c-4bad-8d1f-524ee72b758e" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_089ace95-43ee-4615-a39d-e597b8205915" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.corcept.com/role/StockholdersEquitySummaryofStockBasedCompensationDetails" xlink:type="simple" xlink:href="cort-20220331.xsd#StockholdersEquitySummaryofStockBasedCompensationDetails"/>
  <link:definitionLink xlink:role="http://www.corcept.com/role/StockholdersEquitySummaryofStockBasedCompensationDetails" xlink:type="extended" id="i62e8b2e3d3e74da4905ef8860e5a286a_StockholdersEquitySummaryofStockBasedCompensationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_ea9bf141-4c3d-4784-9446-aa5e74d91905" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_01f55bf4-9394-49ab-b8c2-b15cf978ecfa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_ea9bf141-4c3d-4784-9446-aa5e74d91905" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_01f55bf4-9394-49ab-b8c2-b15cf978ecfa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_594037e1-0215-4981-84e4-e2cf286d1b3e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_ea9bf141-4c3d-4784-9446-aa5e74d91905" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_594037e1-0215-4981-84e4-e2cf286d1b3e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1_84ac2f61-709d-44c6-a2e8-ee0b389fe0d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_ea9bf141-4c3d-4784-9446-aa5e74d91905" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1_84ac2f61-709d-44c6-a2e8-ee0b389fe0d6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_fec0a1ba-117d-4a84-b5a1-4f4cef2c2ca5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_ea9bf141-4c3d-4784-9446-aa5e74d91905" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_fec0a1ba-117d-4a84-b5a1-4f4cef2c2ca5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_e5b66c43-1dd8-453a-8b82-4dbe28d744f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_fec0a1ba-117d-4a84-b5a1-4f4cef2c2ca5" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_e5b66c43-1dd8-453a-8b82-4dbe28d744f6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_e5b66c43-1dd8-453a-8b82-4dbe28d744f6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_e5b66c43-1dd8-453a-8b82-4dbe28d744f6" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_e5b66c43-1dd8-453a-8b82-4dbe28d744f6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_c0b3fc6b-ae31-4286-abae-2b88e759417a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_e5b66c43-1dd8-453a-8b82-4dbe28d744f6" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_c0b3fc6b-ae31-4286-abae-2b88e759417a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_02fad08f-6b8d-4df0-b4e2-b8096ec85c16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_c0b3fc6b-ae31-4286-abae-2b88e759417a" xlink:to="loc_us-gaap_CostOfSalesMember_02fad08f-6b8d-4df0-b4e2-b8096ec85c16" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_f2904e81-b3a9-4489-894b-a2d2b5b027b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_c0b3fc6b-ae31-4286-abae-2b88e759417a" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_f2904e81-b3a9-4489-894b-a2d2b5b027b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_b9df44e6-a129-4fa4-af9f-04e73df0bd53" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_c0b3fc6b-ae31-4286-abae-2b88e759417a" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_b9df44e6-a129-4fa4-af9f-04e73df0bd53" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.corcept.com/role/NetIncomePerShareNarrativeDetails" xlink:type="simple" xlink:href="cort-20220331.xsd#NetIncomePerShareNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.corcept.com/role/NetIncomePerShareNarrativeDetails" xlink:type="extended" id="i81acdaacf1cd490f83a046d127fae551_NetIncomePerShareNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_85884fc3-ee91-4ff2-8a27-7ae255fb684c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_ce1e5462-03f2-4147-83a5-873978375e2a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_85884fc3-ee91-4ff2-8a27-7ae255fb684c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_ce1e5462-03f2-4147-83a5-873978375e2a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_d73a3567-3674-4fed-9820-1978da0e5cfa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_85884fc3-ee91-4ff2-8a27-7ae255fb684c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_d73a3567-3674-4fed-9820-1978da0e5cfa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c89b5184-26e1-480f-b316-dce36649241c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_85884fc3-ee91-4ff2-8a27-7ae255fb684c" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c89b5184-26e1-480f-b316-dce36649241c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_bae75ea0-3214-4f60-84dc-e0301dd234ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_85884fc3-ee91-4ff2-8a27-7ae255fb684c" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_bae75ea0-3214-4f60-84dc-e0301dd234ef" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_4cd74394-1cde-4d30-b7fb-85f4ca24ddc7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_bae75ea0-3214-4f60-84dc-e0301dd234ef" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_4cd74394-1cde-4d30-b7fb-85f4ca24ddc7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4cd74394-1cde-4d30-b7fb-85f4ca24ddc7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_4cd74394-1cde-4d30-b7fb-85f4ca24ddc7" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4cd74394-1cde-4d30-b7fb-85f4ca24ddc7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_d892c271-272c-4924-a5cf-1f9425e99079" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_4cd74394-1cde-4d30-b7fb-85f4ca24ddc7" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_d892c271-272c-4924-a5cf-1f9425e99079" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_dcc2b9a5-b1a9-403b-b051-02d9080a49a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_d892c271-272c-4924-a5cf-1f9425e99079" xlink:to="loc_us-gaap_EmployeeStockOptionMember_dcc2b9a5-b1a9-403b-b051-02d9080a49a8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_1a012e09-92ad-4b12-a683-55467f505c77" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_d892c271-272c-4924-a5cf-1f9425e99079" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_1a012e09-92ad-4b12-a683-55467f505c77" xlink:type="arc" order="1"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>cort-20220331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:e53d3b2d-fdb0-4be1-948b-2f6fb33fb115,g:87e34f93-b135-45b2-b829-febf6d6a95d5-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_cort_StockOptionsFiscalTwentyTwelvePlanMember_ffc1f6b4-2c8e-44c1-89ff-d1d32550bfef_terseLabel_en-US" xlink:label="lab_cort_StockOptionsFiscalTwentyTwelvePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2012 Equity Incentive Award Plan</link:label>
    <link:label id="lab_cort_StockOptionsFiscalTwentyTwelvePlanMember_label_en-US" xlink:label="lab_cort_StockOptionsFiscalTwentyTwelvePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options Fiscal Twenty Twelve Plan [Member]</link:label>
    <link:label id="lab_cort_StockOptionsFiscalTwentyTwelvePlanMember_documentation_en-US" xlink:label="lab_cort_StockOptionsFiscalTwentyTwelvePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options fiscal 2012 plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cort_StockOptionsFiscalTwentyTwelvePlanMember" xlink:href="cort-20220331.xsd#cort_StockOptionsFiscalTwentyTwelvePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cort_StockOptionsFiscalTwentyTwelvePlanMember" xlink:to="lab_cort_StockOptionsFiscalTwentyTwelvePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_d293f2b3-48be-446a-b6e6-43c06a617523_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_f6e0919b-3715-49ad-8814-9811e530cb1e_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosure:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_eaf983c3-1da8-413d-a1b9-ea2d6e884706_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term operating lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5c6c5bd3-336a-4ec2-bcaa-ae71dd31c11f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_fc8c451b-8370-4d9f-b885-eae8ce185264_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_804c06c2-71b5-49b4-9be7-6682dade8ad9_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_9ad51033-72f1-4323-8c96-65bde39ab5e5_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_4ac4779d-5bfe-4f1f-863e-d48f0aa41f36_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use asset</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_7b20cdaf-0e45-40b9-87ab-2777f701fcc7_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use asset</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_b24fde7b-94ea-484b-876d-c5d326cc785b_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_8f83b11f-5981-4d74-8805-4f72b17a1411_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_238edd78-5e92-4aba-bfd6-938ee6401507_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_f5bd1685-7627-4579-bf67-67b436398efc_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_cort_MarketableSecuritiesWeightedAverageMaturityPeriod_286ddfec-80b0-4b3c-b83a-0a02ab5df9d6_terseLabel_en-US" xlink:label="lab_cort_MarketableSecuritiesWeightedAverageMaturityPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average maturity period</link:label>
    <link:label id="lab_cort_MarketableSecuritiesWeightedAverageMaturityPeriod_label_en-US" xlink:label="lab_cort_MarketableSecuritiesWeightedAverageMaturityPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities Weighted Average Maturity Period</link:label>
    <link:label id="lab_cort_MarketableSecuritiesWeightedAverageMaturityPeriod_documentation_en-US" xlink:label="lab_cort_MarketableSecuritiesWeightedAverageMaturityPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities weighted-average maturity period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cort_MarketableSecuritiesWeightedAverageMaturityPeriod" xlink:href="cort-20220331.xsd#cort_MarketableSecuritiesWeightedAverageMaturityPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cort_MarketableSecuritiesWeightedAverageMaturityPeriod" xlink:to="lab_cort_MarketableSecuritiesWeightedAverageMaturityPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_010916cd-7f0b-4805-83aa-12d394395c45_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs)</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_839e07df-ec64-4140-9650-d82a7bfc2883_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cort_AccretionExpenseIncome_47d1f237-d6ce-470e-bf0d-5ac659ce2196_terseLabel_en-US" xlink:label="lab_cort_AccretionExpenseIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of interest income</link:label>
    <link:label id="lab_cort_AccretionExpenseIncome_label_en-US" xlink:label="lab_cort_AccretionExpenseIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion Expense (Income)</link:label>
    <link:label id="lab_cort_AccretionExpenseIncome_documentation_en-US" xlink:label="lab_cort_AccretionExpenseIncome" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion Expense (Income)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cort_AccretionExpenseIncome" xlink:href="cort-20220331.xsd#cort_AccretionExpenseIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cort_AccretionExpenseIncome" xlink:to="lab_cort_AccretionExpenseIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_22384f1c-963e-47d7-85d6-62cc05654c02_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_cort_NumberOfStockOptionPlans_12037940-e833-44af-baf3-9d7b62610805_terseLabel_en-US" xlink:label="lab_cort_NumberOfStockOptionPlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of stock option plans</link:label>
    <link:label id="lab_cort_NumberOfStockOptionPlans_label_en-US" xlink:label="lab_cort_NumberOfStockOptionPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Stock Option Plans</link:label>
    <link:label id="lab_cort_NumberOfStockOptionPlans_documentation_en-US" xlink:label="lab_cort_NumberOfStockOptionPlans" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of stock option plans.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cort_NumberOfStockOptionPlans" xlink:href="cort-20220331.xsd#cort_NumberOfStockOptionPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cort_NumberOfStockOptionPlans" xlink:to="lab_cort_NumberOfStockOptionPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_0a1af2cc-92ca-4dc6-b308-b6554759d653_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_55987bdd-c1c0-494a-9dd7-50ec59a3e38b_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_ac2b475d-0063-4b96-aef4-343e7404da7b_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Treasury securities</link:label>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasurySecuritiesMember" xlink:to="lab_us-gaap_USTreasurySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_3be692aa-6c44-4a80-be0b-0b5b810b46e1_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_07848c89-13bb-4cff-a18f-22b428c52068_terseLabel_en-US" xlink:label="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimate of fair value measurement</link:label>
    <link:label id="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimate of Fair Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:to="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cort_AccruedGovernmentRebateCurrent_7015dc8f-5499-4308-8623-fbe7753e5712_terseLabel_en-US" xlink:label="lab_cort_AccruedGovernmentRebateCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government rebates</link:label>
    <link:label id="lab_cort_AccruedGovernmentRebateCurrent_label_en-US" xlink:label="lab_cort_AccruedGovernmentRebateCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Government Rebate Current</link:label>
    <link:label id="lab_cort_AccruedGovernmentRebateCurrent_documentation_en-US" xlink:label="lab_cort_AccruedGovernmentRebateCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued government rebate current.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cort_AccruedGovernmentRebateCurrent" xlink:href="cort-20220331.xsd#cort_AccruedGovernmentRebateCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cort_AccruedGovernmentRebateCurrent" xlink:to="lab_cort_AccruedGovernmentRebateCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_b62426c0-853c-4cc8-b19c-6da19fde1eff_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_1b803bd2-fd65-440d-8536-bd3ab198c162_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average remaining lease term (months)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_559ed1c7-4ad5-4c6b-afc3-db12e4d50a60_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_0cdb2f30-fcec-4da6-81de-791c94374d96_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation and Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation and Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_388dc90d-81fe-47a4-acc4-61678623fef4_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net decrease in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_cort_NonCashTransactionRecognitionOfRightOfUseAssetAndLeaseLiability_86ce105d-0028-4e7e-9093-04a64865d0bd_terseLabel_en-US" xlink:label="lab_cort_NonCashTransactionRecognitionOfRightOfUseAssetAndLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recognition of right-of-use asset and lease liability</link:label>
    <link:label id="lab_cort_NonCashTransactionRecognitionOfRightOfUseAssetAndLeaseLiability_label_en-US" xlink:label="lab_cort_NonCashTransactionRecognitionOfRightOfUseAssetAndLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Cash Transaction, Recognition Of Right Of Use Asset And Lease Liability</link:label>
    <link:label id="lab_cort_NonCashTransactionRecognitionOfRightOfUseAssetAndLeaseLiability_documentation_en-US" xlink:label="lab_cort_NonCashTransactionRecognitionOfRightOfUseAssetAndLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Cash Transaction, Recognition Of Right Of Use Asset And Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cort_NonCashTransactionRecognitionOfRightOfUseAssetAndLeaseLiability" xlink:href="cort-20220331.xsd#cort_NonCashTransactionRecognitionOfRightOfUseAssetAndLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cort_NonCashTransactionRecognitionOfRightOfUseAssetAndLeaseLiability" xlink:to="lab_cort_NonCashTransactionRecognitionOfRightOfUseAssetAndLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_261a7f9c-8d3a-4686-b22d-0cf18ab07496_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_d4f2f4b5-0ac0-47a6-870f-c3950f0bb2cc_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax (expense) benefit</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_c9b2b80f-1d1b-4f37-ad6a-6d834a5b4582_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax (benefit) expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_8c9ac2b8-9d08-4f54-8110-ead4740e7095_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_16ad43ee-8d66-4d96-9de9-02bdf2e946c7_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade receivables, net of allowances</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_f829e9a3-e0da-4fa3-8512-00eced6edb29_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_35996cda-f8aa-4bf9-985b-c41e0137cdf9_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_c30bb9ba-6de3-4135-aeeb-567b2f1317b7_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_346bd460-767a-4c75-a812-719019609283_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of the classification of available-for-sale securities in condensed consolidated balance sheets</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_6ed37fe6-8103-428e-ac42-3ec426d420df_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_cb944e40-cf9d-4ea0-a3f1-622a5bc8ad65_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_0db0ae89-a271-4a7c-90ca-a6908cff0c91_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_cort_AvailableForSaleSecuritiesIncludingCashEquivalents_22140a35-f699-40e9-bcd1-6d259e775ea7_terseLabel_en-US" xlink:label="lab_cort_AvailableForSaleSecuritiesIncludingCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Fair Value</link:label>
    <link:label id="lab_cort_AvailableForSaleSecuritiesIncludingCashEquivalents_label_en-US" xlink:label="lab_cort_AvailableForSaleSecuritiesIncludingCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available For Sale Securities Including Cash Equivalents</link:label>
    <link:label id="lab_cort_AvailableForSaleSecuritiesIncludingCashEquivalents_documentation_en-US" xlink:label="lab_cort_AvailableForSaleSecuritiesIncludingCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available for sale securities including cash equivalents.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cort_AvailableForSaleSecuritiesIncludingCashEquivalents" xlink:href="cort-20220331.xsd#cort_AvailableForSaleSecuritiesIncludingCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cort_AvailableForSaleSecuritiesIncludingCashEquivalents" xlink:to="lab_cort_AvailableForSaleSecuritiesIncludingCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_90bf63b1-493e-44c7-b0f1-4c66e1f6fd57_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_dcdd2190-1d4f-4d0f-856c-769a74f8e630_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryNet_e104c810-01cb-484c-aed9-32161f089a01_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total inventory classified as current</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_b0d8a09c-9e0b-4e81-a8a8-fe5a9e8b8bba_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_68efbc50-1d3e-44e4-bcf9-9efd21618a30_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_ca79f053-529d-4c45-b9d8-4d2c53dedba2_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from exercise of stock options, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance or Sale of Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_e32b6295-23ad-4d51-a3cd-f9bea5810c38_verboseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average options excluded from the computation of diluted net income per share (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_5c79f82a-a75e-4ce4-95a8-843ab48ca62e_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average discount rate (as a percent)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_e76f8e45-5d4e-4880-9f2c-c0eb2db30ee6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of composition of inventory, current</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_767923b5-81aa-40ab-827f-3ea5f36482c1_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_1578784c-e57f-4c2d-8891-33d80dbcf14d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_label_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:type="arc" order="1"/>
    <link:label id="lab_cort_AvailableForSaleSecuritiesAndFairValueMeasurementsAbstract_c7b0f64a-96df-4683-bf75-74e2105b406d_terseLabel_en-US" xlink:label="lab_cort_AvailableForSaleSecuritiesAndFairValueMeasurementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available For Sale Securities And Fair Value Measurements [Abstract]</link:label>
    <link:label id="lab_cort_AvailableForSaleSecuritiesAndFairValueMeasurementsAbstract_label_en-US" xlink:label="lab_cort_AvailableForSaleSecuritiesAndFairValueMeasurementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available For Sale Securities And Fair Value Measurements [Abstract]</link:label>
    <link:label id="lab_cort_AvailableForSaleSecuritiesAndFairValueMeasurementsAbstract_documentation_en-US" xlink:label="lab_cort_AvailableForSaleSecuritiesAndFairValueMeasurementsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available for sale securities and fair value measurements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cort_AvailableForSaleSecuritiesAndFairValueMeasurementsAbstract" xlink:href="cort-20220331.xsd#cort_AvailableForSaleSecuritiesAndFairValueMeasurementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cort_AvailableForSaleSecuritiesAndFairValueMeasurementsAbstract" xlink:to="lab_cort_AvailableForSaleSecuritiesAndFairValueMeasurementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cort_UnrecognizedTaxBenefitsThatWouldBeOffsetByAChangeInValuationAllowance_3712ebcf-92c2-4620-acb0-d43e10c613c5_terseLabel_en-US" xlink:label="lab_cort_UnrecognizedTaxBenefitsThatWouldBeOffsetByAChangeInValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits that would be offset by a change in valuation allowance</link:label>
    <link:label id="lab_cort_UnrecognizedTaxBenefitsThatWouldBeOffsetByAChangeInValuationAllowance_label_en-US" xlink:label="lab_cort_UnrecognizedTaxBenefitsThatWouldBeOffsetByAChangeInValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits That Would Be Offset By A Change In Valuation Allowance</link:label>
    <link:label id="lab_cort_UnrecognizedTaxBenefitsThatWouldBeOffsetByAChangeInValuationAllowance_documentation_en-US" xlink:label="lab_cort_UnrecognizedTaxBenefitsThatWouldBeOffsetByAChangeInValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits That Would Be Offset By A Change In Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cort_UnrecognizedTaxBenefitsThatWouldBeOffsetByAChangeInValuationAllowance" xlink:href="cort-20220331.xsd#cort_UnrecognizedTaxBenefitsThatWouldBeOffsetByAChangeInValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cort_UnrecognizedTaxBenefitsThatWouldBeOffsetByAChangeInValuationAllowance" xlink:to="lab_cort_UnrecognizedTaxBenefitsThatWouldBeOffsetByAChangeInValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_6dd87224-f596-4ae9-98da-496f97461fa6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average grant date fair value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_934b66b5-aae9-4ca7-bd77-556cd50e2cdb_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_b09e3022-3ad1-4520-b20a-9d3b4f1d88cf_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized loss on available-for-sale investments, net of tax effect of $323 and $61, respectively</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_6be226fe-a6aa-4bec-8856-883d4aa43adf_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_97781305-8370-49aa-8281-90b1f14205a5_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation (loss) gain, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8523214a-3af9-4e4b-b53e-b360f111d0de_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_cort_NumberOfSeriesOfSelectiveCortisolModulators_6f6f2d91-6bfd-4885-a7cd-6996d255a48d_terseLabel_en-US" xlink:label="lab_cort_NumberOfSeriesOfSelectiveCortisolModulators" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of series of selective cortisol modulators</link:label>
    <link:label id="lab_cort_NumberOfSeriesOfSelectiveCortisolModulators_label_en-US" xlink:label="lab_cort_NumberOfSeriesOfSelectiveCortisolModulators" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Series Of Selective Cortisol Modulators</link:label>
    <link:label id="lab_cort_NumberOfSeriesOfSelectiveCortisolModulators_documentation_en-US" xlink:label="lab_cort_NumberOfSeriesOfSelectiveCortisolModulators" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Series Of Selective Cortisol Modulators</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cort_NumberOfSeriesOfSelectiveCortisolModulators" xlink:href="cort-20220331.xsd#cort_NumberOfSeriesOfSelectiveCortisolModulators"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cort_NumberOfSeriesOfSelectiveCortisolModulators" xlink:to="lab_cort_NumberOfSeriesOfSelectiveCortisolModulators" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_680864e7-5b67-4682-b0ae-c6c5f10b0878_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_37a74564-80b6-4df6-838f-82b3e1dd71b4_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_8323b7d6-1d58-42fa-b272-48884151d3a3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of available-for-sale securities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesNoncurrent_0c9e4acc-6b04-4d57-921f-61b3383eda52_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term marketable securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesNoncurrent" xlink:to="lab_us-gaap_MarketableSecuritiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_978e857a-3b32-4a1b-81fe-97896a7b3e66_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedTaxesPayable_ba6c97fe-314f-4834-b3d4-ca5769066b74_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedTaxesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term accrued income taxes</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedTaxesPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedTaxesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Taxes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedTaxesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedTaxesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedTaxesPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedTaxesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_cort_LongTermMarketableSecuritiesMember_f9588cfe-d6b2-4de0-99e2-eb8ae4f22704_terseLabel_en-US" xlink:label="lab_cort_LongTermMarketableSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term marketable securities</link:label>
    <link:label id="lab_cort_LongTermMarketableSecuritiesMember_label_en-US" xlink:label="lab_cort_LongTermMarketableSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long Term Marketable Securities [Member]</link:label>
    <link:label id="lab_cort_LongTermMarketableSecuritiesMember_documentation_en-US" xlink:label="lab_cort_LongTermMarketableSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long Term Marketable Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cort_LongTermMarketableSecuritiesMember" xlink:href="cort-20220331.xsd#cort_LongTermMarketableSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cort_LongTermMarketableSecuritiesMember" xlink:to="lab_cort_LongTermMarketableSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_dbc1b47a-6bca-45e2-ab2c-b50da1635183_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_e2e14a1d-d613-48cf-ba10-10af717bbfc0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grants in period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashEquivalentsMember_1a4571fc-575f-4c1b-8e2b-a663649ab6f8_terseLabel_en-US" xlink:label="lab_us-gaap_CashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_CashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashEquivalentsMember" xlink:to="lab_us-gaap_CashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_a70b718b-388a-4f95-a8d8-2a0ec67ccdd5_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_617aa964-7736-4b74-9aab-fe211d9bb662_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_e49f3921-205b-447e-a747-2479bb5ac51f_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total marketable securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_223bf8e4-d0fc-4020-832d-3b59dce3779b_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_f843a8b6-020a-416c-bfe6-f49f0ad32e11_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_46343389-63b8-4f89-aade-fb1940f93694_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of marketable securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_12f041e1-fb59-4186-9869-2f47fdfec1ba_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_f39915a9-c763-4b59-af2e-c1b18c873411_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_66ba678a-3108-4d01-85c8-bb2ac16871f6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1ee61145-0ad9-46da-9530-e9cd7feb1592_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_cort_InventoryCurrentNoncurrent_e464eace-81c0-4d27-aac0-31c3b31dc35c_totalLabel_en-US" xlink:label="lab_cort_InventoryCurrentNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total inventory</link:label>
    <link:label id="lab_cort_InventoryCurrentNoncurrent_label_en-US" xlink:label="lab_cort_InventoryCurrentNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Current Noncurrent</link:label>
    <link:label id="lab_cort_InventoryCurrentNoncurrent_documentation_en-US" xlink:label="lab_cort_InventoryCurrentNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total inventory.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cort_InventoryCurrentNoncurrent" xlink:href="cort-20220331.xsd#cort_InventoryCurrentNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cort_InventoryCurrentNoncurrent" xlink:to="lab_cort_InventoryCurrentNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_48ad4156-fce4-40ca-b094-e2d7710007cb_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_2bfdaf09-9c3e-4d2f-abb8-d98e41f5876a_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade receivables</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_532a5c6e-c2c1-4d2a-a5a6-5a661d55c6ea_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets obtained in connection with operating lease obligations</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_a26833b9-5c89-4401-93d9-dcd1bc77b499_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of computation of net income per share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_8cfbc4f1-3565-46d8-a0f8-791cdfac8ab5_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_d8ae4f91-b4a8-4997-84ef-82b3d0663327_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_cc99d7c1-ccf5-4d36-b7b9-7de2df14afd7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares purchased to satisfy cost and statutory withholding requirements for net settlement of cashless option exercises</link:label>
    <link:label id="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_891127ca-d801-4ecc-b6b7-6d96977b568e_terseLabel_en-US" xlink:label="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares withheld for tax withholding obligation</link:label>
    <link:label id="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Shares Withheld for Tax Withholding Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_9eb2af08-083e-4822-a045-3665305d5528_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation capitalized in inventory</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Amount Capitalized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_33a9a905-d57b-43fa-908a-9ad368e00867_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_337a60a8-2061-471e-911c-bd4742fe403a_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_3fe181bd-b2a2-4247-b427-93ab05ef1b51_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_0f6d1401-4ae4-41da-8c19-bc71ff82afa2_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_c8a654bf-dc36-4a95-9849-3a383afe77f4_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_72e8cdf5-c182-4cc9-b84e-1a3e0020e05c_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic net income per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_86d0970f-5930-4378-9dce-9b537073ac14_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAbstract_b305ede0-0ac4-4dba-af5c-9af3b002176c_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Numerator:</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAbstract_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAbstract" xlink:to="lab_us-gaap_NetIncomeLossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_e1c1107f-22a1-4532-b1bf-14f5e9d0e86e_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease expenses</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseExpense" xlink:to="lab_us-gaap_OperatingLeaseExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_dd787eee-2888-4412-beab-b9b6ca1504a0_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_4a070e86-7823-45d1-927b-3fc6d97a5758_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_548e0ca2-439f-4575-b9f4-ed97650a2dcc_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Composition of Certain Balance Sheet Items</link:label>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Balance Sheet Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1bcb8a9e-d0f3-4727-b4df-da0cadada200_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation arrangement by share-based payment award, equity instruments other than options, nonvested, number (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease_ead4e728-0d27-4a54-bd73-040373f569d5_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits, period increase</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Period Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosureItemAmountsDomain_8611e6c6-534f-4716-90a3-c8d24c3e2f2f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosureItemAmountsDomain_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:to="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_6ef9a9d4-de2e-4426-b568-1c5cddd4f657_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_7b8e40ac-67bc-44dc-ac58-e36afe12b7db_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and equipment</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_27d8dd8c-e16d-4153-abdd-ae8f8141039e_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of information of leases asset and liabilities</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_0ec50486-279c-427e-884d-47c5fc0f4040_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_ebce69e9-1498-42fa-bdd5-f63f2fabb3bf_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares purchased to satisfy cost and statutory withholding requirements for net settlement of cashless option exercises</link:label>
    <link:label id="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Decrease for Tax Withholding Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_39bf3268-3df7-4bf9-912f-057b42a60a82_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateBondSecuritiesMember_9ba134a0-3b68-4acc-aeed-96b9c444af1a_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateBondSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate bonds</link:label>
    <link:label id="lab_us-gaap_CorporateBondSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateBondSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Bond Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateBondSecuritiesMember" xlink:to="lab_us-gaap_CorporateBondSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_75a15a3e-e756-4934-9879-801abab06ab7_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_58200d23-a62b-4e8a-8c1f-8af2fa9c6590_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average shares used to compute basic net income per share (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_11f86254-b9e3-4197-8e2f-772d074b5b43_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted net income per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_2d995e51-62fc-46cd-9cd1-50924065d255_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_8366abc5-3649-48ee-85b5-58c781b51455_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash amortization of right-of-use asset</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Amortization Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_5083584b-2b15-47f7-a189-18cbd1849513_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_f72acd10-3df0-45a3-9fc5-87b4414efebe_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total comprehensive income</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_09e883d9-2716-4013-96f6-e6286a8ec350_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_c0c4b7f6-c702-47db-aa92-dac72db700cb_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_3e744522-ad5a-475c-8a6c-95faa75a3caa_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_1b94b939-bcb7-412e-ac07-635e99cbaab6_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average shares outstanding used in computing net income per share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_bc980409-e3a8-43c6-9d73-c017ad054a57_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income per share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_8dec68f7-cc33-401b-aa55-5d8fefa0451e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cort_InventoryWorkInProcessCurrentAndNoncurrent_00f479a5-c804-4118-84db-2b14780274df_terseLabel_en-US" xlink:label="lab_cort_InventoryWorkInProcessCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Work in progress</link:label>
    <link:label id="lab_cort_InventoryWorkInProcessCurrentAndNoncurrent_label_en-US" xlink:label="lab_cort_InventoryWorkInProcessCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Work In Process Current And Noncurrent</link:label>
    <link:label id="lab_cort_InventoryWorkInProcessCurrentAndNoncurrent_documentation_en-US" xlink:label="lab_cort_InventoryWorkInProcessCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, work in process. current and noncurrent.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cort_InventoryWorkInProcessCurrentAndNoncurrent" xlink:href="cort-20220331.xsd#cort_InventoryWorkInProcessCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cort_InventoryWorkInProcessCurrentAndNoncurrent" xlink:to="lab_cort_InventoryWorkInProcessCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_68893cc5-4bd8-4e76-9e2e-b46991df9d8b_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denominator:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_96bbd6fb-4538-4928-b102-e9288977ac60_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_2cbe691d-fc1b-43ed-92c6-9aaf6476601e_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_f7b4dae2-35a4-45fc-aefe-ed8e7a7b8aaf_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_c21e1c58-7a76-4501-bd31-d6963b9204e5_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_816133fd-2c60-4920-ae32-662b66a8de17_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization of property and equipment</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_cort_AccruedLegalFeesCurrent_36fa043c-542d-4e6f-9669-2698509e5105_terseLabel_en-US" xlink:label="lab_cort_AccruedLegalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal fees</link:label>
    <link:label id="lab_cort_AccruedLegalFeesCurrent_label_en-US" xlink:label="lab_cort_AccruedLegalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Legal Fees Current</link:label>
    <link:label id="lab_cort_AccruedLegalFeesCurrent_documentation_en-US" xlink:label="lab_cort_AccruedLegalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to legal services. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cort_AccruedLegalFeesCurrent" xlink:href="cort-20220331.xsd#cort_AccruedLegalFeesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cort_AccruedLegalFeesCurrent" xlink:to="lab_cort_AccruedLegalFeesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f977a1fd-6841-4441-ba0f-6731283c672d_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_aedb9369-22cf-467a-b7d6-4568e40f420a_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits that would impact effective tax rate</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits that Would Impact Effective Tax Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_1bdda5b3-12f5-4d94-aa8c-ea554a048012_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_cort_InventoryFinishedGoodsCurrentAndNoncurrent_8b164a5b-dca9-4993-9c59-874a50b08204_terseLabel_en-US" xlink:label="lab_cort_InventoryFinishedGoodsCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_cort_InventoryFinishedGoodsCurrentAndNoncurrent_label_en-US" xlink:label="lab_cort_InventoryFinishedGoodsCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Finished Goods Current And Noncurrent</link:label>
    <link:label id="lab_cort_InventoryFinishedGoodsCurrentAndNoncurrent_documentation_en-US" xlink:label="lab_cort_InventoryFinishedGoodsCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, finished goods, current and noncurrent.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cort_InventoryFinishedGoodsCurrentAndNoncurrent" xlink:href="cort-20220331.xsd#cort_InventoryFinishedGoodsCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cort_InventoryFinishedGoodsCurrentAndNoncurrent" xlink:to="lab_cort_InventoryFinishedGoodsCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_0caae04b-37af-4dc8-ac18-660ea972c512_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_c4c6748a-07da-4ae0-a549-730606ac97a3_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_c66f6f76-5a3b-460a-9151-dba686227211_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e624ba7c-6e4e-43a4-9975-9b9622f54b20_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_b0ba585f-b9b4-44bd-9e41-3788bcbcfdd4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of treasury stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value, Acquired, Cost Method</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:to="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_76ab2302-5d27-4368-aa3f-3c2ce1c5b18d_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_34091024-56de-429e-84f9-52dbbdb03be8_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of sales</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_2d22e3d9-5167-4d96-8df2-accda9f0a814_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock upon exercise of options</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_3884f68a-5985-4d6e-b87b-efc2bbbf0d6d_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComputerSoftwareIntangibleAssetMember_ea5dd891-9b02-4535-b906-d9558eed006e_terseLabel_en-US" xlink:label="lab_us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Software</link:label>
    <link:label id="lab_us-gaap_ComputerSoftwareIntangibleAssetMember_label_en-US" xlink:label="lab_us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Software, Intangible Asset [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:to="lab_us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_eb9df45c-4791-47cd-a216-c37fd7b19aea_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_7bb7bbc9-c283-4df5-87ad-adabd1673e28_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term marketable securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesCurrent" xlink:to="lab_us-gaap_MarketableSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_7bc2d0b8-8028-43f5-95e5-70acb1a33894_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_cort_LongTermMarketableSecuritiesRemainingMaturity_399f9a2d-5777-44f4-b12b-c44b46e1c20d_terseLabel_en-US" xlink:label="lab_cort_LongTermMarketableSecuritiesRemainingMaturity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long term marketable securities, remaining maturity</link:label>
    <link:label id="lab_cort_LongTermMarketableSecuritiesRemainingMaturity_label_en-US" xlink:label="lab_cort_LongTermMarketableSecuritiesRemainingMaturity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long Term Marketable Securities, Remaining Maturity</link:label>
    <link:label id="lab_cort_LongTermMarketableSecuritiesRemainingMaturity_documentation_en-US" xlink:label="lab_cort_LongTermMarketableSecuritiesRemainingMaturity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long Term Marketable Securities, Remaining Maturity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cort_LongTermMarketableSecuritiesRemainingMaturity" xlink:href="cort-20220331.xsd#cort_LongTermMarketableSecuritiesRemainingMaturity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cort_LongTermMarketableSecuritiesRemainingMaturity" xlink:to="lab_cort_LongTermMarketableSecuritiesRemainingMaturity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_c6d723e6-0ff4-4274-872e-b63fb32d9ba6_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_eec099ad-4f60-42a2-b708-01d81f260b19_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_fbd1f411-e2f3-420c-bf29-ac8ce0776aaf_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_b4196243-5b45-47f6-bf1b-67f7aa417487_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_bfc6957f-a29f-4975-9010-173929eeb25c_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of property and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_485fdcea-19e4-4dc4-9c34-07356d62a943_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_75d8290e-0eb9-4acc-adb5-11101f7d8fae_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_6f261caf-9c37-4061-8f58-f064b97aee64_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_e7129735-70ab-4aae-a083-75591ae1a9f4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in shares authorized for grant (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_27b0b772-6575-4933-8a1b-6ef0453691ea_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedMarketingCostsCurrent_0b61a16c-b953-44c3-9da4-e2bd3c55b7a8_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedMarketingCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued selling and marketing costs</link:label>
    <link:label id="lab_us-gaap_AccruedMarketingCostsCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedMarketingCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Marketing Costs, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedMarketingCostsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedMarketingCostsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedMarketingCostsCurrent" xlink:to="lab_us-gaap_AccruedMarketingCostsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_0ace0cf8-7fd9-4175-9faa-187443c5dd15_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net of accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_af1e5ea0-1c84-49fc-a39e-207158d72ab9_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net of accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_70a3a921-4665-4d6c-a7cc-1d093b001b8d_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets, net</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:to="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_6e430d20-56ef-4edb-98cf-27cf5ee5358d_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_115e2ec9-0dec-482d-9448-49e4042e8c46_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liability</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_0373b9bd-c1b3-4dc2-9596-79221022d9ac_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of treasury stock (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_9cc44910-bfda-49ce-a68a-a8c9abf96d98_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock shares acquired</link:label>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_label_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Shares, Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockSharesAcquired" xlink:to="lab_us-gaap_TreasuryStockSharesAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_c27cd4f7-cd87-4617-8fa8-2b351ad1089a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_f1fa8e31-158f-4b1d-b2c5-638bf2dc4d73_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_6d86a40e-582e-465d-9885-8f4fd4ee3dad_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesOutstanding_7918bf29-29d8-4afd-99f1-d891aa3931e4_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_a2eb9ce6-e5ed-4c59-ac2e-5cc5f4305222_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_cort_DepositsForClinicalTrials_a00af7c6-8232-403d-b42a-38e8768939f1_terseLabel_en-US" xlink:label="lab_cort_DepositsForClinicalTrials" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deposits for clinical trials</link:label>
    <link:label id="lab_cort_DepositsForClinicalTrials_label_en-US" xlink:label="lab_cort_DepositsForClinicalTrials" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deposits For Clinical Trials</link:label>
    <link:label id="lab_cort_DepositsForClinicalTrials_documentation_en-US" xlink:label="lab_cort_DepositsForClinicalTrials" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deposits For Clinical Trials</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cort_DepositsForClinicalTrials" xlink:href="cort-20220331.xsd#cort_DepositsForClinicalTrials"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cort_DepositsForClinicalTrials" xlink:to="lab_cort_DepositsForClinicalTrials" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_e0e7200f-1bbe-4cbc-b447-809e2081321f_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total property and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_d4d6ecf9-6c95-47ac-86e4-d24e7fdfe589_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cort_LongLivedTangibleAssetDomain_ca7312cd-c88c-44f1-ac5f-fde59e4e783e_terseLabel_en-US" xlink:label="lab_cort_LongLivedTangibleAssetDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:label id="lab_cort_LongLivedTangibleAssetDomain_label_en-US" xlink:label="lab_cort_LongLivedTangibleAssetDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:label id="lab_cort_LongLivedTangibleAssetDomain_documentation_en-US" xlink:label="lab_cort_LongLivedTangibleAssetDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cort_LongLivedTangibleAssetDomain" xlink:href="cort-20220331.xsd#cort_LongLivedTangibleAssetDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cort_LongLivedTangibleAssetDomain" xlink:to="lab_cort_LongLivedTangibleAssetDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_b0e31cc3-849a-4671-8217-f9fa1c0fe550_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Professional fees</link:label>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Professional Fees, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_cort_ShortTermMarketableSecuritiesMember_eb790e3c-fcf5-418a-80da-de0e3adba7be_terseLabel_en-US" xlink:label="lab_cort_ShortTermMarketableSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term marketable securities</link:label>
    <link:label id="lab_cort_ShortTermMarketableSecuritiesMember_label_en-US" xlink:label="lab_cort_ShortTermMarketableSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short Term Marketable Securities [Member]</link:label>
    <link:label id="lab_cort_ShortTermMarketableSecuritiesMember_documentation_en-US" xlink:label="lab_cort_ShortTermMarketableSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short Term Marketable Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cort_ShortTermMarketableSecuritiesMember" xlink:href="cort-20220331.xsd#cort_ShortTermMarketableSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cort_ShortTermMarketableSecuritiesMember" xlink:to="lab_cort_ShortTermMarketableSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cort_SharesRepurchasedInNetSettlementOfCashlessOptionExercise_01619ffd-348d-404c-8fbc-5e3a8f0afdab_terseLabel_en-US" xlink:label="lab_cort_SharesRepurchasedInNetSettlementOfCashlessOptionExercise" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of shares repurchased for net settlement of cashless option exercises</link:label>
    <link:label id="lab_cort_SharesRepurchasedInNetSettlementOfCashlessOptionExercise_label_en-US" xlink:label="lab_cort_SharesRepurchasedInNetSettlementOfCashlessOptionExercise" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Repurchased In Net Settlement Of Cashless Option Exercise</link:label>
    <link:label id="lab_cort_SharesRepurchasedInNetSettlementOfCashlessOptionExercise_documentation_en-US" xlink:label="lab_cort_SharesRepurchasedInNetSettlementOfCashlessOptionExercise" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Repurchased In Net Settlement Of Cashless Option Exercise</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cort_SharesRepurchasedInNetSettlementOfCashlessOptionExercise" xlink:href="cort-20220331.xsd#cort_SharesRepurchasedInNetSettlementOfCashlessOptionExercise"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cort_SharesRepurchasedInNetSettlementOfCashlessOptionExercise" xlink:to="lab_cort_SharesRepurchasedInNetSettlementOfCashlessOptionExercise" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockCommonValue_036e27c1-0b95-477f-9e7c-ca4aa4eb0531_negatedLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonValue" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonValue_label_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Common, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockCommonValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonValue" xlink:to="lab_us-gaap_TreasuryStockCommonValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_a377813e-3e6f-431f-8682-a01ac408a372_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_a1a4ec16-e383-496b-9ea7-15a8cccc1aeb_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Present value of operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyAccrualAtCarryingValue_dac409a9-0e00-4729-b380-d051f3f7d9a6_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Losses for contingent liability</link:label>
    <link:label id="lab_us-gaap_LossContingencyAccrualAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Accrual</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:to="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_a8233a22-6f07-41ff-81a5-3beabe9981f3_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_6176a37c-2b30-4fa8-8789-9123605317e3_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_0099215a-7c94-4907-83e7-d9300932f714_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest and other income</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_9b8f7a38-dea7-4348-bac1-2d29e2dc262f_terseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesAbstract" xlink:to="lab_us-gaap_CostsAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_db4201e8-6d7b-4fb2-9cf7-21f7ecbc4b20_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cort_AccruedClinicalExpensesCurrent_abcd4dae-5a6f-466d-8884-0e277a0d2c56_terseLabel_en-US" xlink:label="lab_cort_AccruedClinicalExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued research and development expenses</link:label>
    <link:label id="lab_cort_AccruedClinicalExpensesCurrent_label_en-US" xlink:label="lab_cort_AccruedClinicalExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Clinical Expenses Current</link:label>
    <link:label id="lab_cort_AccruedClinicalExpensesCurrent_documentation_en-US" xlink:label="lab_cort_AccruedClinicalExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are associated with clinical research and related activities, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Used to reflect the current portion of clinical accrued liabilities (due within one year or within the normal operating cycle if longer).</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cort_AccruedClinicalExpensesCurrent" xlink:href="cort-20220331.xsd#cort_AccruedClinicalExpensesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cort_AccruedClinicalExpensesCurrent" xlink:to="lab_cort_AccruedClinicalExpensesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_cort_IncreaseDecreaseInAccruedClinicalExpenses_f53b16a0-c637-4042-a64f-9522f5f016f2_terseLabel_en-US" xlink:label="lab_cort_IncreaseDecreaseInAccruedClinicalExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued research and development expenses</link:label>
    <link:label id="lab_cort_IncreaseDecreaseInAccruedClinicalExpenses_label_en-US" xlink:label="lab_cort_IncreaseDecreaseInAccruedClinicalExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase Decrease In Accrued Clinical Expenses</link:label>
    <link:label id="lab_cort_IncreaseDecreaseInAccruedClinicalExpenses_documentation_en-US" xlink:label="lab_cort_IncreaseDecreaseInAccruedClinicalExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) in accrued clinical expenses.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cort_IncreaseDecreaseInAccruedClinicalExpenses" xlink:href="cort-20220331.xsd#cort_IncreaseDecreaseInAccruedClinicalExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cort_IncreaseDecreaseInAccruedClinicalExpenses" xlink:to="lab_cort_IncreaseDecreaseInAccruedClinicalExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_63b81abf-ae51-4bd2-aa48-3e9e6b8c027a_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allocated share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_78716ff5-9bf0-4624-af11-45805b713690_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_12d7e841-77fc-4ec1-a3e3-53a6204fb2ef_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_9cfd0d2a-faed-4d68-8722-237dcd0f25ed_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_0ef122ef-e75f-44b8-8069-3ca8973e0ff2_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesNoncurrent_ce916421-98e4-46ed-9cc9-e27b2f268fce_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term accrued income taxes payable</link:label>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesNoncurrent_label_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Income Taxes, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedIncomeTaxesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:to="lab_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_d952a69b-0960-4133-91dc-4f70ac8042c5_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022 (remainder)</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyAccrualProvision_c793992d-37ca-4d0e-b78d-de8f78d4c290_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualProvision" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for a loss contingency</link:label>
    <link:label id="lab_us-gaap_LossContingencyAccrualProvision_label_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualProvision" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Accrual, Provision</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualProvision" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyAccrualProvision"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyAccrualProvision" xlink:to="lab_us-gaap_LossContingencyAccrualProvision" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_428c1e03-c94f-4e93-9837-364e144cb584_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_3bc73954-d7e8-430f-b98d-bfe6ef72f27f_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_eeb582fe-388a-446f-93bb-1d8b073805f1_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from maturities of marketable securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale and Maturity of Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_e8b0dc63-f013-4b2f-910b-f24a9316e42c_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover page.</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_20010571-e6d5-42e9-a488-e4e0a0966834_terseLabel_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dilutive effect of employee stock options (in shares)</link:label>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_label_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_601ad299-4588-4ab6-9e36-70fbf1ec1d44_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents, at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_029234ff-569d-45c5-a5d0-1e5b952e82d8_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents, at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_94971592-8fe1-45cb-ada7-914b78105ce8_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_b2b91430-d1b0-4684-9765-d5c86d0fcc2f_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_5b18803f-3037-4123-94c2-f4d36d49ad6a_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_8e45e1b3-6ebb-4521-9c31-d0f5b49e4eb6_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less imputed interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_ef21332f-f951-4cc9-9a70-e159588d9734_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_15cd8793-a907-4c9d-ba66-617566cd782e_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNoncurrent_b3652c51-b32f-444f-8f7e-8e9630e6057d_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Strategic inventory</link:label>
    <link:label id="lab_us-gaap_InventoryNoncurrent_a0d030ff-336c-4701-b7e5-65bae55fb3ae_negatedLabel_en-US" xlink:label="lab_us-gaap_InventoryNoncurrent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less strategic inventory classified as non-current</link:label>
    <link:label id="lab_us-gaap_InventoryNoncurrent_label_en-US" xlink:label="lab_us-gaap_InventoryNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNoncurrent" xlink:to="lab_us-gaap_InventoryNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_5ea16970-c9ae-49f6-89b6-cfeb70f09dfd_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock upon exercise of options (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_8ffd9c98-696d-4fd8-bdd2-7b7a40a7e057_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common shares issued upon exercise of options (in share)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_76e1a0b9-5347-4fd6-8283-f68c58a2628c_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net unrealized income (loss) on available-for-sale investments, tax impact</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_2f513c37-407f-4a39-8975-934dea112874_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_599e81ba-b346-4c08-b87f-2af45b8c83fe_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_7247ac8f-03b2-4a6b-a3cd-c1b3dce1f39f_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average shares used to compute diluted net income per share (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_edada520-d5e7-40c8-93ae-54e9d2bf24b0_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_1f4834ec-c995-40ba-a388-123021d3f384_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_5c67e464-a3da-4ec8-b4e4-73a12d90eee9_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued and other liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_9910b3c8-98fc-4b6d-a1b0-e8be90851bcd_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total accrued and other liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c79c00c4-bb81-458f-b949-be4ea010b488_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product revenue, net</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_1d08cb48-e1e2-4f12-9aed-6909b49283bf_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_58314850-4ca3-4659-abc2-b9ea60308755_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_b15ddc8b-8dbf-458f-a294-8cc0beb28292_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_98dd7d40-3394-4685-b039-f86d4dbfc160_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options to Purchase Common Stock</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementBasisAxis_4290e1c0-16b8-4fb6-a559-bf91e9bf904e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Basis [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementBasisAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Basis [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis" xlink:to="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_96dd10a6-7d5d-4b1b-b777-bcf563428529_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_ebed7c6c-933f-467b-be9c-d12a83327448_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_b8b69435-3f2a-483d-9927-81289ea26eb5_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_02356eff-4a9e-49db-aa1f-f3a72da92db7_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestReceivableCurrent_293212ca-4fed-4f6c-84cb-3f5e10d0be54_terseLabel_en-US" xlink:label="lab_us-gaap_InterestReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest receivable, current</link:label>
    <link:label id="lab_us-gaap_InterestReceivableCurrent_label_en-US" xlink:label="lab_us-gaap_InterestReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Receivable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestReceivableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestReceivableCurrent" xlink:to="lab_us-gaap_InterestReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_372ca842-f695-4d4f-88ab-21f37c3e816d_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholders Equity [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_ebe72142-b3dd-470e-aecd-0294adb5c328_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common&#160;Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_93d34793-9103-40c4-8a06-e252e3ad8398_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_ec8bb5f9-0fbb-4d29-95f9-4bf8da3821c5_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_c2e8ce35-f0fe-47d0-9763-b12e6dacb9e5_terseLabel_en-US" xlink:label="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portion at fair value measurement</link:label>
    <link:label id="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portion at Fair Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:to="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_ebf38988-87bc-4c62-a2d4-630fcce95ef6_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_55cd734d-95ef-4dbb-b681-9a946c9f337f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less accumulated depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_649c5df5-8948-4d05-b12c-9181bb726815_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_f43b0729-6316-4f2e-b656-043494b09a0e_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_99d4803b-b5f7-4783-bee6-c4b05b516920_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_3cdc41b7-3e87-482a-a849-efd580e643b4_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_8bb5054f-a759-4244-aafa-66df8daed714_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_9f995f24-ddbe-4f0e-92ed-558f2e55c517_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term operating lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_5b5639f0-acf0-494a-a16c-fe953737ee70_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_f2652c93-eb75-4e86-b2c4-38486784b0eb_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_39090ec4-1135-4b35-a1a8-3595901c3e69_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_2b186a42-41e0-4f2b-b792-80f1bda9afa9_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid to satisfy statutory withholding requirement for net settlement of cashless option exercises</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_383351d0-0484-49ff-97d2-544ae8a08a19_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment tax withholding share-based payment arrangement</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment, Tax Withholding, Share-based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_6674df51-0e42-47a5-b602-730feede49fc_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_cd2ba346-aaed-482e-88d1-0d08ffaab134_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_091cb85d-096a-4553-8baf-60698b91716e_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_0905c8f4-b19e-41ef-887b-39bebd75cb6a_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_c51859ef-730f-45d6-9162-304f816b4982_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockMember_080f5517-8bc1-41f8-b363-1c799fab3a2b_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockMember_label_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockMember" xlink:to="lab_us-gaap_TreasuryStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_71a8282d-6f3f-4266-bcb9-468f1e77cd46_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_cort_AvailableForSaleSecuritiesAndFairValueMeasurementsDisclosureTextBlock_f87196ca-be12-47a6-b448-8cf4d2a6187a_terseLabel_en-US" xlink:label="lab_cort_AvailableForSaleSecuritiesAndFairValueMeasurementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-Sale Securities and Fair Value Measurements</link:label>
    <link:label id="lab_cort_AvailableForSaleSecuritiesAndFairValueMeasurementsDisclosureTextBlock_label_en-US" xlink:label="lab_cort_AvailableForSaleSecuritiesAndFairValueMeasurementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available For Sale Securities And Fair Value Measurements Disclosure [Text Block]</link:label>
    <link:label id="lab_cort_AvailableForSaleSecuritiesAndFairValueMeasurementsDisclosureTextBlock_documentation_en-US" xlink:label="lab_cort_AvailableForSaleSecuritiesAndFairValueMeasurementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available for sale securities and fair value measurements disclosure.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cort_AvailableForSaleSecuritiesAndFairValueMeasurementsDisclosureTextBlock" xlink:href="cort-20220331.xsd#cort_AvailableForSaleSecuritiesAndFairValueMeasurementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cort_AvailableForSaleSecuritiesAndFairValueMeasurementsDisclosureTextBlock" xlink:to="lab_cort_AvailableForSaleSecuritiesAndFairValueMeasurementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryNoncurrentTableTextBlock_686f5c0f-7a25-47bc-ad63-67b186080288_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryNoncurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of composition of inventory, noncurrent</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryNoncurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryNoncurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Noncurrent [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryNoncurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInventoryNoncurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryNoncurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryNoncurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_a9bb496e-7619-4fa4-919a-debad0995940_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesUnrealizedGainLoss_f26ed5f9-a63e-4551-8c47-10d187245ce4_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss), net of tax</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesUnrealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Unrealized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:to="lab_us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_cd4df635-cc5a-4ed7-834d-593c018d9a79_terseLabel_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset-backed securities</link:label>
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset-backed Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetBackedSecuritiesMember" xlink:to="lab_us-gaap_AssetBackedSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_66c983c6-624f-4732-8b8e-ca65b80a2015_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_ef770fa7-1411-414b-9ee3-289eb54989ca_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_74e5411c-32fb-4a6d-b851-6a82ee7170ab_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_02a9b767-7c17-47b3-807d-a65cfceb52d2_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_bbdca3a0-f5a5-48f9-8a21-f44ac3d638c2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of other accrued liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_2423fe77-4dd1-4f27-91d2-8947ec984107_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_49b3c382-b3d2-4d04-86a9-371d6c472c3c_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1_a75b1d31-f46e-4c87-a308-2753be60ce66_totalLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stock-based compensation</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_f4a4990c-ca5a-4a70-abe1-5150061dee08_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of future minimum lease payments under non-cancelable operating leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_e5be696c-4d79-4d29-b687-2b660ce6c67a_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_6359ba50-6d03-4d77-abe2-bbe39cfb7bf3_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_581909f0-88f4-4f1f-a6dd-0490c5aecba7_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfSalesMember_d0875836-b3cc-4cc2-935f-d5a0009146e3_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of sales</link:label>
    <link:label id="lab_us-gaap_CostOfSalesMember_label_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Sales [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesMember" xlink:to="lab_us-gaap_CostOfSalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetRelatedDisclosuresAbstract_6b67f49e-808d-499f-b49f-f157fe769b07_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Related Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetRelatedDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Related Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="lab_us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesCurrent_2765b76e-7ec0-418d-b8e5-99dac32d0f2b_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued income taxes payable</link:label>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Income Taxes, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedIncomeTaxesCurrent" xlink:to="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_9f1cfdc1-a85b-4836-9b9a-cb9b81f8100d_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_85c1be52-c4c8-42bb-95b0-4d0252bd3056_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net income to net cash provided by operations:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cort_LongLivedTangibleAssetAxis_31cd6b2e-5817-4612-99b5-5add0c498c31_terseLabel_en-US" xlink:label="lab_cort_LongLivedTangibleAssetAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:label id="lab_cort_LongLivedTangibleAssetAxis_label_en-US" xlink:label="lab_cort_LongLivedTangibleAssetAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:label id="lab_cort_LongLivedTangibleAssetAxis_documentation_en-US" xlink:label="lab_cort_LongLivedTangibleAssetAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cort_LongLivedTangibleAssetAxis" xlink:href="cort-20220331.xsd#cort_LongLivedTangibleAssetAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cort_LongLivedTangibleAssetAxis" xlink:to="lab_cort_LongLivedTangibleAssetAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_544b45ee-e3ac-4398-91e5-5250ec53ce57_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_cort_MarketableSecuritiesMaximumMaturityPeriod_2949b643-b037-4e55-a4f4-d7d546742533_terseLabel_en-US" xlink:label="lab_cort_MarketableSecuritiesMaximumMaturityPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum maturity period</link:label>
    <link:label id="lab_cort_MarketableSecuritiesMaximumMaturityPeriod_label_en-US" xlink:label="lab_cort_MarketableSecuritiesMaximumMaturityPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities Maximum Maturity Period</link:label>
    <link:label id="lab_cort_MarketableSecuritiesMaximumMaturityPeriod_documentation_en-US" xlink:label="lab_cort_MarketableSecuritiesMaximumMaturityPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities maximum original maturity period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cort_MarketableSecuritiesMaximumMaturityPeriod" xlink:href="cort-20220331.xsd#cort_MarketableSecuritiesMaximumMaturityPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cort_MarketableSecuritiesMaximumMaturityPeriod" xlink:to="lab_cort_MarketableSecuritiesMaximumMaturityPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_7c9d435c-875a-46ba-9c7c-96b72edc1809_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued and other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxesPayableCurrentAndNoncurrent_589bf3c4-c09b-4563-97dc-80fd0d808775_terseLabel_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes payable</link:label>
    <link:label id="lab_us-gaap_TaxesPayableCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxesPayableCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxesPayableCurrentAndNoncurrent" xlink:to="lab_us-gaap_TaxesPayableCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_92374bc3-4423-4513-8aaa-2eaa620b783a_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of common stock</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_5337a6fd-9f97-4bb7-9aa2-4318b516a092_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_5d924f54-5400-47a2-af22-256e4bb1519e_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>cort-20220331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:e53d3b2d-fdb0-4be1-948b-2f6fb33fb115,g:87e34f93-b135-45b2-b829-febf6d6a95d5-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.corcept.com/role/CoverPage" xlink:type="simple" xlink:href="cort-20220331.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.corcept.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_cc6125a5-7ab4-4516-bead-357cba3898c4" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_ff32f1f4-e732-4d69-afcc-e49825fbd044" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cc6125a5-7ab4-4516-bead-357cba3898c4" xlink:to="loc_dei_DocumentType_ff32f1f4-e732-4d69-afcc-e49825fbd044" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_0410f185-5ef5-4e00-a774-aee214b8e4af" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cc6125a5-7ab4-4516-bead-357cba3898c4" xlink:to="loc_dei_DocumentQuarterlyReport_0410f185-5ef5-4e00-a774-aee214b8e4af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_7a9be03b-9f46-48b6-b86a-e2a976b4ddc5" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cc6125a5-7ab4-4516-bead-357cba3898c4" xlink:to="loc_dei_DocumentPeriodEndDate_7a9be03b-9f46-48b6-b86a-e2a976b4ddc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_6c299bb0-99df-4c2e-9674-6385335663f6" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cc6125a5-7ab4-4516-bead-357cba3898c4" xlink:to="loc_dei_DocumentTransitionReport_6c299bb0-99df-4c2e-9674-6385335663f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_3b45db0d-876a-4a50-b563-b0a93809d469" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cc6125a5-7ab4-4516-bead-357cba3898c4" xlink:to="loc_dei_EntityFileNumber_3b45db0d-876a-4a50-b563-b0a93809d469" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_86075338-a8bd-431c-8b67-901a40c95c6c" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cc6125a5-7ab4-4516-bead-357cba3898c4" xlink:to="loc_dei_EntityRegistrantName_86075338-a8bd-431c-8b67-901a40c95c6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_1f09d836-e59d-415c-8085-5972c205e138" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cc6125a5-7ab4-4516-bead-357cba3898c4" xlink:to="loc_dei_EntityIncorporationStateCountryCode_1f09d836-e59d-415c-8085-5972c205e138" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_9237fba9-5eba-4c07-a6fb-a144c62a6de8" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cc6125a5-7ab4-4516-bead-357cba3898c4" xlink:to="loc_dei_EntityTaxIdentificationNumber_9237fba9-5eba-4c07-a6fb-a144c62a6de8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_b70da719-58c6-4fd4-acdd-496c7c96a034" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cc6125a5-7ab4-4516-bead-357cba3898c4" xlink:to="loc_dei_EntityAddressAddressLine1_b70da719-58c6-4fd4-acdd-496c7c96a034" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_eb9e59cd-69ea-439d-9e6d-c884b014e7e3" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cc6125a5-7ab4-4516-bead-357cba3898c4" xlink:to="loc_dei_EntityAddressCityOrTown_eb9e59cd-69ea-439d-9e6d-c884b014e7e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_d3cc1bc5-0c09-41af-a514-2de2ef07a8ce" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cc6125a5-7ab4-4516-bead-357cba3898c4" xlink:to="loc_dei_EntityAddressStateOrProvince_d3cc1bc5-0c09-41af-a514-2de2ef07a8ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_47b3e302-5b69-47fc-88ad-c39b6862afd5" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cc6125a5-7ab4-4516-bead-357cba3898c4" xlink:to="loc_dei_EntityAddressPostalZipCode_47b3e302-5b69-47fc-88ad-c39b6862afd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_5685c75c-8ec5-42df-89e0-6c08e7a9b3be" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cc6125a5-7ab4-4516-bead-357cba3898c4" xlink:to="loc_dei_CityAreaCode_5685c75c-8ec5-42df-89e0-6c08e7a9b3be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_219f2023-7575-4f82-a920-fa071172bc72" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cc6125a5-7ab4-4516-bead-357cba3898c4" xlink:to="loc_dei_LocalPhoneNumber_219f2023-7575-4f82-a920-fa071172bc72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_d2b2981d-cb07-409b-99db-ee90fd9e2c1f" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cc6125a5-7ab4-4516-bead-357cba3898c4" xlink:to="loc_dei_Security12bTitle_d2b2981d-cb07-409b-99db-ee90fd9e2c1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_2fa5658c-aa25-46d6-9a30-939eae89b1c2" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cc6125a5-7ab4-4516-bead-357cba3898c4" xlink:to="loc_dei_TradingSymbol_2fa5658c-aa25-46d6-9a30-939eae89b1c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_fab5f119-bbc2-421b-bf67-da20ec8065c1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cc6125a5-7ab4-4516-bead-357cba3898c4" xlink:to="loc_dei_SecurityExchangeName_fab5f119-bbc2-421b-bf67-da20ec8065c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_7cc23933-09b9-4013-a7ee-bb919de05baf" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cc6125a5-7ab4-4516-bead-357cba3898c4" xlink:to="loc_dei_EntityCurrentReportingStatus_7cc23933-09b9-4013-a7ee-bb919de05baf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_12351be3-a9d0-4dbb-8fc4-c8ef68abccc6" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cc6125a5-7ab4-4516-bead-357cba3898c4" xlink:to="loc_dei_EntityInteractiveDataCurrent_12351be3-a9d0-4dbb-8fc4-c8ef68abccc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_8c633dc2-66e7-4f80-bd2d-382f07ef6ffc" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cc6125a5-7ab4-4516-bead-357cba3898c4" xlink:to="loc_dei_EntityFilerCategory_8c633dc2-66e7-4f80-bd2d-382f07ef6ffc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_cc018602-e48a-4242-ad89-cc57d458fcf2" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cc6125a5-7ab4-4516-bead-357cba3898c4" xlink:to="loc_dei_EntitySmallBusiness_cc018602-e48a-4242-ad89-cc57d458fcf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_9beff981-22a6-499c-9f4e-4f1a6516aa57" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cc6125a5-7ab4-4516-bead-357cba3898c4" xlink:to="loc_dei_EntityEmergingGrowthCompany_9beff981-22a6-499c-9f4e-4f1a6516aa57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_6697f5f1-b58d-4f90-b45d-b03a5a823078" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cc6125a5-7ab4-4516-bead-357cba3898c4" xlink:to="loc_dei_EntityShellCompany_6697f5f1-b58d-4f90-b45d-b03a5a823078" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_84b7f161-ea77-4c0b-8d60-c3c0785c69b8" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cc6125a5-7ab4-4516-bead-357cba3898c4" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_84b7f161-ea77-4c0b-8d60-c3c0785c69b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_a553d2bd-0868-4c0f-a5ce-b07cf81c1369" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cc6125a5-7ab4-4516-bead-357cba3898c4" xlink:to="loc_dei_AmendmentFlag_a553d2bd-0868-4c0f-a5ce-b07cf81c1369" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_a5787669-da59-4e91-8c3b-d584e491d5b9" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cc6125a5-7ab4-4516-bead-357cba3898c4" xlink:to="loc_dei_DocumentFiscalYearFocus_a5787669-da59-4e91-8c3b-d584e491d5b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_0c55dad9-9772-4002-adf8-1d82161f9cec" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cc6125a5-7ab4-4516-bead-357cba3898c4" xlink:to="loc_dei_DocumentFiscalPeriodFocus_0c55dad9-9772-4002-adf8-1d82161f9cec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_c64df992-33fc-4688-bcb6-42e7a9b0a25c" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cc6125a5-7ab4-4516-bead-357cba3898c4" xlink:to="loc_dei_EntityCentralIndexKey_c64df992-33fc-4688-bcb6-42e7a9b0a25c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_ae55eee8-d0f6-4cf5-995f-985427e4ef3f" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cc6125a5-7ab4-4516-bead-357cba3898c4" xlink:to="loc_dei_CurrentFiscalYearEndDate_ae55eee8-d0f6-4cf5-995f-985427e4ef3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.corcept.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="cort-20220331.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETS"/>
  <link:presentationLink xlink:role="http://www.corcept.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_649303fb-254f-4c78-84b4-4cbe2df7941e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_1064311a-5742-441d-9575-37e71a70539e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_649303fb-254f-4c78-84b4-4cbe2df7941e" xlink:to="loc_us-gaap_AssetsAbstract_1064311a-5742-441d-9575-37e71a70539e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_04ab2595-c3b3-4bd9-872a-53e5cb530bb0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1064311a-5742-441d-9575-37e71a70539e" xlink:to="loc_us-gaap_AssetsCurrentAbstract_04ab2595-c3b3-4bd9-872a-53e5cb530bb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1dc2ca94-3463-4102-a1ba-c27c0c52f203" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_04ab2595-c3b3-4bd9-872a-53e5cb530bb0" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1dc2ca94-3463-4102-a1ba-c27c0c52f203" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_7103730b-12d7-4a00-a075-b1e4a346d4f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_04ab2595-c3b3-4bd9-872a-53e5cb530bb0" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_7103730b-12d7-4a00-a075-b1e4a346d4f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_a3b3c7a2-5dad-4543-8807-a5859d0a9fe9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_04ab2595-c3b3-4bd9-872a-53e5cb530bb0" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_a3b3c7a2-5dad-4543-8807-a5859d0a9fe9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_71c17331-94d1-4012-81cf-77769dd75380" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_04ab2595-c3b3-4bd9-872a-53e5cb530bb0" xlink:to="loc_us-gaap_InventoryNet_71c17331-94d1-4012-81cf-77769dd75380" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_df58a784-be7e-4d7f-b998-b02ab5381632" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_04ab2595-c3b3-4bd9-872a-53e5cb530bb0" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_df58a784-be7e-4d7f-b998-b02ab5381632" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_e25b9fac-57b4-44bc-839c-41465b74cb8d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_04ab2595-c3b3-4bd9-872a-53e5cb530bb0" xlink:to="loc_us-gaap_AssetsCurrent_e25b9fac-57b4-44bc-839c-41465b74cb8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent_9014c4d7-b5dc-4155-a0b1-9b322dd0f8a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1064311a-5742-441d-9575-37e71a70539e" xlink:to="loc_us-gaap_InventoryNoncurrent_9014c4d7-b5dc-4155-a0b1-9b322dd0f8a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_c30f6939-f6b7-4ff5-ae7c-36cbb9a7bef4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1064311a-5742-441d-9575-37e71a70539e" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_c30f6939-f6b7-4ff5-ae7c-36cbb9a7bef4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_d53a1f56-9fd5-42a2-af4f-7769485b4d52" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1064311a-5742-441d-9575-37e71a70539e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_d53a1f56-9fd5-42a2-af4f-7769485b4d52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent_94cb3566-73c5-4e43-92e1-e7725404b9a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1064311a-5742-441d-9575-37e71a70539e" xlink:to="loc_us-gaap_MarketableSecuritiesNoncurrent_94cb3566-73c5-4e43-92e1-e7725404b9a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_7da4df98-644d-4bbf-ad3d-ebbfdfa8c8e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1064311a-5742-441d-9575-37e71a70539e" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_7da4df98-644d-4bbf-ad3d-ebbfdfa8c8e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_04fcb0d5-c2a8-445f-8bc9-e14c7b59fca2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1064311a-5742-441d-9575-37e71a70539e" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_04fcb0d5-c2a8-445f-8bc9-e14c7b59fca2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_011573b1-2152-4ff9-aa72-2c2f6c99cd8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1064311a-5742-441d-9575-37e71a70539e" xlink:to="loc_us-gaap_Assets_011573b1-2152-4ff9-aa72-2c2f6c99cd8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5ad45b1d-9a33-46d3-9445-92e0956d9851" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_649303fb-254f-4c78-84b4-4cbe2df7941e" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5ad45b1d-9a33-46d3-9445-92e0956d9851" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_8bf87e45-1324-455a-ad66-ca731ccc977b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5ad45b1d-9a33-46d3-9445-92e0956d9851" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_8bf87e45-1324-455a-ad66-ca731ccc977b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_9ae502f9-3008-443c-9511-a33d463995db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_8bf87e45-1324-455a-ad66-ca731ccc977b" xlink:to="loc_us-gaap_AccountsPayableCurrent_9ae502f9-3008-443c-9511-a33d463995db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cort_AccruedClinicalExpensesCurrent_30855a07-10b1-4a4c-a1b8-ff1fad50b40e" xlink:href="cort-20220331.xsd#cort_AccruedClinicalExpensesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_8bf87e45-1324-455a-ad66-ca731ccc977b" xlink:to="loc_cort_AccruedClinicalExpensesCurrent_30855a07-10b1-4a4c-a1b8-ff1fad50b40e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_544d942a-4a17-4975-99ac-273881cd120b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_8bf87e45-1324-455a-ad66-ca731ccc977b" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_544d942a-4a17-4975-99ac-273881cd120b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_040dc973-ef1d-4fdb-a935-a31a93b3d245" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_8bf87e45-1324-455a-ad66-ca731ccc977b" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_040dc973-ef1d-4fdb-a935-a31a93b3d245" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_d188d461-7d25-4370-925d-724800530440" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_8bf87e45-1324-455a-ad66-ca731ccc977b" xlink:to="loc_us-gaap_LiabilitiesCurrent_d188d461-7d25-4370-925d-724800530440" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_443a1c31-6c99-411e-8f14-aaa775449610" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5ad45b1d-9a33-46d3-9445-92e0956d9851" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_443a1c31-6c99-411e-8f14-aaa775449610" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesNoncurrent_c2c484a9-64d1-4a05-a8c1-725513975c3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedIncomeTaxesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5ad45b1d-9a33-46d3-9445-92e0956d9851" xlink:to="loc_us-gaap_AccruedIncomeTaxesNoncurrent_c2c484a9-64d1-4a05-a8c1-725513975c3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_38549081-c9ab-4a8b-b6b6-9a4dfd002b01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5ad45b1d-9a33-46d3-9445-92e0956d9851" xlink:to="loc_us-gaap_Liabilities_38549081-c9ab-4a8b-b6b6-9a4dfd002b01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_ecc4a665-8291-4fdb-9794-90307bc7ef00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5ad45b1d-9a33-46d3-9445-92e0956d9851" xlink:to="loc_us-gaap_StockholdersEquityAbstract_ecc4a665-8291-4fdb-9794-90307bc7ef00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_550f6856-b14e-4390-860b-af4d6dd08772" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_ecc4a665-8291-4fdb-9794-90307bc7ef00" xlink:to="loc_us-gaap_PreferredStockValue_550f6856-b14e-4390-860b-af4d6dd08772" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_7de89509-ba2b-44d5-9c59-72b8797e5c63" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_ecc4a665-8291-4fdb-9794-90307bc7ef00" xlink:to="loc_us-gaap_CommonStockValue_7de89509-ba2b-44d5-9c59-72b8797e5c63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonValue_47710fae-de4c-4635-a42b-f232a331fe4e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockCommonValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_ecc4a665-8291-4fdb-9794-90307bc7ef00" xlink:to="loc_us-gaap_TreasuryStockCommonValue_47710fae-de4c-4635-a42b-f232a331fe4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_cdfaf1ca-9e46-4f84-8eab-e4a0c257f7e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_ecc4a665-8291-4fdb-9794-90307bc7ef00" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_cdfaf1ca-9e46-4f84-8eab-e4a0c257f7e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_6d5f69f7-7e9d-4330-9932-8c193b73eb7e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_ecc4a665-8291-4fdb-9794-90307bc7ef00" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_6d5f69f7-7e9d-4330-9932-8c193b73eb7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_35af54a1-65c7-40de-afac-cd2ea000ea7e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_ecc4a665-8291-4fdb-9794-90307bc7ef00" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_35af54a1-65c7-40de-afac-cd2ea000ea7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_e403a707-3ac9-4dcf-94e0-ecae6db78b23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_ecc4a665-8291-4fdb-9794-90307bc7ef00" xlink:to="loc_us-gaap_StockholdersEquity_e403a707-3ac9-4dcf-94e0-ecae6db78b23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_970d9446-a5b6-4e6a-8b0a-35efe5f91b3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5ad45b1d-9a33-46d3-9445-92e0956d9851" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_970d9446-a5b6-4e6a-8b0a-35efe5f91b3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" xlink:type="simple" xlink:href="cort-20220331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"/>
  <link:presentationLink xlink:role="http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_37577f43-11fa-431b-8503-b870d962fb21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_430f3289-a45e-41f3-ac01-783faa20864c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_37577f43-11fa-431b-8503-b870d962fb21" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_430f3289-a45e-41f3-ac01-783faa20864c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_905fe27c-9622-46d7-9b96-4131365fea07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_37577f43-11fa-431b-8503-b870d962fb21" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_905fe27c-9622-46d7-9b96-4131365fea07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_2b171e55-d0b0-4dc4-ba6b-171fec481efd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_905fe27c-9622-46d7-9b96-4131365fea07" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_2b171e55-d0b0-4dc4-ba6b-171fec481efd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_0d3a7924-32bf-4e54-9562-d3f6208972a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_905fe27c-9622-46d7-9b96-4131365fea07" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_0d3a7924-32bf-4e54-9562-d3f6208972a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_f44c15a8-683b-4321-9b72-3fe743800d7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_905fe27c-9622-46d7-9b96-4131365fea07" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_f44c15a8-683b-4321-9b72-3fe743800d7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_f8c0d81d-ae6f-4b15-a766-2e299072d680" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_905fe27c-9622-46d7-9b96-4131365fea07" xlink:to="loc_us-gaap_CostsAndExpenses_f8c0d81d-ae6f-4b15-a766-2e299072d680" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_c654656d-aec4-4ecf-9af0-23eb9bcf392f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_37577f43-11fa-431b-8503-b870d962fb21" xlink:to="loc_us-gaap_OperatingIncomeLoss_c654656d-aec4-4ecf-9af0-23eb9bcf392f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_f08b7e02-91f4-42e3-9da6-4e0697caeb00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_37577f43-11fa-431b-8503-b870d962fb21" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_f08b7e02-91f4-42e3-9da6-4e0697caeb00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a9d58252-ffe2-444a-966b-187c7e6d4bf9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_37577f43-11fa-431b-8503-b870d962fb21" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a9d58252-ffe2-444a-966b-187c7e6d4bf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_a1e1127b-e3fd-410a-8421-c06b8f2e2813" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_37577f43-11fa-431b-8503-b870d962fb21" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_a1e1127b-e3fd-410a-8421-c06b8f2e2813" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_156a1ea8-a139-42a4-874d-fdd912d86227" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_37577f43-11fa-431b-8503-b870d962fb21" xlink:to="loc_us-gaap_NetIncomeLoss_156a1ea8-a139-42a4-874d-fdd912d86227" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_08faff43-5737-4eea-8126-468e799914b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_37577f43-11fa-431b-8503-b870d962fb21" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_08faff43-5737-4eea-8126-468e799914b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_4dbefc5b-876d-47b4-b757-4c74e1a20d27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_08faff43-5737-4eea-8126-468e799914b4" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_4dbefc5b-876d-47b4-b757-4c74e1a20d27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_e9505266-4b42-46d9-b65b-e740e48c5a8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_08faff43-5737-4eea-8126-468e799914b4" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_e9505266-4b42-46d9-b65b-e740e48c5a8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_ec9a12c5-3d9b-4a57-a2d3-01149302c828" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_08faff43-5737-4eea-8126-468e799914b4" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_ec9a12c5-3d9b-4a57-a2d3-01149302c828" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_6d2c8bba-385c-4f2b-a041-328c8030faf6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_37577f43-11fa-431b-8503-b870d962fb21" xlink:to="loc_us-gaap_EarningsPerShareBasic_6d2c8bba-385c-4f2b-a041-328c8030faf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_77f03260-58be-4e5c-97cf-0f9921505364" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_37577f43-11fa-431b-8503-b870d962fb21" xlink:to="loc_us-gaap_EarningsPerShareDiluted_77f03260-58be-4e5c-97cf-0f9921505364" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_600cda59-d6d4-4347-924a-2cd03cba9568" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_37577f43-11fa-431b-8503-b870d962fb21" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_600cda59-d6d4-4347-924a-2cd03cba9568" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_19d032bf-de6a-4cfb-bad2-e5c941a94a94" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_600cda59-d6d4-4347-924a-2cd03cba9568" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_19d032bf-de6a-4cfb-bad2-e5c941a94a94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1ef9ac96-4c4a-4a94-a294-5d0907473f47" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_600cda59-d6d4-4347-924a-2cd03cba9568" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1ef9ac96-4c4a-4a94-a294-5d0907473f47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEParenthetical" xlink:type="simple" xlink:href="cort-20220331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEParenthetical"/>
  <link:presentationLink xlink:role="http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_61ee8ffb-762c-4ecd-97ce-67d17ed7a6d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_3bbc34ce-18ce-4719-aa00-391f0a6187de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_61ee8ffb-762c-4ecd-97ce-67d17ed7a6d8" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_3bbc34ce-18ce-4719-aa00-391f0a6187de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="cort-20220331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:presentationLink xlink:role="http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_47f98d40-3962-417d-aff9-5e64628cce50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_35f1d7d6-cdf9-495c-b994-a0bfa3d63a99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_47f98d40-3962-417d-aff9-5e64628cce50" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_35f1d7d6-cdf9-495c-b994-a0bfa3d63a99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_ef6c5fc9-6259-4874-8b43-dcf415295fe0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_35f1d7d6-cdf9-495c-b994-a0bfa3d63a99" xlink:to="loc_us-gaap_ProfitLoss_ef6c5fc9-6259-4874-8b43-dcf415295fe0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_edd8a6cf-90ce-44c2-87c9-61a9b05a06cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_35f1d7d6-cdf9-495c-b994-a0bfa3d63a99" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_edd8a6cf-90ce-44c2-87c9-61a9b05a06cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_741ab4a7-de9a-4ff7-98d7-c00cfd04d560" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_edd8a6cf-90ce-44c2-87c9-61a9b05a06cd" xlink:to="loc_us-gaap_ShareBasedCompensation_741ab4a7-de9a-4ff7-98d7-c00cfd04d560" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cort_AccretionExpenseIncome_bcb86506-b463-49c4-aac8-f9400c6ea512" xlink:href="cort-20220331.xsd#cort_AccretionExpenseIncome"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_edd8a6cf-90ce-44c2-87c9-61a9b05a06cd" xlink:to="loc_cort_AccretionExpenseIncome_bcb86506-b463-49c4-aac8-f9400c6ea512" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_01adf5ca-11b5-461e-8bab-7e9a62c0bedb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_edd8a6cf-90ce-44c2-87c9-61a9b05a06cd" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_01adf5ca-11b5-461e-8bab-7e9a62c0bedb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_a64cfba9-395b-4906-8d0e-00ac9d9985c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_edd8a6cf-90ce-44c2-87c9-61a9b05a06cd" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_a64cfba9-395b-4906-8d0e-00ac9d9985c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_4daa086c-1066-4caf-baee-306e9e5b79bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_edd8a6cf-90ce-44c2-87c9-61a9b05a06cd" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_4daa086c-1066-4caf-baee-306e9e5b79bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7bfee6bb-7722-473c-b01a-d7be30fa5a05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_edd8a6cf-90ce-44c2-87c9-61a9b05a06cd" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7bfee6bb-7722-473c-b01a-d7be30fa5a05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_9c8105b9-a87f-4bc8-bc69-8abe10c55183" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7bfee6bb-7722-473c-b01a-d7be30fa5a05" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_9c8105b9-a87f-4bc8-bc69-8abe10c55183" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_bae52413-291b-4084-a620-60a89133a114" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7bfee6bb-7722-473c-b01a-d7be30fa5a05" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_bae52413-291b-4084-a620-60a89133a114" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_21c48ca7-cf78-4f52-a23c-57640f34a967" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7bfee6bb-7722-473c-b01a-d7be30fa5a05" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_21c48ca7-cf78-4f52-a23c-57640f34a967" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_fd03db82-920c-4bd8-a8c4-bfc757332a1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7bfee6bb-7722-473c-b01a-d7be30fa5a05" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_fd03db82-920c-4bd8-a8c4-bfc757332a1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cort_IncreaseDecreaseInAccruedClinicalExpenses_45b17c30-3fa9-4522-808d-cc240b4c9ce4" xlink:href="cort-20220331.xsd#cort_IncreaseDecreaseInAccruedClinicalExpenses"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7bfee6bb-7722-473c-b01a-d7be30fa5a05" xlink:to="loc_cort_IncreaseDecreaseInAccruedClinicalExpenses_45b17c30-3fa9-4522-808d-cc240b4c9ce4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_bc0f4f97-3774-4050-ba55-bad998a9a948" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccruedLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7bfee6bb-7722-473c-b01a-d7be30fa5a05" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_bc0f4f97-3774-4050-ba55-bad998a9a948" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedTaxesPayable_d1b3c32e-3c03-4222-a5b1-377f02d44316" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedTaxesPayable"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7bfee6bb-7722-473c-b01a-d7be30fa5a05" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedTaxesPayable_d1b3c32e-3c03-4222-a5b1-377f02d44316" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_285d8f13-ba5b-489d-8450-cfb19d9ffaba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7bfee6bb-7722-473c-b01a-d7be30fa5a05" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_285d8f13-ba5b-489d-8450-cfb19d9ffaba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_86f713c1-5788-402c-ad82-e38b8ea35e55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_35f1d7d6-cdf9-495c-b994-a0bfa3d63a99" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_86f713c1-5788-402c-ad82-e38b8ea35e55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_b9bdb704-94f9-4ce0-b334-ed40f20d8c44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_47f98d40-3962-417d-aff9-5e64628cce50" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_b9bdb704-94f9-4ce0-b334-ed40f20d8c44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_49d80c84-6b0a-48c5-89fe-293d8a299fb8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_b9bdb704-94f9-4ce0-b334-ed40f20d8c44" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_49d80c84-6b0a-48c5-89fe-293d8a299fb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_aab80b2b-861e-44d7-98ad-04d98ce713bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_b9bdb704-94f9-4ce0-b334-ed40f20d8c44" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_aab80b2b-861e-44d7-98ad-04d98ce713bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_9251b5b7-8274-4e79-b23c-29258044e54c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_b9bdb704-94f9-4ce0-b334-ed40f20d8c44" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_9251b5b7-8274-4e79-b23c-29258044e54c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1bbd2117-8935-415a-a780-d8d544d33055" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_b9bdb704-94f9-4ce0-b334-ed40f20d8c44" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1bbd2117-8935-415a-a780-d8d544d33055" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_84959913-215c-462c-9364-aa6abaafea19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_47f98d40-3962-417d-aff9-5e64628cce50" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_84959913-215c-462c-9364-aa6abaafea19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_10c38bba-ca13-4252-aba8-76d927b4d04e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_84959913-215c-462c-9364-aa6abaafea19" xlink:to="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_10c38bba-ca13-4252-aba8-76d927b4d04e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_87421bd4-2e2e-4233-b27f-be0b9231b23a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_84959913-215c-462c-9364-aa6abaafea19" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_87421bd4-2e2e-4233-b27f-be0b9231b23a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_f23c2f30-a0d5-42c0-899b-b1c0ac62c787" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_84959913-215c-462c-9364-aa6abaafea19" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_f23c2f30-a0d5-42c0-899b-b1c0ac62c787" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b7d42dd5-da2b-4205-9df5-b6c87a4dcb9b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_84959913-215c-462c-9364-aa6abaafea19" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b7d42dd5-da2b-4205-9df5-b6c87a4dcb9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f3fc8420-9fc7-4552-aff4-102bf9e76a34" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_47f98d40-3962-417d-aff9-5e64628cce50" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f3fc8420-9fc7-4552-aff4-102bf9e76a34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_95e7ab87-fd1e-4297-afe5-2c96f3e263d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_47f98d40-3962-417d-aff9-5e64628cce50" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_95e7ab87-fd1e-4297-afe5-2c96f3e263d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9568d77b-fc3b-441b-827e-22aa441d9158" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_47f98d40-3962-417d-aff9-5e64628cce50" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9568d77b-fc3b-441b-827e-22aa441d9158" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_532bcfec-4f84-45fe-8e7d-ee6b748172e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_47f98d40-3962-417d-aff9-5e64628cce50" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_532bcfec-4f84-45fe-8e7d-ee6b748172e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cort_SharesRepurchasedInNetSettlementOfCashlessOptionExercise_cc248ad7-9ec2-42ac-aaf8-b5aecd81d7b9" xlink:href="cort-20220331.xsd#cort_SharesRepurchasedInNetSettlementOfCashlessOptionExercise"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_532bcfec-4f84-45fe-8e7d-ee6b748172e1" xlink:to="loc_cort_SharesRepurchasedInNetSettlementOfCashlessOptionExercise_cc248ad7-9ec2-42ac-aaf8-b5aecd81d7b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cort_NonCashTransactionRecognitionOfRightOfUseAssetAndLeaseLiability_6ba7a17f-beb8-4816-ad8e-fcbba6a3f5b3" xlink:href="cort-20220331.xsd#cort_NonCashTransactionRecognitionOfRightOfUseAssetAndLeaseLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_532bcfec-4f84-45fe-8e7d-ee6b748172e1" xlink:to="loc_cort_NonCashTransactionRecognitionOfRightOfUseAssetAndLeaseLiability_6ba7a17f-beb8-4816-ad8e-fcbba6a3f5b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="cort-20220331.xsd#CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"/>
  <link:presentationLink xlink:role="http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_432a878a-cfc4-400d-9bd8-38c2e2050339" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_caa328a4-3027-44c0-9d2b-48af2b133d6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_432a878a-cfc4-400d-9bd8-38c2e2050339" xlink:to="loc_us-gaap_StatementTable_caa328a4-3027-44c0-9d2b-48af2b133d6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_c5790f51-c098-4a2e-8872-3b4ff94055ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_caa328a4-3027-44c0-9d2b-48af2b133d6b" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_c5790f51-c098-4a2e-8872-3b4ff94055ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_4d961eb4-47d7-4575-80fa-12bec1624228" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_c5790f51-c098-4a2e-8872-3b4ff94055ba" xlink:to="loc_us-gaap_EquityComponentDomain_4d961eb4-47d7-4575-80fa-12bec1624228" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_49df7d06-a6c2-4a62-82f4-d4d9369f316b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_4d961eb4-47d7-4575-80fa-12bec1624228" xlink:to="loc_us-gaap_CommonStockMember_49df7d06-a6c2-4a62-82f4-d4d9369f316b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_e24b727d-3ac0-45ac-9af2-cfee2dc93e88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_4d961eb4-47d7-4575-80fa-12bec1624228" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_e24b727d-3ac0-45ac-9af2-cfee2dc93e88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_7638f29f-772a-4595-b91a-8f4570cf0249" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_4d961eb4-47d7-4575-80fa-12bec1624228" xlink:to="loc_us-gaap_TreasuryStockMember_7638f29f-772a-4595-b91a-8f4570cf0249" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_f337778f-f339-4426-9b0a-e0f3731def86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_4d961eb4-47d7-4575-80fa-12bec1624228" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_f337778f-f339-4426-9b0a-e0f3731def86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_2d80e94c-1535-40cc-ae1f-4eb27892c21d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_4d961eb4-47d7-4575-80fa-12bec1624228" xlink:to="loc_us-gaap_RetainedEarningsMember_2d80e94c-1535-40cc-ae1f-4eb27892c21d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_2d210720-6e88-4ded-8724-f878834a1ace" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_caa328a4-3027-44c0-9d2b-48af2b133d6b" xlink:to="loc_us-gaap_StatementLineItems_2d210720-6e88-4ded-8724-f878834a1ace" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_77761aef-c366-4f37-9edd-e62278c1a2ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2d210720-6e88-4ded-8724-f878834a1ace" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_77761aef-c366-4f37-9edd-e62278c1a2ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_e01a19be-ce19-4905-80b5-9c876d0fc033" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_77761aef-c366-4f37-9edd-e62278c1a2ab" xlink:to="loc_us-gaap_SharesOutstanding_e01a19be-ce19-4905-80b5-9c876d0fc033" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_1d1f423c-d1d1-4c6e-bb89-ab493bf24b79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_77761aef-c366-4f37-9edd-e62278c1a2ab" xlink:to="loc_us-gaap_StockholdersEquity_1d1f423c-d1d1-4c6e-bb89-ab493bf24b79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_597569b7-6e60-4b22-a9d2-b50a8d2146ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_77761aef-c366-4f37-9edd-e62278c1a2ab" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_597569b7-6e60-4b22-a9d2-b50a8d2146ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_9e4d263b-4d7b-449a-a307-20d6dbb90afb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_77761aef-c366-4f37-9edd-e62278c1a2ab" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_9e4d263b-4d7b-449a-a307-20d6dbb90afb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_40680155-9c56-47f2-8f2f-ea013c111df6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_77761aef-c366-4f37-9edd-e62278c1a2ab" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_40680155-9c56-47f2-8f2f-ea013c111df6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_ee7da8c1-f591-45b7-b2fd-4af0946272ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_77761aef-c366-4f37-9edd-e62278c1a2ab" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_ee7da8c1-f591-45b7-b2fd-4af0946272ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_5cc998b1-46b5-4ad3-a2d6-6eb153c87329" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_77761aef-c366-4f37-9edd-e62278c1a2ab" xlink:to="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_5cc998b1-46b5-4ad3-a2d6-6eb153c87329" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_0657f7e1-f031-4b3f-9743-38ac821924ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_77761aef-c366-4f37-9edd-e62278c1a2ab" xlink:to="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_0657f7e1-f031-4b3f-9743-38ac821924ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_51e19c31-3e7e-417c-977b-4f52b345c0fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_77761aef-c366-4f37-9edd-e62278c1a2ab" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_51e19c31-3e7e-417c-977b-4f52b345c0fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss_fbb3a327-229d-4257-a821-24e704bf5902" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_77761aef-c366-4f37-9edd-e62278c1a2ab" xlink:to="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss_fbb3a327-229d-4257-a821-24e704bf5902" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_cf8b0396-e0c7-4a41-a755-6a7604cb669d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_77761aef-c366-4f37-9edd-e62278c1a2ab" xlink:to="loc_us-gaap_NetIncomeLoss_cf8b0396-e0c7-4a41-a755-6a7604cb669d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_905b6b56-c69f-493d-b66e-00b596ffbce0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_77761aef-c366-4f37-9edd-e62278c1a2ab" xlink:to="loc_us-gaap_SharesOutstanding_905b6b56-c69f-493d-b66e-00b596ffbce0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_14c65718-b123-44fe-944e-2b771c2ad9e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_77761aef-c366-4f37-9edd-e62278c1a2ab" xlink:to="loc_us-gaap_StockholdersEquity_14c65718-b123-44fe-944e-2b771c2ad9e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.corcept.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="cort-20220331.xsd#BasisofPresentationandSummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.corcept.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_fe6a3980-0a8d-4ad2-93c5-1e20076a1bec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_cebf13b7-c0a7-4c55-8980-faf2b825113c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_fe6a3980-0a8d-4ad2-93c5-1e20076a1bec" xlink:to="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_cebf13b7-c0a7-4c55-8980-faf2b825113c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.corcept.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="cort-20220331.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.corcept.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_f6ad8769-552a-4456-80d2-8b7a699e044f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_f775a3d5-fc9c-44b1-a8f9-ac9ee175b599" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f6ad8769-552a-4456-80d2-8b7a699e044f" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_f775a3d5-fc9c-44b1-a8f9-ac9ee175b599" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.corcept.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails" xlink:type="simple" xlink:href="cort-20220331.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails"/>
  <link:presentationLink xlink:role="http://www.corcept.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_b626f2bb-266f-4a06-81ce-caf3a39c7bc8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_cort_NumberOfSeriesOfSelectiveCortisolModulators_b9ea4ee8-2227-4943-9089-5bfb38573b71" xlink:href="cort-20220331.xsd#cort_NumberOfSeriesOfSelectiveCortisolModulators"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b626f2bb-266f-4a06-81ce-caf3a39c7bc8" xlink:to="loc_cort_NumberOfSeriesOfSelectiveCortisolModulators_b9ea4ee8-2227-4943-9089-5bfb38573b71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.corcept.com/role/CompositionofCertainBalanceSheetItems" xlink:type="simple" xlink:href="cort-20220331.xsd#CompositionofCertainBalanceSheetItems"/>
  <link:presentationLink xlink:role="http://www.corcept.com/role/CompositionofCertainBalanceSheetItems" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_ca4b4c9c-73c8-4249-864d-68320b0be2a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_fb3fd346-4faa-47d1-8079-240613130f8c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_ca4b4c9c-73c8-4249-864d-68320b0be2a1" xlink:to="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_fb3fd346-4faa-47d1-8079-240613130f8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.corcept.com/role/CompositionofCertainBalanceSheetItemsTables" xlink:type="simple" xlink:href="cort-20220331.xsd#CompositionofCertainBalanceSheetItemsTables"/>
  <link:presentationLink xlink:role="http://www.corcept.com/role/CompositionofCertainBalanceSheetItemsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_5d794403-288d-47c1-8373-824faca71e28" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_dbfebd19-437a-49b8-bb99-a88891e1c023" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_5d794403-288d-47c1-8373-824faca71e28" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_dbfebd19-437a-49b8-bb99-a88891e1c023" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryNoncurrentTableTextBlock_a3d9be10-20db-408f-8b0b-548894bc88c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInventoryNoncurrentTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_5d794403-288d-47c1-8373-824faca71e28" xlink:to="loc_us-gaap_ScheduleOfInventoryNoncurrentTableTextBlock_a3d9be10-20db-408f-8b0b-548894bc88c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_148c230a-9fca-493d-b2c4-c6db01997cc7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_5d794403-288d-47c1-8373-824faca71e28" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_148c230a-9fca-493d-b2c4-c6db01997cc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_4867dc83-2e56-4413-85c3-b5a7379406ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_5d794403-288d-47c1-8373-824faca71e28" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_4867dc83-2e56-4413-85c3-b5a7379406ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.corcept.com/role/CompositionofCertainBalanceSheetItemsScheduleofCompositionofInventoryDetails" xlink:type="simple" xlink:href="cort-20220331.xsd#CompositionofCertainBalanceSheetItemsScheduleofCompositionofInventoryDetails"/>
  <link:presentationLink xlink:role="http://www.corcept.com/role/CompositionofCertainBalanceSheetItemsScheduleofCompositionofInventoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_bd26dc5d-511c-4cc8-8d44-60a8cfbc2341" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_cort_InventoryWorkInProcessCurrentAndNoncurrent_ad9dfaba-a098-462c-b877-de07ab6ef419" xlink:href="cort-20220331.xsd#cort_InventoryWorkInProcessCurrentAndNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_bd26dc5d-511c-4cc8-8d44-60a8cfbc2341" xlink:to="loc_cort_InventoryWorkInProcessCurrentAndNoncurrent_ad9dfaba-a098-462c-b877-de07ab6ef419" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cort_InventoryFinishedGoodsCurrentAndNoncurrent_903801e9-bef8-430e-9ecc-0bf169b70a75" xlink:href="cort-20220331.xsd#cort_InventoryFinishedGoodsCurrentAndNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_bd26dc5d-511c-4cc8-8d44-60a8cfbc2341" xlink:to="loc_cort_InventoryFinishedGoodsCurrentAndNoncurrent_903801e9-bef8-430e-9ecc-0bf169b70a75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cort_InventoryCurrentNoncurrent_7a92b6e5-16a4-4a1c-bcef-cb25f4fce448" xlink:href="cort-20220331.xsd#cort_InventoryCurrentNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_bd26dc5d-511c-4cc8-8d44-60a8cfbc2341" xlink:to="loc_cort_InventoryCurrentNoncurrent_7a92b6e5-16a4-4a1c-bcef-cb25f4fce448" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent_37339919-5555-4661-ae95-4fab0c4c1cde" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_bd26dc5d-511c-4cc8-8d44-60a8cfbc2341" xlink:to="loc_us-gaap_InventoryNoncurrent_37339919-5555-4661-ae95-4fab0c4c1cde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_71d188bd-e9a3-43ec-b49c-9ad2cece7c1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_bd26dc5d-511c-4cc8-8d44-60a8cfbc2341" xlink:to="loc_us-gaap_InventoryNet_71d188bd-e9a3-43ec-b49c-9ad2cece7c1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.corcept.com/role/CompositionofCertainBalanceSheetItemsScheduleofCompositionofInventoryDetails_1" xlink:type="simple" xlink:href="cort-20220331.xsd#CompositionofCertainBalanceSheetItemsScheduleofCompositionofInventoryDetails_1"/>
  <link:presentationLink xlink:role="http://www.corcept.com/role/CompositionofCertainBalanceSheetItemsScheduleofCompositionofInventoryDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.corcept.com/role/CompositionofCertainBalanceSheetItemsScheduleofPropertyandEquipmentDetails" xlink:type="simple" xlink:href="cort-20220331.xsd#CompositionofCertainBalanceSheetItemsScheduleofPropertyandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://www.corcept.com/role/CompositionofCertainBalanceSheetItemsScheduleofPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_cbfa1786-3d8d-4958-8240-86183b65264b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2070a378-5042-47f3-ac06-f8417bb71b44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_cbfa1786-3d8d-4958-8240-86183b65264b" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2070a378-5042-47f3-ac06-f8417bb71b44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cort_LongLivedTangibleAssetAxis_0e11dc2e-ba00-4efd-bcf6-a4893d5c81f6" xlink:href="cort-20220331.xsd#cort_LongLivedTangibleAssetAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2070a378-5042-47f3-ac06-f8417bb71b44" xlink:to="loc_cort_LongLivedTangibleAssetAxis_0e11dc2e-ba00-4efd-bcf6-a4893d5c81f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cort_LongLivedTangibleAssetDomain_00b47edf-8d31-4804-9389-e0074eb8bd10" xlink:href="cort-20220331.xsd#cort_LongLivedTangibleAssetDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cort_LongLivedTangibleAssetAxis_0e11dc2e-ba00-4efd-bcf6-a4893d5c81f6" xlink:to="loc_cort_LongLivedTangibleAssetDomain_00b47edf-8d31-4804-9389-e0074eb8bd10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_13b21440-793f-42a9-ae7f-a5a8da9ed2e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cort_LongLivedTangibleAssetDomain_00b47edf-8d31-4804-9389-e0074eb8bd10" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_13b21440-793f-42a9-ae7f-a5a8da9ed2e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_1643bffe-17ac-4df6-9853-a6582de4811b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cort_LongLivedTangibleAssetDomain_00b47edf-8d31-4804-9389-e0074eb8bd10" xlink:to="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_1643bffe-17ac-4df6-9853-a6582de4811b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_556be540-7539-48d8-8f69-505d4f4f0f7e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cort_LongLivedTangibleAssetDomain_00b47edf-8d31-4804-9389-e0074eb8bd10" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_556be540-7539-48d8-8f69-505d4f4f0f7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2b4aaae9-77c5-47f4-8d11-22c23f457358" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2070a378-5042-47f3-ac06-f8417bb71b44" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2b4aaae9-77c5-47f4-8d11-22c23f457358" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_0dc76f2c-8477-41bb-b74d-e0617d60aed5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2b4aaae9-77c5-47f4-8d11-22c23f457358" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_0dc76f2c-8477-41bb-b74d-e0617d60aed5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_948a1ea9-dc38-4f74-a030-cfbf96f9cb03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2b4aaae9-77c5-47f4-8d11-22c23f457358" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_948a1ea9-dc38-4f74-a030-cfbf96f9cb03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_4c9da5fc-15a2-431b-8b7b-6ad62601a1af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2b4aaae9-77c5-47f4-8d11-22c23f457358" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_4c9da5fc-15a2-431b-8b7b-6ad62601a1af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.corcept.com/role/CompositionofCertainBalanceSheetItemsScheduleofOtherAccruedLiabilitiesDetails" xlink:type="simple" xlink:href="cort-20220331.xsd#CompositionofCertainBalanceSheetItemsScheduleofOtherAccruedLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.corcept.com/role/CompositionofCertainBalanceSheetItemsScheduleofOtherAccruedLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_a40ccbce-9070-4448-ba24-ce3d1a4ddb4e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_cort_AccruedGovernmentRebateCurrent_05013af6-70f9-49a0-94ae-103d9c84782c" xlink:href="cort-20220331.xsd#cort_AccruedGovernmentRebateCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_a40ccbce-9070-4448-ba24-ce3d1a4ddb4e" xlink:to="loc_cort_AccruedGovernmentRebateCurrent_05013af6-70f9-49a0-94ae-103d9c84782c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_8688ef59-4767-469b-93d5-f4fafd140a44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_a40ccbce-9070-4448-ba24-ce3d1a4ddb4e" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent_8688ef59-4767-469b-93d5-f4fafd140a44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_5ca3c786-72f3-40d4-9d45-91ec6bc72190" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_a40ccbce-9070-4448-ba24-ce3d1a4ddb4e" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_5ca3c786-72f3-40d4-9d45-91ec6bc72190" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cort_AccruedLegalFeesCurrent_2134eb7a-054a-4765-a1ba-4fd5b6b06a25" xlink:href="cort-20220331.xsd#cort_AccruedLegalFeesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_a40ccbce-9070-4448-ba24-ce3d1a4ddb4e" xlink:to="loc_cort_AccruedLegalFeesCurrent_2134eb7a-054a-4765-a1ba-4fd5b6b06a25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedMarketingCostsCurrent_ede365ad-7b07-41d8-8b09-a44a38132643" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedMarketingCostsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_a40ccbce-9070-4448-ba24-ce3d1a4ddb4e" xlink:to="loc_us-gaap_AccruedMarketingCostsCurrent_ede365ad-7b07-41d8-8b09-a44a38132643" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_7f601062-9d7f-4cb0-bc54-dfa749670265" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_a40ccbce-9070-4448-ba24-ce3d1a4ddb4e" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_7f601062-9d7f-4cb0-bc54-dfa749670265" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_32f67e87-fb97-449a-9934-b2791d836f21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_a40ccbce-9070-4448-ba24-ce3d1a4ddb4e" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_32f67e87-fb97-449a-9934-b2791d836f21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_7424c13b-96ed-4fee-8aa9-9e302e418322" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_a40ccbce-9070-4448-ba24-ce3d1a4ddb4e" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_7424c13b-96ed-4fee-8aa9-9e302e418322" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.corcept.com/role/CompositionofCertainBalanceSheetItemsNarrativeDetails" xlink:type="simple" xlink:href="cort-20220331.xsd#CompositionofCertainBalanceSheetItemsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.corcept.com/role/CompositionofCertainBalanceSheetItemsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_281c6393-1089-4cfa-ac07-e19e92ba0641" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_cort_DepositsForClinicalTrials_5e5d45cb-5925-4576-a1bb-9454c9b065e7" xlink:href="cort-20220331.xsd#cort_DepositsForClinicalTrials"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_281c6393-1089-4cfa-ac07-e19e92ba0641" xlink:to="loc_cort_DepositsForClinicalTrials_5e5d45cb-5925-4576-a1bb-9454c9b065e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.corcept.com/role/AvailableforSaleSecuritiesandFairValueMeasurements" xlink:type="simple" xlink:href="cort-20220331.xsd#AvailableforSaleSecuritiesandFairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.corcept.com/role/AvailableforSaleSecuritiesandFairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_cort_AvailableForSaleSecuritiesAndFairValueMeasurementsAbstract_5467703e-bd5f-4181-a854-500eec6f6399" xlink:href="cort-20220331.xsd#cort_AvailableForSaleSecuritiesAndFairValueMeasurementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_cort_AvailableForSaleSecuritiesAndFairValueMeasurementsDisclosureTextBlock_192cdb0b-8368-4aa7-889a-597591861342" xlink:href="cort-20220331.xsd#cort_AvailableForSaleSecuritiesAndFairValueMeasurementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cort_AvailableForSaleSecuritiesAndFairValueMeasurementsAbstract_5467703e-bd5f-4181-a854-500eec6f6399" xlink:to="loc_cort_AvailableForSaleSecuritiesAndFairValueMeasurementsDisclosureTextBlock_192cdb0b-8368-4aa7-889a-597591861342" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.corcept.com/role/AvailableforSaleSecuritiesandFairValueMeasurementsTables" xlink:type="simple" xlink:href="cort-20220331.xsd#AvailableforSaleSecuritiesandFairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.corcept.com/role/AvailableforSaleSecuritiesandFairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_cort_AvailableForSaleSecuritiesAndFairValueMeasurementsAbstract_c562f0d3-106b-48f8-8ed6-730d9aed8caf" xlink:href="cort-20220331.xsd#cort_AvailableForSaleSecuritiesAndFairValueMeasurementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_82b5130d-787d-4539-ba5d-30a796618678" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cort_AvailableForSaleSecuritiesAndFairValueMeasurementsAbstract_c562f0d3-106b-48f8-8ed6-730d9aed8caf" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_82b5130d-787d-4539-ba5d-30a796618678" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_6cf33826-15f4-487b-bac8-b5103edfda7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cort_AvailableForSaleSecuritiesAndFairValueMeasurementsAbstract_c562f0d3-106b-48f8-8ed6-730d9aed8caf" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_6cf33826-15f4-487b-bac8-b5103edfda7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.corcept.com/role/AvailableforSaleSecuritiesandFairValueMeasurementsSummaryoftheClassificationofAvailableforSaleSecuritiesinCondensedConsolidatedBalanceSheetsDetails" xlink:type="simple" xlink:href="cort-20220331.xsd#AvailableforSaleSecuritiesandFairValueMeasurementsSummaryoftheClassificationofAvailableforSaleSecuritiesinCondensedConsolidatedBalanceSheetsDetails"/>
  <link:presentationLink xlink:role="http://www.corcept.com/role/AvailableforSaleSecuritiesandFairValueMeasurementsSummaryoftheClassificationofAvailableforSaleSecuritiesinCondensedConsolidatedBalanceSheetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_cort_AvailableForSaleSecuritiesAndFairValueMeasurementsAbstract_37bb0b02-612a-4965-8596-fa40db7c92b2" xlink:href="cort-20220331.xsd#cort_AvailableForSaleSecuritiesAndFairValueMeasurementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_c1a57f78-d14a-4855-bfcc-82a303bdf121" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cort_AvailableForSaleSecuritiesAndFairValueMeasurementsAbstract_37bb0b02-612a-4965-8596-fa40db7c92b2" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_c1a57f78-d14a-4855-bfcc-82a303bdf121" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_55eeb95c-2945-4d0b-aef4-cc81256274b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_c1a57f78-d14a-4855-bfcc-82a303bdf121" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_55eeb95c-2945-4d0b-aef4-cc81256274b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_3e2e015d-38b0-4834-a74f-277e3e26374c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_55eeb95c-2945-4d0b-aef4-cc81256274b1" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_3e2e015d-38b0-4834-a74f-277e3e26374c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsMember_aa6f535c-3557-4dcd-89bd-9fa6d2ef9c3b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_3e2e015d-38b0-4834-a74f-277e3e26374c" xlink:to="loc_us-gaap_CashEquivalentsMember_aa6f535c-3557-4dcd-89bd-9fa6d2ef9c3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cort_ShortTermMarketableSecuritiesMember_82f77950-1391-4bbb-8f1f-ba4a37da83ae" xlink:href="cort-20220331.xsd#cort_ShortTermMarketableSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_3e2e015d-38b0-4834-a74f-277e3e26374c" xlink:to="loc_cort_ShortTermMarketableSecuritiesMember_82f77950-1391-4bbb-8f1f-ba4a37da83ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cort_LongTermMarketableSecuritiesMember_467dde18-a36d-45ea-a7e1-e5a243c83c32" xlink:href="cort-20220331.xsd#cort_LongTermMarketableSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_3e2e015d-38b0-4834-a74f-277e3e26374c" xlink:to="loc_cort_LongTermMarketableSecuritiesMember_467dde18-a36d-45ea-a7e1-e5a243c83c32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_bece9060-cdc4-4df6-96e8-cfcfb48951f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_c1a57f78-d14a-4855-bfcc-82a303bdf121" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_bece9060-cdc4-4df6-96e8-cfcfb48951f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_3f5cd1f1-bdec-48d3-ab6a-22f07d5f62ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_bece9060-cdc4-4df6-96e8-cfcfb48951f3" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_3f5cd1f1-bdec-48d3-ab6a-22f07d5f62ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.corcept.com/role/AvailableforSaleSecuritiesandFairValueMeasurementsScheduleofAvailableforSaleSecuritiesDetails" xlink:type="simple" xlink:href="cort-20220331.xsd#AvailableforSaleSecuritiesandFairValueMeasurementsScheduleofAvailableforSaleSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.corcept.com/role/AvailableforSaleSecuritiesandFairValueMeasurementsScheduleofAvailableforSaleSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_cort_AvailableForSaleSecuritiesAndFairValueMeasurementsAbstract_cd1e17ed-f295-44e9-888f-f03798b48e98" xlink:href="cort-20220331.xsd#cort_AvailableForSaleSecuritiesAndFairValueMeasurementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_a94aac8d-5f2d-407a-87e8-50d6298f22a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cort_AvailableForSaleSecuritiesAndFairValueMeasurementsAbstract_cd1e17ed-f295-44e9-888f-f03798b48e98" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_a94aac8d-5f2d-407a-87e8-50d6298f22a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_e8f329b2-7c67-4615-9ee8-919bccd69c8c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_a94aac8d-5f2d-407a-87e8-50d6298f22a5" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_e8f329b2-7c67-4615-9ee8-919bccd69c8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_d79e2dec-f5ee-45b2-b132-e32321f5a115" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_e8f329b2-7c67-4615-9ee8-919bccd69c8c" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_d79e2dec-f5ee-45b2-b132-e32321f5a115" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_d864de19-0cb6-4694-a563-57dab69913a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_d79e2dec-f5ee-45b2-b132-e32321f5a115" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_d864de19-0cb6-4694-a563-57dab69913a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_8904f777-bf06-4471-84b4-0f5897f224cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_d864de19-0cb6-4694-a563-57dab69913a8" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_8904f777-bf06-4471-84b4-0f5897f224cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_b32b228e-e5a3-4241-a7c0-5bee18a8fb29" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_a94aac8d-5f2d-407a-87e8-50d6298f22a5" xlink:to="loc_us-gaap_FinancialInstrumentAxis_b32b228e-e5a3-4241-a7c0-5bee18a8fb29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d5c7fa15-f5f5-4c06-b4f2-d0b2af41b74a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_b32b228e-e5a3-4241-a7c0-5bee18a8fb29" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d5c7fa15-f5f5-4c06-b4f2-d0b2af41b74a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_61dda9b9-71d2-42a8-940a-9a8528ce8aba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d5c7fa15-f5f5-4c06-b4f2-d0b2af41b74a" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_61dda9b9-71d2-42a8-940a-9a8528ce8aba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_80615319-5fe5-471c-9749-d62beb13e97c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d5c7fa15-f5f5-4c06-b4f2-d0b2af41b74a" xlink:to="loc_us-gaap_CommercialPaperMember_80615319-5fe5-471c-9749-d62beb13e97c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_96b2b216-c875-443d-be43-15caa9f9d91f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d5c7fa15-f5f5-4c06-b4f2-d0b2af41b74a" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_96b2b216-c875-443d-be43-15caa9f9d91f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_03c92325-d5d9-4399-87b0-edd5746b6ae1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d5c7fa15-f5f5-4c06-b4f2-d0b2af41b74a" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_03c92325-d5d9-4399-87b0-edd5746b6ae1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_20b04007-309f-4634-985d-dfde81af586d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d5c7fa15-f5f5-4c06-b4f2-d0b2af41b74a" xlink:to="loc_us-gaap_MoneyMarketFundsMember_20b04007-309f-4634-985d-dfde81af586d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2a8565ba-c68d-49db-8d4a-93b0840e8d47" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_a94aac8d-5f2d-407a-87e8-50d6298f22a5" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2a8565ba-c68d-49db-8d4a-93b0840e8d47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b5162aa7-fc22-4c2f-994c-afe40ba686f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2a8565ba-c68d-49db-8d4a-93b0840e8d47" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b5162aa7-fc22-4c2f-994c-afe40ba686f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_180e7acd-5a0f-409e-998b-e55ab1a20110" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b5162aa7-fc22-4c2f-994c-afe40ba686f1" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_180e7acd-5a0f-409e-998b-e55ab1a20110" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_aef20dbd-1014-4b2e-8d3c-e84166c8f7e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b5162aa7-fc22-4c2f-994c-afe40ba686f1" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_aef20dbd-1014-4b2e-8d3c-e84166c8f7e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e6d7e907-9d15-4462-beef-bac95a02719f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_a94aac8d-5f2d-407a-87e8-50d6298f22a5" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e6d7e907-9d15-4462-beef-bac95a02719f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_b4965326-7708-45b8-9ab6-5fb591047bc5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e6d7e907-9d15-4462-beef-bac95a02719f" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_b4965326-7708-45b8-9ab6-5fb591047bc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_b5b027e2-10d7-4a33-893a-7e68bc393a25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e6d7e907-9d15-4462-beef-bac95a02719f" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_b5b027e2-10d7-4a33-893a-7e68bc393a25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_11c0101e-9917-4edd-979a-67a4b31947b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e6d7e907-9d15-4462-beef-bac95a02719f" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_11c0101e-9917-4edd-979a-67a4b31947b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cort_AvailableForSaleSecuritiesIncludingCashEquivalents_48a195b3-36a0-4846-90dc-37c0eda44f68" xlink:href="cort-20220331.xsd#cort_AvailableForSaleSecuritiesIncludingCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e6d7e907-9d15-4462-beef-bac95a02719f" xlink:to="loc_cort_AvailableForSaleSecuritiesIncludingCashEquivalents_48a195b3-36a0-4846-90dc-37c0eda44f68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.corcept.com/role/AvailableforSaleSecuritiesandFairValueMeasurementsNarrativeDetails" xlink:type="simple" xlink:href="cort-20220331.xsd#AvailableforSaleSecuritiesandFairValueMeasurementsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.corcept.com/role/AvailableforSaleSecuritiesandFairValueMeasurementsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_cort_AvailableForSaleSecuritiesAndFairValueMeasurementsAbstract_7ea30369-c1d9-419f-b863-885024b35553" xlink:href="cort-20220331.xsd#cort_AvailableForSaleSecuritiesAndFairValueMeasurementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_a0a89187-2d64-4adb-acde-d8956f2e1af0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cort_AvailableForSaleSecuritiesAndFairValueMeasurementsAbstract_7ea30369-c1d9-419f-b863-885024b35553" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_a0a89187-2d64-4adb-acde-d8956f2e1af0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_e467a841-f47f-4862-b518-d1dd83f50faf" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_a0a89187-2d64-4adb-acde-d8956f2e1af0" xlink:to="loc_srt_RangeAxis_e467a841-f47f-4862-b518-d1dd83f50faf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_cc1352f7-e187-4a51-a5dc-15e24d39d2b9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_e467a841-f47f-4862-b518-d1dd83f50faf" xlink:to="loc_srt_RangeMember_cc1352f7-e187-4a51-a5dc-15e24d39d2b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_a77faac1-f7d1-432c-a13d-0a92e6da415e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_cc1352f7-e187-4a51-a5dc-15e24d39d2b9" xlink:to="loc_srt_MinimumMember_a77faac1-f7d1-432c-a13d-0a92e6da415e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_fea5b4ef-b879-4072-87cc-82b04aace081" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_cc1352f7-e187-4a51-a5dc-15e24d39d2b9" xlink:to="loc_srt_MaximumMember_fea5b4ef-b879-4072-87cc-82b04aace081" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_e0207cad-844e-4a32-9f26-681ebc1108cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_a0a89187-2d64-4adb-acde-d8956f2e1af0" xlink:to="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_e0207cad-844e-4a32-9f26-681ebc1108cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_a8ff5493-b5a3-4c8e-9630-9695c5a6dcf5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_e0207cad-844e-4a32-9f26-681ebc1108cb" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_a8ff5493-b5a3-4c8e-9630-9695c5a6dcf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestReceivableCurrent_d499fd37-115d-49b1-adf1-94b12f476884" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestReceivableCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_e0207cad-844e-4a32-9f26-681ebc1108cb" xlink:to="loc_us-gaap_InterestReceivableCurrent_d499fd37-115d-49b1-adf1-94b12f476884" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cort_MarketableSecuritiesMaximumMaturityPeriod_f8581714-bc75-4659-8c49-c90a5cf53c2d" xlink:href="cort-20220331.xsd#cort_MarketableSecuritiesMaximumMaturityPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_e0207cad-844e-4a32-9f26-681ebc1108cb" xlink:to="loc_cort_MarketableSecuritiesMaximumMaturityPeriod_f8581714-bc75-4659-8c49-c90a5cf53c2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cort_MarketableSecuritiesWeightedAverageMaturityPeriod_289fa606-031e-4389-a6d3-9f0d53903d23" xlink:href="cort-20220331.xsd#cort_MarketableSecuritiesWeightedAverageMaturityPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_e0207cad-844e-4a32-9f26-681ebc1108cb" xlink:to="loc_cort_MarketableSecuritiesWeightedAverageMaturityPeriod_289fa606-031e-4389-a6d3-9f0d53903d23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cort_LongTermMarketableSecuritiesRemainingMaturity_302660cd-c86e-45f3-8700-2053f8988e8a" xlink:href="cort-20220331.xsd#cort_LongTermMarketableSecuritiesRemainingMaturity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_e0207cad-844e-4a32-9f26-681ebc1108cb" xlink:to="loc_cort_LongTermMarketableSecuritiesRemainingMaturity_302660cd-c86e-45f3-8700-2053f8988e8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.corcept.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="cort-20220331.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.corcept.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_bad913d0-cbc2-47ce-aeac-bd35571cb77b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_213cdc9b-8986-40cf-b792-958dc02e50f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_bad913d0-cbc2-47ce-aeac-bd35571cb77b" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_213cdc9b-8986-40cf-b792-958dc02e50f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.corcept.com/role/CommitmentsandContingenciesDetails" xlink:type="simple" xlink:href="cort-20220331.xsd#CommitmentsandContingenciesDetails"/>
  <link:presentationLink xlink:role="http://www.corcept.com/role/CommitmentsandContingenciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_f61d6cc8-f4d3-4105-a2ea-51787d52b1ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_bb81c711-0c7f-4dc6-a073-4de8b59a4176" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_f61d6cc8-f4d3-4105-a2ea-51787d52b1ac" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_bb81c711-0c7f-4dc6-a073-4de8b59a4176" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualProvision_cb6f6f95-0291-478c-949e-a2de00b11dd0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyAccrualProvision"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_f61d6cc8-f4d3-4105-a2ea-51787d52b1ac" xlink:to="loc_us-gaap_LossContingencyAccrualProvision_cb6f6f95-0291-478c-949e-a2de00b11dd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.corcept.com/role/Leases" xlink:type="simple" xlink:href="cort-20220331.xsd#Leases"/>
  <link:presentationLink xlink:role="http://www.corcept.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_303e5ed2-04cb-45cc-8c43-98eafaa0bbfa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_b3ba8c46-c0a2-486d-a274-665c285ea06b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_303e5ed2-04cb-45cc-8c43-98eafaa0bbfa" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_b3ba8c46-c0a2-486d-a274-665c285ea06b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.corcept.com/role/LeasesTables" xlink:type="simple" xlink:href="cort-20220331.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://www.corcept.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_c92d07a3-cc16-4027-9b6f-756954be0237" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_374f03ce-63c5-4571-98a6-b9996fcdc9af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c92d07a3-cc16-4027-9b6f-756954be0237" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_374f03ce-63c5-4571-98a6-b9996fcdc9af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_1ab1e21f-aede-4019-b7c3-40d65487382a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c92d07a3-cc16-4027-9b6f-756954be0237" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_1ab1e21f-aede-4019-b7c3-40d65487382a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.corcept.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="cort-20220331.xsd#LeasesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.corcept.com/role/LeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_06a52618-dbe1-47a8-acc5-eca8823b1db8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_4f52d893-9df2-4e5e-a0ed-6bb85381b6eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_06a52618-dbe1-47a8-acc5-eca8823b1db8" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_4f52d893-9df2-4e5e-a0ed-6bb85381b6eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_0703b6fa-9ff8-47e1-b466-61df538f1b25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_06a52618-dbe1-47a8-acc5-eca8823b1db8" xlink:to="loc_us-gaap_OperatingLeaseLiability_0703b6fa-9ff8-47e1-b466-61df538f1b25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense_a189dcc4-fee3-4038-8e15-09c535223ddc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_06a52618-dbe1-47a8-acc5-eca8823b1db8" xlink:to="loc_us-gaap_OperatingLeaseExpense_a189dcc4-fee3-4038-8e15-09c535223ddc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.corcept.com/role/LeasesRightofuseAssetsandRelatedLiabilitiesDetails" xlink:type="simple" xlink:href="cort-20220331.xsd#LeasesRightofuseAssetsandRelatedLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.corcept.com/role/LeasesRightofuseAssetsandRelatedLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_79b84565-134a-4d88-93e4-7f7131a01c34" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_9b1d3e45-d33b-4564-886a-7ead43499b4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_79b84565-134a-4d88-93e4-7f7131a01c34" xlink:to="loc_us-gaap_OperatingLeasePayments_9b1d3e45-d33b-4564-886a-7ead43499b4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_6ea6b9c6-8553-418a-b847-b9bcf242e2da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_79b84565-134a-4d88-93e4-7f7131a01c34" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_6ea6b9c6-8553-418a-b847-b9bcf242e2da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_50145c51-8e4f-4881-8acf-9b58d30c03f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_79b84565-134a-4d88-93e4-7f7131a01c34" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_50145c51-8e4f-4881-8acf-9b58d30c03f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_addfa216-6f72-41cb-acf5-a0d87ff839c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_79b84565-134a-4d88-93e4-7f7131a01c34" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_addfa216-6f72-41cb-acf5-a0d87ff839c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.corcept.com/role/LeasesFutureMinimumLeasePaymentsDetails" xlink:type="simple" xlink:href="cort-20220331.xsd#LeasesFutureMinimumLeasePaymentsDetails"/>
  <link:presentationLink xlink:role="http://www.corcept.com/role/LeasesFutureMinimumLeasePaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_363fc122-387a-413c-b4d9-e091fec92d8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_6ffd162d-d555-41bd-84c2-662a193ddb8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_363fc122-387a-413c-b4d9-e091fec92d8f" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_6ffd162d-d555-41bd-84c2-662a193ddb8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_411f5e03-f087-4592-8d16-abdec52c41ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_363fc122-387a-413c-b4d9-e091fec92d8f" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_411f5e03-f087-4592-8d16-abdec52c41ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_c8ce5ee7-2119-4799-a6ed-b43eab419063" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_363fc122-387a-413c-b4d9-e091fec92d8f" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_c8ce5ee7-2119-4799-a6ed-b43eab419063" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_9b553355-2843-477d-9ae2-f4812dba1498" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_363fc122-387a-413c-b4d9-e091fec92d8f" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_9b553355-2843-477d-9ae2-f4812dba1498" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_47003f09-1f5d-4f77-bc88-bbc2942dfee5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_363fc122-387a-413c-b4d9-e091fec92d8f" xlink:to="loc_us-gaap_OperatingLeaseLiability_47003f09-1f5d-4f77-bc88-bbc2942dfee5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.corcept.com/role/LeasesFutureMinimumLeasePaymentsDetails_1" xlink:type="simple" xlink:href="cort-20220331.xsd#LeasesFutureMinimumLeasePaymentsDetails_1"/>
  <link:presentationLink xlink:role="http://www.corcept.com/role/LeasesFutureMinimumLeasePaymentsDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.corcept.com/role/StockholdersEquity" xlink:type="simple" xlink:href="cort-20220331.xsd#StockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.corcept.com/role/StockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_226b6255-4ea6-446b-b153-e2ca192596c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_d4414b8b-d52c-4427-b737-619e73056184" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_226b6255-4ea6-446b-b153-e2ca192596c0" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_d4414b8b-d52c-4427-b737-619e73056184" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.corcept.com/role/StockholdersEquityTables" xlink:type="simple" xlink:href="cort-20220331.xsd#StockholdersEquityTables"/>
  <link:presentationLink xlink:role="http://www.corcept.com/role/StockholdersEquityTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_cf59f32a-90e9-4ebd-bc99-eda561582003" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_a7566859-72e4-44f7-a0af-8b41bc41ef9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_cf59f32a-90e9-4ebd-bc99-eda561582003" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_a7566859-72e4-44f7-a0af-8b41bc41ef9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.corcept.com/role/StockholdersEquityNarrativeDetails" xlink:type="simple" xlink:href="cort-20220331.xsd#StockholdersEquityNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.corcept.com/role/StockholdersEquityNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_2b9144f4-8988-4bf8-97e2-8b977cb3a278" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_d5292aa2-e281-4c97-b77f-d441208df9f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_2b9144f4-8988-4bf8-97e2-8b977cb3a278" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_d5292aa2-e281-4c97-b77f-d441208df9f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_0056decd-64a3-428d-a7af-93e2203e4a1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_d5292aa2-e281-4c97-b77f-d441208df9f5" xlink:to="loc_us-gaap_PlanNameAxis_0056decd-64a3-428d-a7af-93e2203e4a1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_d39f0151-dbf7-4f28-a910-eea3957aeccc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_0056decd-64a3-428d-a7af-93e2203e4a1f" xlink:to="loc_us-gaap_PlanNameDomain_d39f0151-dbf7-4f28-a910-eea3957aeccc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cort_StockOptionsFiscalTwentyTwelvePlanMember_351a9b14-29ab-46a4-a013-dc8fdd4ece2f" xlink:href="cort-20220331.xsd#cort_StockOptionsFiscalTwentyTwelvePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_d39f0151-dbf7-4f28-a910-eea3957aeccc" xlink:to="loc_cort_StockOptionsFiscalTwentyTwelvePlanMember_351a9b14-29ab-46a4-a013-dc8fdd4ece2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_c0442146-394c-4c01-8f95-2c221ce05cd7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_d5292aa2-e281-4c97-b77f-d441208df9f5" xlink:to="loc_us-gaap_AwardTypeAxis_c0442146-394c-4c01-8f95-2c221ce05cd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_16d665df-c07c-4bad-8d1f-524ee72b758e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_c0442146-394c-4c01-8f95-2c221ce05cd7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_16d665df-c07c-4bad-8d1f-524ee72b758e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_089ace95-43ee-4615-a39d-e597b8205915" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_16d665df-c07c-4bad-8d1f-524ee72b758e" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_089ace95-43ee-4615-a39d-e597b8205915" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_009ea75b-ed09-4097-bb5a-70debc64f60e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_d5292aa2-e281-4c97-b77f-d441208df9f5" xlink:to="loc_us-gaap_ClassOfStockLineItems_009ea75b-ed09-4097-bb5a-70debc64f60e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cort_NumberOfStockOptionPlans_d11f1d63-def3-4044-9adc-8f57fdea2ae2" xlink:href="cort-20220331.xsd#cort_NumberOfStockOptionPlans"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_009ea75b-ed09-4097-bb5a-70debc64f60e" xlink:to="loc_cort_NumberOfStockOptionPlans_d11f1d63-def3-4044-9adc-8f57fdea2ae2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_db229ca3-ac20-46cc-80d3-bf5376a430d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_009ea75b-ed09-4097-bb5a-70debc64f60e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_db229ca3-ac20-46cc-80d3-bf5376a430d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_c5ad446e-8a0c-4e60-b0e3-def4c0688ba6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_009ea75b-ed09-4097-bb5a-70debc64f60e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_c5ad446e-8a0c-4e60-b0e3-def4c0688ba6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_2f738fb5-a3ba-43ca-8c89-6b791cc5ce18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_009ea75b-ed09-4097-bb5a-70debc64f60e" xlink:to="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_2f738fb5-a3ba-43ca-8c89-6b791cc5ce18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_2f53dc99-4e02-4963-a0d8-2e93445b9209" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_009ea75b-ed09-4097-bb5a-70debc64f60e" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_2f53dc99-4e02-4963-a0d8-2e93445b9209" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_2acc51cd-fd54-41af-9297-bf76b3f1fd34" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_009ea75b-ed09-4097-bb5a-70debc64f60e" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_2acc51cd-fd54-41af-9297-bf76b3f1fd34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_620014fe-37f0-47ae-9f2f-6af8acff7d29" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_009ea75b-ed09-4097-bb5a-70debc64f60e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_620014fe-37f0-47ae-9f2f-6af8acff7d29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_98b7a29b-27b4-4472-af8b-7fae9d7a242b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_009ea75b-ed09-4097-bb5a-70debc64f60e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_98b7a29b-27b4-4472-af8b-7fae9d7a242b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.corcept.com/role/StockholdersEquitySummaryofStockBasedCompensationDetails" xlink:type="simple" xlink:href="cort-20220331.xsd#StockholdersEquitySummaryofStockBasedCompensationDetails"/>
  <link:presentationLink xlink:role="http://www.corcept.com/role/StockholdersEquitySummaryofStockBasedCompensationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_e6e45469-3b12-48a7-ac8a-93df97abe269" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_fec0a1ba-117d-4a84-b5a1-4f4cef2c2ca5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_e6e45469-3b12-48a7-ac8a-93df97abe269" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_fec0a1ba-117d-4a84-b5a1-4f4cef2c2ca5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_e5b66c43-1dd8-453a-8b82-4dbe28d744f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_fec0a1ba-117d-4a84-b5a1-4f4cef2c2ca5" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_e5b66c43-1dd8-453a-8b82-4dbe28d744f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_c0b3fc6b-ae31-4286-abae-2b88e759417a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_e5b66c43-1dd8-453a-8b82-4dbe28d744f6" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_c0b3fc6b-ae31-4286-abae-2b88e759417a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_02fad08f-6b8d-4df0-b4e2-b8096ec85c16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfSalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_c0b3fc6b-ae31-4286-abae-2b88e759417a" xlink:to="loc_us-gaap_CostOfSalesMember_02fad08f-6b8d-4df0-b4e2-b8096ec85c16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_f2904e81-b3a9-4489-894b-a2d2b5b027b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_c0b3fc6b-ae31-4286-abae-2b88e759417a" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_f2904e81-b3a9-4489-894b-a2d2b5b027b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_b9df44e6-a129-4fa4-af9f-04e73df0bd53" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_c0b3fc6b-ae31-4286-abae-2b88e759417a" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_b9df44e6-a129-4fa4-af9f-04e73df0bd53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_ea9bf141-4c3d-4784-9446-aa5e74d91905" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_fec0a1ba-117d-4a84-b5a1-4f4cef2c2ca5" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_ea9bf141-4c3d-4784-9446-aa5e74d91905" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_01f55bf4-9394-49ab-b8c2-b15cf978ecfa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_ea9bf141-4c3d-4784-9446-aa5e74d91905" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_01f55bf4-9394-49ab-b8c2-b15cf978ecfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_594037e1-0215-4981-84e4-e2cf286d1b3e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_ea9bf141-4c3d-4784-9446-aa5e74d91905" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_594037e1-0215-4981-84e4-e2cf286d1b3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1_84ac2f61-709d-44c6-a2e8-ee0b389fe0d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_ea9bf141-4c3d-4784-9446-aa5e74d91905" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1_84ac2f61-709d-44c6-a2e8-ee0b389fe0d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.corcept.com/role/NetIncomePerShare" xlink:type="simple" xlink:href="cort-20220331.xsd#NetIncomePerShare"/>
  <link:presentationLink xlink:role="http://www.corcept.com/role/NetIncomePerShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_bcdafe65-1da5-42be-af63-17cb4f20190d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_7fd2a5a3-1dd5-45b8-941d-3daa93c0abcb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_bcdafe65-1da5-42be-af63-17cb4f20190d" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_7fd2a5a3-1dd5-45b8-941d-3daa93c0abcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.corcept.com/role/NetIncomePerShareTables" xlink:type="simple" xlink:href="cort-20220331.xsd#NetIncomePerShareTables"/>
  <link:presentationLink xlink:role="http://www.corcept.com/role/NetIncomePerShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_ab3f3c7a-438a-4386-b50c-f27591291610" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_ccd1c144-09bc-422a-a238-f2d9fff52f48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_ab3f3c7a-438a-4386-b50c-f27591291610" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_ccd1c144-09bc-422a-a238-f2d9fff52f48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.corcept.com/role/NetIncomePerShareScheduleofComputationofNetIncomePerShareDetails" xlink:type="simple" xlink:href="cort-20220331.xsd#NetIncomePerShareScheduleofComputationofNetIncomePerShareDetails"/>
  <link:presentationLink xlink:role="http://www.corcept.com/role/NetIncomePerShareScheduleofComputationofNetIncomePerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_87093b7e-4e31-44d8-b822-2ac3aacd8305" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAbstract_dc67020e-14f7-4516-a909-84a5a8fa95d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_87093b7e-4e31-44d8-b822-2ac3aacd8305" xlink:to="loc_us-gaap_NetIncomeLossAbstract_dc67020e-14f7-4516-a909-84a5a8fa95d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_509329e1-8b1f-4cd1-8a56-c2611196ae0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAbstract_dc67020e-14f7-4516-a909-84a5a8fa95d5" xlink:to="loc_us-gaap_NetIncomeLoss_509329e1-8b1f-4cd1-8a56-c2611196ae0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_96558ebe-aa0d-47f6-a08b-d975bbe81a99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_87093b7e-4e31-44d8-b822-2ac3aacd8305" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_96558ebe-aa0d-47f6-a08b-d975bbe81a99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_30d5af5b-e367-49e0-98bb-3d57cf5ff7d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_96558ebe-aa0d-47f6-a08b-d975bbe81a99" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_30d5af5b-e367-49e0-98bb-3d57cf5ff7d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_a2238187-4e78-481f-917c-d3ee5878e9fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_96558ebe-aa0d-47f6-a08b-d975bbe81a99" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_a2238187-4e78-481f-917c-d3ee5878e9fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_5fb5d709-0f22-4c3b-88a6-89be4492ff88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_96558ebe-aa0d-47f6-a08b-d975bbe81a99" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_5fb5d709-0f22-4c3b-88a6-89be4492ff88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_4d89a32f-83b3-425d-ab0a-b74438f3e921" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_87093b7e-4e31-44d8-b822-2ac3aacd8305" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_4d89a32f-83b3-425d-ab0a-b74438f3e921" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_e779c755-c481-456e-aecc-89ff31779d0b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_4d89a32f-83b3-425d-ab0a-b74438f3e921" xlink:to="loc_us-gaap_EarningsPerShareBasic_e779c755-c481-456e-aecc-89ff31779d0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_7896deb0-80cc-47db-b654-b07b8bcf13a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_4d89a32f-83b3-425d-ab0a-b74438f3e921" xlink:to="loc_us-gaap_EarningsPerShareDiluted_7896deb0-80cc-47db-b654-b07b8bcf13a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.corcept.com/role/NetIncomePerShareNarrativeDetails" xlink:type="simple" xlink:href="cort-20220331.xsd#NetIncomePerShareNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.corcept.com/role/NetIncomePerShareNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_5bfd4f0f-d980-4363-a880-d8e102d20973" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_bae75ea0-3214-4f60-84dc-e0301dd234ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_5bfd4f0f-d980-4363-a880-d8e102d20973" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_bae75ea0-3214-4f60-84dc-e0301dd234ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_4cd74394-1cde-4d30-b7fb-85f4ca24ddc7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_bae75ea0-3214-4f60-84dc-e0301dd234ef" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_4cd74394-1cde-4d30-b7fb-85f4ca24ddc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_d892c271-272c-4924-a5cf-1f9425e99079" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_4cd74394-1cde-4d30-b7fb-85f4ca24ddc7" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_d892c271-272c-4924-a5cf-1f9425e99079" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_dcc2b9a5-b1a9-403b-b051-02d9080a49a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_d892c271-272c-4924-a5cf-1f9425e99079" xlink:to="loc_us-gaap_EmployeeStockOptionMember_dcc2b9a5-b1a9-403b-b051-02d9080a49a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_1a012e09-92ad-4b12-a683-55467f505c77" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_d892c271-272c-4924-a5cf-1f9425e99079" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_1a012e09-92ad-4b12-a683-55467f505c77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_85884fc3-ee91-4ff2-8a27-7ae255fb684c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_bae75ea0-3214-4f60-84dc-e0301dd234ef" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_85884fc3-ee91-4ff2-8a27-7ae255fb684c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_ce1e5462-03f2-4147-83a5-873978375e2a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_85884fc3-ee91-4ff2-8a27-7ae255fb684c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_ce1e5462-03f2-4147-83a5-873978375e2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_d73a3567-3674-4fed-9820-1978da0e5cfa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_85884fc3-ee91-4ff2-8a27-7ae255fb684c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_d73a3567-3674-4fed-9820-1978da0e5cfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c89b5184-26e1-480f-b316-dce36649241c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_85884fc3-ee91-4ff2-8a27-7ae255fb684c" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c89b5184-26e1-480f-b316-dce36649241c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.corcept.com/role/IncomeTaxes" xlink:type="simple" xlink:href="cort-20220331.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.corcept.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_63b07c0a-c688-4227-83af-6537082a6cd9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_80e1728b-3255-42b4-abc0-999e446bb4c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_63b07c0a-c688-4227-83af-6537082a6cd9" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_80e1728b-3255-42b4-abc0-999e446bb4c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.corcept.com/role/IncometaxesDetails" xlink:type="simple" xlink:href="cort-20220331.xsd#IncometaxesDetails"/>
  <link:presentationLink xlink:role="http://www.corcept.com/role/IncometaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_b769117c-c1b7-4365-9c97-487c8751cefd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_e71e9172-5ea5-415e-9c1a-a89c6e325705" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_b769117c-c1b7-4365-9c97-487c8751cefd" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_e71e9172-5ea5-415e-9c1a-a89c6e325705" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease_ffe9d6bb-60c3-41da-8dfb-ecec241db467" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_b769117c-c1b7-4365-9c97-487c8751cefd" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease_ffe9d6bb-60c3-41da-8dfb-ecec241db467" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_707703f2-1046-4deb-8903-f8fbc3378e83" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_b769117c-c1b7-4365-9c97-487c8751cefd" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_707703f2-1046-4deb-8903-f8fbc3378e83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cort_UnrecognizedTaxBenefitsThatWouldBeOffsetByAChangeInValuationAllowance_940ff1e1-b7f3-4f32-af6a-6cde4d802724" xlink:href="cort-20220331.xsd#cort_UnrecognizedTaxBenefitsThatWouldBeOffsetByAChangeInValuationAllowance"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_b769117c-c1b7-4365-9c97-487c8751cefd" xlink:to="loc_cort_UnrecognizedTaxBenefitsThatWouldBeOffsetByAChangeInValuationAllowance_940ff1e1-b7f3-4f32-af6a-6cde4d802724" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrentAndNoncurrent_517e6c4d-b300-4f06-9060-0867a65674d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxesPayableCurrentAndNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_b769117c-c1b7-4365-9c97-487c8751cefd" xlink:to="loc_us-gaap_TaxesPayableCurrentAndNoncurrent_517e6c4d-b300-4f06-9060-0867a65674d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>image.jpg
<TEXT>
begin 644 image.jpg
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M; 50;?QT6(QL#_-OS/#%#[_BYU\$W-4=BLG;SN*6Z]OO<^G2)4R;-@T=.G3
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M@$'P'3BN[8W6/3JCXIH[>! 9C9C+"S!O^@2,7K$%^];,QH V:['?[@1LMVS
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MNB()A2I)*)32*PF%6O*QQ98-4U!WZQVXA?K@[N+A6#)K+>QC7R+2YQ)VUAF
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M!-'[.'3H4"73EV+_94XS:U]$"(7\7 15>G/8IYE=5719O7KU%*];[=JUE<]
M+Z&I8I>6SS[[3$FTH=<T-=/U60PU]J#FU#>W":?U/ZY$$W8T^2=P3?E9M?D@
M*1XO8N/P7/OP?"G@,#(:42EC@9.>(R;R&>*TER6L$0K9T43?8<AV;RR9PAC
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M7L3!U]]7B:_E32$]WHSCY>].+_U;XJZI22KQ$&;L_0LQ@QY" B%+\!B[JVN
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M6!IAE80F9HYSBI]0'A(1@M@( >;,\K4%'I]Y#)<[+G"\+O;)ZS<4\"2X\R:
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M8AP3PYCX0VU)*#1=CPX^PO6OKR,\1SAZ_Z<W9D^9K7[&0/&2;$)2R6N1==1
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ME$HI"87_B"4;QHT;)V"-<R*&R50HI(?PY$EQ?A,G.,$41HO5<PB$Y\4%PM>
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M_TT<7SD,O:H409$2%5&IP2!,M?- X*M N.V=I@X8KX+R3:=CXQ4_G?$^AHH
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MH<?$C3CE98\M<RS0LV$3M.[8'JW:=$>'89MPVOT&'$\LQ;B6M5&_40LTZ;X
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M^6P3R!Y'4HD1#Z%>A4(A8PCU'DIZ*T4Y\F+GV'#4AL\_ZUK6O8?L#N&%EUY
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M[[N-Y'5"=@*7OMZ^*%.A#)8M7Z;4N_IY7EG/ZCV%A,(C]D<0<R<&N1FR0^G
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MZT>#\.O4?3AV2\7]K!\RYGF5NM]4(*0V;-N DF5+PF.5!\[5.X=S@W@2-8A
M*/6-L@2>25[>'&2D&E1L3*SA\H67I+[*'_.<GH+DE$)@D-(GE?">TE!?129&
M8GSP>*S?M1X!(P(0;2DWE1D*S5!HJHQ!X2&I49[+* 4+MWZP.+ "TX/875*O
M?WI2"=?OE79: 4)#&"  $82*@L+B)97<QKF%"S&LYT$LL4O$N5U',+S)<FP^
MQ'$I+QRT6H OASG@;#1AS!_[1BW&R X'X)>>@>P47YQ=.0_#.XY'T^8[T/)'
M?RP^D(#;&>JZS#SGO'8$.CT04ORM_,U%02'/X=.:5&),Q8%">JDX83 SDA]:
M/<*LOT5QTH,[??JTXC'D5%Q<$L]7>C5\_[YX/[/Q[R7&.HZ/)H<[F>FJ=LB8
MXCU3W*02#A<3" OIO!0HUE$"8G%3[;!WS'9LOYF(>S$GL/K'69@]U0-)0BM!
MS@O0>-@N6'G%("WB$DZL6X455L?AEG 'X8=W([+S083U"<#.'O/0N$QK_#!^
M-YRC3(1" K&)227&='KO:8PM,Q:A"T(Q]/.AF#M"'D0UXF$R=F^-F'1$-8F_
M@2Q:1%U1H-C18 PJ@5B+Y!Z(.1B#Q>Z+L6WO-OB-\$/4QB@S%)JAT'09@\(C
MJ>YXSFL4+&S6P"*T&:9ACO*^J>(0\].05$(8Y)!Q_OBPHJ"0QZ\NJ>11I:3$
M8/?88^C?/PC[ N\@YN)V3&RR"%;[V8WTP 'KV:@_^AC.Q[ F\X/MJ&48T\E.
M";]A:Q4?FP+[X\"JT9Z8UF$Q^F_QA<==TVL&>N0X]1 ]M/GC2$V!0GH$G^:D
M$F,J#A3JQ2Q8PLC3' /T3U*,/+ST&NZ0&X'#^UY>7O(\W,2MF%N(](G$[<FW
MD=Y4[OUY\F6Y3Q0@TW"O/K:D$@X9FQC/>E^\U7A_G\M$TN%@'!W<!\/:M\>D
M@Q?A?=45>WN.P=1A&V!SX@#V+!F.EO,.8:^+ PXO&HD>O<9@^?%+B')+1)JU
M'/I.>=9"0^#OL!*]/IN"I5O]31O!5IE4\HCD$MQ<=!.N55T1ZQR++[__$GT'
M]<W[T 3IDTJ6B5V4P[E[!]>N7U.RT3FAMS[6EQ[]4Z=.*9TWAAG0W+V%(.6:
M<U)O_Y'^<)CB #M[.YPZ?4J)WV1G+X2589XX=RFGHF(,,;>G5VY@+J[-O(;C
MPX[#;I]L^[#8(3O3.XD$4:FO@K<$X[OH[S#+:1:"A@:9H= ,A>ID"(4V-K>1
M(XWW%H\$/+=W%RQN?@N+W.<P%1/ROEVTGJ:D$GH)C<% 85#(XS<$0E.'C V5
MDIJ#<R<B,?^W[>@_V!&[PV[BQJ4#6-)T')9N.(_+E_=APY+Q^':1*WQB$Y&:
M< )KNT]$[];6.!>3B+A[67+L6=BP-07.5KM@.:PCANZ\"'<3CX5\QZ02>M@(
M.GGUX7T5!84$P*<]J<28'@<4,@OYHIQ\-AQF/1FB%S<M+4V),60#?U)ZF@X"
M1;8S;&'W@AUN_><60O]?*"(F2H=-+1 2R.A=>EQ))29T7AX2GVW>:ESIXWR"
M ,4:S&K?$%_5;H V0Q?"ZGP +NU9@$43>^/7[D,PLM=H+'3T@.OAN9C0MSDJ
MM?H=8SI/@]N/WKBZ) =WE?O^-J(O[<64UFNQ_=#5HL,B-225/"16/:'"M-W.
M85:U6;CJ=17-?FJ&_@/ZZSXO2BS/<T\@])*.P*T8''4^BJU;MX+SB=)3K(<W
M=MI>?_UUE"I52EGEJTRY,N@_K#_27=/A6<L3P]X>AIH?UU3>_Z'%#PH,MA?
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M&&)C;ROW Q,J..R9'T@+@T(.:5+%32JA9Y/GX*1T# R]8Z9"R-.45$*X-^;
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MPN(I6VYN%WG8"82LCQZ7GD4H=%WGBMEOS49X\W"<>>?,HRN:%"2.(!0GJ81
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MPJ*@D!"A3RK1QW\9BDNW<0W?"*$53A!+H"!(96>G2-D;>/_]'@(56V%K>U<
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MPHTX-^P?UPV]F[;'U,-!",==!*V<@:G-AF/@#%\,[>F#FJV/8<K!8%6#]H9
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MNTKV\?1\DU<7)JY?S,Q.-H1:$A+8&'.8C\.=:I?.HP@3](YQM96PL+PW58@
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MDM].QK$'CE6_]W%EU2*H1!$M=(0Q0I$,!#<Z;,1_FIGL:%(3%+*-)1#*^Z8
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MQ^X"A)<EV0H4-M2A4(?"VZ(:H9!MU-T>5&($0AI!K@)9$7*3HA'IYP%W=QD
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MK"=0QVD!>FS-1((>5*(9)F@AU(-*#&6H-C^OGU.^7WP1B%=?W2CE>4$@I(-
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MO6K1S0HJ(51I 3IC4 DC5;4$E1 F&%3BZ*@]J(2^;P0J3AVJ%:VLQFE[+65
M(#0N^T*P4PN$!"@C$'+J5&U^'L_Z0PLK+926SOKQ76S6K"F"@OSQS3>'\/[[
M1Y3GH,5*2Y#E\R-8:P%"+G=S,X)*6 Y:\I>4<(F1(P*$\9+L! H;W5-02$O<
MDT\^B08-&BC_^^JKKTJ=.J1TIK0>\G]YS.\]I4PHY+/@CA5\-MP*[8^NC<:]
MCZN"0A8!/Y+W#5KZ#&-0B58@Y/MM!$).65O07G%OXOVN^^%VT@V9J9G(=,K$
ME457D+(A!>X.[I@\8S+^_H^_X^>??U86L69]H[C0M*VMK0*&K']7<J]@Y]Z=
MV#QZ,^8^-!<K7ER!4_:GL,5V"YY^YFD,&#! &< 8]S_F@M;\#4(. ?'2Y4NX
ME'4)1Y<=Q:%?#B'>,1[%5XIQ*>42 H,"P74/S4F'0H-T*-0H2Z!PMD!AL7SE
MK0>5Z$$E)A9"M59>2X-*S,G6=HV\DT]CS1H_ <)D].@1IPGH>-UW4U!)9?$]
M.GFR!/_][W8!PG.2MMYS4,C(3EI9A@X=BA$C1F#MVK4RV/13_/C.2B-!*.-B
MS2=/GE12LI:0?@TR0B&?"9_-O=!_5 N%?+_XS[LLJ(1@YA[HCA-[3R!S4R8*
METMG81(4S+V.Z;[ 1:F-8H0P]T3F]+&'AP?<_=P-7_ =EWN?]]D\]/BPA^$S
M4?OV[3%DR!#%&GCBQ(GKZB@MAQX^'HB(CT#BR42DK4Z#]RQO[+;;C<PKF4A)
M3U$8A4O=F),.A0;I4*A1ED"A==9H1,C+Z29 QZE7M2* T8>0TW4R@%(Z-C4B
M0-*J5)N@$H(L@9"63K7GIPAAA!D9"&J:,B8 <+J;4*8%!@A ? 8$&JU!);1,
M\1YH)54K6N0XU6P$0K7/D,_,&%12>6%J2[1CQP$\]UQ/ 8%(:9!7" S857QC
MN6CEY:"$]Z]E4,#[)A!R4*!ERMH85,)K(*"K%:%:FB9Y%H5XXXVO! @72]IY
MSTT?6R(N%$P+#O>7/7[\N&*Y86=[*Z5#H4#AV HH)!!*>Z5LO:8%"&]&4(FT
M5VJ"2DP5%1R%,Y/.(&%X J(V1R$T,!1I&8:]B+EL3&4^X-3_L&'#,&O6+(R;
M. Y31D]!ZA9IZ/?)EW+]O?KTPKL?O&LX6$0_6 YJTF5D22LWX="HW*)<1,5%
M(?I(-))7)R-U=RI\S_IBM\MN99!#5X,H:8RJ@D*N4ZAO<Z=#H6:9AT)G0<(_
M&9 P[V%T/;,$9Z0C2Y&ZI=:Z9 1"/:A$#RJQ-*BDLGC\BA67Y9T,E=](1XL6
M[624;3F$<!!QMP:5&,4^@SZP'!0D)!2B:]=6 H03)=U[@2:6BE-S[&S9D=+/
MZ[0T !;O):M!]SH4>CS@ <]Q H5\OVE9D_?M;@@JN4%\/YE7QIUEOF6("HW"
M%OLMRE[$5&4HI/\@IW[??>]=U&M4#PU?;(C/'OT,I]\XC7(_P\G[#.B#EJU:
M*O]-&:$P*RM+!NM'E/\U*C<_%[''8Y&R*@67=EU"1$ $+J=>1D)B FS6VRA3
MR[1*7JK"0A,J?V\6OXEQ+N-P?LAY'0IU*%0G\U"XVV G+)'_?W(P^AZ,0=9-
M""I1"X3,?[."2CA=6-N@$I/WUF(9+62T$&KICWC-!#D"#0>&:BUT1B#DM'=M
M@TIHH51;ACR>UEU:*&DAU +U,C#&=]]%X957#DA]2,)GG[41"+GFW%V=F)]^
MI+4)*B&(,ZAD]VZ#"X!:F0:5:/%C99ES4,&!#<NSK(Q0V%*'0@M%,*33/W>7
MX"X3IAWPS=0]#87- ^#YD"<\K:2AY99QM! 2Z-3"R,T,*J&%4JW?NAQ?MK\,
MQ6N*4>)=HNQ4PBC?_0?V*RX)%"&D7KUZTJ9*HRIBI+*/KP_V[ML+3U]/A.X)
MQ=GA9W%DVA$49!A&H%RNZ/WWWU?^F^)_#QHT2-K#8NF;/!7(R\W+E?:J'#E^
M.8B;'H>T VFX$'X!YT+/(3DE63F6KA'+I3&B!=RL6X2T=Y=R+F%\['C8;+=!
ML'6P#H4Z%*J3>2C<@OL*'T"=4_U1Y] B3+BH8;Y1I >5Z$$EA&&U026FHG6,
M]__KK[NDH_U"1NGG!(@^M1A".!AA_KLUJ(163@Z("+7&.E!>?F\O7JU5QKUH
M.5W'8(*;K7L5"AL_W!B!;P?BW*/G$/"IC#REW=9DX;L-0277B>W387F_-I;C
MV)QCV&2S"<'AP0@+#Y,V;(OT1[PQ#B[]\=133V$-K04B+DFS=_]>9.5(@\_U
M"X/D]H\DPL[6#BD9AGK6HT</O/GFF\I_4URRZ-=??U7^FP.6%2M7P.6("Y*.
M)"%J2A0\9WLB*R'K:E")<:J84?8,9*$?K5DHE/8J94L*YOK-Q9;=6Q!D':1#
MH0Z%ZG0]%!I,60>N^. ^]^&H<W )ZESH@'E8H7QNJ6C9($QPJHN.^6JM6Y2[
MNR&HA%"A%D8H0@RGK/D>:X$1YN>4L8.#X1FI%:>,";,$*JU!)02BFQ%40CBG
MQ4R-"-%&'T*>7ZV%C].ES,OS$PC5EB&OE_FX#B'=#Y8L62L=;4.!.R_I>+M:
M!"$$0M9!#@K43AE3/"]]"#DHT&(A)'=PRICEH 4(><VT$!((N2:C4??ZCB:U
M$=>#8X0R@P%NMH_AO0B%-CML\,)#+R#@OP%(>R@-%W^4D8N&0$0%",]*,@*A
M6G'0+^W552!4V5Z!]A !0DA[PYU* CT#X7S 60E<8GFZ2X=DW(.8,$9K'6&$
M2LE,4?Z[R(NC8/E P"SY<C*\_+R0G6/H4UGG-K$QK!#_FY]11<5%.';F&$YO
M.(V8A3&(WA"-V'.Q*"XM1EY!GC)-;%I7>2Y:#&]PA9#V"M)>G=]U'I]>^A2S
M]L]"Q) ('0IU*%0G(Q0^]E@L=CEEHS0?6.61A3^[;D6=2_(0Y:^+?T?%5&Y,
M7&J!SJ[F9/0A9$>F!Y5H@P%:M/@,[M6@$M8AGI_Y^3N4G9TZ"/DC!)5P4$ +
M964_4AT*M8M^AEP<>,^>/8K%YV;J7H1"!R<'M'R@)4(;AB+I_Y(0/U&M$Z'H
M-@>5*.=G.R/M#5@E*MHKUA4&+*5QZZGJ) !:?DY&L=+G(4R2ACZ'.YR4[2I#
MUOXLY&=>/RW&*>7*B[/SVJY;Z)SW+>T5I+T*R@O"<_(W;/\P/=!$AT+U(A1R
MF[O''HN1^[V"3!GE6.\_AS]=[B(X^'\*%#ZZY%%E,58F/I=__.,?F#!A0L4O
M7!,[7VX[5IN@$K;3]"&D'YP6_S-:V=F1TD*HUCI&L0.FA9! J"4@@.T'@;"V
M027TPZP8F*H2SVD:5*)6M$Z9 J':9UC;H!+6(=X_W77X'(W3_ILV608A;"<Y
MS<I!":>,U0(A[Y=U@%/&M!!J<3M@&;#\"?5:@TJX_!)7O#!G9=:AL'9B)\MI
M9$8GWTQKX;T(A3Z./ECTKT5(?#$1)_]ZTA!H8JG8MI@"H18+(6< 3(%0;9O/
M]Y,60@(A?T>MA9'M"RUT!$(.X-6Z29'KZ!8B[;VRXXN& :RR91XMG#0\"N*<
ME[_Z\C=\WW!]21H="M6+4#AF3!$>?C@6 P9<0:) V>I+^_"7\G\J0,B__BG]
ME04VF;@>V"NOO*(T@*9B9TH(T(-*#!9"+4"H!Y48+'L$2NZX8FJALP1"F/^/
M%%1"(.0]598.A;67<7TX+E=#2+P9NA>A,'YC/(X]> P9;V3@\/V'X3&&A&>A
M^'Z9 J%:<"$0FOH0J@4R'B_O*3BK2PNA6B!DM2%($NBTG)_YZ8-(H.3Y-?19
MC.XN7U*.(H<B%%PJ0$%1 7R*?%"OK!Y&[A^I0Z$.A>I%*!P]N@2//)*&"1,*
MD2]@XPPG_.4J$M;!+/DS5=NV;=&O7[^*?QE$JPP[0TX9JX4)BLO%<,J84*,U
MJ,3)R0 56JPSIM8A+3Z$M0TJ,?H0\AG6-JB$BX2K!4("E-%"2"#4,N5+$&)0
MB18+'<7[)U 2K"L#E240PJ 0/C]:&K4 (?.O7&D PIIFC,R)=8"#(I:#EORT
M<A*&";55;%:@2(?"FR,&#NR6PF94Y\W0O0B%KO:N^/'A'Q'Y=B3./'BFZKV/
M*\O4AY#6<+70PO>;0&8$0I7ME6*1(Q!*>Z5LP:?%0L=\M,Y)GZ<:""EI;Y3\
MM!!J:*\8S),[-1>V#6WQO]?^AQ:M6RA;/C;[OAG^D? /3#TU58="'0K5B]8U
M*ZL2//QPNG3(AC?#I9J]C[EU5*M6K00*KW4"M"[I024&H-*#2M27(:^7^9B?
MOV/.AZ\F"*%U^H\85&)..A3>',7(@^;:A0P@J.RSI47W(A2NV;D&SS[\+'S?
M\H77 UZ60:$I$&J9,N: T10(U3(]VQ=.&=-"2!<;M7T.^SA:**6]@?1YFH"+
M4]W,3Y]O#>V5,F7M!$1/B4:[!]KAP_8?8N"@@1@X<""^G_8]'DY]&)..3]*A
M4(="]>(TY>#!Q7CDD0L"10;S3%5['U-&*!PZM+\"@(PW84>F!Y7H026U#2JI
M"@BIRA!B.BBAE9<6PC]B4(DYZ5!X<U0DE94[G7 *.4?+7'\EW8M0N-&X3N%_
M ^#Y+S-['U>6J0_A'1148K'8O@1+XI0O+80:^AQE06]:"-E>:VBOK@:5R"#4
M_[0_7FS\(K8Y2N-5H3CY:RA_ND^A#H6:1,O8C>L45@^%K5N_(PU@;V6*BQVA
M%A]"PH,>5&*P[.E!)8;G6!V0F4)(ER[_@Y75 .5SX[0YK=5J@9#W:^HVH(4+
M>/Y;&51B3@8H;"% .$&'PEJ*RWUP:9";L: UK31=NG2Y]Z#P$8'"=P0*'ZP&
M"MFVF *A%@LA+6JF0*BVS>?[6=N@$@*ALR2>7ZUQV1A40J#4,F7-^R502GL%
M::_X[\!S@6C0J $V<^VN"G%'$WWO8QT*-<L2*)PB?T:5E16C??LV H9#E,Y,
M"\Q0!$):"#EUK,6EA]89^G[1?TU+?G; A!$&IFCIS&]W4 D!AGZ8].%CQ+?:
M_'QFS$<8HS^F6A&H")-;M_)],?Q;K5AVO'Y"?4U^I%P\]AH4?BH=<!\IPU*I
M USEOT3*4/T%$ CO]* 2<](MA=>+4[]:T_GSYV50YJ(*"KD4"*V,!3*J,DT]
M>_:4<OGLWH+"[0*%CPD4=A H?%R@<%054/A'"BK1 H3,;QI4HL6'D$ H[16D
MO5*>IX@+6U=FE7/RIT.A#H6:90D4SI0_4[5O;X>N74]HFFJC" -&_S<MXD+N
MM%!QREJ+>,]V=@8+CY:@EML=5$(K*V&:UB4M0$?1,D@HU7+]%(&4,,7?T2):
M]A@8Q+I@B;9MVZ9TM'Y^/OCRRX_PY).?X:VW3@L0C4.;-E\(& I=J=#=$E1B
M3N7EQ0+&0P0(MTIRE&?0^)Z%0JZ9^O'''VM.#)JC=2_!PD)@I/+4J5.E#6RO
M./6;IH<>>@A=/^\J==0/_VEV#T'AXP*%'PH4/ED%%.I!);4/*F%^::\4(#1I
M;\P!D0Z%!NE0J%&60.&;>_^+OOUZ8]"@4>C=^RS^\8_=>/KI$<H4,A/W=:PI
M]>O7!U96,S!P8!#>>><<7GYY/G[YI;=T)N:/KYSZ].'Y1TO^P_CD$R_\][\S
MT+U['U7Y!P^>A"%#3N'33Z-1K]Y*Z<SZRV^:/]Z8^O3I(\]G)$Z>/*X\&Z.%
MD$#X>P:59&0D8\&":1@Q8AU^_#%6GN$AO/UV7^4:^TG95+YN<XG/:N# 9?+<
MO-&APSY\])$U>O:T//^  ;WE^<V7/%%XXPUWM&PY"3UZ6)Z?QPT9,DI^QT\Z
MT5"!ND7X_GO#[[)\S.4QIG???5?JW!.(B C"JE4[I".WE_(\AY]^FHZ__.7_
M8?-FPSZDENAN"BHQI\+",GD'/ 4(4R79"A0VNJU02*@:-FQ8Q3>_CQ8M6B3U
M9H"R=FJ=.M)*U2+]^]__EGI@>44@ +[PP@O*=+&2AD@:.A!C)HV!\WYG^(?Z
MX_E7GL>&G9RG_&-KXX&->.Z)Y^#;R1=>3WK="(6F0*@'E1@LGFK%H!+Z$'+*
MN%(UU:%0A\*;+DN@L-&6%_'!>VU0[Z6O!08.2H>T1]*O,LIN@S9M:DX=.K1!
MJU9M\<03O=&@@;N,LCWPX8=#T*Z=^>,K)Q['5+_^-]()[)#\1]"I4Q_YK)W9
MXRLGYN64]XLO=I<.P 6M6X<($(V7Z^IH]GC3],$''PATU)%.;Z R14@+'6%
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M5>)2(]RIA)'":F&$(L30ND<_/BTPPORUV:F$ '/@0 GJU9N)$2/8RJ@3(9A
MQ* 2M3Z$%(&0RYT02#9M"L ++_P;MK9K*KZM6;Q^4R T3KE:*A[/"&^6 7]'
M;1G0&D;+8'4[E=0D AV!B&!JSLI;T[M**S6M:[<SJ(060@)A;&S%ARK$9\[Z
M0ZCEGMX&W?XE:>C#^=9;;RF[@G3MVA7UZ]?'\.'#Y3T9H2E96ULK?GIW>F)P
MRS__^<]KT=:$&%JD%DGB^G527R.W1^*5IUY!ZT]:8_ XR5=3&B]I\F",^VX<
M7-YRP<4!%[%G\AZ,G#02@R?(=S6EB9(F#<;P@<.QY9,M".X7#/M)]LIG9H^O
MG"KR#_EM"+:UW8;X'^-Q=-)16$VR,G^\F31DRA",M!J)(W-EY,099 WM[4T)
M*N%T+8-*"(35]#EL-QY^^&&T;-D28T:-P:1IDS!B[ B,_W(\_'KZX>*TBW"8
MZX!I,Z=AVG1)TZI/4Z9-P<BI(S'JAU%P^]X-R1.2L7_>?LR9-<>B_,KYI\GY
M/Q^/$ZU/H'!D(3P7>&+QG,75YI\U:Y:T#2LQ9]X<C)XV&A/Z3,#B;HLQV'LP
M#A\\C.2AR4BT241YF88IMKM$.A3>9)F#PEV%;OAW<'?\N/<D7@J7E[U\B?*Y
MI:)EA#! RP8[4[73I10M?+79J80!!2P^+DRM8@FRJR( ^$K#XN)2B"9-WH*5
MU:\5WU@F6C6U!I50!$):I@A4H:&$LW-HVM3R.LGSFP*AVF=(&"&0,;^\#JJM
MO,S/M2@9_Z'50L@Z0 MA=3N5! 4%*>\JER:I+-9M^N^Q#FH1[YEU@&"O5;3L
MT4JHY?X)U:Q#=!?B[YCJBR_:W79+(9=@&3UZM#*-_-MOO\G KTB9OJH\Q55=
MHL\NI_'N)G$9&^Y>HH@#%4+A"$FS)4DQL$[6:U(/V[=OEP\L%"W07&Z$8*ER
M\*6(LSA!D@AD9@9/-8IYI)XJZ_!IL&8KHN\<SZ\E/V>!3(%0;9NO,JB$_JB-
M&S66MN$04@M2<>+@"63;9N/\T//8-6T7;+?98KO3=C@Y.=6<=COAP-X#2-F9
M@H11"7 =Z:J\'UMW;(7C#D>E;:HN[7#:@6,NQY"])QO9 [-QY)LCV+!R VQW
MR#7LV&XVCS'Q_ <.'<"1 T=P<==%I,Y*Q::1F_#VA;=A?\P>.8-SD&"3H$.A
M#H66RQ0*=SAFHUP:%[O@=-SG[( _G_\)?RK]&Z9C0L71EHG6)5IG"(9:1(L.
M+62$&BVB_QG]UXPS/&I%H"(,\/K3TXO0KMW[Z-^_7\6W-<N87VM0"2&6($6@
MXN]0(2&&.FGJ4%R="'2T+-&'48LXU<W\6H"6,$/?0UIH>?U:H)[[21.*Y7VO
MUD+)=_799Y]5@AWH[Q40X">?1</=/1?#AJ5B[-@0@3)? 53ZHMWH'U8YT;<L
M,#!,CL^004TR9LPX)P,30U[+\OM*_G-R'<G8NC5#KBM,P-9/9?X02:FPL\M%
MKU[16+?.X._&>^#_>GN?Q=MOORQ .%'2[ML"A4>D<!C]2R#D\^_1HX?<IZLR
MK;I32-S2Q$ 1YF$YW@UB<!57)+AJ*>1@:;&D;R3QU92Z?R[T'!HTO'Z7B6I%
MB&)7PYW*M  =@>B,)%K)"%=J1:L>O5)X?BV;$="6P+;>.&6L5KQGMO72YBE
MJ)9?..#BP(] R.5C+!AC$"2>>_XYS%LP#V/'C,5G?_L,1^H?P8(F"]"B20LT
M:M((C9LT5NIX=:GARPW1J$$C='RV(_;6VXNM3;;BLR:?H7%3R=NTB0SDFU:?
M7FV*EYN^C*\?_QHGZY[$J<:GT*U)-XOSUV]0'__\^S_1_%_-8?NB+?8WW8].
MG3OA[Q?^CBFGIR!F<(P^?:Q#H3H9H?"QQV)E9'L%.=(H#'<YCSKG>Z-.R;\4
MO\)Q):.OCNQI":!%@-O=7?LL3W'8+2@HP9DS99@YLTB@+E\Z]CPYSO"]\=BJ
M4D%!OJ1BQ,:68LN60AP_;LA?5%1S?L/Y#?EC8LJP9$FQ %4^DI(,YR^@DZ^9
M?,;$_+RO@H(B>1ZEV+^_"'OW%@B<,?*U &W:M+K6"=0@6I=J$U1B"H0$(N.T
M.^OD2R^]=-6AF,^;'10=IAG%R_+(SR] 9F:)P%R)=- %DB</V=F&^[?D&?(9
MY.<72[Y2R5\(#X\\^3WC=^;S&1._-Y1!B4!4&5:N+,*! WD"Z);E9^)UL@PB
M(DIE%%P$+R_6J>HCD^+CS^/EEQNA;MVGI)%N() B#67]?FC0P ___K>#?-Y)
MOF\@#6@#Y?N:4N/&#25O5_F=O7CNN?62OY6J_$P-&[:2M $OOK@7SSS35?E-
M_H:Y8RNGQHT;R/D_1+UZ#GC^>3\\_G@_^6_I."0_OV-JU*@^'GGD7_C+7Y;?
M-DLAZPJGCAET0;"SL;&Y"GF6)B,8+EFR1/EWF9;1P^\LX][O_0=(>T!XX9(C
M7)VFMZ0*B_*YB@&<1?T'_8P9R,PE1S2L:G!U+U]"D0;W#"40A)'3](?DM:@M
M KID\+[OX* 2<XJ*BD(#>=^>>?H9_/303W!IXH+@]<%PW^\N@WD7[-ZS&[MW
M5Y/XO?-N[-F_!P>7'X3O2%]D[LE$1E@&HB.B$1IF/JCINA1>\;_[0Q$S* 8Y
MJW*0$Y*#N,@XR_++,;10=GBB ]:V7(MTIW1DAV?C0-P!U"VNBQ$'1^B!)CH4
MJA>A</3H(NED8C!\^!4D^@+S(]QP7\D3QE 3U%WW'-Y[[STEO?_^^^C0H8/B
MX'WML_?0NO7_9 2]2SJL8#S\\"1P3;L//C!\9SRNJL1C6K7J),<OPAMOG,;3
M3X_$ZZ^W5O*;.[YR,N3_1.!ME>0/QZ./+A,PZ"#_MOS\+5NVE?--0O/FW"5C
MIG3"K3%@0"]<O!B'CS_N;!$4F@:5: DH(! :]Q+F\C>F?IC<N)_KHW%=-EXS
MG>RYL'9B8B+FSY^/]NW;RCW\)-_M%KC8+?7W)[SU%N_+_#U73H9G^+$<OP&O
MOGI(GI\U_O,?0WY+G^$''[24M%7J0(@ V4R\]MK[JO*W:L4T2\K^M-SG:+G'
M3O(NLK>H3OGP]3V.@P=W"(AOE0')-GSYY4DL7)@JGYV7P8F+-/);E>\L21LV
MV$M9'Y#\<0*UX?(;NU7E=W3<BJ%#=V/2I'"I!W&2_P#V[;,W>ZRYY."P%;_]
MYH*??CHO@[14&:"<E,^W8=>NK=>E0X><\?//%P4*;>59_?[K%)J*@Y+4U%09
MA"5)>W)956+D\KY]^Y2.EK]SITN!P@\$"H=*>T"(VRIIK*1IDBJL^N>"+>P_
MN!L1]['=(8G6.K4B$-(Z2"C4X.^J6/5V2N(]$&[5BE/>MWNG$@(AW;VY4XB*
M_(P&/G;J&!S'.N)$GQ,X,>D$%BU>A 6K%F#%ZA7*X+NZM'+U2BQ;OPQ'YQ^%
M;R]?'!MS# 59&LR\7$R"%F9.W:MTT:'*8LMPH-$!),VZ9J*-D;^&\C=\WW!]
M21H="M5+VF6,&5,B()<,:^L"9"4"N\J<\)>K2%@'[^Q_YP9':UJM^.^A0P=+
MOL$"(!,5H!HP(%9^;XM\-NQJGNK2D"&#,6+$8'SRR2@!""?ID(,Q<N0ZBQW/
MF7_8L,'X]--Q:-S81>DH1X_>([\YTNSQE1/S\QZZ=1LNY]\BG7&PP+&]0%8K
MU*W[##B=2$?ZFJ"0%L*;$51"'T+ZXG$*UE29F9E8MFR9/!O#?=%:4;=N73G6
M'YT[M\%CCSV#SS^?C2^^."/?GY%[F*W<5^7[-9=X7+]^@]&ERUCYK8,"F[Z2
M?Y52KN:.KYR8?]"@P6C1PDJ>X5'TZA6/4:.V2;D,49ZON3RFR<IJL)QOL,#W
M8!EP;)/?"Y;?6(,__[FW?.8AUP;YM_DD7"SGDGY9.F:F[[^'U$5(/6"]OO:Y
MI4FJ-SIV!+IW-_]]38D;>W3N#'SUE?GO:TI2O,JYAPPQ;,5(M[3*R='1X![!
MZZQ39X- 84/$Q-P=TZ_FQ$;]L(R&[BHH'"+M :&&G3G!;JXD3TDBBZ"0$&0C
MB19"+4"8+HDP12#4DI]YG"012"+Y@4J9 J$6%Y7?,:BD2M$R2IB4]CHL(@PN
M^UW@O-=9L116FUPER6#3>;$S J<$XLS8,U@W>QW2,E0N3<"%L;DP-0<%&H+@
M^ Q25J3 YFD;!-OSQPPZIR]>K4B'0HWBFFDC1I3@D4<RL&Z=X<URP1Z!PFN+
M5\^2/U/1T7KHT*$5_S($=; #X\*\6D0@8D )ITNUB$$ANW<; E.T1#ESR0]:
MYNA#:(QPI9,X%ZGUE@]KVMN5/H3,6YN@$EH("826^F'R^IHU>TV@D'L!6^.S
MSQ8HY]:R9 K%*%LN^:(E0I9B/OIP\OJUS +R&3#*W+B?-:^G?OT4_.UON7*?
M0+MV-Z8//S3 EVGZ[CL(V /??GOC=Y:D;[X!?OA!>_ZOOS;D)YR:^[ZFQ+P3
M)AB645J\F-NYF4_SYT/J)/#FFQM0KUY#1$;>G5!(-PCZ27IZ>MY=T\?]*MH#
MP@RG+J=+LA0*N1@SO^)BUQJ"X!2K(&&4"RMK>=\)<0QJH860UZ)6!!@C$&I9
M]Y1 R*E>(Q"J+7:>GWGY# F6:H&2%D:^+@RJJ13 9;&2)1'(!:CCHN/@<M %
M6=DJ"I,@7LU.)36*YY?V.G1V*%H^U1+;M\IHL4(Z%!JD0Z%&T>_-VIK3QQ?A
ML,W@I5QY1Y.9\F>JMFU;P\K*$'C!?627+C6L1ZBE3:>EDC!W;;D-=>(T+8N)
MEA,CT*D1%\;FTCD,:B#<&44G<4)A31O^WXJ@$DNT90MWE*@OS]T?7;J<D6MT
M5YZE6K',").,D&59$I#5B,<3Y@FT?(ZFS]!2L0YRRIV_8SQ_5%017GHI'.^_
MGZ' (C^OG+*R<N5=#9,R\H>7E^_5Y.U][;^UI)N1OS:_X>-C2,;?N3$QF"8$
M&1E92CUE6\4VZVX3_6$C(B)D,'D6%R]>5/Y]I^LJ%!K; UH+V4U8"H6<,J:%
MD#Y\S*M6A$#"&*=-.7VM1GR\A#A&.!-(>2UJQ/R<LJZ-A=#H0TB@(A"J+7(-
M0277B4!(HQJ? <^OUCC-ZZ5K$(&2]R&*3XB'ZP%7:8\L@$+FYW/GVI:T$&H!
M0I;[ 4G2+@:>#43]1O6Q82,?B$$Z%!JD0Z%&$21&C#!$'SML,W@JW[#-7?%8
MZ>QSE921D2X=];L8.+"_8M7ALC,$0K5 QO:?NVOLD!>CJC7H:A(AC#NE,,J5
MEB:U8I0S@8Q+EE1>0X]E7Q,4YDFC3LO8S0@JH:52S<H<MK:;I(Z^BO7K ]&R
MY0FYOI-2ORN^M%"\7BYUPF5G>'[I[U2)^0GSO'ZNQ:=VV176 2Y.SN?'2',^
M3Z/"PO(%"KG'<JH"J^9TZI0;7G[Y1;SR2CV\^FK]NR:]]EH#-&O6&&^\T<1L
M^L]_FN#UUZM+C=&HT8OR[M@*3-.'M(F4W]T)A5P2Y*14'@9-W0VZ 0HY"+(4
M"CEHK$U0"2UDA*G:!)700D@@)=BH!05.6=?&AY ^<\8I8\ZHJ"UR'F\,*N'O
MJ,W/ZZ6%DD!'(%2;WPATTEXIYZ]HK\Y'G\>>/7L4%Y\:Q?S29RK!/18<?H-8
M[OLDL0[(\PPX%Z! X>8MUR+=P^2O@?SI4*A#H281"BNO4U@9"NNNJWLU(.#=
M=]_!/_[Q;VD8YRE3QK0.T9].K3C=Z.1D@"HMUB7"!*?8")5:+&1\?VD=))29
M6Y2X)B@DQ-ZJH!)+9&_O@?KU9V/ITEB\_79?6%M/K?C&,A$@C>L0\ORF0&:I
MZ"Y "R%WJ]&R#A_/S^?':>O*=2@L+ _UZM%?,EE9@-J<6$;WWW\_9LR8@:U;
MM]XU:=NV;7!V=A88WJLI<6TR!ASQO@\>/%@!A5*(=YFX/B'=((ZR$MXET@R%
MA $]J.3:E+%:-Y]:!)5<%6=BN/0.IXRUC$$XY<O\/']%>\4 *T\/3\7:S8C\
M:L7STD)((-0R[<\Z0*!E/:C('Q 8@(8-&BIMBE%ZH(E!.A1JE"50^.Z!=V%E
M985APZPP?/A0=.JT"#__'*KX 6KQ#:</(J>,:[53R7J#PSW7)%0KKH''?HA
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MR2J///((FC=OCIX]>RKI\W&?X\'D!S'I^"0="G4H5"]+H- TT,085,(I8RU
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MTTDI$QD^VS&J]4+8;(\PF161B\OPDG(9@"&3EF-;A&&^@[Z7-065F%-86*Y
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M3N*3_G:PWL&YZVQD^.[ Z#9+L&EW=$6[5X[RPGB$'5B%B>/68^.!&&7&A77
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MF-&Y=XL8??G__M__P]=??XTGGWP2/7KT4*R'ZE2.LO0(!&T:@!]^^PG_71:
M\,Q<%)Q;A?GC!Z/'@-&8/7HP?NJY&7M.>L'[^%YLFK\0*Q9/P* >0S!_MP^"
M W9C^[R^^&'D'"Q?-A'#NH["U#G'$:G%6F2!%"C\0*!PF+QO[, Y7=A'T@1)
MA"-1E7L?5U9M@TJ81]IK/:A$DLJ@DDOIES!QSD3L&+ #GO_SQ.'>AQ'B$X+
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M4V!XUZY$20?@Z>DNO^VI# *"@H*4R+U''GD$;=NVO2[_B!'#Y9D'*WGI0\C
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M#L G/M.P76]Y)I)"]L*^^QAL^FHO(FE=8G"#6K%K,/4A5&NAHY\X@9@60BU
MR*Z;YV=0!L%,"_$3")E?KC_ *P OO?P2=NS>(8.(299!(9N9-9(8W%.IO;)(
M-R.HA!9" B&GKZO052AT&8ES$\Y)F4?B;EOR2HUT*+S),@>%>P4+C4#(O\F8
MHGQN5'5!);0&,J*2%D+3W0OH,W7PH(O T&6!#V^\^.)QZ>PJOJR0@X,#7G[Y
M9<7*:"HN==&D21-LW;H%R<F7Y'^/8/_^? %.0X!';&PHPL/#%?^FQHT;*U!2
MG4R#2LP!(55=I_=[!Y54%H]?NC16[O4X'!TO"[RUQ*!!O2J^O5&TVKFXN%P'
MQL(<L+*Z).58A.^_[X://VY3\<TU;=NV#4V;-KVA/%)2T@7H?\&OO[K!SR\7
M'AY^\/;VD.LR#-VY+ G+X]BQ8VC0H(&R=EUE\;X)A%)-E.=16;<4"G,N(GK_
M/$RU_@9OSCP ETNYR#LT!\O'#\4<WV1DIGO!]LM)\KVSXO)TU2#A/@4C%@U#
MRP$C,>^'+IAT(%YIVU/6S\"<KX=A_;DKR+J);2^7J:&%FV7'P14;O\C(2.79
M<L#%^[>QL5&^KW+]M%NDZMX/RU6*XIBC<%DY'#U[?(_/!TW!N.U^4C<\<<1^
M.8;U'8*)4Z=@["X_A$:>Q*Z%D_'=%P,P:L)X3)HZ _.=?1$D[WZPVWK,'#,)
M,Z>-Q\AYCMA^]I(!B&Z!S$(A?>/,0>'FBOZ#5D'-025I*)6&PO\-7X0.+T;^
M<7NLV3 ,'6S#$)&>A=P#HS%M\7S,.>"/()<%Z#]\&'X=/ RCQZ[&FEUA2"*\
MY68A9?@1'.CEBU.^9>IYBN^G*1"J_0&.96YC4(DB3OD:=RH1!08'HLG+391]
MN"=.G%@S%/*\=V!0B3D9H7"8RS#X3?&305:8#H4Z%%HN<U#HA)VX7_Y>EK^'
MY6^<_%&L5PS$X)1Q54$EW.S?N)"MJ64C)R<+>_?N$9",Q[??7D:S9B<%"KWA
MZ^LEH&@(-]ZZ=2N>?_YY!0Y]?7V5Z4<J5*B 4Z5V=IL0$9&#!0M"I%,L5ZQ]
MIN)Z4H2029,F*?D)HI5% "'(F0:5F%/E3F]@Q;ID['L)<ZP:G'I5*U,?0@:5
MJ!7;+4896UGYX[77ULHUQ,OU=91.JE_%$3>*4.CF=E">9[R27]XAK%Y=BBU;
M+LDUI K<_80WWWQ#F:[D<V/BKA0LAQ=>>.%J>?C[^\KQL5+V.?*<CPN8,G^4
ME.DI>:XWMG0L-]/R8/[@X!BI'V57+815L<PMGSZ^?!:G[4:@]:)#V'TQ%9=W
MS,;RH:.P,3(+&?FA</UQ-.8-ML=98P=6=!YGEP[$B%DS,&'=.FRQ_A[#%F_#
M-D]O[)LS%%/[6F&5G^15W>/6+#;H##[A\Z0%D9#]W__^5][91_',,\_@I9=>
M4MZYWU,W!PI%)7G"+&E(OIR,U-1T9.06&XQ0>5(FL5&(B$M!5A$?:C$*KF0B
M-3D9*9*2D].0GE-HX(MB@?&$*('E6%Q,SU?-'&IT Q2RVC/@@*MV540?!P4'
MX:6&+V']IO77K#M:=RI)S4?IXG!XO1J,LZXER,K<"9OEH]%F?1@BY;W.W3<2
MT^=.Q^S3F2B0ERD_+Q-7+A_!ZA[6Z/W1,IR,$0@,*,+E?D[8-/4XG"RV4E:(
MUT\@- :5J!7OF?=.< Z2I-;":!I4PN9<[90QCV=T-K>^XWU4N-@0)&AHJ!$*
M608$2I8Q@SJTC+TXIKX9026T4%I@Y35"X22720B?'(Y0EU ="G4HM%SFH' +
M-J.I_.V2OPYHCR$8J+P<EZL)*C&*%@M:,MB!,:# J-S</($Z#\R9DX66+7?B
M'_]X2YYQ?31JU$"9:J;X@O[M;W_#<\\]A_KUZV/)$FX1P*"#,#FND?Q["YR=
M2P5&$LQ:E\X+9;&#Y+IIS-^[=V\I\VNM2%5!)>9T?:?W&08/[JL<3^OD[QU4
M8A3/3Q\\,M"($5OQ^NNM$!# Z,\NU7;*V=E9 H7[D9@8KTQU<\K[Z-$2^9TX
M*?\$!2C__O>_"X354YX;$Z?JZ8/XSW_^4RF/!@WJR_?U\>670Z0,$_#BBXNQ
M?;L_$A+.X^3)$W)M-SY,T_(PY&\D<-\/HT:E*%;B2@;(ZW3+H3#-!YX.H]%V
MR1$X)Z8A9><U*,S,#X/K#X3";?!B6UHNWWNLQR3K>9AK'XA+G'X^M@*S^WZ&
MMSI^A%=?_0#?_S0*:P)SD'T+VUZZ91#6:8%GW>S3IX^\"TNE+%[4]@QJH9L&
MA37(\L=I")JZU;H!"CF-.$L2U_>OF#7@XM6-&C;"QH72?Q"$:"'48EUB&^5:
MB L#?3#VY;58MR=*!@>'8;=R(MK,. KW^"B$V%AAVK2Y6!/$H+!B>0:E*"WQ
MP\[!8S'IG24(="U%T?%4> ZQQHPIBV$74PR%L2V1*1 2R-0"'=O'VQU40J C
M4-+D;P)D%D&A,?_-""IA'=!BOF;W54U0B3D%RE_#\H:P<;%!^N1T!+L$ZU"H
M0Z'E,@>%.^"(1^2OO?P]@Z<P$2.1$B/OA8R4:&6KSO>= 0U<=XW36XF)UZ(W
MSIW+%["Z+%!9AAX]1J!IT\;8NM5._KU=CC-XS-)2^/333V/^_/G*]#,M?U1X
M>)Q Q2_2"1[#IDUQ G77FREI16%C;;1,L<&FHSY]LHPR#2JI.%VU,NWT/O_\
M8_SXXV\*4-('C[.P:H&0%C'3*6.U^<FV!$(")2V%JU;9R/4U!BVM-2VNG9U-
MJY^=7'NDLN0+XW4N7\X14'1%?'PL!@X<I$P3$P3YW)D(='R&SS[[+!8LF(^=
M.[=+Y[,=\^:=%:@,%6!K@6W;=@BHY"B+O'+*V C@M!8SDH_!101-6EF=G+9C
M^O0=<JWNDJ_0+-2;ZO> 0J_M H7+3L#U4@YR#\[%\M'66.R?@HP,'SA\-1XS
MANU#*+*1$GD0Z^:NP4K'(,08.X:B-"2<<\?A(VLQJLMOZ-EY'IPO%"J&C5LE
M/L^//_Y8@9*__O6O"A!RT6N6'7TX?T_]7E!XI\DL%'+J>+2D"BB,C8C%+_5_
M@5M/-X!-F!;_,4Z2R. U<?QIS.[X(UY]J!7:_F\>=GF<P$&GI1C8]5>,GCH*
MOWP]!.,6',#9J"!XV<_"[!7+L6#Q4"SO/A5.?<-P>6\B_)?.QO VC?#VVZW1
M;>XN'(XI0&%-C$#K%('0.&6LUOQ*HP&!D$$E_)UJ9F:K%)\GIWPC)5T;VULN
M3OD2R'C^2A8ZBZ#0&%1"(-02%,*Z0: E5&MQ!R8$&X-*5"P=Q!U-:"F<[C(=
MYR>?URV%.A2JDWF?PKTF'H5UT"UJ'D[M ;S-!)68$Y?3(%CX^7E+92R0#JL8
M$R9D8<F2' 5HA@W[#>W;W^C#Q@5Q^:(R M-4/CY9 @@'Y.5-$$"X*!WA'ND@
M/93(S!3Y0?JNT7I"GT+F9S!%91'HJ@HJ,2>6?;-FKTJ%\\,WW\Q&\^8KI0$Q
M6.G4JK9!)7SF!$+F-[H%VME9WBG3PK1TJ8] =:# 698\MV)YCH%8OWZ= /(E
M#!DR1,JC?<71UT1_M5=>:2+/.$&!:@X(&"'L[1V$1HV>$T!?KQSGY^>G-*XL
M=^._^0YQ.KI)D_HX?)CS'L#IT]>NOR;=4BC,/(^P/5,PK-M[>.RS@>B^\2R"
MCFV W:R!^-9Z 58O'(Y??IJ-F=O\$1NZ"QN[?8AV[7MAX/3E6.=X!&ZGPI"4
M< X>?AXXY+ 8\X;.Q:REWH@OT."OI4*;-FU2 JX8^#-UZE0$! 3 WMY>L:)K
M N-:2(="$RB<(6F,I IWDBR_+.ROMQ^Q8V-E1&;X3)4(A)RJW%F&E(.^<%@U
M"],G3,>,V;MP-.0"+ET(@/O:A5BU9 &F+7;%H8!T7,F*0?BAM5B]825635F*
MPQ,]D"A061R;BLC#6[!QP61,F3P'*QR.PO-2$8JJ8P1V Z9 J-9"=R<%E="'
MT,RL5HU0R->I-D$E'!W2QY1V"4.WJDZ$6 N"2LR)EL*GY6^PZV#X3_9'F(ON
M4ZA#H0J9@T)G[*J(/?X+ZL1UQO^<3\&/E=O"EY.6HG/G I3@ S>WBY@^_0JF
M34O%I4N&X=K//_^L="AL8$VU>O5J//'$$TIG9Q0M;#8VEW#__=.Q90O?\%*!
M#G\%.MDA,3J3&Y;3.LERXU3EM]]^BU6K5F'MVLU8M^X49LR($X@JLA@(J4V;
MUN'55Y\7X/07,(E%Z];A\OL57ZH0+6*F0*AVBHN/R B$- 81SBA+.V7FY_G7
MK"D7,(R1YQ6$D!!_Q<)$2RK!^M=??U46(JY<'NO7K\:___T$=N\.4%P&"(54
M4%" /.<GE/*B&%C$,B ,,A""O\T7-20D&"^]]"JZ=5N#?OWB\>&'>S!W[DHI
MDY7*FGS5Z99"86H0O+=/Q; !W?!E[Z'HN_HXO"+.(?C()HP;,AJ3QPS'L(V'
M<29;'G;<,>RU'HC)4V9A]N(EF+OF /:?B4)ZW'$Y_S),'#812^V/PE>+KY%*
M<=#$0"H&7AG%SS0]@UI*A\)*4,CI8P)0'I"\*1G+GEV& (=K[9C%XBP&IPJY
M==WY,I2C&*4EQAV$2J[M(%2>BXS+:<@N+#6942Q"7E02,EWR442@4):]*1<@
M8/X2%!>7H*2XM/IFG!9\4R!4V5[=<4$E50"I62@LJSB8YS4&E2COM0SV,J(0
M( VQYT5>H%Q4<0HB3Q^ T_I-<'#S0&!&/@H+DA!U\A B-_D@8G@8=G4[BD.>
M24C+CD:XIS,V;W3$+M< Q&54+$)>E=@-6QA48D[1)='X*ODKS'.<!Y^I/CH4
MZE"H3N:A< ?N*_\7ZEQLC3I.*S#67>50I4+'CU_ T*'Q @+92$Z^-E\X9<H4
M 85N-YCKN60*I\>X= V5*HT:^7#Y\DBT:/&Q@ ??$EK.B@24(A1?1$(AE_"@
M.(7)3?J;-FVB3$^_\$)+@9JITI$>DV/5#=?L[;<)E+3 @@7!>.LM7UA9L851
MIYL15&($0O;YIH_+DDZ9 .GK2[@S1(JGI7&*/5"9VF<=-_H!5E4>>_;LQBNO
M?"S/(%(!6B,SLGQ83BPOHQC,PNE-EHDQP.?BQ02YQJ%X^ND]:-3HA)3#3TJY
MO/)*XZM^I%7) (6^^/13[5#(^S/;&$KC7YB3@9249*2FI"']2B&4-:F+KR#S
M8A1"(N*1G%.,E/0T!/IYXNB!?7#=YZ+X6+H=/84C4J#>)_8A-#  $1<SE&,S
MLS*59V JNE+P,P9<T8I*?UMSOI>6RGB_1K<*JJ9G<*MD2?W[(\HL%-*GD+%X
MG"Z5INO<0ND_GI+^8ZN*_H/UCQ,D7/]NJR0M6]?Q6HP+4QN:1'7BF)U R.G.
MNS6HA!!5*:C$G$RA<,+$"6C9KB6*2J3]8R"',:A$<9,J0VE6-**<1N/'"=/0
M;7>R<$0VBD(W8WK_GOBR=7M\^^MP#-U\%N&1>^#P26_8/[X:.U_?@VYMQL!Z
MF_0]V^9CH=7W:-WI.WS_]0C,=(M";%6F6D*HBJ"2&Y0E[;Q?&E9[K(:CK2/.
M3#^C0Z$.A>ID=OJX_"#N2^B".HXK4<>K#R87VBB?JQ%G@)<O9X1KL72*?.[7
M*B4[R>3DY!LJ*CM-1AS3'XV!RX0AIO3T(B5((B_O&MC1?XW'<VK4^#O\+"GI
M$F)BH@7&(K%U:S26+4L&ETW)5[D7[]:MY_#<<ULP?'B"-![?8<0(.@U9KIL5
M5&(."*F:.F7FI^\@@V(8'$.+*U5<3'^^'.49&V6N//B?(2&Y6+,F2<Y1?!4(
M*>9E.55>!H468@/X&%KS\^=+,7Y\AEQ#GD!>KI3+104H:4VLG+>RPL/S\=)+
M00*?J<K]FU-U0,1[2951A7$Y'0(O8=5T>1WNJ1T?%X=<D\CI4GD^%Q,,#CQ+
M%R_&\R^\B(:-&PO4-L2++[P@UR3_;M@ ;=NT5O(6EY;C?'0,#KL=5$"7%FNC
M;R6?Z?[]^Q4K*I=)XG0Z!S!:&VAS]UO=,[B5JJG^_5%U Q2R.LV4-%328DE2
M#$%G@_!"PQ<,T<>6RF@AM)5$.%377!E\WLY*,@*AVBIF"H0$,K5 Q^;D3@@J
M(1!6"BHQI^N@<-($M&K;"D61TL@2:$V#2LKSD1.Z#TZ3NZ!YSQ'X:5\*\C/"
M$+:A'X;.78?-)X_";<5B#/[?0AS:[0#/=JXX]$T8?$/3$1N7*.WD66SK/AHS
MK3=CG\<![%HQ%!_./XA=468<\]ELJ PJN4YLHP\!<:OBT#VJ.Q:[+H;W5&\=
M"G4H5*?KH'";P=*Q.S89]^W<BCH^?5$G[PE,4N9&+!=G!KF/+0U)%6YFJD0?
M/.X48@RJT**P,$-@24T!#>9$ )LZ-54:C1@X.V>B??MW,&C0KQ7?UBSRCNF4
ML=:@$B,0$C KJZ9.F4L&<1W%$]+(U,!?9L7S<RU&7G]E(+5$X>$,AC&4H;GK
MKTDA(24"8&D"A?G*,S"GZH"(%CEO;V\P^(BB[^GDR9.53J"@@G 9X&1M/12N
M FU&,4K>P^,L\N2A#1PX4 8&S\/1<8>R_1R72VK]P0=* ([K_@/*@.3HD<.*
M%9%^L/1I7;-F#8SK07*:=\^>/8I5FU9L[LC#1=P)U%HLAN;NM[IG<"M54_W[
MH^H&*&23.5'2EY((%-)VG8N0_J.QBOZ#8Q!:ICAEK&&Z4)DF)A#*X$\!0K55
MB^T#@5#:&P7(_F!!)>9DA$(N7KUDUA)\\_0W*%XD-\X)#-,^J[P$Q9EQB'$:
MA9\F3$?W XG(O.B!$^-_QI3U;O"5F[_H:H<5;TZ!U\"3<'AE)?J_8XWA6YS@
M%G81V4F'L;CK=,R8["-5Y2+"#\U"*ZNM6.-1:4L;0K"&H)*K8IGQ_I=+VQD:
M@E<+7\68_6,0,#E AT(="M7)"(6//18+)Z=L9$N%'.><@#^='8LZ14\JGH63
M*M8IM$1<+HUKT''IFF0-YF\&,G!FD4N65,P*JQ(!A#"H)JC$5#0D23^'K[XZ
MA==?GR)P&8TOOO@(_?I9UNG=S* 2]O-517I7[I1-KX_^?P1" ID6*.;Y&:7-
MX!Q3"Z&EXG4+&YG=J<02\1FN75N")YY(1]>N!0*(%5]4$I]!=5!( ./ZB!3]
M'A<L6( 5*U9(O3!4#%KRQHT;ASESYESUTS.LZ>BF6$\'#QY\70!.NW;M,&S8
ML(I_L:[ERSOC='4+1?IGTB+('4B8GR#(("AC@\PH>>[R0HLAK:IJ9>Y^JWL&
MMU*5Z]\]!X4#*NZ7$-=;TK>2"&4B+DEC<?]A#"K9)DG+4I-D"TXWL@KRM]2*
M1G)3(%1KH;L+@DK,*2 P /6:U(/M7EM$S8G"OF?WH72[T*C9]E+>7_]E&"[M
M1[?]%Y 6?P:'AO?$W UN<LH<Y+H<@5>S_3@[/0:[%NS&JMFS,'/Z5,R8, [K
M[!=CP$<+,'=V(/($"B..+$'[OENPZK0)^1%B-0:5*.(]$Z@Y[2W/@-''+\K?
M<)?A")P<J$.A#H7J1/ :/9J6PAC,F)&-"YX"B6<.X<]E3RE :(!"\WL?5Q9A
M@M.56[>R<ZWX4(5H%20,$@JU6!AI$2,0<0,-K4!(ZQB#EP<,6(O77JLO@%?S
MDB]&W<R@$O;QU7%#Y4[9VKJ_<C[Z8+(,^!RU6 AIY>6&, 1CK19" B$'!5J
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MC[)K4HDJ>BB9C,'AYG[]YBL/L8]/^HD<]B* /<JDDO2N(<NF/11VZ/"[//@
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M/'^IK^S/@2"A"PH)L03R+)I4HB4+"FVRH-"D]$%A'R0*!.Z7AX- E-FD$C-
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M@8?':8'(V]+XVA)\M,1KD)VAD!V5["H+"E//E^$4@\0:B\T6$TCDE#0%"A?
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MV^6'L!_"<+RI'("9!XMU/(>;V=/+HDDE[$0STU@%0ONISI1K_A222NZ+]U"
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M9<AXG_1.SYQQ.$@>_U-,*E&4ZB%48EKD'BI3TLC+RCZVH-"4"(6]>R<A1XY
MM&QY!7Y200WR=;.;D$9[[6-'.0*AT3)(&+$'0JE[#8G;,ZF$*Y70LY31M#.<
MKH836[/G=^S800&84#GV6$R>?!:K5Y\6$/'"O'FSE?G(9@@A$20S$H>Z"81K
MUF2\?RTQ,YA))9P<.J.D$E9.<^;,48YO^O2I<KS;$1P<BU6KXC%F3 3<W;UQ
MY,A>Q2/*N>1NZW#7<9B;,#=]NNU>&A5WP?A+)J:88126&4*Y<(8\>S?PYIO'
M4+;LQ7033=X2B)XLC?(%!OKI-'^Q_6)W[=[3:]SVR 0@7N[5[K9 M,/GF;$(
ML<UR4CYR'^SO%F,+.3I97LRQW;>@\,GJ/A1VD?/E,\HFHI\87;F<)%FD"PK9
M^+-*H7<LLTDE!$(3WGC%.T8@I)O=1'W%B:G#NX=C2XDMN.![ 15^KH#6OZ=F
M9>L1(92C (R34&9%,"AZ:7G^4E\IB34&1.#S<O-"X-! [&B^ ZN'K49(9 A"
MPT(5KR"GFSERY(CB/-@LE2)'6!X"*]Y#-:F$YV'4RTN@M0="HT,7W!_]&79
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MQ7^A\E\K8T_N/5A??#T6=;)-BLWS^^&''Z0N989_<>G<559B+2E"X2>??((
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M9R\6C^J%SITZH:= >9?6@S!Y9P1.J_-..HKGZR2I1$L6%-ID0:%)&8'">W9
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M!87&I V%:VU^PI3_@TMP$S39Z8_3\G!FZ.IV$ &.#3J!D#!A=,B9PY-<2YE
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M)8):6_1&L=$F#/"O49B@U*02QL%E)JF$0&,FJ81KR-.SQ=@U=:42(XT>SYE
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M(]'WL=E[8J7$S.!0=H="59RZA-/9$"H<SR4[Z"$HY"EP-B@FFG03.R#/S=$
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M^\95*LPTQLQ4YER$A#HS'CX>,V&"4&EVI1+N?YH8P<YH.\\BPCD_"10$*Z-
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M$2:LI!(KJ22S227TSK$,.'CH=$$A/7P$PJR05,(RH*'0T%!E!@*U[:85J%H
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M%S$D? C635F'XYV/6U!H02$OQAU$1D9BY<J5RE)@S YTFEEER9(E2R;%QH9
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MN84% W=BYK0E6+;'$K?\DY%M#%?C;1E(*M$'$RG4XG^6%*:FIL+/ST]:0F:
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MV(8.0.342(RH.@(/;<C,2Z)MV[:8.G6J=.+8Y<N7I<,F9(3XAN#.ECM(V)6
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M;HY+0?P=753T')F9F5*[,(;1J(U$?P.(.A<%YY>=D=@X$4/_,12+YS_K-Z/
MX4%%RD/=Z:53"G8'9\7<OXV_8<2LM@Q("&G(J R-V/],EQ0RBU"*5R(9Y>Q>
MC8>/X:KT#I*0/7- &P\:3RYS\?[5>%E)2!D[16-*0Z1'9;TP4BCZ]_'7CZ4D
M%^\>HG'TJ5-9!FC(V(XT;$K!)3Z28A(2-3)$%</A3F*OAHQP(L)[YS.40^@.
M'SXLD4).7B52.*%(EU"%T3O'9W@1)Y60!,L;4_/Z2MN0?:9+""N(X9-)H<4%
M"\Q9.@>?M_P<V2ZB$9AD]**32CB.]5R_0E)(/7!!%,J FKTH><^<%)!4JMDZ
MB+K/B*02?> Q=S7$:_F!Y0B9$F(BA292J!R_-"FD0,;$Q$C+"R2'! -K&:,G
M;^S,WV-*OBY"0D*DI6*2/EFH69^>02X?TP/)@2QO)<!EC-V[=TL)+0QXYAG-
M)*$DI:51T7/PVE08S)+^K0THMAV?G<]%SRA):WI*.M(.I2&N:AQ2VZ6B;96V
M&#_7^#Z2O%%4?E3D-&B&\V[T@T.+)&:'*)P9*_5,L(DI"O00DE 969_Q.M7>
MK29M9[+JIU7:^E3$:O9@(_?G4A6],YS9&Z<NGD&7$-)3IE1L:'P9=T0/)8VY
M@?J_!BFDC'%L<?QPC"8D)B _)Q^QO6*+26%A?JD;I,S0(<_8)WIXU!AS]AOE
MAX90#:'D-;E4]RN<5$)]*9/"GKU[8NRDL=HV()'\'SJI1":%YRW/8^V:M>A9
MHR>R]PA22$+WHI-*#"S;ZR6%<I(CK\E)Y2Y1N/RO=!SS9SBIYF^HT0.LS[XW
M(JE$'[P+O?%)]B?8\/,&!$T),I%"$RE4CE^:%!)<]F7\'Q--&$/(Q!$&*//:
M!'^/66NZLS7^/Y>$229YOC %FTDG/*"<OT=B2,^@'.]',LBL8Q)'[B#/[2(,
M@<_!Z]%#J0]<HN;]_=:22VBL^;R,=>32.I>PNG[=%5OG;T7*VA2X5'5!0JL$
MM'NU'<;.57#F,DD(E1@-RC-GK?%@_:VBT,.BILED0D;/B((8/+]@/^DXP;::
MMGC826A2_H::^"V2$7IV2 AIS)4:4Y()74*HM#ZC'DB&:,AHS,LQ!+\T*>0$
MBQ,QQNK.GCT;'W[X(;KUZ8;(T$AD#LDT3 H9-D 9("E3$_]%&:"'F3*@ICZ]
M*R2C]# I)2,$"1"O3^^0$4?7E2"%?7MBW$BA2R@[O#[)A%(/G2XAI"PI)=54
MG;H>PF>JU'CP_A4>74<=7K=A71RS.";M@WBMSC7D7Q$#0,V2[R^05*(/94AA
M6T$*"XL:[*0HC$-4X^$C2.@H1VH((?4&O<0\J<2(I)(R$)."F+@8K/!=(>V+
MZ37=RT0*3:10.7X-4D@B2*\;R0P]?3=OWI2RB+D<3$R>/%G:UJ!+ER[HUJV;
M5)C>3T\%B23KD !R.9>DCT+.SQA32'+$S^A59)8QDTT8]%WZ]UB6+ETJ78^&
MCPI]V+!ATM^Z(/'R]_>7SKOD;_T60"\HDVZ8],)G98PDETX9IUF[;FV,'S,>
MB<<3<>/U&XC]+!8=7^Z(\?.,[",:$BZ5T*BK6:XC'Z$AI3)7LU3$F3W)' VB
M0D+W./PQIM6<ACV:/7@R2EQ<S9(Q19">'2XUJ8D=XC-7AA#RF>D98>P3EUXK
MZ(-?BA12YFUL;*2QR= -GM;#\<&E^5?_^RH"? *0,RQ'/RFD :,,D!"I(70D
M ^P#$D(2;*7@-4D(6=3(  F9'#]F9$(!]26SD9U=G3%_P'QL:+M!*\,DA$K!
MZS,$F$N>E"6E9(#?UR6$2NNS*XV,(2P-=Q]WO%W_;1R8<P IWZ3 K94;"A*4
MND@%?J&D$GW0)84+%BY J\ZMD),L2"$]S/M%81LJ!=N0A)!RK&;)F?79?P9.
M*JD0K"_T5[!M, :&#,3^G_?#;YJ?B12:2*%R_!JD4 :)(3>+]O+RDKQ],KAA
M*#.0APP94EPX8 E>DQW/@&YN$Z +_@8]&O;V]I)1DV,4^7N\1]W?8]FX<:/T
M.;%MVS;)&U@:&1D9TF]QBX$7/9CH%20)))DFZ24!YKWI;@Y+C^BT9=.0<"L!
M-]^XJ8P4TBOU/))*Z.52XQE0D%2B#WD.>7!XVP'S-?-AN8+:6"$JFU3">_X%
MDTKTX7F20DZ .,'@F.2$BX20LB8?W[APX4*)%-9L4!/!_L'(^4%+"KUZ> D;
M5#0V*#M<:B.Q54I&",9>L@U(2-0L.5,ET)C22ZV-1E$&]B%5#3U,"A);]A_>
MC_<^? ^N#UWAT-L!]EWM#2:EE L20LK/[R"I1!\B0R(QL\%,. UWPO$.QS&O
MTSSD%BI<^W]>224<QT:$@,ND\+S%>6D;G<X-.R/GI&@X3LQ^1TDEQ:#,L.\%
MJ>960M6SJV/9T66FF$(3*52'7Y,4_A[ &"H:29)0DE@N71M;&-_'?TDL*P.2
M/L8U\D@]+A$;(JCL#\;#3%\\'0G7%9!"#H7*))40]&K1LT'OD!K0@"M(*BD!
MWK]0_D]W/\6!UP[@OYK_8O+BR=K/C$5EDTIHO,C%:,A(;I7"B*02?7A>I)">
M=H9G</-WAG90WDJ#2VNZI##SATS8:\0$K)^_UE/(*HPCY7,H)2,$98!U2>K4
MQ!!RF9CRP_F FB5CUN'U^0P*MQPY>?PD6M9O"<]#GKC>ZCIN32.K4@C*T.\H
MJ:0,A,QF7<^"3VT?Y&[.Q;A1X_!%NR^0G:,@!N5Y)I48*0,D3ESR/GGI)&ZN
MOXF-53<B;ZMH/#7CF/?\@I)*)' B25W.-A035&8?UQ$O4_:QB12JAHD4E@2)
M('?GW[5KE[0E#?^?<8W&%'[WZ-&CTG%'7.ZEQT4I0>0 YM(PDV9HK!E;2:^-
M/J@BA50B5%Y*DTKRG^+ITS2DI.<AGP9H9P&RC\4ARM<?ON&/$?]4O,_OY:0B
M)2H( ;[!"(W/1);T9B'RLIX@(3(0P0$12/;/0:'"I))BL"EHR&X H:M#4>_5
M>A)Q6;!X@?2Q4: W@4J4A*R\I)+"/.0^34=21@Z>YA4I5D'*<B(2D6B>@,A3
MF4@-$<\MOO/D<3""?7S@$Q2#N#3QGOC>TR>/$1'L!R^?8(3'I>*IK)LI$O0J
M5)!4H@_9A:+/>U6.%#)!B5Y!CGEF\AN2,9D4UFI0"T'^04CX(4$ZJH]9R!(A
M9D _,TS5&'/V@9Q4HI3,$+PFXQ=)ZM3$L7*A@EYB&F..!X5VT_ZX/3;6VHC0
M%:'H_5%O3)T^M>@3(T$9(!E0FU3"<:-+")76Y_=5Q! 6@WT6+N96"Q)P^+^'
M$7DY$E,73L67;;Z4]%*%H+C)DP)ZV]5X"%F?*Q6,Q54P*>!YP_4:UL/1?4?Q
M=/I3!'P:@,(0%<2)CRDGE9"<*OT)UF??,ZE$C0S(7EZV(?M0U#=M2:.%B116
M B926!)<DJ:GD.3N^/'C$C$TMO#D$^Z+*!]7Q$U=2>Z,!0TS$VCH(>22.+TY
MY4$5*:0!49Q4DH<,__.X<G(;=F\.1](:\=9%/US;M )C>O7$L!&3,/N<._PS
M4A%_^R!VC>F-;X;]A/ZSSL#:A];W,3RLMV'9\!%8/V@YK@UQ0>C)?*2K"=ED
MS!;/T[TI)LB/ O&?=_\C$9<EBY=('U<(!4DEA5&/</?\>OQT^"%L(^A6R4*F
MJRL\AXM)0$=SC/KV(GZ^[XY %TL<_.$[C!\Y%+T'S<.*PPZ"J#GCX<$I&#-N
M%+[I]3W&+SV(T\'IR&.\%)6X$4DE^I!=4#E/(0DA0Q&8M,4)D&XH0FF4)H4Q
M/\1(GL+8>L(:,Q*#WATU\5^_LZ02?8C8%(%'C1\A_GH\ONSR)49-'%7TB1'0
M)82_HZ22$N!))99"A+?XHG7-UKAB?04+EBR0])%1I/!72BK1!W\??_2HWP,V
MW]C@4<M'.-+I"/+SE#(R 1*Y%Y540CK#/J27G&$/13)D(H5:F$AA)6 BA25!
M8I::ICUM)3PB7,J4-K9PZ9EQBSQ;E,DNM6K5PMBQQF<!,^MY[]Z]TM*U;B:V
M(2@FA>0.BI-*"I"7Z ['P[-QN/=BW/PF"9GGLY%P8S/6K)Z%"4LV8M_:^1@Q
M^&=<.'\2VW>LQO<3EF++OG68]],D;#C[" Z.IW!AW7#,GGP8MF.OP:+Q3AQ:
M>DO298I 0LCL0"[5"&(1'!6,&K6*-J]>_$Q.#8*$D$J4'KJ*8G_2HQ!\<1GF
MCNF..@LM<39"-%AB-*)6WX!5MQNXN?,FUDR>B\7;?H:%@RONGCB/JU?,\;/9
MCYBR; NVV_G"[ZX%+E^QQJ6?YV/([$48M,H=Z8SA9"BK$4DE^I#M+/J\N7I2
MR&02QNLRP[@BZ)+"P(! 1/\0#4^-)[*:"@O$I  U,83TJ-!#2%+THI)*V/[T
M,)&4*P7G!L(87Q]Q'9,^G 1_;W]T[]<=X\<9J1-Y__2./J^D$J,G=D4@/Y"7
MC$GLU! R+I?2RR[^=;_CCIJ-:L+<PAR+%RTVCA3R^I0?QN&IF12P/I-*N-JA
M0@92?%-PH\$-)$U+PN(^B]&O8S_DY"M@UFQ#3HBH2W@O2L'Z#)UA4@D3:Y3J
M =:G_N+DDJL].C)D(H5:F$AA)> >Y8YJ#:OAYZ-<"^+$YWPQ(>3+3+QT\7G[
MSS%ZQNBBOTPH#6[-T/"SA@@(#T"?07TP8NR(HD_*!S.,Z2%DC!?W(30&94CA
MZX(4?B)(X;_UD$+5226"%*;XP7>=!2Y\;HN+,Q*1G! -WR/CL&S5-IQ.>(KT
M@.O8TFHFMHX?CAYKMF.P^6-DI/O!8]./F+?7'(>NGH;KBO6P'!F,>QON8_7@
M]5B_]3H"C56&U&D,1B]U4DEPB,Z))A610J5))1DQB+BY'6O-!J/Q6FN<<Q=3
M>[M@W!I_#7.6!2)(?!YY9C)6+UV![=XY@BMD(<7_#L[/&@>SY7MQ*C0;DLIY
MX@=/JWE8/F4UMHT)0PZ-*;U32AT3)#.B#[.OJ2.%E!4FD3"KW]A3>HIC"AO6
M1%!H$-)_3$>D)A*9W3-16+P6K@"_TZ228I#KT+,FR-3>.7M1^\/:L'>Q1Y_>
M?8R;*+,/?\=))1+8;I1ADG)Q?4\_3S1L7'+/OW))X:^<5%(&8B*2OB4=#M4=
MD'$A ^/,QJ%YV^9&3<(E\&N_A:02>LFIRTOI$1,IU,)$"M4B ?#?[X\.U3O@
MW"%A;443W<R^B7HY]5 [IS8:9S3&.J]UB+*-0KAM.(*N!J%OD[Z8WGNZ]'=%
M)<8V!G&V<8BPC=#[>7DES#9,JI]LFRQ=GW_K^YZAPN]'VD8BT381T;;1BNNS
M\+YY_[&VL27>*Z_LF;T'/9KT@+>]-W[H\0/F3)A3U-B&P24\QG@Q+K&\Y;S2
MT$L*/Q:D\%\ZI%">57*90S$A%&!]*J&UT;CPTR/T/^@%OV1_>&R<C W+=\$F
M(P]/@N_@6/O16/EM#[1;O0T_74O&TR<!\#_Z$V;O/8&S5L%(F'\/IUJ?PZIY
M,]!WVF9L.A\LV<@*P6'+91(N$]'#H^,9*'',77FDD,9#35))XB,XFT_'H-6V
MN&HN^N6, _8O.X2V1WSA]R0)&39SL73#:JQU3D6V(,%.AU=B2MNAF+SP/!YD
MLN%2$.=\# ?&_(0C;8XC;&D><ORU3:H(]*8P=DD8\VQ!-MOT4$8*Z?WF4O&^
M??NDS']C(9/"=VN^BV#17P7="Q"N$>.Z9XQR0\-^HV>#A$1M4@GK/H^D$C4>
M0I)8>MA):N,$+SEY"!]^].&S$TTJ(H44=FX[0[-"0J04O#Z[^44EE;"^G%S&
M.-*B.$Y/+YUC[BHBA71.D\R0$*N9%' RR"5W!4DE)4 ]( A9R/@0C'IS%.RO
MV&/.XCG2/1M%"DEB.0XKDU3"D(GGD51"+[,>R*1PQ?X5ILVK3:10!2Z)L?V7
M%%C^GZ4TJ^ L.NIH%$X</X&C)X_"=J<M'G5X!-N7;&']DC6L_FF%\W\Z#XL_
M6TA_ZRM6+UGAXDL7<>&E"[CWTCTXO>0$FY=LI/?U?5]?L7S)$F=?.HL[+]V!
MWTM^N/G235QZZ9+>[^HK_.[YE\[CZDM7X?F2)^Z^=%=1_<LO78;%2Q92'<>7
M'/'@I0?2>\8\P[F_G<.-=V[@R=HGV/?1/ER8KMU:ISS(^Q"ZNG(]QWB4(85%
MR\<=7NZ <0O&:0D5O3.5.:F$A))+-=NNXM">#>AXPAL!R:'PW3P)ZY;OA'5Z
M/E(%*3S2=BQ6#^J%K]9LQ["KB<A,%:3PT&CL7G<:=F8!N#'A!J9NN@#SXZLP
MXX>9F+/Q)GPK6OKB]6G(2 CI)=1N:UD,HT@A#8$Q227ZD.2(H*.+<6RF!T)H
M"!Z<P^Y=\]'FD _\4U*0834;R]:MPCKG+$'TGB(ET &W-X['I,7KL<(^5=C1
M7!1$!.+)&E?<;/$ 9V;Y(C2G4-$M2-XI>B9(1I+$G[FBSWLK(X6,396W-2J]
MK5-Y*/845JV)H!E!2/DX!6X:-T3W%-9=R4.P#W['2262,:>'3%XN%/4/'7FV
M>76%I) $[/>>5,+KDQ#22ZE#R&@O*R2%E)47E%12#/9!D1YQO^2.Q@T;P\+2
MHOB>*R2%?*3?6%*)/LBD<-W^=0B;$F8BA292J!#"T!5J"I&MR49^52%E-41C
M5LO'T^I/D5TM&X5OBL_^+QM)FB0D:!*DDJ')0*HFM?COTB5>$U]<GFB>($63
M4OQ^Z>_J*W+=.$T<DC7)2->D(U&3:'1]%KD^ZZ5ITJ3?45I?+KQ_/H?\M[[O
MZQ9>*_<O@@R\50"?O_L@;&'YN]G2B\/-N;E)=[G++GJ@EQ1^'HOVK[3'N(6"
M%'*+!7)2SO"5_;06]*C0D-(0N)[ GCUS\-5!3_@F/$;8P2E8L6(3CH8D(-;U
M,C:VGHUM4T:BW]JM&'3"!]&Q/O!>M@IW)M[#G9\.8\^,Q5CK&([P.'?<F#\.
M2Q?M@F5%W$*.(:0B+D4(B0I)(<F(D4DE>A$2@+"EIW%ZO"\".3./OX1#NP4I
M7'<?3C&1"#DZ#2N6K\).CZ>2SB[,%V/#=BDFKEJ*P9?"D<$\(2MQT:./<;+W
M24&&+>"66V \GZ(N)YE@_%716<K9XJ4T^YA[$1XX<$#R%NK+,C8$F136JET+
M0;>"$-M?>\Q== _1<<:V)?N 7FH^AYKX,1)"+C>R#=20 1(0$GHNUZDAA!PW
M14D54A\4D5K:!Z-((9^9WB$YJ<2XR)!GT"6$W+K("(=6&<B$D,^AAI"1A- <
M4@^4RGTSBA3*224D56J32IBO1SV@,*E$ MM</JDDH6A+FO?KXMR%<\:30L80
M4H[5$$*.%3FIA#*@5!>S/ON0,LC)23DRQ+./ZQ74PX']!_!DRA-X67N92*&)
M%"J 4#:Y/7/Q^%^/D?&CF$KM$!.RK;%P'.^(J#Y1V+AZ([[M]BUZ:7JAMZ:W
M466H9BC.:<[AH>8AEFF6H:>FI][O&2I]-7UQ67,989HP[-3LE.HKN3[+;LUN
MN&I<L5FS&?TU_1777Z!9 !>-"XYICF&89IBB9_A&\PUFOC(3<1WC$/N?6#R>
M6_[F5[FYN=)6-B2%2E&:%-YXXP9BF\5B8-6!F-=KGC9V165"@[14Q4V);?*1
MZW<?-_9^CRX=/\;K_>=C]IE'\+FZ">L63,?@"?.Q?O$D]!NY#V>NG,>!38LP
M>L@TT-.V.@  __1)1$%4G%IY%+?;V,!^8SR\KYW$D>6C,';A#NP_N!'SQTW'
MHJU6<!4&TZ"ZTDTJT9YD6 ;EDD(E225Z4!@>@\1UMW"\Q0ZT:387/VRWA5N,
M&QQ/K\?(ON.P:/T23/AN"I8LVXIC-I>P:^5N'#YZ$#MF3\2XC>NQ\;P/(F>%
MPF6$)RY,78MQ(Y9@^@XG1.87;_M</KA<1Y$@(6(<5E$EI=G'#$?@R3?<J%WI
M"3W%I+"1((4108C^*5HBA3$]8HPCA;_WI!+R!!(9AA[02Z,#HT@A[_^/DE2B
MLV2LBPI)(:__ I-*I&?F;@4DY6Q# 7=/=S1L5/*>#9)"MN%O-*E$'V1/X;;]
MVQ ])1K>UMXF4F@BA0J0)/3FX@PXO.& V&O:R.VDQTDX9WT.XYS'X77QJFM?
M%T.G#ZVXS!1E\E",^V8<+/H)DC/V(=9/7Z__N_K*+%&F#<6P3L-@W=D:P2.#
ML7_Z?OW?U5=FB#)'E'Y#<:#' ;B,<\&NZ;LP8OH(_=_75UA_R%"L[+H2SB.=
M<6K:*4R</E'_=_454;]EGY9H4*T!_*;[(:INE+3L9@@TV,QREH_O4XK2I-#F
M#1LD-$N >15S7.TE+*F2^#E=T( P&)]+;EGYR(L7I/#H2LR:,1GC%F_&NLM>
MB(CR@OVE(U@^>P'6;-B$]3?]$)25@OA'%V$S:14LO[^,AX(0!PB%EH9P^-\Q
MQXZ5:[%YPQJLV'L%-NZ)^IT>LB$KE52B#P9)(0FAG%2BI@V>B-NX&8.XU8]P
M;K8YQIJMP?1CM^ 6GXK,H >XN7XI-JY9@=DK+N#*'1=X.]O@YZ7KL67S1JS<
M>@#F9QP0OC\&L:-]<&OQ->Q=NPE;SUKA5I36HU@A2&:XS,9E[U*G9"C=O%H^
M*YO))9R *$$Q*=39DN:.Y@Y">XB;JH@4DM33.\2)B9KX,:YRTYBR#=0DE="C
M1<\.":':I!(2(EZ_B$SHHD)22 )$,D8O-<F \0Y:+>C18[?*A%"IAY""QG'$
M^FJ32DA"Y*02 [MCZ26%>46DD+)+0JAV8VJ2(1)JGC1"C[-2L(X\*="9&))(
ME+YGO:20C\&^JTQ2"66 7FK&DRH%989]3QDL9\E8%[HQA8%3 DW+QR92J!!"
MV6;.R83SZ\Z(.Q8GS<3B3L1A\97%^%OVWZ3LXQ7B930X"&G,*,A*E2#!Y1DN
M$=#5KG1635#QL2X#PM6, RH!SNC5*C&AB&^ONXWA_QF.X '!"*T6BJ#9ADDA
M-[:FP>;1=48%.I=""5)X(P%65:R0V#@1#_[Q "[SJ$44@FU&SP27:FA09093
MF(N<IUG(2,] 5F8FGN84+8'FIB$M_C$BXM*?V:P84<DJ QGGLY"84B#I10F%
M.<A.Y#8_<4C,-$"-^*-<)J$,E$HJT8<2I'!9$2GD$F-E3BJA1XLR;"?N/>@I
M4C-2D)&5CJRG><B3'KI /$HRXB*B$9^64]1$XME2HA'Y.!P1(9G()B$5ABS?
M(P4Q82$(CD[ $V.S=4DFZ)VB9T /(59*"DE:KERY(NU/J!2E26'L#[&XIKD&
MGQ["T.B>?5P:[#?>/PVB,AZJ!?N0=>F=4;-DS#J\_O-(*C%P[%FYI)"D_@^8
M5*(/94AA>T$*A8Q*MH!DAMYN-;KT>225,'2&A*R4A\\H4DA2_AM/*M$'4_:Q
M%B92J!8DA?,RX5K5%0EF"=*L[K+-9?PCYQ]%&])HL$R\C (',0<!284:0T#E
M1\\.E:F:62T]"YS1TLNEG%]IZW#PDE2JN3X)I;AWV]ZV&/G&2 1_%XSPZN&(
M-.,:FGY0$=VPO8&PB/+C#@V!I) G"$Q;/@UI=]+P\-6'2*B>@,E_FHSU"]<7
M?<M(<'C0 '+)F*3*N.%2$O0FT AR=FW,\F)I<)F8A(HS<R,,@2XI7+!L@;8/
M>%(*O1M4J$IT(;_+?I<(H2B&N\TP:$AX_URN4F-(9,\$R0C;0D\?Z)+"\YKS
M:%2[$0*B#+LQF+QTX\8-H?^4=XA,"M]K^!XBPR*1,#Q!(H6^/7P-DT(:8VY]
MI#:IA&W(/B2I4[/D3 +#/J Q)AE0:@])8'232@R,@S*D<$(1*60?RC&$:L8!
M]9 N(51:G]_7C2%42LBHNWE].:G$@(=0ABXI-%MLAA9M6R [7#0"[U]M4@DG
M%?3N,7Q$#2'D_(?+S9S<%L7BZJ)"4L@^)!&K3%()'0M,*E$C QPWE#V. 2,]
MA#(84UA+O%8<6&$BA292J )Q0G[-LA'R6@A2!PL-+&9&Y]-*[E.HNWFU0>@J
M(35*@(+/YC9"">E%90.9J41HB&C(N/2H%)P54H$)8W1BY0E\6NU3>(WQ0DKM
M%,3.-KSV]23M"2Y87D!PF!H&(?HN+QNMVK;"Q 43D7\E'_%5XY'R00K:O]0>
M$\TF%GW+2-  T9!R9JK&&+/=N%2D-J& RIMDBAY"/4DE^D!2^,Z[[TC$9=&$
M1=IK<ZF)S:E4$9-,T(AQN9.&0&E]>F-D0JC&F%-O\_[9AFP+ ^JJ-"FL7ZL^
M/$,->PJ=W9QQR^Z6^'GEAF'AHH52V[[;X%T$!6H]A=<UUPV30A+"/V!2B3[H
MDL)>O7MAW)1QV@]( EYD4@F7;"G#? XUJRT*=7$Q*;2X@(4K%J)UW=;(/B<:
MDF=)J]'%SS.IQ(!:E4DA]X1EV E)88G0"GHW?P=))?I@\A1J82*%:B&$/G]T
M/I)>3L+3U4+ZA"*_*%Z&3C0I \H:!5@FA&H,006!S!6",RH:$;6!S'+L$A6I
M&B5$ D4EQ)FU(*<'SAS >S7>@]<T+Q1\7( -#3>@\Z#.>LM7_;Y"KS:]8'^'
M-Z\<W/*D;\^^&-IX*.Q;V\.]BCN2.R2C[6MM,7:N\2>I<*FH<%LAPG>%X_J%
MZ[AXY:(4Y\@C]V2<.W<. P8,0)<N7="YL[A_4<Y=.H?HP&B<^.X$;K>YC1GU
M9J#SYYVQ?LMZA(6%8>[<N=+O$"1P/,N9)VIP^YV8:.W:<&9R)NY,N0.WUF[8
M4G,+.K_?&4-'#45T+*U#^? -]L5;-=_"!YH/8--%L%F%P>"Y>;F8MWP>]JS?
MHS7&5.8ZA)#WS.>FI\W*RDI*V"#H5: RXK/9.=O!S<8-T6NC$;LL%GFN>0@*
M#H+U-6MI"YA[]^Y)QQ^2//CZ^DKO,<Y/S@*.2XW#?;O[>'))6&!.3.@T+D>'
MRZ1PJ68IK#76T/Q%@^9=FF-Z_^D8TV\,.O<7?2.7?IW1O'-SC#<;+QY)*4L%
M9BV9)9%"S;\U^++3ESA2[8B4:.+;4P\I9+M5-JF$XYAZ0$T,(>N32/P"227Z
MH$L*N_3M@I$_C*2;1KO<R=]12LCX?=E#2$)8$9DH+2,4)PY7JA).2I1>GU"A
MBVDOZS>LCY.73\)^E3T.-CB(O'N"32LE0P3;G6<HT,NG1@9D74Q2;F#9G^ X
M)BF\?OTZ5J]>C;9MVXKF*^(')'*4 36+-^P3VI+*)I5P<JF"$+)^5&H4Y@3/
M@?D6<WA/]S:10A,I5  *G"!".9US$/[/<*1=U$[KC":%LHN;2HRS2S6S0B,"
MF<M%90.920))!CF0C?1.E0 ](Z4"F0^=.81Z;]>#]RC!M#X!;#0VF*Z97J),
MU4S%6,U8C-*,PE;-5D1U%FQRMJBLI,P5=F!A 6P;VL)68RN=-!'_KWAD-,]
MVW^VE8B 42#/$8HXY7 *;MO<AO5-:TE97KUZ%=>N79/B'@G&3/WM;W_#=X._
MP]"A0S'TAZ&PL;-!Q,D('-(<PKVO[V'%B!48.GRH=%2?L[,SJE6K)FV%DI"0
M()$J_BX)(7_[GOT]1,=$(_U..FZ_<AMNS=UP8-0!#!TQ%%.G3T5<7,4,/2P\
M#(-K#L8:S1HD#T[6+ADK0$Y!#H9]-@PK6ZS4MH,.#XV)B9'NE]X$$CM;6UMI
MN8D&)24E!=8VUKAV_QKL;]K#?Z,_HLRB<'W-=<0^CH63IQ,.'SDLM8&+BXM$
M!/G,_#T23!)-;@^3)5ZN#UUQ:\4M/#DJ!D Y234R2 I;]VP-,XT9(JM$8N:'
M,S'Z]=%85W4=EKVU3 I=D,I_1'EK)$;\WPALK;\5!<>%_J,7DYY4[O5&XTGC
M2_FE9VVK*!R+?)]%$*RK$Z]BRIM3,/XOXS'F[3&PK2/D[$^1"/DZ!(5Y.H;F
M#YY4H@^T#Q]\] %<W%VPZ-M%V/3%)FT,&TF%<:;F&>CAU%TR+O809B(]RA?W
MS)WA%?!$6MG-3_"#S_E=V+-U,]8<N8>[X1G::!V2\EM/$;SE%N[;BN^'NN/A
M\;58,7\.9L];A*7+=^/@*5<$I1O8$DFE+G;S=L/;#=[&P74'\7C$8]S^\C8*
M4I0V@ #UYR^05*(/M/&OO_XZNG?OCH\^^@@-FS:$KXNO-#$+61>"R-N1RB=1
M[ 0Z1W[%I)(R$/HCXD$$)OE-PLE=)^$SW<=$"DVD4 &X4XI0 IE?9\+IWTZ(
M.Z,UPD:10@X $D+90UB90&9Z1]1X"&G .8#4!C*3!/+^N2FNVD!F&B+&X#US
MJ.'0B4-H6+,A/)9ZP*>-#VYH;N"*YDJ)<E-S$T&:(&G_0VX&G% K 6@F*AM;
MOBCZ][]"_VD").)II;&2LLA31J3@JQI?8?RL"D@A]00-T7X@_6@Z/%P\8.]L
M+Q$>@D2.!"XH*$CR:O$,YPX=.DB?%4/TN\=,#QRJ?PAY"26GQ;KCB/OD65MS
M^JW%D_0G<'5W18!= !+6)N#X?X\CPMH(1E0*61Y9N%']AK3UT,-ERK?TR4_,
MQ[46U^#0UZ&,(6("$(FL;BP>3YTY=_8<$I\DXOJ=ZPAU%1TO)B4YAW,0<BT$
MQX\?1TA$B.01M+UI*QU72*\BVY2DDI[%U-146%RTP*7KE_#@Q@.X;W-'ZOY4
M%(8;I[A)"C]M_ZFT_5'2*TDH;%F(S :92&B<@+B/XI#X0:*V-!'EHT2$_R,<
M,?^.0>$0\?L_B1_X3I0AHO#TQ1]$:2>*F+R@LRC?BS*TJ/"["\10[9Z+0$T@
M8C^*15JK-+C_Q1VNW5V?[7>HFU2BU#-"D!"R+KTC:B:&K,^ZOV!2B3[L/[P?
MM9K4@NL=5_CW]H=7*R\ML50*7E_70U@L;CG(3K;'C=U+\=U'R['S7(AX)PU!
MU_=B_L"^&#IR$#I],P4K?[Z#>(;/W,M!W)Z+6-&I%WY:L E'[*[C[-R^Z/9E
M<[3XI#;>>.4C-&B[&S:Q>27Y1B5U,<,*OFWP+6Y-N85C/8]A1H<9BK/<I:5Z
M>O<84ZY&!@SH8D/@A&S(D"%HT:(%OFSW)<8.'PO[+?:(61$#Y^/.>.CR$ &!
M =)J![];X2E3=+!PE8'A-VH((3N$1);VC),*-: ,B(F5^WUWU,RHB15'33&%
M)E*H%+3!0@@SIV?"^0UGQ)_46L4*22$%6'?)6"DAH[Z@$C0RD+D,V(WT)M 0
MJ0UD)HDE&:0BIE%1"BY5R8',I989*#=-/VP*5T=7C!@R F^^]"8:O-W@67FG
M 3ZO^CE6O[(:U]ZZADG5)^'N!:%1J(R-*;PV[]E'-,6> FS\8B.:OMT4U5ZM
MAL\:?P9?5U_TZM'K6>"[/K -:4!I2 6I"0\)QY7K5Q 7_\P[1T7"DU;HY:*W
M<.K4J6C6K!F"0H*0_%BP:"HA80>/CSPND>!KMM<0'A%>G.7J[>TMC:,-&S8@
M/#Q<(H;%$#JJ(*@ !5<+X+/8!Q^\^0$V;M\H)=PD)AKILA5]F'<\#]95K?&^
MYGUIJ5,1A!SFW\_'\8;'<6WR-2U)U@'WC>12MZY"=75QQ;V']Y"2F0*[RW8(
M6!& S.V9"+0,A(VU#<Y=/(?X^'AX>'A(1Q9RFR$N07-S<A+&AP^TQ#7]:3H.
M[CN(XS\>1\)6,2%@6QJ)W/Q<?#O\6_1XHP<>O?8($=4CX%C#$58UK&#QKB";
M-2X]*^]>PMGJ9^'0S0&%-N(Y.&;I6:?L\U_V/X\Q7RL*21&]1+K%7DP.UB?@
M4O5+L*AA@</_/HR9FIG8UGL;\@N$(F!7_P\DE>C#\1/'\6F=3^&YW1,^S7W@
M,5'\D(+Z$N@1U/40EF!K*4CR/8L],T:CPP?+L.UR) IR'N+<WA7H8&:)&X%N
MN+]M)DY/.@!?\SRD772&^<+)^+Y52WP_;R\L'^<C-S,=:6F)2'JT%=-^F(3N
MDVW@F:ESDY75Q0*I#JFPK6^+)WN?8.K$J6C;KBVR<Q2L'3_/I!(CEWPYICEA
M2\M,0WIB.I[>>XJ\4WDH""] 3FX.PB+#I$D<]_9DZ <G>=1K>LD5'_4%)95(
MX"VQ#;GD?UN0I#QWU!:OE0=6FDBAB10J!!62F%5ESLV$R^LNQI-"74+XOYQ4
M8B"062*%'S6%D[L3N@_HCJ\'?HT''@^TQ5-;[/?8(W1]*!+M$^'GZ8<GN0H;
M@FU HRV48'A .!YY/,*<Y7-0]Z.Z</)V0I]^?3!^7#FDD(20RX6<F8HV#'T<
M*A&@TIL;\V\N=]+3M63I$OSCI7_@_4;O8T;C&0A9+#29$!GSX^;XOW_^GW3J
M1:-&C;!C!YF&N(10I'7KUL6*%2NDI5C.N(O!"0GCOX0<!3P,0+7:U?!F]3>E
M^ERFKC!3EJ)Z7S3#LBA\^?*7^#_-_TEGF!H-$A!!:'.NY:!OH[XPFVZF?5\'
M]O;VTE8NNB> \"2$^\[W\33N*2)61B!R422BKT7#T\-3(M5GS,\@-B96TB$T
M*"3"W&Z(7D?^S7]E>*[WA/\R?Q2$*F,23!@)"0N!_PE_I&Q(0=:5+*2XI"#!
M)0'Q+O%E2IQ;'%)#Q -3;CGFY<+8,R:HDR!RDD'CIEOX?4$:<A)SD."1@!BG
M& QL.1"O:E[%-WV^07Z,Z"/*X/] 4HD^N)QRP:X:NQ Q/0(C&H[ XMGEQ%[K
M _N@W*22/$'J_.%Q<2?&MMJ ?1?#D)5HB7W;S=!FGP?\T]*1>^0\;HV^ JM%
MMW!U_4JL/GX ZR8,QYH5.W&A>+@E(V#O5,R=L@0K;R= .I);1F5UL2#EL9MC
ML:/Z#H1<"L'4A5/1LDW+DIM7EX=?(:FD0G!20!G4ACA+H&>01T-R@L=)W:E3
MIZ1)'O58"5!-O<"D$@G4A;Q_9KP+]2TEFA2:$DU,I% MA#&02&%5(T@AY4J7
M$*HQ!'^4I))R IDE4BAG)?;JA>G3IQ=]4@36HR%58P@)SNP9N\0E+QU#1M+!
MZSHZ.I9_[!:5#WD;"6%1'S"VC]ZLB(B(XJ42*O:0D! \>O1(6@*=/G<Z:M2N
M@<US-N/JT*M(/B,>0,C$R0LG\>9;;V+>W'G8MFV;1*8(V5-(DNCGZX<[CXK6
M54AHA1%(/R1FZ#%/I621N@WJ2LLYK,^9>;E*C$2>"0WB_@-L E"E>A4I&6+)
MXB72QQ6"[4X/LU#B3X.>XM,6GV+"C G21[I@/*#NDC?QP/T!+(]:XNF)IW@\
M_S&2;R8C*RU+\OPQ*>?8L6.2$2$A9OP@O0N9F9G2OVS'._:B#>B=>22&TMI@
M1-^L.)E&+S@.V,P*/(PE0#) [PP)B0)//Q.CV-;???(="LX+?4H95./AX]CE
M./Z=))64@1@BB:L3$=H@%$_./$&SMLWPTR2NMQL)&G_=)6.#9"()B8YG,+?=
M%ART"$5:S 7LWC,'7Q[T1("S^)%MSC@[?!L&?3T$'5IU0+_)$S&R9UOT;C\<
M,P_Y(KH@!_D)5[&FWTB,F78,#W3[^GGH8B&#?@?\\%6MKW#-ZAKF+YXO9?(:
M10I9_U=(*C$(JAC.T4C(REERIB[BQ(Z>0^JFA_8/Q1#F(!;@A.I%)940Y*@<
M1WR.(GMBRC[6PD0*U2)2D,+Q@A2^)DCAJ7)((06>@YA*C ;%E%1B$+JDL 0Y
M8QM2>:C='9_@"BR7Z]@'I6#PNKH@F>=));P''2]O5F:6)/=4>ESJ)4@(F601
M&J[5F(NG+L:P)L.T9(1?*>J#@P<.2IE\S*C5!7^O?OWZ$E'R]/'$D2-'D.(D
MK(]H0P9S.U@Z"%N8#7</=S2HWT!*:JD0)(14HHP]$O(8'!6,&N\9..9.'RAW
M\K8S0AZ8?=RL93-IO,^>/;M$V;-G#^SL[*1$$9)FCV /6!^QEF)%TW:DX?[N
M^PCP"T!Z9CJ>)#^13@SALY(<\ME)*.EAI;<U/"P<-K=L8&LC!A#)B)#CNX?N
MPMV-@T(!J-LI R0S-"1*EYH(D@'&7M';KL 0Y1;DHE?/7OA0\R$N?7P)A;;B
M9M1<7YZ8<5+R.TDJ*0$24M%M#@,=L/G#S0CU#467?EW*]\SK@N-.=\FXC(=0
M%T_PQ.4\S#KLQLEKL<C.LL*E7?,Q95D08FT*D+WI"+9,FXK^<U=AAMD:;%@[
M']-ZMD3'MB,P^U0P'F=%(LIR)H8.60ZS8\'/U/;STL7B_CT>>>"]QN_AK,59
M+%ZDW=ZE0E)(_?<K)97H!6]/H2[F.+[_\#XL;2SA\L %&=894CSV"TLJH;JE
MRJ2G4F=B9B*%6IA(H5H$"1TU1)#"EP4I/*V?%)KEFFD)H>PA-"65E M=<M:C
M=P^,G3I6J_BIB+G<Q;94"BH-SH9Y#P:"V<LEA=0)-$1<JJ&748\22DI*DD@A
MES@92WC__GTIPS8S6\L>+4=88O];^U%PO>0X8J;Q?__[7VEPZH)9NGS_P)$#
MB$N/@]T>.X0L"D'XVG#<.'$##SVT\75>GEYXZZVW,'KT:"DKEX5+V7+6<S'8
M!R0RW/*C*#PQ.*2<LX]+@XJ3A)!A T4Y+<S#7+!@ 5JW;BW%2^J6W;MW2X'F
MEZPNP<'= 9>/7X;C7$?IV+),]TRI?1XY/Y+(()^=?[/M2 3I6> ST%OJX^L#
MNX=VL+$0?Q\1 X&$3DS&G)R=X!>H@)50AB@#]&QP/"DU).PVDBAZ-G@/1<X.
M8Y$G7EM[;L4,S0P\^OH1"G-5&!H20H[#WUE223$HDB0!@A#M&[4/#9HT@(.K
M _KT[F/8,Z\+7E_70UAN'SY%1KPC;NU9A 'U)F#&ZIOP"KX)O_7[<;;W0]S:
M<1>'IXS!_)7;8!Z2C9S<I\A.]<$-LQ^P8.Y&G(E\B@3OB]@]M"^&KSH#*TZ*
MG[<N%O#T]D3#QB4W@BZ7%/[*225E0'7&B9D*74Q]$>P9#-M9M@@<&XBG=U2X
M]]CG)*)LPTHFE4BZK-0MF$BA%B92J!;!^DGA_Q,O$L*_Y_\=:X+7/".$2@D9
ME1"5X!\TJ40?=,E9G[Y],&'4!*T2(!GCMA%*QR<]C#PIC_= HVY C,N00CG1
MA-^G 249(*$HAPQPF9,G8-!KY^KFBO0L\?"\7T&H_$?XP[6/*PIT ]4%SIPY
M@U:M6DE+IKKP]?-%J]:MI#B[PK1"Y![.1>3R2-PZ?0L^P3[(SM4:#A*O+[[X
M C5KUD3MVK6ETJY=.VDINQ@T:%2B]&[HG%3"I5JC2"%=)#(A+-4'7!KG<Y/,
MZ18:MH+" B2G)2/4,Q3Q>^.1=U!TAN@+QADFIR9+]RXGDS#>2,ZZI%>!'L/
MH$ $A0;A<<1C9-IFHN"R:#NAT L+"I&2GH*,3"-G6/Q9\D=Z-OAO.7VH%Y0A
MDH$MHI ,J%FJ$GW@T=$#PS3#,*GG),ESJ @<N[_3I!()["K&;5&7"1DX>.2@
MM"6-HU,%X1HR2.IU/805DOI8A-_?CR5#>N'+^AW1Z>O5.'/(%7';O'"]UU',
MGSX'?0?-Q^J?[26>):$P&B[;S+!K^S'81CU&\/4]&-=O-;98^B&1,L 8QN>L
MBSV]])Q];(@4OH"DDA+@;9&(,?1 C2X6(E]XMQ!/9C[!_=7WX1^D<&;!/J#L
M/:>D$GU>9A,IU,)$"M6"I/#[DJ300KQD+V'OX-YX=.N1.D)(4/#9C&J4$,&!
MRP'$F1T5@E*P3F622OC,W-.-@<Q&SBHI-Q\T_0#.+LZ8]LTTK&R^4OO\',QJ
MQB:Y%I48C7HY2TVZI% Z86%2T0D+)*1R4HD1QC@K*PO)R<G(>EK4X10+H81R
MK7.1$U;V!AB0'1 0(&7SZ>)I]E-I6X<G;J+C.2L7L_O<Q[EXDO($.?G/?H=$
MBIXUWC?C[EA(3(L-"Z]/&3@L"OM 1Y$:10I))G0)H5)%+,A KKFP!I0#$E*=
M^KQWWB>)I6Y""I4PDV68A9G]5)#+>^(S*G+.\(U30R5!,L$VH"R4(P,&P?%+
M0D@Y5#..A-P4FA=BX_L;4453!=UZ=D->/BV<D: H<;F118T>( 'A<B&]0VH(
M(46);4!"2 :E5 ;89O+1==1%XM$/'2_',U\:[#-=#Z%1??@4F0G!\'*XAWNW
M[\+^5"!BS^>@T.DIDEV]<-_N-J[;!R(L2;<?\I$9%8+(J%@D9V4@/38(+AZ1
M>)PN+DA"_ OH8MI+HT@A$U](YMB/6E.C#"IT<1DP](A>1C6$D#+#I=H=HJI]
M(:[97(/= SMI[!L%UN?DGC)(65 Y,9/&$&71P#@VD4(M3*10+?20PI/B]9?"
MOZ!;<#=LO[4=@:["$JHQ)/\#227Z</#00=1K6@^NSJYPZ.< ^Q[B 4J&VQD/
M*@]Z&+DR6X$-UB6%W?MTQ^A)H[5*B#&$)(1J# $] ^P#)L:H\=*RWTD(:0AT
MDH^-AIQ4PJ4F/1M35T@*Y:02RH :0LBP WJG3HM"0J:T/E4.Y9<3$WHVU.AF
M]CV7>^GE4>HA)'A]9N@R?LQ(QV0)L-UNB$>_DX_^;?M+;=VM1S>)]!H%CEW*
M$/6 FAA"UG^1226\/B<4]+#Q=XJ,N>YX*Y<4\ONZA-" $ZU<T-/-D FU>H03
M2L;OJ5TR+D<7&T4*6?]WD%1B$*Q/6\+5%NH3(?J/DQ[#TM)22D"ID'3Q8T[.
MJ4M(SM400CU))?I@(H5:F$BA6N@AA;9YMO@V^%MLM=V*T:ZC<3B=+AJ%D .9
M*TL(U2:54/$\CZ02*C(C Y%E'#]V')_5_0P>.SQPJ_DMV$VC15&!<I)*]('R
M^F'3#^'LZHSQWXS'XB\%22*9H3%4TX8T0#0BG)4J7>ZC#F(?\@0->6:N%"2$
M5.(T9C1J>E N*:3BI!&3":%24 G3,T)"RN4^I1X^$C :$!)R-4M=;$,^-_N/
MI$(I(25(8N2D$C5DA/?--G 4E\_,1[=^W:2V[M&CAW&D4#>I1,W$C!,9R@\)
M(=M *?C,; ->7T'X9C%(@!@Z0Q5(6=*1 :-((2=2NH2P'*<2/?0,6]!MU]3P
M5'BL],2#[QY@4^]-F#5V)F;.G85Y9O.Q=MTZ+!8D;-8L\=Y,;9DU:Q96KER)
M1P^915$$H4=R]^8BW3P=><G/9I8D<4N7+BVN*Y<R"5\5Z.(*22'U)PDUO7QJ
M5FLJH8LE\%;DI!*%)QY)X$2,_<>)%3V%.N . TPN*W=S:\H,)S.407JKE>H1
M@KJ8W6*$+C:10BU,I% M=$GA.2TIC F-P=%;1S'>=3Q>S7@5T\7+:'  T9!1
M":B=E>H&,JN94?V*227Z\.#4 ZRJM0JABT/QTX<_8='T146?& G:!!H0WH.!
MI!)].'#H .HVK0L79Q?<^D:0T<:"C%*9J]$'5$*REU5I'W"8T4-)[PZ5N1K/
M /N@5%*)/A@DA52<\I*Q\H-2GF4Y\_HT1$K;D)X=DA$2*C6$E.2!,D!2S/&D
ME!"R#RJ15")!)L4<2P(\]JM'SQ[&D\(_2E()S0 )42E42 IY?5U":*"Y&((0
M'1T-+R\O:=-SAD[$)0L&+?HP9'^(=(3DT29',;C%8#1KKDV":MRXL=0/E'W=
MY*C//OL,?_[SGS'#;(;VQ\7825J9A,C=D?!]Y NO "]I[SV2MO;MV^/55U\M
M49_EYY_)OHI@1(*?7E*85T0*?\=))1*H^T@$#9Q4PAT:N$,!]9!>8L@^I_Y@
M&_X"227Z8"*%6IA(H5H4D4+GEYVU6]((8Q9U.PJS76?CE:Q7I+C"A>)E%&AX
MJ 1)"*D(U2J!(L^$<7$WI<!!0T-$,J,VD)G>-<:^%$=O*X!H@\A-D;#_P!X)
M=@EHWZT]QDTHBNTS!M0K)%05))7HPY%C1]"D01-XGO1$=+MHA(T*JW#)N0RH
M.^1 9BHAI62"]RMD2KI_%C6)/?0HD<B42BK1AQ*D<&D1*:0AT(TA5$/HZ*&E
MAU(-(:0,TC-!,D*%KK0^V[RR225<:N:&NIR8*27U!/N ;4!#6"1#/,&$9- H
M4L@^X+4YEI5ZF0E.)DF(26IIS)6V(0D,5RODY4*E]:D'Y!A"]J6><5@N*:3N
MTB6$Y8QC)BKQ7&QFK]/ G3EW!G:W[) ;G"L=(;FSYDXDN">@0-@O>A.9Q,33
M=IB810(GQ[7R?1Y-^?$7'V/4^%&2[&=MRH+K E=XW_*&A[\'+EZZ*!W5R.\Q
MF6O4J%%2?3G9BK\A)8#Q?N5) 75Q.:$CNJ1PX:*%:/U5:RTI9!_*225J;$%E
M=3%YJ9Q4HF8<LC[#9N232O3T(<D6=QC@UEWT\I8 QPUU(=N0'D*E$SO>KPI=
M;"*%6IA(H5J0%/Z0"9=_NR!^E6!DWD*7NU['FUEO%J6::+!$O(Q"99-*&'-&
M0\J9G13[E(WLK#0D9^3JC*<"Y&=G(BTY T_%F\]$/1>%"6EX:I&#7"IB-820
MAJ2R@<R^@H\.OHVY3>8BP", 7?ITP;CQ"D@A/2)&))7H [-Z9U:;B> 1P=CP
MW@8<G$-VKA D _0NEA/(7"YH@&D$Z"%4LVS/ZU.)ZDDJT0==4KAHQ2*M0% .
M94*H5!'+A)#/8%2&:"GP^C0D;$-Z*(U3.25!,L$VH"RHF1A5-JF$?4#O#)]#
M)P:1)- H4LAQQ.=G4:,'2$ H/[^5I!(#I-H@*>3UC%PR9G(2MX'B,B0)&4E?
M7%P<'/<Y(NUT&L[./HM6]5LA,*3DNB?EOD&#!CAYDH):$FT[M\7$-A.E,12^
M/1SACN'2<6Y9V5F29XLDAHED7WWU%:9,F5)4JQ0X=BB#?/X*9*@T*?RRPY?(
M#A6=P$D=^Y$3?:5X'KJ8WEW*L9J)(?N0$R).K-@&E"D#X-GP/#B ;5H,UO\5
MDDKT@:2P=F%MK-QO.N;.1 K50 RX[!^S$?BO0#R9+32X,&3GTL\5$T*^RAQS
MIP\<.%0"JI:,Q8ASCH/?BE!<W!*/)PD<46%P.+L3BW\<@6FSEV&373 B\W.0
MZ6*!LXM'8?RTV9BPT1;WPW+$>(]$UMV[\!MV%\>[GL+Z72YXF*30O4)O!I40
M>92:N!6*%HVH W!TX5$T:]I,RCYF%K#! /32H&>02HS_*O7P"<3]' ??.KY(
MWI6,+LV[8/+4R46?& G.2N6E(C7&G(20;<AG4)-40B7(I!HN-5&A&@&)%+ZK
M)87S)L_3>A;9#_0,*"4#)+%4XGP&+EDKK4^1HR'BS/Y%)970H\'E5MZ#VJ02
M>BCY'"3(.C"*%-)XT9#Q^I5)*N$*IIH80!(P>H?8AFJ6&WE]KC)0#S!THQPR
M4(843BT:YR3S,B$LIS[!-N0FYXX..FN+0@?[K_9'IDVF=(3DGU_^,YJW:(Y.
MG3KAZ%'&,VCEGELWO?_^^]+["Q<N%.)6*-10 8YV.HI;;6XA_D0\;IK?Q)/T
M9X.9Y("[!- SV+U[=[SSSCM2_:%#ATH;M$N@=XM]2&^[$3(DD\)S%N>P8=4&
M]*G1!]G;Q(.S#]0FE3P/7<RQS'&H%!RW\DDE;(,*=#%)X87S%Z1=&"3P^NQ[
MACZH)82ZR_8*=;&;>%47KV4'EB%D2HB)%)I(H4((XYO;/Q=1_XQ"^A:A$<4
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M76-1(2FD7:4!H3%40P@ITC2@%T0S]CF+[A]TEP8)3U(QVD-))<29L9&!S"7
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MQB_[Q\/+ YEYF?"\[HF(-6)J2\^$F)U%1$<@*3E)BCWDP$](J$"ST1#0$'$
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M1U()":'2^K)WA_<0 ^S;L0\-FC:0MJ3A6*E:M:K>OI.*D(&.73OB3-<S\/O
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M2$)$,J&T#^A=(AF1DTKX>TK ^Z7LRTDE"@EI;GXNYG2<@]-=3\-VM"T&U!^
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M#X>Q/V+T3^.Q)2 9J4GGL+[;-,R;>EE,H&,0<GHZVHQ>B(4?+8=G?U^$72E
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MQN'X@N/P'^./"VLN*!YJYV/.RDD[-19QG<MA%YS==!912Z)0<+( )=EZ&:%
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M! 3IJ'_-'R';0Y#X2R*RKF0A*CCJUKM56]3Z%_T1M#H(R9.3D>>2A[A@[82
MX.!@A1#2N-T!*Y-*%)E3"2%_I]SQP^,3>:J/^3/<4?A\J@QM$7TP(0JY]KE(
M]TO7+0/^SJ(-%X8@_5 Z;OK?1'A0N*[Z <Y"A@9%(&M-%K+]LA$5HK,/+ION
MG[HA%1F!&8@(%C(48*$,\#[_;4DE02G*:1G5U:=L\$2H6[C7NI@3:O(E;@Y.
M1X,&>&0?/6YWE*CR?STC$;56R+!C+O*"\A =&8VPR+ [KG5S<U.V(N,9R)7
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M=0X8;$RR,<%IG8T#QA$,V#B!L;%-SCDG(7(&D;,22 ($"D0E)"$DE'/. >6
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MI $A(>']E2IR<7WXY'#$O!2#I,-)Z/]X_T9#-63(D/9)(=N+S\U)"<F0J']
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M$BFD$N1LBEY"-1Y"SFJYQ$%%IF8 4+?30\A9-6?82@T1P<%+)<#8&Q.< 2U
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M_80)$YJ2PB,&8X:*ER2"$P-.ZI7V(<__A9)*C&'ZS.GX=,"G2%F=@LV/;T;
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MR>&^N.(HQMY93UR]D8K<BC(4)P;AAHL#',YZP"TH!T72_F<">:)M+Y:BU*8
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M6-O.Y,T C:2PFZA;IJ@;9;>5&$).)$E"20CE/F'=.%%*24L1=K<&#K,<<&R
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M#$DA/>D]G^ZIJQOM1T>32GAO6W&07.I$5Y)7RCS#!AAR(H-M*(VOP@(L6+
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M=^3E/J6> 2I^.?ZLC:028_AA\@]X;?!KR+N0!_^G_9&^786+E</R+B>52#+
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MD>Y+)49EI/<L3!DGB-.'@C@%"%+XU !8'V*D=2O@Y+^=I!+*T,"7!AJO'V6
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MR$DX^L4AJ?C?)\<:-&C0H$'#;QV_*D\ADT#<W'3DCLO"'4TJ(7)S=<O,'AY
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M]';S8[A<4(V:^@I4ISMC\X3-V+###^E-ZIP"S]5[L.V+U;!TL839_*TXZ!"
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MF /S1<NQ><\>'-PP"Q,V6V/]^G4XO=\<AZ,KH:T::]"@08,&#>WCKI/":=.
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M.#B3&9L.H+E1@RWGG# U.8GI_AE,WWB0?9O7L]/P""MG'N?L<B=B:THHC+%
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ML4/,G[.'(]LVLN/K'KSUWC ^U+]!>(HG.B><L+-U)23I"NLUQ5O3O!5H'3/
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MEO+$VX3=]L,G7#PWXI+(C+J.[U4WKMC;XW0]D("89%*"?0GR]^**YU7<;]S
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ME<=X8+5R :MGSV2A@2..SL;H:&K0?Y4)MC9:&!CL8>DV78X=,L3VY&;V[=C
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ML&CJ'+9^\RDS-J]BW(*#[-NKAYF^'B<V[4!+[P ;CCGA')Y-7H0;%LLV<<C
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9;C:"_Q\AA]5U)=E-#0    !)14Y$KD)@@@$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139714823580792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Apr. 28, 2022</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-50679<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">CORCEPT THERAPEUTICS INC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">77-0487658<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">149 Commonwealth Drive<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Menlo Park<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">327-3270<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.001 par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CORT<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">106,250,716<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001088856<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139714823834360">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 61,862<span></span>
</td>
<td class="nump">$ 77,617<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Short-term marketable securities</a></td>
<td class="nump">283,665<span></span>
</td>
<td class="nump">145,918<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Trade receivables, net of allowances</a></td>
<td class="nump">27,178<span></span>
</td>
<td class="nump">27,625<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">5,079<span></span>
</td>
<td class="nump">4,988<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">10,436<span></span>
</td>
<td class="nump">10,315<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">388,220<span></span>
</td>
<td class="nump">266,463<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNoncurrent', window );">Strategic inventory</a></td>
<td class="nump">13,098<span></span>
</td>
<td class="nump">12,962<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset</a></td>
<td class="nump">2,816<span></span>
</td>
<td class="nump">514<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net of accumulated depreciation</a></td>
<td class="nump">726<span></span>
</td>
<td class="nump">1,002<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesNoncurrent', window );">Long-term marketable securities</a></td>
<td class="nump">22,566<span></span>
</td>
<td class="nump">112,277<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">2,984<span></span>
</td>
<td class="nump">3,083<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Deferred tax assets, net</a></td>
<td class="nump">37,713<span></span>
</td>
<td class="nump">27,455<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">468,123<span></span>
</td>
<td class="nump">423,756<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">9,269<span></span>
</td>
<td class="nump">6,908<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cort_AccruedClinicalExpensesCurrent', window );">Accrued research and development expenses</a></td>
<td class="nump">13,051<span></span>
</td>
<td class="nump">12,442<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued and other liabilities</a></td>
<td class="nump">32,660<span></span>
</td>
<td class="nump">27,665<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Short-term operating lease liability</a></td>
<td class="nump">2,264<span></span>
</td>
<td class="nump">526<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">57,244<span></span>
</td>
<td class="nump">47,541<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term operating lease liability</a></td>
<td class="nump">552<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesNoncurrent', window );">Long-term accrued income taxes payable</a></td>
<td class="nump">2,516<span></span>
</td>
<td class="nump">409<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">60,312<span></span>
</td>
<td class="nump">47,950<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock</a></td>
<td class="nump">128<span></span>
</td>
<td class="nump">127<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonValue', window );">Treasury stock</a></td>
<td class="num">(417,448)<span></span>
</td>
<td class="num">(410,411)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">608,717<span></span>
</td>
<td class="nump">591,349<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(1,351)<span></span>
</td>
<td class="num">(227)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings</a></td>
<td class="nump">217,765<span></span>
</td>
<td class="nump">194,968<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">407,811<span></span>
</td>
<td class="nump">375,806<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 468,123<span></span>
</td>
<td class="nump">$ 423,756<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cort_AccruedClinicalExpensesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are associated with clinical research and related activities, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Used to reflect the current portion of clinical accrued liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cort_AccruedClinicalExpensesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cort_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due beyond one year or the operating cycle, whichever is longer. Alternate captions include income taxes payable, noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139714823626072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Product revenue, net</a></td>
<td class="nump">$ 93,688<span></span>
</td>
<td class="nump">$ 79,437<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of sales</a></td>
<td class="nump">1,250<span></span>
</td>
<td class="nump">1,268<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">28,120<span></span>
</td>
<td class="nump">29,022<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">37,549<span></span>
</td>
<td class="nump">29,509<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating expenses</a></td>
<td class="nump">66,919<span></span>
</td>
<td class="nump">59,799<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income from operations</a></td>
<td class="nump">26,769<span></span>
</td>
<td class="nump">19,638<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Interest and other income</a></td>
<td class="nump">80<span></span>
</td>
<td class="nump">275<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income before income taxes</a></td>
<td class="nump">26,849<span></span>
</td>
<td class="nump">19,913<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax (expense) benefit</a></td>
<td class="num">(4,052)<span></span>
</td>
<td class="nump">3,552<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">22,797<span></span>
</td>
<td class="nump">23,465<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized loss on available-for-sale investments, net of tax effect of $323 and $61, respectively</a></td>
<td class="num">(1,019)<span></span>
</td>
<td class="num">(192)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation (loss) gain, net of tax</a></td>
<td class="num">(105)<span></span>
</td>
<td class="nump">26<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Total comprehensive income</a></td>
<td class="nump">$ 21,673<span></span>
</td>
<td class="nump">$ 23,299<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net income per share (in dollars per share)</a></td>
<td class="nump">$ 0.22<span></span>
</td>
<td class="nump">$ 0.20<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net income per share (in dollars per share)</a></td>
<td class="nump">$ 0.20<span></span>
</td>
<td class="nump">$ 0.18<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract', window );"><strong>Weighted-average shares outstanding used in computing net income per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (in shares)</a></td>
<td class="nump">106,012<span></span>
</td>
<td class="nump">116,818<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (in shares)</a></td>
<td class="nump">115,037<span></span>
</td>
<td class="nump">129,668<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123384075&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139714822263208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax', window );">Net unrealized income (loss) on available-for-sale investments, tax impact</a></td>
<td class="nump">$ 323<span></span>
</td>
<td class="nump">$ 61<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before adjustment, of tax expense (benefit) for unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e640-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139714823887032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">$ 22,797<span></span>
</td>
<td class="nump">$ 23,465<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income to net cash provided by operations:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">10,761<span></span>
</td>
<td class="nump">10,101<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cort_AccretionExpenseIncome', window );">Amortization of interest income</a></td>
<td class="nump">1,106<span></span>
</td>
<td class="nump">1,194<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization of property and equipment</a></td>
<td class="nump">288<span></span>
</td>
<td class="nump">254<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income taxes</a></td>
<td class="num">(9,935)<span></span>
</td>
<td class="num">(5,360)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Non-cash amortization of right-of-use asset</a></td>
<td class="nump">514<span></span>
</td>
<td class="nump">489<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Trade receivables</a></td>
<td class="nump">447<span></span>
</td>
<td class="nump">3,998<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="num">(163)<span></span>
</td>
<td class="nump">866<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(9)<span></span>
</td>
<td class="num">(2,850)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">2,256<span></span>
</td>
<td class="num">(3,493)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cort_IncreaseDecreaseInAccruedClinicalExpenses', window );">Accrued research and development expenses</a></td>
<td class="nump">609<span></span>
</td>
<td class="num">(138)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities', window );">Accrued and other liabilities</a></td>
<td class="nump">4,995<span></span>
</td>
<td class="num">(3,217)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedTaxesPayable', window );">Long-term accrued income taxes</a></td>
<td class="nump">2,107<span></span>
</td>
<td class="nump">597<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="num">(526)<span></span>
</td>
<td class="num">(484)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by operating activities</a></td>
<td class="nump">35,247<span></span>
</td>
<td class="nump">25,422<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(12)<span></span>
</td>
<td class="num">(126)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Proceeds from maturities of marketable securities</a></td>
<td class="nump">42,127<span></span>
</td>
<td class="nump">124,230<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchases of marketable securities</a></td>
<td class="num">(92,611)<span></span>
</td>
<td class="num">(127,388)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(50,496)<span></span>
</td>
<td class="num">(3,284)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from exercise of stock options, net of issuance costs</a></td>
<td class="nump">1,382<span></span>
</td>
<td class="nump">4,038<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Repurchase of common stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(33,541)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Cash paid to satisfy statutory withholding requirement for net settlement of cashless option exercises</a></td>
<td class="num">(1,888)<span></span>
</td>
<td class="num">(16,444)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash used in financing activities</a></td>
<td class="num">(506)<span></span>
</td>
<td class="num">(45,947)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net decrease in cash and cash equivalents</a></td>
<td class="num">(15,755)<span></span>
</td>
<td class="num">(23,809)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, at beginning of period</a></td>
<td class="nump">77,617<span></span>
</td>
<td class="nump">76,190<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, at end of period</a></td>
<td class="nump">61,862<span></span>
</td>
<td class="nump">52,381<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cort_SharesRepurchasedInNetSettlementOfCashlessOptionExercise', window );">Cost of shares repurchased for net settlement of cashless option exercises</a></td>
<td class="nump">5,149<span></span>
</td>
<td class="nump">6,045<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cort_NonCashTransactionRecognitionOfRightOfUseAssetAndLeaseLiability', window );">Recognition of right-of-use asset and lease liability</a></td>
<td class="nump">$ 2,816<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cort_AccretionExpenseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accretion Expense (Income)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cort_AccretionExpenseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cort_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cort_IncreaseDecreaseInAccruedClinicalExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) in accrued clinical expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cort_IncreaseDecreaseInAccruedClinicalExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cort_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cort_NonCashTransactionRecognitionOfRightOfUseAssetAndLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non Cash Transaction, Recognition Of Right Of Use Asset And Lease Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cort_NonCashTransactionRecognitionOfRightOfUseAssetAndLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cort_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cort_SharesRepurchasedInNetSettlementOfCashlessOptionExercise">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shares Repurchased In Net Settlement Of Cashless Option Exercise</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cort_SharesRepurchasedInNetSettlementOfCashlessOptionExercise</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cort_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedTaxesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period of all taxes owed but not paid, including income, property and other taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedTaxesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in other expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139714817299784">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common&#160;Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Treasury Stock</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss)</div></th>
<th class="th"><div>Retained Earnings</div></th>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">116,735<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="nump">$ 523,338<span></span>
</td>
<td class="nump">$ 122<span></span>
</td>
<td class="nump">$ 516,140<span></span>
</td>
<td class="num">$ (75,795)<span></span>
</td>
<td class="nump">$ 415<span></span>
</td>
<td class="nump">$ 82,456<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of options (in shares)</a></td>
<td class="nump">1,800<span></span>
</td>
<td class="nump">1,832<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of options</a></td>
<td class="nump">$ 10,083<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">10,081<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Purchases of treasury stock (in shares)</a></td>
<td class="num">(21,300)<span></span>
</td>
<td class="num">(1,282)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Purchases of treasury stock</a></td>
<td class="num">$ (33,540)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(33,540)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation', window );">Shares purchased to satisfy cost and statutory withholding requirements for net settlement of cashless option exercises</a></td>
<td class="num">(800)<span></span>
</td>
<td class="num">(808)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Shares purchased to satisfy cost and statutory withholding requirements for net settlement of cashless option exercises</a></td>
<td class="num">$ (22,520)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(22,520)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">10,142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="num">(166)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(166)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">23,465<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,465<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">116,477<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2021</a></td>
<td class="nump">510,802<span></span>
</td>
<td class="nump">$ 124<span></span>
</td>
<td class="nump">536,363<span></span>
</td>
<td class="num">(131,855)<span></span>
</td>
<td class="nump">249<span></span>
</td>
<td class="nump">105,921<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">105,940<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="nump">$ 375,806<span></span>
</td>
<td class="nump">$ 127<span></span>
</td>
<td class="nump">591,349<span></span>
</td>
<td class="num">(410,411)<span></span>
</td>
<td class="num">(227)<span></span>
</td>
<td class="nump">194,968<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of options (in shares)</a></td>
<td class="nump">600<span></span>
</td>
<td class="nump">586<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of options</a></td>
<td class="nump">$ 6,544<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">6,543<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Purchases of treasury stock (in shares)</a></td>
<td class="num">(21,600)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation', window );">Shares purchased to satisfy cost and statutory withholding requirements for net settlement of cashless option exercises</a></td>
<td class="num">(300)<span></span>
</td>
<td class="num">(305)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Shares purchased to satisfy cost and statutory withholding requirements for net settlement of cashless option exercises</a></td>
<td class="num">$ (7,037)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,037)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">10,825<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,825<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="num">(1,124)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,124)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">22,797<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,797<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">106,221<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2022</a></td>
<td class="nump">$ 407,811<span></span>
</td>
<td class="nump">$ 128<span></span>
</td>
<td class="nump">$ 608,717<span></span>
</td>
<td class="num">$ (417,448)<span></span>
</td>
<td class="num">$ (1,351)<span></span>
</td>
<td class="nump">$ 217,765<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123468992&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredCostMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAcquiredCostMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139714822159368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">Basis of Presentation and Summary of Significant Accounting Policies</a></td>
<td class="text">Basis of Presentation and Summary of Significant Accounting Policies<div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Description of Business and Basis of Presentation</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corcept Therapeutics Incorporated is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe endocrine, metabolic, oncologic, and neurological disorders by modulating the effects of the hormone cortisol.&#160;In 2012, the United States Food and Drug Administration (&#8220;FDA&#8221;) approved Korlym&#160;(&#8220;mifepristone&#8221;) 300&#160;mg tablets, as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing&#8217;s syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. We have discovered&#160;and patented four&#160;structurally distinct series of selective cortisol modulators, consisting of more than&#160;1,000&#160;compounds. We are developing compounds from these series as potential treatments for a broad range of serious disorders.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We were incorporated in the State of&#160;Delaware&#160;in&#160;May 1998. Our headquarters are located in Menlo Park, California.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have prepared the following in accordance with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X: (i) condensed consolidated balance sheet as of March&#160;31, 2022 and (ii) condensed consolidated statements of comprehensive income, cash flows and stockholders&#8217; equity for the three-month periods ended March&#160;31, 2022 and 2021. These do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments considered necessary for a fair presentation (which in the applicable periods consist only of normal, recurring adjustments) have been included. Operating results for the three months ended March 31, 2022 are not necessarily indicative of the results for the remainder of 2022 or any other period. These financial statements and notes should be read in conjunction with the financial statements for the year ended December&#160;31, 2021 included in our Annual Report on Form 10-K. The December&#160;31, 2021 balance sheet was derived from audited financial statements at that date.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material changes to the significant accounting policies described in our Annual Report on Form&#160;10-K for the year ended&#160;December&#160;31, 2021.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).  Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139714822174712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Composition of Certain Balance Sheet Items<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">Composition of Certain Balance Sheet Items</a></td>
<td class="text">Composition of Certain Balance Sheet Items<div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Inventory</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.028%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.545%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in progress</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,637&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,450&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,540&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventory</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,177&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,950&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less strategic inventory classified as non-current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,098)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,962)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventory classified as current</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,079&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,988&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because we rely on a single manufacturer to produce Korlym&#8217;s active pharmaceutical ingredient (&#8220;API&#8221;), we have purchased and hold significant quantities of API, included in work in progress inventory. We classify inventory we do not expect to sell within 12 months of the balance sheet date as &#8220;Strategic Inventory,&#8221; a long-term asset.&#160;</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Property and equipment</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.882%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.545%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and equipment</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,169&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,157&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,508&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,508&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,262&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,262&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,939&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,927&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,213)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,925)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net of accumulated depreciation and amortization</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">726&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,002&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accrued and other liabilities</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.882%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.545%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government rebates</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,377&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,174&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued income taxes payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,523&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">513&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,968&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,339&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legal fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,802&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">842&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued selling and marketing costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">861&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,351&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">652&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">477&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">296&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued and other liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,660&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,665&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other assets</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2022 and December&#160;31, 2021, other assets included $2.8 million and $2.9 million of deposits for clinical trials, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -URI http://asc.fasb.org/topic&amp;trid=2122208<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139714822201528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Available-for-Sale Securities and Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cort_AvailableForSaleSecuritiesAndFairValueMeasurementsAbstract', window );"><strong>Available For Sale Securities And Fair Value Measurements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cort_AvailableForSaleSecuritiesAndFairValueMeasurementsDisclosureTextBlock', window );">Available-for-Sale Securities and Fair Value Measurements</a></td>
<td class="text">Available-for-Sale Securities and Fair Value Measurements<div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The available-for-sale securities in our Condensed Consolidated Balance Sheets are as follows:</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.028%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.545%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,266&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,088&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">283,665&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145,918&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,566&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112,277&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total marketable securities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">330,497&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">303,283&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents our available-for-sale securities grouped by asset type:</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:16.590%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.538%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value<br/>Hierarchy<br/>Level</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr style="height:29pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="45" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">147,177&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,023)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">146,158&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">125,370&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(276)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">125,097&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">56,751&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">56,751&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30,963&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30,963&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29,372&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(110)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29,262&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">57,801&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(67)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">57,734&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">74,363&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(303)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">74,060&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44,473&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(72)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44,401&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24,266&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24,266&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45,088&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45,088&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">331,929&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,436)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">330,497&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">303,695&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(415)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">303,283&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate the fair value of marketable securities classified as Level 1 using quoted market prices for these or identical investments obtained from a commercial pricing service. We estimate the fair value of marketable securities classified as Level 2 using inputs that may include benchmark yields, reported trades, broker/dealer quotes and issuer spreads.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We periodically review our debt securities to determine if any of our investments is impaired due to credit-related or other issues. If the fair value of our investment in any debt security is less than our amortized cost basis, we determine whether an allowance for credit losses is appropriate by assessing quantitative and subjective factors including, but not limited to, the nature of security, changes in credit ratings, analyst reports concerning the security&#8217;s issuer and industry, interest rate fluctuations and general market conditions.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2022 and December&#160;31, 2021, unrealized losses on our available-for-sale debt securities were $1.4 million and $0.4 million, respectively.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of our investments, including those with unrealized losses, are not impaired. Unrealized losses on our investments are due to interest rate fluctuations. We do not intend to sell investments that currently have unrealized losses and it is highly unlikely that we will sell any investment before recovery of its amortized cost basis, which may be at maturity. Accordingly, we have not recorded an allowance for credit losses associated with these investments.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We classified accrued interest on our marketable securities of $1.0 million and $1.4 million as of March&#160;31, 2022 and December&#160;31, 2021, respectively, as prepaid and other current assets on our condensed consolidated balance sheets.</span></div>As of March&#160;31, 2022, all our marketable securities had original maturities of less than two years. The weighted-average maturity of our holdings was seven months. As of March&#160;31, 2022, our long-term marketable securities had remaining maturities ranging from 12 to 24 months. None of our marketable securities changed from one fair value hierarchy to another during the three months ended March 31, 2022<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cort_AvailableForSaleSecuritiesAndFairValueMeasurementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Available for sale securities and fair value measurements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cort_AvailableForSaleSecuritiesAndFairValueMeasurementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cort_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cort_AvailableForSaleSecuritiesAndFairValueMeasurementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Available for sale securities and fair value measurements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cort_AvailableForSaleSecuritiesAndFairValueMeasurementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cort_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139714822174712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies<div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> There have been no material changes in our obligations under contractual agreements described in our Annual Report on Form&#160;10-K for the year ended&#160;December&#160;31, 2021. </span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of business, we may be subject to legal claims and regulatory actions that could have a material adverse effect on our business or financial position. We assess our potential liability in such situations by analyzing potential </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">outcomes under various litigation, regulatory and settlement strategies.&#160;If we determine a loss is probable and its amount can be reasonably estimated, we accrue an amount equal to the estimated loss.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No losses and&#160;no provision for a loss contingency have been recorded to date.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139714822204744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">Leases<div style="margin-top:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We lease our office facilities in Menlo Park, California. In March 2022, we amended our lease to extend its term from March 31, 2022 to June 30, 2023. As a result of this amendment, we recognized an additional right-of-use asset and corresponding lease liability of $2.8 million. The right-of-use asset and lease liability recognized equals the present value of the remaining payments due under our amended lease.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the operating lease for our facilities does not include an expressly stated interest rate, we calculated the present value of remaining lease payments using a discount rate equal to the interest rate we would pay on a collateralized loan with monthly payments and a term equal to the monthly payments and remaining term of our lease. We recognize operating lease payments as expenses using the straight-line method over the term of the lease.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease expense for each of the three months ended March&#160;31, 2022 and 2021 was approximately $0.5&#160;million.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our right-of-use assets and related lease liabilities were as follows </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(in thousands, except weighted average amounts)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.213%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.452%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.454%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for operating lease liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">530&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">514&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for new operating lease obligations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,816&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 months</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 months</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2022, future minimum lease payments under non-cancelable operating leases were as follows </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(in thousands)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:83.256%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.544%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022 (remainder)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,735&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,157&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,892&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(76)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of operating lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,816&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139714822364312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders&#8217; Equity</a></td>
<td class="text">Stockholders&#8217; Equity<div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Incentive Award Plan</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have one stock option plan &#8211; the 2012 Incentive Award Plan (the &#8220;2012 Plan&#8221;).&#160;In December 2021, our Board of Directors authorized a 4.2&#160;million increase in the shares available for grant under the 2012 Plan.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2022, we issued 0.6&#160;million shares of our common stock upon the exercise of stock options. Certain option holders exercised their options on a &#8220;net exercise&#8221; basis, pursuant to which they surrendered to us, and we purchased from them at the current market price, enough shares to cover the exercise price and tax withholding obligations arising from the exercise. During the three months ended March 31, 2022, we purchased 0.3&#160;million shares in connection with such option net exercises. In connection with the shares purchased, during the three months ended March 31, 2022, we paid $1.9&#160;million to satisfy associated tax withholding obligations.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2021, we issued 1.8&#160;million shares of our common stock upon the exercise of stock options. We purchased 0.8&#160;million shares in connection with option net exercises, at a total cost of $16.4&#160;million, to satisfy associated tax withholding obligations.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recorded purchased shares as treasury stock on our condensed consolidated balance sheets at cost. As of March&#160;31, 2022 and December&#160;31, 2021, we had 21.6&#160;million and 21.3&#160;million treasury shares outstanding, respectively.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units (&#8220;RSUs&#8221;)</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2022, we granted employees 0.2 million RSUs with a weighted-average grant date fair value of $19.34 per share. No RSUs vested during the period.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Stock Purchase Plan (&#8220;ESPP&#8221;)</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2022 we adopted an ESPP that allows employees to set aside, by means of payroll deductions, up to ten percent of their annual compensation for the purchase of our commons stock. Shares are issued to participating employees from the 2012 Plan on March 1st and September 1st of each year (or, if those dates fall on holidays, on the first business day thereafter) at the then-current fair market value of our stock, as determined at the close of trading on those days. Payroll deductions for participating employees began April 1, 2022, and the first purchase under the plan will take place on September 1, 2022.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For each purchased share held for one year, the purchasing employee will receive one matching share, also issued from the 2012 Plan, net of any applicable tax withholding. There is no vesting requirement with respect to shares issued pursuant to the ESPP. Shares purchased pursuant to the ESPP as well as any matching shares issued upon satisfaction of the one-year holding requirement may be held, sold or otherwise transferred at the employee&#8217;s sole discretion.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-based Compensation</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense associated with stock options and awards of restricted stock is measured at the grant date based on the fair value of the award, and is recognized, net of forfeitures, as expense over the remaining requisite service period on a straight-line basis.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company values restricted stock at the closing market price of the Company&#8217;s common stock on the date of grant.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our stock-based compensation by account:</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.882%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.545%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation capitalized in inventory</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,371&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,505&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,374&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,586&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,825&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,142&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139714822214648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income Per Share<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Income Per Share</a></td>
<td class="text">Net Income Per ShareWe compute basic and diluted net income per share by dividing our net income by the weighted-average number of common shares outstanding during the period, including potentially dilutive stock options and RSUs. We use the treasury stock method to determine the number of dilutive shares of common stock resulting from stock options and restricted stock.<div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the computation of net income per share for each period:</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.882%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.545%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,797&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,465&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares used to compute basic net income per share</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106,012&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116,818&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive effect of employee stock options and restricted stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,025&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,850&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares used to compute diluted net income per share</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115,037&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129,668&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.20&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.18&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2022, we had 26.0 million stock options and 0.2 million RSUs outstanding. As of March&#160;31, 2021, we had 26.8 million stock options outstanding.</span></div>We excluded from the computation of diluted net income per share, on a weighted-average basis,&#160;6.9 million stock options and RSUs outstanding during the three months ended March 31, 2022 and 2.4 million stock options outstanding during the three months ended March 31, 2021, because including them would have reduced dilution<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139714822364312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes<div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recorded income tax expense of $4.1 million for the three months ended March 31, 2022, and an income tax benefit of $3.6 million for the three months ended March 31, 2021. The increase in income tax expense during the three months ended March 31, 2022 was primarily due to increased income before income taxes and decreased excess tax deductions from stock-based compensation as compared to the corresponding period in 2021.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our effective tax rate differs from the federal statutory rate due to state income taxes and the non-deductible portion of our stock-based compensation, which increased our tax expense, offset by tax benefits for research and development tax credits and the excess tax deduction arising from the exercise of employee stock options, which reduced our taxable income.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2022, unrecognized tax benefits increased by $0.4 million. As of March&#160;31, 2022, the Company had unrecognized tax benefits of $7.7 million that, if recognized, would affect the Company&#8217;s effective tax rate and approximately $1.9 million of unrecognized tax benefits that would not impact the effective tax rate as they would be offset by a corresponding change in valuation allowance.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each quarter, we assess the likelihood that we will generate sufficient taxable income to make use of our federal and state deferred tax assets. If we believe that recovery of these deferred tax assets is not more likely than not, we establish a valuation allowance offsetting such assets on our balance sheet. Significant judgment is required in assessing the need for a valuation allowance. We consider all available evidence, including our recent operating results and our forecasts of future taxable income. Other than valuation allowances against our California net deferred tax assets, we have determined that it is more likely than not we will realize the benefit related to all other deferred tax assets. To the extent we increase a valuation allowance, we will include an expense in the Condensed Consolidated Statement of Comprehensive Income in the period in which such determination is made.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in 2022, the Tax Cuts and Jobs Act of 2017 (&#8220;TCJA&#8221;) eliminates the right to deduct research and development expenditures for tax purposes in the period the expenses were incurred and instead requires all U.S. and foreign research and development expenditures to be amortized over five and fifteen tax years, respectively. Although Congress is considering legislation that would defer the amortization requirement to later years, it is not certain that the provision will be repealed or otherwise modified. As of March&#160;31, 2022, the requirement has not been modified. We have capitalized our research and development expenses, which caused our taxes payable to increase to $11.5 million as of March&#160;31, 2022, compared to $0.5 million as of December&#160;31, 2021.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139714822354184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have prepared the following in accordance with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X: (i) condensed consolidated balance sheet as of March&#160;31, 2022 and (ii) condensed consolidated statements of comprehensive income, cash flows and stockholders&#8217; equity for the three-month periods ended March&#160;31, 2022 and 2021. These do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments considered necessary for a fair presentation (which in the applicable periods consist only of normal, recurring adjustments) have been included. Operating results for the three months ended March 31, 2022 are not necessarily indicative of the results for the remainder of 2022 or any other period. These financial statements and notes should be read in conjunction with the financial statements for the year ended December&#160;31, 2021 included in our Annual Report on Form 10-K. The December&#160;31, 2021 balance sheet was derived from audited financial statements at that date.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139714825741432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Composition of Certain Balance Sheet Items (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of composition of inventory, current</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Inventory</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.028%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.545%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in progress</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,637&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,450&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,540&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventory</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,177&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,950&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less strategic inventory classified as non-current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,098)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,962)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventory classified as current</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,079&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,988&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryNoncurrentTableTextBlock', window );">Schedule of composition of inventory, noncurrent</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Inventory</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.028%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.545%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in progress</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,637&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,450&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,540&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventory</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,177&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,950&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less strategic inventory classified as non-current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,098)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,962)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventory classified as current</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,079&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,988&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of property and equipment</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Property and equipment</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.882%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.545%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and equipment</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,169&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,157&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,508&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,508&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,262&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,262&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,939&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,927&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,213)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,925)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net of accumulated depreciation and amortization</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">726&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,002&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of other accrued liabilities</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accrued and other liabilities</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.882%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.545%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government rebates</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,377&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,174&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued income taxes payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,523&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">513&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,968&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,339&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legal fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,802&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">842&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued selling and marketing costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">861&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,351&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">652&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">477&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">296&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued and other liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,660&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,665&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryNoncurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle including inventoried costs relating to long-term contracts or programs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryNoncurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139714822267784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Available-for-Sale Securities and Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cort_AvailableForSaleSecuritiesAndFairValueMeasurementsAbstract', window );"><strong>Available For Sale Securities And Fair Value Measurements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Summary of the classification of available-for-sale securities in condensed consolidated balance sheets</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The available-for-sale securities in our Condensed Consolidated Balance Sheets are as follows:</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.028%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.545%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,266&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,088&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">283,665&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145,918&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,566&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112,277&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total marketable securities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">330,497&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">303,283&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock', window );">Schedule of available-for-sale securities</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents our available-for-sale securities grouped by asset type:</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:16.590%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.538%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value<br/>Hierarchy<br/>Level</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr style="height:29pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="45" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">147,177&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,023)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">146,158&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">125,370&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(276)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">125,097&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">56,751&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">56,751&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30,963&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30,963&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29,372&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(110)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29,262&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">57,801&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(67)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">57,734&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">74,363&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(303)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">74,060&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44,473&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(72)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44,401&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24,266&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24,266&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45,088&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45,088&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">331,929&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,436)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">330,497&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">303,695&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(415)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">303,283&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cort_AvailableForSaleSecuritiesAndFairValueMeasurementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Available for sale securities and fair value measurements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cort_AvailableForSaleSecuritiesAndFairValueMeasurementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cort_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139714822243320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of information of leases asset and liabilities</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our right-of-use assets and related lease liabilities were as follows </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(in thousands, except weighted average amounts)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.213%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.452%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.454%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for operating lease liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">530&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">514&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for new operating lease obligations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,816&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 months</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 months</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of future minimum lease payments under non-cancelable operating leases</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2022, future minimum lease payments under non-cancelable operating leases were as follows </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(in thousands)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:83.256%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.544%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022 (remainder)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,735&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,157&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,892&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(76)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of operating lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,816&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139714822268904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Summary of stock-based compensation</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our stock-based compensation by account:</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.882%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.545%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation capitalized in inventory</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,371&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,505&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,374&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,586&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,825&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,142&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139714823237624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of computation of net income per share</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the computation of net income per share for each period:</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.882%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.545%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,797&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,465&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares used to compute basic net income per share</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106,012&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116,818&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive effect of employee stock options and restricted stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,025&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,850&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares used to compute diluted net income per share</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115,037&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129,668&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.20&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.18&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139714822270024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2022 </div>
<div>series</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cort_NumberOfSeriesOfSelectiveCortisolModulators', window );">Number of series of selective cortisol modulators</a></td>
<td class="nump">4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cort_NumberOfSeriesOfSelectiveCortisolModulators">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Series Of Selective Cortisol Modulators</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cort_NumberOfSeriesOfSelectiveCortisolModulators</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cort_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139714824829048">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Composition of Certain Balance Sheet Items - Schedule of Composition of Inventory (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cort_InventoryWorkInProcessCurrentAndNoncurrent', window );">Work in progress</a></td>
<td class="nump">$ 12,637<span></span>
</td>
<td class="nump">$ 11,450<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cort_InventoryFinishedGoodsCurrentAndNoncurrent', window );">Finished goods</a></td>
<td class="nump">5,540<span></span>
</td>
<td class="nump">6,500<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cort_InventoryCurrentNoncurrent', window );">Total inventory</a></td>
<td class="nump">18,177<span></span>
</td>
<td class="nump">17,950<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNoncurrent', window );">Less strategic inventory classified as non-current</a></td>
<td class="num">(13,098)<span></span>
</td>
<td class="num">(12,962)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total inventory classified as current</a></td>
<td class="nump">$ 5,079<span></span>
</td>
<td class="nump">$ 4,988<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cort_InventoryCurrentNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cort_InventoryCurrentNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cort_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cort_InventoryFinishedGoodsCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Inventory, finished goods, current and noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cort_InventoryFinishedGoodsCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cort_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cort_InventoryWorkInProcessCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Inventory, work in process. current and noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cort_InventoryWorkInProcessCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cort_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139714820443304">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Composition of Certain Balance Sheet Items - Schedule of Property and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 3,939<span></span>
</td>
<td class="nump">$ 3,927<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less accumulated depreciation and amortization</a></td>
<td class="num">(3,213)<span></span>
</td>
<td class="num">(2,925)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net of accumulated depreciation</a></td>
<td class="nump">726<span></span>
</td>
<td class="nump">1,002<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cort_LongLivedTangibleAssetAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">1,169<span></span>
</td>
<td class="nump">1,157<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cort_LongLivedTangibleAssetAxis=us-gaap_ComputerSoftwareIntangibleAssetMember', window );">Software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">1,508<span></span>
</td>
<td class="nump">1,508<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cort_LongLivedTangibleAssetAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 1,262<span></span>
</td>
<td class="nump">$ 1,262<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cort_LongLivedTangibleAssetAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cort_LongLivedTangibleAssetAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cort_LongLivedTangibleAssetAxis=us-gaap_ComputerSoftwareIntangibleAssetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cort_LongLivedTangibleAssetAxis=us-gaap_ComputerSoftwareIntangibleAssetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cort_LongLivedTangibleAssetAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cort_LongLivedTangibleAssetAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139714820415144">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Composition of Certain Balance Sheet Items - Schedule of Other Accrued Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cort_AccruedGovernmentRebateCurrent', window );">Government rebates</a></td>
<td class="nump">$ 12,377<span></span>
</td>
<td class="nump">$ 11,174<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesCurrent', window );">Accrued income taxes payable</a></td>
<td class="nump">11,523<span></span>
</td>
<td class="nump">513<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation</a></td>
<td class="nump">4,968<span></span>
</td>
<td class="nump">13,339<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cort_AccruedLegalFeesCurrent', window );">Legal fees</a></td>
<td class="nump">1,802<span></span>
</td>
<td class="nump">842<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedMarketingCostsCurrent', window );">Accrued selling and marketing costs</a></td>
<td class="nump">861<span></span>
</td>
<td class="nump">1,351<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Professional fees</a></td>
<td class="nump">652<span></span>
</td>
<td class="nump">150<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">477<span></span>
</td>
<td class="nump">296<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued and other liabilities</a></td>
<td class="nump">$ 32,660<span></span>
</td>
<td class="nump">$ 27,665<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cort_AccruedGovernmentRebateCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued government rebate current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cort_AccruedGovernmentRebateCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cort_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cort_AccruedLegalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to legal services. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cort_AccruedLegalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cort_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedMarketingCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for the marketing, trade and selling of the entity's goods and services.   Marketing costs would include expenditures for planning and executing the conception, pricing, promotion, and distribution of ideas, goods, and services; costs of public relations and corporate promotions; and obligations incurred and payable for sales discounts, rebates, price protection programs, etc. offered to customers and under government programs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedMarketingCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139714822134360">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Composition of Certain Balance Sheet Items - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cort_DepositsForClinicalTrials', window );">Deposits for clinical trials</a></td>
<td class="nump">$ 2.8<span></span>
</td>
<td class="nump">$ 2.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cort_DepositsForClinicalTrials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deposits For Clinical Trials</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cort_DepositsForClinicalTrials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cort_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139714824844536">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Available-for-Sale Securities and Fair Value Measurements - Summary of the Classification of Available-for-Sale Securities in Condensed Consolidated Balance Sheets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">$ 330,497<span></span>
</td>
<td class="nump">$ 303,283<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_CashEquivalentsMember', window );">Cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">24,266<span></span>
</td>
<td class="nump">45,088<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=cort_ShortTermMarketableSecuritiesMember', window );">Short-term marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">283,665<span></span>
</td>
<td class="nump">145,918<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=cort_LongTermMarketableSecuritiesMember', window );">Long-term marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">$ 22,566<span></span>
</td>
<td class="nump">$ 112,277<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_CashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_CashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=cort_ShortTermMarketableSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=cort_ShortTermMarketableSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=cort_LongTermMarketableSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=cort_LongTermMarketableSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139714820403064">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Available-for-Sale Securities and Fair Value Measurements - Schedule of Available-for-Sale Securities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">$ (1,400)<span></span>
</td>
<td class="num">$ (400)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of fair value measurement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">331,929<span></span>
</td>
<td class="nump">303,695<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(1,436)<span></span>
</td>
<td class="num">(415)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cort_AvailableForSaleSecuritiesIncludingCashEquivalents', window );">Estimated Fair Value</a></td>
<td class="nump">330,497<span></span>
</td>
<td class="nump">303,283<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of fair value measurement | Corporate bonds | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">147,177<span></span>
</td>
<td class="nump">125,370<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(1,023)<span></span>
</td>
<td class="num">(276)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cort_AvailableForSaleSecuritiesIncludingCashEquivalents', window );">Estimated Fair Value</a></td>
<td class="nump">146,158<span></span>
</td>
<td class="nump">125,097<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of fair value measurement | Commercial paper | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">56,751<span></span>
</td>
<td class="nump">30,963<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cort_AvailableForSaleSecuritiesIncludingCashEquivalents', window );">Estimated Fair Value</a></td>
<td class="nump">56,751<span></span>
</td>
<td class="nump">30,963<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of fair value measurement | Asset-backed securities | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">29,372<span></span>
</td>
<td class="nump">57,801<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(110)<span></span>
</td>
<td class="num">(67)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cort_AvailableForSaleSecuritiesIncludingCashEquivalents', window );">Estimated Fair Value</a></td>
<td class="nump">29,262<span></span>
</td>
<td class="nump">57,734<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of fair value measurement | U.S. Treasury securities | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">74,363<span></span>
</td>
<td class="nump">44,473<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(303)<span></span>
</td>
<td class="num">(72)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cort_AvailableForSaleSecuritiesIncludingCashEquivalents', window );">Estimated Fair Value</a></td>
<td class="nump">74,060<span></span>
</td>
<td class="nump">44,401<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of fair value measurement | Money market funds | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">24,266<span></span>
</td>
<td class="nump">45,088<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cort_AvailableForSaleSecuritiesIncludingCashEquivalents', window );">Estimated Fair Value</a></td>
<td class="nump">$ 24,266<span></span>
</td>
<td class="nump">$ 45,088<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cort_AvailableForSaleSecuritiesIncludingCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Available for sale securities including cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cort_AvailableForSaleSecuritiesIncludingCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cort_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139714823160312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Available-for-Sale Securities and Fair Value Measurements - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">$ (1,400)<span></span>
</td>
<td class="num">$ (400)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestReceivableCurrent', window );">Interest receivable, current</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">$ 1,400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cort_MarketableSecuritiesMaximumMaturityPeriod', window );">Maximum maturity period</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cort_MarketableSecuritiesWeightedAverageMaturityPeriod', window );">Weighted average maturity period</a></td>
<td class="text">7 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cort_LongTermMarketableSecuritiesRemainingMaturity', window );">Long term marketable securities, remaining maturity</a></td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cort_LongTermMarketableSecuritiesRemainingMaturity', window );">Long term marketable securities, remaining maturity</a></td>
<td class="text">24 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cort_LongTermMarketableSecuritiesRemainingMaturity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long Term Marketable Securities, Remaining Maturity</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cort_LongTermMarketableSecuritiesRemainingMaturity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cort_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cort_MarketableSecuritiesMaximumMaturityPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Marketable securities maximum original maturity period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cort_MarketableSecuritiesMaximumMaturityPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cort_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cort_MarketableSecuritiesWeightedAverageMaturityPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Marketable securities weighted-average maturity period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cort_MarketableSecuritiesWeightedAverageMaturityPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cort_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of current interest earned but not received. Also called accrued interest or accrued interest receivable. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139714826592472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Losses for contingent liability</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualProvision', window );">Provision for a loss contingency</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss contingency liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualProvision">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount charged against operating income increasing loss contingency liability, after adjustments to reduce previously estimated charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualProvision</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139714823634632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jan. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset</a></td>
<td class="nump">$ 2,816<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 514<span></span>
</td>
<td class="nump">$ 2,800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">2,816<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating lease expenses</a></td>
<td class="nump">$ 500<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139714823635336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Right-of-use Assets and Related Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash paid for operating lease liabilities</a></td>
<td class="nump">$ 530<span></span>
</td>
<td class="nump">$ 514<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets obtained in connection with operating lease obligations</a></td>
<td class="nump">$ 2,816<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term (months)</a></td>
<td class="text">15 months<span></span>
</td>
<td class="text">12 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate (as a percent)</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">4.80%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139714820450040">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Future Minimum Lease Payments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Jan. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2022 (remainder)</a></td>
<td class="nump">$ 1,735<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2023</a></td>
<td class="nump">1,157<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">2,892<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less imputed interest</a></td>
<td class="num">(76)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of operating lease liabilities</a></td>
<td class="nump">$ 2,816<span></span>
</td>
<td class="nump">$ 2,800<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139714823139304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Narrative (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($) </div>
<div>stockOptionPlan </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Shareholders Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cort_NumberOfStockOptionPlans', window );">Number of stock option plans | stockOptionPlan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Common shares issued upon exercise of options (in share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="nump">1,800,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation', window );">Shares withheld for tax withholding obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="nump">800,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Payment tax withholding share-based payment arrangement | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,888<span></span>
</td>
<td class="nump">$ 16,444<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Treasury stock shares acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,600,000<span></span>
</td>
<td class="nump">21,300,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Shareholders Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Grants in period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19.34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cort_StockOptionsFiscalTwentyTwelvePlanMember', window );">2012 Equity Incentive Award Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Shareholders Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Increase in shares authorized for grant (in shares)</a></td>
<td class="nump">4,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cort_NumberOfStockOptionPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of stock option plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cort_NumberOfStockOptionPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cort_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=cort_StockOptionsFiscalTwentyTwelvePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=cort_StockOptionsFiscalTwentyTwelvePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139714824851192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Summary of Stock-Based Compensation (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount', window );">Stock-based compensation capitalized in inventory</a></td>
<td class="nump">$ 64<span></span>
</td>
<td class="nump">$ 41<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1', window );">Total stock-based compensation</a></td>
<td class="nump">10,825<span></span>
</td>
<td class="nump">10,142<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated share-based compensation expense</a></td>
<td class="nump">16<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated share-based compensation expense</a></td>
<td class="nump">3,371<span></span>
</td>
<td class="nump">3,505<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated share-based compensation expense</a></td>
<td class="nump">$ 7,374<span></span>
</td>
<td class="nump">$ 6,586<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost capitalized for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost expensed and capitalized for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139714820382008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income Per Share - Schedule of Computation of Net Income Per Share (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 22,797<span></span>
</td>
<td class="nump">$ 23,465<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average shares used to compute basic net income per share (in shares)</a></td>
<td class="nump">106,012<span></span>
</td>
<td class="nump">116,818<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Dilutive effect of employee stock options (in shares)</a></td>
<td class="nump">9,025<span></span>
</td>
<td class="nump">12,850<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average shares used to compute diluted net income per share (in shares)</a></td>
<td class="nump">115,037<span></span>
</td>
<td class="nump">129,668<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract', window );"><strong>Net income per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (in dollars per share)</a></td>
<td class="nump">$ 0.22<span></span>
</td>
<td class="nump">$ 0.20<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (in dollars per share)</a></td>
<td class="nump">$ 0.20<span></span>
</td>
<td class="nump">$ 0.18<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1707-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28A<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1500-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1757-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139714824795144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income Per Share - Narrative (Details) - shares<br> shares in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Stock options outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options to Purchase Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Stock options outstanding (in shares)</a></td>
<td class="nump">26.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Weighted average options excluded from the computation of diluted net income per share (in shares)</a></td>
<td class="nump">6.9<span></span>
</td>
<td class="nump">2.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Share-based compensation arrangement by share-based payment award, equity instruments other than options, nonvested, number (in shares)</a></td>
<td class="nump">0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139714823639688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax (benefit) expense</a></td>
<td class="nump">$ 4,052<span></span>
</td>
<td class="num">$ (3,552)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease', window );">Unrecognized tax benefits, period increase</a></td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate', window );">Unrecognized tax benefits that would impact effective tax rate</a></td>
<td class="nump">7,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cort_UnrecognizedTaxBenefitsThatWouldBeOffsetByAChangeInValuationAllowance', window );">Unrecognized tax benefits that would be offset by a change in valuation allowance</a></td>
<td class="nump">1,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxesPayableCurrentAndNoncurrent', window );">Taxes payable</a></td>
<td class="nump">$ 11,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cort_UnrecognizedTaxBenefitsThatWouldBeOffsetByAChangeInValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized Tax Benefits That Would Be Offset By A Change In Valuation Allowance</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cort_UnrecognizedTaxBenefitsThatWouldBeOffsetByAChangeInValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cort_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxesPayableCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxesPayableCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in unrecognized tax benefits attributable to uncertain tax positions taken in tax returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>cort-20220331_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:cort="http://www.corcept.com/20220331"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="cort-20220331.xsd" xlink:type="simple"/>
    <context id="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001088856</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ib88f9c07449d45b0b9e7fb78200517da_I20220428">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001088856</identifier>
        </entity>
        <period>
            <instant>2022-04-28</instant>
        </period>
    </context>
    <context id="i93f424f685944c1aab994f99b0146441_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001088856</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="iac7c0f0822b942fa8f45ea15693a76af_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001088856</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0ebb8d8bac3445859e468a3d048cfaf5_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001088856</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="idf01ece55408406c8103d0d47b49800a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001088856</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i82ca1385b4a848fd8ea581edd7dcbfdb_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001088856</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i5ff8ab6f19e4485da8179e610307bf6f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001088856</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia2e3456ee78d4b7e862e98401e421964_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001088856</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iead727f3eb2b4b8fadf3c853db5498a8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001088856</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3c4a2585fb954bd1a1458a2999b7852e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001088856</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iefe5359585e240dbbfd8196f176fb8d6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001088856</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ibb5595d6b13d41d2bcc8ba20feea26f6_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001088856</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i4e7dfdbf5bce4f52bb81937e0ca5ac46_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001088856</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i3e50c96f60264b66aa29d189127a2f73_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001088856</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i785869b1921844f2925c8f4fcaf4ba3c_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001088856</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i56ca5c5bdd7045309e1ff91b29ed0b86_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001088856</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i9a1952ba686644179308d0cef13927e8_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001088856</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i20c028d8e2514f38962d2bb482734e70_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001088856</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i4202ad56ab444c9cb8f35568184c2c74_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001088856</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i73577ab94ef744cb885730e8ac822b29_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001088856</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ib16bf7702efd44cdbe57df570c7d75fb_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001088856</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="icfafed6603474886b192b0632a2c6200_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001088856</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i01f702e8e03c41358b69877f0f51d991_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001088856</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6c9d9c7004234ed49109777c938ab2ce_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001088856</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8b5fa79d20ab4ee28c43d8f3802fba08_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001088856</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia7ed3ef4514f42b8bd6ae955926a1ea8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001088856</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0f04c1d847904902a0065f4c9a444cf1_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001088856</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i1687f4482d3249aa9d6829a5eabaa2b3_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001088856</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i6208146b7098480389c1e89596396c07_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001088856</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i46f01246740a46a892ddb27be4dd69aa_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001088856</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i583bb074d98646df863c37e27250f660_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001088856</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i06b129367f5c4d9ab7b570f6972b2ed1_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001088856</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i47740de74c10439fbf11f8788c4cba45_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001088856</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i5f57f8164f0a46daacc1c2551a60659f_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001088856</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ic45e1a7a754a469fa7d8a3ad69b13727_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001088856</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i75024e565e314398a3b2b50b649c5486_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001088856</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i6b6f130b2b314f4cb240b19c11d8ccfc_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001088856</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cort:LongLivedTangibleAssetAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i320d5eb76f6e462191442b9efd3d1df7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001088856</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cort:LongLivedTangibleAssetAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i300a48854f3e4841a4231047bf2b6d83_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001088856</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cort:LongLivedTangibleAssetAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="if054d789bd774097bce632cad662d551_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001088856</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cort:LongLivedTangibleAssetAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9a00554864174d1583c51eb587009a9e_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001088856</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cort:LongLivedTangibleAssetAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i9a314602e38747e383f53643af483ebe_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001088856</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cort:LongLivedTangibleAssetAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3b8ab391633246798d3dcce8ecce1732_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001088856</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i8199115c34a347bfa2af4840cc8fab44_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001088856</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if03d19cb5acb4fc88cca882cb4bdfcc0_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001088856</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">cort:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="idecfc47be18a4b0abf858e6bac29beee_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001088856</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">cort:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9ae15632947d447792ec41cd858483f8_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001088856</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">cort:LongTermMarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ib244710dd5db4d8095a0f665560759d1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001088856</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">cort:LongTermMarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id653930fdecf4c64ad438a3b2c5adabb_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001088856</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i9384505b63ff4625835d945a86192942_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001088856</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i189a43eed86a4d37b00b3efd25b569ec_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001088856</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ie44aabc8e0234ddab3cc8531b3c28b30_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001088856</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibb4f2da4afdc4173bbcc618511bfd330_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001088856</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ib430d4f8526c49d2965e6d0cbfc5179d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001088856</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iddcc04669caf4c4f8e77d0b0ead4adba_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001088856</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i80d4096c7b334e54b411518bb6b5d22b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001088856</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic608ebc41f164c878a62e74c33164b0a_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001088856</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ifa8d40f1022a4fdbad599ef4cc0332c2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001088856</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5f690dc4c12e4400835f0643973b82b2_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001088856</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ibd5d76c213a042ae897b90f0a8ec4a60_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001088856</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i99f1fc2c348e48a0bb5c6c67e90ffd73_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001088856</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ieaf64132df2543a583e4e8f6aa3d5517_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001088856</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="id8d3c6d4eed84ccdb36200d115427751_I20190131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001088856</identifier>
        </entity>
        <period>
            <instant>2019-01-31</instant>
        </period>
    </context>
    <context id="iea23a3d3fb214422896877163db10055_D20211201-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001088856</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cort:StockOptionsFiscalTwentyTwelvePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i52a9c7a889214b11ad5675cc29794ba8_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001088856</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i84ac47ee98bd42c490c47ffe50f5648d_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001088856</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i6b5e7570f4ee4e91920827cf4275116e_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001088856</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i715a1de9af124f9bbf4fc1f32f12f6c8_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001088856</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i056b689380d140aca93fdcee21bcdca1_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001088856</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i6cbc329d8aed49d7b08ed92b59aa995b_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001088856</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ia5de86b46aad4df397dd31ed521a5161_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001088856</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ia962305aacde4486929d4801fcf01b30_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001088856</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ibdfffff05fb64ff191febd1261049d75_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001088856</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i79418e09cbdb47588dfeae9d2b02dc38_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001088856</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i461a8de5644c45629b64932556c34fff_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001088856</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="series">
        <measure>cort:series</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="stockoptionplan">
        <measure>cort:stockOptionPlan</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV80L2ZyYWc6MzFmYzVlMTM1N2E1NDgzM2FiZDY0ZGZiNDI0ODExM2EvdGFibGU6Y2ZlZjRlMGM3N2UzNDJmZWFiNTdkZjZkNjM3MjA0NzYvdGFibGVyYW5nZTpjZmVmNGUwYzc3ZTM0MmZlYWI1N2RmNmQ2MzcyMDQ3Nl8zLTEtMS0xLTI4MjIx_b50b3db0-0d3b-49a2-b084-fd7e4c2070ab">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV80L2ZyYWc6MzFmYzVlMTM1N2E1NDgzM2FiZDY0ZGZiNDI0ODExM2EvdGFibGU6Y2ZlZjRlMGM3N2UzNDJmZWFiNTdkZjZkNjM3MjA0NzYvdGFibGVyYW5nZTpjZmVmNGUwYzc3ZTM0MmZlYWI1N2RmNmQ2MzcyMDQ3Nl80LTEtMS0xLTI4MjIx_c1a7716f-4877-4b36-9a29-515d6bc36577">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV80L2ZyYWc6MzFmYzVlMTM1N2E1NDgzM2FiZDY0ZGZiNDI0ODExM2EvdGFibGU6Y2ZlZjRlMGM3N2UzNDJmZWFiNTdkZjZkNjM3MjA0NzYvdGFibGVyYW5nZTpjZmVmNGUwYzc3ZTM0MmZlYWI1N2RmNmQ2MzcyMDQ3Nl81LTEtMS0xLTI4MjIx_de507060-1c7b-45ba-9640-8b230a5401d2">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV80L2ZyYWc6MzFmYzVlMTM1N2E1NDgzM2FiZDY0ZGZiNDI0ODExM2EvdGFibGU6Y2ZlZjRlMGM3N2UzNDJmZWFiNTdkZjZkNjM3MjA0NzYvdGFibGVyYW5nZTpjZmVmNGUwYzc3ZTM0MmZlYWI1N2RmNmQ2MzcyMDQ3Nl84LTEtMS0xLTI4MjIx_b16bb318-7f1f-4fe3-bb2c-3ef9d8d16ca7">0001088856</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV80L2ZyYWc6MzFmYzVlMTM1N2E1NDgzM2FiZDY0ZGZiNDI0ODExM2EvdGFibGU6Y2ZlZjRlMGM3N2UzNDJmZWFiNTdkZjZkNjM3MjA0NzYvdGFibGVyYW5nZTpjZmVmNGUwYzc3ZTM0MmZlYWI1N2RmNmQ2MzcyMDQ3Nl85LTEtMS0xLTI4MjIx_2f43ce6c-896b-4bf2-90fd-456f2d4f8cc0">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentType
      contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xL2ZyYWc6ZjUyZWNlMDExOWFmNDY0NzllZmY1ODA1ZmI3NmY5YWUvdGV4dHJlZ2lvbjpmNTJlY2UwMTE5YWY0NjQ3OWVmZjU4MDVmYjc2ZjlhZV8yMzk4_8f37ee92-b6f4-44cf-ba57-36874f46e6bf">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xL2ZyYWc6ZjUyZWNlMDExOWFmNDY0NzllZmY1ODA1ZmI3NmY5YWUvdGFibGU6YjFlY2VmZDk3YTUyNDI3NmFjMWI3YjFlODYwYzlhZTcvdGFibGVyYW5nZTpiMWVjZWZkOTdhNTI0Mjc2YWMxYjdiMWU4NjBjOWFlN18wLTAtMS0xLTI4MjIx_d8054509-5bd1-41d1-aae8-d5f5aeface38">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xL2ZyYWc6ZjUyZWNlMDExOWFmNDY0NzllZmY1ODA1ZmI3NmY5YWUvdGV4dHJlZ2lvbjpmNTJlY2UwMTE5YWY0NjQ3OWVmZjU4MDVmYjc2ZjlhZV8yMzg_b8180fa0-2280-4f15-be93-fef211c61ad1">2022-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xL2ZyYWc6ZjUyZWNlMDExOWFmNDY0NzllZmY1ODA1ZmI3NmY5YWUvdGFibGU6NWUzZWZmNzY5ZDAwNDI2ZDgyMTkxMmY0OTgzNDE4YTAvdGFibGVyYW5nZTo1ZTNlZmY3NjlkMDA0MjZkODIxOTEyZjQ5ODM0MThhMF8wLTAtMS0xLTI4MjIx_2eca9613-90ed-4a5b-943d-bddec40b08ff">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xL2ZyYWc6ZjUyZWNlMDExOWFmNDY0NzllZmY1ODA1ZmI3NmY5YWUvdGV4dHJlZ2lvbjpmNTJlY2UwMTE5YWY0NjQ3OWVmZjU4MDVmYjc2ZjlhZV8yMzkz_f510c461-c557-43dd-9def-7935555458c1">000-50679</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xL2ZyYWc6ZjUyZWNlMDExOWFmNDY0NzllZmY1ODA1ZmI3NmY5YWUvdGV4dHJlZ2lvbjpmNTJlY2UwMTE5YWY0NjQ3OWVmZjU4MDVmYjc2ZjlhZV8yMzk0_041bb6e7-0ef9-49b1-a71c-d70c94f7cd6a">CORCEPT THERAPEUTICS INC</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xL2ZyYWc6ZjUyZWNlMDExOWFmNDY0NzllZmY1ODA1ZmI3NmY5YWUvdGFibGU6NWZiYWI3Y2RiYmZjNDc3ZDg3MDIxYWIyYWMxNWNmZmYvdGFibGVyYW5nZTo1ZmJhYjdjZGJiZmM0NzdkODcwMjFhYjJhYzE1Y2ZmZl8wLTAtMS0xLTI4MjIx_5c9b1a01-1ff5-4016-82ea-acab00403744">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xL2ZyYWc6ZjUyZWNlMDExOWFmNDY0NzllZmY1ODA1ZmI3NmY5YWUvdGFibGU6NWZiYWI3Y2RiYmZjNDc3ZDg3MDIxYWIyYWMxNWNmZmYvdGFibGVyYW5nZTo1ZmJhYjdjZGJiZmM0NzdkODcwMjFhYjJhYzE1Y2ZmZl8wLTEtMS0xLTI4MjIx_a4b9cc96-d2d4-4264-b18a-fbce5772bbaf">77-0487658</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xL2ZyYWc6ZjUyZWNlMDExOWFmNDY0NzllZmY1ODA1ZmI3NmY5YWUvdGV4dHJlZ2lvbjpmNTJlY2UwMTE5YWY0NjQ3OWVmZjU4MDVmYjc2ZjlhZV8yMzk1_55aa67ef-b290-42f3-b330-92add0a6affd">149 Commonwealth Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xL2ZyYWc6ZjUyZWNlMDExOWFmNDY0NzllZmY1ODA1ZmI3NmY5YWUvdGV4dHJlZ2lvbjpmNTJlY2UwMTE5YWY0NjQ3OWVmZjU4MDVmYjc2ZjlhZV8yMzk2_cb808003-4b82-4fd7-b72b-54e19c1b748a">Menlo Park</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xL2ZyYWc6ZjUyZWNlMDExOWFmNDY0NzllZmY1ODA1ZmI3NmY5YWUvdGV4dHJlZ2lvbjpmNTJlY2UwMTE5YWY0NjQ3OWVmZjU4MDVmYjc2ZjlhZV8yMzk5_2db4719b-f70d-4bcb-bb6a-e550eee398a4">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xL2ZyYWc6ZjUyZWNlMDExOWFmNDY0NzllZmY1ODA1ZmI3NmY5YWUvdGV4dHJlZ2lvbjpmNTJlY2UwMTE5YWY0NjQ3OWVmZjU4MDVmYjc2ZjlhZV8yNDAw_c93a3331-50ef-49f5-95a0-002b390f2aea">94025</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xL2ZyYWc6ZjUyZWNlMDExOWFmNDY0NzllZmY1ODA1ZmI3NmY5YWUvdGV4dHJlZ2lvbjpmNTJlY2UwMTE5YWY0NjQ3OWVmZjU4MDVmYjc2ZjlhZV8yMzkw_de7d2328-e903-41fc-a3dd-273d21affda7">650</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xL2ZyYWc6ZjUyZWNlMDExOWFmNDY0NzllZmY1ODA1ZmI3NmY5YWUvdGV4dHJlZ2lvbjpmNTJlY2UwMTE5YWY0NjQ3OWVmZjU4MDVmYjc2ZjlhZV8yNDAx_c4d4499a-6c19-4dd3-8342-7802dabf29e0">327-3270</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xL2ZyYWc6ZjUyZWNlMDExOWFmNDY0NzllZmY1ODA1ZmI3NmY5YWUvdGFibGU6NGQxOTYxNGJhYWUyNDgyMTk1ZThlMmNlOGZhYTU3ZjUvdGFibGVyYW5nZTo0ZDE5NjE0YmFhZTI0ODIxOTVlOGUyY2U4ZmFhNTdmNV8xLTAtMS0xLTI4MjIx_f451d4b9-388d-4984-906b-ae3f57655382">Common Stock, $0.001 par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xL2ZyYWc6ZjUyZWNlMDExOWFmNDY0NzllZmY1ODA1ZmI3NmY5YWUvdGFibGU6NGQxOTYxNGJhYWUyNDgyMTk1ZThlMmNlOGZhYTU3ZjUvdGFibGVyYW5nZTo0ZDE5NjE0YmFhZTI0ODIxOTVlOGUyY2U4ZmFhNTdmNV8xLTEtMS0xLTI4MjIx_f7783942-a77b-4249-8565-ca5bd46494bd">CORT</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xL2ZyYWc6ZjUyZWNlMDExOWFmNDY0NzllZmY1ODA1ZmI3NmY5YWUvdGFibGU6NGQxOTYxNGJhYWUyNDgyMTk1ZThlMmNlOGZhYTU3ZjUvdGFibGVyYW5nZTo0ZDE5NjE0YmFhZTI0ODIxOTVlOGUyY2U4ZmFhNTdmNV8xLTItMS0xLTI4MjIx_892b3a45-0eda-4ce6-8ac2-ddd1b728e211">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xL2ZyYWc6ZjUyZWNlMDExOWFmNDY0NzllZmY1ODA1ZmI3NmY5YWUvdGV4dHJlZ2lvbjpmNTJlY2UwMTE5YWY0NjQ3OWVmZjU4MDVmYjc2ZjlhZV8yMzkx_262122e0-f660-493f-87bd-a2f1ca97ebdd">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xL2ZyYWc6ZjUyZWNlMDExOWFmNDY0NzllZmY1ODA1ZmI3NmY5YWUvdGV4dHJlZ2lvbjpmNTJlY2UwMTE5YWY0NjQ3OWVmZjU4MDVmYjc2ZjlhZV8yMzky_20f14249-3490-4d45-8b7f-3f9f4ced44cd">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xL2ZyYWc6ZjUyZWNlMDExOWFmNDY0NzllZmY1ODA1ZmI3NmY5YWUvdGFibGU6M2I2NWNjZGNlNzI0NDlhMzhiZTg1MWNjMzk3MGE1MGUvdGFibGVyYW5nZTozYjY1Y2NkY2U3MjQ0OWEzOGJlODUxY2MzOTcwYTUwZV8wLTAtMS0xLTI4MjIx_553e34ca-ff34-44de-a408-60ced8fc1b7b">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xL2ZyYWc6ZjUyZWNlMDExOWFmNDY0NzllZmY1ODA1ZmI3NmY5YWUvdGFibGU6M2I2NWNjZGNlNzI0NDlhMzhiZTg1MWNjMzk3MGE1MGUvdGFibGVyYW5nZTozYjY1Y2NkY2U3MjQ0OWEzOGJlODUxY2MzOTcwYTUwZV8xLTQtMS0xLTI4MjIx_6fe6c5d4-dffa-4c79-9a8c-60058b708b75">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xL2ZyYWc6ZjUyZWNlMDExOWFmNDY0NzllZmY1ODA1ZmI3NmY5YWUvdGFibGU6M2I2NWNjZGNlNzI0NDlhMzhiZTg1MWNjMzk3MGE1MGUvdGFibGVyYW5nZTozYjY1Y2NkY2U3MjQ0OWEzOGJlODUxY2MzOTcwYTUwZV8yLTQtMS0xLTI4MjIx_0ca48bb9-ee14-441d-b577-e3b684b899d8">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xL2ZyYWc6ZjUyZWNlMDExOWFmNDY0NzllZmY1ODA1ZmI3NmY5YWUvdGV4dHJlZ2lvbjpmNTJlY2UwMTE5YWY0NjQ3OWVmZjU4MDVmYjc2ZjlhZV84MjQ2MzM3MjEwNzQ2_fc4b6788-e540-4a90-a4ae-8b38fd3360b1">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="ib88f9c07449d45b0b9e7fb78200517da_I20220428"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xL2ZyYWc6ZjUyZWNlMDExOWFmNDY0NzllZmY1ODA1ZmI3NmY5YWUvdGV4dHJlZ2lvbjpmNTJlY2UwMTE5YWY0NjQ3OWVmZjU4MDVmYjc2ZjlhZV8yMzE1_f498eefd-86e1-4f22-a581-caac8c7e124c"
      unitRef="shares">106250716</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i93f424f685944c1aab994f99b0146441_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xNi9mcmFnOmU4MjIyODA5YjE3NDQ2N2ZiMmJmZTk1NDliZjYyYmVkL3RhYmxlOmQwYzI0YzI3ZmRmZjQ3MTE5OTFmZTEyNWUzNjkwZmQzL3RhYmxlcmFuZ2U6ZDBjMjRjMjdmZGZmNDcxMTk5MWZlMTI1ZTM2OTBmZDNfNC0xLTEtMS0yODIyMQ_4d76b186-2cae-44bb-86a6-be42090b05a9"
      unitRef="usd">61862000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="iac7c0f0822b942fa8f45ea15693a76af_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xNi9mcmFnOmU4MjIyODA5YjE3NDQ2N2ZiMmJmZTk1NDliZjYyYmVkL3RhYmxlOmQwYzI0YzI3ZmRmZjQ3MTE5OTFmZTEyNWUzNjkwZmQzL3RhYmxlcmFuZ2U6ZDBjMjRjMjdmZGZmNDcxMTk5MWZlMTI1ZTM2OTBmZDNfNC0zLTEtMS0yODIyMQ_14ce683b-3481-4676-b64f-4fa50fe621dc"
      unitRef="usd">77617000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i93f424f685944c1aab994f99b0146441_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xNi9mcmFnOmU4MjIyODA5YjE3NDQ2N2ZiMmJmZTk1NDliZjYyYmVkL3RhYmxlOmQwYzI0YzI3ZmRmZjQ3MTE5OTFmZTEyNWUzNjkwZmQzL3RhYmxlcmFuZ2U6ZDBjMjRjMjdmZGZmNDcxMTk5MWZlMTI1ZTM2OTBmZDNfNS0xLTEtMS0yODIyMQ_4dd29eb8-096f-4535-af6d-c27db04f622a"
      unitRef="usd">283665000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="iac7c0f0822b942fa8f45ea15693a76af_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xNi9mcmFnOmU4MjIyODA5YjE3NDQ2N2ZiMmJmZTk1NDliZjYyYmVkL3RhYmxlOmQwYzI0YzI3ZmRmZjQ3MTE5OTFmZTEyNWUzNjkwZmQzL3RhYmxlcmFuZ2U6ZDBjMjRjMjdmZGZmNDcxMTk5MWZlMTI1ZTM2OTBmZDNfNS0zLTEtMS0yODIyMQ_775e5e26-27fb-493c-93ea-2b80a096b338"
      unitRef="usd">145918000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i93f424f685944c1aab994f99b0146441_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xNi9mcmFnOmU4MjIyODA5YjE3NDQ2N2ZiMmJmZTk1NDliZjYyYmVkL3RhYmxlOmQwYzI0YzI3ZmRmZjQ3MTE5OTFmZTEyNWUzNjkwZmQzL3RhYmxlcmFuZ2U6ZDBjMjRjMjdmZGZmNDcxMTk5MWZlMTI1ZTM2OTBmZDNfNi0xLTEtMS0yODIyMQ_117cc670-31d3-4e20-bc90-74f14f1b8f44"
      unitRef="usd">27178000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="iac7c0f0822b942fa8f45ea15693a76af_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xNi9mcmFnOmU4MjIyODA5YjE3NDQ2N2ZiMmJmZTk1NDliZjYyYmVkL3RhYmxlOmQwYzI0YzI3ZmRmZjQ3MTE5OTFmZTEyNWUzNjkwZmQzL3RhYmxlcmFuZ2U6ZDBjMjRjMjdmZGZmNDcxMTk5MWZlMTI1ZTM2OTBmZDNfNi0zLTEtMS0yODIyMQ_09de070c-794f-4063-8cf5-33da4b1ec226"
      unitRef="usd">27625000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="i93f424f685944c1aab994f99b0146441_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xNi9mcmFnOmU4MjIyODA5YjE3NDQ2N2ZiMmJmZTk1NDliZjYyYmVkL3RhYmxlOmQwYzI0YzI3ZmRmZjQ3MTE5OTFmZTEyNWUzNjkwZmQzL3RhYmxlcmFuZ2U6ZDBjMjRjMjdmZGZmNDcxMTk5MWZlMTI1ZTM2OTBmZDNfNy0xLTEtMS0yODIyMQ_32d334d1-c862-4b20-b80f-e106cad05a4a"
      unitRef="usd">5079000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="iac7c0f0822b942fa8f45ea15693a76af_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xNi9mcmFnOmU4MjIyODA5YjE3NDQ2N2ZiMmJmZTk1NDliZjYyYmVkL3RhYmxlOmQwYzI0YzI3ZmRmZjQ3MTE5OTFmZTEyNWUzNjkwZmQzL3RhYmxlcmFuZ2U6ZDBjMjRjMjdmZGZmNDcxMTk5MWZlMTI1ZTM2OTBmZDNfNy0zLTEtMS0yODIyMQ_a163f515-08ac-4a5a-82f1-3ea2e7073438"
      unitRef="usd">4988000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i93f424f685944c1aab994f99b0146441_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xNi9mcmFnOmU4MjIyODA5YjE3NDQ2N2ZiMmJmZTk1NDliZjYyYmVkL3RhYmxlOmQwYzI0YzI3ZmRmZjQ3MTE5OTFmZTEyNWUzNjkwZmQzL3RhYmxlcmFuZ2U6ZDBjMjRjMjdmZGZmNDcxMTk5MWZlMTI1ZTM2OTBmZDNfOC0xLTEtMS0yODIyMQ_fe6a2f68-9c3a-4ce5-9220-142d70b74be4"
      unitRef="usd">10436000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="iac7c0f0822b942fa8f45ea15693a76af_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xNi9mcmFnOmU4MjIyODA5YjE3NDQ2N2ZiMmJmZTk1NDliZjYyYmVkL3RhYmxlOmQwYzI0YzI3ZmRmZjQ3MTE5OTFmZTEyNWUzNjkwZmQzL3RhYmxlcmFuZ2U6ZDBjMjRjMjdmZGZmNDcxMTk5MWZlMTI1ZTM2OTBmZDNfOC0zLTEtMS0yODIyMQ_bfddf265-0fbc-4062-8786-af56baafffb2"
      unitRef="usd">10315000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i93f424f685944c1aab994f99b0146441_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xNi9mcmFnOmU4MjIyODA5YjE3NDQ2N2ZiMmJmZTk1NDliZjYyYmVkL3RhYmxlOmQwYzI0YzI3ZmRmZjQ3MTE5OTFmZTEyNWUzNjkwZmQzL3RhYmxlcmFuZ2U6ZDBjMjRjMjdmZGZmNDcxMTk5MWZlMTI1ZTM2OTBmZDNfOS0xLTEtMS0yODIyMQ_d644c8e0-0c05-451e-b33a-8c0dd301cbc6"
      unitRef="usd">388220000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="iac7c0f0822b942fa8f45ea15693a76af_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xNi9mcmFnOmU4MjIyODA5YjE3NDQ2N2ZiMmJmZTk1NDliZjYyYmVkL3RhYmxlOmQwYzI0YzI3ZmRmZjQ3MTE5OTFmZTEyNWUzNjkwZmQzL3RhYmxlcmFuZ2U6ZDBjMjRjMjdmZGZmNDcxMTk5MWZlMTI1ZTM2OTBmZDNfOS0zLTEtMS0yODIyMQ_b29b7463-8850-49a9-beeb-2af4ff12d7f6"
      unitRef="usd">266463000</us-gaap:AssetsCurrent>
    <us-gaap:InventoryNoncurrent
      contextRef="i93f424f685944c1aab994f99b0146441_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xNi9mcmFnOmU4MjIyODA5YjE3NDQ2N2ZiMmJmZTk1NDliZjYyYmVkL3RhYmxlOmQwYzI0YzI3ZmRmZjQ3MTE5OTFmZTEyNWUzNjkwZmQzL3RhYmxlcmFuZ2U6ZDBjMjRjMjdmZGZmNDcxMTk5MWZlMTI1ZTM2OTBmZDNfMTAtMS0xLTEtMjgyMjE_3a8e2754-3a8d-4c07-bef9-0d21400e74a3"
      unitRef="usd">13098000</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryNoncurrent
      contextRef="iac7c0f0822b942fa8f45ea15693a76af_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xNi9mcmFnOmU4MjIyODA5YjE3NDQ2N2ZiMmJmZTk1NDliZjYyYmVkL3RhYmxlOmQwYzI0YzI3ZmRmZjQ3MTE5OTFmZTEyNWUzNjkwZmQzL3RhYmxlcmFuZ2U6ZDBjMjRjMjdmZGZmNDcxMTk5MWZlMTI1ZTM2OTBmZDNfMTAtMy0xLTEtMjgyMjE_15250e1e-55a1-45bf-8a72-e956998c15e3"
      unitRef="usd">12962000</us-gaap:InventoryNoncurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i93f424f685944c1aab994f99b0146441_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xNi9mcmFnOmU4MjIyODA5YjE3NDQ2N2ZiMmJmZTk1NDliZjYyYmVkL3RhYmxlOmQwYzI0YzI3ZmRmZjQ3MTE5OTFmZTEyNWUzNjkwZmQzL3RhYmxlcmFuZ2U6ZDBjMjRjMjdmZGZmNDcxMTk5MWZlMTI1ZTM2OTBmZDNfMTEtMS0xLTEtMjgyMjE_aa0e3c79-052b-4841-a1c2-3bc00ca43722"
      unitRef="usd">2816000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="iac7c0f0822b942fa8f45ea15693a76af_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xNi9mcmFnOmU4MjIyODA5YjE3NDQ2N2ZiMmJmZTk1NDliZjYyYmVkL3RhYmxlOmQwYzI0YzI3ZmRmZjQ3MTE5OTFmZTEyNWUzNjkwZmQzL3RhYmxlcmFuZ2U6ZDBjMjRjMjdmZGZmNDcxMTk5MWZlMTI1ZTM2OTBmZDNfMTEtMy0xLTEtMjgyMjE_9d2abb1c-7613-4afa-9be1-461f041c3833"
      unitRef="usd">514000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i93f424f685944c1aab994f99b0146441_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xNi9mcmFnOmU4MjIyODA5YjE3NDQ2N2ZiMmJmZTk1NDliZjYyYmVkL3RhYmxlOmQwYzI0YzI3ZmRmZjQ3MTE5OTFmZTEyNWUzNjkwZmQzL3RhYmxlcmFuZ2U6ZDBjMjRjMjdmZGZmNDcxMTk5MWZlMTI1ZTM2OTBmZDNfMTItMS0xLTEtMjgyMjE_4566c21a-0f6a-4968-856d-f40f53b4ac65"
      unitRef="usd">726000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="iac7c0f0822b942fa8f45ea15693a76af_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xNi9mcmFnOmU4MjIyODA5YjE3NDQ2N2ZiMmJmZTk1NDliZjYyYmVkL3RhYmxlOmQwYzI0YzI3ZmRmZjQ3MTE5OTFmZTEyNWUzNjkwZmQzL3RhYmxlcmFuZ2U6ZDBjMjRjMjdmZGZmNDcxMTk5MWZlMTI1ZTM2OTBmZDNfMTItMy0xLTEtMjgyMjE_828db3e2-8d42-4834-823e-5dbcbad29e87"
      unitRef="usd">1002000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="i93f424f685944c1aab994f99b0146441_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xNi9mcmFnOmU4MjIyODA5YjE3NDQ2N2ZiMmJmZTk1NDliZjYyYmVkL3RhYmxlOmQwYzI0YzI3ZmRmZjQ3MTE5OTFmZTEyNWUzNjkwZmQzL3RhYmxlcmFuZ2U6ZDBjMjRjMjdmZGZmNDcxMTk5MWZlMTI1ZTM2OTBmZDNfMTMtMS0xLTEtMjgyMjE_aaf76697-d8ff-45f8-b90a-5d391523d72d"
      unitRef="usd">22566000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="iac7c0f0822b942fa8f45ea15693a76af_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xNi9mcmFnOmU4MjIyODA5YjE3NDQ2N2ZiMmJmZTk1NDliZjYyYmVkL3RhYmxlOmQwYzI0YzI3ZmRmZjQ3MTE5OTFmZTEyNWUzNjkwZmQzL3RhYmxlcmFuZ2U6ZDBjMjRjMjdmZGZmNDcxMTk5MWZlMTI1ZTM2OTBmZDNfMTMtMy0xLTEtMjgyMjE_31d0eadb-c8f3-43f3-9660-61aff797f530"
      unitRef="usd">112277000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i93f424f685944c1aab994f99b0146441_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xNi9mcmFnOmU4MjIyODA5YjE3NDQ2N2ZiMmJmZTk1NDliZjYyYmVkL3RhYmxlOmQwYzI0YzI3ZmRmZjQ3MTE5OTFmZTEyNWUzNjkwZmQzL3RhYmxlcmFuZ2U6ZDBjMjRjMjdmZGZmNDcxMTk5MWZlMTI1ZTM2OTBmZDNfMTQtMS0xLTEtMjgyMjE_c0ccd199-c3e7-4cec-872d-7d1c5820e66c"
      unitRef="usd">2984000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="iac7c0f0822b942fa8f45ea15693a76af_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xNi9mcmFnOmU4MjIyODA5YjE3NDQ2N2ZiMmJmZTk1NDliZjYyYmVkL3RhYmxlOmQwYzI0YzI3ZmRmZjQ3MTE5OTFmZTEyNWUzNjkwZmQzL3RhYmxlcmFuZ2U6ZDBjMjRjMjdmZGZmNDcxMTk5MWZlMTI1ZTM2OTBmZDNfMTQtMy0xLTEtMjgyMjE_495c7ebd-29e3-4621-8295-111ed526892e"
      unitRef="usd">3083000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="i93f424f685944c1aab994f99b0146441_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xNi9mcmFnOmU4MjIyODA5YjE3NDQ2N2ZiMmJmZTk1NDliZjYyYmVkL3RhYmxlOmQwYzI0YzI3ZmRmZjQ3MTE5OTFmZTEyNWUzNjkwZmQzL3RhYmxlcmFuZ2U6ZDBjMjRjMjdmZGZmNDcxMTk5MWZlMTI1ZTM2OTBmZDNfMTUtMS0xLTEtMjgyMjE_62d9d0bb-4df2-45d3-a299-4d304172d265"
      unitRef="usd">37713000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="iac7c0f0822b942fa8f45ea15693a76af_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xNi9mcmFnOmU4MjIyODA5YjE3NDQ2N2ZiMmJmZTk1NDliZjYyYmVkL3RhYmxlOmQwYzI0YzI3ZmRmZjQ3MTE5OTFmZTEyNWUzNjkwZmQzL3RhYmxlcmFuZ2U6ZDBjMjRjMjdmZGZmNDcxMTk5MWZlMTI1ZTM2OTBmZDNfMTUtMy0xLTEtMjgyMjE_b063efa8-138f-4076-a534-7809c4fcb95d"
      unitRef="usd">27455000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:Assets
      contextRef="i93f424f685944c1aab994f99b0146441_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xNi9mcmFnOmU4MjIyODA5YjE3NDQ2N2ZiMmJmZTk1NDliZjYyYmVkL3RhYmxlOmQwYzI0YzI3ZmRmZjQ3MTE5OTFmZTEyNWUzNjkwZmQzL3RhYmxlcmFuZ2U6ZDBjMjRjMjdmZGZmNDcxMTk5MWZlMTI1ZTM2OTBmZDNfMTYtMS0xLTEtMjgyMjE_b97623a0-f980-4527-abf3-2d50963566ff"
      unitRef="usd">468123000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="iac7c0f0822b942fa8f45ea15693a76af_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xNi9mcmFnOmU4MjIyODA5YjE3NDQ2N2ZiMmJmZTk1NDliZjYyYmVkL3RhYmxlOmQwYzI0YzI3ZmRmZjQ3MTE5OTFmZTEyNWUzNjkwZmQzL3RhYmxlcmFuZ2U6ZDBjMjRjMjdmZGZmNDcxMTk5MWZlMTI1ZTM2OTBmZDNfMTYtMy0xLTEtMjgyMjE_108abb93-8a2e-4658-a4cc-80d985dabc71"
      unitRef="usd">423756000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i93f424f685944c1aab994f99b0146441_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xNi9mcmFnOmU4MjIyODA5YjE3NDQ2N2ZiMmJmZTk1NDliZjYyYmVkL3RhYmxlOmQwYzI0YzI3ZmRmZjQ3MTE5OTFmZTEyNWUzNjkwZmQzL3RhYmxlcmFuZ2U6ZDBjMjRjMjdmZGZmNDcxMTk5MWZlMTI1ZTM2OTBmZDNfMTktMS0xLTEtMjgyMjE_ad35240d-af80-4bdb-9a8f-4e5f5abd1f17"
      unitRef="usd">9269000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="iac7c0f0822b942fa8f45ea15693a76af_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xNi9mcmFnOmU4MjIyODA5YjE3NDQ2N2ZiMmJmZTk1NDliZjYyYmVkL3RhYmxlOmQwYzI0YzI3ZmRmZjQ3MTE5OTFmZTEyNWUzNjkwZmQzL3RhYmxlcmFuZ2U6ZDBjMjRjMjdmZGZmNDcxMTk5MWZlMTI1ZTM2OTBmZDNfMTktMy0xLTEtMjgyMjE_72887183-d734-470f-b8c7-7fc288ef3de0"
      unitRef="usd">6908000</us-gaap:AccountsPayableCurrent>
    <cort:AccruedClinicalExpensesCurrent
      contextRef="i93f424f685944c1aab994f99b0146441_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xNi9mcmFnOmU4MjIyODA5YjE3NDQ2N2ZiMmJmZTk1NDliZjYyYmVkL3RhYmxlOmQwYzI0YzI3ZmRmZjQ3MTE5OTFmZTEyNWUzNjkwZmQzL3RhYmxlcmFuZ2U6ZDBjMjRjMjdmZGZmNDcxMTk5MWZlMTI1ZTM2OTBmZDNfMjAtMS0xLTEtMjgyMjE_f833e04b-33b7-4c0b-a67c-e4a609428d86"
      unitRef="usd">13051000</cort:AccruedClinicalExpensesCurrent>
    <cort:AccruedClinicalExpensesCurrent
      contextRef="iac7c0f0822b942fa8f45ea15693a76af_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xNi9mcmFnOmU4MjIyODA5YjE3NDQ2N2ZiMmJmZTk1NDliZjYyYmVkL3RhYmxlOmQwYzI0YzI3ZmRmZjQ3MTE5OTFmZTEyNWUzNjkwZmQzL3RhYmxlcmFuZ2U6ZDBjMjRjMjdmZGZmNDcxMTk5MWZlMTI1ZTM2OTBmZDNfMjAtMy0xLTEtMjgyMjE_603f3a54-0a1f-4f93-a620-fed9c34aed3b"
      unitRef="usd">12442000</cort:AccruedClinicalExpensesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i93f424f685944c1aab994f99b0146441_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xNi9mcmFnOmU4MjIyODA5YjE3NDQ2N2ZiMmJmZTk1NDliZjYyYmVkL3RhYmxlOmQwYzI0YzI3ZmRmZjQ3MTE5OTFmZTEyNWUzNjkwZmQzL3RhYmxlcmFuZ2U6ZDBjMjRjMjdmZGZmNDcxMTk5MWZlMTI1ZTM2OTBmZDNfMjEtMS0xLTEtMjgyMjE_8564740d-ab01-4d87-87a7-2a7ee3ef2f8e"
      unitRef="usd">32660000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="iac7c0f0822b942fa8f45ea15693a76af_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xNi9mcmFnOmU4MjIyODA5YjE3NDQ2N2ZiMmJmZTk1NDliZjYyYmVkL3RhYmxlOmQwYzI0YzI3ZmRmZjQ3MTE5OTFmZTEyNWUzNjkwZmQzL3RhYmxlcmFuZ2U6ZDBjMjRjMjdmZGZmNDcxMTk5MWZlMTI1ZTM2OTBmZDNfMjEtMy0xLTEtMjgyMjE_115cc370-97fe-44be-ba5c-0593744e6f90"
      unitRef="usd">27665000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i93f424f685944c1aab994f99b0146441_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xNi9mcmFnOmU4MjIyODA5YjE3NDQ2N2ZiMmJmZTk1NDliZjYyYmVkL3RhYmxlOmQwYzI0YzI3ZmRmZjQ3MTE5OTFmZTEyNWUzNjkwZmQzL3RhYmxlcmFuZ2U6ZDBjMjRjMjdmZGZmNDcxMTk5MWZlMTI1ZTM2OTBmZDNfMjItMS0xLTEtMjgyMjE_e3febf93-47d2-40e5-bb43-f7c33cfbbc6c"
      unitRef="usd">2264000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="iac7c0f0822b942fa8f45ea15693a76af_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xNi9mcmFnOmU4MjIyODA5YjE3NDQ2N2ZiMmJmZTk1NDliZjYyYmVkL3RhYmxlOmQwYzI0YzI3ZmRmZjQ3MTE5OTFmZTEyNWUzNjkwZmQzL3RhYmxlcmFuZ2U6ZDBjMjRjMjdmZGZmNDcxMTk5MWZlMTI1ZTM2OTBmZDNfMjItMy0xLTEtMjgyMjE_5efb28da-0b43-4572-a39d-77c615b3b2d1"
      unitRef="usd">526000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i93f424f685944c1aab994f99b0146441_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xNi9mcmFnOmU4MjIyODA5YjE3NDQ2N2ZiMmJmZTk1NDliZjYyYmVkL3RhYmxlOmQwYzI0YzI3ZmRmZjQ3MTE5OTFmZTEyNWUzNjkwZmQzL3RhYmxlcmFuZ2U6ZDBjMjRjMjdmZGZmNDcxMTk5MWZlMTI1ZTM2OTBmZDNfMjMtMS0xLTEtMjgyMjE_2acdc02d-dded-483c-8932-8c2f5cecaaf7"
      unitRef="usd">57244000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="iac7c0f0822b942fa8f45ea15693a76af_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xNi9mcmFnOmU4MjIyODA5YjE3NDQ2N2ZiMmJmZTk1NDliZjYyYmVkL3RhYmxlOmQwYzI0YzI3ZmRmZjQ3MTE5OTFmZTEyNWUzNjkwZmQzL3RhYmxlcmFuZ2U6ZDBjMjRjMjdmZGZmNDcxMTk5MWZlMTI1ZTM2OTBmZDNfMjMtMy0xLTEtMjgyMjE_31e7dcaf-807a-460e-81e8-4c63831cee98"
      unitRef="usd">47541000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i93f424f685944c1aab994f99b0146441_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xNi9mcmFnOmU4MjIyODA5YjE3NDQ2N2ZiMmJmZTk1NDliZjYyYmVkL3RhYmxlOmQwYzI0YzI3ZmRmZjQ3MTE5OTFmZTEyNWUzNjkwZmQzL3RhYmxlcmFuZ2U6ZDBjMjRjMjdmZGZmNDcxMTk5MWZlMTI1ZTM2OTBmZDNfMjQtMS0xLTEtMjgyMjE_8fbd720a-b0ff-4f50-a775-77b9d108ed70"
      unitRef="usd">552000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="iac7c0f0822b942fa8f45ea15693a76af_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xNi9mcmFnOmU4MjIyODA5YjE3NDQ2N2ZiMmJmZTk1NDliZjYyYmVkL3RhYmxlOmQwYzI0YzI3ZmRmZjQ3MTE5OTFmZTEyNWUzNjkwZmQzL3RhYmxlcmFuZ2U6ZDBjMjRjMjdmZGZmNDcxMTk5MWZlMTI1ZTM2OTBmZDNfMjQtMy0xLTEtMjgyMjE_7ccbc64d-0d73-4aa4-8afd-358822db490f"
      unitRef="usd">0</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:AccruedIncomeTaxesNoncurrent
      contextRef="i93f424f685944c1aab994f99b0146441_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xNi9mcmFnOmU4MjIyODA5YjE3NDQ2N2ZiMmJmZTk1NDliZjYyYmVkL3RhYmxlOmQwYzI0YzI3ZmRmZjQ3MTE5OTFmZTEyNWUzNjkwZmQzL3RhYmxlcmFuZ2U6ZDBjMjRjMjdmZGZmNDcxMTk5MWZlMTI1ZTM2OTBmZDNfMjUtMS0xLTEtMjgyMjE_e3ac91cb-379e-4f50-930a-17b1331cc601"
      unitRef="usd">2516000</us-gaap:AccruedIncomeTaxesNoncurrent>
    <us-gaap:AccruedIncomeTaxesNoncurrent
      contextRef="iac7c0f0822b942fa8f45ea15693a76af_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xNi9mcmFnOmU4MjIyODA5YjE3NDQ2N2ZiMmJmZTk1NDliZjYyYmVkL3RhYmxlOmQwYzI0YzI3ZmRmZjQ3MTE5OTFmZTEyNWUzNjkwZmQzL3RhYmxlcmFuZ2U6ZDBjMjRjMjdmZGZmNDcxMTk5MWZlMTI1ZTM2OTBmZDNfMjUtMy0xLTEtMjgyMjE_8d1025b4-aace-472c-ba15-f1f8d4bd1f72"
      unitRef="usd">409000</us-gaap:AccruedIncomeTaxesNoncurrent>
    <us-gaap:Liabilities
      contextRef="i93f424f685944c1aab994f99b0146441_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xNi9mcmFnOmU4MjIyODA5YjE3NDQ2N2ZiMmJmZTk1NDliZjYyYmVkL3RhYmxlOmQwYzI0YzI3ZmRmZjQ3MTE5OTFmZTEyNWUzNjkwZmQzL3RhYmxlcmFuZ2U6ZDBjMjRjMjdmZGZmNDcxMTk5MWZlMTI1ZTM2OTBmZDNfMjYtMS0xLTEtMjgyMjE_776270f0-d467-48b9-b7a5-f1132a06ed1e"
      unitRef="usd">60312000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="iac7c0f0822b942fa8f45ea15693a76af_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xNi9mcmFnOmU4MjIyODA5YjE3NDQ2N2ZiMmJmZTk1NDliZjYyYmVkL3RhYmxlOmQwYzI0YzI3ZmRmZjQ3MTE5OTFmZTEyNWUzNjkwZmQzL3RhYmxlcmFuZ2U6ZDBjMjRjMjdmZGZmNDcxMTk5MWZlMTI1ZTM2OTBmZDNfMjYtMy0xLTEtMjgyMjE_e22f9fe5-1a01-4d79-8601-80bc4c43aeb5"
      unitRef="usd">47950000</us-gaap:Liabilities>
    <us-gaap:PreferredStockValue
      contextRef="i93f424f685944c1aab994f99b0146441_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xNi9mcmFnOmU4MjIyODA5YjE3NDQ2N2ZiMmJmZTk1NDliZjYyYmVkL3RhYmxlOmQwYzI0YzI3ZmRmZjQ3MTE5OTFmZTEyNWUzNjkwZmQzL3RhYmxlcmFuZ2U6ZDBjMjRjMjdmZGZmNDcxMTk5MWZlMTI1ZTM2OTBmZDNfMjktMS0xLTEtMjgyMjE_db9256c7-32e9-490d-98e6-a99bb95be8b8"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="iac7c0f0822b942fa8f45ea15693a76af_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xNi9mcmFnOmU4MjIyODA5YjE3NDQ2N2ZiMmJmZTk1NDliZjYyYmVkL3RhYmxlOmQwYzI0YzI3ZmRmZjQ3MTE5OTFmZTEyNWUzNjkwZmQzL3RhYmxlcmFuZ2U6ZDBjMjRjMjdmZGZmNDcxMTk5MWZlMTI1ZTM2OTBmZDNfMjktMy0xLTEtMjgyMjE_185786e0-8212-4fd5-a98d-283883c0d46d"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockValue
      contextRef="i93f424f685944c1aab994f99b0146441_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xNi9mcmFnOmU4MjIyODA5YjE3NDQ2N2ZiMmJmZTk1NDliZjYyYmVkL3RhYmxlOmQwYzI0YzI3ZmRmZjQ3MTE5OTFmZTEyNWUzNjkwZmQzL3RhYmxlcmFuZ2U6ZDBjMjRjMjdmZGZmNDcxMTk5MWZlMTI1ZTM2OTBmZDNfMzAtMS0xLTEtMjgyMjE_58c1b73e-4383-4e48-a383-d0b95bf4d6fa"
      unitRef="usd">128000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="iac7c0f0822b942fa8f45ea15693a76af_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xNi9mcmFnOmU4MjIyODA5YjE3NDQ2N2ZiMmJmZTk1NDliZjYyYmVkL3RhYmxlOmQwYzI0YzI3ZmRmZjQ3MTE5OTFmZTEyNWUzNjkwZmQzL3RhYmxlcmFuZ2U6ZDBjMjRjMjdmZGZmNDcxMTk5MWZlMTI1ZTM2OTBmZDNfMzAtMy0xLTEtMjgyMjE_769c2d71-c428-4a19-9880-3edfdc2268c8"
      unitRef="usd">127000</us-gaap:CommonStockValue>
    <us-gaap:TreasuryStockCommonValue
      contextRef="i93f424f685944c1aab994f99b0146441_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xNi9mcmFnOmU4MjIyODA5YjE3NDQ2N2ZiMmJmZTk1NDliZjYyYmVkL3RhYmxlOmQwYzI0YzI3ZmRmZjQ3MTE5OTFmZTEyNWUzNjkwZmQzL3RhYmxlcmFuZ2U6ZDBjMjRjMjdmZGZmNDcxMTk5MWZlMTI1ZTM2OTBmZDNfMzEtMS0xLTEtMzExNjE_9be36633-8941-4ba5-9397-033fb0e35900"
      unitRef="usd">417448000</us-gaap:TreasuryStockCommonValue>
    <us-gaap:TreasuryStockCommonValue
      contextRef="iac7c0f0822b942fa8f45ea15693a76af_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xNi9mcmFnOmU4MjIyODA5YjE3NDQ2N2ZiMmJmZTk1NDliZjYyYmVkL3RhYmxlOmQwYzI0YzI3ZmRmZjQ3MTE5OTFmZTEyNWUzNjkwZmQzL3RhYmxlcmFuZ2U6ZDBjMjRjMjdmZGZmNDcxMTk5MWZlMTI1ZTM2OTBmZDNfMzEtMy0xLTEtMzExNjE_dd49ee52-a1e0-4609-bbfa-30581568ec62"
      unitRef="usd">410411000</us-gaap:TreasuryStockCommonValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i93f424f685944c1aab994f99b0146441_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xNi9mcmFnOmU4MjIyODA5YjE3NDQ2N2ZiMmJmZTk1NDliZjYyYmVkL3RhYmxlOmQwYzI0YzI3ZmRmZjQ3MTE5OTFmZTEyNWUzNjkwZmQzL3RhYmxlcmFuZ2U6ZDBjMjRjMjdmZGZmNDcxMTk5MWZlMTI1ZTM2OTBmZDNfMzEtMS0xLTEtMjgyMjE_f9f2fcdb-6fa6-4438-8c70-e7583b927d29"
      unitRef="usd">608717000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="iac7c0f0822b942fa8f45ea15693a76af_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xNi9mcmFnOmU4MjIyODA5YjE3NDQ2N2ZiMmJmZTk1NDliZjYyYmVkL3RhYmxlOmQwYzI0YzI3ZmRmZjQ3MTE5OTFmZTEyNWUzNjkwZmQzL3RhYmxlcmFuZ2U6ZDBjMjRjMjdmZGZmNDcxMTk5MWZlMTI1ZTM2OTBmZDNfMzEtMy0xLTEtMjgyMjE_306b8011-4fbc-4778-9ee2-248c80aba479"
      unitRef="usd">591349000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i93f424f685944c1aab994f99b0146441_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xNi9mcmFnOmU4MjIyODA5YjE3NDQ2N2ZiMmJmZTk1NDliZjYyYmVkL3RhYmxlOmQwYzI0YzI3ZmRmZjQ3MTE5OTFmZTEyNWUzNjkwZmQzL3RhYmxlcmFuZ2U6ZDBjMjRjMjdmZGZmNDcxMTk5MWZlMTI1ZTM2OTBmZDNfMzMtMS0xLTEtMjgyMjE_b4a3c592-a011-41e2-9798-af1e4247b21a"
      unitRef="usd">-1351000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="iac7c0f0822b942fa8f45ea15693a76af_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xNi9mcmFnOmU4MjIyODA5YjE3NDQ2N2ZiMmJmZTk1NDliZjYyYmVkL3RhYmxlOmQwYzI0YzI3ZmRmZjQ3MTE5OTFmZTEyNWUzNjkwZmQzL3RhYmxlcmFuZ2U6ZDBjMjRjMjdmZGZmNDcxMTk5MWZlMTI1ZTM2OTBmZDNfMzMtMy0xLTEtMjgyMjE_05bcf237-412a-4cf2-98d6-223df3ee2b01"
      unitRef="usd">-227000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i93f424f685944c1aab994f99b0146441_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xNi9mcmFnOmU4MjIyODA5YjE3NDQ2N2ZiMmJmZTk1NDliZjYyYmVkL3RhYmxlOmQwYzI0YzI3ZmRmZjQ3MTE5OTFmZTEyNWUzNjkwZmQzL3RhYmxlcmFuZ2U6ZDBjMjRjMjdmZGZmNDcxMTk5MWZlMTI1ZTM2OTBmZDNfMzQtMS0xLTEtMjgyMjE_2b2264e5-d4b2-4f9f-a287-7ff9ec2e3c10"
      unitRef="usd">217765000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="iac7c0f0822b942fa8f45ea15693a76af_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xNi9mcmFnOmU4MjIyODA5YjE3NDQ2N2ZiMmJmZTk1NDliZjYyYmVkL3RhYmxlOmQwYzI0YzI3ZmRmZjQ3MTE5OTFmZTEyNWUzNjkwZmQzL3RhYmxlcmFuZ2U6ZDBjMjRjMjdmZGZmNDcxMTk5MWZlMTI1ZTM2OTBmZDNfMzQtMy0xLTEtMjgyMjE_923cfb76-0825-422e-a1dc-3c868295d680"
      unitRef="usd">194968000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="i93f424f685944c1aab994f99b0146441_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xNi9mcmFnOmU4MjIyODA5YjE3NDQ2N2ZiMmJmZTk1NDliZjYyYmVkL3RhYmxlOmQwYzI0YzI3ZmRmZjQ3MTE5OTFmZTEyNWUzNjkwZmQzL3RhYmxlcmFuZ2U6ZDBjMjRjMjdmZGZmNDcxMTk5MWZlMTI1ZTM2OTBmZDNfMzUtMS0xLTEtMjgyMjE_086ca7f5-8d31-4401-b05d-5ccaa930fede"
      unitRef="usd">407811000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iac7c0f0822b942fa8f45ea15693a76af_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xNi9mcmFnOmU4MjIyODA5YjE3NDQ2N2ZiMmJmZTk1NDliZjYyYmVkL3RhYmxlOmQwYzI0YzI3ZmRmZjQ3MTE5OTFmZTEyNWUzNjkwZmQzL3RhYmxlcmFuZ2U6ZDBjMjRjMjdmZGZmNDcxMTk5MWZlMTI1ZTM2OTBmZDNfMzUtMy0xLTEtMjgyMjE_ff7002ba-b400-43fa-bee4-4275b68cf28f"
      unitRef="usd">375806000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i93f424f685944c1aab994f99b0146441_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xNi9mcmFnOmU4MjIyODA5YjE3NDQ2N2ZiMmJmZTk1NDliZjYyYmVkL3RhYmxlOmQwYzI0YzI3ZmRmZjQ3MTE5OTFmZTEyNWUzNjkwZmQzL3RhYmxlcmFuZ2U6ZDBjMjRjMjdmZGZmNDcxMTk5MWZlMTI1ZTM2OTBmZDNfMzYtMS0xLTEtMjgyMjE_17802af9-c581-4ef6-8585-0b23e5704cb7"
      unitRef="usd">468123000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="iac7c0f0822b942fa8f45ea15693a76af_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xNi9mcmFnOmU4MjIyODA5YjE3NDQ2N2ZiMmJmZTk1NDliZjYyYmVkL3RhYmxlOmQwYzI0YzI3ZmRmZjQ3MTE5OTFmZTEyNWUzNjkwZmQzL3RhYmxlcmFuZ2U6ZDBjMjRjMjdmZGZmNDcxMTk5MWZlMTI1ZTM2OTBmZDNfMzYtMy0xLTEtMjgyMjE_089f9127-aa44-411f-8de9-1d7103e76ca5"
      unitRef="usd">423756000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xOS9mcmFnOjY0MjE1YWY5MjUwYzQwYzU5ZThiMWE4ODQwNmExYzNiL3RhYmxlOmMxZGEzOWUyYWE0MzQxNWQ4MzYzOGE4MmEwMmFhZjFiL3RhYmxlcmFuZ2U6YzFkYTM5ZTJhYTQzNDE1ZDgzNjM4YTgyYTAyYWFmMWJfMi0xLTEtMS0yODIyMQ_3b4944c0-9dc3-482e-894b-ab0bcb771666"
      unitRef="usd">93688000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0ebb8d8bac3445859e468a3d048cfaf5_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xOS9mcmFnOjY0MjE1YWY5MjUwYzQwYzU5ZThiMWE4ODQwNmExYzNiL3RhYmxlOmMxZGEzOWUyYWE0MzQxNWQ4MzYzOGE4MmEwMmFhZjFiL3RhYmxlcmFuZ2U6YzFkYTM5ZTJhYTQzNDE1ZDgzNjM4YTgyYTAyYWFmMWJfMi0zLTEtMS0yODIyMQ_48194608-6f89-4f16-a791-8fd581a8f4d6"
      unitRef="usd">79437000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xOS9mcmFnOjY0MjE1YWY5MjUwYzQwYzU5ZThiMWE4ODQwNmExYzNiL3RhYmxlOmMxZGEzOWUyYWE0MzQxNWQ4MzYzOGE4MmEwMmFhZjFiL3RhYmxlcmFuZ2U6YzFkYTM5ZTJhYTQzNDE1ZDgzNjM4YTgyYTAyYWFmMWJfNC0xLTEtMS0yODIyMQ_8478a20c-ebb4-4660-af01-bc98f5c7c983"
      unitRef="usd">1250000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i0ebb8d8bac3445859e468a3d048cfaf5_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xOS9mcmFnOjY0MjE1YWY5MjUwYzQwYzU5ZThiMWE4ODQwNmExYzNiL3RhYmxlOmMxZGEzOWUyYWE0MzQxNWQ4MzYzOGE4MmEwMmFhZjFiL3RhYmxlcmFuZ2U6YzFkYTM5ZTJhYTQzNDE1ZDgzNjM4YTgyYTAyYWFmMWJfNC0zLTEtMS0yODIyMQ_887beeda-9bb4-417b-8fda-2907f63139b1"
      unitRef="usd">1268000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xOS9mcmFnOjY0MjE1YWY5MjUwYzQwYzU5ZThiMWE4ODQwNmExYzNiL3RhYmxlOmMxZGEzOWUyYWE0MzQxNWQ4MzYzOGE4MmEwMmFhZjFiL3RhYmxlcmFuZ2U6YzFkYTM5ZTJhYTQzNDE1ZDgzNjM4YTgyYTAyYWFmMWJfNS0xLTEtMS0yODIyMQ_5fd11f9e-e341-4843-b666-75b66cb050bf"
      unitRef="usd">28120000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i0ebb8d8bac3445859e468a3d048cfaf5_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xOS9mcmFnOjY0MjE1YWY5MjUwYzQwYzU5ZThiMWE4ODQwNmExYzNiL3RhYmxlOmMxZGEzOWUyYWE0MzQxNWQ4MzYzOGE4MmEwMmFhZjFiL3RhYmxlcmFuZ2U6YzFkYTM5ZTJhYTQzNDE1ZDgzNjM4YTgyYTAyYWFmMWJfNS0zLTEtMS0yODIyMQ_9f593a49-cf97-4e87-a6e2-18380ca13a98"
      unitRef="usd">29022000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xOS9mcmFnOjY0MjE1YWY5MjUwYzQwYzU5ZThiMWE4ODQwNmExYzNiL3RhYmxlOmMxZGEzOWUyYWE0MzQxNWQ4MzYzOGE4MmEwMmFhZjFiL3RhYmxlcmFuZ2U6YzFkYTM5ZTJhYTQzNDE1ZDgzNjM4YTgyYTAyYWFmMWJfNi0xLTEtMS0yODIyMQ_b977c004-01c8-4775-b49b-001112987edc"
      unitRef="usd">37549000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i0ebb8d8bac3445859e468a3d048cfaf5_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xOS9mcmFnOjY0MjE1YWY5MjUwYzQwYzU5ZThiMWE4ODQwNmExYzNiL3RhYmxlOmMxZGEzOWUyYWE0MzQxNWQ4MzYzOGE4MmEwMmFhZjFiL3RhYmxlcmFuZ2U6YzFkYTM5ZTJhYTQzNDE1ZDgzNjM4YTgyYTAyYWFmMWJfNi0zLTEtMS0yODIyMQ_4ed86c97-00ac-4073-85b2-6352300b8865"
      unitRef="usd">29509000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:CostsAndExpenses
      contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xOS9mcmFnOjY0MjE1YWY5MjUwYzQwYzU5ZThiMWE4ODQwNmExYzNiL3RhYmxlOmMxZGEzOWUyYWE0MzQxNWQ4MzYzOGE4MmEwMmFhZjFiL3RhYmxlcmFuZ2U6YzFkYTM5ZTJhYTQzNDE1ZDgzNjM4YTgyYTAyYWFmMWJfNy0xLTEtMS0yODIyMQ_829fd094-17d2-412c-9e00-64743b1b89cf"
      unitRef="usd">66919000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i0ebb8d8bac3445859e468a3d048cfaf5_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xOS9mcmFnOjY0MjE1YWY5MjUwYzQwYzU5ZThiMWE4ODQwNmExYzNiL3RhYmxlOmMxZGEzOWUyYWE0MzQxNWQ4MzYzOGE4MmEwMmFhZjFiL3RhYmxlcmFuZ2U6YzFkYTM5ZTJhYTQzNDE1ZDgzNjM4YTgyYTAyYWFmMWJfNy0zLTEtMS0yODIyMQ_c9b3a573-e138-4d96-a782-f9baea4fa6bc"
      unitRef="usd">59799000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xOS9mcmFnOjY0MjE1YWY5MjUwYzQwYzU5ZThiMWE4ODQwNmExYzNiL3RhYmxlOmMxZGEzOWUyYWE0MzQxNWQ4MzYzOGE4MmEwMmFhZjFiL3RhYmxlcmFuZ2U6YzFkYTM5ZTJhYTQzNDE1ZDgzNjM4YTgyYTAyYWFmMWJfOC0xLTEtMS0yODIyMQ_d4a92377-a4bc-48e4-a08c-9df102227f71"
      unitRef="usd">26769000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i0ebb8d8bac3445859e468a3d048cfaf5_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xOS9mcmFnOjY0MjE1YWY5MjUwYzQwYzU5ZThiMWE4ODQwNmExYzNiL3RhYmxlOmMxZGEzOWUyYWE0MzQxNWQ4MzYzOGE4MmEwMmFhZjFiL3RhYmxlcmFuZ2U6YzFkYTM5ZTJhYTQzNDE1ZDgzNjM4YTgyYTAyYWFmMWJfOC0zLTEtMS0yODIyMQ_4d33b9c4-1e4b-4dfc-af19-9af386765013"
      unitRef="usd">19638000</us-gaap:OperatingIncomeLoss>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xOS9mcmFnOjY0MjE1YWY5MjUwYzQwYzU5ZThiMWE4ODQwNmExYzNiL3RhYmxlOmMxZGEzOWUyYWE0MzQxNWQ4MzYzOGE4MmEwMmFhZjFiL3RhYmxlcmFuZ2U6YzFkYTM5ZTJhYTQzNDE1ZDgzNjM4YTgyYTAyYWFmMWJfOS0xLTEtMS0yODIyMQ_b55fa211-e21a-4f9b-9904-87fabd408589"
      unitRef="usd">80000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i0ebb8d8bac3445859e468a3d048cfaf5_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xOS9mcmFnOjY0MjE1YWY5MjUwYzQwYzU5ZThiMWE4ODQwNmExYzNiL3RhYmxlOmMxZGEzOWUyYWE0MzQxNWQ4MzYzOGE4MmEwMmFhZjFiL3RhYmxlcmFuZ2U6YzFkYTM5ZTJhYTQzNDE1ZDgzNjM4YTgyYTAyYWFmMWJfOS0zLTEtMS0yODIyMQ_0c9e46a3-0022-4810-acaf-49cba8eb52ee"
      unitRef="usd">275000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xOS9mcmFnOjY0MjE1YWY5MjUwYzQwYzU5ZThiMWE4ODQwNmExYzNiL3RhYmxlOmMxZGEzOWUyYWE0MzQxNWQ4MzYzOGE4MmEwMmFhZjFiL3RhYmxlcmFuZ2U6YzFkYTM5ZTJhYTQzNDE1ZDgzNjM4YTgyYTAyYWFmMWJfMTAtMS0xLTEtMjgyMjE_ebe00406-4d3e-403d-8261-711fb82d2b84"
      unitRef="usd">26849000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i0ebb8d8bac3445859e468a3d048cfaf5_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xOS9mcmFnOjY0MjE1YWY5MjUwYzQwYzU5ZThiMWE4ODQwNmExYzNiL3RhYmxlOmMxZGEzOWUyYWE0MzQxNWQ4MzYzOGE4MmEwMmFhZjFiL3RhYmxlcmFuZ2U6YzFkYTM5ZTJhYTQzNDE1ZDgzNjM4YTgyYTAyYWFmMWJfMTAtMy0xLTEtMjgyMjE_247bbadd-93af-4e03-a5b1-5f85926b689c"
      unitRef="usd">19913000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xOS9mcmFnOjY0MjE1YWY5MjUwYzQwYzU5ZThiMWE4ODQwNmExYzNiL3RhYmxlOmMxZGEzOWUyYWE0MzQxNWQ4MzYzOGE4MmEwMmFhZjFiL3RhYmxlcmFuZ2U6YzFkYTM5ZTJhYTQzNDE1ZDgzNjM4YTgyYTAyYWFmMWJfMTEtMS0xLTEtMjgyMjE_d23a5868-7f5e-40fa-a328-9d7f841d68c2"
      unitRef="usd">4052000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i0ebb8d8bac3445859e468a3d048cfaf5_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xOS9mcmFnOjY0MjE1YWY5MjUwYzQwYzU5ZThiMWE4ODQwNmExYzNiL3RhYmxlOmMxZGEzOWUyYWE0MzQxNWQ4MzYzOGE4MmEwMmFhZjFiL3RhYmxlcmFuZ2U6YzFkYTM5ZTJhYTQzNDE1ZDgzNjM4YTgyYTAyYWFmMWJfMTEtMy0xLTEtMjgyMjE_4d2131be-bf1e-4ad0-b5b0-f302d4d454e5"
      unitRef="usd">-3552000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xOS9mcmFnOjY0MjE1YWY5MjUwYzQwYzU5ZThiMWE4ODQwNmExYzNiL3RhYmxlOmMxZGEzOWUyYWE0MzQxNWQ4MzYzOGE4MmEwMmFhZjFiL3RhYmxlcmFuZ2U6YzFkYTM5ZTJhYTQzNDE1ZDgzNjM4YTgyYTAyYWFmMWJfMTItMS0xLTEtMjgyMjE_4f021180-7b89-454d-8786-2379ec4d4fb2"
      unitRef="usd">22797000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i0ebb8d8bac3445859e468a3d048cfaf5_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xOS9mcmFnOjY0MjE1YWY5MjUwYzQwYzU5ZThiMWE4ODQwNmExYzNiL3RhYmxlOmMxZGEzOWUyYWE0MzQxNWQ4MzYzOGE4MmEwMmFhZjFiL3RhYmxlcmFuZ2U6YzFkYTM5ZTJhYTQzNDE1ZDgzNjM4YTgyYTAyYWFmMWJfMTItMy0xLTEtMjgyMjE_2cd59acc-beea-4e6a-8b23-eec790e51cf3"
      unitRef="usd">23465000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
      contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xOS9mcmFnOjY0MjE1YWY5MjUwYzQwYzU5ZThiMWE4ODQwNmExYzNiL3RhYmxlOmMxZGEzOWUyYWE0MzQxNWQ4MzYzOGE4MmEwMmFhZjFiL3RhYmxlcmFuZ2U6YzFkYTM5ZTJhYTQzNDE1ZDgzNjM4YTgyYTAyYWFmMWJfMTQtMC0xLTEtMjgyMjEvdGV4dHJlZ2lvbjowMWE0N2M3NWFjZTA0YjcwODg4OGY5ZTMzYWI2M2FiZF84OA_7546fec8-f564-444d-a256-a9cc465ca6a6"
      unitRef="usd">323000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
      contextRef="i0ebb8d8bac3445859e468a3d048cfaf5_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xOS9mcmFnOjY0MjE1YWY5MjUwYzQwYzU5ZThiMWE4ODQwNmExYzNiL3RhYmxlOmMxZGEzOWUyYWE0MzQxNWQ4MzYzOGE4MmEwMmFhZjFiL3RhYmxlcmFuZ2U6YzFkYTM5ZTJhYTQzNDE1ZDgzNjM4YTgyYTAyYWFmMWJfMTQtMC0xLTEtMjgyMjEvdGV4dHJlZ2lvbjowMWE0N2M3NWFjZTA0YjcwODg4OGY5ZTMzYWI2M2FiZF85Ng_3953ca27-f4a9-45e6-8386-6e5b0ee5b7b1"
      unitRef="usd">61000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xOS9mcmFnOjY0MjE1YWY5MjUwYzQwYzU5ZThiMWE4ODQwNmExYzNiL3RhYmxlOmMxZGEzOWUyYWE0MzQxNWQ4MzYzOGE4MmEwMmFhZjFiL3RhYmxlcmFuZ2U6YzFkYTM5ZTJhYTQzNDE1ZDgzNjM4YTgyYTAyYWFmMWJfMTQtMS0xLTEtMjgyMjE_0ec31587-b278-445c-a6f2-e761751c0c1c"
      unitRef="usd">-1019000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i0ebb8d8bac3445859e468a3d048cfaf5_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xOS9mcmFnOjY0MjE1YWY5MjUwYzQwYzU5ZThiMWE4ODQwNmExYzNiL3RhYmxlOmMxZGEzOWUyYWE0MzQxNWQ4MzYzOGE4MmEwMmFhZjFiL3RhYmxlcmFuZ2U6YzFkYTM5ZTJhYTQzNDE1ZDgzNjM4YTgyYTAyYWFmMWJfMTQtMy0xLTEtMjgyMjE_cf479975-e49e-40dc-a4ae-26f8a5e5c316"
      unitRef="usd">-192000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xOS9mcmFnOjY0MjE1YWY5MjUwYzQwYzU5ZThiMWE4ODQwNmExYzNiL3RhYmxlOmMxZGEzOWUyYWE0MzQxNWQ4MzYzOGE4MmEwMmFhZjFiL3RhYmxlcmFuZ2U6YzFkYTM5ZTJhYTQzNDE1ZDgzNjM4YTgyYTAyYWFmMWJfMTUtMS0xLTEtMjgyMjE_428bbbb3-ee36-428d-836c-175622dbc65b"
      unitRef="usd">-105000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i0ebb8d8bac3445859e468a3d048cfaf5_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xOS9mcmFnOjY0MjE1YWY5MjUwYzQwYzU5ZThiMWE4ODQwNmExYzNiL3RhYmxlOmMxZGEzOWUyYWE0MzQxNWQ4MzYzOGE4MmEwMmFhZjFiL3RhYmxlcmFuZ2U6YzFkYTM5ZTJhYTQzNDE1ZDgzNjM4YTgyYTAyYWFmMWJfMTUtMy0xLTEtMjgyMjE_61816b24-67d1-4cb1-a7c0-984a372a8e5d"
      unitRef="usd">26000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xOS9mcmFnOjY0MjE1YWY5MjUwYzQwYzU5ZThiMWE4ODQwNmExYzNiL3RhYmxlOmMxZGEzOWUyYWE0MzQxNWQ4MzYzOGE4MmEwMmFhZjFiL3RhYmxlcmFuZ2U6YzFkYTM5ZTJhYTQzNDE1ZDgzNjM4YTgyYTAyYWFmMWJfMTYtMS0xLTEtMjgyMjE_16fb0b25-400e-45dc-8f16-3b6784764280"
      unitRef="usd">21673000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i0ebb8d8bac3445859e468a3d048cfaf5_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xOS9mcmFnOjY0MjE1YWY5MjUwYzQwYzU5ZThiMWE4ODQwNmExYzNiL3RhYmxlOmMxZGEzOWUyYWE0MzQxNWQ4MzYzOGE4MmEwMmFhZjFiL3RhYmxlcmFuZ2U6YzFkYTM5ZTJhYTQzNDE1ZDgzNjM4YTgyYTAyYWFmMWJfMTYtMy0xLTEtMjgyMjE_742e30bf-9430-4a68-8487-a6230e9c0b44"
      unitRef="usd">23299000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareBasic
      contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xOS9mcmFnOjY0MjE1YWY5MjUwYzQwYzU5ZThiMWE4ODQwNmExYzNiL3RhYmxlOmMxZGEzOWUyYWE0MzQxNWQ4MzYzOGE4MmEwMmFhZjFiL3RhYmxlcmFuZ2U6YzFkYTM5ZTJhYTQzNDE1ZDgzNjM4YTgyYTAyYWFmMWJfMTgtMS0xLTEtMjgyMjE_1e3c4b72-25f0-4e72-9c6c-d0f16ff09afc"
      unitRef="usdPerShare">0.22</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i0ebb8d8bac3445859e468a3d048cfaf5_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xOS9mcmFnOjY0MjE1YWY5MjUwYzQwYzU5ZThiMWE4ODQwNmExYzNiL3RhYmxlOmMxZGEzOWUyYWE0MzQxNWQ4MzYzOGE4MmEwMmFhZjFiL3RhYmxlcmFuZ2U6YzFkYTM5ZTJhYTQzNDE1ZDgzNjM4YTgyYTAyYWFmMWJfMTgtMy0xLTEtMjgyMjE_a52bc082-8023-4ad1-9071-e7019e1b3a41"
      unitRef="usdPerShare">0.20</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xOS9mcmFnOjY0MjE1YWY5MjUwYzQwYzU5ZThiMWE4ODQwNmExYzNiL3RhYmxlOmMxZGEzOWUyYWE0MzQxNWQ4MzYzOGE4MmEwMmFhZjFiL3RhYmxlcmFuZ2U6YzFkYTM5ZTJhYTQzNDE1ZDgzNjM4YTgyYTAyYWFmMWJfMjAtMS0xLTEtMjgyMjE_ca02b6ea-ccc2-4715-85c6-7b61bfce762a"
      unitRef="usdPerShare">0.20</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i0ebb8d8bac3445859e468a3d048cfaf5_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xOS9mcmFnOjY0MjE1YWY5MjUwYzQwYzU5ZThiMWE4ODQwNmExYzNiL3RhYmxlOmMxZGEzOWUyYWE0MzQxNWQ4MzYzOGE4MmEwMmFhZjFiL3RhYmxlcmFuZ2U6YzFkYTM5ZTJhYTQzNDE1ZDgzNjM4YTgyYTAyYWFmMWJfMjAtMy0xLTEtMjgyMjE_4b4e3778-5b04-4f07-9b1a-e3ac6121dd0e"
      unitRef="usdPerShare">0.18</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xOS9mcmFnOjY0MjE1YWY5MjUwYzQwYzU5ZThiMWE4ODQwNmExYzNiL3RhYmxlOmMxZGEzOWUyYWE0MzQxNWQ4MzYzOGE4MmEwMmFhZjFiL3RhYmxlcmFuZ2U6YzFkYTM5ZTJhYTQzNDE1ZDgzNjM4YTgyYTAyYWFmMWJfMjMtMS0xLTEtMjgyMjE_2415efe6-dbc3-4f65-b0d5-d791380e3dec"
      unitRef="shares">106012000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i0ebb8d8bac3445859e468a3d048cfaf5_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xOS9mcmFnOjY0MjE1YWY5MjUwYzQwYzU5ZThiMWE4ODQwNmExYzNiL3RhYmxlOmMxZGEzOWUyYWE0MzQxNWQ4MzYzOGE4MmEwMmFhZjFiL3RhYmxlcmFuZ2U6YzFkYTM5ZTJhYTQzNDE1ZDgzNjM4YTgyYTAyYWFmMWJfMjMtMy0xLTEtMjgyMjE_9aecb556-e242-44f8-a242-05aa4f1c8a13"
      unitRef="shares">116818000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xOS9mcmFnOjY0MjE1YWY5MjUwYzQwYzU5ZThiMWE4ODQwNmExYzNiL3RhYmxlOmMxZGEzOWUyYWE0MzQxNWQ4MzYzOGE4MmEwMmFhZjFiL3RhYmxlcmFuZ2U6YzFkYTM5ZTJhYTQzNDE1ZDgzNjM4YTgyYTAyYWFmMWJfMjQtMS0xLTEtMjgyMjE_9aa0aace-2e86-4f26-97ac-c977acf479a0"
      unitRef="shares">115037000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i0ebb8d8bac3445859e468a3d048cfaf5_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8xOS9mcmFnOjY0MjE1YWY5MjUwYzQwYzU5ZThiMWE4ODQwNmExYzNiL3RhYmxlOmMxZGEzOWUyYWE0MzQxNWQ4MzYzOGE4MmEwMmFhZjFiL3RhYmxlcmFuZ2U6YzFkYTM5ZTJhYTQzNDE1ZDgzNjM4YTgyYTAyYWFmMWJfMjQtMy0xLTEtMjgyMjE_f3a7cbb2-3de8-4038-ae6d-cc495eb422e1"
      unitRef="shares">129668000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:ProfitLoss
      contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yMi9mcmFnOjE0YmZlMmE4ZmYxMDRkZTk5MmJlYWMwYWM0MmY1NjA2L3RhYmxlOmZiY2M3NTk2ZDZhZjQ1NjRhYzg2NThhZTA2MjMyMGVjL3RhYmxlcmFuZ2U6ZmJjYzc1OTZkNmFmNDU2NGFjODY1OGFlMDYyMzIwZWNfMy0xLTEtMS0yODIyMQ_a66c9fa4-6065-48ee-8689-0996d5b67946"
      unitRef="usd">22797000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i0ebb8d8bac3445859e468a3d048cfaf5_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yMi9mcmFnOjE0YmZlMmE4ZmYxMDRkZTk5MmJlYWMwYWM0MmY1NjA2L3RhYmxlOmZiY2M3NTk2ZDZhZjQ1NjRhYzg2NThhZTA2MjMyMGVjL3RhYmxlcmFuZ2U6ZmJjYzc1OTZkNmFmNDU2NGFjODY1OGFlMDYyMzIwZWNfMy0zLTEtMS0yODIyMQ_b9f9f788-e827-4576-a45d-1f014c2186b7"
      unitRef="usd">23465000</us-gaap:ProfitLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yMi9mcmFnOjE0YmZlMmE4ZmYxMDRkZTk5MmJlYWMwYWM0MmY1NjA2L3RhYmxlOmZiY2M3NTk2ZDZhZjQ1NjRhYzg2NThhZTA2MjMyMGVjL3RhYmxlcmFuZ2U6ZmJjYzc1OTZkNmFmNDU2NGFjODY1OGFlMDYyMzIwZWNfNS0xLTEtMS0yODIyMQ_42d31c6b-c1bb-4c60-b152-b17532d52439"
      unitRef="usd">10761000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i0ebb8d8bac3445859e468a3d048cfaf5_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yMi9mcmFnOjE0YmZlMmE4ZmYxMDRkZTk5MmJlYWMwYWM0MmY1NjA2L3RhYmxlOmZiY2M3NTk2ZDZhZjQ1NjRhYzg2NThhZTA2MjMyMGVjL3RhYmxlcmFuZ2U6ZmJjYzc1OTZkNmFmNDU2NGFjODY1OGFlMDYyMzIwZWNfNS0zLTEtMS0yODIyMQ_700d679f-9c99-4a7b-afa6-971e3ce86c95"
      unitRef="usd">10101000</us-gaap:ShareBasedCompensation>
    <cort:AccretionExpenseIncome
      contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yMi9mcmFnOjE0YmZlMmE4ZmYxMDRkZTk5MmJlYWMwYWM0MmY1NjA2L3RhYmxlOmZiY2M3NTk2ZDZhZjQ1NjRhYzg2NThhZTA2MjMyMGVjL3RhYmxlcmFuZ2U6ZmJjYzc1OTZkNmFmNDU2NGFjODY1OGFlMDYyMzIwZWNfNy0xLTEtMS0yODIyMQ_13c27b17-8663-4aad-802c-1d37161d3044"
      unitRef="usd">1106000</cort:AccretionExpenseIncome>
    <cort:AccretionExpenseIncome
      contextRef="i0ebb8d8bac3445859e468a3d048cfaf5_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yMi9mcmFnOjE0YmZlMmE4ZmYxMDRkZTk5MmJlYWMwYWM0MmY1NjA2L3RhYmxlOmZiY2M3NTk2ZDZhZjQ1NjRhYzg2NThhZTA2MjMyMGVjL3RhYmxlcmFuZ2U6ZmJjYzc1OTZkNmFmNDU2NGFjODY1OGFlMDYyMzIwZWNfNy0zLTEtMS0yODIyMQ_b30618d5-65c9-4fde-b8c9-cfcddbbab43c"
      unitRef="usd">1194000</cort:AccretionExpenseIncome>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yMi9mcmFnOjE0YmZlMmE4ZmYxMDRkZTk5MmJlYWMwYWM0MmY1NjA2L3RhYmxlOmZiY2M3NTk2ZDZhZjQ1NjRhYzg2NThhZTA2MjMyMGVjL3RhYmxlcmFuZ2U6ZmJjYzc1OTZkNmFmNDU2NGFjODY1OGFlMDYyMzIwZWNfOC0xLTEtMS0yODIyMQ_3866098e-7ecd-4447-b83c-eee873d364fc"
      unitRef="usd">288000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i0ebb8d8bac3445859e468a3d048cfaf5_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yMi9mcmFnOjE0YmZlMmE4ZmYxMDRkZTk5MmJlYWMwYWM0MmY1NjA2L3RhYmxlOmZiY2M3NTk2ZDZhZjQ1NjRhYzg2NThhZTA2MjMyMGVjL3RhYmxlcmFuZ2U6ZmJjYzc1OTZkNmFmNDU2NGFjODY1OGFlMDYyMzIwZWNfOC0zLTEtMS0yODIyMQ_2cededa8-fd5d-4f82-abcb-a0cc385b3466"
      unitRef="usd">254000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yMi9mcmFnOjE0YmZlMmE4ZmYxMDRkZTk5MmJlYWMwYWM0MmY1NjA2L3RhYmxlOmZiY2M3NTk2ZDZhZjQ1NjRhYzg2NThhZTA2MjMyMGVjL3RhYmxlcmFuZ2U6ZmJjYzc1OTZkNmFmNDU2NGFjODY1OGFlMDYyMzIwZWNfOS0xLTEtMS0zMTI1NA_131f6bb4-d58f-492b-ae48-355acb58ac89"
      unitRef="usd">-9935000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i0ebb8d8bac3445859e468a3d048cfaf5_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yMi9mcmFnOjE0YmZlMmE4ZmYxMDRkZTk5MmJlYWMwYWM0MmY1NjA2L3RhYmxlOmZiY2M3NTk2ZDZhZjQ1NjRhYzg2NThhZTA2MjMyMGVjL3RhYmxlcmFuZ2U6ZmJjYzc1OTZkNmFmNDU2NGFjODY1OGFlMDYyMzIwZWNfOS0zLTEtMS0zMTI1NA_ed451d89-a2a4-41f9-aecd-3edf82745d84"
      unitRef="usd">-5360000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yMi9mcmFnOjE0YmZlMmE4ZmYxMDRkZTk5MmJlYWMwYWM0MmY1NjA2L3RhYmxlOmZiY2M3NTk2ZDZhZjQ1NjRhYzg2NThhZTA2MjMyMGVjL3RhYmxlcmFuZ2U6ZmJjYzc1OTZkNmFmNDU2NGFjODY1OGFlMDYyMzIwZWNfOS0xLTEtMS0yODIyMQ_2b8b0d3e-b154-4e04-8b6d-6f3af0b3d43e"
      unitRef="usd">514000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="i0ebb8d8bac3445859e468a3d048cfaf5_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yMi9mcmFnOjE0YmZlMmE4ZmYxMDRkZTk5MmJlYWMwYWM0MmY1NjA2L3RhYmxlOmZiY2M3NTk2ZDZhZjQ1NjRhYzg2NThhZTA2MjMyMGVjL3RhYmxlcmFuZ2U6ZmJjYzc1OTZkNmFmNDU2NGFjODY1OGFlMDYyMzIwZWNfOS0zLTEtMS0yODIyMQ_52ece2d1-c9d8-4406-8904-a0abfaaf4f50"
      unitRef="usd">489000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yMi9mcmFnOjE0YmZlMmE4ZmYxMDRkZTk5MmJlYWMwYWM0MmY1NjA2L3RhYmxlOmZiY2M3NTk2ZDZhZjQ1NjRhYzg2NThhZTA2MjMyMGVjL3RhYmxlcmFuZ2U6ZmJjYzc1OTZkNmFmNDU2NGFjODY1OGFlMDYyMzIwZWNfMTEtMS0xLTEtMjgyMjE_6ed23314-4b5c-41be-9316-14cfe08a6cb1"
      unitRef="usd">-447000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i0ebb8d8bac3445859e468a3d048cfaf5_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yMi9mcmFnOjE0YmZlMmE4ZmYxMDRkZTk5MmJlYWMwYWM0MmY1NjA2L3RhYmxlOmZiY2M3NTk2ZDZhZjQ1NjRhYzg2NThhZTA2MjMyMGVjL3RhYmxlcmFuZ2U6ZmJjYzc1OTZkNmFmNDU2NGFjODY1OGFlMDYyMzIwZWNfMTEtMy0xLTEtMjgyMjE_fa166ed4-0ec0-4fde-81a5-e551326db01c"
      unitRef="usd">-3998000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yMi9mcmFnOjE0YmZlMmE4ZmYxMDRkZTk5MmJlYWMwYWM0MmY1NjA2L3RhYmxlOmZiY2M3NTk2ZDZhZjQ1NjRhYzg2NThhZTA2MjMyMGVjL3RhYmxlcmFuZ2U6ZmJjYzc1OTZkNmFmNDU2NGFjODY1OGFlMDYyMzIwZWNfMTItMS0xLTEtMjgyMjE_3b3f6c40-47c9-419d-8bf5-95bad65c4790"
      unitRef="usd">163000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i0ebb8d8bac3445859e468a3d048cfaf5_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yMi9mcmFnOjE0YmZlMmE4ZmYxMDRkZTk5MmJlYWMwYWM0MmY1NjA2L3RhYmxlOmZiY2M3NTk2ZDZhZjQ1NjRhYzg2NThhZTA2MjMyMGVjL3RhYmxlcmFuZ2U6ZmJjYzc1OTZkNmFmNDU2NGFjODY1OGFlMDYyMzIwZWNfMTItMy0xLTEtMjgyMjE_38744232-bca5-4cd8-b596-880484d2310c"
      unitRef="usd">-866000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yMi9mcmFnOjE0YmZlMmE4ZmYxMDRkZTk5MmJlYWMwYWM0MmY1NjA2L3RhYmxlOmZiY2M3NTk2ZDZhZjQ1NjRhYzg2NThhZTA2MjMyMGVjL3RhYmxlcmFuZ2U6ZmJjYzc1OTZkNmFmNDU2NGFjODY1OGFlMDYyMzIwZWNfMTMtMS0xLTEtMjgyMjE_f055e798-1e87-4fb3-a639-457dc04b6852"
      unitRef="usd">9000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i0ebb8d8bac3445859e468a3d048cfaf5_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yMi9mcmFnOjE0YmZlMmE4ZmYxMDRkZTk5MmJlYWMwYWM0MmY1NjA2L3RhYmxlOmZiY2M3NTk2ZDZhZjQ1NjRhYzg2NThhZTA2MjMyMGVjL3RhYmxlcmFuZ2U6ZmJjYzc1OTZkNmFmNDU2NGFjODY1OGFlMDYyMzIwZWNfMTMtMy0xLTEtMjgyMjE_ab6837b5-84ca-431b-bae6-1e4df1241eb0"
      unitRef="usd">2850000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yMi9mcmFnOjE0YmZlMmE4ZmYxMDRkZTk5MmJlYWMwYWM0MmY1NjA2L3RhYmxlOmZiY2M3NTk2ZDZhZjQ1NjRhYzg2NThhZTA2MjMyMGVjL3RhYmxlcmFuZ2U6ZmJjYzc1OTZkNmFmNDU2NGFjODY1OGFlMDYyMzIwZWNfMTQtMS0xLTEtMjgyMjE_252fb358-b986-4410-ba2c-a118f57333e2"
      unitRef="usd">2256000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i0ebb8d8bac3445859e468a3d048cfaf5_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yMi9mcmFnOjE0YmZlMmE4ZmYxMDRkZTk5MmJlYWMwYWM0MmY1NjA2L3RhYmxlOmZiY2M3NTk2ZDZhZjQ1NjRhYzg2NThhZTA2MjMyMGVjL3RhYmxlcmFuZ2U6ZmJjYzc1OTZkNmFmNDU2NGFjODY1OGFlMDYyMzIwZWNfMTQtMy0xLTEtMjgyMjE_418fedad-fbdd-417d-9048-9b904b41a912"
      unitRef="usd">-3493000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <cort:IncreaseDecreaseInAccruedClinicalExpenses
      contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yMi9mcmFnOjE0YmZlMmE4ZmYxMDRkZTk5MmJlYWMwYWM0MmY1NjA2L3RhYmxlOmZiY2M3NTk2ZDZhZjQ1NjRhYzg2NThhZTA2MjMyMGVjL3RhYmxlcmFuZ2U6ZmJjYzc1OTZkNmFmNDU2NGFjODY1OGFlMDYyMzIwZWNfMTUtMS0xLTEtMjgyMjE_34d9d904-7d10-471d-a6fb-817c3c29d23e"
      unitRef="usd">609000</cort:IncreaseDecreaseInAccruedClinicalExpenses>
    <cort:IncreaseDecreaseInAccruedClinicalExpenses
      contextRef="i0ebb8d8bac3445859e468a3d048cfaf5_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yMi9mcmFnOjE0YmZlMmE4ZmYxMDRkZTk5MmJlYWMwYWM0MmY1NjA2L3RhYmxlOmZiY2M3NTk2ZDZhZjQ1NjRhYzg2NThhZTA2MjMyMGVjL3RhYmxlcmFuZ2U6ZmJjYzc1OTZkNmFmNDU2NGFjODY1OGFlMDYyMzIwZWNfMTUtMy0xLTEtMjgyMjE_cfb1dd1b-540e-497f-962a-d1120c0608df"
      unitRef="usd">-138000</cort:IncreaseDecreaseInAccruedClinicalExpenses>
    <us-gaap:IncreaseDecreaseInOtherAccruedLiabilities
      contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yMi9mcmFnOjE0YmZlMmE4ZmYxMDRkZTk5MmJlYWMwYWM0MmY1NjA2L3RhYmxlOmZiY2M3NTk2ZDZhZjQ1NjRhYzg2NThhZTA2MjMyMGVjL3RhYmxlcmFuZ2U6ZmJjYzc1OTZkNmFmNDU2NGFjODY1OGFlMDYyMzIwZWNfMTYtMS0xLTEtMjgyMjE_dbd3f8b5-f7a6-42f0-8d4d-4b6e4698c997"
      unitRef="usd">4995000</us-gaap:IncreaseDecreaseInOtherAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherAccruedLiabilities
      contextRef="i0ebb8d8bac3445859e468a3d048cfaf5_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yMi9mcmFnOjE0YmZlMmE4ZmYxMDRkZTk5MmJlYWMwYWM0MmY1NjA2L3RhYmxlOmZiY2M3NTk2ZDZhZjQ1NjRhYzg2NThhZTA2MjMyMGVjL3RhYmxlcmFuZ2U6ZmJjYzc1OTZkNmFmNDU2NGFjODY1OGFlMDYyMzIwZWNfMTYtMy0xLTEtMjgyMjE_7fa82dfb-9531-4124-adc2-58a1a1a7b490"
      unitRef="usd">-3217000</us-gaap:IncreaseDecreaseInOtherAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedTaxesPayable
      contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yMi9mcmFnOjE0YmZlMmE4ZmYxMDRkZTk5MmJlYWMwYWM0MmY1NjA2L3RhYmxlOmZiY2M3NTk2ZDZhZjQ1NjRhYzg2NThhZTA2MjMyMGVjL3RhYmxlcmFuZ2U6ZmJjYzc1OTZkNmFmNDU2NGFjODY1OGFlMDYyMzIwZWNfMTctMS0xLTEtMjgyMjE_05c00244-2448-41ae-b963-22fecf4d1353"
      unitRef="usd">2107000</us-gaap:IncreaseDecreaseInAccruedTaxesPayable>
    <us-gaap:IncreaseDecreaseInAccruedTaxesPayable
      contextRef="i0ebb8d8bac3445859e468a3d048cfaf5_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yMi9mcmFnOjE0YmZlMmE4ZmYxMDRkZTk5MmJlYWMwYWM0MmY1NjA2L3RhYmxlOmZiY2M3NTk2ZDZhZjQ1NjRhYzg2NThhZTA2MjMyMGVjL3RhYmxlcmFuZ2U6ZmJjYzc1OTZkNmFmNDU2NGFjODY1OGFlMDYyMzIwZWNfMTctMy0xLTEtMjgyMjE_68948a46-5a51-4f65-855b-776a91e42f95"
      unitRef="usd">597000</us-gaap:IncreaseDecreaseInAccruedTaxesPayable>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yMi9mcmFnOjE0YmZlMmE4ZmYxMDRkZTk5MmJlYWMwYWM0MmY1NjA2L3RhYmxlOmZiY2M3NTk2ZDZhZjQ1NjRhYzg2NThhZTA2MjMyMGVjL3RhYmxlcmFuZ2U6ZmJjYzc1OTZkNmFmNDU2NGFjODY1OGFlMDYyMzIwZWNfMTgtMS0xLTEtMjgyMjE_31c54d88-bc18-469c-8e38-e6e94255350d"
      unitRef="usd">-526000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="i0ebb8d8bac3445859e468a3d048cfaf5_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yMi9mcmFnOjE0YmZlMmE4ZmYxMDRkZTk5MmJlYWMwYWM0MmY1NjA2L3RhYmxlOmZiY2M3NTk2ZDZhZjQ1NjRhYzg2NThhZTA2MjMyMGVjL3RhYmxlcmFuZ2U6ZmJjYzc1OTZkNmFmNDU2NGFjODY1OGFlMDYyMzIwZWNfMTgtMy0xLTEtMjgyMjE_85e5f1c5-0779-4f3b-ac54-3d3cf14113cf"
      unitRef="usd">-484000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yMi9mcmFnOjE0YmZlMmE4ZmYxMDRkZTk5MmJlYWMwYWM0MmY1NjA2L3RhYmxlOmZiY2M3NTk2ZDZhZjQ1NjRhYzg2NThhZTA2MjMyMGVjL3RhYmxlcmFuZ2U6ZmJjYzc1OTZkNmFmNDU2NGFjODY1OGFlMDYyMzIwZWNfMTktMS0xLTEtMjgyMjE_0c2bdfb7-1a4c-4d5b-b21c-602d83e090b3"
      unitRef="usd">35247000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i0ebb8d8bac3445859e468a3d048cfaf5_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yMi9mcmFnOjE0YmZlMmE4ZmYxMDRkZTk5MmJlYWMwYWM0MmY1NjA2L3RhYmxlOmZiY2M3NTk2ZDZhZjQ1NjRhYzg2NThhZTA2MjMyMGVjL3RhYmxlcmFuZ2U6ZmJjYzc1OTZkNmFmNDU2NGFjODY1OGFlMDYyMzIwZWNfMTktMy0xLTEtMjgyMjE_50057706-7681-413d-b0cc-309bff541145"
      unitRef="usd">25422000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yMi9mcmFnOjE0YmZlMmE4ZmYxMDRkZTk5MmJlYWMwYWM0MmY1NjA2L3RhYmxlOmZiY2M3NTk2ZDZhZjQ1NjRhYzg2NThhZTA2MjMyMGVjL3RhYmxlcmFuZ2U6ZmJjYzc1OTZkNmFmNDU2NGFjODY1OGFlMDYyMzIwZWNfMjEtMS0xLTEtMjgyMjE_1554b063-989c-44a0-8a16-ca7fc5feaa3c"
      unitRef="usd">12000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i0ebb8d8bac3445859e468a3d048cfaf5_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yMi9mcmFnOjE0YmZlMmE4ZmYxMDRkZTk5MmJlYWMwYWM0MmY1NjA2L3RhYmxlOmZiY2M3NTk2ZDZhZjQ1NjRhYzg2NThhZTA2MjMyMGVjL3RhYmxlcmFuZ2U6ZmJjYzc1OTZkNmFmNDU2NGFjODY1OGFlMDYyMzIwZWNfMjEtMy0xLTEtMjgyMjE_58f8219e-431a-4dab-8017-e7fb3942f844"
      unitRef="usd">126000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yMi9mcmFnOjE0YmZlMmE4ZmYxMDRkZTk5MmJlYWMwYWM0MmY1NjA2L3RhYmxlOmZiY2M3NTk2ZDZhZjQ1NjRhYzg2NThhZTA2MjMyMGVjL3RhYmxlcmFuZ2U6ZmJjYzc1OTZkNmFmNDU2NGFjODY1OGFlMDYyMzIwZWNfMjItMS0xLTEtMjgyMjE_e08c9b37-9d48-4e6c-8781-5ee1ce065549"
      unitRef="usd">42127000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="i0ebb8d8bac3445859e468a3d048cfaf5_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yMi9mcmFnOjE0YmZlMmE4ZmYxMDRkZTk5MmJlYWMwYWM0MmY1NjA2L3RhYmxlOmZiY2M3NTk2ZDZhZjQ1NjRhYzg2NThhZTA2MjMyMGVjL3RhYmxlcmFuZ2U6ZmJjYzc1OTZkNmFmNDU2NGFjODY1OGFlMDYyMzIwZWNfMjItMy0xLTEtMjgyMjE_65c8006d-ebfc-4ba7-bdbb-e0a889b07f70"
      unitRef="usd">124230000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yMi9mcmFnOjE0YmZlMmE4ZmYxMDRkZTk5MmJlYWMwYWM0MmY1NjA2L3RhYmxlOmZiY2M3NTk2ZDZhZjQ1NjRhYzg2NThhZTA2MjMyMGVjL3RhYmxlcmFuZ2U6ZmJjYzc1OTZkNmFmNDU2NGFjODY1OGFlMDYyMzIwZWNfMjMtMS0xLTEtMjgyMjE_74fd2bf0-70b3-4872-a8a6-4e343f9f6a53"
      unitRef="usd">92611000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="i0ebb8d8bac3445859e468a3d048cfaf5_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yMi9mcmFnOjE0YmZlMmE4ZmYxMDRkZTk5MmJlYWMwYWM0MmY1NjA2L3RhYmxlOmZiY2M3NTk2ZDZhZjQ1NjRhYzg2NThhZTA2MjMyMGVjL3RhYmxlcmFuZ2U6ZmJjYzc1OTZkNmFmNDU2NGFjODY1OGFlMDYyMzIwZWNfMjMtMy0xLTEtMjgyMjE_7fc5042a-9d8d-4dec-a18a-58e6b4e81017"
      unitRef="usd">127388000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yMi9mcmFnOjE0YmZlMmE4ZmYxMDRkZTk5MmJlYWMwYWM0MmY1NjA2L3RhYmxlOmZiY2M3NTk2ZDZhZjQ1NjRhYzg2NThhZTA2MjMyMGVjL3RhYmxlcmFuZ2U6ZmJjYzc1OTZkNmFmNDU2NGFjODY1OGFlMDYyMzIwZWNfMjQtMS0xLTEtMjgyMjE_13faaac0-ccbf-4ea5-b03d-daa5754dba2a"
      unitRef="usd">-50496000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i0ebb8d8bac3445859e468a3d048cfaf5_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yMi9mcmFnOjE0YmZlMmE4ZmYxMDRkZTk5MmJlYWMwYWM0MmY1NjA2L3RhYmxlOmZiY2M3NTk2ZDZhZjQ1NjRhYzg2NThhZTA2MjMyMGVjL3RhYmxlcmFuZ2U6ZmJjYzc1OTZkNmFmNDU2NGFjODY1OGFlMDYyMzIwZWNfMjQtMy0xLTEtMjgyMjE_a0af3fd9-f914-4ffc-8c61-35adfb6630ed"
      unitRef="usd">-3284000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yMi9mcmFnOjE0YmZlMmE4ZmYxMDRkZTk5MmJlYWMwYWM0MmY1NjA2L3RhYmxlOmZiY2M3NTk2ZDZhZjQ1NjRhYzg2NThhZTA2MjMyMGVjL3RhYmxlcmFuZ2U6ZmJjYzc1OTZkNmFmNDU2NGFjODY1OGFlMDYyMzIwZWNfMjYtMS0xLTEtMjgyMjE_d1f23e61-0f57-4472-89e9-a0b09f398528"
      unitRef="usd">1382000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="i0ebb8d8bac3445859e468a3d048cfaf5_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yMi9mcmFnOjE0YmZlMmE4ZmYxMDRkZTk5MmJlYWMwYWM0MmY1NjA2L3RhYmxlOmZiY2M3NTk2ZDZhZjQ1NjRhYzg2NThhZTA2MjMyMGVjL3RhYmxlcmFuZ2U6ZmJjYzc1OTZkNmFmNDU2NGFjODY1OGFlMDYyMzIwZWNfMjYtMy0xLTEtMjgyMjE_e3152dea-d3d5-413c-9100-96dc33e03256"
      unitRef="usd">4038000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yMi9mcmFnOjE0YmZlMmE4ZmYxMDRkZTk5MmJlYWMwYWM0MmY1NjA2L3RhYmxlOmZiY2M3NTk2ZDZhZjQ1NjRhYzg2NThhZTA2MjMyMGVjL3RhYmxlcmFuZ2U6ZmJjYzc1OTZkNmFmNDU2NGFjODY1OGFlMDYyMzIwZWNfMjctMS0xLTEtMjgyMjE_fba2d0db-f182-4b4d-b9af-b2051ca4a076"
      unitRef="usd">0</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i0ebb8d8bac3445859e468a3d048cfaf5_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yMi9mcmFnOjE0YmZlMmE4ZmYxMDRkZTk5MmJlYWMwYWM0MmY1NjA2L3RhYmxlOmZiY2M3NTk2ZDZhZjQ1NjRhYzg2NThhZTA2MjMyMGVjL3RhYmxlcmFuZ2U6ZmJjYzc1OTZkNmFmNDU2NGFjODY1OGFlMDYyMzIwZWNfMjctMy0xLTEtMjgyMjE_a23f9720-f9cd-4cc0-ba54-f5695e605ef8"
      unitRef="usd">33541000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yMi9mcmFnOjE0YmZlMmE4ZmYxMDRkZTk5MmJlYWMwYWM0MmY1NjA2L3RhYmxlOmZiY2M3NTk2ZDZhZjQ1NjRhYzg2NThhZTA2MjMyMGVjL3RhYmxlcmFuZ2U6ZmJjYzc1OTZkNmFmNDU2NGFjODY1OGFlMDYyMzIwZWNfMjgtMS0xLTEtMjgyMjE_dc706619-103e-4181-a128-ae1edc12bc3d"
      unitRef="usd">1888000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i0ebb8d8bac3445859e468a3d048cfaf5_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yMi9mcmFnOjE0YmZlMmE4ZmYxMDRkZTk5MmJlYWMwYWM0MmY1NjA2L3RhYmxlOmZiY2M3NTk2ZDZhZjQ1NjRhYzg2NThhZTA2MjMyMGVjL3RhYmxlcmFuZ2U6ZmJjYzc1OTZkNmFmNDU2NGFjODY1OGFlMDYyMzIwZWNfMjgtMy0xLTEtMjgyMjE_ddf58ccf-0235-435a-8ba3-3b696e2f3013"
      unitRef="usd">16444000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yMi9mcmFnOjE0YmZlMmE4ZmYxMDRkZTk5MmJlYWMwYWM0MmY1NjA2L3RhYmxlOmZiY2M3NTk2ZDZhZjQ1NjRhYzg2NThhZTA2MjMyMGVjL3RhYmxlcmFuZ2U6ZmJjYzc1OTZkNmFmNDU2NGFjODY1OGFlMDYyMzIwZWNfMjktMS0xLTEtMjgyMjE_14fd0ea9-3fb9-4db5-86eb-5979221961fb"
      unitRef="usd">-506000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i0ebb8d8bac3445859e468a3d048cfaf5_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yMi9mcmFnOjE0YmZlMmE4ZmYxMDRkZTk5MmJlYWMwYWM0MmY1NjA2L3RhYmxlOmZiY2M3NTk2ZDZhZjQ1NjRhYzg2NThhZTA2MjMyMGVjL3RhYmxlcmFuZ2U6ZmJjYzc1OTZkNmFmNDU2NGFjODY1OGFlMDYyMzIwZWNfMjktMy0xLTEtMjgyMjE_45676314-a111-47b3-8ba3-b64e367fc8e4"
      unitRef="usd">-45947000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yMi9mcmFnOjE0YmZlMmE4ZmYxMDRkZTk5MmJlYWMwYWM0MmY1NjA2L3RhYmxlOmZiY2M3NTk2ZDZhZjQ1NjRhYzg2NThhZTA2MjMyMGVjL3RhYmxlcmFuZ2U6ZmJjYzc1OTZkNmFmNDU2NGFjODY1OGFlMDYyMzIwZWNfMzAtMS0xLTEtMjgyMjE_43598ba1-d6c7-4fbc-becf-38cb34df8141"
      unitRef="usd">-15755000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i0ebb8d8bac3445859e468a3d048cfaf5_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yMi9mcmFnOjE0YmZlMmE4ZmYxMDRkZTk5MmJlYWMwYWM0MmY1NjA2L3RhYmxlOmZiY2M3NTk2ZDZhZjQ1NjRhYzg2NThhZTA2MjMyMGVjL3RhYmxlcmFuZ2U6ZmJjYzc1OTZkNmFmNDU2NGFjODY1OGFlMDYyMzIwZWNfMzAtMy0xLTEtMjgyMjE_035b80f3-99c7-43e8-a540-d8eb64aa9a36"
      unitRef="usd">-23809000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="iac7c0f0822b942fa8f45ea15693a76af_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yMi9mcmFnOjE0YmZlMmE4ZmYxMDRkZTk5MmJlYWMwYWM0MmY1NjA2L3RhYmxlOmZiY2M3NTk2ZDZhZjQ1NjRhYzg2NThhZTA2MjMyMGVjL3RhYmxlcmFuZ2U6ZmJjYzc1OTZkNmFmNDU2NGFjODY1OGFlMDYyMzIwZWNfMzEtMS0xLTEtMjgyMjE_99ffa09c-55ca-4608-b993-a0351284168a"
      unitRef="usd">77617000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="idf01ece55408406c8103d0d47b49800a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yMi9mcmFnOjE0YmZlMmE4ZmYxMDRkZTk5MmJlYWMwYWM0MmY1NjA2L3RhYmxlOmZiY2M3NTk2ZDZhZjQ1NjRhYzg2NThhZTA2MjMyMGVjL3RhYmxlcmFuZ2U6ZmJjYzc1OTZkNmFmNDU2NGFjODY1OGFlMDYyMzIwZWNfMzEtMy0xLTEtMjgyMjE_51407fdf-bfed-415c-9e00-66332930b03f"
      unitRef="usd">76190000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i93f424f685944c1aab994f99b0146441_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yMi9mcmFnOjE0YmZlMmE4ZmYxMDRkZTk5MmJlYWMwYWM0MmY1NjA2L3RhYmxlOmZiY2M3NTk2ZDZhZjQ1NjRhYzg2NThhZTA2MjMyMGVjL3RhYmxlcmFuZ2U6ZmJjYzc1OTZkNmFmNDU2NGFjODY1OGFlMDYyMzIwZWNfMzItMS0xLTEtMjgyMjE_c0aa1c3f-40c3-4473-9c83-628034f63fde"
      unitRef="usd">61862000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i82ca1385b4a848fd8ea581edd7dcbfdb_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yMi9mcmFnOjE0YmZlMmE4ZmYxMDRkZTk5MmJlYWMwYWM0MmY1NjA2L3RhYmxlOmZiY2M3NTk2ZDZhZjQ1NjRhYzg2NThhZTA2MjMyMGVjL3RhYmxlcmFuZ2U6ZmJjYzc1OTZkNmFmNDU2NGFjODY1OGFlMDYyMzIwZWNfMzItMy0xLTEtMjgyMjE_03d57dbd-ae54-4a4f-b5d7-473ad8fb2979"
      unitRef="usd">52381000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <cort:SharesRepurchasedInNetSettlementOfCashlessOptionExercise
      contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yMi9mcmFnOjE0YmZlMmE4ZmYxMDRkZTk5MmJlYWMwYWM0MmY1NjA2L3RhYmxlOmZiY2M3NTk2ZDZhZjQ1NjRhYzg2NThhZTA2MjMyMGVjL3RhYmxlcmFuZ2U6ZmJjYzc1OTZkNmFmNDU2NGFjODY1OGFlMDYyMzIwZWNfMzUtMS0xLTEtMjgyMjE_06dba241-46e3-4e56-aabc-bf499b68d558"
      unitRef="usd">5149000</cort:SharesRepurchasedInNetSettlementOfCashlessOptionExercise>
    <cort:SharesRepurchasedInNetSettlementOfCashlessOptionExercise
      contextRef="i0ebb8d8bac3445859e468a3d048cfaf5_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yMi9mcmFnOjE0YmZlMmE4ZmYxMDRkZTk5MmJlYWMwYWM0MmY1NjA2L3RhYmxlOmZiY2M3NTk2ZDZhZjQ1NjRhYzg2NThhZTA2MjMyMGVjL3RhYmxlcmFuZ2U6ZmJjYzc1OTZkNmFmNDU2NGFjODY1OGFlMDYyMzIwZWNfMzUtMy0xLTEtMjgyMjE_cede10d8-1f10-4e16-9fe2-d852af38f6c3"
      unitRef="usd">6045000</cort:SharesRepurchasedInNetSettlementOfCashlessOptionExercise>
    <cort:NonCashTransactionRecognitionOfRightOfUseAssetAndLeaseLiability
      contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yMi9mcmFnOjE0YmZlMmE4ZmYxMDRkZTk5MmJlYWMwYWM0MmY1NjA2L3RhYmxlOmZiY2M3NTk2ZDZhZjQ1NjRhYzg2NThhZTA2MjMyMGVjL3RhYmxlcmFuZ2U6ZmJjYzc1OTZkNmFmNDU2NGFjODY1OGFlMDYyMzIwZWNfMzYtMS0xLTEtMzU5NTk_cc3ff20c-3d5c-4c3c-9ae5-4d2f0d270752"
      unitRef="usd">2816000</cort:NonCashTransactionRecognitionOfRightOfUseAssetAndLeaseLiability>
    <cort:NonCashTransactionRecognitionOfRightOfUseAssetAndLeaseLiability
      contextRef="i0ebb8d8bac3445859e468a3d048cfaf5_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yMi9mcmFnOjE0YmZlMmE4ZmYxMDRkZTk5MmJlYWMwYWM0MmY1NjA2L3RhYmxlOmZiY2M3NTk2ZDZhZjQ1NjRhYzg2NThhZTA2MjMyMGVjL3RhYmxlcmFuZ2U6ZmJjYzc1OTZkNmFmNDU2NGFjODY1OGFlMDYyMzIwZWNfMzYtMy0xLTEtMzU5NTk_e3e8b142-0e3a-4157-bc19-41a696bf9c7a"
      unitRef="usd">0</cort:NonCashTransactionRecognitionOfRightOfUseAssetAndLeaseLiability>
    <us-gaap:SharesOutstanding
      contextRef="i5ff8ab6f19e4485da8179e610307bf6f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yNS9mcmFnOmM1YmM1ZTZhMTI5NjQyZGJiZjExYjI1MWYxMjkyOTc4L3RhYmxlOjFiYTMwMzQ5NmYzMzRkOGI4ZTFjN2ZjYjYyMWZkNmIxL3RhYmxlcmFuZ2U6MWJhMzAzNDk2ZjMzNGQ4YjhlMWM3ZmNiNjIxZmQ2YjFfMi0xLTEtMS0yODIyMQ_7c6e9d97-9c5d-4d18-bd97-24a9470b8d9f"
      unitRef="shares">116735000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i5ff8ab6f19e4485da8179e610307bf6f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yNS9mcmFnOmM1YmM1ZTZhMTI5NjQyZGJiZjExYjI1MWYxMjkyOTc4L3RhYmxlOjFiYTMwMzQ5NmYzMzRkOGI4ZTFjN2ZjYjYyMWZkNmIxL3RhYmxlcmFuZ2U6MWJhMzAzNDk2ZjMzNGQ4YjhlMWM3ZmNiNjIxZmQ2YjFfMi0zLTEtMS0yODIyMQ_9a8401bb-9085-4244-8f8a-a38ca36ab0c9"
      unitRef="usd">122000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia2e3456ee78d4b7e862e98401e421964_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yNS9mcmFnOmM1YmM1ZTZhMTI5NjQyZGJiZjExYjI1MWYxMjkyOTc4L3RhYmxlOjFiYTMwMzQ5NmYzMzRkOGI4ZTFjN2ZjYjYyMWZkNmIxL3RhYmxlcmFuZ2U6MWJhMzAzNDk2ZjMzNGQ4YjhlMWM3ZmNiNjIxZmQ2YjFfMi01LTEtMS0yODIyMQ_514aba18-e079-427a-b50c-70c29902a157"
      unitRef="usd">516140000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iead727f3eb2b4b8fadf3c853db5498a8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yNS9mcmFnOmM1YmM1ZTZhMTI5NjQyZGJiZjExYjI1MWYxMjkyOTc4L3RhYmxlOjFiYTMwMzQ5NmYzMzRkOGI4ZTFjN2ZjYjYyMWZkNmIxL3RhYmxlcmFuZ2U6MWJhMzAzNDk2ZjMzNGQ4YjhlMWM3ZmNiNjIxZmQ2YjFfMi03LTEtMS0yODIyMQ_1520ae43-9a5c-4eef-9362-1e7a33482e88"
      unitRef="usd">-75795000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i3c4a2585fb954bd1a1458a2999b7852e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yNS9mcmFnOmM1YmM1ZTZhMTI5NjQyZGJiZjExYjI1MWYxMjkyOTc4L3RhYmxlOjFiYTMwMzQ5NmYzMzRkOGI4ZTFjN2ZjYjYyMWZkNmIxL3RhYmxlcmFuZ2U6MWJhMzAzNDk2ZjMzNGQ4YjhlMWM3ZmNiNjIxZmQ2YjFfMi05LTEtMS0yODIyMQ_748f93b8-64a8-4cfe-b46a-25b13f51572b"
      unitRef="usd">415000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iefe5359585e240dbbfd8196f176fb8d6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yNS9mcmFnOmM1YmM1ZTZhMTI5NjQyZGJiZjExYjI1MWYxMjkyOTc4L3RhYmxlOjFiYTMwMzQ5NmYzMzRkOGI4ZTFjN2ZjYjYyMWZkNmIxL3RhYmxlcmFuZ2U6MWJhMzAzNDk2ZjMzNGQ4YjhlMWM3ZmNiNjIxZmQ2YjFfMi0xMS0xLTEtMjgyMjE_64e9236b-cf02-486e-851d-de3a80f06add"
      unitRef="usd">82456000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="idf01ece55408406c8103d0d47b49800a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yNS9mcmFnOmM1YmM1ZTZhMTI5NjQyZGJiZjExYjI1MWYxMjkyOTc4L3RhYmxlOjFiYTMwMzQ5NmYzMzRkOGI4ZTFjN2ZjYjYyMWZkNmIxL3RhYmxlcmFuZ2U6MWJhMzAzNDk2ZjMzNGQ4YjhlMWM3ZmNiNjIxZmQ2YjFfMi0xMy0xLTEtMjgyMjE_af79423e-93ba-4a33-bc15-fc05d15fdc17"
      unitRef="usd">523338000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ibb5595d6b13d41d2bcc8ba20feea26f6_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yNS9mcmFnOmM1YmM1ZTZhMTI5NjQyZGJiZjExYjI1MWYxMjkyOTc4L3RhYmxlOjFiYTMwMzQ5NmYzMzRkOGI4ZTFjN2ZjYjYyMWZkNmIxL3RhYmxlcmFuZ2U6MWJhMzAzNDk2ZjMzNGQ4YjhlMWM3ZmNiNjIxZmQ2YjFfMy0xLTEtMS0yODIyMQ_4e6dc776-d632-4126-b0a6-3c12a68ccc29"
      unitRef="shares">1832000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ibb5595d6b13d41d2bcc8ba20feea26f6_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yNS9mcmFnOmM1YmM1ZTZhMTI5NjQyZGJiZjExYjI1MWYxMjkyOTc4L3RhYmxlOjFiYTMwMzQ5NmYzMzRkOGI4ZTFjN2ZjYjYyMWZkNmIxL3RhYmxlcmFuZ2U6MWJhMzAzNDk2ZjMzNGQ4YjhlMWM3ZmNiNjIxZmQ2YjFfMy0zLTEtMS0yODIyMQ_3fc580c0-dfa5-498a-9eb1-d1625ffa713c"
      unitRef="usd">2000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i4e7dfdbf5bce4f52bb81937e0ca5ac46_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yNS9mcmFnOmM1YmM1ZTZhMTI5NjQyZGJiZjExYjI1MWYxMjkyOTc4L3RhYmxlOjFiYTMwMzQ5NmYzMzRkOGI4ZTFjN2ZjYjYyMWZkNmIxL3RhYmxlcmFuZ2U6MWJhMzAzNDk2ZjMzNGQ4YjhlMWM3ZmNiNjIxZmQ2YjFfMy01LTEtMS0yODIyMQ_a2ee2489-c72a-42a6-9083-3edf42312e79"
      unitRef="usd">10081000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i0ebb8d8bac3445859e468a3d048cfaf5_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yNS9mcmFnOmM1YmM1ZTZhMTI5NjQyZGJiZjExYjI1MWYxMjkyOTc4L3RhYmxlOjFiYTMwMzQ5NmYzMzRkOGI4ZTFjN2ZjYjYyMWZkNmIxL3RhYmxlcmFuZ2U6MWJhMzAzNDk2ZjMzNGQ4YjhlMWM3ZmNiNjIxZmQ2YjFfMy0xMy0xLTEtMjgyMjE_6a121a95-1242-4be1-b6a6-6aec82154fb9"
      unitRef="usd">10083000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="ibb5595d6b13d41d2bcc8ba20feea26f6_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yNS9mcmFnOmM1YmM1ZTZhMTI5NjQyZGJiZjExYjI1MWYxMjkyOTc4L3RhYmxlOjFiYTMwMzQ5NmYzMzRkOGI4ZTFjN2ZjYjYyMWZkNmIxL3RhYmxlcmFuZ2U6MWJhMzAzNDk2ZjMzNGQ4YjhlMWM3ZmNiNjIxZmQ2YjFfNC0xLTEtMS0yODIyMQ_6525ac13-e7b1-495c-bbb6-817d82d6f812"
      unitRef="shares">1282000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i3e50c96f60264b66aa29d189127a2f73_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yNS9mcmFnOmM1YmM1ZTZhMTI5NjQyZGJiZjExYjI1MWYxMjkyOTc4L3RhYmxlOjFiYTMwMzQ5NmYzMzRkOGI4ZTFjN2ZjYjYyMWZkNmIxL3RhYmxlcmFuZ2U6MWJhMzAzNDk2ZjMzNGQ4YjhlMWM3ZmNiNjIxZmQ2YjFfNC03LTEtMS0yODIyMQ_f951f951-5700-44dc-a93f-54e227c55216"
      unitRef="usd">33540000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i0ebb8d8bac3445859e468a3d048cfaf5_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yNS9mcmFnOmM1YmM1ZTZhMTI5NjQyZGJiZjExYjI1MWYxMjkyOTc4L3RhYmxlOjFiYTMwMzQ5NmYzMzRkOGI4ZTFjN2ZjYjYyMWZkNmIxL3RhYmxlcmFuZ2U6MWJhMzAzNDk2ZjMzNGQ4YjhlMWM3ZmNiNjIxZmQ2YjFfNC0xMy0xLTEtMjgyMjE_c0e76f14-c870-4155-88cb-cad263b10a9f"
      unitRef="usd">33540000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation
      contextRef="ibb5595d6b13d41d2bcc8ba20feea26f6_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yNS9mcmFnOmM1YmM1ZTZhMTI5NjQyZGJiZjExYjI1MWYxMjkyOTc4L3RhYmxlOjFiYTMwMzQ5NmYzMzRkOGI4ZTFjN2ZjYjYyMWZkNmIxL3RhYmxlcmFuZ2U6MWJhMzAzNDk2ZjMzNGQ4YjhlMWM3ZmNiNjIxZmQ2YjFfNS0xLTEtMS0zMTI3OA_029aafec-4e78-461b-a114-5e681c32ad1d"
      unitRef="shares">808000</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i3e50c96f60264b66aa29d189127a2f73_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yNS9mcmFnOmM1YmM1ZTZhMTI5NjQyZGJiZjExYjI1MWYxMjkyOTc4L3RhYmxlOjFiYTMwMzQ5NmYzMzRkOGI4ZTFjN2ZjYjYyMWZkNmIxL3RhYmxlcmFuZ2U6MWJhMzAzNDk2ZjMzNGQ4YjhlMWM3ZmNiNjIxZmQ2YjFfNS03LTEtMS0zMTI3OA_8975ca5c-9ca1-4a02-a08c-392ff3f34db9"
      unitRef="usd">22520000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i0ebb8d8bac3445859e468a3d048cfaf5_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yNS9mcmFnOmM1YmM1ZTZhMTI5NjQyZGJiZjExYjI1MWYxMjkyOTc4L3RhYmxlOjFiYTMwMzQ5NmYzMzRkOGI4ZTFjN2ZjYjYyMWZkNmIxL3RhYmxlcmFuZ2U6MWJhMzAzNDk2ZjMzNGQ4YjhlMWM3ZmNiNjIxZmQ2YjFfNS0xMy0xLTEtMzEyNzg_6687cd5d-a01d-4cd3-ae89-975076fd7a68"
      unitRef="usd">22520000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i4e7dfdbf5bce4f52bb81937e0ca5ac46_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yNS9mcmFnOmM1YmM1ZTZhMTI5NjQyZGJiZjExYjI1MWYxMjkyOTc4L3RhYmxlOjFiYTMwMzQ5NmYzMzRkOGI4ZTFjN2ZjYjYyMWZkNmIxL3RhYmxlcmFuZ2U6MWJhMzAzNDk2ZjMzNGQ4YjhlMWM3ZmNiNjIxZmQ2YjFfNS01LTEtMS0yODIyMQ_62596c26-d409-4281-b806-527e3dc7d881"
      unitRef="usd">10142000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i0ebb8d8bac3445859e468a3d048cfaf5_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yNS9mcmFnOmM1YmM1ZTZhMTI5NjQyZGJiZjExYjI1MWYxMjkyOTc4L3RhYmxlOjFiYTMwMzQ5NmYzMzRkOGI4ZTFjN2ZjYjYyMWZkNmIxL3RhYmxlcmFuZ2U6MWJhMzAzNDk2ZjMzNGQ4YjhlMWM3ZmNiNjIxZmQ2YjFfNS0xMy0xLTEtMjgyMjE_040e54ee-65d9-4f76-9815-98d8e7de9132"
      unitRef="usd">10142000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="i785869b1921844f2925c8f4fcaf4ba3c_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yNS9mcmFnOmM1YmM1ZTZhMTI5NjQyZGJiZjExYjI1MWYxMjkyOTc4L3RhYmxlOjFiYTMwMzQ5NmYzMzRkOGI4ZTFjN2ZjYjYyMWZkNmIxL3RhYmxlcmFuZ2U6MWJhMzAzNDk2ZjMzNGQ4YjhlMWM3ZmNiNjIxZmQ2YjFfNi05LTEtMS0yODIyMQ_341049fb-08ff-42c5-a40c-016c7048bc98"
      unitRef="usd">-166000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="i0ebb8d8bac3445859e468a3d048cfaf5_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yNS9mcmFnOmM1YmM1ZTZhMTI5NjQyZGJiZjExYjI1MWYxMjkyOTc4L3RhYmxlOjFiYTMwMzQ5NmYzMzRkOGI4ZTFjN2ZjYjYyMWZkNmIxL3RhYmxlcmFuZ2U6MWJhMzAzNDk2ZjMzNGQ4YjhlMWM3ZmNiNjIxZmQ2YjFfNi0xMy0xLTEtMjgyMjE_edd5022b-eafa-48e9-b55f-7152c88c2735"
      unitRef="usd">-166000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i56ca5c5bdd7045309e1ff91b29ed0b86_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yNS9mcmFnOmM1YmM1ZTZhMTI5NjQyZGJiZjExYjI1MWYxMjkyOTc4L3RhYmxlOjFiYTMwMzQ5NmYzMzRkOGI4ZTFjN2ZjYjYyMWZkNmIxL3RhYmxlcmFuZ2U6MWJhMzAzNDk2ZjMzNGQ4YjhlMWM3ZmNiNjIxZmQ2YjFfNy0xMS0xLTEtMjgyMjE_8c9517fb-d18b-41d9-a5cf-11dfcb499de4"
      unitRef="usd">23465000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i0ebb8d8bac3445859e468a3d048cfaf5_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yNS9mcmFnOmM1YmM1ZTZhMTI5NjQyZGJiZjExYjI1MWYxMjkyOTc4L3RhYmxlOjFiYTMwMzQ5NmYzMzRkOGI4ZTFjN2ZjYjYyMWZkNmIxL3RhYmxlcmFuZ2U6MWJhMzAzNDk2ZjMzNGQ4YjhlMWM3ZmNiNjIxZmQ2YjFfNy0xMy0xLTEtMjgyMjE_56743350-7e56-4c65-bcd2-f32c5239092a"
      unitRef="usd">23465000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i9a1952ba686644179308d0cef13927e8_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yNS9mcmFnOmM1YmM1ZTZhMTI5NjQyZGJiZjExYjI1MWYxMjkyOTc4L3RhYmxlOjFiYTMwMzQ5NmYzMzRkOGI4ZTFjN2ZjYjYyMWZkNmIxL3RhYmxlcmFuZ2U6MWJhMzAzNDk2ZjMzNGQ4YjhlMWM3ZmNiNjIxZmQ2YjFfOC0xLTEtMS0yODIyMQ_6dabf6ef-aa83-474c-8ebd-e6f1bde6f94b"
      unitRef="shares">116477000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i9a1952ba686644179308d0cef13927e8_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yNS9mcmFnOmM1YmM1ZTZhMTI5NjQyZGJiZjExYjI1MWYxMjkyOTc4L3RhYmxlOjFiYTMwMzQ5NmYzMzRkOGI4ZTFjN2ZjYjYyMWZkNmIxL3RhYmxlcmFuZ2U6MWJhMzAzNDk2ZjMzNGQ4YjhlMWM3ZmNiNjIxZmQ2YjFfOC0zLTEtMS0yODIyMQ_ac0d6f54-08b5-4742-a0b7-2e2921f85b3e"
      unitRef="usd">124000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i20c028d8e2514f38962d2bb482734e70_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yNS9mcmFnOmM1YmM1ZTZhMTI5NjQyZGJiZjExYjI1MWYxMjkyOTc4L3RhYmxlOjFiYTMwMzQ5NmYzMzRkOGI4ZTFjN2ZjYjYyMWZkNmIxL3RhYmxlcmFuZ2U6MWJhMzAzNDk2ZjMzNGQ4YjhlMWM3ZmNiNjIxZmQ2YjFfOC01LTEtMS0yODIyMQ_bf14ddbd-ad35-4bcf-8c8c-72307f78fe20"
      unitRef="usd">536363000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i4202ad56ab444c9cb8f35568184c2c74_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yNS9mcmFnOmM1YmM1ZTZhMTI5NjQyZGJiZjExYjI1MWYxMjkyOTc4L3RhYmxlOjFiYTMwMzQ5NmYzMzRkOGI4ZTFjN2ZjYjYyMWZkNmIxL3RhYmxlcmFuZ2U6MWJhMzAzNDk2ZjMzNGQ4YjhlMWM3ZmNiNjIxZmQ2YjFfOC03LTEtMS0yODIyMQ_5622a65d-c240-4608-a1c2-058871f70417"
      unitRef="usd">-131855000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i73577ab94ef744cb885730e8ac822b29_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yNS9mcmFnOmM1YmM1ZTZhMTI5NjQyZGJiZjExYjI1MWYxMjkyOTc4L3RhYmxlOjFiYTMwMzQ5NmYzMzRkOGI4ZTFjN2ZjYjYyMWZkNmIxL3RhYmxlcmFuZ2U6MWJhMzAzNDk2ZjMzNGQ4YjhlMWM3ZmNiNjIxZmQ2YjFfOC05LTEtMS0yODIyMQ_3c8f2cd3-76ca-4f4f-aa23-21d1ca645cb5"
      unitRef="usd">249000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib16bf7702efd44cdbe57df570c7d75fb_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yNS9mcmFnOmM1YmM1ZTZhMTI5NjQyZGJiZjExYjI1MWYxMjkyOTc4L3RhYmxlOjFiYTMwMzQ5NmYzMzRkOGI4ZTFjN2ZjYjYyMWZkNmIxL3RhYmxlcmFuZ2U6MWJhMzAzNDk2ZjMzNGQ4YjhlMWM3ZmNiNjIxZmQ2YjFfOC0xMS0xLTEtMjgyMjE_d2109268-1a97-4476-964a-056188d2eb3c"
      unitRef="usd">105921000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i82ca1385b4a848fd8ea581edd7dcbfdb_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yNS9mcmFnOmM1YmM1ZTZhMTI5NjQyZGJiZjExYjI1MWYxMjkyOTc4L3RhYmxlOjFiYTMwMzQ5NmYzMzRkOGI4ZTFjN2ZjYjYyMWZkNmIxL3RhYmxlcmFuZ2U6MWJhMzAzNDk2ZjMzNGQ4YjhlMWM3ZmNiNjIxZmQ2YjFfOC0xMy0xLTEtMjgyMjE_c45f4cea-6601-4f4a-803a-b7011a5d9846"
      unitRef="usd">510802000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="icfafed6603474886b192b0632a2c6200_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yNS9mcmFnOmM1YmM1ZTZhMTI5NjQyZGJiZjExYjI1MWYxMjkyOTc4L3RhYmxlOjFiYTMwMzQ5NmYzMzRkOGI4ZTFjN2ZjYjYyMWZkNmIxL3RhYmxlcmFuZ2U6MWJhMzAzNDk2ZjMzNGQ4YjhlMWM3ZmNiNjIxZmQ2YjFfMTAtMS0xLTEtMjgyMjE_b1c17722-a354-429e-95b1-4c44efa0461c"
      unitRef="shares">105940000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="icfafed6603474886b192b0632a2c6200_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yNS9mcmFnOmM1YmM1ZTZhMTI5NjQyZGJiZjExYjI1MWYxMjkyOTc4L3RhYmxlOjFiYTMwMzQ5NmYzMzRkOGI4ZTFjN2ZjYjYyMWZkNmIxL3RhYmxlcmFuZ2U6MWJhMzAzNDk2ZjMzNGQ4YjhlMWM3ZmNiNjIxZmQ2YjFfMTAtMy0xLTEtMjgyMjE_6a80e682-e1d0-44e8-a759-c9ab9ce1edb9"
      unitRef="usd">127000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i01f702e8e03c41358b69877f0f51d991_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yNS9mcmFnOmM1YmM1ZTZhMTI5NjQyZGJiZjExYjI1MWYxMjkyOTc4L3RhYmxlOjFiYTMwMzQ5NmYzMzRkOGI4ZTFjN2ZjYjYyMWZkNmIxL3RhYmxlcmFuZ2U6MWJhMzAzNDk2ZjMzNGQ4YjhlMWM3ZmNiNjIxZmQ2YjFfMTAtNS0xLTEtMjgyMjE_0a392857-546f-4757-917b-5c51687bfde5"
      unitRef="usd">591349000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6c9d9c7004234ed49109777c938ab2ce_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yNS9mcmFnOmM1YmM1ZTZhMTI5NjQyZGJiZjExYjI1MWYxMjkyOTc4L3RhYmxlOjFiYTMwMzQ5NmYzMzRkOGI4ZTFjN2ZjYjYyMWZkNmIxL3RhYmxlcmFuZ2U6MWJhMzAzNDk2ZjMzNGQ4YjhlMWM3ZmNiNjIxZmQ2YjFfMTAtNy0xLTEtMjgyMjE_18dac129-859e-4cd4-85e4-117e9823c31a"
      unitRef="usd">-410411000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i8b5fa79d20ab4ee28c43d8f3802fba08_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yNS9mcmFnOmM1YmM1ZTZhMTI5NjQyZGJiZjExYjI1MWYxMjkyOTc4L3RhYmxlOjFiYTMwMzQ5NmYzMzRkOGI4ZTFjN2ZjYjYyMWZkNmIxL3RhYmxlcmFuZ2U6MWJhMzAzNDk2ZjMzNGQ4YjhlMWM3ZmNiNjIxZmQ2YjFfMTAtOS0xLTEtMjgyMjE_83ff1c27-de4e-497e-bb0f-71a15ae03efd"
      unitRef="usd">-227000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia7ed3ef4514f42b8bd6ae955926a1ea8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yNS9mcmFnOmM1YmM1ZTZhMTI5NjQyZGJiZjExYjI1MWYxMjkyOTc4L3RhYmxlOjFiYTMwMzQ5NmYzMzRkOGI4ZTFjN2ZjYjYyMWZkNmIxL3RhYmxlcmFuZ2U6MWJhMzAzNDk2ZjMzNGQ4YjhlMWM3ZmNiNjIxZmQ2YjFfMTAtMTEtMS0xLTI4MjIx_c2f3565f-d827-4891-83b6-b472de103c64"
      unitRef="usd">194968000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iac7c0f0822b942fa8f45ea15693a76af_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yNS9mcmFnOmM1YmM1ZTZhMTI5NjQyZGJiZjExYjI1MWYxMjkyOTc4L3RhYmxlOjFiYTMwMzQ5NmYzMzRkOGI4ZTFjN2ZjYjYyMWZkNmIxL3RhYmxlcmFuZ2U6MWJhMzAzNDk2ZjMzNGQ4YjhlMWM3ZmNiNjIxZmQ2YjFfMTAtMTMtMS0xLTI4MjIx_3a90785a-e782-46b4-8968-f5242c821296"
      unitRef="usd">375806000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i0f04c1d847904902a0065f4c9a444cf1_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yNS9mcmFnOmM1YmM1ZTZhMTI5NjQyZGJiZjExYjI1MWYxMjkyOTc4L3RhYmxlOjFiYTMwMzQ5NmYzMzRkOGI4ZTFjN2ZjYjYyMWZkNmIxL3RhYmxlcmFuZ2U6MWJhMzAzNDk2ZjMzNGQ4YjhlMWM3ZmNiNjIxZmQ2YjFfMTEtMS0xLTEtMjgyMjE_97c384f9-8fd0-4f03-9000-8358991bf0a2"
      unitRef="shares">586000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i0f04c1d847904902a0065f4c9a444cf1_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yNS9mcmFnOmM1YmM1ZTZhMTI5NjQyZGJiZjExYjI1MWYxMjkyOTc4L3RhYmxlOjFiYTMwMzQ5NmYzMzRkOGI4ZTFjN2ZjYjYyMWZkNmIxL3RhYmxlcmFuZ2U6MWJhMzAzNDk2ZjMzNGQ4YjhlMWM3ZmNiNjIxZmQ2YjFfMTEtMy0xLTEtMjgyMjE_83a03cca-8c48-4ec7-948a-9c012e0cc73b"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i1687f4482d3249aa9d6829a5eabaa2b3_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yNS9mcmFnOmM1YmM1ZTZhMTI5NjQyZGJiZjExYjI1MWYxMjkyOTc4L3RhYmxlOjFiYTMwMzQ5NmYzMzRkOGI4ZTFjN2ZjYjYyMWZkNmIxL3RhYmxlcmFuZ2U6MWJhMzAzNDk2ZjMzNGQ4YjhlMWM3ZmNiNjIxZmQ2YjFfMTEtNS0xLTEtMjgyMjE_8f2f8f4c-f6ba-4397-affb-fb47851a0769"
      unitRef="usd">6543000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yNS9mcmFnOmM1YmM1ZTZhMTI5NjQyZGJiZjExYjI1MWYxMjkyOTc4L3RhYmxlOjFiYTMwMzQ5NmYzMzRkOGI4ZTFjN2ZjYjYyMWZkNmIxL3RhYmxlcmFuZ2U6MWJhMzAzNDk2ZjMzNGQ4YjhlMWM3ZmNiNjIxZmQ2YjFfMTEtMTMtMS0xLTI4MjIx_f8e6f14a-3db7-4092-86ae-377d938d6856"
      unitRef="usd">6544000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation
      contextRef="i0f04c1d847904902a0065f4c9a444cf1_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yNS9mcmFnOmM1YmM1ZTZhMTI5NjQyZGJiZjExYjI1MWYxMjkyOTc4L3RhYmxlOjFiYTMwMzQ5NmYzMzRkOGI4ZTFjN2ZjYjYyMWZkNmIxL3RhYmxlcmFuZ2U6MWJhMzAzNDk2ZjMzNGQ4YjhlMWM3ZmNiNjIxZmQ2YjFfMTMtMS0xLTEtMjgyMjE_4a4a293a-0d26-4b18-a8f4-1d4bf0679e86"
      unitRef="shares">305000</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i6208146b7098480389c1e89596396c07_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yNS9mcmFnOmM1YmM1ZTZhMTI5NjQyZGJiZjExYjI1MWYxMjkyOTc4L3RhYmxlOjFiYTMwMzQ5NmYzMzRkOGI4ZTFjN2ZjYjYyMWZkNmIxL3RhYmxlcmFuZ2U6MWJhMzAzNDk2ZjMzNGQ4YjhlMWM3ZmNiNjIxZmQ2YjFfMTMtNy0xLTEtMjgyMjE_4d122151-cf4c-42e1-8eee-714ee4946329"
      unitRef="usd">7037000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yNS9mcmFnOmM1YmM1ZTZhMTI5NjQyZGJiZjExYjI1MWYxMjkyOTc4L3RhYmxlOjFiYTMwMzQ5NmYzMzRkOGI4ZTFjN2ZjYjYyMWZkNmIxL3RhYmxlcmFuZ2U6MWJhMzAzNDk2ZjMzNGQ4YjhlMWM3ZmNiNjIxZmQ2YjFfMTMtMTMtMS0xLTI4MjIx_b5037f49-dd06-442d-b19b-8701fefc0297"
      unitRef="usd">7037000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i1687f4482d3249aa9d6829a5eabaa2b3_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yNS9mcmFnOmM1YmM1ZTZhMTI5NjQyZGJiZjExYjI1MWYxMjkyOTc4L3RhYmxlOjFiYTMwMzQ5NmYzMzRkOGI4ZTFjN2ZjYjYyMWZkNmIxL3RhYmxlcmFuZ2U6MWJhMzAzNDk2ZjMzNGQ4YjhlMWM3ZmNiNjIxZmQ2YjFfMTQtNS0xLTEtMjgyMjE_e59e0939-c2a3-450a-ae43-89c13ea44b65"
      unitRef="usd">10825000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yNS9mcmFnOmM1YmM1ZTZhMTI5NjQyZGJiZjExYjI1MWYxMjkyOTc4L3RhYmxlOjFiYTMwMzQ5NmYzMzRkOGI4ZTFjN2ZjYjYyMWZkNmIxL3RhYmxlcmFuZ2U6MWJhMzAzNDk2ZjMzNGQ4YjhlMWM3ZmNiNjIxZmQ2YjFfMTQtMTMtMS0xLTI4MjIx_ee5b9259-0cc8-4a26-bf67-cc6eb7af6a4d"
      unitRef="usd">10825000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="i46f01246740a46a892ddb27be4dd69aa_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yNS9mcmFnOmM1YmM1ZTZhMTI5NjQyZGJiZjExYjI1MWYxMjkyOTc4L3RhYmxlOjFiYTMwMzQ5NmYzMzRkOGI4ZTFjN2ZjYjYyMWZkNmIxL3RhYmxlcmFuZ2U6MWJhMzAzNDk2ZjMzNGQ4YjhlMWM3ZmNiNjIxZmQ2YjFfMTUtOS0xLTEtMjgyMjE_89987c4b-137b-4227-83f6-74625025c14e"
      unitRef="usd">-1124000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yNS9mcmFnOmM1YmM1ZTZhMTI5NjQyZGJiZjExYjI1MWYxMjkyOTc4L3RhYmxlOjFiYTMwMzQ5NmYzMzRkOGI4ZTFjN2ZjYjYyMWZkNmIxL3RhYmxlcmFuZ2U6MWJhMzAzNDk2ZjMzNGQ4YjhlMWM3ZmNiNjIxZmQ2YjFfMTUtMTMtMS0xLTI4MjIx_14cb3900-a058-461a-8de9-50ced5ab8366"
      unitRef="usd">-1124000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i583bb074d98646df863c37e27250f660_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yNS9mcmFnOmM1YmM1ZTZhMTI5NjQyZGJiZjExYjI1MWYxMjkyOTc4L3RhYmxlOjFiYTMwMzQ5NmYzMzRkOGI4ZTFjN2ZjYjYyMWZkNmIxL3RhYmxlcmFuZ2U6MWJhMzAzNDk2ZjMzNGQ4YjhlMWM3ZmNiNjIxZmQ2YjFfMTYtMTEtMS0xLTI4MjIx_53f4a467-4af8-40f5-9155-f043a3a8d86a"
      unitRef="usd">22797000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yNS9mcmFnOmM1YmM1ZTZhMTI5NjQyZGJiZjExYjI1MWYxMjkyOTc4L3RhYmxlOjFiYTMwMzQ5NmYzMzRkOGI4ZTFjN2ZjYjYyMWZkNmIxL3RhYmxlcmFuZ2U6MWJhMzAzNDk2ZjMzNGQ4YjhlMWM3ZmNiNjIxZmQ2YjFfMTYtMTMtMS0xLTI4MjIx_959e18e3-68b8-46a8-a22e-ce4839a408ff"
      unitRef="usd">22797000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i06b129367f5c4d9ab7b570f6972b2ed1_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yNS9mcmFnOmM1YmM1ZTZhMTI5NjQyZGJiZjExYjI1MWYxMjkyOTc4L3RhYmxlOjFiYTMwMzQ5NmYzMzRkOGI4ZTFjN2ZjYjYyMWZkNmIxL3RhYmxlcmFuZ2U6MWJhMzAzNDk2ZjMzNGQ4YjhlMWM3ZmNiNjIxZmQ2YjFfMTctMS0xLTEtMjgyMjE_62aff1ca-6618-4e6d-9daa-e39689a14233"
      unitRef="shares">106221000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i06b129367f5c4d9ab7b570f6972b2ed1_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yNS9mcmFnOmM1YmM1ZTZhMTI5NjQyZGJiZjExYjI1MWYxMjkyOTc4L3RhYmxlOjFiYTMwMzQ5NmYzMzRkOGI4ZTFjN2ZjYjYyMWZkNmIxL3RhYmxlcmFuZ2U6MWJhMzAzNDk2ZjMzNGQ4YjhlMWM3ZmNiNjIxZmQ2YjFfMTctMy0xLTEtMjgyMjE_b9142781-ff0c-42a3-ab6c-e9be33328c3c"
      unitRef="usd">128000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i47740de74c10439fbf11f8788c4cba45_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yNS9mcmFnOmM1YmM1ZTZhMTI5NjQyZGJiZjExYjI1MWYxMjkyOTc4L3RhYmxlOjFiYTMwMzQ5NmYzMzRkOGI4ZTFjN2ZjYjYyMWZkNmIxL3RhYmxlcmFuZ2U6MWJhMzAzNDk2ZjMzNGQ4YjhlMWM3ZmNiNjIxZmQ2YjFfMTctNS0xLTEtMjgyMjE_9122f2a8-6ef3-4d43-bc3a-034db49bfeac"
      unitRef="usd">608717000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5f57f8164f0a46daacc1c2551a60659f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yNS9mcmFnOmM1YmM1ZTZhMTI5NjQyZGJiZjExYjI1MWYxMjkyOTc4L3RhYmxlOjFiYTMwMzQ5NmYzMzRkOGI4ZTFjN2ZjYjYyMWZkNmIxL3RhYmxlcmFuZ2U6MWJhMzAzNDk2ZjMzNGQ4YjhlMWM3ZmNiNjIxZmQ2YjFfMTctNy0xLTEtMjgyMjE_d5d83358-864f-4283-bd80-046a0e2cafbd"
      unitRef="usd">-417448000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic45e1a7a754a469fa7d8a3ad69b13727_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yNS9mcmFnOmM1YmM1ZTZhMTI5NjQyZGJiZjExYjI1MWYxMjkyOTc4L3RhYmxlOjFiYTMwMzQ5NmYzMzRkOGI4ZTFjN2ZjYjYyMWZkNmIxL3RhYmxlcmFuZ2U6MWJhMzAzNDk2ZjMzNGQ4YjhlMWM3ZmNiNjIxZmQ2YjFfMTctOS0xLTEtMjgyMjE_2637180c-305b-4f54-8960-86feb629ae17"
      unitRef="usd">-1351000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i75024e565e314398a3b2b50b649c5486_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yNS9mcmFnOmM1YmM1ZTZhMTI5NjQyZGJiZjExYjI1MWYxMjkyOTc4L3RhYmxlOjFiYTMwMzQ5NmYzMzRkOGI4ZTFjN2ZjYjYyMWZkNmIxL3RhYmxlcmFuZ2U6MWJhMzAzNDk2ZjMzNGQ4YjhlMWM3ZmNiNjIxZmQ2YjFfMTctMTEtMS0xLTI4MjIx_a53f27bf-cfa1-40a0-b145-c909a6323b44"
      unitRef="usd">217765000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i93f424f685944c1aab994f99b0146441_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8yNS9mcmFnOmM1YmM1ZTZhMTI5NjQyZGJiZjExYjI1MWYxMjkyOTc4L3RhYmxlOjFiYTMwMzQ5NmYzMzRkOGI4ZTFjN2ZjYjYyMWZkNmIxL3RhYmxlcmFuZ2U6MWJhMzAzNDk2ZjMzNGQ4YjhlMWM3ZmNiNjIxZmQ2YjFfMTctMTMtMS0xLTI4MjIx_c8949280-0c87-4027-a557-598e8e911a16"
      unitRef="usd">407811000</us-gaap:StockholdersEquity>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock
      contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zMS9mcmFnOjE4Y2EyYjU1ODFkZjQzZmNhZWY1M2QyMWU1YzkyOGMzL3RleHRyZWdpb246MThjYTJiNTU4MWRmNDNmY2FlZjUzZDIxZTVjOTI4YzNfMjg2NA_28e216a4-3f65-421a-a105-341d13e75478">Basis of Presentation and Summary of Significant Accounting Policies&lt;div style="margin-top:9pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Description of Business and Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Corcept Therapeutics Incorporated is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe endocrine, metabolic, oncologic, and neurological disorders by modulating the effects of the hormone cortisol.&#160;In 2012, the United States Food and Drug Administration (&#x201c;FDA&#x201d;) approved Korlym&#160;(&#x201c;mifepristone&#x201d;) 300&#160;mg tablets, as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing&#x2019;s syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. We have discovered&#160;and patented four&#160;structurally distinct series of selective cortisol modulators, consisting of more than&#160;1,000&#160;compounds. We are developing compounds from these series as potential treatments for a broad range of serious disorders.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We were incorporated in the State of&#160;Delaware&#160;in&#160;May 1998. Our headquarters are located in Menlo Park, California.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have prepared the following in accordance with U.S. generally accepted accounting principles (&#x201c;GAAP&#x201d;) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X: (i) condensed consolidated balance sheet as of March&#160;31, 2022 and (ii) condensed consolidated statements of comprehensive income, cash flows and stockholders&#x2019; equity for the three-month periods ended March&#160;31, 2022 and 2021. These do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments considered necessary for a fair presentation (which in the applicable periods consist only of normal, recurring adjustments) have been included. Operating results for the three months ended March 31, 2022 are not necessarily indicative of the results for the remainder of 2022 or any other period. These financial statements and notes should be read in conjunction with the financial statements for the year ended December&#160;31, 2021 included in our Annual Report on Form 10-K. The December&#160;31, 2021 balance sheet was derived from audited financial statements at that date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There have been no material changes to the significant accounting policies described in our Annual Report on Form&#160;10-K for the year ended&#160;December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <cort:NumberOfSeriesOfSelectiveCortisolModulators
      contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zMS9mcmFnOjE4Y2EyYjU1ODFkZjQzZmNhZWY1M2QyMWU1YzkyOGMzL3RleHRyZWdpb246MThjYTJiNTU4MWRmNDNmY2FlZjUzZDIxZTVjOTI4YzNfNzY2_acdf09b1-2fd9-4fa4-b4d7-0aa9f6f4ea36"
      unitRef="series">4</cort:NumberOfSeriesOfSelectiveCortisolModulators>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zMS9mcmFnOjE4Y2EyYjU1ODFkZjQzZmNhZWY1M2QyMWU1YzkyOGMzL3RleHRyZWdpb246MThjYTJiNTU4MWRmNDNmY2FlZjUzZDIxZTVjOTI4YzNfMjg0OA_210f8c6c-ad72-4d6a-b382-3d0ffe376b54">&lt;div style="margin-top:9pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have prepared the following in accordance with U.S. generally accepted accounting principles (&#x201c;GAAP&#x201d;) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X: (i) condensed consolidated balance sheet as of March&#160;31, 2022 and (ii) condensed consolidated statements of comprehensive income, cash flows and stockholders&#x2019; equity for the three-month periods ended March&#160;31, 2022 and 2021. These do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments considered necessary for a fair presentation (which in the applicable periods consist only of normal, recurring adjustments) have been included. Operating results for the three months ended March 31, 2022 are not necessarily indicative of the results for the remainder of 2022 or any other period. These financial statements and notes should be read in conjunction with the financial statements for the year ended December&#160;31, 2021 included in our Annual Report on Form 10-K. The December&#160;31, 2021 balance sheet was derived from audited financial statements at that date.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock
      contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNC9mcmFnOjJjMDM1ZTVhYzJjNDQwN2U4NzM5NmY1YjU2ZDg1NWVkL3RleHRyZWdpb246MmMwMzVlNWFjMmM0NDA3ZTg3Mzk2ZjViNTZkODU1ZWRfNTEz_f7ff9c4b-9689-484a-8969-a79bf1e1626d">Composition of Certain Balance Sheet Items&lt;div style="margin-top:9pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Inventory&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.028%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work in progress&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,637&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inventory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less strategic inventory classified as non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,098)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,962)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inventory classified as current&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,079&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,988&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Because we rely on a single manufacturer to produce Korlym&#x2019;s active pharmaceutical ingredient (&#x201c;API&#x201d;), we have purchased and hold significant quantities of API, included in work in progress inventory. We classify inventory we do not expect to sell within 12 months of the balance sheet date as &#x201c;Strategic Inventory,&#x201d; a long-term asset.&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Property and equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,939&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,927&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,213)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,925)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, net of accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,002&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accrued and other liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government rebates&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued income taxes payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,523&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,968&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Legal fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,802&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;842&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued selling and marketing costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;861&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Professional fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;652&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total accrued and other liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,660&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2022 and December&#160;31, 2021, other assets included $2.8 million and $2.9 million of deposits for clinical trials, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNC9mcmFnOjJjMDM1ZTVhYzJjNDQwN2U4NzM5NmY1YjU2ZDg1NWVkL3RleHRyZWdpb246MmMwMzVlNWFjMmM0NDA3ZTg3Mzk2ZjViNTZkODU1ZWRfNTAz_5597066b-f438-4408-a651-1a175c0006d1">&lt;div style="margin-top:9pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Inventory&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.028%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work in progress&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,637&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inventory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less strategic inventory classified as non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,098)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,962)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inventory classified as current&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,079&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,988&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:ScheduleOfInventoryNoncurrentTableTextBlock
      contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNC9mcmFnOjJjMDM1ZTVhYzJjNDQwN2U4NzM5NmY1YjU2ZDg1NWVkL3RleHRyZWdpb246MmMwMzVlNWFjMmM0NDA3ZTg3Mzk2ZjViNTZkODU1ZWRfNTAz_9327322b-f5d6-4dee-a3d9-0857ca0840a6">&lt;div style="margin-top:9pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Inventory&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.028%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work in progress&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,637&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inventory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less strategic inventory classified as non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,098)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,962)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inventory classified as current&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,079&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,988&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryNoncurrentTableTextBlock>
    <cort:InventoryWorkInProcessCurrentAndNoncurrent
      contextRef="i93f424f685944c1aab994f99b0146441_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNC9mcmFnOjJjMDM1ZTVhYzJjNDQwN2U4NzM5NmY1YjU2ZDg1NWVkL3RhYmxlOjNmYjFhM2JiMjc2MTQ3NGY4NTNmNDRiZjY0ZDc2YTg3L3RhYmxlcmFuZ2U6M2ZiMWEzYmIyNzYxNDc0Zjg1M2Y0NGJmNjRkNzZhODdfNC0xLTEtMS0yODIyMQ_9a688ad4-d31d-46a4-a24a-7978c625c3d5"
      unitRef="usd">12637000</cort:InventoryWorkInProcessCurrentAndNoncurrent>
    <cort:InventoryWorkInProcessCurrentAndNoncurrent
      contextRef="iac7c0f0822b942fa8f45ea15693a76af_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNC9mcmFnOjJjMDM1ZTVhYzJjNDQwN2U4NzM5NmY1YjU2ZDg1NWVkL3RhYmxlOjNmYjFhM2JiMjc2MTQ3NGY4NTNmNDRiZjY0ZDc2YTg3L3RhYmxlcmFuZ2U6M2ZiMWEzYmIyNzYxNDc0Zjg1M2Y0NGJmNjRkNzZhODdfNC0zLTEtMS0yODIyMQ_c3d4a1fc-8c75-48b4-a070-245396d625e2"
      unitRef="usd">11450000</cort:InventoryWorkInProcessCurrentAndNoncurrent>
    <cort:InventoryFinishedGoodsCurrentAndNoncurrent
      contextRef="i93f424f685944c1aab994f99b0146441_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNC9mcmFnOjJjMDM1ZTVhYzJjNDQwN2U4NzM5NmY1YjU2ZDg1NWVkL3RhYmxlOjNmYjFhM2JiMjc2MTQ3NGY4NTNmNDRiZjY0ZDc2YTg3L3RhYmxlcmFuZ2U6M2ZiMWEzYmIyNzYxNDc0Zjg1M2Y0NGJmNjRkNzZhODdfNS0xLTEtMS0yODIyMQ_8d2edc40-51bb-444e-865d-26f31b53c30d"
      unitRef="usd">5540000</cort:InventoryFinishedGoodsCurrentAndNoncurrent>
    <cort:InventoryFinishedGoodsCurrentAndNoncurrent
      contextRef="iac7c0f0822b942fa8f45ea15693a76af_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNC9mcmFnOjJjMDM1ZTVhYzJjNDQwN2U4NzM5NmY1YjU2ZDg1NWVkL3RhYmxlOjNmYjFhM2JiMjc2MTQ3NGY4NTNmNDRiZjY0ZDc2YTg3L3RhYmxlcmFuZ2U6M2ZiMWEzYmIyNzYxNDc0Zjg1M2Y0NGJmNjRkNzZhODdfNS0zLTEtMS0yODIyMQ_7a50245a-1ac3-40dc-8c73-f1e992628f9e"
      unitRef="usd">6500000</cort:InventoryFinishedGoodsCurrentAndNoncurrent>
    <cort:InventoryCurrentNoncurrent
      contextRef="i93f424f685944c1aab994f99b0146441_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNC9mcmFnOjJjMDM1ZTVhYzJjNDQwN2U4NzM5NmY1YjU2ZDg1NWVkL3RhYmxlOjNmYjFhM2JiMjc2MTQ3NGY4NTNmNDRiZjY0ZDc2YTg3L3RhYmxlcmFuZ2U6M2ZiMWEzYmIyNzYxNDc0Zjg1M2Y0NGJmNjRkNzZhODdfNi0xLTEtMS0yODIyMQ_72030d5e-ede4-4700-8cab-6758fefcd581"
      unitRef="usd">18177000</cort:InventoryCurrentNoncurrent>
    <cort:InventoryCurrentNoncurrent
      contextRef="iac7c0f0822b942fa8f45ea15693a76af_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNC9mcmFnOjJjMDM1ZTVhYzJjNDQwN2U4NzM5NmY1YjU2ZDg1NWVkL3RhYmxlOjNmYjFhM2JiMjc2MTQ3NGY4NTNmNDRiZjY0ZDc2YTg3L3RhYmxlcmFuZ2U6M2ZiMWEzYmIyNzYxNDc0Zjg1M2Y0NGJmNjRkNzZhODdfNi0zLTEtMS0yODIyMQ_26ac613d-879b-42d0-b440-a5fe48f81faf"
      unitRef="usd">17950000</cort:InventoryCurrentNoncurrent>
    <us-gaap:InventoryNoncurrent
      contextRef="i93f424f685944c1aab994f99b0146441_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNC9mcmFnOjJjMDM1ZTVhYzJjNDQwN2U4NzM5NmY1YjU2ZDg1NWVkL3RhYmxlOjNmYjFhM2JiMjc2MTQ3NGY4NTNmNDRiZjY0ZDc2YTg3L3RhYmxlcmFuZ2U6M2ZiMWEzYmIyNzYxNDc0Zjg1M2Y0NGJmNjRkNzZhODdfNy0xLTEtMS0yODIyMQ_95d2dd36-358e-493a-800c-dca773ae5629"
      unitRef="usd">13098000</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryNoncurrent
      contextRef="iac7c0f0822b942fa8f45ea15693a76af_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNC9mcmFnOjJjMDM1ZTVhYzJjNDQwN2U4NzM5NmY1YjU2ZDg1NWVkL3RhYmxlOjNmYjFhM2JiMjc2MTQ3NGY4NTNmNDRiZjY0ZDc2YTg3L3RhYmxlcmFuZ2U6M2ZiMWEzYmIyNzYxNDc0Zjg1M2Y0NGJmNjRkNzZhODdfNy0zLTEtMS0yODIyMQ_6aa07b2b-51c2-473f-af70-6bc62c10e9d3"
      unitRef="usd">12962000</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryNet
      contextRef="i93f424f685944c1aab994f99b0146441_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNC9mcmFnOjJjMDM1ZTVhYzJjNDQwN2U4NzM5NmY1YjU2ZDg1NWVkL3RhYmxlOjNmYjFhM2JiMjc2MTQ3NGY4NTNmNDRiZjY0ZDc2YTg3L3RhYmxlcmFuZ2U6M2ZiMWEzYmIyNzYxNDc0Zjg1M2Y0NGJmNjRkNzZhODdfOC0xLTEtMS0yODIyMQ_e2162cc8-7097-4894-b050-b15b39566e98"
      unitRef="usd">5079000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="iac7c0f0822b942fa8f45ea15693a76af_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNC9mcmFnOjJjMDM1ZTVhYzJjNDQwN2U4NzM5NmY1YjU2ZDg1NWVkL3RhYmxlOjNmYjFhM2JiMjc2MTQ3NGY4NTNmNDRiZjY0ZDc2YTg3L3RhYmxlcmFuZ2U6M2ZiMWEzYmIyNzYxNDc0Zjg1M2Y0NGJmNjRkNzZhODdfOC0zLTEtMS0yODIyMQ_d8e2570e-1519-4d1b-a3d2-54aaa77cdd5f"
      unitRef="usd">4988000</us-gaap:InventoryNet>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNC9mcmFnOjJjMDM1ZTVhYzJjNDQwN2U4NzM5NmY1YjU2ZDg1NWVkL3RleHRyZWdpb246MmMwMzVlNWFjMmM0NDA3ZTg3Mzk2ZjViNTZkODU1ZWRfNTE3_1a3e7a28-02f0-4792-a330-ec085918744c">&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Property and equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,939&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,927&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,213)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,925)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, net of accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,002&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i6b6f130b2b314f4cb240b19c11d8ccfc_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNC9mcmFnOjJjMDM1ZTVhYzJjNDQwN2U4NzM5NmY1YjU2ZDg1NWVkL3RhYmxlOmNkZWMwZDBiMDdkMzRjOTliNGNhNTg1YzFkN2U5OTBjL3RhYmxlcmFuZ2U6Y2RlYzBkMGIwN2QzNGM5OWI0Y2E1ODVjMWQ3ZTk5MGNfMy0xLTEtMS0yODIyMQ_0d75a32b-7766-4d6a-a32f-879b99501dcf"
      unitRef="usd">1169000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i320d5eb76f6e462191442b9efd3d1df7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNC9mcmFnOjJjMDM1ZTVhYzJjNDQwN2U4NzM5NmY1YjU2ZDg1NWVkL3RhYmxlOmNkZWMwZDBiMDdkMzRjOTliNGNhNTg1YzFkN2U5OTBjL3RhYmxlcmFuZ2U6Y2RlYzBkMGIwN2QzNGM5OWI0Y2E1ODVjMWQ3ZTk5MGNfMy0zLTEtMS0yODIyMQ_4a74b681-61e6-411a-b4f9-d18bdaea7927"
      unitRef="usd">1157000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i300a48854f3e4841a4231047bf2b6d83_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNC9mcmFnOjJjMDM1ZTVhYzJjNDQwN2U4NzM5NmY1YjU2ZDg1NWVkL3RhYmxlOmNkZWMwZDBiMDdkMzRjOTliNGNhNTg1YzFkN2U5OTBjL3RhYmxlcmFuZ2U6Y2RlYzBkMGIwN2QzNGM5OWI0Y2E1ODVjMWQ3ZTk5MGNfNC0xLTEtMS0yODIyMQ_dc263b09-8875-4ce5-96a7-e30f86784a33"
      unitRef="usd">1508000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="if054d789bd774097bce632cad662d551_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNC9mcmFnOjJjMDM1ZTVhYzJjNDQwN2U4NzM5NmY1YjU2ZDg1NWVkL3RhYmxlOmNkZWMwZDBiMDdkMzRjOTliNGNhNTg1YzFkN2U5OTBjL3RhYmxlcmFuZ2U6Y2RlYzBkMGIwN2QzNGM5OWI0Y2E1ODVjMWQ3ZTk5MGNfNC0zLTEtMS0yODIyMQ_1d35799e-2fa4-49cc-8484-78ad697dcb25"
      unitRef="usd">1508000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i9a00554864174d1583c51eb587009a9e_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNC9mcmFnOjJjMDM1ZTVhYzJjNDQwN2U4NzM5NmY1YjU2ZDg1NWVkL3RhYmxlOmNkZWMwZDBiMDdkMzRjOTliNGNhNTg1YzFkN2U5OTBjL3RhYmxlcmFuZ2U6Y2RlYzBkMGIwN2QzNGM5OWI0Y2E1ODVjMWQ3ZTk5MGNfNS0xLTEtMS0yODIyMQ_7f792909-8e10-4c7b-8c0d-31c8f4d6b50a"
      unitRef="usd">1262000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i9a314602e38747e383f53643af483ebe_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNC9mcmFnOjJjMDM1ZTVhYzJjNDQwN2U4NzM5NmY1YjU2ZDg1NWVkL3RhYmxlOmNkZWMwZDBiMDdkMzRjOTliNGNhNTg1YzFkN2U5OTBjL3RhYmxlcmFuZ2U6Y2RlYzBkMGIwN2QzNGM5OWI0Y2E1ODVjMWQ3ZTk5MGNfNS0zLTEtMS0yODIyMQ_353487e1-5ae9-4bb6-9f4b-2c2332e380b1"
      unitRef="usd">1262000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i93f424f685944c1aab994f99b0146441_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNC9mcmFnOjJjMDM1ZTVhYzJjNDQwN2U4NzM5NmY1YjU2ZDg1NWVkL3RhYmxlOmNkZWMwZDBiMDdkMzRjOTliNGNhNTg1YzFkN2U5OTBjL3RhYmxlcmFuZ2U6Y2RlYzBkMGIwN2QzNGM5OWI0Y2E1ODVjMWQ3ZTk5MGNfNi0xLTEtMS0yODIyMQ_f55ed158-30d5-466a-8a8a-3d2ff92f284d"
      unitRef="usd">3939000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="iac7c0f0822b942fa8f45ea15693a76af_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNC9mcmFnOjJjMDM1ZTVhYzJjNDQwN2U4NzM5NmY1YjU2ZDg1NWVkL3RhYmxlOmNkZWMwZDBiMDdkMzRjOTliNGNhNTg1YzFkN2U5OTBjL3RhYmxlcmFuZ2U6Y2RlYzBkMGIwN2QzNGM5OWI0Y2E1ODVjMWQ3ZTk5MGNfNi0zLTEtMS0yODIyMQ_2fad7fa2-32f1-4eac-899a-5f3fad9d106c"
      unitRef="usd">3927000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i93f424f685944c1aab994f99b0146441_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNC9mcmFnOjJjMDM1ZTVhYzJjNDQwN2U4NzM5NmY1YjU2ZDg1NWVkL3RhYmxlOmNkZWMwZDBiMDdkMzRjOTliNGNhNTg1YzFkN2U5OTBjL3RhYmxlcmFuZ2U6Y2RlYzBkMGIwN2QzNGM5OWI0Y2E1ODVjMWQ3ZTk5MGNfNy0xLTEtMS0yODIyMQ_e2023ccc-af56-4fc0-ab66-2468b65c941a"
      unitRef="usd">3213000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="iac7c0f0822b942fa8f45ea15693a76af_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNC9mcmFnOjJjMDM1ZTVhYzJjNDQwN2U4NzM5NmY1YjU2ZDg1NWVkL3RhYmxlOmNkZWMwZDBiMDdkMzRjOTliNGNhNTg1YzFkN2U5OTBjL3RhYmxlcmFuZ2U6Y2RlYzBkMGIwN2QzNGM5OWI0Y2E1ODVjMWQ3ZTk5MGNfNy0zLTEtMS0yODIyMQ_72f51641-7d60-4fd4-ac50-2609b5df8ba5"
      unitRef="usd">2925000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i93f424f685944c1aab994f99b0146441_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNC9mcmFnOjJjMDM1ZTVhYzJjNDQwN2U4NzM5NmY1YjU2ZDg1NWVkL3RhYmxlOmNkZWMwZDBiMDdkMzRjOTliNGNhNTg1YzFkN2U5OTBjL3RhYmxlcmFuZ2U6Y2RlYzBkMGIwN2QzNGM5OWI0Y2E1ODVjMWQ3ZTk5MGNfOC0xLTEtMS0yODIyMQ_fb29fd6a-ec49-4de4-981d-dd236330ca96"
      unitRef="usd">726000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="iac7c0f0822b942fa8f45ea15693a76af_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNC9mcmFnOjJjMDM1ZTVhYzJjNDQwN2U4NzM5NmY1YjU2ZDg1NWVkL3RhYmxlOmNkZWMwZDBiMDdkMzRjOTliNGNhNTg1YzFkN2U5OTBjL3RhYmxlcmFuZ2U6Y2RlYzBkMGIwN2QzNGM5OWI0Y2E1ODVjMWQ3ZTk5MGNfOC0zLTEtMS0yODIyMQ_a9d3200c-ef1d-44be-8218-af6f12a6d265"
      unitRef="usd">1002000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNC9mcmFnOjJjMDM1ZTVhYzJjNDQwN2U4NzM5NmY1YjU2ZDg1NWVkL3RleHRyZWdpb246MmMwMzVlNWFjMmM0NDA3ZTg3Mzk2ZjViNTZkODU1ZWRfNTEx_049ad0df-c76a-4328-940e-1d30bb719698">&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accrued and other liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government rebates&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued income taxes payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,523&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,968&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Legal fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,802&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;842&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued selling and marketing costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;861&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Professional fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;652&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total accrued and other liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,660&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <cort:AccruedGovernmentRebateCurrent
      contextRef="i93f424f685944c1aab994f99b0146441_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNC9mcmFnOjJjMDM1ZTVhYzJjNDQwN2U4NzM5NmY1YjU2ZDg1NWVkL3RhYmxlOjAzZTIyMGI5ZWZlMDQ2YmM5MTExZjc2MjZkMzhkNmM0L3RhYmxlcmFuZ2U6MDNlMjIwYjllZmUwNDZiYzkxMTFmNzYyNmQzOGQ2YzRfMy0xLTEtMS0yODIyMQ_e998d12e-12b5-4910-8326-074c77c74baa"
      unitRef="usd">12377000</cort:AccruedGovernmentRebateCurrent>
    <cort:AccruedGovernmentRebateCurrent
      contextRef="iac7c0f0822b942fa8f45ea15693a76af_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNC9mcmFnOjJjMDM1ZTVhYzJjNDQwN2U4NzM5NmY1YjU2ZDg1NWVkL3RhYmxlOjAzZTIyMGI5ZWZlMDQ2YmM5MTExZjc2MjZkMzhkNmM0L3RhYmxlcmFuZ2U6MDNlMjIwYjllZmUwNDZiYzkxMTFmNzYyNmQzOGQ2YzRfMy0zLTEtMS0yODIyMQ_4bacaea1-6932-48c9-b13d-adb287d17ef6"
      unitRef="usd">11174000</cort:AccruedGovernmentRebateCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="i93f424f685944c1aab994f99b0146441_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNC9mcmFnOjJjMDM1ZTVhYzJjNDQwN2U4NzM5NmY1YjU2ZDg1NWVkL3RhYmxlOjAzZTIyMGI5ZWZlMDQ2YmM5MTExZjc2MjZkMzhkNmM0L3RhYmxlcmFuZ2U6MDNlMjIwYjllZmUwNDZiYzkxMTFmNzYyNmQzOGQ2YzRfMy0xLTEtMS0zNzA5Nw_2ea23080-399a-4d1c-a925-8bf8a38e4c80"
      unitRef="usd">11523000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="iac7c0f0822b942fa8f45ea15693a76af_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNC9mcmFnOjJjMDM1ZTVhYzJjNDQwN2U4NzM5NmY1YjU2ZDg1NWVkL3RhYmxlOjAzZTIyMGI5ZWZlMDQ2YmM5MTExZjc2MjZkMzhkNmM0L3RhYmxlcmFuZ2U6MDNlMjIwYjllZmUwNDZiYzkxMTFmNzYyNmQzOGQ2YzRfMy0zLTEtMS0zNzA5Nw_f8be67f3-df57-4ec8-98dc-0411155d9adc"
      unitRef="usd">513000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i93f424f685944c1aab994f99b0146441_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNC9mcmFnOjJjMDM1ZTVhYzJjNDQwN2U4NzM5NmY1YjU2ZDg1NWVkL3RhYmxlOjAzZTIyMGI5ZWZlMDQ2YmM5MTExZjc2MjZkMzhkNmM0L3RhYmxlcmFuZ2U6MDNlMjIwYjllZmUwNDZiYzkxMTFmNzYyNmQzOGQ2YzRfNC0xLTEtMS0yODIyMQ_deafcefc-1743-40b9-852d-11a727bef6f3"
      unitRef="usd">4968000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="iac7c0f0822b942fa8f45ea15693a76af_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNC9mcmFnOjJjMDM1ZTVhYzJjNDQwN2U4NzM5NmY1YjU2ZDg1NWVkL3RhYmxlOjAzZTIyMGI5ZWZlMDQ2YmM5MTExZjc2MjZkMzhkNmM0L3RhYmxlcmFuZ2U6MDNlMjIwYjllZmUwNDZiYzkxMTFmNzYyNmQzOGQ2YzRfNC0zLTEtMS0yODIyMQ_d5546046-9158-4ac4-9691-a237a3f53d12"
      unitRef="usd">13339000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <cort:AccruedLegalFeesCurrent
      contextRef="i93f424f685944c1aab994f99b0146441_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNC9mcmFnOjJjMDM1ZTVhYzJjNDQwN2U4NzM5NmY1YjU2ZDg1NWVkL3RhYmxlOjAzZTIyMGI5ZWZlMDQ2YmM5MTExZjc2MjZkMzhkNmM0L3RhYmxlcmFuZ2U6MDNlMjIwYjllZmUwNDZiYzkxMTFmNzYyNmQzOGQ2YzRfNS0xLTEtMS0yODIyMQ_0a512fb1-0551-4fca-bfea-c79a6b791af7"
      unitRef="usd">1802000</cort:AccruedLegalFeesCurrent>
    <cort:AccruedLegalFeesCurrent
      contextRef="iac7c0f0822b942fa8f45ea15693a76af_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNC9mcmFnOjJjMDM1ZTVhYzJjNDQwN2U4NzM5NmY1YjU2ZDg1NWVkL3RhYmxlOjAzZTIyMGI5ZWZlMDQ2YmM5MTExZjc2MjZkMzhkNmM0L3RhYmxlcmFuZ2U6MDNlMjIwYjllZmUwNDZiYzkxMTFmNzYyNmQzOGQ2YzRfNS0zLTEtMS0yODIyMQ_d326fbfd-1f96-4f33-980a-a13a94722cb9"
      unitRef="usd">842000</cort:AccruedLegalFeesCurrent>
    <us-gaap:AccruedMarketingCostsCurrent
      contextRef="i93f424f685944c1aab994f99b0146441_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNC9mcmFnOjJjMDM1ZTVhYzJjNDQwN2U4NzM5NmY1YjU2ZDg1NWVkL3RhYmxlOjAzZTIyMGI5ZWZlMDQ2YmM5MTExZjc2MjZkMzhkNmM0L3RhYmxlcmFuZ2U6MDNlMjIwYjllZmUwNDZiYzkxMTFmNzYyNmQzOGQ2YzRfNi0xLTEtMS0yODIyMQ_beaf3af4-86dc-4463-9df1-3c168569e8b6"
      unitRef="usd">861000</us-gaap:AccruedMarketingCostsCurrent>
    <us-gaap:AccruedMarketingCostsCurrent
      contextRef="iac7c0f0822b942fa8f45ea15693a76af_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNC9mcmFnOjJjMDM1ZTVhYzJjNDQwN2U4NzM5NmY1YjU2ZDg1NWVkL3RhYmxlOjAzZTIyMGI5ZWZlMDQ2YmM5MTExZjc2MjZkMzhkNmM0L3RhYmxlcmFuZ2U6MDNlMjIwYjllZmUwNDZiYzkxMTFmNzYyNmQzOGQ2YzRfNi0zLTEtMS0yODIyMQ_b7bd4d65-c686-4aec-9e23-d4af976e0490"
      unitRef="usd">1351000</us-gaap:AccruedMarketingCostsCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="i93f424f685944c1aab994f99b0146441_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNC9mcmFnOjJjMDM1ZTVhYzJjNDQwN2U4NzM5NmY1YjU2ZDg1NWVkL3RhYmxlOjAzZTIyMGI5ZWZlMDQ2YmM5MTExZjc2MjZkMzhkNmM0L3RhYmxlcmFuZ2U6MDNlMjIwYjllZmUwNDZiYzkxMTFmNzYyNmQzOGQ2YzRfNi0xLTEtMS0zNjQ0MQ_35097420-ce78-4dd6-9721-06624da4c703"
      unitRef="usd">652000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="iac7c0f0822b942fa8f45ea15693a76af_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNC9mcmFnOjJjMDM1ZTVhYzJjNDQwN2U4NzM5NmY1YjU2ZDg1NWVkL3RhYmxlOjAzZTIyMGI5ZWZlMDQ2YmM5MTExZjc2MjZkMzhkNmM0L3RhYmxlcmFuZ2U6MDNlMjIwYjllZmUwNDZiYzkxMTFmNzYyNmQzOGQ2YzRfNi0zLTEtMS0zNjQ0MQ_2884f18f-4d0d-4e33-95a9-817d504bb96c"
      unitRef="usd">150000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i93f424f685944c1aab994f99b0146441_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNC9mcmFnOjJjMDM1ZTVhYzJjNDQwN2U4NzM5NmY1YjU2ZDg1NWVkL3RhYmxlOjAzZTIyMGI5ZWZlMDQ2YmM5MTExZjc2MjZkMzhkNmM0L3RhYmxlcmFuZ2U6MDNlMjIwYjllZmUwNDZiYzkxMTFmNzYyNmQzOGQ2YzRfOC0xLTEtMS0yODIyMQ_2d3ed213-bbbe-45f9-bf38-d5f7e949790a"
      unitRef="usd">477000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="iac7c0f0822b942fa8f45ea15693a76af_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNC9mcmFnOjJjMDM1ZTVhYzJjNDQwN2U4NzM5NmY1YjU2ZDg1NWVkL3RhYmxlOjAzZTIyMGI5ZWZlMDQ2YmM5MTExZjc2MjZkMzhkNmM0L3RhYmxlcmFuZ2U6MDNlMjIwYjllZmUwNDZiYzkxMTFmNzYyNmQzOGQ2YzRfOC0zLTEtMS0yODIyMQ_dcbe0f45-814c-4486-8cc0-3aaec0904a96"
      unitRef="usd">296000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i93f424f685944c1aab994f99b0146441_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNC9mcmFnOjJjMDM1ZTVhYzJjNDQwN2U4NzM5NmY1YjU2ZDg1NWVkL3RhYmxlOjAzZTIyMGI5ZWZlMDQ2YmM5MTExZjc2MjZkMzhkNmM0L3RhYmxlcmFuZ2U6MDNlMjIwYjllZmUwNDZiYzkxMTFmNzYyNmQzOGQ2YzRfOS0xLTEtMS0yODIyMQ_6d3a0d6c-36f3-4b6a-bb75-0bbee0f8d0d9"
      unitRef="usd">32660000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="iac7c0f0822b942fa8f45ea15693a76af_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNC9mcmFnOjJjMDM1ZTVhYzJjNDQwN2U4NzM5NmY1YjU2ZDg1NWVkL3RhYmxlOjAzZTIyMGI5ZWZlMDQ2YmM5MTExZjc2MjZkMzhkNmM0L3RhYmxlcmFuZ2U6MDNlMjIwYjllZmUwNDZiYzkxMTFmNzYyNmQzOGQ2YzRfOS0zLTEtMS0yODIyMQ_9e3bb8ea-84ca-4d4e-b915-08578d1a9fd9"
      unitRef="usd">27665000</us-gaap:AccruedLiabilitiesCurrent>
    <cort:DepositsForClinicalTrials
      contextRef="i93f424f685944c1aab994f99b0146441_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNC9mcmFnOjJjMDM1ZTVhYzJjNDQwN2U4NzM5NmY1YjU2ZDg1NWVkL3RleHRyZWdpb246MmMwMzVlNWFjMmM0NDA3ZTg3Mzk2ZjViNTZkODU1ZWRfMjE5OTAyMzI1NjU2Ng_2f385757-2dca-45e5-adb0-c9cbd1aa5575"
      unitRef="usd">2800000</cort:DepositsForClinicalTrials>
    <cort:DepositsForClinicalTrials
      contextRef="iac7c0f0822b942fa8f45ea15693a76af_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNC9mcmFnOjJjMDM1ZTVhYzJjNDQwN2U4NzM5NmY1YjU2ZDg1NWVkL3RleHRyZWdpb246MmMwMzVlNWFjMmM0NDA3ZTg3Mzk2ZjViNTZkODU1ZWRfMjE5OTAyMzI1NjU1OA_a4bf4a01-aaac-496b-a0a1-7b6e2509286d"
      unitRef="usd">2900000</cort:DepositsForClinicalTrials>
    <cort:AvailableForSaleSecuritiesAndFairValueMeasurementsDisclosureTextBlock
      contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNy9mcmFnOmZlMTQxZDk2ZjU2MTRmM2ZhMmZhYjQ3OTgwODk1YzkxL3RleHRyZWdpb246ZmUxNDFkOTZmNTYxNGYzZmEyZmFiNDc5ODA4OTVjOTFfMjEyNw_b02d48a9-7097-4edf-a5a4-68b4616d680f">Available-for-Sale Securities and Fair Value Measurements&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The available-for-sale securities in our Condensed Consolidated Balance Sheets are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.028%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,088&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;283,665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;145,918&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112,277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;330,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;303,283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents our available-for-sale securities grouped by asset type:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.590%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;br/&gt;Hierarchy&lt;br/&gt;Level&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:29pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="45" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;147,177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,023)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;146,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;125,370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(276)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;125,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;56,751&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;56,751&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;30,963&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;30,963&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;29,372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(110)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;29,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;57,801&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(67)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;57,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;74,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(303)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;74,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;44,473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(72)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;44,401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;24,266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;24,266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;45,088&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;45,088&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;331,929&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,436)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;330,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;303,695&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(415)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;303,283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We estimate the fair value of marketable securities classified as Level 1 using quoted market prices for these or identical investments obtained from a commercial pricing service. We estimate the fair value of marketable securities classified as Level 2 using inputs that may include benchmark yields, reported trades, broker/dealer quotes and issuer spreads.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We periodically review our debt securities to determine if any of our investments is impaired due to credit-related or other issues. If the fair value of our investment in any debt security is less than our amortized cost basis, we determine whether an allowance for credit losses is appropriate by assessing quantitative and subjective factors including, but not limited to, the nature of security, changes in credit ratings, analyst reports concerning the security&#x2019;s issuer and industry, interest rate fluctuations and general market conditions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2022 and December&#160;31, 2021, unrealized losses on our available-for-sale debt securities were $1.4 million and $0.4 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All of our investments, including those with unrealized losses, are not impaired. Unrealized losses on our investments are due to interest rate fluctuations. We do not intend to sell investments that currently have unrealized losses and it is highly unlikely that we will sell any investment before recovery of its amortized cost basis, which may be at maturity. Accordingly, we have not recorded an allowance for credit losses associated with these investments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We classified accrued interest on our marketable securities of $1.0 million and $1.4 million as of March&#160;31, 2022 and December&#160;31, 2021, respectively, as prepaid and other current assets on our condensed consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;As of March&#160;31, 2022, all our marketable securities had original maturities of less than two years. The weighted-average maturity of our holdings was seven months. As of March&#160;31, 2022, our long-term marketable securities had remaining maturities ranging from 12 to 24 months. None of our marketable securities changed from one fair value hierarchy to another during the three months ended March 31, 2022</cort:AvailableForSaleSecuritiesAndFairValueMeasurementsDisclosureTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock
      contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNy9mcmFnOmZlMTQxZDk2ZjU2MTRmM2ZhMmZhYjQ3OTgwODk1YzkxL3RleHRyZWdpb246ZmUxNDFkOTZmNTYxNGYzZmEyZmFiNDc5ODA4OTVjOTFfMjEzMQ_f2ba99c1-dfc1-443f-bb38-00d25ead5fa5">&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The available-for-sale securities in our Condensed Consolidated Balance Sheets are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.028%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,088&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;283,665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;145,918&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112,277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;330,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;303,283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i3b8ab391633246798d3dcce8ecce1732_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNy9mcmFnOmZlMTQxZDk2ZjU2MTRmM2ZhMmZhYjQ3OTgwODk1YzkxL3RhYmxlOmYwZjE1ZWE5MTRiNDQwZGRhODg4MjA3ZDc1YjMwZmNlL3RhYmxlcmFuZ2U6ZjBmMTVlYTkxNGI0NDBkZGE4ODgyMDdkNzViMzBmY2VfMy0xLTEtMS0yODIyMQ_4aa8f065-2e17-4814-8bda-cd2444b8ba87"
      unitRef="usd">24266000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8199115c34a347bfa2af4840cc8fab44_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNy9mcmFnOmZlMTQxZDk2ZjU2MTRmM2ZhMmZhYjQ3OTgwODk1YzkxL3RhYmxlOmYwZjE1ZWE5MTRiNDQwZGRhODg4MjA3ZDc1YjMwZmNlL3RhYmxlcmFuZ2U6ZjBmMTVlYTkxNGI0NDBkZGE4ODgyMDdkNzViMzBmY2VfMy0zLTEtMS0yODIyMQ_402f19ac-9c99-4379-9e93-0ed1ab6bc5fb"
      unitRef="usd">45088000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if03d19cb5acb4fc88cca882cb4bdfcc0_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNy9mcmFnOmZlMTQxZDk2ZjU2MTRmM2ZhMmZhYjQ3OTgwODk1YzkxL3RhYmxlOmYwZjE1ZWE5MTRiNDQwZGRhODg4MjA3ZDc1YjMwZmNlL3RhYmxlcmFuZ2U6ZjBmMTVlYTkxNGI0NDBkZGE4ODgyMDdkNzViMzBmY2VfNC0xLTEtMS0yODIyMQ_9cbadf81-d189-48b9-8ea1-fcaaaecc6c9e"
      unitRef="usd">283665000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="idecfc47be18a4b0abf858e6bac29beee_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNy9mcmFnOmZlMTQxZDk2ZjU2MTRmM2ZhMmZhYjQ3OTgwODk1YzkxL3RhYmxlOmYwZjE1ZWE5MTRiNDQwZGRhODg4MjA3ZDc1YjMwZmNlL3RhYmxlcmFuZ2U6ZjBmMTVlYTkxNGI0NDBkZGE4ODgyMDdkNzViMzBmY2VfNC0zLTEtMS0yODIyMQ_d4f7d032-80c0-4446-b193-1f580de00304"
      unitRef="usd">145918000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9ae15632947d447792ec41cd858483f8_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNy9mcmFnOmZlMTQxZDk2ZjU2MTRmM2ZhMmZhYjQ3OTgwODk1YzkxL3RhYmxlOmYwZjE1ZWE5MTRiNDQwZGRhODg4MjA3ZDc1YjMwZmNlL3RhYmxlcmFuZ2U6ZjBmMTVlYTkxNGI0NDBkZGE4ODgyMDdkNzViMzBmY2VfNS0xLTEtMS0yODIyMQ_9479f81d-7fc6-47ae-a3b0-0df6d4026a99"
      unitRef="usd">22566000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib244710dd5db4d8095a0f665560759d1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNy9mcmFnOmZlMTQxZDk2ZjU2MTRmM2ZhMmZhYjQ3OTgwODk1YzkxL3RhYmxlOmYwZjE1ZWE5MTRiNDQwZGRhODg4MjA3ZDc1YjMwZmNlL3RhYmxlcmFuZ2U6ZjBmMTVlYTkxNGI0NDBkZGE4ODgyMDdkNzViMzBmY2VfNS0zLTEtMS0yODIyMQ_2668859c-74e7-4783-91b4-1a8abe79a7c1"
      unitRef="usd">112277000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i93f424f685944c1aab994f99b0146441_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNy9mcmFnOmZlMTQxZDk2ZjU2MTRmM2ZhMmZhYjQ3OTgwODk1YzkxL3RhYmxlOmYwZjE1ZWE5MTRiNDQwZGRhODg4MjA3ZDc1YjMwZmNlL3RhYmxlcmFuZ2U6ZjBmMTVlYTkxNGI0NDBkZGE4ODgyMDdkNzViMzBmY2VfNi0xLTEtMS0yODIyMQ_20f674c7-7899-4cfa-b513-eedc0ab40434"
      unitRef="usd">330497000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iac7c0f0822b942fa8f45ea15693a76af_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNy9mcmFnOmZlMTQxZDk2ZjU2MTRmM2ZhMmZhYjQ3OTgwODk1YzkxL3RhYmxlOmYwZjE1ZWE5MTRiNDQwZGRhODg4MjA3ZDc1YjMwZmNlL3RhYmxlcmFuZ2U6ZjBmMTVlYTkxNGI0NDBkZGE4ODgyMDdkNzViMzBmY2VfNi0zLTEtMS0yODIyMQ_7c970acc-f3c6-49dc-abd7-c099c74c3812"
      unitRef="usd">303283000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock
      contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNy9mcmFnOmZlMTQxZDk2ZjU2MTRmM2ZhMmZhYjQ3OTgwODk1YzkxL3RleHRyZWdpb246ZmUxNDFkOTZmNTYxNGYzZmEyZmFiNDc5ODA4OTVjOTFfMjEyNA_1efa97d4-de5a-4c5b-89aa-cd45d34567a7">&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents our available-for-sale securities grouped by asset type:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.590%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;br/&gt;Hierarchy&lt;br/&gt;Level&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:29pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="45" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;147,177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,023)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;146,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;125,370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(276)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;125,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;56,751&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;56,751&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;30,963&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;30,963&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;29,372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(110)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;29,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;57,801&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(67)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;57,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;74,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(303)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;74,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;44,473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(72)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;44,401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;24,266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;24,266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;45,088&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;45,088&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;331,929&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,436)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;330,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;303,695&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(415)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;303,283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="id653930fdecf4c64ad438a3b2c5adabb_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNy9mcmFnOmZlMTQxZDk2ZjU2MTRmM2ZhMmZhYjQ3OTgwODk1YzkxL3RhYmxlOjA5MDBhY2M4MTE5MjQ5N2RiYWI3YTU2NjVkMjg0ZGNhL3RhYmxlcmFuZ2U6MDkwMGFjYzgxMTkyNDk3ZGJhYjdhNTY2NWQyODRkY2FfNC0zLTEtMS0yODIyMQ_bf344695-97b4-443a-8eaf-4408af14f8d0"
      unitRef="usd">147177000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="id653930fdecf4c64ad438a3b2c5adabb_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNy9mcmFnOmZlMTQxZDk2ZjU2MTRmM2ZhMmZhYjQ3OTgwODk1YzkxL3RhYmxlOjA5MDBhY2M4MTE5MjQ5N2RiYWI3YTU2NjVkMjg0ZGNhL3RhYmxlcmFuZ2U6MDkwMGFjYzgxMTkyNDk3ZGJhYjdhNTY2NWQyODRkY2FfNC01LTEtMS0yODIyMQ_7d0ed209-ff91-4e8a-8279-bd4622506e25"
      unitRef="usd">4000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="id653930fdecf4c64ad438a3b2c5adabb_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNy9mcmFnOmZlMTQxZDk2ZjU2MTRmM2ZhMmZhYjQ3OTgwODk1YzkxL3RhYmxlOjA5MDBhY2M4MTE5MjQ5N2RiYWI3YTU2NjVkMjg0ZGNhL3RhYmxlcmFuZ2U6MDkwMGFjYzgxMTkyNDk3ZGJhYjdhNTY2NWQyODRkY2FfNC03LTEtMS0yODIyMQ_9b518262-525c-464f-ba56-f6f99186c3f9"
      unitRef="usd">1023000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <cort:AvailableForSaleSecuritiesIncludingCashEquivalents
      contextRef="id653930fdecf4c64ad438a3b2c5adabb_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNy9mcmFnOmZlMTQxZDk2ZjU2MTRmM2ZhMmZhYjQ3OTgwODk1YzkxL3RhYmxlOjA5MDBhY2M4MTE5MjQ5N2RiYWI3YTU2NjVkMjg0ZGNhL3RhYmxlcmFuZ2U6MDkwMGFjYzgxMTkyNDk3ZGJhYjdhNTY2NWQyODRkY2FfNC05LTEtMS0yODIyMQ_2a804abf-c9df-4557-bfe2-68376689807e"
      unitRef="usd">146158000</cort:AvailableForSaleSecuritiesIncludingCashEquivalents>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i9384505b63ff4625835d945a86192942_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNy9mcmFnOmZlMTQxZDk2ZjU2MTRmM2ZhMmZhYjQ3OTgwODk1YzkxL3RhYmxlOjA5MDBhY2M4MTE5MjQ5N2RiYWI3YTU2NjVkMjg0ZGNhL3RhYmxlcmFuZ2U6MDkwMGFjYzgxMTkyNDk3ZGJhYjdhNTY2NWQyODRkY2FfNC0xMS0xLTEtMjgyMjE_179e68b0-dd22-4516-9aa4-f49a653d5956"
      unitRef="usd">125370000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i9384505b63ff4625835d945a86192942_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNy9mcmFnOmZlMTQxZDk2ZjU2MTRmM2ZhMmZhYjQ3OTgwODk1YzkxL3RhYmxlOjA5MDBhY2M4MTE5MjQ5N2RiYWI3YTU2NjVkMjg0ZGNhL3RhYmxlcmFuZ2U6MDkwMGFjYzgxMTkyNDk3ZGJhYjdhNTY2NWQyODRkY2FfNC0xMy0xLTEtMjgyMjE_8c9ac8c2-36b0-4375-95f3-0056969a994b"
      unitRef="usd">3000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i9384505b63ff4625835d945a86192942_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNy9mcmFnOmZlMTQxZDk2ZjU2MTRmM2ZhMmZhYjQ3OTgwODk1YzkxL3RhYmxlOjA5MDBhY2M4MTE5MjQ5N2RiYWI3YTU2NjVkMjg0ZGNhL3RhYmxlcmFuZ2U6MDkwMGFjYzgxMTkyNDk3ZGJhYjdhNTY2NWQyODRkY2FfNC0xNS0xLTEtMjgyMjE_4f980794-4442-48bc-97bc-9b431d8d36ec"
      unitRef="usd">276000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <cort:AvailableForSaleSecuritiesIncludingCashEquivalents
      contextRef="i9384505b63ff4625835d945a86192942_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNy9mcmFnOmZlMTQxZDk2ZjU2MTRmM2ZhMmZhYjQ3OTgwODk1YzkxL3RhYmxlOjA5MDBhY2M4MTE5MjQ5N2RiYWI3YTU2NjVkMjg0ZGNhL3RhYmxlcmFuZ2U6MDkwMGFjYzgxMTkyNDk3ZGJhYjdhNTY2NWQyODRkY2FfNC0xNy0xLTEtMjgyMjE_76e6027f-c35d-4b90-a7b4-f2d3cde0d729"
      unitRef="usd">125097000</cort:AvailableForSaleSecuritiesIncludingCashEquivalents>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i189a43eed86a4d37b00b3efd25b569ec_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNy9mcmFnOmZlMTQxZDk2ZjU2MTRmM2ZhMmZhYjQ3OTgwODk1YzkxL3RhYmxlOjA5MDBhY2M4MTE5MjQ5N2RiYWI3YTU2NjVkMjg0ZGNhL3RhYmxlcmFuZ2U6MDkwMGFjYzgxMTkyNDk3ZGJhYjdhNTY2NWQyODRkY2FfNS0zLTEtMS0yODIyMQ_18addb9a-86d4-4608-b6c4-7e427ac10d6d"
      unitRef="usd">56751000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i189a43eed86a4d37b00b3efd25b569ec_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNy9mcmFnOmZlMTQxZDk2ZjU2MTRmM2ZhMmZhYjQ3OTgwODk1YzkxL3RhYmxlOjA5MDBhY2M4MTE5MjQ5N2RiYWI3YTU2NjVkMjg0ZGNhL3RhYmxlcmFuZ2U6MDkwMGFjYzgxMTkyNDk3ZGJhYjdhNTY2NWQyODRkY2FfNS01LTEtMS0yODIyMQ_e2126747-828a-45bf-950f-e92f1f2f1d56"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i189a43eed86a4d37b00b3efd25b569ec_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNy9mcmFnOmZlMTQxZDk2ZjU2MTRmM2ZhMmZhYjQ3OTgwODk1YzkxL3RhYmxlOjA5MDBhY2M4MTE5MjQ5N2RiYWI3YTU2NjVkMjg0ZGNhL3RhYmxlcmFuZ2U6MDkwMGFjYzgxMTkyNDk3ZGJhYjdhNTY2NWQyODRkY2FfNS03LTEtMS0yODIyMQ_29767199-56e2-4957-8acf-3b3544ccfed9"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <cort:AvailableForSaleSecuritiesIncludingCashEquivalents
      contextRef="i189a43eed86a4d37b00b3efd25b569ec_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNy9mcmFnOmZlMTQxZDk2ZjU2MTRmM2ZhMmZhYjQ3OTgwODk1YzkxL3RhYmxlOjA5MDBhY2M4MTE5MjQ5N2RiYWI3YTU2NjVkMjg0ZGNhL3RhYmxlcmFuZ2U6MDkwMGFjYzgxMTkyNDk3ZGJhYjdhNTY2NWQyODRkY2FfNS05LTEtMS0yODIyMQ_99d33098-9b54-4ae6-8e57-a9f1a645087d"
      unitRef="usd">56751000</cort:AvailableForSaleSecuritiesIncludingCashEquivalents>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ie44aabc8e0234ddab3cc8531b3c28b30_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNy9mcmFnOmZlMTQxZDk2ZjU2MTRmM2ZhMmZhYjQ3OTgwODk1YzkxL3RhYmxlOjA5MDBhY2M4MTE5MjQ5N2RiYWI3YTU2NjVkMjg0ZGNhL3RhYmxlcmFuZ2U6MDkwMGFjYzgxMTkyNDk3ZGJhYjdhNTY2NWQyODRkY2FfNS0xMS0xLTEtMjgyMjE_8b5bc008-4fbf-4993-8516-d44264c868d8"
      unitRef="usd">30963000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ie44aabc8e0234ddab3cc8531b3c28b30_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNy9mcmFnOmZlMTQxZDk2ZjU2MTRmM2ZhMmZhYjQ3OTgwODk1YzkxL3RhYmxlOjA5MDBhY2M4MTE5MjQ5N2RiYWI3YTU2NjVkMjg0ZGNhL3RhYmxlcmFuZ2U6MDkwMGFjYzgxMTkyNDk3ZGJhYjdhNTY2NWQyODRkY2FfNS0xMy0xLTEtMjgyMjE_07f2dac3-dacc-435b-b0c0-4c59afb93565"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ie44aabc8e0234ddab3cc8531b3c28b30_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNy9mcmFnOmZlMTQxZDk2ZjU2MTRmM2ZhMmZhYjQ3OTgwODk1YzkxL3RhYmxlOjA5MDBhY2M4MTE5MjQ5N2RiYWI3YTU2NjVkMjg0ZGNhL3RhYmxlcmFuZ2U6MDkwMGFjYzgxMTkyNDk3ZGJhYjdhNTY2NWQyODRkY2FfNS0xNS0xLTEtMjgyMjE_e686f60e-9bb7-4aaf-b524-c7019dc81d24"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <cort:AvailableForSaleSecuritiesIncludingCashEquivalents
      contextRef="ie44aabc8e0234ddab3cc8531b3c28b30_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNy9mcmFnOmZlMTQxZDk2ZjU2MTRmM2ZhMmZhYjQ3OTgwODk1YzkxL3RhYmxlOjA5MDBhY2M4MTE5MjQ5N2RiYWI3YTU2NjVkMjg0ZGNhL3RhYmxlcmFuZ2U6MDkwMGFjYzgxMTkyNDk3ZGJhYjdhNTY2NWQyODRkY2FfNS0xNy0xLTEtMjgyMjE_370458d2-35fc-4a60-aa82-b7bff38381ef"
      unitRef="usd">30963000</cort:AvailableForSaleSecuritiesIncludingCashEquivalents>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ibb4f2da4afdc4173bbcc618511bfd330_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNy9mcmFnOmZlMTQxZDk2ZjU2MTRmM2ZhMmZhYjQ3OTgwODk1YzkxL3RhYmxlOjA5MDBhY2M4MTE5MjQ5N2RiYWI3YTU2NjVkMjg0ZGNhL3RhYmxlcmFuZ2U6MDkwMGFjYzgxMTkyNDk3ZGJhYjdhNTY2NWQyODRkY2FfNi0zLTEtMS0yODIyMQ_2eca22a7-8047-4643-97f5-481430ce8cef"
      unitRef="usd">29372000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ibb4f2da4afdc4173bbcc618511bfd330_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNy9mcmFnOmZlMTQxZDk2ZjU2MTRmM2ZhMmZhYjQ3OTgwODk1YzkxL3RhYmxlOjA5MDBhY2M4MTE5MjQ5N2RiYWI3YTU2NjVkMjg0ZGNhL3RhYmxlcmFuZ2U6MDkwMGFjYzgxMTkyNDk3ZGJhYjdhNTY2NWQyODRkY2FfNi01LTEtMS0yODIyMQ_7764fe70-2f1c-4fb3-8803-af939d91a9b3"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ibb4f2da4afdc4173bbcc618511bfd330_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNy9mcmFnOmZlMTQxZDk2ZjU2MTRmM2ZhMmZhYjQ3OTgwODk1YzkxL3RhYmxlOjA5MDBhY2M4MTE5MjQ5N2RiYWI3YTU2NjVkMjg0ZGNhL3RhYmxlcmFuZ2U6MDkwMGFjYzgxMTkyNDk3ZGJhYjdhNTY2NWQyODRkY2FfNi03LTEtMS0yODIyMQ_2dbb7977-c147-468d-a251-2bc6209b771a"
      unitRef="usd">110000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <cort:AvailableForSaleSecuritiesIncludingCashEquivalents
      contextRef="ibb4f2da4afdc4173bbcc618511bfd330_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNy9mcmFnOmZlMTQxZDk2ZjU2MTRmM2ZhMmZhYjQ3OTgwODk1YzkxL3RhYmxlOjA5MDBhY2M4MTE5MjQ5N2RiYWI3YTU2NjVkMjg0ZGNhL3RhYmxlcmFuZ2U6MDkwMGFjYzgxMTkyNDk3ZGJhYjdhNTY2NWQyODRkY2FfNi05LTEtMS0yODIyMQ_7aba70bd-aa47-4a43-a686-8abe1cf9cd38"
      unitRef="usd">29262000</cort:AvailableForSaleSecuritiesIncludingCashEquivalents>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ib430d4f8526c49d2965e6d0cbfc5179d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNy9mcmFnOmZlMTQxZDk2ZjU2MTRmM2ZhMmZhYjQ3OTgwODk1YzkxL3RhYmxlOjA5MDBhY2M4MTE5MjQ5N2RiYWI3YTU2NjVkMjg0ZGNhL3RhYmxlcmFuZ2U6MDkwMGFjYzgxMTkyNDk3ZGJhYjdhNTY2NWQyODRkY2FfNi0xMS0xLTEtMjgyMjE_9d5cb352-3d85-46c2-96ed-8d08bfbf6e20"
      unitRef="usd">57801000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ib430d4f8526c49d2965e6d0cbfc5179d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNy9mcmFnOmZlMTQxZDk2ZjU2MTRmM2ZhMmZhYjQ3OTgwODk1YzkxL3RhYmxlOjA5MDBhY2M4MTE5MjQ5N2RiYWI3YTU2NjVkMjg0ZGNhL3RhYmxlcmFuZ2U6MDkwMGFjYzgxMTkyNDk3ZGJhYjdhNTY2NWQyODRkY2FfNi0xMy0xLTEtMjgyMjE_8781cc20-98f8-472d-837e-eb7eea1acded"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ib430d4f8526c49d2965e6d0cbfc5179d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNy9mcmFnOmZlMTQxZDk2ZjU2MTRmM2ZhMmZhYjQ3OTgwODk1YzkxL3RhYmxlOjA5MDBhY2M4MTE5MjQ5N2RiYWI3YTU2NjVkMjg0ZGNhL3RhYmxlcmFuZ2U6MDkwMGFjYzgxMTkyNDk3ZGJhYjdhNTY2NWQyODRkY2FfNi0xNS0xLTEtMjgyMjE_5ec24f0e-daa1-49f4-9164-0e165a6207b0"
      unitRef="usd">67000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <cort:AvailableForSaleSecuritiesIncludingCashEquivalents
      contextRef="ib430d4f8526c49d2965e6d0cbfc5179d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNy9mcmFnOmZlMTQxZDk2ZjU2MTRmM2ZhMmZhYjQ3OTgwODk1YzkxL3RhYmxlOjA5MDBhY2M4MTE5MjQ5N2RiYWI3YTU2NjVkMjg0ZGNhL3RhYmxlcmFuZ2U6MDkwMGFjYzgxMTkyNDk3ZGJhYjdhNTY2NWQyODRkY2FfNi0xNy0xLTEtMjgyMjE_cc9a66f4-e4b8-4491-9f29-6e00973bdc8c"
      unitRef="usd">57734000</cort:AvailableForSaleSecuritiesIncludingCashEquivalents>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="iddcc04669caf4c4f8e77d0b0ead4adba_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNy9mcmFnOmZlMTQxZDk2ZjU2MTRmM2ZhMmZhYjQ3OTgwODk1YzkxL3RhYmxlOjA5MDBhY2M4MTE5MjQ5N2RiYWI3YTU2NjVkMjg0ZGNhL3RhYmxlcmFuZ2U6MDkwMGFjYzgxMTkyNDk3ZGJhYjdhNTY2NWQyODRkY2FfNy0zLTEtMS0yODIyMQ_e44f62ef-fa57-4450-95f7-2f306f51734a"
      unitRef="usd">74363000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="iddcc04669caf4c4f8e77d0b0ead4adba_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNy9mcmFnOmZlMTQxZDk2ZjU2MTRmM2ZhMmZhYjQ3OTgwODk1YzkxL3RhYmxlOjA5MDBhY2M4MTE5MjQ5N2RiYWI3YTU2NjVkMjg0ZGNhL3RhYmxlcmFuZ2U6MDkwMGFjYzgxMTkyNDk3ZGJhYjdhNTY2NWQyODRkY2FfNy01LTEtMS0yODIyMQ_b7b88696-f3cb-4d8a-aaec-64e6ab3e5eff"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="iddcc04669caf4c4f8e77d0b0ead4adba_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNy9mcmFnOmZlMTQxZDk2ZjU2MTRmM2ZhMmZhYjQ3OTgwODk1YzkxL3RhYmxlOjA5MDBhY2M4MTE5MjQ5N2RiYWI3YTU2NjVkMjg0ZGNhL3RhYmxlcmFuZ2U6MDkwMGFjYzgxMTkyNDk3ZGJhYjdhNTY2NWQyODRkY2FfNy03LTEtMS0yODIyMQ_e9011551-4bc7-4e57-8a15-3e01cd629f5a"
      unitRef="usd">303000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <cort:AvailableForSaleSecuritiesIncludingCashEquivalents
      contextRef="iddcc04669caf4c4f8e77d0b0ead4adba_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNy9mcmFnOmZlMTQxZDk2ZjU2MTRmM2ZhMmZhYjQ3OTgwODk1YzkxL3RhYmxlOjA5MDBhY2M4MTE5MjQ5N2RiYWI3YTU2NjVkMjg0ZGNhL3RhYmxlcmFuZ2U6MDkwMGFjYzgxMTkyNDk3ZGJhYjdhNTY2NWQyODRkY2FfNy05LTEtMS0yODIyMQ_4a806cbe-d23d-45cd-a706-e6e21fc680f3"
      unitRef="usd">74060000</cort:AvailableForSaleSecuritiesIncludingCashEquivalents>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i80d4096c7b334e54b411518bb6b5d22b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNy9mcmFnOmZlMTQxZDk2ZjU2MTRmM2ZhMmZhYjQ3OTgwODk1YzkxL3RhYmxlOjA5MDBhY2M4MTE5MjQ5N2RiYWI3YTU2NjVkMjg0ZGNhL3RhYmxlcmFuZ2U6MDkwMGFjYzgxMTkyNDk3ZGJhYjdhNTY2NWQyODRkY2FfNy0xMS0xLTEtMjgyMjE_0fe98ca6-945c-4e3d-ab66-91ee05a378b1"
      unitRef="usd">44473000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i80d4096c7b334e54b411518bb6b5d22b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNy9mcmFnOmZlMTQxZDk2ZjU2MTRmM2ZhMmZhYjQ3OTgwODk1YzkxL3RhYmxlOjA5MDBhY2M4MTE5MjQ5N2RiYWI3YTU2NjVkMjg0ZGNhL3RhYmxlcmFuZ2U6MDkwMGFjYzgxMTkyNDk3ZGJhYjdhNTY2NWQyODRkY2FfNy0xMy0xLTEtMjgyMjE_f62ae142-9439-4904-bc41-4117a2445e43"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i80d4096c7b334e54b411518bb6b5d22b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNy9mcmFnOmZlMTQxZDk2ZjU2MTRmM2ZhMmZhYjQ3OTgwODk1YzkxL3RhYmxlOjA5MDBhY2M4MTE5MjQ5N2RiYWI3YTU2NjVkMjg0ZGNhL3RhYmxlcmFuZ2U6MDkwMGFjYzgxMTkyNDk3ZGJhYjdhNTY2NWQyODRkY2FfNy0xNS0xLTEtMjgyMjE_49104567-a8cb-435e-91f2-a2ae5831aae4"
      unitRef="usd">72000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <cort:AvailableForSaleSecuritiesIncludingCashEquivalents
      contextRef="i80d4096c7b334e54b411518bb6b5d22b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNy9mcmFnOmZlMTQxZDk2ZjU2MTRmM2ZhMmZhYjQ3OTgwODk1YzkxL3RhYmxlOjA5MDBhY2M4MTE5MjQ5N2RiYWI3YTU2NjVkMjg0ZGNhL3RhYmxlcmFuZ2U6MDkwMGFjYzgxMTkyNDk3ZGJhYjdhNTY2NWQyODRkY2FfNy0xNy0xLTEtMjgyMjE_d22f0d09-4dd2-428b-a1c1-7619e67af6e3"
      unitRef="usd">44401000</cort:AvailableForSaleSecuritiesIncludingCashEquivalents>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ic608ebc41f164c878a62e74c33164b0a_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNy9mcmFnOmZlMTQxZDk2ZjU2MTRmM2ZhMmZhYjQ3OTgwODk1YzkxL3RhYmxlOjA5MDBhY2M4MTE5MjQ5N2RiYWI3YTU2NjVkMjg0ZGNhL3RhYmxlcmFuZ2U6MDkwMGFjYzgxMTkyNDk3ZGJhYjdhNTY2NWQyODRkY2FfOC0zLTEtMS0yODIyMQ_3ccc7b70-b8b7-49f9-92b1-186737fbb502"
      unitRef="usd">24266000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ic608ebc41f164c878a62e74c33164b0a_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNy9mcmFnOmZlMTQxZDk2ZjU2MTRmM2ZhMmZhYjQ3OTgwODk1YzkxL3RhYmxlOjA5MDBhY2M4MTE5MjQ5N2RiYWI3YTU2NjVkMjg0ZGNhL3RhYmxlcmFuZ2U6MDkwMGFjYzgxMTkyNDk3ZGJhYjdhNTY2NWQyODRkY2FfOC01LTEtMS0yODIyMQ_b405316b-9766-4eee-9813-ed2d22245d38"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ic608ebc41f164c878a62e74c33164b0a_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNy9mcmFnOmZlMTQxZDk2ZjU2MTRmM2ZhMmZhYjQ3OTgwODk1YzkxL3RhYmxlOjA5MDBhY2M4MTE5MjQ5N2RiYWI3YTU2NjVkMjg0ZGNhL3RhYmxlcmFuZ2U6MDkwMGFjYzgxMTkyNDk3ZGJhYjdhNTY2NWQyODRkY2FfOC03LTEtMS0yODIyMQ_141d0456-c8d8-46a3-9a42-10a6c3003332"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <cort:AvailableForSaleSecuritiesIncludingCashEquivalents
      contextRef="ic608ebc41f164c878a62e74c33164b0a_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNy9mcmFnOmZlMTQxZDk2ZjU2MTRmM2ZhMmZhYjQ3OTgwODk1YzkxL3RhYmxlOjA5MDBhY2M4MTE5MjQ5N2RiYWI3YTU2NjVkMjg0ZGNhL3RhYmxlcmFuZ2U6MDkwMGFjYzgxMTkyNDk3ZGJhYjdhNTY2NWQyODRkY2FfOC05LTEtMS0yODIyMQ_fcefd6dd-60b6-4c56-9c3e-7107b7690e66"
      unitRef="usd">24266000</cort:AvailableForSaleSecuritiesIncludingCashEquivalents>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ifa8d40f1022a4fdbad599ef4cc0332c2_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNy9mcmFnOmZlMTQxZDk2ZjU2MTRmM2ZhMmZhYjQ3OTgwODk1YzkxL3RhYmxlOjA5MDBhY2M4MTE5MjQ5N2RiYWI3YTU2NjVkMjg0ZGNhL3RhYmxlcmFuZ2U6MDkwMGFjYzgxMTkyNDk3ZGJhYjdhNTY2NWQyODRkY2FfOC0xMS0xLTEtMjgyMjE_df9b6f55-b0c9-4f43-9c07-edfca2cdea4b"
      unitRef="usd">45088000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ifa8d40f1022a4fdbad599ef4cc0332c2_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNy9mcmFnOmZlMTQxZDk2ZjU2MTRmM2ZhMmZhYjQ3OTgwODk1YzkxL3RhYmxlOjA5MDBhY2M4MTE5MjQ5N2RiYWI3YTU2NjVkMjg0ZGNhL3RhYmxlcmFuZ2U6MDkwMGFjYzgxMTkyNDk3ZGJhYjdhNTY2NWQyODRkY2FfOC0xMy0xLTEtMjgyMjE_b09a80c5-f05a-42bc-8d06-dd93ec203f76"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ifa8d40f1022a4fdbad599ef4cc0332c2_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNy9mcmFnOmZlMTQxZDk2ZjU2MTRmM2ZhMmZhYjQ3OTgwODk1YzkxL3RhYmxlOjA5MDBhY2M4MTE5MjQ5N2RiYWI3YTU2NjVkMjg0ZGNhL3RhYmxlcmFuZ2U6MDkwMGFjYzgxMTkyNDk3ZGJhYjdhNTY2NWQyODRkY2FfOC0xNS0xLTEtMjgyMjE_417596d6-e143-4a56-8e90-ff764ebbb312"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <cort:AvailableForSaleSecuritiesIncludingCashEquivalents
      contextRef="ifa8d40f1022a4fdbad599ef4cc0332c2_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNy9mcmFnOmZlMTQxZDk2ZjU2MTRmM2ZhMmZhYjQ3OTgwODk1YzkxL3RhYmxlOjA5MDBhY2M4MTE5MjQ5N2RiYWI3YTU2NjVkMjg0ZGNhL3RhYmxlcmFuZ2U6MDkwMGFjYzgxMTkyNDk3ZGJhYjdhNTY2NWQyODRkY2FfOC0xNy0xLTEtMjgyMjE_f5d5e099-acb8-4912-ae6b-f1f67d14584e"
      unitRef="usd">45088000</cort:AvailableForSaleSecuritiesIncludingCashEquivalents>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i5f690dc4c12e4400835f0643973b82b2_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNy9mcmFnOmZlMTQxZDk2ZjU2MTRmM2ZhMmZhYjQ3OTgwODk1YzkxL3RhYmxlOjA5MDBhY2M4MTE5MjQ5N2RiYWI3YTU2NjVkMjg0ZGNhL3RhYmxlcmFuZ2U6MDkwMGFjYzgxMTkyNDk3ZGJhYjdhNTY2NWQyODRkY2FfOS0zLTEtMS0yODIyMQ_f565dfc0-7115-47d8-bf4f-ded5adf4865c"
      unitRef="usd">331929000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i5f690dc4c12e4400835f0643973b82b2_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNy9mcmFnOmZlMTQxZDk2ZjU2MTRmM2ZhMmZhYjQ3OTgwODk1YzkxL3RhYmxlOjA5MDBhY2M4MTE5MjQ5N2RiYWI3YTU2NjVkMjg0ZGNhL3RhYmxlcmFuZ2U6MDkwMGFjYzgxMTkyNDk3ZGJhYjdhNTY2NWQyODRkY2FfOS01LTEtMS0yODIyMQ_8e89e883-2ddc-43ec-b8ef-9af464f84241"
      unitRef="usd">4000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i5f690dc4c12e4400835f0643973b82b2_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNy9mcmFnOmZlMTQxZDk2ZjU2MTRmM2ZhMmZhYjQ3OTgwODk1YzkxL3RhYmxlOjA5MDBhY2M4MTE5MjQ5N2RiYWI3YTU2NjVkMjg0ZGNhL3RhYmxlcmFuZ2U6MDkwMGFjYzgxMTkyNDk3ZGJhYjdhNTY2NWQyODRkY2FfOS03LTEtMS0yODIyMQ_8e7e0433-23c7-4f8d-a10e-8fadef1a0f32"
      unitRef="usd">1436000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <cort:AvailableForSaleSecuritiesIncludingCashEquivalents
      contextRef="i5f690dc4c12e4400835f0643973b82b2_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNy9mcmFnOmZlMTQxZDk2ZjU2MTRmM2ZhMmZhYjQ3OTgwODk1YzkxL3RhYmxlOjA5MDBhY2M4MTE5MjQ5N2RiYWI3YTU2NjVkMjg0ZGNhL3RhYmxlcmFuZ2U6MDkwMGFjYzgxMTkyNDk3ZGJhYjdhNTY2NWQyODRkY2FfOS05LTEtMS0yODIyMQ_233d9323-57ad-47fc-ad58-05b553e93b9d"
      unitRef="usd">330497000</cort:AvailableForSaleSecuritiesIncludingCashEquivalents>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ibd5d76c213a042ae897b90f0a8ec4a60_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNy9mcmFnOmZlMTQxZDk2ZjU2MTRmM2ZhMmZhYjQ3OTgwODk1YzkxL3RhYmxlOjA5MDBhY2M4MTE5MjQ5N2RiYWI3YTU2NjVkMjg0ZGNhL3RhYmxlcmFuZ2U6MDkwMGFjYzgxMTkyNDk3ZGJhYjdhNTY2NWQyODRkY2FfOS0xMS0xLTEtMjgyMjE_ceda885c-3ab3-46a5-933c-56bddca9c382"
      unitRef="usd">303695000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ibd5d76c213a042ae897b90f0a8ec4a60_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNy9mcmFnOmZlMTQxZDk2ZjU2MTRmM2ZhMmZhYjQ3OTgwODk1YzkxL3RhYmxlOjA5MDBhY2M4MTE5MjQ5N2RiYWI3YTU2NjVkMjg0ZGNhL3RhYmxlcmFuZ2U6MDkwMGFjYzgxMTkyNDk3ZGJhYjdhNTY2NWQyODRkY2FfOS0xMy0xLTEtMjgyMjE_08e572ae-618c-4e31-81cd-75c8ef930e8a"
      unitRef="usd">3000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ibd5d76c213a042ae897b90f0a8ec4a60_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNy9mcmFnOmZlMTQxZDk2ZjU2MTRmM2ZhMmZhYjQ3OTgwODk1YzkxL3RhYmxlOjA5MDBhY2M4MTE5MjQ5N2RiYWI3YTU2NjVkMjg0ZGNhL3RhYmxlcmFuZ2U6MDkwMGFjYzgxMTkyNDk3ZGJhYjdhNTY2NWQyODRkY2FfOS0xNS0xLTEtMjgyMjE_3273c78f-9588-4189-818f-7fc34db21755"
      unitRef="usd">415000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <cort:AvailableForSaleSecuritiesIncludingCashEquivalents
      contextRef="ibd5d76c213a042ae897b90f0a8ec4a60_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNy9mcmFnOmZlMTQxZDk2ZjU2MTRmM2ZhMmZhYjQ3OTgwODk1YzkxL3RhYmxlOjA5MDBhY2M4MTE5MjQ5N2RiYWI3YTU2NjVkMjg0ZGNhL3RhYmxlcmFuZ2U6MDkwMGFjYzgxMTkyNDk3ZGJhYjdhNTY2NWQyODRkY2FfOS0xNy0xLTEtMjgyMjE_ac10152e-135f-4610-a25d-d0c3e9086b05"
      unitRef="usd">303283000</cort:AvailableForSaleSecuritiesIncludingCashEquivalents>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i93f424f685944c1aab994f99b0146441_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNy9mcmFnOmZlMTQxZDk2ZjU2MTRmM2ZhMmZhYjQ3OTgwODk1YzkxL3RleHRyZWdpb246ZmUxNDFkOTZmNTYxNGYzZmEyZmFiNDc5ODA4OTVjOTFfMjE5OTAyMzI2MjA2NA_0ed7a987-0770-420f-af2a-f1765ee49320"
      unitRef="usd">1400000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="iac7c0f0822b942fa8f45ea15693a76af_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNy9mcmFnOmZlMTQxZDk2ZjU2MTRmM2ZhMmZhYjQ3OTgwODk1YzkxL3RleHRyZWdpb246ZmUxNDFkOTZmNTYxNGYzZmEyZmFiNDc5ODA4OTVjOTFfMjE5OTAyMzI2MjA3Mg_96984209-fd79-4436-a759-17ba65290000"
      unitRef="usd">400000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:InterestReceivableCurrent
      contextRef="i93f424f685944c1aab994f99b0146441_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNy9mcmFnOmZlMTQxZDk2ZjU2MTRmM2ZhMmZhYjQ3OTgwODk1YzkxL3RleHRyZWdpb246ZmUxNDFkOTZmNTYxNGYzZmEyZmFiNDc5ODA4OTVjOTFfMTY3MQ_9eaf397b-0d88-43c5-a094-153c0ca01ee2"
      unitRef="usd">1000000</us-gaap:InterestReceivableCurrent>
    <us-gaap:InterestReceivableCurrent
      contextRef="iac7c0f0822b942fa8f45ea15693a76af_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNy9mcmFnOmZlMTQxZDk2ZjU2MTRmM2ZhMmZhYjQ3OTgwODk1YzkxL3RleHRyZWdpb246ZmUxNDFkOTZmNTYxNGYzZmEyZmFiNDc5ODA4OTVjOTFfMTY3OA_d98ec88f-bff6-44da-a034-4dfcb380b319"
      unitRef="usd">1400000</us-gaap:InterestReceivableCurrent>
    <cort:MarketableSecuritiesMaximumMaturityPeriod
      contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNy9mcmFnOmZlMTQxZDk2ZjU2MTRmM2ZhMmZhYjQ3OTgwODk1YzkxL3RleHRyZWdpb246ZmUxNDFkOTZmNTYxNGYzZmEyZmFiNDc5ODA4OTVjOTFfMTg3MQ_c2bf08fc-1716-4f8c-a6df-6e45fe88edd8">P2Y</cort:MarketableSecuritiesMaximumMaturityPeriod>
    <cort:MarketableSecuritiesWeightedAverageMaturityPeriod
      contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNy9mcmFnOmZlMTQxZDk2ZjU2MTRmM2ZhMmZhYjQ3OTgwODk1YzkxL3RleHRyZWdpb246ZmUxNDFkOTZmNTYxNGYzZmEyZmFiNDc5ODA4OTVjOTFfMTkyNQ_65301e8d-3f92-4cba-a66e-1703ef6a9ba7">P7M</cort:MarketableSecuritiesWeightedAverageMaturityPeriod>
    <cort:LongTermMarketableSecuritiesRemainingMaturity
      contextRef="i99f1fc2c348e48a0bb5c6c67e90ffd73_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNy9mcmFnOmZlMTQxZDk2ZjU2MTRmM2ZhMmZhYjQ3OTgwODk1YzkxL3RleHRyZWdpb246ZmUxNDFkOTZmNTYxNGYzZmEyZmFiNDc5ODA4OTVjOTFfMjAxMw_7382c091-b9fe-468d-8891-1e7567d7127e">P12M</cort:LongTermMarketableSecuritiesRemainingMaturity>
    <cort:LongTermMarketableSecuritiesRemainingMaturity
      contextRef="ieaf64132df2543a583e4e8f6aa3d5517_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV8zNy9mcmFnOmZlMTQxZDk2ZjU2MTRmM2ZhMmZhYjQ3OTgwODk1YzkxL3RleHRyZWdpb246ZmUxNDFkOTZmNTYxNGYzZmEyZmFiNDc5ODA4OTVjOTFfMjAxOQ_ebaef7cd-388f-4ace-9108-e2e94dc0ac54">P24M</cort:LongTermMarketableSecuritiesRemainingMaturity>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV80MC9mcmFnOmYyOWJhODdjNmQ0YzRlNDZiN2JkMjY0MGZlY2Y3NzMxL3RleHRyZWdpb246ZjI5YmE4N2M2ZDRjNGU0NmI3YmQyNjQwZmVjZjc3MzFfNzIy_b1f98d76-9e53-4253-8c3e-b2586f8e3c33">Commitments and Contingencies&lt;div style="margin-top:9pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; There have been no material changes in our obligations under contractual agreements described in our Annual Report on Form&#160;10-K for the year ended&#160;December&#160;31, 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the ordinary course of business, we may be subject to legal claims and regulatory actions that could have a material adverse effect on our business or financial position. We assess our potential liability in such situations by analyzing potential &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;outcomes under various litigation, regulatory and settlement strategies.&#160;If we determine a loss is probable and its amount can be reasonably estimated, we accrue an amount equal to the estimated loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;No losses and&#160;no provision for a loss contingency have been recorded to date.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="i93f424f685944c1aab994f99b0146441_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV80MC9mcmFnOmYyOWJhODdjNmQ0YzRlNDZiN2JkMjY0MGZlY2Y3NzMxL3RleHRyZWdpb246ZjI5YmE4N2M2ZDRjNGU0NmI3YmQyNjQwZmVjZjc3MzFfNzE4_23884279-9cc2-42bf-afe2-3eafdf03e081"
      unitRef="usd">0</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:LossContingencyAccrualProvision
      contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV80MC9mcmFnOmYyOWJhODdjNmQ0YzRlNDZiN2JkMjY0MGZlY2Y3NzMxL3RleHRyZWdpb246ZjI5YmE4N2M2ZDRjNGU0NmI3YmQyNjQwZmVjZjc3MzFfNzE5_8ef169be-1790-40fd-8f63-09927bb8f447"
      unitRef="usd">0</us-gaap:LossContingencyAccrualProvision>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV84MzgvZnJhZzpkNjM0YjRiZTYxZGI0MDVjYTk4MGRhOWJlMDhlMjcwYS90ZXh0cmVnaW9uOmQ2MzRiNGJlNjFkYjQwNWNhOTgwZGE5YmUwOGUyNzBhXzYwNDczMTM5NTQ1NzM_8de2abef-4b29-41c6-ae47-75d035e85bf8">Leases&lt;div style="margin-top:9pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We lease our office facilities in Menlo Park, California. In March 2022, we amended our lease to extend its term from March 31, 2022 to June 30, 2023. As a result of this amendment, we recognized an additional right-of-use asset and corresponding lease liability of $2.8 million. The right-of-use asset and lease liability recognized equals the present value of the remaining payments due under our amended lease.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As the operating lease for our facilities does not include an expressly stated interest rate, we calculated the present value of remaining lease payments using a discount rate equal to the interest rate we would pay on a collateralized loan with monthly payments and a term equal to the monthly payments and remaining term of our lease. We recognize operating lease payments as expenses using the straight-line method over the term of the lease.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease expense for each of the three months ended March&#160;31, 2022 and 2021 was approximately $0.5&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our right-of-use assets and related lease liabilities were as follows &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in thousands, except weighted average amounts)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.213%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.452%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.381%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.454%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid for operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;530&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;514&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets obtained in exchange for new operating lease obligations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,816&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining lease term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15 months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12 months&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2022, future minimum lease payments under non-cancelable operating leases were as follows &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:83.256%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022 (remainder)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,735&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,892&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(76)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,816&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="id8d3c6d4eed84ccdb36200d115427751_I20190131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV84MzgvZnJhZzpkNjM0YjRiZTYxZGI0MDVjYTk4MGRhOWJlMDhlMjcwYS90ZXh0cmVnaW9uOmQ2MzRiNGJlNjFkYjQwNWNhOTgwZGE5YmUwOGUyNzBhXzIxOTkwMjMyNTczMzU_ad5ec2c1-72d0-4450-910f-f2e0fc211566"
      unitRef="usd">2800000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="id8d3c6d4eed84ccdb36200d115427751_I20190131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV84MzgvZnJhZzpkNjM0YjRiZTYxZGI0MDVjYTk4MGRhOWJlMDhlMjcwYS90ZXh0cmVnaW9uOmQ2MzRiNGJlNjFkYjQwNWNhOTgwZGE5YmUwOGUyNzBhXzIxOTkwMjMyNTczMzU_b8e7a75f-fe9a-43fa-9eda-9996a8fa8137"
      unitRef="usd">2800000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseExpense
      contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV84MzgvZnJhZzpkNjM0YjRiZTYxZGI0MDVjYTk4MGRhOWJlMDhlMjcwYS90ZXh0cmVnaW9uOmQ2MzRiNGJlNjFkYjQwNWNhOTgwZGE5YmUwOGUyNzBhXzIxOTkwMjMyNTczODk_a185d092-92cd-49b1-a9ab-51cd10e6e951"
      unitRef="usd">500000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="i0ebb8d8bac3445859e468a3d048cfaf5_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV84MzgvZnJhZzpkNjM0YjRiZTYxZGI0MDVjYTk4MGRhOWJlMDhlMjcwYS90ZXh0cmVnaW9uOmQ2MzRiNGJlNjFkYjQwNWNhOTgwZGE5YmUwOGUyNzBhXzIxOTkwMjMyNTczODk_b17d8422-31c8-4fe8-a18c-f1507ef9d831"
      unitRef="usd">500000</us-gaap:OperatingLeaseExpense>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV84MzgvZnJhZzpkNjM0YjRiZTYxZGI0MDVjYTk4MGRhOWJlMDhlMjcwYS90ZXh0cmVnaW9uOmQ2MzRiNGJlNjFkYjQwNWNhOTgwZGE5YmUwOGUyNzBhXzYwNDczMTM5NTQ1NzQ_d97326bc-a21e-4250-ad42-506b51f2289e">&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our right-of-use assets and related lease liabilities were as follows &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in thousands, except weighted average amounts)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.213%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.452%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.381%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.454%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid for operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;530&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;514&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets obtained in exchange for new operating lease obligations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,816&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining lease term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15 months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12 months&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeasePayments
      contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV84MzgvZnJhZzpkNjM0YjRiZTYxZGI0MDVjYTk4MGRhOWJlMDhlMjcwYS90YWJsZTowZjE0ZWVkYTAwMjE0MjUwYjc3ZGQ2NzE1NTJhNjQ5OC90YWJsZXJhbmdlOjBmMTRlZWRhMDAyMTQyNTBiNzdkZDY3MTU1MmE2NDk4XzItMS0xLTEtMzUyNjI_ff2a01fc-eb44-4145-aa91-69cda159ae10"
      unitRef="usd">530000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="i0ebb8d8bac3445859e468a3d048cfaf5_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV84MzgvZnJhZzpkNjM0YjRiZTYxZGI0MDVjYTk4MGRhOWJlMDhlMjcwYS90YWJsZTowZjE0ZWVkYTAwMjE0MjUwYjc3ZGQ2NzE1NTJhNjQ5OC90YWJsZXJhbmdlOjBmMTRlZWRhMDAyMTQyNTBiNzdkZDY3MTU1MmE2NDk4XzItMy0xLTEtMzUyNjI_4aece9d7-2401-4536-b19a-9fcc85896330"
      unitRef="usd">514000</us-gaap:OperatingLeasePayments>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV84MzgvZnJhZzpkNjM0YjRiZTYxZGI0MDVjYTk4MGRhOWJlMDhlMjcwYS90YWJsZTowZjE0ZWVkYTAwMjE0MjUwYjc3ZGQ2NzE1NTJhNjQ5OC90YWJsZXJhbmdlOjBmMTRlZWRhMDAyMTQyNTBiNzdkZDY3MTU1MmE2NDk4XzMtMS0xLTEtMzUyNjI_deb247f9-d16d-4124-9947-a91939df75be"
      unitRef="usd">2816000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i0ebb8d8bac3445859e468a3d048cfaf5_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV84MzgvZnJhZzpkNjM0YjRiZTYxZGI0MDVjYTk4MGRhOWJlMDhlMjcwYS90YWJsZTowZjE0ZWVkYTAwMjE0MjUwYjc3ZGQ2NzE1NTJhNjQ5OC90YWJsZXJhbmdlOjBmMTRlZWRhMDAyMTQyNTBiNzdkZDY3MTU1MmE2NDk4XzMtMy0xLTEtMzUyNjI_a2312419-cfd3-4b7e-a653-42d73d2c3f12"
      unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i93f424f685944c1aab994f99b0146441_I20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV84MzgvZnJhZzpkNjM0YjRiZTYxZGI0MDVjYTk4MGRhOWJlMDhlMjcwYS90YWJsZTowZjE0ZWVkYTAwMjE0MjUwYjc3ZGQ2NzE1NTJhNjQ5OC90YWJsZXJhbmdlOjBmMTRlZWRhMDAyMTQyNTBiNzdkZDY3MTU1MmE2NDk4XzQtMS0xLTEtMzUyNjI_77026c60-b75d-4a54-8817-f7648d0b4550">P15M</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i82ca1385b4a848fd8ea581edd7dcbfdb_I20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV84MzgvZnJhZzpkNjM0YjRiZTYxZGI0MDVjYTk4MGRhOWJlMDhlMjcwYS90YWJsZTowZjE0ZWVkYTAwMjE0MjUwYjc3ZGQ2NzE1NTJhNjQ5OC90YWJsZXJhbmdlOjBmMTRlZWRhMDAyMTQyNTBiNzdkZDY3MTU1MmE2NDk4XzQtMy0xLTEtMzUyNjI_67bc8173-c26f-4f46-8927-2ecda76063a4">P12M</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i93f424f685944c1aab994f99b0146441_I20220331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV84MzgvZnJhZzpkNjM0YjRiZTYxZGI0MDVjYTk4MGRhOWJlMDhlMjcwYS90YWJsZTowZjE0ZWVkYTAwMjE0MjUwYjc3ZGQ2NzE1NTJhNjQ5OC90YWJsZXJhbmdlOjBmMTRlZWRhMDAyMTQyNTBiNzdkZDY3MTU1MmE2NDk4XzUtMS0xLTEtMzUyNjI_cf0becc4-03b4-4385-8e29-97d0f3a17563"
      unitRef="number">0.040</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i82ca1385b4a848fd8ea581edd7dcbfdb_I20210331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV84MzgvZnJhZzpkNjM0YjRiZTYxZGI0MDVjYTk4MGRhOWJlMDhlMjcwYS90YWJsZTowZjE0ZWVkYTAwMjE0MjUwYjc3ZGQ2NzE1NTJhNjQ5OC90YWJsZXJhbmdlOjBmMTRlZWRhMDAyMTQyNTBiNzdkZDY3MTU1MmE2NDk4XzUtMy0xLTEtMzUyNjI_032cf413-dffd-4ba6-9500-1edbe9667841"
      unitRef="number">0.048</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV84MzgvZnJhZzpkNjM0YjRiZTYxZGI0MDVjYTk4MGRhOWJlMDhlMjcwYS90ZXh0cmVnaW9uOmQ2MzRiNGJlNjFkYjQwNWNhOTgwZGE5YmUwOGUyNzBhXzYwNDczMTM5NTQ1NzU_9ae1b7bf-0033-4e64-a5c1-7a801b94407a">&lt;div style="margin-top:9pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2022, future minimum lease payments under non-cancelable operating leases were as follows &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:83.256%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022 (remainder)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,735&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,892&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(76)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,816&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="i93f424f685944c1aab994f99b0146441_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV84MzgvZnJhZzpkNjM0YjRiZTYxZGI0MDVjYTk4MGRhOWJlMDhlMjcwYS90YWJsZTphMjk2MTBhYjc5MjU0YmE4YTFlZGE1YzNkOTNjNjA0YS90YWJsZXJhbmdlOmEyOTYxMGFiNzkyNTRiYThhMWVkYTVjM2Q5M2M2MDRhXzAtMS0xLTEtMzUyNzA_56914309-4f76-40b2-bc49-b27f6a339e29"
      unitRef="usd">1735000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="i93f424f685944c1aab994f99b0146441_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV84MzgvZnJhZzpkNjM0YjRiZTYxZGI0MDVjYTk4MGRhOWJlMDhlMjcwYS90YWJsZTphMjk2MTBhYjc5MjU0YmE4YTFlZGE1YzNkOTNjNjA0YS90YWJsZXJhbmdlOmEyOTYxMGFiNzkyNTRiYThhMWVkYTVjM2Q5M2M2MDRhXzEtMS0xLTEtMzUyNzA_d9a27276-17ea-4200-8bc2-9edac20b4036"
      unitRef="usd">1157000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i93f424f685944c1aab994f99b0146441_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV84MzgvZnJhZzpkNjM0YjRiZTYxZGI0MDVjYTk4MGRhOWJlMDhlMjcwYS90YWJsZTphMjk2MTBhYjc5MjU0YmE4YTFlZGE1YzNkOTNjNjA0YS90YWJsZXJhbmdlOmEyOTYxMGFiNzkyNTRiYThhMWVkYTVjM2Q5M2M2MDRhXzItMS0xLTEtMzUyNzA_fa0a4014-1a6d-4759-9fb1-1481ac4b0d14"
      unitRef="usd">2892000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="i93f424f685944c1aab994f99b0146441_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV84MzgvZnJhZzpkNjM0YjRiZTYxZGI0MDVjYTk4MGRhOWJlMDhlMjcwYS90YWJsZTphMjk2MTBhYjc5MjU0YmE4YTFlZGE1YzNkOTNjNjA0YS90YWJsZXJhbmdlOmEyOTYxMGFiNzkyNTRiYThhMWVkYTVjM2Q5M2M2MDRhXzMtMS0xLTEtMzUyNzA_a219a2f8-097b-44c9-81b2-105af36d76be"
      unitRef="usd">76000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="i93f424f685944c1aab994f99b0146441_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV84MzgvZnJhZzpkNjM0YjRiZTYxZGI0MDVjYTk4MGRhOWJlMDhlMjcwYS90YWJsZTphMjk2MTBhYjc5MjU0YmE4YTFlZGE1YzNkOTNjNjA0YS90YWJsZXJhbmdlOmEyOTYxMGFiNzkyNTRiYThhMWVkYTVjM2Q5M2M2MDRhXzQtMS0xLTEtMzUyNzA_759e26cb-5067-4d08-a05f-74f0440d8e30"
      unitRef="usd">2816000</us-gaap:OperatingLeaseLiability>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV80My9mcmFnOjZlMTRkN2FhMWVjYTQ2NDQ4MTNkOTU3ZjhlNTNkMzc0L3RleHRyZWdpb246NmUxNGQ3YWExZWNhNDY0NDgxM2Q5NTdmOGU1M2QzNzRfMjQxNQ_e2cd587f-dfd9-4175-857b-47c731481806">Stockholders&#x2019; Equity&lt;div style="margin-top:9pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Incentive Award Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have one stock option plan &#x2013; the 2012 Incentive Award Plan (the &#x201c;2012 Plan&#x201d;).&#160;In December 2021, our Board of Directors authorized a 4.2&#160;million increase in the shares available for grant under the 2012 Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock Options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March 31, 2022, we issued 0.6&#160;million shares of our common stock upon the exercise of stock options. Certain option holders exercised their options on a &#x201c;net exercise&#x201d; basis, pursuant to which they surrendered to us, and we purchased from them at the current market price, enough shares to cover the exercise price and tax withholding obligations arising from the exercise. During the three months ended March 31, 2022, we purchased 0.3&#160;million shares in connection with such option net exercises. In connection with the shares purchased, during the three months ended March 31, 2022, we paid $1.9&#160;million to satisfy associated tax withholding obligations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March 31, 2021, we issued 1.8&#160;million shares of our common stock upon the exercise of stock options. We purchased 0.8&#160;million shares in connection with option net exercises, at a total cost of $16.4&#160;million, to satisfy associated tax withholding obligations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recorded purchased shares as treasury stock on our condensed consolidated balance sheets at cost. As of March&#160;31, 2022 and December&#160;31, 2021, we had 21.6&#160;million and 21.3&#160;million treasury shares outstanding, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted Stock Units (&#x201c;RSUs&#x201d;)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March 31, 2022, we granted employees 0.2 million RSUs with a weighted-average grant date fair value of $19.34 per share. No RSUs vested during the period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Employee Stock Purchase Plan (&#x201c;ESPP&#x201d;)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2022 we adopted an ESPP that allows employees to set aside, by means of payroll deductions, up to ten percent of their annual compensation for the purchase of our commons stock. Shares are issued to participating employees from the 2012 Plan on March 1st and September 1st of each year (or, if those dates fall on holidays, on the first business day thereafter) at the then-current fair market value of our stock, as determined at the close of trading on those days. Payroll deductions for participating employees began April 1, 2022, and the first purchase under the plan will take place on September 1, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For each purchased share held for one year, the purchasing employee will receive one matching share, also issued from the 2012 Plan, net of any applicable tax withholding. There is no vesting requirement with respect to shares issued pursuant to the ESPP. Shares purchased pursuant to the ESPP as well as any matching shares issued upon satisfaction of the one-year holding requirement may be held, sold or otherwise transferred at the employee&#x2019;s sole discretion.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation expense associated with stock options and awards of restricted stock is measured at the grant date based on the fair value of the award, and is recognized, net of forfeitures, as expense over the remaining requisite service period on a straight-line basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company values restricted stock at the closing market price of the Company&#x2019;s common stock on the date of grant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our stock-based compensation by account:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation capitalized in inventory&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,586&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <cort:NumberOfStockOptionPlans
      contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV80My9mcmFnOjZlMTRkN2FhMWVjYTQ2NDQ4MTNkOTU3ZjhlNTNkMzc0L3RleHRyZWdpb246NmUxNGQ3YWExZWNhNDY0NDgxM2Q5NTdmOGU1M2QzNzRfNjA0NzMxMzk4Njk2Mw_6f2bf276-f2b0-41df-b41b-2e13014028bb"
      unitRef="stockoptionplan">1</cort:NumberOfStockOptionPlans>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="iea23a3d3fb214422896877163db10055_D20211201-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV80My9mcmFnOjZlMTRkN2FhMWVjYTQ2NDQ4MTNkOTU3ZjhlNTNkMzc0L3RleHRyZWdpb246NmUxNGQ3YWExZWNhNDY0NDgxM2Q5NTdmOGU1M2QzNzRfMjE5OTAyMzI1ODA1MA_5da00738-749d-438e-9830-ac81eca02b8b"
      unitRef="shares">4200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV80My9mcmFnOjZlMTRkN2FhMWVjYTQ2NDQ4MTNkOTU3ZjhlNTNkMzc0L3RleHRyZWdpb246NmUxNGQ3YWExZWNhNDY0NDgxM2Q5NTdmOGU1M2QzNzRfMzI5_5b589f29-9489-48ba-8ae2-b5a214ce2ed5"
      unitRef="shares">600000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation
      contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV80My9mcmFnOjZlMTRkN2FhMWVjYTQ2NDQ4MTNkOTU3ZjhlNTNkMzc0L3RleHRyZWdpb246NmUxNGQ3YWExZWNhNDY0NDgxM2Q5NTdmOGU1M2QzNzRfNjgy_5dc2025d-e5c7-42ef-a7b5-6d3b251b55ee"
      unitRef="shares">300000</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV80My9mcmFnOjZlMTRkN2FhMWVjYTQ2NDQ4MTNkOTU3ZjhlNTNkMzc0L3RleHRyZWdpb246NmUxNGQ3YWExZWNhNDY0NDgxM2Q5NTdmOGU1M2QzNzRfMjE5OTAyMzI1ODU5OQ_d3fc2204-2875-4a83-94c5-48e5e070597e"
      unitRef="usd">1900000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i0ebb8d8bac3445859e468a3d048cfaf5_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV80My9mcmFnOjZlMTRkN2FhMWVjYTQ2NDQ4MTNkOTU3ZjhlNTNkMzc0L3RleHRyZWdpb246NmUxNGQ3YWExZWNhNDY0NDgxM2Q5NTdmOGU1M2QzNzRfODg0_07838585-d7fc-4ab4-8acb-47fa42cabd5a"
      unitRef="shares">1800000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation
      contextRef="i0ebb8d8bac3445859e468a3d048cfaf5_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV80My9mcmFnOjZlMTRkN2FhMWVjYTQ2NDQ4MTNkOTU3ZjhlNTNkMzc0L3RleHRyZWdpb246NmUxNGQ3YWExZWNhNDY0NDgxM2Q5NTdmOGU1M2QzNzRfMjE5OTAyMzI5MDEzMA_db5f17f0-0f7d-4639-af99-82eb37b27433"
      unitRef="shares">800000</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i0ebb8d8bac3445859e468a3d048cfaf5_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV80My9mcmFnOjZlMTRkN2FhMWVjYTQ2NDQ4MTNkOTU3ZjhlNTNkMzc0L3RleHRyZWdpb246NmUxNGQ3YWExZWNhNDY0NDgxM2Q5NTdmOGU1M2QzNzRfMjE5OTAyMzI5MDEwNw_3fc61cc3-07c9-4b77-ab76-83bc7d486aca"
      unitRef="usd">16400000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV80My9mcmFnOjZlMTRkN2FhMWVjYTQ2NDQ4MTNkOTU3ZjhlNTNkMzc0L3RleHRyZWdpb246NmUxNGQ3YWExZWNhNDY0NDgxM2Q5NTdmOGU1M2QzNzRfMjI1OQ_37256e3b-9938-4fbe-8b89-a51cf479a883"
      unitRef="shares">21600000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i0ebb8d8bac3445859e468a3d048cfaf5_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV80My9mcmFnOjZlMTRkN2FhMWVjYTQ2NDQ4MTNkOTU3ZjhlNTNkMzc0L3RleHRyZWdpb246NmUxNGQ3YWExZWNhNDY0NDgxM2Q5NTdmOGU1M2QzNzRfMjI2Ng_b5f303cc-c950-4a70-bd82-b65f0a1403c7"
      unitRef="shares">21300000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i52a9c7a889214b11ad5675cc29794ba8_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV80My9mcmFnOjZlMTRkN2FhMWVjYTQ2NDQ4MTNkOTU3ZjhlNTNkMzc0L3RleHRyZWdpb246NmUxNGQ3YWExZWNhNDY0NDgxM2Q5NTdmOGU1M2QzNzRfMjE5OTAyMzI4OTcxNw_b4f23974-762a-45c6-9c53-94f1c4969a56"
      unitRef="shares">200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i52a9c7a889214b11ad5675cc29794ba8_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV80My9mcmFnOjZlMTRkN2FhMWVjYTQ2NDQ4MTNkOTU3ZjhlNTNkMzc0L3RleHRyZWdpb246NmUxNGQ3YWExZWNhNDY0NDgxM2Q5NTdmOGU1M2QzNzRfMjE5OTAyMzI4OTcyOQ_3a89ecb9-e8b9-4e78-8e58-6e96a553701f"
      unitRef="usdPerShare">19.34</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV80My9mcmFnOjZlMTRkN2FhMWVjYTQ2NDQ4MTNkOTU3ZjhlNTNkMzc0L3RleHRyZWdpb246NmUxNGQ3YWExZWNhNDY0NDgxM2Q5NTdmOGU1M2QzNzRfMjQxNA_dd947806-b0a1-4f55-8b47-2d353cb0643b">&lt;div style="margin-top:9pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our stock-based compensation by account:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation capitalized in inventory&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,586&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV80My9mcmFnOjZlMTRkN2FhMWVjYTQ2NDQ4MTNkOTU3ZjhlNTNkMzc0L3RhYmxlOmE0YTQwZmI1MjdhYTQ5MzY5M2Q0YTNmODRkMjQzMmU2L3RhYmxlcmFuZ2U6YTRhNDBmYjUyN2FhNDkzNjkzZDRhM2Y4NGQyNDMyZTZfNC0xLTEtMS0yODIyMQ_5e4f5378-db56-4b70-ad9f-46a64f00a2c7"
      unitRef="usd">64000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="i0ebb8d8bac3445859e468a3d048cfaf5_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV80My9mcmFnOjZlMTRkN2FhMWVjYTQ2NDQ4MTNkOTU3ZjhlNTNkMzc0L3RhYmxlOmE0YTQwZmI1MjdhYTQ5MzY5M2Q0YTNmODRkMjQzMmU2L3RhYmxlcmFuZ2U6YTRhNDBmYjUyN2FhNDkzNjkzZDRhM2Y4NGQyNDMyZTZfNC0zLTEtMS0yODIyMQ_6afda0b6-484a-4454-9941-727789e6752a"
      unitRef="usd">41000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i84ac47ee98bd42c490c47ffe50f5648d_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV80My9mcmFnOjZlMTRkN2FhMWVjYTQ2NDQ4MTNkOTU3ZjhlNTNkMzc0L3RhYmxlOmE0YTQwZmI1MjdhYTQ5MzY5M2Q0YTNmODRkMjQzMmU2L3RhYmxlcmFuZ2U6YTRhNDBmYjUyN2FhNDkzNjkzZDRhM2Y4NGQyNDMyZTZfNS0xLTEtMS0yODIyMQ_c1bddd90-c282-4234-9f69-2f95a7aef1e9"
      unitRef="usd">16000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i6b5e7570f4ee4e91920827cf4275116e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV80My9mcmFnOjZlMTRkN2FhMWVjYTQ2NDQ4MTNkOTU3ZjhlNTNkMzc0L3RhYmxlOmE0YTQwZmI1MjdhYTQ5MzY5M2Q0YTNmODRkMjQzMmU2L3RhYmxlcmFuZ2U6YTRhNDBmYjUyN2FhNDkzNjkzZDRhM2Y4NGQyNDMyZTZfNS0zLTEtMS0yODIyMQ_95971c0f-5692-41f7-aaea-564a7b034356"
      unitRef="usd">10000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i715a1de9af124f9bbf4fc1f32f12f6c8_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV80My9mcmFnOjZlMTRkN2FhMWVjYTQ2NDQ4MTNkOTU3ZjhlNTNkMzc0L3RhYmxlOmE0YTQwZmI1MjdhYTQ5MzY5M2Q0YTNmODRkMjQzMmU2L3RhYmxlcmFuZ2U6YTRhNDBmYjUyN2FhNDkzNjkzZDRhM2Y4NGQyNDMyZTZfNi0xLTEtMS0yODIyMQ_b46b91fd-0e8b-4a34-93a1-d366ae3b4aee"
      unitRef="usd">3371000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i056b689380d140aca93fdcee21bcdca1_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV80My9mcmFnOjZlMTRkN2FhMWVjYTQ2NDQ4MTNkOTU3ZjhlNTNkMzc0L3RhYmxlOmE0YTQwZmI1MjdhYTQ5MzY5M2Q0YTNmODRkMjQzMmU2L3RhYmxlcmFuZ2U6YTRhNDBmYjUyN2FhNDkzNjkzZDRhM2Y4NGQyNDMyZTZfNi0zLTEtMS0yODIyMQ_d667fcb8-8c1b-43ea-b8fe-1d2c7c6fa685"
      unitRef="usd">3505000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i6cbc329d8aed49d7b08ed92b59aa995b_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV80My9mcmFnOjZlMTRkN2FhMWVjYTQ2NDQ4MTNkOTU3ZjhlNTNkMzc0L3RhYmxlOmE0YTQwZmI1MjdhYTQ5MzY5M2Q0YTNmODRkMjQzMmU2L3RhYmxlcmFuZ2U6YTRhNDBmYjUyN2FhNDkzNjkzZDRhM2Y4NGQyNDMyZTZfNy0xLTEtMS0yODIyMQ_e660a3ad-8bcc-46d5-a961-58395073ee7b"
      unitRef="usd">7374000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ia5de86b46aad4df397dd31ed521a5161_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV80My9mcmFnOjZlMTRkN2FhMWVjYTQ2NDQ4MTNkOTU3ZjhlNTNkMzc0L3RhYmxlOmE0YTQwZmI1MjdhYTQ5MzY5M2Q0YTNmODRkMjQzMmU2L3RhYmxlcmFuZ2U6YTRhNDBmYjUyN2FhNDkzNjkzZDRhM2Y4NGQyNDMyZTZfNy0zLTEtMS0yODIyMQ_bcb25147-f12e-48c2-8dea-c326530c9c47"
      unitRef="usd">6586000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
      contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV80My9mcmFnOjZlMTRkN2FhMWVjYTQ2NDQ4MTNkOTU3ZjhlNTNkMzc0L3RhYmxlOmE0YTQwZmI1MjdhYTQ5MzY5M2Q0YTNmODRkMjQzMmU2L3RhYmxlcmFuZ2U6YTRhNDBmYjUyN2FhNDkzNjkzZDRhM2Y4NGQyNDMyZTZfOC0xLTEtMS0yODIyMQ_5dfa9abd-f0a1-4779-bc97-6b1dfd591d0a"
      unitRef="usd">10825000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
      contextRef="i0ebb8d8bac3445859e468a3d048cfaf5_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV80My9mcmFnOjZlMTRkN2FhMWVjYTQ2NDQ4MTNkOTU3ZjhlNTNkMzc0L3RhYmxlOmE0YTQwZmI1MjdhYTQ5MzY5M2Q0YTNmODRkMjQzMmU2L3RhYmxlcmFuZ2U6YTRhNDBmYjUyN2FhNDkzNjkzZDRhM2Y4NGQyNDMyZTZfOC0zLTEtMS0yODIyMQ_09006278-82eb-4ac2-bfd6-dc89a180d5eb"
      unitRef="usd">10142000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV80Ni9mcmFnOjU5Mjk1M2U0NTk3NjQwNThiYWQ2MjQ2ZDJhOTVlM2FjL3RleHRyZWdpb246NTkyOTUzZTQ1OTc2NDA1OGJhZDYyNDZkMmE5NWUzYWNfNzUz_d9a53f9d-14ee-418c-8356-c9e3462c9509">Net Income Per ShareWe compute basic and diluted net income per share by dividing our net income by the weighted-average number of common shares outstanding during the period, including potentially dilutive stock options and RSUs. We use the treasury stock method to determine the number of dilutive shares of common stock resulting from stock options and restricted stock.&lt;div style="margin-top:9pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table shows the computation of net income per share for each period:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,797&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average shares used to compute basic net income per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106,012&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116,818&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dilutive effect of employee stock options and restricted stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,025&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average shares used to compute diluted net income per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115,037&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;129,668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2022, we had 26.0 million stock options and 0.2 million RSUs outstanding. As of March&#160;31, 2021, we had 26.8 million stock options outstanding.&lt;/span&gt;&lt;/div&gt;We excluded from the computation of diluted net income per share, on a weighted-average basis,&#160;6.9 million stock options and RSUs outstanding during the three months ended March 31, 2022 and 2.4 million stock options outstanding during the three months ended March 31, 2021, because including them would have reduced dilution</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV80Ni9mcmFnOjU5Mjk1M2U0NTk3NjQwNThiYWQ2MjQ2ZDJhOTVlM2FjL3RleHRyZWdpb246NTkyOTUzZTQ1OTc2NDA1OGJhZDYyNDZkMmE5NWUzYWNfNzU1_4ec5eee6-3e96-4f5a-b936-088c45171d62">&lt;div style="margin-top:9pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table shows the computation of net income per share for each period:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,797&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average shares used to compute basic net income per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106,012&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116,818&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dilutive effect of employee stock options and restricted stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,025&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average shares used to compute diluted net income per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115,037&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;129,668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV80Ni9mcmFnOjU5Mjk1M2U0NTk3NjQwNThiYWQ2MjQ2ZDJhOTVlM2FjL3RhYmxlOjAyMmVjYWUwNjQwNTQxOTE5Nzc1YmY5NzA0NWJmZTQxL3RhYmxlcmFuZ2U6MDIyZWNhZTA2NDA1NDE5MTk3NzViZjk3MDQ1YmZlNDFfNS0xLTEtMS0yODIyMQ_4991e9d3-9f2a-41e4-8176-409761da4afd"
      unitRef="usd">22797000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i0ebb8d8bac3445859e468a3d048cfaf5_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV80Ni9mcmFnOjU5Mjk1M2U0NTk3NjQwNThiYWQ2MjQ2ZDJhOTVlM2FjL3RhYmxlOjAyMmVjYWUwNjQwNTQxOTE5Nzc1YmY5NzA0NWJmZTQxL3RhYmxlcmFuZ2U6MDIyZWNhZTA2NDA1NDE5MTk3NzViZjk3MDQ1YmZlNDFfNS0zLTEtMS0yODIyMQ_6e16372d-992a-44c8-a9b6-1b107fc33d10"
      unitRef="usd">23465000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV80Ni9mcmFnOjU5Mjk1M2U0NTk3NjQwNThiYWQ2MjQ2ZDJhOTVlM2FjL3RhYmxlOjAyMmVjYWUwNjQwNTQxOTE5Nzc1YmY5NzA0NWJmZTQxL3RhYmxlcmFuZ2U6MDIyZWNhZTA2NDA1NDE5MTk3NzViZjk3MDQ1YmZlNDFfNy0xLTEtMS0yODIyMQ_2d60ac57-1bce-4492-9fba-4fc2a8101060"
      unitRef="shares">106012000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i0ebb8d8bac3445859e468a3d048cfaf5_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV80Ni9mcmFnOjU5Mjk1M2U0NTk3NjQwNThiYWQ2MjQ2ZDJhOTVlM2FjL3RhYmxlOjAyMmVjYWUwNjQwNTQxOTE5Nzc1YmY5NzA0NWJmZTQxL3RhYmxlcmFuZ2U6MDIyZWNhZTA2NDA1NDE5MTk3NzViZjk3MDQ1YmZlNDFfNy0zLTEtMS0yODIyMQ_0ce276dd-0b91-4cf2-a020-35f0df619114"
      unitRef="shares">116818000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV80Ni9mcmFnOjU5Mjk1M2U0NTk3NjQwNThiYWQ2MjQ2ZDJhOTVlM2FjL3RhYmxlOjAyMmVjYWUwNjQwNTQxOTE5Nzc1YmY5NzA0NWJmZTQxL3RhYmxlcmFuZ2U6MDIyZWNhZTA2NDA1NDE5MTk3NzViZjk3MDQ1YmZlNDFfOC0xLTEtMS0yODIyMQ_dedda398-a94e-4012-a367-05794b6d2bbf"
      unitRef="shares">9025000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i0ebb8d8bac3445859e468a3d048cfaf5_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV80Ni9mcmFnOjU5Mjk1M2U0NTk3NjQwNThiYWQ2MjQ2ZDJhOTVlM2FjL3RhYmxlOjAyMmVjYWUwNjQwNTQxOTE5Nzc1YmY5NzA0NWJmZTQxL3RhYmxlcmFuZ2U6MDIyZWNhZTA2NDA1NDE5MTk3NzViZjk3MDQ1YmZlNDFfOC0zLTEtMS0yODIyMQ_e99cca95-e6a7-4e00-8b6a-42aa28c72ea5"
      unitRef="shares">12850000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV80Ni9mcmFnOjU5Mjk1M2U0NTk3NjQwNThiYWQ2MjQ2ZDJhOTVlM2FjL3RhYmxlOjAyMmVjYWUwNjQwNTQxOTE5Nzc1YmY5NzA0NWJmZTQxL3RhYmxlcmFuZ2U6MDIyZWNhZTA2NDA1NDE5MTk3NzViZjk3MDQ1YmZlNDFfOS0xLTEtMS0yODIyMQ_d4bdce85-ddbd-405e-8785-2961338993e6"
      unitRef="shares">115037000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i0ebb8d8bac3445859e468a3d048cfaf5_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV80Ni9mcmFnOjU5Mjk1M2U0NTk3NjQwNThiYWQ2MjQ2ZDJhOTVlM2FjL3RhYmxlOjAyMmVjYWUwNjQwNTQxOTE5Nzc1YmY5NzA0NWJmZTQxL3RhYmxlcmFuZ2U6MDIyZWNhZTA2NDA1NDE5MTk3NzViZjk3MDQ1YmZlNDFfOS0zLTEtMS0yODIyMQ_89a1ecce-7222-46f5-a122-f0b36fefe727"
      unitRef="shares">129668000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV80Ni9mcmFnOjU5Mjk1M2U0NTk3NjQwNThiYWQ2MjQ2ZDJhOTVlM2FjL3RhYmxlOjAyMmVjYWUwNjQwNTQxOTE5Nzc1YmY5NzA0NWJmZTQxL3RhYmxlcmFuZ2U6MDIyZWNhZTA2NDA1NDE5MTk3NzViZjk3MDQ1YmZlNDFfMTEtMS0xLTEtMjgyMjE_3e0b089a-3922-4553-9f0a-c817499e04c5"
      unitRef="usdPerShare">0.22</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i0ebb8d8bac3445859e468a3d048cfaf5_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV80Ni9mcmFnOjU5Mjk1M2U0NTk3NjQwNThiYWQ2MjQ2ZDJhOTVlM2FjL3RhYmxlOjAyMmVjYWUwNjQwNTQxOTE5Nzc1YmY5NzA0NWJmZTQxL3RhYmxlcmFuZ2U6MDIyZWNhZTA2NDA1NDE5MTk3NzViZjk3MDQ1YmZlNDFfMTEtMy0xLTEtMjgyMjE_a72365a1-9f1b-4deb-ac0d-c22092a40dd7"
      unitRef="usdPerShare">0.20</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV80Ni9mcmFnOjU5Mjk1M2U0NTk3NjQwNThiYWQ2MjQ2ZDJhOTVlM2FjL3RhYmxlOjAyMmVjYWUwNjQwNTQxOTE5Nzc1YmY5NzA0NWJmZTQxL3RhYmxlcmFuZ2U6MDIyZWNhZTA2NDA1NDE5MTk3NzViZjk3MDQ1YmZlNDFfMTItMS0xLTEtMjgyMjE_ca90c21d-c4a2-4a2d-bf77-ea454c0674a6"
      unitRef="usdPerShare">0.20</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i0ebb8d8bac3445859e468a3d048cfaf5_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV80Ni9mcmFnOjU5Mjk1M2U0NTk3NjQwNThiYWQ2MjQ2ZDJhOTVlM2FjL3RhYmxlOjAyMmVjYWUwNjQwNTQxOTE5Nzc1YmY5NzA0NWJmZTQxL3RhYmxlcmFuZ2U6MDIyZWNhZTA2NDA1NDE5MTk3NzViZjk3MDQ1YmZlNDFfMTItMy0xLTEtMjgyMjE_be356707-d84a-4607-9e09-08e1408ba6e8"
      unitRef="usdPerShare">0.18</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ia962305aacde4486929d4801fcf01b30_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV80Ni9mcmFnOjU5Mjk1M2U0NTk3NjQwNThiYWQ2MjQ2ZDJhOTVlM2FjL3RleHRyZWdpb246NTkyOTUzZTQ1OTc2NDA1OGJhZDYyNDZkMmE5NWUzYWNfNDgy_21fdb546-689c-4e93-9e77-ac05eb606c4e"
      unitRef="shares">26000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="ibdfffff05fb64ff191febd1261049d75_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV80Ni9mcmFnOjU5Mjk1M2U0NTk3NjQwNThiYWQ2MjQ2ZDJhOTVlM2FjL3RleHRyZWdpb246NTkyOTUzZTQ1OTc2NDA1OGJhZDYyNDZkMmE5NWUzYWNfMjE5OTAyMzI1ODUyMg_f597d969-9fb0-48ce-a5ec-d7b545b62aba"
      unitRef="shares">200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i82ca1385b4a848fd8ea581edd7dcbfdb_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV80Ni9mcmFnOjU5Mjk1M2U0NTk3NjQwNThiYWQ2MjQ2ZDJhOTVlM2FjL3RleHRyZWdpb246NTkyOTUzZTQ1OTc2NDA1OGJhZDYyNDZkMmE5NWUzYWNfMjE5OTAyMzI1ODUzMA_f9147a13-c3c5-43dc-a59d-c04bd9556e8c"
      unitRef="shares">26800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i79418e09cbdb47588dfeae9d2b02dc38_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV80Ni9mcmFnOjU5Mjk1M2U0NTk3NjQwNThiYWQ2MjQ2ZDJhOTVlM2FjL3RleHRyZWdpb246NTkyOTUzZTQ1OTc2NDA1OGJhZDYyNDZkMmE5NWUzYWNfNjgw_e3cdd73c-6f78-4ff2-b07a-a3eea651d180"
      unitRef="shares">6900000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i461a8de5644c45629b64932556c34fff_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV80Ni9mcmFnOjU5Mjk1M2U0NTk3NjQwNThiYWQ2MjQ2ZDJhOTVlM2FjL3RleHRyZWdpb246NTkyOTUzZTQ1OTc2NDA1OGJhZDYyNDZkMmE5NWUzYWNfNjg3_99fa9596-b7c6-4f7f-9cc6-9688a6f4681b"
      unitRef="shares">2400000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV80OS9mcmFnOjNjYWViMjFiYWNkZDQwZGFiY2JiYjUzN2Q5Nzk0ZTc0L3RleHRyZWdpb246M2NhZWIyMWJhY2RkNDBkYWJjYmJiNTM3ZDk3OTRlNzRfMTkwOQ_1324d364-1936-4048-9d2b-47ad60e82615">Income Taxes&lt;div style="margin-top:9pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recorded income tax expense of $4.1 million for the three months ended March 31, 2022, and an income tax benefit of $3.6 million for the three months ended March 31, 2021. The increase in income tax expense during the three months ended March 31, 2022 was primarily due to increased income before income taxes and decreased excess tax deductions from stock-based compensation as compared to the corresponding period in 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our effective tax rate differs from the federal statutory rate due to state income taxes and the non-deductible portion of our stock-based compensation, which increased our tax expense, offset by tax benefits for research and development tax credits and the excess tax deduction arising from the exercise of employee stock options, which reduced our taxable income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March 31, 2022, unrecognized tax benefits increased by $0.4 million. As of March&#160;31, 2022, the Company had unrecognized tax benefits of $7.7 million that, if recognized, would affect the Company&#x2019;s effective tax rate and approximately $1.9 million of unrecognized tax benefits that would not impact the effective tax rate as they would be offset by a corresponding change in valuation allowance.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Each quarter, we assess the likelihood that we will generate sufficient taxable income to make use of our federal and state deferred tax assets. If we believe that recovery of these deferred tax assets is not more likely than not, we establish a valuation allowance offsetting such assets on our balance sheet. Significant judgment is required in assessing the need for a valuation allowance. We consider all available evidence, including our recent operating results and our forecasts of future taxable income. Other than valuation allowances against our California net deferred tax assets, we have determined that it is more likely than not we will realize the benefit related to all other deferred tax assets. To the extent we increase a valuation allowance, we will include an expense in the Condensed Consolidated Statement of Comprehensive Income in the period in which such determination is made.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Beginning in 2022, the Tax Cuts and Jobs Act of 2017 (&#x201c;TCJA&#x201d;) eliminates the right to deduct research and development expenditures for tax purposes in the period the expenses were incurred and instead requires all U.S. and foreign research and development expenditures to be amortized over five and fifteen tax years, respectively. Although Congress is considering legislation that would defer the amortization requirement to later years, it is not certain that the provision will be repealed or otherwise modified. As of March&#160;31, 2022, the requirement has not been modified. We have capitalized our research and development expenses, which caused our taxes payable to increase to $11.5 million as of March&#160;31, 2022, compared to $0.5 million as of December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV80OS9mcmFnOjNjYWViMjFiYWNkZDQwZGFiY2JiYjUzN2Q5Nzk0ZTc0L3RleHRyZWdpb246M2NhZWIyMWJhY2RkNDBkYWJjYmJiNTM3ZDk3OTRlNzRfNTg_7fc0acdd-f9b5-44cd-8b2e-cbc4f07eecec"
      unitRef="usd">4100000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i0ebb8d8bac3445859e468a3d048cfaf5_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV80OS9mcmFnOjNjYWViMjFiYWNkZDQwZGFiY2JiYjUzN2Q5Nzk0ZTc0L3RleHRyZWdpb246M2NhZWIyMWJhY2RkNDBkYWJjYmJiNTM3ZDk3OTRlNzRfMTAy_eeb12625-af1c-4595-9f94-e6ffdbe26f5c"
      unitRef="usd">-3600000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:UnrecognizedTaxBenefitsPeriodIncreaseDecrease
      contextRef="i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV80OS9mcmFnOjNjYWViMjFiYWNkZDQwZGFiY2JiYjUzN2Q5Nzk0ZTc0L3RleHRyZWdpb246M2NhZWIyMWJhY2RkNDBkYWJjYmJiNTM3ZDk3OTRlNzRfNjg5_171b279f-5e3e-4f27-a144-3dbe28891e34"
      unitRef="usd">400000</us-gaap:UnrecognizedTaxBenefitsPeriodIncreaseDecrease>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
      contextRef="i93f424f685944c1aab994f99b0146441_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV80OS9mcmFnOjNjYWViMjFiYWNkZDQwZGFiY2JiYjUzN2Q5Nzk0ZTc0L3RleHRyZWdpb246M2NhZWIyMWJhY2RkNDBkYWJjYmJiNTM3ZDk3OTRlNzRfNzQ4_af61395d-f9df-48d8-b615-f226c061fee2"
      unitRef="usd">7700000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <cort:UnrecognizedTaxBenefitsThatWouldBeOffsetByAChangeInValuationAllowance
      contextRef="i93f424f685944c1aab994f99b0146441_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV80OS9mcmFnOjNjYWViMjFiYWNkZDQwZGFiY2JiYjUzN2Q5Nzk0ZTc0L3RleHRyZWdpb246M2NhZWIyMWJhY2RkNDBkYWJjYmJiNTM3ZDk3OTRlNzRfODY2_d5030926-eec6-40c4-b562-5fc814e4c522"
      unitRef="usd">1900000</cort:UnrecognizedTaxBenefitsThatWouldBeOffsetByAChangeInValuationAllowance>
    <us-gaap:TaxesPayableCurrentAndNoncurrent
      contextRef="i93f424f685944c1aab994f99b0146441_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV80OS9mcmFnOjNjYWViMjFiYWNkZDQwZGFiY2JiYjUzN2Q5Nzk0ZTc0L3RleHRyZWdpb246M2NhZWIyMWJhY2RkNDBkYWJjYmJiNTM3ZDk3OTRlNzRfMjE5OTAyMzI2OTExNw_7ec241a6-e560-425a-b73b-053b00cc55ba"
      unitRef="usd">11500000</us-gaap:TaxesPayableCurrentAndNoncurrent>
    <us-gaap:TaxesPayableCurrentAndNoncurrent
      contextRef="iac7c0f0822b942fa8f45ea15693a76af_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNDQ3NjU4MzJjMTQxNjE4MWU1NzI5ZDZhYWY3MDU5L3NlYzowYTQ0NzY1ODMyYzE0MTYxODFlNTcyOWQ2YWFmNzA1OV80OS9mcmFnOjNjYWViMjFiYWNkZDQwZGFiY2JiYjUzN2Q5Nzk0ZTc0L3RleHRyZWdpb246M2NhZWIyMWJhY2RkNDBkYWJjYmJiNTM3ZDk3OTRlNzRfMjE5OTAyMzI2OTEyOA_7459a859-ccc6-48ee-b8c8-616d23b17e76"
      unitRef="usd">500000</us-gaap:TaxesPayableCurrentAndNoncurrent>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>51
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MC9G0 O!]R;G:#_0$U>7,Y#]02P,$%     @ (H*E5*Q!1NV+ @  =@4  !@
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M:"J)P2N2@C1\WDB[$617.(62%;$BH70HW",A>(Y T2.8I@%O1(ZC)@5=CB)
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MTWF7KJ(HVJ;M>D7)> H+*;H7!GRBT<;)O[N+9UF4)ADR%8F:YJ>/@!"1 KS
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MY&*ZV:8[.+T-\\1*.TPG85MA'&3C"?!_K;4['+R"8<"\^ =02P,$%     @
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M(I%*>DG+4L,=:F7@7MC'/MP*):D3M10#^$!+PB99B%@?*@1!W4+9"% UJ#>
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MHL)?M$O4,IVJQ7RQ>$'?<@AS*?J6S^B+@:G?+]<^.%3"'R_H7 TZ5Z)S]7]
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M5U0UI=T3/)F/6)AUQX1J"//D0OD1>H?#(-:Q+^.F-AK4=:?+EF).?TR6*]4
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M\>AL&H!NGZYV8U7MGXN-LO3X^,^27GO43H'DA:)>[S;.0?__8?4;4$L#!!0
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M::MNR.LV1C9NL%I+0V.:6Q8T%Z.R O1](Z79;ZR!8=)>_0502P,$%     @
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M7N6D;,M&_XS D\#L07&A:Y[CQ*.30*-Z0&]Z2Q#?!20;!?,.U/P8U&4+:N%
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MTM!+PPVW]+1#915H?2VE.4QL@.ZQ./T74$L#!!0    ( "*"I50#2:+W0P,
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MG*L(DQ:[.WDW4+PRU]J**[PDS6.&WS$@M '.IYRK_4#?E.V7T?0_4$L#!!0
M   ( "*"I51FV\_A( (  )L$   9    >&PO=V]R:W-H965T<R]S:&5E=#(U
M+GAM;(U446^;,!#^*R?4AU;:8@+MEE4$J2&:UH=.4:)N#],>'#B"58.9[83N
MW^]L"$JEI-H+^.S[/G_W^>RD4_K%5(@67FO9F'E06=O>,V;R"FMN)JK%AE9*
MI6MN*=0[9EJ-O/"@6K(H##^QFHLF2!,_M])IHO96B@97&LR^KKG^NT"INGDP
M#8X3:[&KK)M@:=+R'6[0/K<K31$;60I18V.$:D!C.0\>IO=9[/)]P@^!G3D9
M@ZMDJ]2+"QZ+>1 Z02@QMXZ!T^^ &4KIB$C&GX$S&+=TP-/QD?VKKYUJV7*#
MF9(_16&K>3 +H,"2[Z5=J^X;#O7<.;Y<2>._T VY80#YWEA5#V!24(NF__/7
MP8<3P/3V B : -'_ N(!X)UCO3)?UI);GB9:=:!=-K&Y@??&HZD:T;A3W%A-
MJX)P-LU4W2HCO*6JA RUI:.'!9>\R1$VOI,>+=8&/L)WKC5WML/U$BE/FAN:
M?=XLX?KJ!JZ @$]"2N(R";.DSNW!\D')HE<275#RQ/4$XND'B,(H.@//WH<O
M,1_AT[=P1IZ,QD2C,9'GBR_PO75@C9);+& I3"Z5V6LT\.MA:ZRF/OS]SG;Q
MN%WLM[N]*-\?@P&ZF)#3JLBY!*L%EV>][-EFGLW=U$,:368).YP:=B[GRYC3
MRV0GK>.N+9W"3C0&)):$"B>?[P+0_57H ZM:WTU;9:DW_;"BUP.U2Z#U4BE[
M#%R#CN]1^@]02P,$%     @ (H*E5+(T=3[S @  C0D  !D   !X;"]W;W)K
M<VAE971S+W-H965T,C8N>&ULO59=3^,P$/PK5G0/( %)G"9M45L)6J%# @E1
MX!Y.]^ FV\;"B8OMM-R_OW420NB7T GQTMC.SNSNC&MGL);J6:< AKQF(M=#
M)S5F>>ZZ.DXA8_I,+B''-W.I,F9PJA:N7BI@20G*A$L]+W(SQG-G-"C7[M1H
M( LC> YWBN@BRYCZ>PE"KH>.[[PMW/-%:NR".QHLV0*F8!Z7=PIG;L.2\ QR
MS65.%,R'SH5_/O:I!9013QS6NC4FMI69E,]V<IT,'<]6! )B8RD8/E8P!B$L
M$];Q4I,Z34X+;(_?V*_*YK&9&=,PEN(73TPZ='H.26#."F'NY?HGU V%EB^6
M0I>_9%W'>@Z)"VUD5H.Q@HSGU9.]UD*T 'YG#X#6 /I90% #@K+1JK*RK0DS
M;#10<DV4C48V.RBU*='8#<^MC5.C\"U'G!E=K!@7;";@%+?$Z90)(%.("\4-
M!TU8GI KQA5Y8J( <@M,%PK01:/)*9E6UA,Y)R8%,A9,:S[G,2L-PM7#Y#PG
M8YDGN"4@L2,M!4^8P<DE$RR/,=BVI<G1! P2Z6/,^3B=D*,?Q^2'A3^DLM!8
MHQZX!K6P';EQW?=EU3?=T_<M4V<D\$\(]2C= 1\?AD\@;N#^1[B+#C0VT,8&
M6O(%>_EFIJ7-R89TVDKW^P9!Y-I IO\<2!DT*8,R96=/R@=IF,"MI)Y174Q$
M=)-^EYP56522V;-A-0H"K]/O#MQ56[8=85Y >T$3]J'63E-KYV"M8Z93 B\%
M7Z$0N/D.M!\VE.%W*1XU*:.O5+PB"UM2T@Z-H@W!MZ,ZH=?K[=:[VU3:/5CI
M-)7*G!I0V6?*_9"BUZ3H?9?^_29E_ROU[V_KWPNB*-PP8#O,[X1]?X\#OO=^
M,'L'J[V1^>+_+/!;A[__72;X[T>=3[_2AIJM?:10&F[]#W:$^3ZEW>Z&#V[K
MKK0?*G@1+'BNB8 Y KVS+CJIJKN_FABY+*_/F31X&9?#%+^70-D ?#^7TKQ-
M[(W<?(&-_@%02P,$%     @ (H*E5'9:\KH2!0  Y1D  !D   !X;"]W;W)K
M<VAE971S+W-H965T,C<N>&ULO5G;;MLX$/T5PNA#"]212.IB%8Z!--EV"R1
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M-#UO7^83JRK? 3PH2_V$'TZHY4/M#.C[2"G[,G$;-$UD_P]02P,$%     @
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M)=;3Z&/$2MCR1N*C.7R!+I\@L##2A2\[M+Z3-&)%X]"H#DP*E-#MRE^Z.IP
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MY5Q6AC,!UXKHJBBH^K4"+@\++_2.$U_9/C=VPE_.2[J'+9B;\EKAR&]9,E:
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M4O7EH1X86;KS]TX:/,W=8XX7+E V -_OI#3'@?U >X5;_@902P,$%     @
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M%     @ (H*E5)>*NQS     $P(   L   !?<F5L<R\N<F5L<YV2N6[#, Q
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M]99WZNW#HW1^['FN\?QW4AWZ;]UX_+!\;D[8&7"V< V]_P502P,$%     @
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M8U!R;W!S+V%P<"YX;6Q02P$"% ,4    "  B@J54CW.>J^X    K @  $0
M            @ &O    9&]C4')O<',O8V]R92YX;6Q02P$"% ,4    "  B
M@J54F5R<(Q &  "<)P  $P              @ ', 0  >&PO=&AE;64O=&AE
M;64Q+GAM;%!+ 0(4 Q0    ( "*"I50?VFM7. 4  &05   8
M  " @0T(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4    "  B
M@J540(P@\_0%   #&   &               @(%[#0  >&PO=V]R:W-H965T
M<R]S:&5E=#(N>&UL4$L! A0#%     @ (H*E5#E\@NDL!0  J!$  !@
M         ("!I1,  'AL+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0
M   ( "*"I52L04;MBP(  '8%   8              " @0<9  !X;"]W;W)K
M<VAE971S+W-H965T-"YX;6Q02P$"% ,4    "  B@J54E*9@<-T&  "]&@
M&               @('(&P  >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L!
M A0#%     @ (H*E5%VW_N(F!@  EQL  !@              ("!VR(  'AL
M+W=O<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0    ( "*"I52HV&-K508
M 'X.   8              " @3<I  !X;"]W;W)K<VAE971S+W-H965T-RYX
M;6Q02P$"% ,4    "  B@J54P/(DVKH$  !L"@  &               @('"
M+P  >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%     @ (H*E5.F4
M-IJ%!@  5A   !@              ("!LC0  'AL+W=O<FMS:&5E=',O<VAE
M970Y+GAM;%!+ 0(4 Q0    ( "*"I506711U4@,  $('   9
M  " @6T[  !X;"]W;W)K<VAE971S+W-H965T,3 N>&UL4$L! A0#%     @
M(H*E5+&U?"N)!   K H  !D              ("!]CX  'AL+W=O<FMS:&5E
M=',O<VAE970Q,2YX;6Q02P$"% ,4    "  B@J54[290 7D'  "2$@  &0
M            @(&V0P  >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4
M Q0    ( "*"I50_R)?C=P,  $L(   9              " @69+  !X;"]W
M;W)K<VAE971S+W-H965T,3,N>&UL4$L! A0#%     @ (H*E5')LF0]%!@
MH@\  !D              ("!%$\  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX
M;6Q02P$"% ,4    "  B@J54]KN98!($   W"0  &0              @(&0
M50  >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    ( "*"I51X
M),'S'@0  '4+   9              " @=E9  !X;"]W;W)K<VAE971S+W-H
M965T,38N>&UL4$L! A0#%     @ (H*E5)BK:NXC!   . H  !D
M     ("!+EX  'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( "*"I53^$!=IP@(  %T'   9              "
M@69N  !X;"]W;W)K<VAE971S+W-H965T,C(N>&UL4$L! A0#%     @ (H*E
M5"M?L;(7 P  A H  !D              ("!7W$  'AL+W=O<FMS:&5E=',O
M<VAE970R,RYX;6Q02P$"% ,4    "  B@J54R#<9="4#   E"0  &0
M        @(&M=   >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0
M   ( "*"I51FV\_A( (  )L$   9              " @0EX  !X;"]W;W)K
M<VAE971S+W-H965T,C4N>&UL4$L! A0#%     @ (H*E5+(T=3[S @  C0D
M !D              ("!8'H  'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q0
M2P$"% ,4    "  B@J54=EKRNA(%  #E&0  &0              @(&*?0
M>&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    ( "*"I524!QS?
M. ,  % *   9              " @=."  !X;"]W;W)K<VAE971S+W-H965T
M,C@N>&UL4$L! A0#%     @ (H*E5+*:'B$J @  ]@0  !D
M ("!0H8  'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q02P$"% ,4    "  B
M@J54K9?[-98"  !>!P  &0              @(&CB   >&PO=V]R:W-H965T
M<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    ( "*"I52GK./WW (  ,H'   9
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M970S-2YX;6Q02P$"% ,4    "  B@J54&>B80DX#  ">"0  &0
M    @(%HG   >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4 Q0    (
M "*"I51!?%HPX0(   <(   9              " @>V?  !X;"]W;W)K<VAE
M971S+W-H965T,S<N>&UL4$L! A0#%     @ (H*E5$@06%,6 P  9A$   T
M             ( !!:,  'AL+W-T>6QE<RYX;6Q02P$"% ,4    "  B@J54
MEXJ[',     3 @  "P              @ %&I@  7W)E;',O+G)E;'-02P$"
M% ,4    "  B@J54RRADA(0#   O&0  #P              @ $OIP  >&PO
M=V]R:V)O;VLN>&UL4$L! A0#%     @ (H*E5)D^HH1\ 0  EA8  !H
M         ( !X*H  'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#
M%     @ (H*E5*IG%&&8 0  "Q<  !,              ( !E*P  %M#;VYT
D96YT7U1Y<&5S72YX;6Q02P4&     "T +0 R#   7:X

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>76</ContextCount>
  <ElementCount>181</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>28</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="cort-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.corcept.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="cort-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.corcept.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="cort-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="cort-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="cort-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="cort-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="cort-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.corcept.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="cort-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2104102 - Disclosure - Composition of Certain Balance Sheet Items</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.corcept.com/role/CompositionofCertainBalanceSheetItems</Role>
      <ShortName>Composition of Certain Balance Sheet Items</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="cort-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2110103 - Disclosure - Available-for-Sale Securities and Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.corcept.com/role/AvailableforSaleSecuritiesandFairValueMeasurements</Role>
      <ShortName>Available-for-Sale Securities and Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="cort-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2115104 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.corcept.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="cort-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2117105 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.corcept.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="cort-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2122106 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.corcept.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="cort-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2126107 - Disclosure - Net Income Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.corcept.com/role/NetIncomePerShare</Role>
      <ShortName>Net Income Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="cort-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2130108 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.corcept.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="cort-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2202201 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.corcept.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.corcept.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies</ParentRole>
      <Position>15</Position>
    </Report>
    <Report instance="cort-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2305301 - Disclosure - Composition of Certain Balance Sheet Items (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.corcept.com/role/CompositionofCertainBalanceSheetItemsTables</Role>
      <ShortName>Composition of Certain Balance Sheet Items (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.corcept.com/role/CompositionofCertainBalanceSheetItems</ParentRole>
      <Position>16</Position>
    </Report>
    <Report instance="cort-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2311302 - Disclosure - Available-for-Sale Securities and Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.corcept.com/role/AvailableforSaleSecuritiesandFairValueMeasurementsTables</Role>
      <ShortName>Available-for-Sale Securities and Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.corcept.com/role/AvailableforSaleSecuritiesandFairValueMeasurements</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="cort-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2318303 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.corcept.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.corcept.com/role/Leases</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="cort-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2323304 - Disclosure - Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.corcept.com/role/StockholdersEquityTables</Role>
      <ShortName>Stockholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.corcept.com/role/StockholdersEquity</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="cort-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2327305 - Disclosure - Net Income Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.corcept.com/role/NetIncomePerShareTables</Role>
      <ShortName>Net Income Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.corcept.com/role/NetIncomePerShare</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="cort-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2403401 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.corcept.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.corcept.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="cort-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - Composition of Certain Balance Sheet Items - Schedule of Composition of Inventory (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.corcept.com/role/CompositionofCertainBalanceSheetItemsScheduleofCompositionofInventoryDetails</Role>
      <ShortName>Composition of Certain Balance Sheet Items - Schedule of Composition of Inventory (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="cort-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2407403 - Disclosure - Composition of Certain Balance Sheet Items - Schedule of Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.corcept.com/role/CompositionofCertainBalanceSheetItemsScheduleofPropertyandEquipmentDetails</Role>
      <ShortName>Composition of Certain Balance Sheet Items - Schedule of Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="cort-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2408404 - Disclosure - Composition of Certain Balance Sheet Items - Schedule of Other Accrued Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.corcept.com/role/CompositionofCertainBalanceSheetItemsScheduleofOtherAccruedLiabilitiesDetails</Role>
      <ShortName>Composition of Certain Balance Sheet Items - Schedule of Other Accrued Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="cort-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2409405 - Disclosure - Composition of Certain Balance Sheet Items - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.corcept.com/role/CompositionofCertainBalanceSheetItemsNarrativeDetails</Role>
      <ShortName>Composition of Certain Balance Sheet Items - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="cort-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2412406 - Disclosure - Available-for-Sale Securities and Fair Value Measurements - Summary of the Classification of Available-for-Sale Securities in Condensed Consolidated Balance Sheets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.corcept.com/role/AvailableforSaleSecuritiesandFairValueMeasurementsSummaryoftheClassificationofAvailableforSaleSecuritiesinCondensedConsolidatedBalanceSheetsDetails</Role>
      <ShortName>Available-for-Sale Securities and Fair Value Measurements - Summary of the Classification of Available-for-Sale Securities in Condensed Consolidated Balance Sheets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="cort-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2413407 - Disclosure - Available-for-Sale Securities and Fair Value Measurements - Schedule of Available-for-Sale Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.corcept.com/role/AvailableforSaleSecuritiesandFairValueMeasurementsScheduleofAvailableforSaleSecuritiesDetails</Role>
      <ShortName>Available-for-Sale Securities and Fair Value Measurements - Schedule of Available-for-Sale Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="cort-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2414408 - Disclosure - Available-for-Sale Securities and Fair Value Measurements - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.corcept.com/role/AvailableforSaleSecuritiesandFairValueMeasurementsNarrativeDetails</Role>
      <ShortName>Available-for-Sale Securities and Fair Value Measurements - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.corcept.com/role/AvailableforSaleSecuritiesandFairValueMeasurementsTables</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="cort-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2416409 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.corcept.com/role/CommitmentsandContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.corcept.com/role/CommitmentsandContingencies</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="cort-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2419410 - Disclosure - Leases - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.corcept.com/role/LeasesNarrativeDetails</Role>
      <ShortName>Leases - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="cort-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2420411 - Disclosure - Leases - Right-of-use Assets and Related Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.corcept.com/role/LeasesRightofuseAssetsandRelatedLiabilitiesDetails</Role>
      <ShortName>Leases - Right-of-use Assets and Related Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="cort-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2421412 - Disclosure - Leases - Future Minimum Lease Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.corcept.com/role/LeasesFutureMinimumLeasePaymentsDetails</Role>
      <ShortName>Leases - Future Minimum Lease Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="cort-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2424413 - Disclosure - Stockholders' Equity - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.corcept.com/role/StockholdersEquityNarrativeDetails</Role>
      <ShortName>Stockholders' Equity - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="cort-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2425414 - Disclosure - Stockholders' Equity - Summary of Stock-Based Compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.corcept.com/role/StockholdersEquitySummaryofStockBasedCompensationDetails</Role>
      <ShortName>Stockholders' Equity - Summary of Stock-Based Compensation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="cort-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2428415 - Disclosure - Net Income Per Share - Schedule of Computation of Net Income Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.corcept.com/role/NetIncomePerShareScheduleofComputationofNetIncomePerShareDetails</Role>
      <ShortName>Net Income Per Share - Schedule of Computation of Net Income Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="cort-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2429416 - Disclosure - Net Income Per Share - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.corcept.com/role/NetIncomePerShareNarrativeDetails</Role>
      <ShortName>Net Income Per Share - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="cort-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2431417 - Disclosure - Income taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.corcept.com/role/IncometaxesDetails</Role>
      <ShortName>Income taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="cort-20220331.htm">cort-20220331.htm</File>
    <File>cort-20220331.xsd</File>
    <File>cort-20220331_cal.xml</File>
    <File>cort-20220331_def.xml</File>
    <File>cort-20220331_lab.xml</File>
    <File>cort-20220331_pre.xml</File>
    <File>cort33122ex101seventhamend.htm</File>
    <File>cort33122ex311.htm</File>
    <File>cort33122ex312.htm</File>
    <File>cort33122ex321.htm</File>
    <File>cort33122ex322.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="354">http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy items="29">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>56
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "cort-20220331.htm": {
   "axisCustom": 1,
   "axisStandard": 10,
   "contextCount": 76,
   "dts": {
    "calculationLink": {
     "local": [
      "cort-20220331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "cort-20220331_def.xml"
     ]
    },
    "inline": {
     "local": [
      "cort-20220331.htm"
     ]
    },
    "labelLink": {
     "local": [
      "cort-20220331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "cort-20220331_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "cort-20220331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"
     ]
    }
   },
   "elementCount": 275,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2021q4": 5,
    "total": 5
   },
   "keyCustom": 19,
   "keyStandard": 162,
   "memberCustom": 3,
   "memberStandard": 24,
   "nsprefix": "cort",
   "nsuri": "http://www.corcept.com/20220331",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cort-20220331.htm",
      "contextRef": "i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover Page",
     "role": "http://www.corcept.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cort-20220331.htm",
      "contextRef": "i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cort-20220331.htm",
      "contextRef": "i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2115104 - Disclosure - Commitments and Contingencies",
     "role": "http://www.corcept.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cort-20220331.htm",
      "contextRef": "i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cort-20220331.htm",
      "contextRef": "i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2117105 - Disclosure - Leases",
     "role": "http://www.corcept.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cort-20220331.htm",
      "contextRef": "i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cort-20220331.htm",
      "contextRef": "i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2122106 - Disclosure - Stockholders' Equity",
     "role": "http://www.corcept.com/role/StockholdersEquity",
     "shortName": "Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cort-20220331.htm",
      "contextRef": "i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cort-20220331.htm",
      "contextRef": "i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2126107 - Disclosure - Net Income Per Share",
     "role": "http://www.corcept.com/role/NetIncomePerShare",
     "shortName": "Net Income Per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cort-20220331.htm",
      "contextRef": "i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cort-20220331.htm",
      "contextRef": "i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2130108 - Disclosure - Income Taxes",
     "role": "http://www.corcept.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cort-20220331.htm",
      "contextRef": "i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cort-20220331.htm",
      "contextRef": "i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2202201 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)",
     "role": "http://www.corcept.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cort-20220331.htm",
      "contextRef": "i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cort-20220331.htm",
      "contextRef": "i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2305301 - Disclosure - Composition of Certain Balance Sheet Items (Tables)",
     "role": "http://www.corcept.com/role/CompositionofCertainBalanceSheetItemsTables",
     "shortName": "Composition of Certain Balance Sheet Items (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cort-20220331.htm",
      "contextRef": "i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cort-20220331.htm",
      "contextRef": "i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2311302 - Disclosure - Available-for-Sale Securities and Fair Value Measurements (Tables)",
     "role": "http://www.corcept.com/role/AvailableforSaleSecuritiesandFairValueMeasurementsTables",
     "shortName": "Available-for-Sale Securities and Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cort-20220331.htm",
      "contextRef": "i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cort-20220331.htm",
      "contextRef": "i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2318303 - Disclosure - Leases (Tables)",
     "role": "http://www.corcept.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cort-20220331.htm",
      "contextRef": "i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cort-20220331.htm",
      "contextRef": "i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2323304 - Disclosure - Stockholders' Equity (Tables)",
     "role": "http://www.corcept.com/role/StockholdersEquityTables",
     "shortName": "Stockholders' Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cort-20220331.htm",
      "contextRef": "i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cort-20220331.htm",
      "contextRef": "i93f424f685944c1aab994f99b0146441_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS",
     "role": "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cort-20220331.htm",
      "contextRef": "i93f424f685944c1aab994f99b0146441_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cort-20220331.htm",
      "contextRef": "i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2327305 - Disclosure - Net Income Per Share (Tables)",
     "role": "http://www.corcept.com/role/NetIncomePerShareTables",
     "shortName": "Net Income Per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cort-20220331.htm",
      "contextRef": "i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cort-20220331.htm",
      "contextRef": "i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "cort:NumberOfSeriesOfSelectiveCortisolModulators",
      "reportCount": 1,
      "unique": true,
      "unitRef": "series",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2403401 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Details)",
     "role": "http://www.corcept.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cort-20220331.htm",
      "contextRef": "i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "cort:NumberOfSeriesOfSelectiveCortisolModulators",
      "reportCount": 1,
      "unique": true,
      "unitRef": "series",
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryNoncurrentTableTextBlock",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cort-20220331.htm",
      "contextRef": "i93f424f685944c1aab994f99b0146441_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "cort:InventoryWorkInProcessCurrentAndNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406402 - Disclosure - Composition of Certain Balance Sheet Items - Schedule of Composition of Inventory (Details)",
     "role": "http://www.corcept.com/role/CompositionofCertainBalanceSheetItemsScheduleofCompositionofInventoryDetails",
     "shortName": "Composition of Certain Balance Sheet Items - Schedule of Composition of Inventory (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryNoncurrentTableTextBlock",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cort-20220331.htm",
      "contextRef": "i93f424f685944c1aab994f99b0146441_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "cort:InventoryWorkInProcessCurrentAndNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cort-20220331.htm",
      "contextRef": "i93f424f685944c1aab994f99b0146441_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407403 - Disclosure - Composition of Certain Balance Sheet Items - Schedule of Property and Equipment (Details)",
     "role": "http://www.corcept.com/role/CompositionofCertainBalanceSheetItemsScheduleofPropertyandEquipmentDetails",
     "shortName": "Composition of Certain Balance Sheet Items - Schedule of Property and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cort-20220331.htm",
      "contextRef": "i93f424f685944c1aab994f99b0146441_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cort-20220331.htm",
      "contextRef": "i93f424f685944c1aab994f99b0146441_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "cort:AccruedGovernmentRebateCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408404 - Disclosure - Composition of Certain Balance Sheet Items - Schedule of Other Accrued Liabilities (Details)",
     "role": "http://www.corcept.com/role/CompositionofCertainBalanceSheetItemsScheduleofOtherAccruedLiabilitiesDetails",
     "shortName": "Composition of Certain Balance Sheet Items - Schedule of Other Accrued Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cort-20220331.htm",
      "contextRef": "i93f424f685944c1aab994f99b0146441_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "cort:AccruedGovernmentRebateCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cort-20220331.htm",
      "contextRef": "i93f424f685944c1aab994f99b0146441_I20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "cort:DepositsForClinicalTrials",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409405 - Disclosure - Composition of Certain Balance Sheet Items - Narrative (Details)",
     "role": "http://www.corcept.com/role/CompositionofCertainBalanceSheetItemsNarrativeDetails",
     "shortName": "Composition of Certain Balance Sheet Items - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cort-20220331.htm",
      "contextRef": "i93f424f685944c1aab994f99b0146441_I20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "cort:DepositsForClinicalTrials",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cort-20220331.htm",
      "contextRef": "i93f424f685944c1aab994f99b0146441_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2412406 - Disclosure - Available-for-Sale Securities and Fair Value Measurements - Summary of the Classification of Available-for-Sale Securities in Condensed Consolidated Balance Sheets (Details)",
     "role": "http://www.corcept.com/role/AvailableforSaleSecuritiesandFairValueMeasurementsSummaryoftheClassificationofAvailableforSaleSecuritiesinCondensedConsolidatedBalanceSheetsDetails",
     "shortName": "Available-for-Sale Securities and Fair Value Measurements - Summary of the Classification of Available-for-Sale Securities in Condensed Consolidated Balance Sheets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cort-20220331.htm",
      "contextRef": "i93f424f685944c1aab994f99b0146441_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cort-20220331.htm",
      "contextRef": "i93f424f685944c1aab994f99b0146441_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413407 - Disclosure - Available-for-Sale Securities and Fair Value Measurements - Schedule of Available-for-Sale Securities (Details)",
     "role": "http://www.corcept.com/role/AvailableforSaleSecuritiesandFairValueMeasurementsScheduleofAvailableforSaleSecuritiesDetails",
     "shortName": "Available-for-Sale Securities and Fair Value Measurements - Schedule of Available-for-Sale Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cort-20220331.htm",
      "contextRef": "i5f690dc4c12e4400835f0643973b82b2_I20220331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cort-20220331.htm",
      "contextRef": "i93f424f685944c1aab994f99b0146441_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2414408 - Disclosure - Available-for-Sale Securities and Fair Value Measurements - Narrative (Details)",
     "role": "http://www.corcept.com/role/AvailableforSaleSecuritiesandFairValueMeasurementsNarrativeDetails",
     "shortName": "Available-for-Sale Securities and Fair Value Measurements - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cort-20220331.htm",
      "contextRef": "i93f424f685944c1aab994f99b0146441_I20220331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:InterestReceivableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cort-20220331.htm",
      "contextRef": "i93f424f685944c1aab994f99b0146441_I20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LossContingencyAccrualAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2416409 - Disclosure - Commitments and Contingencies (Details)",
     "role": "http://www.corcept.com/role/CommitmentsandContingenciesDetails",
     "shortName": "Commitments and Contingencies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cort-20220331.htm",
      "contextRef": "i93f424f685944c1aab994f99b0146441_I20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LossContingencyAccrualAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cort-20220331.htm",
      "contextRef": "i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME",
     "role": "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cort-20220331.htm",
      "contextRef": "i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cort-20220331.htm",
      "contextRef": "i93f424f685944c1aab994f99b0146441_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2419410 - Disclosure - Leases - Narrative (Details)",
     "role": "http://www.corcept.com/role/LeasesNarrativeDetails",
     "shortName": "Leases - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cort-20220331.htm",
      "contextRef": "id8d3c6d4eed84ccdb36200d115427751_I20190131",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cort-20220331.htm",
      "contextRef": "i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2420411 - Disclosure - Leases - Right-of-use Assets and Related Liabilities (Details)",
     "role": "http://www.corcept.com/role/LeasesRightofuseAssetsandRelatedLiabilitiesDetails",
     "shortName": "Leases - Right-of-use Assets and Related Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cort-20220331.htm",
      "contextRef": "i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cort-20220331.htm",
      "contextRef": "i93f424f685944c1aab994f99b0146441_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2421412 - Disclosure - Leases - Future Minimum Lease Payments (Details)",
     "role": "http://www.corcept.com/role/LeasesFutureMinimumLeasePaymentsDetails",
     "shortName": "Leases - Future Minimum Lease Payments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cort-20220331.htm",
      "contextRef": "i93f424f685944c1aab994f99b0146441_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cort-20220331.htm",
      "contextRef": "i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "cort:NumberOfStockOptionPlans",
      "reportCount": 1,
      "unique": true,
      "unitRef": "stockoptionplan",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2424413 - Disclosure - Stockholders' Equity - Narrative (Details)",
     "role": "http://www.corcept.com/role/StockholdersEquityNarrativeDetails",
     "shortName": "Stockholders' Equity - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cort-20220331.htm",
      "contextRef": "i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "cort:NumberOfStockOptionPlans",
      "reportCount": 1,
      "unique": true,
      "unitRef": "stockoptionplan",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cort-20220331.htm",
      "contextRef": "i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2425414 - Disclosure - Stockholders' Equity - Summary of Stock-Based Compensation (Details)",
     "role": "http://www.corcept.com/role/StockholdersEquitySummaryofStockBasedCompensationDetails",
     "shortName": "Stockholders' Equity - Summary of Stock-Based Compensation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cort-20220331.htm",
      "contextRef": "i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cort-20220331.htm",
      "contextRef": "i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2428415 - Disclosure - Net Income Per Share - Schedule of Computation of Net Income Per Share (Details)",
     "role": "http://www.corcept.com/role/NetIncomePerShareScheduleofComputationofNetIncomePerShareDetails",
     "shortName": "Net Income Per Share - Schedule of Computation of Net Income Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cort-20220331.htm",
      "contextRef": "i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cort-20220331.htm",
      "contextRef": "i82ca1385b4a848fd8ea581edd7dcbfdb_I20210331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2429416 - Disclosure - Net Income Per Share - Narrative (Details)",
     "role": "http://www.corcept.com/role/NetIncomePerShareNarrativeDetails",
     "shortName": "Net Income Per Share - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cort-20220331.htm",
      "contextRef": "i82ca1385b4a848fd8ea581edd7dcbfdb_I20210331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cort-20220331.htm",
      "contextRef": "i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2431417 - Disclosure - Income taxes (Details)",
     "role": "http://www.corcept.com/role/IncometaxesDetails",
     "shortName": "Income taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cort-20220331.htm",
      "contextRef": "i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefitsPeriodIncreaseDecrease",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cort-20220331.htm",
      "contextRef": "i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Parenthetical)",
     "role": "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEParenthetical",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cort-20220331.htm",
      "contextRef": "i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cort-20220331.htm",
      "contextRef": "i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "role": "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cort-20220331.htm",
      "contextRef": "i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cort-20220331.htm",
      "contextRef": "i5ff8ab6f19e4485da8179e610307bf6f_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY",
     "role": "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
     "shortName": "CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cort-20220331.htm",
      "contextRef": "i5ff8ab6f19e4485da8179e610307bf6f_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cort-20220331.htm",
      "contextRef": "i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies",
     "role": "http://www.corcept.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cort-20220331.htm",
      "contextRef": "i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cort-20220331.htm",
      "contextRef": "i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2104102 - Disclosure - Composition of Certain Balance Sheet Items",
     "role": "http://www.corcept.com/role/CompositionofCertainBalanceSheetItems",
     "shortName": "Composition of Certain Balance Sheet Items",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cort-20220331.htm",
      "contextRef": "i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cort-20220331.htm",
      "contextRef": "i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cort:AvailableForSaleSecuritiesAndFairValueMeasurementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2110103 - Disclosure - Available-for-Sale Securities and Fair Value Measurements",
     "role": "http://www.corcept.com/role/AvailableforSaleSecuritiesandFairValueMeasurements",
     "shortName": "Available-for-Sale Securities and Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cort-20220331.htm",
      "contextRef": "i86164d40b16f4f6eb23d07ad170a9c4f_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cort:AvailableForSaleSecuritiesAndFairValueMeasurementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 28,
   "tag": {
    "cort_AccretionExpenseIncome": {
     "auth_ref": [],
     "calculation": {
      "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accretion Expense (Income)",
        "label": "Accretion Expense (Income)",
        "terseLabel": "Amortization of interest income"
       }
      }
     },
     "localname": "AccretionExpenseIncome",
     "nsuri": "http://www.corcept.com/20220331",
     "presentation": [
      "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cort_AccruedClinicalExpensesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are associated with clinical research and related activities, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Used to reflect the current portion of clinical accrued liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Clinical Expenses Current",
        "terseLabel": "Accrued research and development expenses"
       }
      }
     },
     "localname": "AccruedClinicalExpensesCurrent",
     "nsuri": "http://www.corcept.com/20220331",
     "presentation": [
      "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cort_AccruedGovernmentRebateCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.corcept.com/role/CompositionofCertainBalanceSheetItemsScheduleofOtherAccruedLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued government rebate current.",
        "label": "Accrued Government Rebate Current",
        "terseLabel": "Government rebates"
       }
      }
     },
     "localname": "AccruedGovernmentRebateCurrent",
     "nsuri": "http://www.corcept.com/20220331",
     "presentation": [
      "http://www.corcept.com/role/CompositionofCertainBalanceSheetItemsScheduleofOtherAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cort_AccruedLegalFeesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.corcept.com/role/CompositionofCertainBalanceSheetItemsScheduleofOtherAccruedLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to legal services. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Legal Fees Current",
        "terseLabel": "Legal fees"
       }
      }
     },
     "localname": "AccruedLegalFeesCurrent",
     "nsuri": "http://www.corcept.com/20220331",
     "presentation": [
      "http://www.corcept.com/role/CompositionofCertainBalanceSheetItemsScheduleofOtherAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cort_AvailableForSaleSecuritiesAndFairValueMeasurementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Available for sale securities and fair value measurements.",
        "label": "Available For Sale Securities And Fair Value Measurements [Abstract]",
        "terseLabel": "Available For Sale Securities And Fair Value Measurements [Abstract]"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesAndFairValueMeasurementsAbstract",
     "nsuri": "http://www.corcept.com/20220331",
     "xbrltype": "stringItemType"
    },
    "cort_AvailableForSaleSecuritiesAndFairValueMeasurementsDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Available for sale securities and fair value measurements disclosure.",
        "label": "Available For Sale Securities And Fair Value Measurements Disclosure [Text Block]",
        "terseLabel": "Available-for-Sale Securities and Fair Value Measurements"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesAndFairValueMeasurementsDisclosureTextBlock",
     "nsuri": "http://www.corcept.com/20220331",
     "presentation": [
      "http://www.corcept.com/role/AvailableforSaleSecuritiesandFairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cort_AvailableForSaleSecuritiesIncludingCashEquivalents": {
     "auth_ref": [],
     "calculation": {
      "http://www.corcept.com/role/AvailableforSaleSecuritiesandFairValueMeasurementsScheduleofAvailableforSaleSecuritiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Available for sale securities including cash equivalents.",
        "label": "Available For Sale Securities Including Cash Equivalents",
        "terseLabel": "Estimated Fair Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesIncludingCashEquivalents",
     "nsuri": "http://www.corcept.com/20220331",
     "presentation": [
      "http://www.corcept.com/role/AvailableforSaleSecuritiesandFairValueMeasurementsScheduleofAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cort_DepositsForClinicalTrials": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deposits For Clinical Trials",
        "label": "Deposits For Clinical Trials",
        "terseLabel": "Deposits for clinical trials"
       }
      }
     },
     "localname": "DepositsForClinicalTrials",
     "nsuri": "http://www.corcept.com/20220331",
     "presentation": [
      "http://www.corcept.com/role/CompositionofCertainBalanceSheetItemsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cort_IncreaseDecreaseInAccruedClinicalExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (decrease) in accrued clinical expenses.",
        "label": "Increase Decrease In Accrued Clinical Expenses",
        "terseLabel": "Accrued research and development expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedClinicalExpenses",
     "nsuri": "http://www.corcept.com/20220331",
     "presentation": [
      "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cort_InventoryCurrentNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.corcept.com/role/CompositionofCertainBalanceSheetItemsScheduleofCompositionofInventoryDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.corcept.com/role/CompositionofCertainBalanceSheetItemsScheduleofCompositionofInventoryDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total inventory.",
        "label": "Inventory Current Noncurrent",
        "totalLabel": "Total inventory"
       }
      }
     },
     "localname": "InventoryCurrentNoncurrent",
     "nsuri": "http://www.corcept.com/20220331",
     "presentation": [
      "http://www.corcept.com/role/CompositionofCertainBalanceSheetItemsScheduleofCompositionofInventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cort_InventoryFinishedGoodsCurrentAndNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.corcept.com/role/CompositionofCertainBalanceSheetItemsScheduleofCompositionofInventoryDetails": {
       "order": 2.0,
       "parentTag": "cort_InventoryCurrentNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inventory, finished goods, current and noncurrent.",
        "label": "Inventory Finished Goods Current And Noncurrent",
        "terseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoodsCurrentAndNoncurrent",
     "nsuri": "http://www.corcept.com/20220331",
     "presentation": [
      "http://www.corcept.com/role/CompositionofCertainBalanceSheetItemsScheduleofCompositionofInventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cort_InventoryWorkInProcessCurrentAndNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.corcept.com/role/CompositionofCertainBalanceSheetItemsScheduleofCompositionofInventoryDetails": {
       "order": 1.0,
       "parentTag": "cort_InventoryCurrentNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inventory, work in process. current and noncurrent.",
        "label": "Inventory Work In Process Current And Noncurrent",
        "terseLabel": "Work in progress"
       }
      }
     },
     "localname": "InventoryWorkInProcessCurrentAndNoncurrent",
     "nsuri": "http://www.corcept.com/20220331",
     "presentation": [
      "http://www.corcept.com/role/CompositionofCertainBalanceSheetItemsScheduleofCompositionofInventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cort_LongLivedTangibleAssetAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-Lived Tangible Asset",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Long-Lived Tangible Asset [Axis]"
       }
      }
     },
     "localname": "LongLivedTangibleAssetAxis",
     "nsuri": "http://www.corcept.com/20220331",
     "presentation": [
      "http://www.corcept.com/role/CompositionofCertainBalanceSheetItemsScheduleofPropertyandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cort_LongLivedTangibleAssetDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-Lived Tangible Asset",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Long-Lived Tangible Asset [Domain]"
       }
      }
     },
     "localname": "LongLivedTangibleAssetDomain",
     "nsuri": "http://www.corcept.com/20220331",
     "presentation": [
      "http://www.corcept.com/role/CompositionofCertainBalanceSheetItemsScheduleofPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cort_LongTermMarketableSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long Term Marketable Securities [Member]",
        "label": "Long Term Marketable Securities [Member]",
        "terseLabel": "Long-term marketable securities"
       }
      }
     },
     "localname": "LongTermMarketableSecuritiesMember",
     "nsuri": "http://www.corcept.com/20220331",
     "presentation": [
      "http://www.corcept.com/role/AvailableforSaleSecuritiesandFairValueMeasurementsSummaryoftheClassificationofAvailableforSaleSecuritiesinCondensedConsolidatedBalanceSheetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cort_LongTermMarketableSecuritiesRemainingMaturity": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long Term Marketable Securities, Remaining Maturity",
        "label": "Long Term Marketable Securities, Remaining Maturity",
        "terseLabel": "Long term marketable securities, remaining maturity"
       }
      }
     },
     "localname": "LongTermMarketableSecuritiesRemainingMaturity",
     "nsuri": "http://www.corcept.com/20220331",
     "presentation": [
      "http://www.corcept.com/role/AvailableforSaleSecuritiesandFairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "cort_MarketableSecuritiesMaximumMaturityPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Marketable securities maximum original maturity period.",
        "label": "Marketable Securities Maximum Maturity Period",
        "terseLabel": "Maximum maturity period"
       }
      }
     },
     "localname": "MarketableSecuritiesMaximumMaturityPeriod",
     "nsuri": "http://www.corcept.com/20220331",
     "presentation": [
      "http://www.corcept.com/role/AvailableforSaleSecuritiesandFairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "cort_MarketableSecuritiesWeightedAverageMaturityPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Marketable securities weighted-average maturity period.",
        "label": "Marketable Securities Weighted Average Maturity Period",
        "terseLabel": "Weighted average maturity period"
       }
      }
     },
     "localname": "MarketableSecuritiesWeightedAverageMaturityPeriod",
     "nsuri": "http://www.corcept.com/20220331",
     "presentation": [
      "http://www.corcept.com/role/AvailableforSaleSecuritiesandFairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "cort_NonCashTransactionRecognitionOfRightOfUseAssetAndLeaseLiability": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non Cash Transaction, Recognition Of Right Of Use Asset And Lease Liability",
        "label": "Non Cash Transaction, Recognition Of Right Of Use Asset And Lease Liability",
        "terseLabel": "Recognition of right-of-use asset and lease liability"
       }
      }
     },
     "localname": "NonCashTransactionRecognitionOfRightOfUseAssetAndLeaseLiability",
     "nsuri": "http://www.corcept.com/20220331",
     "presentation": [
      "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cort_NumberOfSeriesOfSelectiveCortisolModulators": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Series Of Selective Cortisol Modulators",
        "label": "Number Of Series Of Selective Cortisol Modulators",
        "terseLabel": "Number of series of selective cortisol modulators"
       }
      }
     },
     "localname": "NumberOfSeriesOfSelectiveCortisolModulators",
     "nsuri": "http://www.corcept.com/20220331",
     "presentation": [
      "http://www.corcept.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "cort_NumberOfStockOptionPlans": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of stock option plans.",
        "label": "Number Of Stock Option Plans",
        "terseLabel": "Number of stock option plans"
       }
      }
     },
     "localname": "NumberOfStockOptionPlans",
     "nsuri": "http://www.corcept.com/20220331",
     "presentation": [
      "http://www.corcept.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "cort_SharesRepurchasedInNetSettlementOfCashlessOptionExercise": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares Repurchased In Net Settlement Of Cashless Option Exercise",
        "label": "Shares Repurchased In Net Settlement Of Cashless Option Exercise",
        "terseLabel": "Cost of shares repurchased for net settlement of cashless option exercises"
       }
      }
     },
     "localname": "SharesRepurchasedInNetSettlementOfCashlessOptionExercise",
     "nsuri": "http://www.corcept.com/20220331",
     "presentation": [
      "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cort_ShortTermMarketableSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short Term Marketable Securities [Member]",
        "label": "Short Term Marketable Securities [Member]",
        "terseLabel": "Short-term marketable securities"
       }
      }
     },
     "localname": "ShortTermMarketableSecuritiesMember",
     "nsuri": "http://www.corcept.com/20220331",
     "presentation": [
      "http://www.corcept.com/role/AvailableforSaleSecuritiesandFairValueMeasurementsSummaryoftheClassificationofAvailableforSaleSecuritiesinCondensedConsolidatedBalanceSheetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cort_StockOptionsFiscalTwentyTwelvePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock options fiscal 2012 plan.",
        "label": "Stock Options Fiscal Twenty Twelve Plan [Member]",
        "terseLabel": "2012 Equity Incentive Award Plan"
       }
      }
     },
     "localname": "StockOptionsFiscalTwentyTwelvePlanMember",
     "nsuri": "http://www.corcept.com/20220331",
     "presentation": [
      "http://www.corcept.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cort_UnrecognizedTaxBenefitsThatWouldBeOffsetByAChangeInValuationAllowance": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unrecognized Tax Benefits That Would Be Offset By A Change In Valuation Allowance",
        "label": "Unrecognized Tax Benefits That Would Be Offset By A Change In Valuation Allowance",
        "terseLabel": "Unrecognized tax benefits that would be offset by a change in valuation allowance"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsThatWouldBeOffsetByAChangeInValuationAllowance",
     "nsuri": "http://www.corcept.com/20220331",
     "presentation": [
      "http://www.corcept.com/role/IncometaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.corcept.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.corcept.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover page."
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.corcept.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.corcept.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.corcept.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.corcept.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r414"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.corcept.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r415"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.corcept.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.corcept.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.corcept.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.corcept.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.corcept.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.corcept.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.corcept.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.corcept.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.corcept.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.corcept.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.corcept.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.corcept.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.corcept.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.corcept.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.corcept.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.corcept.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.corcept.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.corcept.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.corcept.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r411"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.corcept.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r413"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.corcept.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.corcept.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r202",
      "r212",
      "r248",
      "r249",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r370",
      "r399",
      "r400",
      "r408",
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/AvailableforSaleSecuritiesandFairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r202",
      "r212",
      "r248",
      "r249",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r370",
      "r399",
      "r400",
      "r408",
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/AvailableforSaleSecuritiesandFairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r202",
      "r212",
      "r239",
      "r248",
      "r249",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r370",
      "r399",
      "r400",
      "r408",
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/AvailableforSaleSecuritiesandFairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r202",
      "r212",
      "r239",
      "r248",
      "r249",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r370",
      "r399",
      "r400",
      "r408",
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/AvailableforSaleSecuritiesandFairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r37",
      "r339"
     ],
     "calculation": {
      "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r4",
      "r19",
      "r145",
      "r146"
     ],
     "calculation": {
      "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Trade receivables, net of allowances"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedIncomeTaxesCurrent": {
     "auth_ref": [
      "r15",
      "r375",
      "r388"
     ],
     "calculation": {
      "http://www.corcept.com/role/CompositionofCertainBalanceSheetItemsScheduleofOtherAccruedLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.",
        "label": "Accrued Income Taxes, Current",
        "terseLabel": "Accrued income taxes payable"
       }
      }
     },
     "localname": "AccruedIncomeTaxesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/CompositionofCertainBalanceSheetItemsScheduleofOtherAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedIncomeTaxesNoncurrent": {
     "auth_ref": [
      "r16",
      "r375",
      "r388"
     ],
     "calculation": {
      "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due beyond one year or the operating cycle, whichever is longer. Alternate captions include income taxes payable, noncurrent.",
        "label": "Accrued Income Taxes, Noncurrent",
        "terseLabel": "Long-term accrued income taxes payable"
       }
      }
     },
     "localname": "AccruedIncomeTaxesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r40"
     ],
     "calculation": {
      "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.corcept.com/role/CompositionofCertainBalanceSheetItemsScheduleofOtherAccruedLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued and other liabilities",
        "totalLabel": "Total accrued and other liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.corcept.com/role/CompositionofCertainBalanceSheetItemsScheduleofOtherAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedMarketingCostsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.corcept.com/role/CompositionofCertainBalanceSheetItemsScheduleofOtherAccruedLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for the marketing, trade and selling of the entity's goods and services.   Marketing costs would include expenditures for planning and executing the conception, pricing, promotion, and distribution of ideas, goods, and services; costs of public relations and corporate promotions; and obligations incurred and payable for sales discounts, rebates, price protection programs, etc. offered to customers and under government programs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Marketing Costs, Current",
        "terseLabel": "Accrued selling and marketing costs"
       }
      }
     },
     "localname": "AccruedMarketingCostsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/CompositionofCertainBalanceSheetItemsScheduleofOtherAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r8",
      "r9",
      "r40"
     ],
     "calculation": {
      "http://www.corcept.com/role/CompositionofCertainBalanceSheetItemsScheduleofOtherAccruedLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Professional fees"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/CompositionofCertainBalanceSheetItemsScheduleofOtherAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r35",
      "r181"
     ],
     "calculation": {
      "http://www.corcept.com/role/CompositionofCertainBalanceSheetItemsScheduleofPropertyandEquipmentDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedTerseLabel": "Less accumulated depreciation and amortization"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/CompositionofCertainBalanceSheetItemsScheduleofPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r22",
      "r55",
      "r57",
      "r58",
      "r390",
      "r405",
      "r406"
     ],
     "calculation": {
      "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r54",
      "r58",
      "r64",
      "r65",
      "r66",
      "r95",
      "r96",
      "r97",
      "r299",
      "r401",
      "r402",
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r20"
     ],
     "calculation": {
      "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r95",
      "r96",
      "r97",
      "r264",
      "r265",
      "r266",
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Decrease for Tax Withholding Obligation",
        "negatedTerseLabel": "Shares purchased to satisfy cost and statutory withholding requirements for net settlement of cashless option exercises"
       }
      }
     },
     "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r250",
      "r252",
      "r269",
      "r270"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net income to net cash provided by operations:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r252",
      "r261",
      "r268"
     ],
     "calculation": {
      "http://www.corcept.com/role/StockholdersEquitySummaryofStockBasedCompensationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Allocated share-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/StockholdersEquitySummaryofStockBasedCompensationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r118"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "verboseLabel": "Weighted average options excluded from the computation of diluted net income per share (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/NetIncomePerShareNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r118"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/NetIncomePerShareNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/NetIncomePerShareNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r118"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/NetIncomePerShareNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetBackedSecuritiesMember": {
     "auth_ref": [
      "r156",
      "r240"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities that are primarily serviced by the cash flows of a discrete pool of receivables or other financial assets for example, but not limited to, credit card receivables, car loans, recreational vehicle loans, and mobile home loans.",
        "label": "Asset-backed Securities [Member]",
        "terseLabel": "Asset-backed securities"
       }
      }
     },
     "localname": "AssetBackedSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/AvailableforSaleSecuritiesandFairValueMeasurementsScheduleofAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r89",
      "r131",
      "r134",
      "r140",
      "r166",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r295",
      "r300",
      "r317",
      "r337",
      "r339",
      "r374",
      "r387"
     ],
     "calculation": {
      "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r6",
      "r7",
      "r49",
      "r89",
      "r166",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r295",
      "r300",
      "r317",
      "r337",
      "r339"
     ],
     "calculation": {
      "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r152"
     ],
     "calculation": {
      "http://www.corcept.com/role/AvailableforSaleSecuritiesandFairValueMeasurementsScheduleofAvailableforSaleSecuritiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Gross Unrealized Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/AvailableforSaleSecuritiesandFairValueMeasurementsScheduleofAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r153"
     ],
     "calculation": {
      "http://www.corcept.com/role/AvailableforSaleSecuritiesandFairValueMeasurementsScheduleofAvailableforSaleSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedTerseLabel": "Gross Unrealized Losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/AvailableforSaleSecuritiesandFairValueMeasurementsNarrativeDetails",
      "http://www.corcept.com/role/AvailableforSaleSecuritiesandFairValueMeasurementsScheduleofAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r150",
      "r173"
     ],
     "calculation": {
      "http://www.corcept.com/role/AvailableforSaleSecuritiesandFairValueMeasurementsScheduleofAvailableforSaleSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Amortized Cost",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/AvailableforSaleSecuritiesandFairValueMeasurementsScheduleofAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r148",
      "r151",
      "r173",
      "r377"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale",
        "terseLabel": "Total marketable securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/AvailableforSaleSecuritiesandFairValueMeasurementsSummaryoftheClassificationofAvailableforSaleSecuritiesinCondensedConsolidatedBalanceSheetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r253",
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/AvailableforSaleSecuritiesandFairValueMeasurementsSummaryoftheClassificationofAvailableforSaleSecuritiesinCondensedConsolidatedBalanceSheetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r304",
      "r305"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/AvailableforSaleSecuritiesandFairValueMeasurementsSummaryoftheClassificationofAvailableforSaleSecuritiesinCondensedConsolidatedBalanceSheetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BalanceSheetRelatedDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Balance Sheet Related Disclosures [Abstract]",
        "terseLabel": "Balance Sheet Related Disclosures [Abstract]"
       }
      }
     },
     "localname": "BalanceSheetRelatedDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r94"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).  Accounting policies describe all significant accounting policies of the reporting entity.",
        "label": "Basis of Presentation and Significant Accounting Policies [Text Block]",
        "terseLabel": "Basis of Presentation and Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r2",
      "r32",
      "r85"
     ],
     "calculation": {
      "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r80",
      "r85",
      "r86"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents, at end of period",
        "periodStartLabel": "Cash and cash equivalents, at beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r80",
      "r318"
     ],
     "calculation": {
      "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net decrease in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashEquivalentsMember": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash Equivalents [Member]",
        "terseLabel": "Cash equivalents"
       }
      }
     },
     "localname": "CashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/AvailableforSaleSecuritiesandFairValueMeasurementsSummaryoftheClassificationofAvailableforSaleSecuritiesinCondensedConsolidatedBalanceSheetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Shareholders Equity [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r190"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial paper"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/AvailableforSaleSecuritiesandFairValueMeasurementsScheduleofAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r185",
      "r186",
      "r187",
      "r189",
      "r407"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r95",
      "r96",
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common\u00a0Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r18",
      "r339"
     ],
     "calculation": {
      "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r60",
      "r62",
      "r63",
      "r69",
      "r380",
      "r395"
     ],
     "calculation": {
      "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Total comprehensive income"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComputerSoftwareIntangibleAssetMember": {
     "auth_ref": [
      "r178",
      "r179",
      "r293"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collection of computer programs and related data that provide instructions to a computer, for example, but not limited to, application program, control module or operating system, that perform one or more particular functions or tasks.",
        "label": "Computer Software, Intangible Asset [Member]",
        "terseLabel": "Software"
       }
      }
     },
     "localname": "ComputerSoftwareIntangibleAssetMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/CompositionofCertainBalanceSheetItemsScheduleofPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CorporateBondSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about long-term debt securities that are issued by either a domestic or foreign corporate business entity with a date certain promise of repayment and a return to the holder for the time value of money (for example, variable or fixed interest, original issue discount).",
        "label": "Corporate Bond Securities [Member]",
        "terseLabel": "Corporate bonds"
       }
      }
     },
     "localname": "CorporateBondSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/AvailableforSaleSecuritiesandFairValueMeasurementsScheduleofAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r73",
      "r372"
     ],
     "calculation": {
      "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of sales"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing cost of sales.",
        "label": "Cost of Sales [Member]",
        "terseLabel": "Cost of sales"
       }
      }
     },
     "localname": "CostOfSalesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/StockholdersEquitySummaryofStockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Costs and Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "CostsAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "auth_ref": [
      "r162"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale [Table Text Block]",
        "terseLabel": "Summary of the classification of available-for-sale securities in condensed consolidated balance sheets"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/AvailableforSaleSecuritiesandFairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredIncomeTaxAssetsNet": {
     "auth_ref": [
      "r272",
      "r273"
     ],
     "calculation": {
      "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 7.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.",
        "label": "Deferred Income Tax Assets, Net",
        "terseLabel": "Deferred tax assets, net"
       }
      }
     },
     "localname": "DeferredIncomeTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r83",
      "r90",
      "r280",
      "r285",
      "r286",
      "r287"
     ],
     "calculation": {
      "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "verboseLabel": "Deferred income taxes"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r83",
      "r129"
     ],
     "calculation": {
      "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization of property and equipment"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r70",
      "r100",
      "r101",
      "r102",
      "r103",
      "r104",
      "r108",
      "r110",
      "r115",
      "r116",
      "r117",
      "r121",
      "r122",
      "r308",
      "r309",
      "r381",
      "r396"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Basic net income per share (in dollars per share)",
        "verboseLabel": "Basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME",
      "http://www.corcept.com/role/NetIncomePerShareScheduleofComputationofNetIncomePerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract]",
        "terseLabel": "Weighted-average shares outstanding used in computing net income per share",
        "verboseLabel": "Net income per share"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME",
      "http://www.corcept.com/role/NetIncomePerShareScheduleofComputationofNetIncomePerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r70",
      "r100",
      "r101",
      "r102",
      "r103",
      "r104",
      "r110",
      "r115",
      "r116",
      "r117",
      "r121",
      "r122",
      "r308",
      "r309",
      "r381",
      "r396"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Diluted net income per share (in dollars per share)",
        "verboseLabel": "Diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME",
      "http://www.corcept.com/role/NetIncomePerShareScheduleofComputationofNetIncomePerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r118",
      "r119",
      "r120",
      "r123"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Income Per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/NetIncomePerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r40"
     ],
     "calculation": {
      "http://www.corcept.com/role/CompositionofCertainBalanceSheetItemsScheduleofOtherAccruedLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Accrued compensation"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/CompositionofCertainBalanceSheetItemsScheduleofOtherAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount": {
     "auth_ref": [
      "r262"
     ],
     "calculation": {
      "http://www.corcept.com/role/StockholdersEquitySummaryofStockBasedCompensationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost capitalized for award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Amount Capitalized",
        "terseLabel": "Stock-based compensation capitalized in inventory"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/StockholdersEquitySummaryofStockBasedCompensationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/StockholdersEquitySummaryofStockBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock Options to Purchase Common Stock"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/NetIncomePerShareNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r64",
      "r65",
      "r66",
      "r95",
      "r96",
      "r97",
      "r99",
      "r105",
      "r107",
      "r124",
      "r167",
      "r226",
      "r233",
      "r264",
      "r265",
      "r266",
      "r281",
      "r282",
      "r307",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r401",
      "r402",
      "r403",
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EstimateOfFairValueFairValueDisclosureMember": {
     "auth_ref": [
      "r203",
      "r205",
      "r206",
      "r314"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured as an estimate of fair value.",
        "label": "Estimate of Fair Value Measurement [Member]",
        "terseLabel": "Estimate of fair value measurement"
       }
      }
     },
     "localname": "EstimateOfFairValueFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/AvailableforSaleSecuritiesandFairValueMeasurementsScheduleofAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]",
        "terseLabel": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]"
       }
      }
     },
     "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/AvailableforSaleSecuritiesandFairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByBalanceSheetGroupingTable": {
     "auth_ref": [
      "r310",
      "r315",
      "r316"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.",
        "label": "Fair Value, by Balance Sheet Grouping [Table]",
        "terseLabel": "Fair Value, by Balance Sheet Grouping [Table]"
       }
      }
     },
     "localname": "FairValueByBalanceSheetGroupingTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/AvailableforSaleSecuritiesandFairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r203",
      "r205",
      "r206",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r311",
      "r343",
      "r344",
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/AvailableforSaleSecuritiesandFairValueMeasurementsScheduleofAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementBasisAxis": {
     "auth_ref": [
      "r203",
      "r205",
      "r206",
      "r310",
      "r312"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement basis.",
        "label": "Measurement Basis [Axis]",
        "terseLabel": "Measurement Basis [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementBasisAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/AvailableforSaleSecuritiesandFairValueMeasurementsScheduleofAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosureItemAmountsDomain": {
     "auth_ref": [
      "r203",
      "r205",
      "r206"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement basis, for example, but not limited to, reported value, fair value, portion at fair value, portion at other than fair value.",
        "label": "Fair Value Measurement [Domain]",
        "terseLabel": "Fair Value Measurement [Domain]"
       }
      }
     },
     "localname": "FairValueDisclosureItemAmountsDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/AvailableforSaleSecuritiesandFairValueMeasurementsScheduleofAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r203",
      "r240",
      "r241",
      "r246",
      "r247",
      "r311",
      "r343"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/AvailableforSaleSecuritiesandFairValueMeasurementsScheduleofAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r203",
      "r205",
      "r206",
      "r240",
      "r241",
      "r246",
      "r247",
      "r311",
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/AvailableforSaleSecuritiesandFairValueMeasurementsScheduleofAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r203",
      "r205",
      "r206",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r343",
      "r344",
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/AvailableforSaleSecuritiesandFairValueMeasurementsScheduleofAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r156",
      "r157",
      "r163",
      "r164",
      "r165",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r174",
      "r175",
      "r176",
      "r177",
      "r204",
      "r224",
      "r306",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/AvailableforSaleSecuritiesandFairValueMeasurementsScheduleofAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture and equipment"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/CompositionofCertainBalanceSheetItemsScheduleofPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r67",
      "r131",
      "r133",
      "r136",
      "r139",
      "r141",
      "r373",
      "r378",
      "r382",
      "r397"
     ],
     "calculation": {
      "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Income before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r183",
      "r184"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/StockholdersEquitySummaryofStockBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r184"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/StockholdersEquitySummaryofStockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r91",
      "r275",
      "r278",
      "r279",
      "r283",
      "r288",
      "r290",
      "r291",
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r92",
      "r106",
      "r107",
      "r130",
      "r274",
      "r284",
      "r289",
      "r398"
     ],
     "calculation": {
      "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedLabel": "Income tax (expense) benefit",
        "terseLabel": "Income tax (benefit) expense"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME",
      "http://www.corcept.com/role/IncometaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Trade receivables"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedTaxesPayable": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period of all taxes owed but not paid, including income, property and other taxes.",
        "label": "Increase (Decrease) in Accrued Taxes Payable",
        "terseLabel": "Long-term accrued income taxes"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedTaxesPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Inventory"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "auth_ref": [
      "r82",
      "r329"
     ],
     "calculation": {
      "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation for operating lease.",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "terseLabel": "Operating lease liability"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherAccruedLiabilities": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in other expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Other Accrued Liabilities",
        "terseLabel": "Accrued and other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": {
     "auth_ref": [
      "r111",
      "r112",
      "r113",
      "r117"
     ],
     "calculation": {
      "http://www.corcept.com/role/NetIncomePerShareScheduleofComputationofNetIncomePerShareDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements",
        "terseLabel": "Dilutive effect of employee stock options (in shares)"
       }
      }
     },
     "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/NetIncomePerShareScheduleofComputationofNetIncomePerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_InterestReceivableCurrent": {
     "auth_ref": [
      "r48"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of current interest earned but not received. Also called accrued interest or accrued interest receivable. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.",
        "label": "Interest Receivable, Current",
        "terseLabel": "Interest receivable, current"
       }
      }
     },
     "localname": "InterestReceivableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/AvailableforSaleSecuritiesandFairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r3",
      "r46",
      "r339"
     ],
     "calculation": {
      "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.corcept.com/role/CompositionofCertainBalanceSheetItemsScheduleofCompositionofInventoryDetails_1": {
       "order": 2.0,
       "parentTag": "cort_InventoryCurrentNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventory",
        "verboseLabel": "Total inventory classified as current"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.corcept.com/role/CompositionofCertainBalanceSheetItemsScheduleofCompositionofInventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNoncurrent": {
     "auth_ref": [
      "r47"
     ],
     "calculation": {
      "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.corcept.com/role/CompositionofCertainBalanceSheetItemsScheduleofCompositionofInventoryDetails_1": {
       "order": 1.0,
       "parentTag": "cort_InventoryCurrentNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.",
        "label": "Inventory, Noncurrent",
        "negatedLabel": "Less strategic inventory classified as non-current",
        "terseLabel": "Strategic inventory"
       }
      }
     },
     "localname": "InventoryNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.corcept.com/role/CompositionofCertainBalanceSheetItemsScheduleofCompositionofInventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Schedule of information of leases asset and liabilities"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r180"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/CompositionofCertainBalanceSheetItemsScheduleofPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]",
        "terseLabel": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r334"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Schedule of future minimum lease payments under non-cancelable operating leases"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r334"
     ],
     "calculation": {
      "http://www.corcept.com/role/LeasesFutureMinimumLeasePaymentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.corcept.com/role/LeasesFutureMinimumLeasePaymentsDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/LeasesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r334"
     ],
     "calculation": {
      "http://www.corcept.com/role/LeasesFutureMinimumLeasePaymentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/LeasesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r334"
     ],
     "calculation": {
      "http://www.corcept.com/role/LeasesFutureMinimumLeasePaymentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "terseLabel": "2022 (remainder)"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/LeasesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r334"
     ],
     "calculation": {
      "http://www.corcept.com/role/LeasesFutureMinimumLeasePaymentsDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedTerseLabel": "Less imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/LeasesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r336"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r38",
      "r89",
      "r135",
      "r166",
      "r191",
      "r192",
      "r193",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r296",
      "r300",
      "r301",
      "r317",
      "r337",
      "r338"
     ],
     "calculation": {
      "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r25",
      "r89",
      "r166",
      "r317",
      "r339",
      "r376",
      "r392"
     ],
     "calculation": {
      "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r41",
      "r89",
      "r166",
      "r191",
      "r192",
      "r193",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r296",
      "r300",
      "r301",
      "r317",
      "r337",
      "r338",
      "r339"
     ],
     "calculation": {
      "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingencyAccrualAtCarryingValue": {
     "auth_ref": [
      "r188"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss contingency liability.",
        "label": "Loss Contingency Accrual",
        "terseLabel": "Losses for contingent liability"
       }
      }
     },
     "localname": "LossContingencyAccrualAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyAccrualProvision": {
     "auth_ref": [
      "r188"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount charged against operating income increasing loss contingency liability, after adjustments to reduce previously estimated charges.",
        "label": "Loss Contingency Accrual, Provision",
        "terseLabel": "Provision for a loss contingency"
       }
      }
     },
     "localname": "LossContingencyAccrualProvision",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesCurrent": {
     "auth_ref": [
      "r5",
      "r39"
     ],
     "calculation": {
      "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security, classified as current.",
        "label": "Marketable Securities, Current",
        "terseLabel": "Short-term marketable securities"
       }
      }
     },
     "localname": "MarketableSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesNoncurrent": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security, classified as noncurrent.",
        "label": "Marketable Securities, Noncurrent",
        "terseLabel": "Long-term marketable securities"
       }
      }
     },
     "localname": "MarketableSecuritiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesUnrealizedGainLoss": {
     "auth_ref": [
      "r71"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment in marketable security.",
        "label": "Marketable Securities, Unrealized Gain (Loss)",
        "terseLabel": "Other comprehensive income (loss), net of tax"
       }
      }
     },
     "localname": "MarketableSecuritiesUnrealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r240"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/AvailableforSaleSecuritiesandFairValueMeasurementsScheduleofAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash used in financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r80",
      "r81",
      "r84"
     ],
     "calculation": {
      "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash provided by operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r1",
      "r59",
      "r61",
      "r66",
      "r68",
      "r84",
      "r89",
      "r98",
      "r100",
      "r101",
      "r102",
      "r103",
      "r106",
      "r107",
      "r114",
      "r131",
      "r133",
      "r136",
      "r139",
      "r141",
      "r166",
      "r191",
      "r192",
      "r193",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r309",
      "r317",
      "r379",
      "r394"
     ],
     "calculation": {
      "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net income",
        "totalLabel": "Net income"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME",
      "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.corcept.com/role/NetIncomePerShareScheduleofComputationofNetIncomePerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Attributable to Parent [Abstract]",
        "terseLabel": "Numerator:"
       }
      }
     },
     "localname": "NetIncomeLossAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/NetIncomePerShareScheduleofComputationofNetIncomePerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "terseLabel": "Interest and other income"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r131",
      "r133",
      "r136",
      "r139",
      "r141"
     ],
     "calculation": {
      "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Income from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseExpense": {
     "auth_ref": [
      "r327"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating lease expense. Excludes sublease income.",
        "label": "Operating Lease, Expense",
        "terseLabel": "Operating lease expenses"
       }
      }
     },
     "localname": "OperatingLeaseExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r326"
     ],
     "calculation": {
      "http://www.corcept.com/role/LeasesFutureMinimumLeasePaymentsDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Total operating lease liabilities",
        "verboseLabel": "Present value of operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/LeasesFutureMinimumLeasePaymentsDetails",
      "http://www.corcept.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r326"
     ],
     "calculation": {
      "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Short-term operating lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r326"
     ],
     "calculation": {
      "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Long-term operating lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r328",
      "r329"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Cash paid for operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/LeasesRightofuseAssetsandRelatedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r325"
     ],
     "calculation": {
      "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use asset",
        "verboseLabel": "Operating lease right-of-use asset"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.corcept.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "auth_ref": [
      "r83"
     ],
     "calculation": {
      "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for right-of-use asset from operating lease.",
        "label": "Operating Lease, Right-of-Use Asset, Amortization Expense",
        "terseLabel": "Non-cash amortization of right-of-use asset"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r332",
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted-average discount rate (as a percent)"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/LeasesRightofuseAssetsandRelatedLiabilitiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r331",
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted-average remaining lease term (months)"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/LeasesRightofuseAssetsandRelatedLiabilitiesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r8",
      "r9",
      "r10",
      "r40"
     ],
     "calculation": {
      "http://www.corcept.com/role/CompositionofCertainBalanceSheetItemsScheduleofOtherAccruedLiabilitiesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/CompositionofCertainBalanceSheetItemsScheduleofOtherAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "auth_ref": [
      "r51"
     ],
     "calculation": {
      "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": {
       "order": 3.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "terseLabel": "Foreign currency translation (loss) gain, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]",
        "terseLabel": "Other comprehensive income:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r52",
      "r55"
     ],
     "calculation": {
      "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "verboseLabel": "Unrealized loss on available-for-sale investments, net of tax effect of $323 and $61, respectively"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax": {
     "auth_ref": [
      "r53",
      "r56"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before adjustment, of tax expense (benefit) for unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax",
        "terseLabel": "Net unrealized income (loss) on available-for-sale investments, tax impact"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to reacquire common stock during the period.",
        "label": "Payments for Repurchase of Common Stock",
        "negatedLabel": "Repurchase of common stock"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Payment, Tax Withholding, Share-based Payment Arrangement",
        "negatedLabel": "Cash paid to satisfy statutory withholding requirement for net settlement of cashless option exercises",
        "terseLabel": "Payment tax withholding share-based payment arrangement"
       }
      }
     },
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.corcept.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "auth_ref": [
      "r149"
     ],
     "calculation": {
      "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for purchase of marketable security.",
        "label": "Payments to Acquire Marketable Securities",
        "negatedLabel": "Purchases of marketable securities"
       }
      }
     },
     "localname": "PaymentsToAcquireMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r253",
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PortionAtFairValueFairValueDisclosureMember": {
     "auth_ref": [
      "r313"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured at fair value for financial reporting purposes.",
        "label": "Portion at Fair Value Measurement [Member]",
        "terseLabel": "Portion at fair value measurement"
       }
      }
     },
     "localname": "PortionAtFairValueFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/AvailableforSaleSecuritiesandFairValueMeasurementsScheduleofAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r17",
      "r339"
     ],
     "calculation": {
      "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r6",
      "r30",
      "r31"
     ],
     "calculation": {
      "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.",
        "label": "Proceeds from Issuance or Sale of Equity",
        "terseLabel": "Proceeds from exercise of stock options, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOrSaleOfEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.",
        "label": "Proceeds from Sale and Maturity of Marketable Securities",
        "terseLabel": "Proceeds from maturities of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r1",
      "r59",
      "r61",
      "r66",
      "r79",
      "r89",
      "r98",
      "r106",
      "r107",
      "r131",
      "r133",
      "r136",
      "r139",
      "r141",
      "r166",
      "r191",
      "r192",
      "r193",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r294",
      "r297",
      "r298",
      "r302",
      "r303",
      "r309",
      "r317",
      "r382"
     ],
     "calculation": {
      "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net income"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r34",
      "r180"
     ],
     "calculation": {
      "http://www.corcept.com/role/CompositionofCertainBalanceSheetItemsScheduleofPropertyandEquipmentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Total property and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/CompositionofCertainBalanceSheetItemsScheduleofPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/CompositionofCertainBalanceSheetItemsScheduleofPropertyandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r13",
      "r14",
      "r182",
      "r339",
      "r386",
      "r393"
     ],
     "calculation": {
      "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.corcept.com/role/CompositionofCertainBalanceSheetItemsScheduleofPropertyandEquipmentDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net of accumulated depreciation",
        "totalLabel": "Property and equipment, net of accumulated depreciation"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.corcept.com/role/CompositionofCertainBalanceSheetItemsScheduleofPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r13",
      "r182"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of property and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/CompositionofCertainBalanceSheetItemsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r271",
      "r371",
      "r410"
     ],
     "calculation": {
      "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/StockholdersEquitySummaryofStockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted Stock Units (RSUs)"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/NetIncomePerShareNarrativeDetails",
      "http://www.corcept.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r21",
      "r233",
      "r267",
      "r339",
      "r391",
      "r404",
      "r406"
     ],
     "calculation": {
      "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 6.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Retained earnings"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r95",
      "r96",
      "r97",
      "r99",
      "r105",
      "r107",
      "r167",
      "r264",
      "r265",
      "r266",
      "r281",
      "r282",
      "r307",
      "r401",
      "r403"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Retained Earnings"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r127",
      "r128",
      "r132",
      "r137",
      "r138",
      "r142",
      "r143",
      "r144",
      "r237",
      "r238",
      "r372"
     ],
     "calculation": {
      "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Product revenue, net"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r330",
      "r335"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Right-of-use assets obtained in connection with operating lease obligations"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/LeasesRightofuseAssetsandRelatedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of other accrued liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/CompositionofCertainBalanceSheetItemsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r118"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/NetIncomePerShareNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-sale [Line Items]",
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/AvailableforSaleSecuritiesandFairValueMeasurementsScheduleofAvailableforSaleSecuritiesDetails",
      "http://www.corcept.com/role/AvailableforSaleSecuritiesandFairValueMeasurementsSummaryoftheClassificationofAvailableforSaleSecuritiesinCondensedConsolidatedBalanceSheetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.",
        "label": "Schedule of Available-for-sale Securities Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of available-for-sale securities"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/AvailableforSaleSecuritiesandFairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesTable": {
     "auth_ref": [
      "r154",
      "r155",
      "r158",
      "r159",
      "r160",
      "r161",
      "r384",
      "r385"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.",
        "label": "Schedule of Available-for-sale Securities [Table]",
        "terseLabel": "Schedule of Available-for-sale Securities [Table]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/AvailableforSaleSecuritiesandFairValueMeasurementsScheduleofAvailableforSaleSecuritiesDetails",
      "http://www.corcept.com/role/AvailableforSaleSecuritiesandFairValueMeasurementsSummaryoftheClassificationofAvailableforSaleSecuritiesinCondensedConsolidatedBalanceSheetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r117"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of computation of net income per share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/NetIncomePerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r252",
      "r260",
      "r268"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/StockholdersEquitySummaryofStockBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r252",
      "r260",
      "r268"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Summary of stock-based compensation"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r11",
      "r26",
      "r27",
      "r28"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Schedule of composition of inventory, current"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/CompositionofCertainBalanceSheetItemsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryNoncurrentTableTextBlock": {
     "auth_ref": [
      "r11",
      "r26",
      "r27",
      "r28",
      "r29"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle including inventoried costs relating to long-term contracts or programs.",
        "label": "Schedule of Inventory, Noncurrent [Table Text Block]",
        "terseLabel": "Schedule of composition of inventory, noncurrent"
       }
      }
     },
     "localname": "ScheduleOfInventoryNoncurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/CompositionofCertainBalanceSheetItemsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r35",
      "r182"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/CompositionofCertainBalanceSheetItemsScheduleofPropertyandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r42",
      "r87",
      "r125",
      "r126",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r215",
      "r219",
      "r224",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.",
        "label": "Selling, General and Administrative Expenses [Member]",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/StockholdersEquitySummaryofStockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r258"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Grants in period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r258"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant date fair value (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "terseLabel": "Share-based compensation arrangement by share-based payment award, equity instruments other than options, nonvested, number (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/NetIncomePerShareNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized",
        "terseLabel": "Increase in shares authorized for grant (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r255",
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "terseLabel": "Stock options outstanding (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/NetIncomePerShareNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r251",
      "r254"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1": {
     "auth_ref": [
      "r260"
     ],
     "calculation": {
      "http://www.corcept.com/role/StockholdersEquitySummaryofStockBasedCompensationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost expensed and capitalized for award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount",
        "totalLabel": "Total stock-based compensation"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/StockholdersEquitySummaryofStockBasedCompensationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Shares Withheld for Tax Withholding Obligation",
        "negatedTerseLabel": "Shares purchased to satisfy cost and statutory withholding requirements for net settlement of cashless option exercises",
        "terseLabel": "Shares withheld for tax withholding obligation"
       }
      }
     },
     "localname": "SharesPaidForTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.corcept.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r44",
      "r64",
      "r65",
      "r66",
      "r95",
      "r96",
      "r97",
      "r99",
      "r105",
      "r107",
      "r124",
      "r167",
      "r226",
      "r233",
      "r264",
      "r265",
      "r266",
      "r281",
      "r282",
      "r307",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r401",
      "r402",
      "r403",
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r95",
      "r96",
      "r97",
      "r124",
      "r372"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r17",
      "r18",
      "r226",
      "r233",
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "terseLabel": "Issuance of common stock upon exercise of options (in shares)",
        "verboseLabel": "Common shares issued upon exercise of options (in share)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.corcept.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r44",
      "r226",
      "r233"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Issuance of common stock upon exercise of options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r18",
      "r23",
      "r24",
      "r89",
      "r147",
      "r166",
      "r317",
      "r339"
     ],
     "calculation": {
      "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r88",
      "r211",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r225",
      "r233",
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Stockholders\u2019 Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/StockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": {
     "auth_ref": [
      "r50"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.",
        "label": "Supplemental Balance Sheet Disclosures [Text Block]",
        "terseLabel": "Composition of Certain Balance Sheet Items"
       }
      }
     },
     "localname": "SupplementalBalanceSheetDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/CompositionofCertainBalanceSheetItems"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosure:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxesPayableCurrentAndNoncurrent": {
     "auth_ref": [
      "r15",
      "r375",
      "r389"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes.",
        "label": "Taxes Payable",
        "terseLabel": "Taxes payable"
       }
      }
     },
     "localname": "TaxesPayableCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/IncometaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r156",
      "r157",
      "r163",
      "r164",
      "r165",
      "r204",
      "r224",
      "r306",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/AvailableforSaleSecuritiesandFairValueMeasurementsScheduleofAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockCommonValue": {
     "auth_ref": [
      "r45",
      "r234",
      "r235"
     ],
     "calculation": {
      "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury.",
        "label": "Treasury Stock, Common, Value",
        "negatedLabel": "Treasury stock"
       }
      }
     },
     "localname": "TreasuryStockCommonValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TreasuryStockMember": {
     "auth_ref": [
      "r43",
      "r234"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Treasury Stock [Member]",
        "terseLabel": "Treasury Stock"
       }
      }
     },
     "localname": "TreasuryStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockSharesAcquired": {
     "auth_ref": [
      "r18",
      "r226",
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been repurchased during the period and are being held in treasury.",
        "label": "Treasury Stock, Shares, Acquired",
        "negatedTerseLabel": "Purchases of treasury stock (in shares)",
        "terseLabel": "Treasury stock shares acquired"
       }
      }
     },
     "localname": "TreasuryStockSharesAcquired",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.corcept.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockValueAcquiredCostMethod": {
     "auth_ref": [
      "r226",
      "r233",
      "r234"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.",
        "label": "Treasury Stock, Value, Acquired, Cost Method",
        "negatedTerseLabel": "Purchases of treasury stock"
       }
      }
     },
     "localname": "TreasuryStockValueAcquiredCostMethod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "auth_ref": [
      "r93",
      "r240",
      "r247",
      "r383"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).",
        "label": "US Treasury Securities [Member]",
        "terseLabel": "U.S. Treasury securities"
       }
      }
     },
     "localname": "USTreasurySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/AvailableforSaleSecuritiesandFairValueMeasurementsScheduleofAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease": {
     "auth_ref": [
      "r276"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in unrecognized tax benefits attributable to uncertain tax positions taken in tax returns.",
        "label": "Unrecognized Tax Benefits, Period Increase (Decrease)",
        "terseLabel": "Unrecognized tax benefits, period increase"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsPeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/IncometaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": {
     "auth_ref": [
      "r277"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.",
        "label": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate",
        "terseLabel": "Unrecognized tax benefits that would impact effective tax rate"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/IncometaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r109",
      "r117"
     ],
     "calculation": {
      "http://www.corcept.com/role/NetIncomePerShareScheduleofComputationofNetIncomePerShareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Diluted (in shares)",
        "totalLabel": "Weighted-average shares used to compute diluted net income per share (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME",
      "http://www.corcept.com/role/NetIncomePerShareScheduleofComputationofNetIncomePerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]",
        "terseLabel": "Denominator:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/NetIncomePerShareScheduleofComputationofNetIncomePerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r108",
      "r117"
     ],
     "calculation": {
      "http://www.corcept.com/role/NetIncomePerShareScheduleofComputationofNetIncomePerShareDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Basic (in shares)",
        "verboseLabel": "Weighted-average shares used to compute basic net income per share (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.corcept.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME",
      "http://www.corcept.com/role/NetIncomePerShareScheduleofComputationofNetIncomePerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 6
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e7018-107765"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1707-109256"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1757-109256"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1500-109256"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27198-111563"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL120269820-111563"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27290-111563"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27337-111563"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(24))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27340-111563"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27357-111563"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21553-112644"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21484-112644"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21488-112644"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(d))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "38",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5504-128473"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594809&loc=d3e13220-108610"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13467-108611"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13476-108611"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.12)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/subtopic&trid=77888251"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62557-112803"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62557-112803"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62586-112803"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(15)(b)(1))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(15))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.2)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r411": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r412": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r413": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r414": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r415": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r416": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r417": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)"
  },
  "r418": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)"
  },
  "r419": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.28,29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)"
  },
  "r421": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)"
  },
  "r422": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)"
  },
  "r423": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29,30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(d))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "210",
   "URI": "http://asc.fasb.org/topic&trid=2122208"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e640-108580"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(7)(c))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>57
<FILENAME>0001628280-22-012662-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-22-012662-xbrl.zip
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M7X_>J]/:Z9\GU>V/I'IZ0"M7?Y]6ZA\OJJ<E6OET@*I797:T?71R^"E>L7W
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M#^N;8YJC@X[JU73O^%[-+Y7MS:@YHO[8+E_4ZJ7+H]./+)8]EOODI+)SC^;
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MH:XIP/=^?3ULWZK%5(E#J+\];%]^QC"@7"43FF*17.SVI1$!D*!"[/H=I;;
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M_.QQ0^'9^&E(EMM?(Q(ZW<O"A3%K37%=U9&!"NJ9&O5<3F@(@ATAU"%@)<>
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M3WS 0:90;KS*^;02<\^1CZ: \0R<&@6,7P#&X_/:B%E+! 1*! \H-1X8S2R
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MT;(X+S]T1]G[>\G:A9=R]CL6#RL\1]<_NGGNBQF4J6B+R;Q SBC,N!6 8*\
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MZVX[OD"QW]#,?1VC*B\-:_P6(VW[T+"-8LGX%!EI,D<--AASZAEPU*3H+A6
MQC)MD!:4M]@3BU(B<216Q?,SB1>^COD%]+1\'06@7QC08Q)#X9166W 03<D
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M#RJW=_V4@6Z4*>E6ZKR6[AXWVGE)U5W86Y]V[ID=PO,[KC?Z\6GV^YC'^9K
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M]KS;C5@8NJC>F-]BSN3$T$RC^?RAUWRS[6K)5+E7O>"KI_'5Y"Y> 3+FA9(
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M,W\<=01A(3%+DFVX^IVU)'&0P 8C0!(5T8T!H:6JRLJGGLS*0Y31<"H$$S@
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MTLH:(;*IV(/#[4I*Z;-$?MQ-VY<OH_2!*#<=%#(SB+MBB8W;-A88NP^,G4_
MF+&:8^(<,E@+Q"GG2(.LD&7:6R:MP]X C-&2%3^W\6F/A%)+"4261L:%C%'I
MP)V*6M)HL@9$G@O+\X< 42%;,T,I,H%2@G#K+%"LB)4!E%(6.8$]4MA38S"U
M1*B5-0%DB_ 'UV(JP;(%C'Y]:O>IJ1MM4%0E%AUUW.ED0V)>"Q:<X$9;?3L:
MW5)*M\#2H\(2FX E(BBVD3-D;([@AYV*#),4D:@L8US3J/7*FA)-96904;L
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MOK.&#GUNC=-!Y8\L*$&CWVWT;+_52V<PWUZ_83MYH6U_T.]69XUOK?Y1OE^
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MAW.>V.I+[.>??+=7*AH^V7W%]GC=7^=E+\#S"\ S73C(19MR83JD9?"(<PG
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M7NQNK//=_;^/=_??9!@\V_GVV6$:N+8&*6QRR8"0D!66(ZD=!ZD$J7$:'EJ
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M6$@CC36&NY6U!R=S%G0JZ/0TWJKGAJ<);U6!IWO!T\X$A>(I6W0F7_5QFLO
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ME$&<,XFL$@81Y:P4U&0 7%G#/]@HF:OT3H='3?ML&4"YW;Z!1#0OCT\XV[K
M,+^U^D?36 R'(B!L/EO'E&.U\>$VP+Y*4O+;1N3D]A.QIJ2A.WP^_%4G']V
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M=PTO<LW4LH*0+^KXMXFS)R"[0.@O(U %$03D:4/1*E>285(Y9J"4E?OH)\V
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M8SZMKI,R5(M8F94=;3(KRADRJ&FN70TR(&=XS%P#Q:I &B]$?[<97(D%IH'
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M,\ A\PZ,2UA&Y*X?(P&_$00L-[Y:")I1DV"K8<B;CT %O<SXE;H1?Y8_O<]
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M?'Y".9:;4^N0KI"$^D)2ZM')GYII=\,%(L1.=.M9AM^F0N^>5+C]1-BCG%X
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MO;D=V]^4*3P]^//L-RETS:W'"T^:$7QH%E^A*%-6#.>RGO]-J9+W8QC;*Z"
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MDH)F$6-1D"A7:TL%RL5HB1>-<0%QFNWJJ4C48_@" (@TF&ODB"#KM3"9BN)
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M;XARXDLS15,/P738=:OY#/6,V^AVL2#B$A3'BHP8VL:Q@R*5#,XN^0\C\28
MWP.%[PIMC@"_W[,94*GV&2O^L1$VM6-4A 8>^+1P^,) $8^_[6KO>3[&N,97
M[ (#YI\$_,XN,0)?*% 4!%[!\, V5D-K0H]+6<B=&_/;53"9N.:5Q)[U)4T0
M+E#HC*#Y.!]12D'UZQ(FE0@:C6(8X8C"*)G%&0JW9#:==VH@W\#QH%FN >\(
M-BD.L&[R!:*P3J^6SU$7-7/%2:"Q4L0/5WJ6K,G4@+H)&S&9<$O>9RK>)#+I
M98H-*@.(]5NHUK)K6)M52F\CFT)U267"$SMKUDU0@5P+>&99JVK'N;>13*PJ
M%:N8KSN_>/&]:S"%8A)KAK5<GO5^XUKSBNWGV(N"C7QU6=E8X(:H^PW%69V_
M$=;23&+Z1Q-J[_@5'\(::1_XF%RB@*O'3U>TK1PN"KAWC-[;1:E78LV3IRW?
M+-L(MDB^Q6Q6BBI6DO$C6=U1Z)6W"[VU<JLC2B5DT:R2<7B41^/*5PW3R1+5
MOYU%PJDAYGB&@=PH/^OB$XOSNY=(%-J(5\NFG3S<R<.=/+QW7&1=1.K'E+M*
MK%4)2%A=)T8; PJZG ^U5UWM.)O&P":;(F[AIYOTI8;+ (<,BHIAZ2=O'X25
M=V[AXX*K?0!RRA(9KJ'<+/OC)(^+; R;=S9_ 'Y?Y2D2X[\CWW] YBHYG;7C
M*(_.47['<!C+V(7#;,^I.&@Y/Y;C5$45OQ*C22<Y'[.Z\$1;<^I)UUYE>15\
M][:@NJ:?N/\.PUJ/JB#69B<89?RQG$ QJ7]S; JI'8Q5H;L/(/M$[6S1ZE16
M.%=?514A0T][\>^##[U>7;NE72&Q#E,AQQ&V"Y7.5>412:O03>']D.[F03:1
M957H>M&?@I#J0 PV1@D+STDYA8)C)"^5'614<KP$*111Q"VN^@@AI0J4$>_'
MU)U6Q&XIJRAFHP@62P0BXHJ+NX1,D<M*R:]BGL+'KDHZ4G<QZJYU)N9]-> D
M*+ ,)(Q(2+T<@^U1(6LXUP$8P'.JPMIKNNL('HGA/RDO1+LYB3D4376U@RD-
MCQPFJ\:8Y%RDV=?.#I7T2]*Y%LK$N0LF)T!IV+#WL,BRG=Y,%*=LU)LLXWS"
M%5&=H5ME/))E"XB0&XOS+.0@EH>1J2]53D<$T]8328")VC*1"R'"B+'+J>II
M!*.!>>J4F)VINO* ?43,5RRZN9;4JE <+B$[,>D7X0Z<RD+@HF8P0U?KJ1ZO
M"Y(6Z9"J>RI*4@D4 @]UL.4B7--13U05].>"!E'>R[ZV4^RZ*,4Z02B2[++\
MJ HX01T<YIWD,NI:UL>781YS 2+(/<?JWH@J5$-49U5-=^M #55%'X=8]]3-
MFP4,E:2_=SUJSW_B==QZK4)N6,%=>]-[?7IT_"QKN!U4+0ME><Z%)F]TI,I6
MTP0JO-[57JEFY_(!'9(;Z6S89'LBT0H+M=?G%H@UOZJ.ASB7K9*X8P%;97W.
MX5Q6S6R6%LHW;)HA!)!(:8 #PV7HD:PAC]K36!TL#/M;&FPARG* +MGJ1X'M
M)I8J@0*O[VJ'R \$NQXU6G90N5T [IS8!O_.X*T1C4I5-C[Z^V!/-T.0RV@%
MRV+5+D+<)I:+3JB(QY"\;S86>C$Q -'NM3$N3,MI'?7VF:X:N,JVO*@/XEA
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MT]O:/:O'MB]V]77_76A!^15K+K5JLA6!Z_=KECK,1@ :8QX+I['0N=\6G#-
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MJ(/>'?US6#RIC.'N9<9T!1E3]5!JHVB('EQEU!?&ZN8LJR+>&Y 3]&5'(U=
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M<WONT*+Q51&\IX)^FVQ93 73'95<XFY *0U:&SZ8\^HMVA?1@0"PA7(V-]=
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M*X\#>N,4)N=G'_IK<5I>TK;[J2"E]OQKA/<?7&+?7X*P"7@BOD)?$4Y(.TX
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M&]C-V;M'U+L'\3;P)LE@C\%JP-$FYE"((PR=PHZDN276:.LM39K<4)803Y5
M=66X>&<D29BP1G5EC3!Y?AUXY$<]YHD$+DB(3\/ M'4(V^G* /39=FVA*1::
M\F(+3;D%;LGX<\.5T&S@B)XB+\&3*LEXFS0B&W&J9L4)C2'+N;K,.:I8; /L
MB.'3@<=/MHX& )C&!9_[YQE" UJD)LI,<.I IE:D2GWB/1OAH&0N T07(]:M
M-DZ:N.V("JG>@P>*$^N!LMW[TTXE]'EHQUWH54P-*"\+J0'= T6/.DZ5;RX
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M\:!;9H"L+RHST>7]/%]?;W/V!)])#,V$S,!55D1I!&X"8)<KSQ0IGK2[B7_
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M8]T>:IJ0]I2BO68J]IR.H)SJ]PWTZB%@+FTKLQ#EB*;)>5&+%Z!'WL!%6=1
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M?_B1@3+QV\]0X,GG\7Q8(C89L*RE,I>(FF9*I8!KJ2,]<CO]8AP)DT3\8 Q
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M\KO_:'<KP5L)OL,2_"Q]^.C9;91@<2@&@.^])R2?WZS(?86OFM=\Y-YE6O?
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MI6-5?C"9U'U%Z)2-NOS.5I-O3>'X^>;"\8^G]73E_L^\6Y1__[]02P,$%
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MD@[VAZJG/A=2S)1V20^&A':9A86*4MG>CTU+296)*WSYS5A@G,Q\NU3.WX/
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M6\]NZ\*Q#</D*1EGF(92RP!4\AZBS@%DL3(;';C2I6?5V-WJ3+]!R5@C#=!
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M.EO/-T7ZV-<I-^'7?>N4G5JMQD[UN_%^W>P\W5?_;<.K%V4X@%/_I1=40+4
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MNL$2P:"NVVN<UV]>]9M"7T1\U09G#:A5LXH;@-U/FK%38R^6%U:V5(TJ@F6
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M3N"\]!?]=M:C8G;T4H^RK%3(J%6<^H@LD5VPL1R\I&)VQD+,=5K35Q)H][/
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M?^IP:7N]+=[)W^O_E+[>:KE:3KE^>I4Y^/M\NBJ_?ON]61O%,"8PYP(4*F8
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M(<GJ#27U&[HM+]R+VC3#6=$?T4^RUO7GB-7:]FD?= @N)RQA6*,)!60 J;0
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M8+_NR(Z$81V(8\8=3/E'+^I3EWAOP;B9_M<IHWL)II,D@2BF:094;FH5QY(
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MUY-^]=V4-ZM[N=2ZSV_JZ*^_Z4>LRH_SNJ+1WCEG]<=W="77KL0D%P(728*
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MN9?0M83";RW=<T*'+:IK"<%!=5W;^WJF3IJ-^&O.ET]2;(EJ5E\353 DJ$Q
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MP7&VO^K)!PS;3O6<'0?=4\_><%')"^W3*5F65:V=#W*=WS!AL4PAYRG B%"
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MS%2CY_A;'%_\BQP57-(2I%#D9FL@ G H%9"9@$KJK(2L]"E#B8G_!%4JK?J
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MZGTG$/N GXWJA]G-)@4!+[8-NM[VI"W*BQ#B'$0GJ,GIES:IB1D<]*E)&?[
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M#@ PFO.S[[V3$7X.#*S+]CGTZ,W=FVR7M^\?UG\>:*?3'&*B2\N3P"P)G1*
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MI*,0"I\A-CFI\/N7*209!<X8<N'SE]QXE?S>ABG;;C;/^_Y4)6.XS!%02FB
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M',(( 53L0\,8C+RB&$,@C YC]+YXLCC&T-"Z@8S!9_T6N[1-AOM+Z\PY8L]
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M,+>%?]H!NFQ5#]X!^MJ\N%F,N&A'-BL#':#W@WBA#M .($[1 ?J:&G/H .T
MDV,':)<WW4!#)T[IJSJ\8J^>#X\TX8O*+G<??[W>[K(%+[#(%+1G-*(!DK0
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MWGSW;__2_L1\L50^__8O_P-02P,$%     @ (H*E5*?=TVN!1P  S!L# !4
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M,,I#=F"T%W5.A@[+9S.S,;L-L!H&RVM?2@.GP/A@#<FI9(^Y,\@L*,*CTUD
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M>#A'*XOKYOWP1_GJ>F( $X$SB>;5.)'+)%V'8:/)Q"MODW>0.-1IB[&>IN:
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M^+)L)8M=) @>.+=04JN"2"X9\292H@( L][FP%V=#?AI@EY+VG$O1Z\#730
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MEH[OSJ@0P#+OZM3[;DMIS^G:&B:IJK)>$1@7KN9 T*1\+O<PA,8UZX 29T/
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MW3!NI,<'XJWB7/KD)@'*.%<V(W$2*T".1)!T+91-<FUK]"/:-#H/0*F,3J3
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M]_MR[_U2_5G==NE[MY._ 5!+ P04    "  B@J54OPJ(:00%  "($P  $@
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MNV[SV=L]6<+D=/$AF)W^4NZNG3QT>[ X@^#=#):3R[>3B]G26OSU?O8%)M-
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M,S,Q7V-A;"YX;6Q02P$"% ,4    "  B@J54CLIF,.<;  "3&@$ %0
M        @ &PC@$ 8V]R="TR,#(R,#,S,5]D968N>&UL4$L! A0#%     @
M(H*E5$_?8 38?P  7S4% !4              ( !RJH! &-O<G0M,C R,C S
M,S%?;&%B+GAM;%!+ 0(4 Q0    ( "*"I52GW=-K@4<  ,P; P 5
M      "  =4J @!C;W)T+3(P,C(P,S,Q7W!R92YX;6Q02P$"% ,4    "  B
M@J54@M(^.CP0  ")B@  '@              @ &)<@( 8V]R=#,S,3(R97@Q
M,#%S979E;G1H86UE;F0N:'1M4$L! A0#%     @ (H*E5)EG]G7<!P  Q20
M !(              ( ! 8," &-O<G0S,S$R,F5X,S$Q+FAT;5!+ 0(4 Q0
M   ( "*"I51X4B;PPP<  )PD   2              "  0V+ @!C;W)T,S,Q
M,C)E>#,Q,BYH=&U02P$"% ,4    "  B@J54<^.+CB<%  #2$P  $@
M        @ $ DP( 8V]R=#,S,3(R97@S,C$N:'1M4$L! A0#%     @ (H*E
M5+\*B&D$!0  B!,  !(              ( !5Y@" &-O<G0S,S$R,F5X,S(R
:+FAT;5!+!08     "P + -8"  "+G0(    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
